<SEC-DOCUMENT>0000950123-21-000138.txt : 20210305
<SEC-HEADER>0000950123-21-000138.hdr.sgml : 20210305
<ACCEPTANCE-DATETIME>20210108150300
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-000138
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		32
FILED AS OF DATE:		20210108
<PUBLIC-REL-DATE>20210305
DATE AS OF CHANGE:		20210108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ikena Oncology, Inc.
		CENTRAL INDEX KEY:			0001835579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04000
		FILM NUMBER:		21517196

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-343-8292

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on January 8, 2021.
This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The
Securities Act of 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:21pt; font-family:Times New Roman" ALIGN="center"><B>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-1697316</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>50 Northern Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02210 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(857)
<FONT STYLE="white-space:nowrap">273-8343</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Mark
Manfredi, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ikena Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>50 Northern Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02210 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(857)
<FONT STYLE="white-space:nowrap">273-8343</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of
agent for service) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Richard Hoffman, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Stephanie Richards, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>William D. Collins, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>100
Northern Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02210</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Lisa Firenze, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Craig Hilts, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Wilmer Cutler Pickering Hale&nbsp;&amp; Dorr LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>7 World Trade Center</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>250 Greenwich Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10007</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">230-8800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act
of 1933, as amended, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to
Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective
amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Non-Accelerated Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION
OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of each Class&nbsp;of<BR>Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering Price<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common Stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Includes the offering price of shares that the underwriters may purchase pursuant to an option to purchase
additional shares. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall
file&nbsp;a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#eb0029"><B>SUBJECT TO COMPLETION, DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g95x53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. This is our initial public offering of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our shares. We expect that the initial public offering price will be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. We intend to apply to list our common
stock on The Nasdaq Global Market under the symbol &#147;IKNA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; under the federal securities laws and,
as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and for future filings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our common
stock involves a high degree of risk. See &#147;<A HREF="#rom197729_4">Risk Factors</A>&#148; beginning on page&nbsp;14 of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither
the Securities and Exchange Commission nor any state securities commission approved or disapproved of the securities that may be offered under this prospectus, nor have any of these organizations determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PER<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;Underwriting&#148; beginning on page 204 for additional information regarding
underwriting compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delivery of the shares of common stock will be made on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option
for a period of 30 days to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. If the underwriters exercise the option in full, the total
underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint
Book-Running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Credit&nbsp;Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_2">THE OFFERING </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_4">RISK FACTORS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_8">CAPITALIZATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_9">DILUTION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_10">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_11">MANAGEMENT &#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_12">BUSINESS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_13">MANAGEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_14">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_15"><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR
COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_17">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_18">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_19">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_20">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.&nbsp;HOLDERS</FONT> OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_21">UNDERWRITING </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_22">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_23">EXPERTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_24">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom197729_25">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (25 days after the commencement
of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a
prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the underwriters have not,
authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we
have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered
hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its
date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe
any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market
data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable
sources. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such
information. We are responsible for all of the disclosure contained in this prospectus, and we believe that these sources are reliable; however, we have not independently verified the information contained in such publications. While we are not
aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to
change based on various factors, including those discussed under the section entitled &#147;Risk Factors&#148; and elsewhere in this prospectus. Some data are also based on our good faith estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your
investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus. You should also consider, among
other things, the matters described under &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case appearing elsewhere in this prospectus. Unless the context
otherwise requires, the terms &#147;Ikena,&#148; &#147;Ikena Oncology,&#148; &#147;the Company,&#148; &#147;the Registrant,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; in this prospectus refer to Ikena Oncology, Inc. and its
subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a targeted oncology
company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved
or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of
wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. Since we
commenced operations in 2016, we have discovered or developed five oncology programs that include four product candidates in either <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead targeted oncology product candidate, <FONT STYLE="white-space:nowrap">IK-930,</FONT> is an oral small molecule inhibitor of the transcriptional
enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is widely accepted as a key and prevalent driver of cancer pathogenesis and is genetically altered in approximately 10% of all cancers, and
such genetic alterations are generally associated with poor clinical outcomes. We intend to pursue clinical development of <FONT STYLE="white-space:nowrap">IK-930</FONT> across a wide range of tumor types with known Hippo pathway mutations, and plan
to focus our initial development efforts on indications that provide the potential for rapid clinical development to achieve <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> such as mesothelioma and
soft tissue sarcomas. We intend to submit an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for <FONT STYLE="white-space:nowrap">IK-930</FONT> in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our second targeted oncology program, we have discovered and plan to develop oral small molecule inhibitors of extracellular signal-related kinase 5, or
ERK5, a downstream enzyme in the RAS signaling pathway, which have the potential to bring therapeutic benefit to cancer patients with a mutation in the kirsten rat sarcoma, or KRAS, gene, which is an oncogene implicated in many cancers. We
anticipate nominating a development candidate for the ERK5 program and initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021 with the goal of submitting an IND in the second half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the programs described above, we have ongoing discovery programs in targeted oncology focused on the development of novel drug candidates that
target key nodes within the RAS pathway, and expect to nominate the first development candidate resulting from these discovery programs in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition to our targeted oncology programs, we have three product candidates designed to modulate the tumor microenvironment in specific patient populations by leveraging biomarker-driven patient enrichment strategies. Two of these product
candidates, <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> are partnered with Bristol-Myers Squibb Company, or BMS, which we believe validates our ability to rapidly advance internally developed
product candidates into clinical development using biomarker-driven patient enrichment strategies. The programs are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">IK-175</FONT> is an oral inhibitor of aryl hydrocarbon receptor, or AHR. We are
currently enrolling patients with bladder cancer with activated AHR in a dose expansion cohort of a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">IK-175</FONT> </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
as a monotherapy. Additionally, we plan on assessing <FONT STYLE="white-space:nowrap">IK-175</FONT> in combination with nivolumab in patients with bladder cancer in the first half of 2021 in the
Phase 1b portion of the clinical trial. We expect to complete enrollment in both treatment arms in the second half of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">IK-412</FONT> is an enzyme therapy designed to lower levels of immunosuppressive
kynurenine in the tumor microenvironment. We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">IK-412</FONT> and intend to submit an IND in the second half of 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Finally, we are evaluating <FONT STYLE="white-space:nowrap">IK-007,</FONT> an oral antagonist of prostaglandin E2
receptor 4, or EP4, in a Phase 1b clinical trial in biomarker-enriched patients with microsatellite stable colorectal cancer, or MSS CRC, who express high levels of an EP4 pathway metabolite called PGE2 Metabolite, or PGEM. We expect to complete
enrollment for the Phase 1b clinical trial in the second half of 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current pipeline of discovery and clinical programs is shown
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g93v29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Discovery and Development Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ a patient-centric research and development, or R&amp;D, approach across discovery chemistry and biology, translational science and clinical
development. We select new programs based on two key strategic principles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cancer driver targets must have a compelling biological rationale, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tumor intrinsic changes such as mutations, gene fusions, and gene amplifications; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong clinical rationale with the potential to develop a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Alignment with a translational path in disease indications with high unmet medical need, including:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No currently approved therapies, or patient populations that are underserved by current treatments; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A biomarker-driven
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical development plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We pursue
the discovery and development of small molecule modulators of targets in any target classes that meet these key strategic principles, using structural biology-guided chemistry and applying our deep cancer biology expertise to rigorously select the
best molecules for development. In parallel, we generate and validate biomarkers in order to enrich our programs for patients who we believe may be most likely to benefit from treatment with our product candidates. We then develop our own assays to
analyze the impact that our product candidates have on these biomarkers, based on our translational insights. We then design clinical trials with the potential to demonstrate rapid
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> based on these biomarker strategies for the treatment of patients in disease indications with high unmet medical needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Targeted Oncology Programs </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">IK-930,</FONT> a TEAD inhibitor </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead targeted oncology product candidate,
<FONT STYLE="white-space:nowrap">IK-930,</FONT> is an internally discovered, oral small molecule inhibitor of the transcription factor known as TEAD. Aberrant activation of TEAD caused by mutations in the Hippo tumor suppressor pathway can drive the
formation and survival of tumors and the development of resistance to multiple existing therapies. We believe that <FONT STYLE="white-space:nowrap">IK-930</FONT> is one of the most advanced TEAD inhibitors currently in development for this
important, but historically undruggable, target. The Hippo pathway is widely accepted as a key and prevalent driver of cancer pathogenesis and is genetically altered in approximately 10% of all cancers, and such genetic alterations are generally
associated with poor patient outcomes. In certain tumors, such as mesothelioma and epithelioid hemangioendothelioma, or EHE, a type of soft tissue sarcoma, genetic alterations in the Hippo pathway are found in over 40% of patients. <FONT
STYLE="white-space:nowrap">IK-930</FONT> is designed to potently and selectively bind to TEAD and inhibit TEAD-dependent gene expression. In our preclinical studies, <FONT STYLE="white-space:nowrap">IK-930</FONT> has been well tolerated and has
shown favorable pharmacokinetics and pharmacodynamics. Moreover, we observed potent antitumor activity in preclinical studies using tumor models that harbored genetic alterations within the Hippo pathway. We intend to pursue clinical development of <FONT
STYLE="white-space:nowrap">IK-930</FONT> across a wide range of tumor types with known Hippo pathway genetic alterations, and plan to focus our initial development efforts on indications such as mesothelioma and soft tissue sarcomas, that provide
the potential for rapid clinical development to achieve <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in disease indications with high unmet medical need. Moreover, we believe there is potential for
a tumor agnostic approach for <FONT STYLE="white-space:nowrap">IK-930</FONT> given the prevalence of Hippo pathway genetic alterations in many forms of cancers. We also plan to explore <FONT STYLE="white-space:nowrap">IK-930</FONT> in combination
with other targeted therapies, such as epidermal growth factor receptor, or EGFR, inhibitors, in more prevalent tumor indications. We intend to submit an IND for <FONT STYLE="white-space:nowrap">IK-930</FONT> to the FDA in the second half of 2021.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ERK5 inhibitor / RAS Signaling Pathway inhibitor program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. KRAS mutations in the RAS signaling pathway occur in
approximately 26% of all cancers. Although there has been recent progress with development-stage compounds that are designed to directly inhibit certain KRAS mutations, approximately 85% of KRAS mutations are not being addressed by current product
candidates or approved therapies. We believe that inhibiting ERK5 provides an opportunity to address a high unmet medical need by modulating a key target downstream in the RAS signaling pathway. In preclinical studies in mice, we observed that
knockout of ERK5 prevented tumor formation in genetically engineered KRAS mutant lung and pancreatic cancer. We also observed that inhibition of the target using an ERK5 inhibitor tool compound blocked tumor
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
growth in patient-derived KRAS mutated xenograft models. Additionally, in preclinical studies in KRAS primary human tumor models of lung and pancreatic cancer, we observed synergistic effects on
tumor inhibition by combining an ERK5 inhibitor and trametinib, a mitogen-activated protein kinase, or MEK inhibitor. We plan to pursue clinical development of oral ERK5 inhibitors both as single agent in KRAS mutated pancreatic and lung cancer and
in combination with other targeted therapies to address resistance to MEK inhibitors. We anticipate nominating a development candidate and initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in this program in the second half of
2021 and submitting an IND in the second half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RAS Pathway discovery programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our TEAD and ERK5 programs, we have several early stage discovery programs in targeted oncology in the RAS pathway. We are focused on well-known
targets and mutations in this pathway that lack approved or effective therapies and therefore have the potential to address high unmet medical needs. We expect to nominate the first development candidate resulting from these discovery programs in
2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Tumor Microenvironment Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition to our core targeted oncology efforts, we are developing biomarker-driven programs against pathways to modulate the tumor microenvironment. We believe these programs have the potential, either as monotherapies or in combination with
checkpoint immunotherapies, to overcome broad immunosuppression by modulating both the innate and adaptive immune systems. We have developed biomarkers that we believe will enable us to identify patients who will have a greater likelihood of
benefiting from our tumor microenvironment therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-175,</FONT> an AHR antagonist </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">IK-175,</FONT> a potent, selective AHR antagonist. AHR is a ligand-dependent transcription factor that
drives tumor progression through direct cancer cell and immunosuppressive effect in the tumor microenvironment. In preclinical studies, we observed that inhibition of AHR by <FONT STYLE="white-space:nowrap">IK-175</FONT> had potent antitumor
activity in <FONT STYLE="white-space:nowrap">AHR-dependent</FONT> tumors and led to immune-driven antitumor responses. In addition, the combination of <FONT STYLE="white-space:nowrap">IK-175</FONT> and an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> checkpoint inhibitor had superior antitumor activity than either agent alone in preclinical tumor models. We have generated translational insights indicating that AHR is activated in a number of
cancers including a subset of bladder cancers. We are currently conducting an open-label Phase 1 clinical trial to evaluate <FONT STYLE="white-space:nowrap">IK-175</FONT> as both a monotherapy and in combination with a
<FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitor in solid tumors, including bladder cancer. To date, in the monotherapy dose escalation cohorts, <FONT STYLE="white-space:nowrap">IK-175</FONT> has been well tolerated and we observed
encouraging evidence of pharmacodynamic modulation. We recently initiated monotherapy expansion in bladder cancer patients with tumors that exhibit activated AHR and we are enriching the clinical trial for these patients using our proprietary
assays. We plan on assessing <FONT STYLE="white-space:nowrap">IK-175</FONT> in combination with nivolumab in patients with bladder cancer in the first half of 2021 in the Phase 1b portion of the clinical trial and expect to complete enrollment in
both treatment arms in the second half of 2022. Our <FONT STYLE="white-space:nowrap">IK-175</FONT> program is partnered with BMS, which has the right to exclusively license the program through the completion of the Phase 1b portion of the clinical
trial. See &#147;&#151;License and Collaboration Agreements&#151;Master Collaboration Agreement with Bristol-Myers Squibb&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-412,</FONT> a recombinant human kynurenine-degrading enzyme </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">IK-412,</FONT> a recombinant human kynurenine-degrading enzyme that we believe may be able to reduce tumor
resistance to checkpoint inhibitors and has the potential to address the shortcomings of other kynurenine-reducing approaches such as inhibition of IDO1 by small molecule inhibitors. Kynurenine is a metabolite of the tryptophan degradation pathway
and has long been recognized as an important contributor to immunosuppression. Recent clinical data from BMS suggests that increased kynurenine is an adaptive resistance </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mechanism to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy in multiple cancers. We designed <FONT STYLE="white-space:nowrap">IK-412</FONT> to
be optimized to degrade kynurenine regardless of the source from the kynurenine-producing enzymes IDO1 or TDO2 and to have high stability in plasma, which we observed in <FONT STYLE="white-space:nowrap">non-human</FONT> primates to be consistent
with weekly or biweekly dosing in humans. In preclinical studies, we observed after a single dose in <FONT STYLE="white-space:nowrap">non-human</FONT> primates that <FONT STYLE="white-space:nowrap">IK-412</FONT> led to durable depletion of over 95%
of serum levels of kynurenine. In other preclinical studies, we also observed antitumor activity when dosed both as a monotherapy and in combination with checkpoint inhibitors and increased overall survival when dosed in combination with checkpoint
inhibitors. To inform our indication selection, we developed several translational assays, including an immunohistochemistry assay using IDO1 or TDO2 antibodies to guide selection of certain solid tumors. We are also working on detecting kynurenine
in tumors and in the blood of patients with certain solid tumors. We intend to submit an IND for <FONT STYLE="white-space:nowrap">IK-412</FONT> in the second half of 2021. Our <FONT STYLE="white-space:nowrap">IK-412</FONT> program is also partnered
with BMS, which has the right to exclusively license the program through the completion of the Phase 1b portion of the clinical trial. See &#147;&#151;License and Collaboration Agreements&#151;Master Collaboration Agreement with Bristol-Myers
Squibb&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-007,</FONT> an EP4 antagonist </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also developing <FONT STYLE="white-space:nowrap">IK-007,</FONT> an oral selective EP4 receptor antagonist, for the treatment of microsatellite stable
colorectal cancer, or MSS CRC, which represents approximately 80% of all patients with CRC. These patients generally do not respond to approved checkpoint inhibitors. In the ongoing Phase 1b clinical trial of
<FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab in MSS CRC, we observed encouraging preliminary evidence of antitumor activity in the initial dose escalation cohort and have not observed any dose limiting toxicities,
or DLTs. In addition, we have identified an association between higher levels of PGEM, a metabolite in the EP4 pathway, in urine samples collected at study entry with those patients that demonstrated increased clinical benefit. We are enrolling
patients in a dose expansion cohort using baseline levels of urinary PGEM to enrich for MSS CRC patients, who we believe will be more likely to respond to treatment. We expect to complete enrollment for the Phase 1b clinical trial in the second half
of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dedicated to bringing
next generation targeted oncology therapies to cancer patients. We plan to achieve this goal by leveraging our deep understanding of complex biologic pathways and biomarker-driven discovery and clinical development. The key components of our
strategy are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advance <FONT STYLE="white-space:nowrap">IK-930</FONT> through clinical development.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expeditiously progress a development candidate for the RAS signaling program through clinical development.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deepen our pipeline of biomarker-driven targeted oncology programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our pipeline by retaining commercial rights to our targeted oncology programs.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> our <FONT
STYLE="white-space:nowrap">BMS-partnered</FONT> programs, through Phase 1b clinical trials and achieve key near-term financial milestones. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assembled a leadership team of highly
experienced researchers, clinicians and business leaders to advance and broaden our portfolio of patient-directed oncology therapies. Our leadership team includes senior experts with a track record of success at leading biopharmaceutical companies
including Takeda Pharmaceutical Company, or Takeda, Merck&nbsp;&amp; Co., Eli Lilly and Company, Pfizer Inc., Novartis International AG, </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
GlaxoSmithKline plc, H. Lundbeck A/S and Millennium Pharmaceuticals, Inc. Our senior management team includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mark Manfredi, Ph.D., our Chief Executive Officer and founder, has more than 20 years of oncology R&amp;D
experience, previously serving as chief scientific officer of Raze Therapeutics and as an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Entrepreneur-in-Residence</FONT></FONT> at Atlas Venture. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Douglas Carlson, our Chief Financial Officer, brings over 18 years of experience with a multi-disciplinary
background in corporate finance, venture capital, mergers and acquisitions, business development and commercial operations with both large and emerging growth healthcare companies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jeffrey Ecsedy, Ph.D., our Chief Scientific Officer, brings over 20 years of experience in both discovery science
and clinical translational medicine, and previously served as the head of oncology, translational medicine at Takeda. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sergio Santillana, M.D., M.Sc., MBA, our Chief Medical Officer, is a medical oncologist with more than 25 years
of oncology drug development and clinical practice experience. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maude Tessier, Ph.D., our Chief Business Officer, brings over 15 years of business development, licensing and
alliance management experience in pharma, biotech and academia. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of our R&amp;D leadership and executive teams bring 23 years of
experience on average and have contributed to over 50 INDs and 14 regulatory drug approvals throughout their careers. In addition, we have formed a multidisciplinary advisory board composed of prominent oncology thought leaders from Dana-Farber
Cancer Institute, University of California, San Francisco and Vall d&#146;Hebron Institute of Oncology, who will bring extensive strategic, clinical, translational and drug development expertise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Leading Investors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2020, we have
raised over $160&nbsp;million from leading life sciences investors and companies that include Atlas Venture, OrbiMed, BMS, Fidelity Management and Research Company, Omega Funds, Surveyor Capital (a Citadel company), Invus, Farallon Capital
Management, BVF Partners, L.P., Cowen Healthcare Investments, Logos Capital, and HealthCor Management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amplify Acquisition </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2020, we acquired
Amplify Medicines, Inc., or Amplify, pursuant to an Agreement and Plan of Merger. In connection with the merger, we issued 7,863,094 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock and 3,048,764 shares of common
stock to Amplify shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B preferred stock financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2020, we issued and sold 85,806,214 shares of our Series B preferred stock at a purchase price of $1.3985 per share for gross proceeds of
approximately $120.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization declared the outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> a global pandemic, which continues to
spread throughout the United States and worldwide. To date, we have been carefully monitoring the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its potential impact on our business and have taken important steps to help ensure the
safety of our employees and their families and to reduce the spread <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19.</FONT> We have established a work-from-home policy for all employees, other than those performing or supporting business-critical
operations, such </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as certain members of our laboratory and facilities staff. For those employees, we have implemented stringent safety measures designed to comply with applicable federal, state and local
guidelines instituted in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We have also maintained efficient communication with our partners and clinical sites as the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
situation has progressed. We have taken these precautionary steps while maintaining business continuity so that we can continue to progress our programs. While we have experienced some delays in enrollment and site closures at certain of our
third-party clinical trial sites, these delays have not had a material impact on our development timelines for our product candidates. We will continue to monitor developments as we address the disruptions and uncertainties relating to <FONT
STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> See &#147;Risk Factors&#148; for a discussion of the potential adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, results of operations
and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are
described more fully in the section entitled &#147;Risk Factors&#148; in this prospectus. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a targeted oncology company with a limited operating history. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses
for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have no products approved for commercial sale and have not generated any revenue from product sales.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we consummate this offering, we will need to raise substantial additional funding. If we are unable to
raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or a similar pandemic, epidemic, or outbreak of an
infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have never successfully completed any clinical trials for our oncology programs, and we may be unable to do so
for any product candidates we develop. Certain of our targeted oncology programs are still in preclinical development and may never advance to clinical development. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or
biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical product development involves a lengthy and expensive process, with an uncertain outcome.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests
for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> and preliminary data from our clinical trials that we
announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We anticipate that certain of our current product candidates and future product candidates will be used in
combination with third-party drugs or biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to file INDs to commence clinical trials on the timelines we expect, and even if we are able
to, the FDA may not permit us to proceed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA
and comparable foreign regulatory authorities may not accept data from such trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products
before or more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the market opportunities for our programs and product candidates are smaller than we estimate or if any
regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our current product candidates or any future product candidates do not achieve broad market acceptance, the
revenue that we generate from their sales may be limited, and we may never become profitable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT>
and Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">IK-175</FONT> and expect to rely on third parties to conduct clinical trials for our targeted oncology programs, as well as investigator-sponsored clinical trials of our product
candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates
and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have entered into collaborations and may enter into additional collaborations in the future, and we might not
realize the anticipated benefits of such collaborations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We contract with third parties for the manufacture of our product candidates for preclinical development and
clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost,
which could delay, prevent or impair our development or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and
product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully
commercialize our technology and drugs may be impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. We may miss a filing deadline for patent
protection on these inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our
intellectual property rights, which could be expensive, time-consuming, and unsuccessful. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we
will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may seek priority review designation for one or more of our other product candidates, but we might not receive
such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to retain key executives and experienced scientists and to attract,
retain and motivate qualified personnel. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in February 2016. We are the successor in interest to KYN Therapeutics L.L.C., a limited liability
company formed under the laws of the State of Texas in September&nbsp;2014. In December 2019, we changed our name from Kyn Therapeutics, Inc. to Ikena Oncology, Inc. Our principal corporate office is located at 50 Northern Avenue, 7th Floor, Boston,
MA 02210, and our telephone number is (857) <FONT STYLE="white-space:nowrap">273-8343.</FONT> Our website address is www.ikenaoncology.com. We do not incorporate the information on or accessible through our website into this prospectus, and you
should not consider any information on, or that can be accessed through, our website as part of this prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own various U.S. federal trademark
applications and unregistered trademarks, including our company name. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this
prospectus are referred to without the symbols <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, but such references should not be construed as any indicator that their
respective owners will not assert, to the fullest extent under applicable law, their rights thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended. As an emerging growth
company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to only disclose two years of audited financial statements in addition to any required unaudited
interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any
golden parachute arrangements not previously approved; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until the fifth anniversary of our initial public offering or such earlier time
that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion or more;
(ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years;
or (iv)&nbsp;the last day of the fiscal year in which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June&nbsp;30th. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this
prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. We are in the process of evaluating the benefits of relying on other exemptions and
reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation, providing an auditor&#146;s attestation report on our system
of internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding<BR> immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase additional shares in full).
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase<BR> additional shares </P></TD>
<TD>We have granted the underwriters an option, exercisable for 30 days after the date of this prospectus, to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares from us. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in full their option to purchase additional shares, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the development of our targeted oncology programs,
<FONT STYLE="white-space:nowrap">IK-930,</FONT> ERK5 and other targeted oncology preclinical programs; to advance development of <FONT STYLE="white-space:nowrap">IK-175,</FONT> <FONT STYLE="white-space:nowrap">IK-412,</FONT> <FONT
STYLE="white-space:nowrap">IK-007;</FONT> and to fund working capital and general corporate purposes. See &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol </P></TD>
<TD>IKNA </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 191,466,396 shares of our common stock
outstanding as of September&nbsp;30, 2020, which assumes the automatic conversion of 75,727,268 shares of preferred stock outstanding as of September&nbsp;30, 2020, 7,863,094 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT>
preferred stock issued on October&nbsp;1, 2020 and 85,806,214 shares of Series B preferred stock issued on December&nbsp;21, 2020 into an aggregate of 169,396,576 shares of common stock upon the completion of this offering, and includes 3,048,764
shares of common stock issued on October&nbsp;1, 2020, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19,046,758 shares of common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2020, at a weighted average exercise price of $0.48 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that will
become available for future issuance under our 2021<B> </B>Stock Option and Incentive Plan, or 2021 Plan, which will become effective in connection with the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that will
become available for future issuance under our 2021<B> </B>Employee Stock Purchase Plan, or ESPP, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 169,396,576
shares of our common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT> reverse split of our common stock, which will become effective prior to the completion
of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing of our fifth amended and restated certificate of incorporation and the adoption of our amended and
restated bylaws, which will occur immediately prior to the completion of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the following summary financial data together with our consolidated financial statements and the related notes appearing at the end of this
prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. We have derived the statement of operations
data for the years ended December&nbsp;31, 2018 and 2019 from our audited consolidated financial statements appearing elsewhere in this prospectus. The statement of operations data for the nine months ended September&nbsp;30, 2019 and 2020 and the
balance sheet data as of September&nbsp;30, 2020 have been derived from our unaudited financial statements appearing elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of
management, the unaudited data reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of
results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full year. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended</B><br><B>September&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="15" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share and&nbsp;per&nbsp;share&nbsp;data)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue under collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue (related party)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,193,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,945,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,938,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,013,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share of common stock attributable to common stockholders, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 16 and to our consolidated financial statements appearing elsewhere in this prospectus for details on
the calculation of basic and diluted net loss per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma basic and diluted net loss per share attributable to common stockholders have been prepared to give
effect to the automatic conversion of all shares of preferred stock outstanding into shares of common stock as if the conversion had occurred on the later of the beginning of the period presented or the date the preferred shares were issued.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth summary balance sheet data as of September&nbsp;30, 2020: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the acquisition of Amplify, which occurred on October&nbsp;1,
2020, which includes the issuance of 7,863,094 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock and 3,048,764 shares of common stock, the recognition of $10.7&nbsp;million of expense related to the <FONT
STYLE="white-space:nowrap">write-off</FONT> of acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets with no future alternative use, and the recognition of other assets acquired and liabilities assumed,
(ii)&nbsp;the issuance of 85,806,214 shares of our Series B preferred stock which occurred on December&nbsp;21, 2020 for net proceeds of $116.4&nbsp;million, and (iii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock
into an aggregate of 169,396,576 shares of common stock immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to further give effect to our issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;as<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 55,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash
equivalents, total assets, working capital and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as set forth on
the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total assets, working capital and total stockholders&#146; equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us. This information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in
this prospectus, including our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; before deciding whether to invest in our common stock.
The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all
or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a targeted oncology company with a limited operating history. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced operations in 2016 and are a targeted oncology company with a limited operating history. Biopharmaceutical product development is a highly
speculative undertaking and involves a substantial degree of risk. Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, acquiring intellectual property, business planning, raising capital,
conducting discovery, research and development activities, and providing general and administrative support for these operations. We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and
we do not expect to in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates, and there is no assurance that we will obtain approvals in the future. Our targeted oncology programs are still in
preclinical development. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have
an adverse effect on our stockholders&#146; deficit and working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses since our inception and anticipate
that we will continue to incur losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net losses were $40.9&nbsp;million and $16.8&nbsp;million for the years
ended December&nbsp;31, 2018 and 2019, respectively, and $11.7&nbsp;million and $18.2&nbsp;million for the nine months ended September&nbsp;30, 2019 and 2020, respectively. We had an accumulated deficit of $85.3&nbsp;million as of September&nbsp;30,
2020. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and development
expenses to increase significantly in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain regulatory approval for our product candidates, we will incur significant sales,
marketing and manufacturing expenses. Once we are a public company, we will incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the
foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become
profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of our future losses is uncertain and
our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating
results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of clinical trials for our product candidates or competing product candidates,
or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully open clinical trial sites and recruit and retain subjects for clinical trials, and
any delays caused by difficulties in such efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such
approvals we may receive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research and development activities relating to our product
candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates and products, should they receive regulatory approval, which may
vary depending on the quantity of production and the terms of our agreements with manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract, hire and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we will or may incur to develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our products should they receive regulatory approval, which may vary significantly;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved,
and existing and potential future therapeutics that compete with our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the changing and volatile U.S. and global economic environments, including as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result,
comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the
expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide
to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no products approved for commercial sale and have not generated any revenue from product sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to become profitable depends upon our ability to generate revenue. To date, we have generated minimal collaborative revenue from our product
candidates and have not generated revenue from product sales, and we do not expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant revenue unless and until we obtain regulatory approval
of, and begin to sell, one or more of our product candidates. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully complete our ongoing and planned preclinical studies for our targeted oncology and tumor
microenvironment programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely file and the acceptance of our investigational new drug applications, or IND, for <FONT
STYLE="white-space:nowrap">IK-930</FONT> and our other programs in order to commence our planned clinical trials or future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully enroll subjects in, and complete, our ongoing and planned clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and successfully complete all safety and efficacy studies required to obtain U.S. and foreign regulatory
approval for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical
supply and commercial manufacturing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain acceptance of the products, if and when approved, by patients, the medical community and
third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">position our products to effectively compete with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain healthcare coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enforce and defend intellectual property rights and claims; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement measures to help minimize the risk of <FONT STYLE="white-space:nowrap">COVID-19</FONT> to our employees
as well as patients and subjects enrolled in our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain a continued acceptable safety profile of our products following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully
commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we consummate this offering, we will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms
acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
development of pharmaceutical products is capital-intensive. We are currently advancing our targeted oncology programs through preclinical development. We plan to file an IND for <FONT STYLE="white-space:nowrap">IK-930</FONT> in the second half of
2021 and begin a Phase 1 clinical trial shortly thereafter. We also expect to begin <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for our extracellular signal-related kinase 5, or ERK5, RAS signaling program in the second half of
2021. We have three tumor microenvironment product candidates, of which <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-007</FONT> are in Phase 1 and Phase 1b clinical development, respectively. Additionally,
we expect to submit an IND for our third tumor microenvironment program, <FONT STYLE="white-space:nowrap">IK-412,</FONT> in the second half of 2021. Consequently, we expect our expenses to significantly increase in connection with our ongoing
activities, particularly as we continue the research and development of, initiate and complete clinical trials of, and seek regulatory approval for, our product candidates. In addition, depending on the status of regulatory approval or, if we obtain
regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we choose to
pursue additional indications and/or geographies for our current or future product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, upon the closing of this offering, we expect to incur additional costs
associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced
to delay, reduce or eliminate certain of our research and development programs or future commercialization efforts </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the net proceeds from
this offering, together with our existing cash and cash equivalents will be sufficient to fund our operations through at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, our future
capital requirements will depend on and could increase significantly as a result of many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of product discovery, preclinical and clinical development, laboratory
testing and clinical trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential additional expenses attributable to adjusting our development plans (including any supply related
matters) to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, prioritization and number of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain additional collaborations on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones or occurrence of other developments that trigger payments under our existing
collaboration agreements or any additional collaboration agreements we may establish; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under
future collaboration agreements, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of securing manufacturing arrangements for clinical and commercial production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to the development of any companion diagnostics we may use in the future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals
to market our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical development testing and clinical
trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates,
if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on
additional financing to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. Disruptions in the financial markets in general and more
recently due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that
future financing will be available in sufficient amounts or on terms acceptable to us, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis or
on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product that has received regulatory approval or be unable to expand our
operations or otherwise capitalize on our business opportunities as desired, which could materially affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or
require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product
revenue, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. The
terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to
decline. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of those securities may include liquidation
or other preferences that may materially adversely affect your rights as a common stockholder. Debt financing, if available, would increase our fixed payment obligations and may involve </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, acquiring, selling or licensing intellectual property rights,
and making capital expenditures, declaring dividends or other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to meet certain milestones in connection with debt financing and the
failure to achieve such milestones by certain dates may force us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us which could have a material adverse effect on our business,
operating results and prospects </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also could be required to seek funds through arrangements with additional collaborators or otherwise at an earlier
stage than otherwise would be desirable. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue
streams, research programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves, any of which may
have a material adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development of our Targeted Oncology and Other
Programs and Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or a similar pandemic, epidemic, or outbreak of
an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public health crises such as pandemics or similar outbreaks could adversely impact our business. Recently, a novel strain of a virus named <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes <FONT STYLE="white-space:nowrap">COVID-19</FONT> has spread to most countries across
the world, including all 50 states within the U.S., including Boston, Massachusetts, where our primary office and laboratory space is located. The coronavirus pandemic is evolving, and has led to the implementation of various responses, including
government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which the coronavirus impacts our operations or those of our third party partners, including our preclinical studies or clinical trial
operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions
to contain the coronavirus or treat its impact, among others. The continued spread <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;globally</FONT> could adversely impact our preclinical or clinical trial operations in the U.S., including our
ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure <FONT STYLE="white-space:nowrap">to&nbsp;COVID-19&nbsp;if</FONT> an outbreak occurs in their
geography.&nbsp;For example, similar to other biopharmaceutical companies, we may experience delays in initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, protocol deviations, enrolling our clinical trials, or dosing of patients
in our clinical trials as well as in activating new trial sites. <FONT STYLE="white-space:nowrap">COVID-19</FONT> may also affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. In
addition, as a result of medical complications associated with microsatellite stable colorectal cancer, or MSS CRC,, the patient populations that our most advanced and other product candidates target may be particularly susceptible to <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> which may make it more difficult for us to identify patients able to enroll in our current and future clinical trials and may impact the ability of enrolled patients to complete any such trials. Any
negative <FONT STYLE="white-space:nowrap">impact&nbsp;COVID-19&nbsp;has</FONT> to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our
ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, timely enrollment in planned clinical trials is dependent upon clinical trial sites which
could be adversely affected by global health matters, such as pandemics. We plan to conduct clinical trials for our product candidates in geographies which are currently being affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic. Some factors from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic that will delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic
concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on travel that could interrupt key trial and business activities, such as clinical trial site
initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients,
employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> meetings and other interactions with
potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential negative affect on the operations of our third-party manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples,
investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on
employees working from home, disruptions to or delays in ongoing laboratory experiments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely
impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and
approval timelines. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees,
including temporarily requiring certain of our employees to work remotely, suspending all <FONT STYLE="white-space:nowrap">non-essential</FONT> travel worldwide for our employees and discouraging employee attendance at industry events and <FONT
STYLE="white-space:nowrap">in-person</FONT> work-related meetings, which could negatively affect our business. We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government
agencies, such as the Securities and Exchange Commission, or the SEC, or FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other factors arising from
<FONT STYLE="white-space:nowrap">COVID-19</FONT> could worsen in countries that are already afflicted with <FONT STYLE="white-space:nowrap">COVID-19</FONT> or could continue to spread to additional countries. Any of these factors, and other factors
related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operation and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the
economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never successfully completed any clinical trials for our oncology programs, and we may be
unable to do so for any product candidates we develop. Certain of our oncology programs are still in preclinical development and may never advance to clinical development. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet demonstrated our ability to successfully complete clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals,
manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Our targeted oncology programs are still in preclinical development
and may never advance to clinical development.<B> </B>We plan to file an IND for our <FONT STYLE="white-space:nowrap">IK-930</FONT> program in the second half of 2021 and expect to begin a Phase 1 clinical trial shortly thereafter. We expect to
begin <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for our ERK5 RAS signaling program in the second half of 2021. Additionally, we expect to submit an IND for our third tumor microenvironment program,
<FONT STYLE="white-space:nowrap">IK-412,</FONT> in the second half of 2021. We may not be able to file such IND or INDs for any of our other product candidates on the timelines we expect, if at all. Moreover, we cannot be sure that submission of an
IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design
based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their position, including on the acceptability
of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or result in the composition of stricter approval conditions than we currently expect. Successful completion of our clinical trials
is a prerequisite to submitting a new drug application, or NDA, or a biologics license application, or BLA, to the FDA, a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, or other marketing applications to
regulatory authorities in other jurisdictions, for each product candidate and, consequently, the regulatory approval of each product candidate. We currently only have two product candidates from our tumor microenvironment program in clinical
development. We are conducting a Phase 1 trial with <FONT STYLE="white-space:nowrap">IK-175</FONT> in patients with bladder cancer with activated aryl hydrocarbon receptor, or AHR, and a Phase 1b trial with
<FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab for the treatment of patients with advanced or progressive microsatellite stable colorectal cancer, or MSS CRC. However, we do not know whether these or any of our
future clinical trials will begin on time or be completed on schedule, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional preclinical studies or
clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are
not positive or are only modestly positive or if there are safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining regulatory approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not obtain regulatory approval at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to be subject to post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience having the product removed from the market after obtaining regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a
rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discovery and development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers is an emerging field, and the
scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both
preliminary and limited. Although we believe, based on our preclinical work, that the genetic alterations targeted by our programs drive the formation and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
spread of cancer, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for our product candidates are
limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations.
Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations. Furthermore, even if we are
successful in identifying patients with specific target alterations, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type and
commercialize our product candidates and achieve profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical product development involves a lengthy and expensive process, with an
uncertain outcome. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our preclinical studies and future and ongoing clinical trials may not be successful. Currently, all our targeted oncology
programs are in preclinical development. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory
authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult
to design and implement, can take many years to complete and outcomes are uncertain. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be
predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many
companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. Our preclinical studies and future and
ongoing clinical trials may not be successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to successfully validate, develop and obtain regulatory approval for companion
diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or otherwise obtain
access to<I>&nbsp;in vitro</I>&nbsp;companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Such companion diagnostics would be used during our
clinical trials as well as in connection with the commercialization of our products that receive regulatory approval. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical
challenges. The FDA and comparable foreign regulatory authorities regulate<I>&nbsp;in vitro</I>&nbsp;companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the
safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may
require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to
resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and
early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future
collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic product candidates themselves, including
issues with achieving regulatory clearance or approval, production of sufficient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic
product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain regulatory approval, and we may not realize the full
commercial potential of any of these therapeutic products that obtain regulatory approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract
may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise
terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on
commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> and preliminary data from our clinical trials that we announce or publish from time to time
may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data from our clinical trials, which is
based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions
as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results that we report may
differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim data from clinical trials are subject to the risk that one or
more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim or <FONT STYLE="white-space:nowrap">top-line</FONT> data also remain subject to audit and verification
procedures that may result in the final data being materially different from the preliminary <FONT STYLE="white-space:nowrap">top-line</FONT> data we previously published. As a result, preliminary, interim and
<FONT STYLE="white-space:nowrap">top-line</FONT> data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects and may
cause the price of our common stock to fluctuate or decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, regulatory agencies and others, may not accept or agree with our assumptions,
estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could adversely impact the potential of the particular program, the likelihood of obtaining regulatory approval of the particular
product candidate, commercialization of any approved product and the business prospects of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is derived from information
that is typically extensive, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the preliminary, interim or <FONT STYLE="white-space:nowrap">top-line</FONT> data that we report differ from actual results, or if regulatory authorities
or others, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be significantly impaired, which could materially harm our business, operating results, prospects or financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and
commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience delays in initiating or completing our preclinical studies or clinical trials,
including as a result of delays in obtaining, or failure to obtain, the FDA&#146;s clearance to initiate clinical trials under future INDs. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates
will not require redesign, will enroll an adequate number of subjects on time, or will be completed on schedule, if at all. We may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical trials
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may receive feedback from regulatory authorities that require us to modify the design or implementation of our
preclinical studies or clinical trials or to delay or terminate a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or institutional review boards, or IRBs, or ethics committees may delay or may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial
sites and prospective clinical research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical studies or clinical trials of our product candidates may fail to show safety or efficacy or otherwise
produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may decide to abandon product research or development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical studies or clinical trials of our product candidates may not produce differentiated or clinically
significant results across tumor types or indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality
controls, be unable to provide us with sufficient product supply to conduct or complete preclinical studies or clinical trials, fail to meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial
protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or
terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may be delayed due to complications associated with the evolving <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our
product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our
investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as
we anticipate </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions at which
such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors,
including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, adverse findings upon an inspection of the clinical trial operations or trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
site by the FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval
of our product candidates. Further, the FDA may disagree with our clinical trial design or our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our
clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our current and future clinical trials may serve as scientific advisors or consultants to us from
time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign
regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the interpretation of the study. The FDA or comparable foreign regulatory authority may
therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by
the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical
trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical study or clinical trial delays, including those caused by the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would
impair our ability to successfully commercialize our product candidates and may significantly harm our business, operating results, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed
or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a
sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities, or as needed to provide appropriate statistical power for a given trial. In particular, because we are focused
on patients with specific genetic mutations for the development of our targeted oncology programs, and on patients with specific biomarkers for the development of our tumor microenvironment programs, our ability to enroll eligible patients may be
limited or may result in slower enrollment than we anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience difficulties with identifying specific patient populations for any
biomarker-defined trial cohorts. The patient eligibility criteria defined in our trial protocols, including biomarker-driven identification may limit the patient populations eligible for our clinical trials to a greater extent than competing
clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria. We will also rely on the willingness and ability of clinicians to screen their patients for biomarkers to indicate which patients may be eligible
for enrollment in our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same
indications as do our product candidates, and patients who would otherwise be eligible for our clinical trials may choose instead to enroll in clinical trials of our competitors&#146; product candidates. Furthermore, our ability to enroll patients
may be significantly delayed by the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and we cannot accurately predict the extent and scope of such delays at this point. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the competitive trial environment, the eligibility criteria of our planned clinical trials will further limit the pool of available study
participants as we will require that patients have specific characteristics that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able
to identify, recruit or enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical
trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients,
conducting studies and obtaining regulatory approval of potential products may be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also engage third parties to develop companion
diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, limiting our ability to identify patients with the targeted genetic mutations for our clinical trials. Further, if we
are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in the FDA&#146;s expedited review and development programs, including
Breakthrough Therapy Designation and Fast Track Designation, or otherwise seek to accelerate clinical development and regulatory timelines. Patient enrollment may be affected by other factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts to obtain and maintain patient consents and facilitate timely enrollment in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial
completion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reporting of the preliminary results of any of our clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">factors we may not be able to control, including the impacts of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, that may limit patients, principal investigators or staff or clinical site availability. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We anticipate that certain of our current product candidates and future product candidates will be used in combination with third-party drugs or
biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our current product candidates and any future product candidates have the potential to be administered in combination with checkpoint inhibitor
immunotherapies or other standards of care like chemotherapies, targeted therapies or radiotherapy. For example, we plan to explore combinations of <FONT STYLE="white-space:nowrap">IK-930</FONT> in combination with epidermal growth factor receptor,
or EGFR, inhibitors in certain indications and to evaluate <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412</FONT> in combination with nivolumab, which is marketed by Bristol-Myers Squibb Company, or BMS. We
are also currently conducting a Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab, which is marketed by Merck. Our ability to develop and ultimately commercialize our current programs and
product candidates and any future programs or product candidates used in combination with EGFR inhibitors, nivolumab, pembrolizumab, or other checkpoint inhibitor immunotherapies will depend on our ability to access such drugs or biologics on
commercially reasonable terms for the clinical trials and their availability for use with our commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of
such drugs or biologics on commercially reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any failure to maintain or enter into new successful commercial relationships, or the
expense of purchasing checkpoint inhibitor immunotherapies or other comparator therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future
product candidates as commercially viable therapies. If any of these occur, our business, financial condition, operating results, stock price and prospects may be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the development of product candidates for use in combination with another product or product
candidate may present challenges that are not faced for single agent product candidates. The FDA or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each
product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the combination therapy and not our current product candidates and any
future product candidates. Moreover, following product approval, the FDA or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have
rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects
should we receive regulatory approval. Such developments may include changes to the other product&#146;s safety or efficacy profile, changes to the availability of the other product, quality, manufacturing and supply issues with respect to the other
product, and changes to the standard of care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that BMS, Merck or any future collaborator or supplier cannot continue to supply their
products on commercially reasonable terms, we would need to identify alternatives for accessing checkpoint inhibitor immunotherapies. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted,
delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative supply, or are unable to do so on commercially reasonable terms, our business, financial condition, operating results,
stock price and prospects may be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results from early preclinical studies and clinical trials of our programs and product
candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier preclinical studies and clinical trials of our
programs and product candidates in our later preclinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any results from our early preclinical studies and clinical trials of our targeted oncology and tumor microenvironment programs or our product candidates may
not necessarily be predictive of the results from later preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies and clinical trials of our product candidates according to our current
development timeline, the results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive
results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or
safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and
many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to file INDs for our targeted oncology and other programs to commence clinical trials on the timelines we expect, and even if we are
able to, the FDA may not permit us to proceed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our targeted oncology program, we expect to file an IND for
<FONT STYLE="white-space:nowrap">IK-930</FONT> and <FONT STYLE="white-space:nowrap">IK-412</FONT> in the second half of 2021 and to initiate <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for our ERK5 program in the second half of
2022. However, we may not be able to file such INDs or INDs for future product candidates for our targeted oncology or other programs on the timelines we expect. For example, we may experience manufacturing delays or other delays with <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical
trials. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that it will not change its requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file
INDs on the timelines we expect or to obtain regulatory approvals for our planned clinical trials may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely basis, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical
studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before
obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target
indication. Clinical testing is expensive and can take many years to complete, and outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. Because our targeted oncology programs and our product candidates
are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through
clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. For example, we conducted a
second open-label single arm Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab in patients with advanced or metastatic post <FONT STYLE="white-space:nowrap">anti-PD-</FONT> 1/L1 treatment in <FONT
STYLE="white-space:nowrap">non-small-cell</FONT> lung carcinoma, or NSCLC, but based on the combined data generated in the interim period for efficacy and safety, we decided not to further explore this combination in NSCLC and terminated this
clinical trial in December 2020. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, if we do not meet the clinical endpoints with
statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented from, or delayed in, obtaining regulatory approval for such product candidates. In some instances, there
can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of
the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. While we have not yet initiated clinical trials for our targeted oncology programs and are in early stages
of clinical trials for <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-007,</FONT> our tumor microenvironment programs, it is likely, as is the case with many oncology therapies, that there may be side effects
associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities
could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the
trial or result in potential product liability claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, our product candidates could cause undesirable side effects in clinical trials related to
<FONT STYLE="white-space:nowrap">on-target</FONT> toxicity. If <FONT STYLE="white-space:nowrap">on-target</FONT> toxicity is observed, or if our product candidates have characteristics that are unexpected, we may need to abandon their development or
limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In addition, our product candidates could
cause undesirable side effects that we have not yet observed. Many compounds that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound.
Most product candidates that commence clinical trials are never approved as products, and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development or regulatory
approval of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may develop future product candidates, in combination with one or more cancer therapies. The uncertainty
resulting from the use of our product candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. As is the case with many treatments for cancer and rare diseases, it is
likely that there may be side effects associated with the use of our product candidates. If significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our
trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product
candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially
showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining regulatory approval,
undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, operating results, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, and utilize novel binding locations,
which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our product candidates modulate pathway for which there are currently no approved or effective therapies, which may result in uncertainty. We select
programs for cancer driver targets based on compelling biological rationale. We explore new programs based on extensive preclinical data analysis which sometimes cannot predict efficacy or safety in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our product candidates utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could
delay or prevent approval, or discovery of unknown or unanticipated adverse effects. We utilize structural biology in tight integration with our medicinal chemistry and biology capabilities to predict and design the compounds that will achieve the
most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. A disruption in any of these capabilities may have significant adverse effects in our ability to expand our pipeline of product candidates,
and we cannot predict whether we will continue to have access to these capabilities in the future to support our pipeline development. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the
necessary compounds or that these or other problems related to the development of product candidates will not arise in the future, which may cause significant delays or we raise problems we may not be able to resolve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively
studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#146; lack of experience with them. The novelty of the mechanism of action of any of our product candidates may lengthen the regulatory review process,
require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to
significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel
for research, development and manufacturing positions. If our inhibitors utilize a novel mechanism of action that has not been the subject of extensive study compared to more well-known product candidates, there is also an increased risk that we may
discover previously unknown or unanticipated adverse effects during our preclinical studies and clinical trials. Any such events could adversely impact our business prospects, operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA and comparable foreign regulatory
authorities may not accept data from such trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may in the future choose to conduct additional clinical trials outside the United States,
including in Europe, Australia or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for regulatory
approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are applicable to the United States population and United States medical practices, (ii)&nbsp;the trials
were performed by clinical investigators of recognized competence and (iii)&nbsp;the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA or, if the FDA considers such an
inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of
patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the
trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign
regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving
regulatory approval or clearance for commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Although we intend to explore other therapeutic
opportunities in addition to the programs and product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional product
candidates, our business could be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research programs to pursue the development of our existing and planned product candidates
for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in
identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential indications and/or product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, after further study, be shown to have harmful adverse effects or other
characteristics that indicate they are unlikely to be effective products; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources than we will possess to identify additional therapeutic
opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of
indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance
that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable product candidates through internal research programs, which could materially adversely affect our future growth and
prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to
commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory
authorities. Before we can commercialize any of our product candidates, we must obtain regulatory approval. Currently, all of our product candidates are in discovery, preclinical or clinical development, and we have not received approval to market
any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have limited
experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of
extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing regulatory approval also requires the
submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to
have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing
process or facilities or that of third-party contract manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a comparable
foreign regulatory authority requires that we perform additional preclinical studies or clinical trials, approval may be delayed, if obtained at all. The length of such a delay varies substantially based upon a variety of factors, including the
type, complexity and novelty of the product candidate involved. Changes in regulatory approval policies during the development period, changes in or enactment of additional statutes or regulations, or changes in regulatory review policies for each
submitted NDA, BLA, premarket approval application, or PMA, or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable foreign regulatory authorities have substantial discretion in the
approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to
receive, regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to enroll a sufficient number of patients in our clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that
a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of an NDA, BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change such that our clinical data are insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we were to obtain regulatory approval, regulatory authorities
may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the
performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining, or if we fail to
obtain, approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face
substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. We compete in the segments of the
pharmaceutical, biotechnology, and other related markets that address structural biology-guided chemistry-based drug design to develop therapies in the fields of cancer and genetic diseases. There are other companies focusing on targeted oncology to
develop therapies in the fields of cancer and other diseases. We also compete more broadly across the market for cost-effective and reimbursable cancer treatments. Some of these competitive products and therapies are based on scientific approaches
that are the same as or similar to our approach, and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. We face competition with
respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and
biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates that we successfully develop and commercialize will
compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets. Key product features that would affect our ability to effectively
compete with other therapeutics include the efficacy, safety and convenience of our products. We believe principal competitive factors to our business include, among other things, our ability to identify biomarkers, ability to successfully
transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of
the companies that we compete against or which we may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory
approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or
early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and
management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. If these or other barriers to entry do not remain in
place, other companies may be able to more directly or effectively compete with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval
for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the
success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based
on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The incidence and prevalence for target patient populations of our programs and product candidates have not been established with precision. Our lead targeted
oncology product candidate, <FONT STYLE="white-space:nowrap">IK-930,</FONT> is an oral small molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is
genetically altered in approximately 10% of all cancers and these genetic alterations are generally associated with poor clinical outcomes. We are developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. KRAS
mutations in the RAS signaling pathway occur in approximately 26% of all cancers. Additionally, we are currently evaluating the safety and tolerability of <FONT STYLE="white-space:nowrap">IK-175</FONT> in a Phase 1 dose expansion clinical trial in
patients with solid tumors and intend to pursue development in patients with bladder cancer with activated AHR. AHR amplifications have been described in approximately 5% to 22% of bladder cancer patients. We are also developing <FONT
STYLE="white-space:nowrap">IK-007</FONT> in a Phase 1b clinical trial in patients with MSS CRC. Patients with MSS CRC represent approximately 80% of all colorectal cancer patients, and these patients generally do not respond to approved checkpoint
inhibitors. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our programs and product candidates, are based on our
estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total addressable market opportunity will ultimately depend upon, among other things, the diagnosis criteria included in the final label,
the indications for which our product candidates are approved for sale, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with the cancers and solid tumors for which our product
candidates may be approved as treatment may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which
would adversely affect our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain
product candidates, which may prove to be the wrong choice and may adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our current product candidates or any future
product candidates do not achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never commercialized a product candidate for any indication. Even if our current product candidates and any future product candidates are approved by
the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval do not
gain an adequate level of market acceptance, we may not generate significant revenue and may not become profitable or may be significantly delayed in achieving profitability. Market acceptance of our current product candidates and any future product
candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to
switch, from existing therapies even when new and potentially more effective or safer treatments enter the market. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our or our
competitors&#146; products, our products may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accepted by the general public or the medical community. Future adverse events in targeted oncology, immuno-oncology or the biopharmaceutical industry could also result in greater governmental
regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to educate the
medical community and third-party payors on the benefits of our current product candidates and any future product candidates may require significant resources and may not be successful. If our current product candidates or any future product
candidates are approved but do not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any of our current product candidates and any
future product candidates will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy of our current product candidates and any future product candidates as single agents and in
combination with marketed checkpoint inhibitor immunotherapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercial success of the checkpoint blockade drugs with which our products may be <FONT
STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of adverse events associated with our current product candidates and any future
product candidates or those products with which they may be <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which our product candidates are approved and the approved claims that we may make
for the products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the product&#146;s <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
labeling or those of comparable foreign regulatory authorities, including potential limitations or warnings for our current product candidates and any future product candidates that may be more restrictive than other competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care for the targeted indications for our current product candidates and any future
product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative convenience and ease of administration of our current product candidates and any future product
candidates and any products with which they are <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of adequate coverage or reimbursement by third party payors, including government healthcare
programs such as Medicare and Medicaid and other healthcare payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price concessions required by third-party payors to obtain coverage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of adequate coverage and reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and strength of our marketing and distribution of our current product candidates and any future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already
used or that may later be approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to
our current product candidates and any future product candidates or to which we agree as part of a risk evaluation and mitigation strategy, or REMS, or voluntary risk management plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our current product candidates and any future product candidates, as well as
competitive products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our current product candidates and any future product candidates for sale at competitive
prices; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and strength of our third-party manufacturer and supplier support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the actions of companies that market any products with which our current product candidates and any future
product candidates may be <FONT STYLE="white-space:nowrap">co-administered;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of other new products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity about our current product candidates and any future product candidates or any products with
which they are <FONT STYLE="white-space:nowrap">co-administered,</FONT> or favorable publicity about competitive products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
rely on third parties to conduct our Phase 1 clinical trial of IK-175 and Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT> and expect to rely on third parties to conduct clinical trials for our targeted oncology and other
tumor microenvironment programs, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected
deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have the ability to independently conduct clinical trials. We rely and expect to continue to rely on medical institutions, clinical investigators,
contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates, including our Phase 1 clinical trial of IK-175 and Phase 1b clinical trial of
<FONT STYLE="white-space:nowrap">IK-007,</FONT> as well as <FONT STYLE="white-space:nowrap">IK-930</FONT> and any other product candidates that emerge from our targeted oncology and tumor microenvironment programs. We may also rely on academic and
private <FONT STYLE="white-space:nowrap">non-academic</FONT> institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator-sponsored trials, and it is possible
that the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any
one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such arrangements will likely
provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials.
However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the
investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their
obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by
us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely and expect to continue to rely heavily
on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the
applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials,
we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, our principal investigators and our CROs are required to comply with regulations, including Good
Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the
potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities
for any products in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our principal investigators or our CROs fail to comply with
applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications.
We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced under current Good Manufacturing
Practice, or cGMP, regulations. Our failure or the failure of our principal investigators or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process, significantly increase
our expenditures and could also subject us to enforcement action. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain
timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we designed our Phase 1 clinical trial of
IK-175 and Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT> and intend to design the future clinical trials for our product candidates, these trials are conducted by CROs and we expect CROs will conduct all of our future
clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct
control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as
difficulties in coordinating activities. Outside parties may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have staffing difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to comply with contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience regulatory compliance issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undergo changes in priorities or become financially distressed; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form relationships with other entities, some of which may be our competitors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost
increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory
approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development program may be materially and irreversibly harmed. If we are unable
to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and
require significantly greater expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third-party principal investigators or CROs terminate, we may not be
able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the
clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for, or successfully commercialize, our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication
would be harmed, our costs could increase and our ability to generate revenue could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have entered into collaborations and may enter
into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research, development,
commercialization and/or strategic collaborations, including the existing collaboration that we have with Celgene Corporation (now part of BMS), are subject to numerous risks, which include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may have significant control or discretion in determining the efforts and resources that they will
apply to a collaboration, and might not commit sufficient efforts and resources or might misapply those efforts and resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have limited influence or control over the approaches to research, development and/or commercialization of
product candidates in the territories in which our collaboration partners lead research, development and/or commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might not pursue research, development and/or commercialization of collaboration product candidates
or might elect not to continue or renew research, development and/or commercialization programs based on nonclinical and/or clinical trial results, changes in their strategic focus, availability of funding or other factors, such as a business
combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might delay, provide insufficient resources to, or modify or stop research or clinical development
for collaboration product candidates or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with sales, marketing and distribution rights to one or more product candidates might not commit
sufficient resources to sales, marketing and distribution or might otherwise fail to successfully commercialize those product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might not properly maintain or defend our intellectual property rights or might use our
intellectual property improperly or in a way that jeopardizes our intellectual property or exposes us to potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaboration activities might result in the collaborator having intellectual property covering our activities or
product candidates, which could limit our rights or ability to research, develop and/or commercialize our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators might not be in compliance with laws applicable to their activities under the collaboration, which
could impact the collaboration and us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes might arise between a collaborator and us that could cause a delay or termination of the collaboration
or result in costly litigation that diverts management attention and resources; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations might be terminated, which could result in a need for additional capital to pursue further
research, development and/or commercialization of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, funding provided by a collaborator might not be
sufficient to advance product candidates under the collaboration. For example, although BMS provided us with an $80.5&nbsp;million upfront payment and a $14.5&nbsp;million equity investment upon entering into that certain master collaboration
agreement with Celgene Corporation (now BMS), we might need additional funding to advance product candidates prior to the completion of a Phase 1b clinical trial for each of <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT
STYLE="white-space:nowrap">IK-412,</FONT> which are the clinical milestones when BMS must decide whether to exercise its exclusive license rights to those product candidates. On November&nbsp;20, 2019, BMS acquired Celgene Corporation and BMS may
take a different approach to our collaboration or determine not to continue the collaboration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a collaborator terminates a collaboration or a program under a collaboration, including by failing to
exercise a license or other option under the collaboration, whether because we fail to meet a milestone or otherwise, any potential revenue from the collaboration would be significantly reduced or eliminated. In addition, we will likely need to
either secure other funding to advance research, development and/or commercialization of the relevant product candidate or abandon that program, the development of the relevant product candidate could be significantly delayed, and our cash
expenditures could increase significantly if we are to continue research, development and/or commercialization of the relevant product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
one or more of these risks, if realized, could reduce or eliminate future revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations and/or growth
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of our product candidates for preclinical development and clinical testing, and
expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay,
prevent or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently own or operate, nor do we have any plans to establish in the
future, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our products
if any of our product candidates receive regulatory approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality,
which could delay, prevent or impair our development or commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The facilities used by our contract manufacturers to manufacture our
product candidates must be inspected by the FDA pursuant to <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process
of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our
specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the
ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the
manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory
approval for or market our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any contract manufacturing organization, or CMO, with whom we contract fails to perform
its obligations, we may be forced to enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials supply could be delayed significantly as we establish alternative
supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from,
transferring such skills to a <FONT STYLE="white-space:nowrap">back-up</FONT> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify
that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will
produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates
or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or
require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in
our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, our failure, or the failure of our third party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us,
including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect our business and supplies of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be unable to establish any additional
agreements with third-party manufacturers or do so on acceptable terms. Reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance and quality assurance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates and any products that we may develop may compete with other product candidates and approved
products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development or regulatory approval. If our current contract
manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any such replacement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit
margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The third parties upon
whom we rely for the supply of the active pharmaceutical ingredients used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The active pharmaceutical ingredients, or API, used in all of our product candidates are supplied to us from single-source suppliers. Our ability to
successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API for these products in accordance with regulatory
requirements and in sufficient quantities for clinical testing and commercialization. Moreover, for <FONT STYLE="white-space:nowrap">IK-412,</FONT> we depend on a single-source supplier of high grade polyethylene glycol, or PEG, a key component that
is added to the API and contributes to the properties of <FONT STYLE="white-space:nowrap">IK-412.</FONT> We do not currently have arrangements in place for a redundant or second-source supply of any such API in the event any of our current suppliers
of such API cease their operations for any reason. We are also unable to predict how changing global economic conditions or potential global health concerns such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic&nbsp;will affect our
third-party suppliers and manufacturers. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all of our product candidates, we intend to identify and qualify additional manufacturers to provide
such API prior to submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those
suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our
suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Establishing additional or replacement suppliers for the API used in our product candidates, if required, may not be accomplished quickly. If we are able to
find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the API used in our
product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts,
which could harm our business, results of operations, financial condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biologics is complex and our
third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of product candidates for clinical trials or products for patients, if
approved,&nbsp;could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing biologics, especially in large quantities, is often complex and may require the use of
innovative technologies to handle living cells. Each lot of an approved biologic must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated
for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and
testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency
of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the
contamination, which could delay clinical trials and adversely harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing
for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, compliance with good manufacturing
practices, lot consistency and timely availability of raw materials. Even if we obtain regulatory approval for any of our current product candidates or any future product candidates, there is no assurance that our manufacturers will be able to
manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to
meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would&nbsp;be impaired, which would have an adverse effect on
our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to establish additional collaborations, and, if we are
not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and
biotechnology companies for the development and potential commercialization of those product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking
appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s own evaluation of a potential collaboration. Such factors a potential collaborator will use
to evaluate a collaboration may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities
of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without
regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a
collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations
are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future
collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we
may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope
of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own,
we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product
revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend
heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration
arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These
disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other
party. Any such termination or expiration would adversely affect us financially and could harm our business reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our
Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product
candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize
our technology and drugs may be impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual
property protection in the U.S. and other countries for our current or future product candidates, including our current lead product candidates, <FONT STYLE="white-space:nowrap">IK-930,</FONT> <FONT STYLE="white-space:nowrap">IK-175,</FONT> <FONT
STYLE="white-space:nowrap">IK-412,</FONT> <FONT STYLE="white-space:nowrap">IK-007,</FONT> and our other future product candidates, such as against our Ras signaling target, ERK5, as well as for their respective compositions, formulations, methods
used to manufacture them, and methods of treatment, in addition to successfully defending these patents against third-party challenges. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent
applications in the U.S. and abroad related to our proprietary technology, inventions, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improvements that are important to the development and implementation of our business. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, or importing
our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and
continuing technological innovation to develop and maintain our proprietary and intellectual property position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and
pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent protection we require to successfully commercialize our current or
future product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our patents have, or that
any of our pending patent applications that mature into issued patents will include, claims with a scope sufficient to protect <FONT STYLE="white-space:nowrap">IK-930,</FONT> <FONT STYLE="white-space:nowrap">IK-175,</FONT> <FONT
STYLE="white-space:nowrap">IK-412,</FONT> <FONT STYLE="white-space:nowrap">IK-007</FONT> or our other current or future product candidates, including against our Ras signaling pathway, target ERK5. In addition, if the breadth or strength of
protection provided by our patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or
future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example,
in jurisdictions outside the U.S., a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. Accordingly, any actual or purported <FONT STYLE="white-space:nowrap">co-owner</FONT> of our
patent rights could seek monetary or equitable relief requiring us to pay it compensation for, or refrain from, exploiting these patents due to such <FONT STYLE="white-space:nowrap">co-ownership.</FONT> Furthermore, patents have a limited lifespan.
In the U.S., and most other jurisdictions in which we have undertaken patent filings, the natural expiration of a patent is generally twenty years after it is filed, assuming all maintenance fees are paid. Various extensions may be available, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis; however, the life of a patent, and thus the protection it affords, is limited. Given the amount of time required for the development,
testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, patents we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing drugs similar or identical to our current or future product candidates, including
generic versions of such drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed
or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same compounds, methods,
formulations or other subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in
the U.S. and other jurisdictions are typically not published until at least 18 months after the earliest priority date of patent filing, or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the
inventions claimed in patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope,
validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the patent prosecution process is
expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to certain pending patent applications covering our current
or future product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the relevant patent office(s) may be significantly narrowed by the
time they issue, if they ever do. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the
right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced
in a manner consistent with the best interests of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we acquire patent protection that we expect should enable us to establish and/or maintain a
competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship,
scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may become involved in post-grant proceedings such as opposition, derivation, reexamination, <I>inter partes</I> review,
post-grant review, or interference proceedings challenging our patent rights or the patent rights of others from whom we may in the future obtain licenses to such rights, in the U.S. Patent and Trademark Office (USPTO), the European Patent Office
(EPO), or in other countries. In addition, we may be subject to a third-party submission to the USPTO, the EPO, or elsewhere, that may reduce the scope or preclude the granting of claims from our pending patent applications. Competitors may allege
that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing their patents and that we therefore cannot practice
our technology as claimed under our patents or patent applications. Competitors may also contest our patents by claiming to an administrative patent authority or judge that the invention was not patent-eligible, was not original, was not novel, was
obvious, and/or lacked inventive step, and/or that the patent application filing failed to meet relevant requirements relating to description, basis, enablement, and/or support; in litigation, a competitor could claim that our patents, if issued,
are not valid or are unenforceable for a number of reasons. If a court or administrative patent authority agrees, we would lose our protection of those challenged patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent
applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary
<FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our
intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, without payment to us, or could limit the duration of the patent protection
covering our technology and current or future product candidates. Such challenges may also result in our inability to manufacture or commercialize our current or future product candidates without infringing third-party patent rights. In addition, if
the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if they are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent
competitors from designing around our patent claims to circumvent patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> by developing similar or alternative technologies or drugs in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For example, a third-party may develop a competitive drug that provides benefits similar to one or more of our current or future product candidates but that has a different composition
that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is not sufficiently broad to impede such
competition, our ability to successfully commercialize our current or future product candidates could be negatively affected, which would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, even if we are able to issue patents with claims of valuable scope in one or more jurisdictions, we may not be able to secure such claims in all
relevant jurisdictions, or in a sufficient number to meaningfully reduce competition. Our competitors may be able to develop and commercialize their products, including products identical to ours, in any jurisdiction in which we are unable to
obtain, maintain, or enforce such patent claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. We may miss a filing deadline for
patent protection on these inventions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The USPTO and foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition, periodic maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be
paid periodically. While an inadvertent lapse can, in some cases, be cured by payment of a late fee, or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to
official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with
similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our
trademarks and trade names for our products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the launch of product brand names, use different trademarks or tradenames in
different countries, or face other potentially adverse consequences to building our product brand recognition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may
be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these
trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from
the USPTO or from comparable agencies in foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in
the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may
be filed against our trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks
and trade names, we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to adequately protect and
enforce our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents we may own or <FONT
STYLE="white-space:nowrap">in-license,</FONT> we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that may not be patentable,
processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that may not be
covered by patents. Although we require all of our employees, consultants, advisors, and any third parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology to enter into confidentiality
agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances
and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to
obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the U.S. As
a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will
not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is
unpredictable. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to
protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain
access to our trade secrets or disclose our technology. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or
information to compete with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees,
consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential
information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific
circumstances. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. In the case of employees, the agreements
provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are
our exclusive property. Although we require all of our employees to assign their inventions to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our
own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine
the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be
expensive, time-consuming, and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe any patents we may own or
<FONT STYLE="white-space:nowrap">in-license.</FONT> In addition, any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> also may become involved in inventorship, priority, validity or unenforceability disputes. To counter
infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be
commercially meaningful. In addition, in an infringement proceeding, a court may decide that one or more of any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> is not valid or is unenforceable or that the other party&#146;s
use of our technology that may be patented falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271(e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other
party from using the technology at issue on the grounds that any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> do not cover the technology in question or that such third-party&#146;s activities do not infringe our patent
applications or any patents we may own or in-license. An adverse result in any litigation or defense proceedings could put one or more of any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> at risk of being invalidated, held
unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the
initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-grant proceedings provoked by third-parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to
our patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license.</FONT> These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights and could require us to cease
using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO
post-grant proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices or courts where our patents may be challenged. The costs of these proceedings could be substantial, and
may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result in a post-grant challenge proceeding may result in the loss of our right to exclude others from practicing one or more of our inventions in the
relevant country or jurisdiction, which could have a material adverse effect on our business. Litigation or post-grant proceedings within patent offices may result in a decision adverse to our interests and, even if we are successful, may result in
substantial costs and distract our management and other employees. We may not be able to prevent, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in
the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be
able to detect infringement against any patents we may own or <FONT STYLE="white-space:nowrap">in-license.</FONT> Even if we detect infringement by a third-party of any patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> we may
choose not to pursue litigation against or settlement with the third-party. If we later sue such third-party for patent infringement, the third-party may have certain legal defenses available to it, which otherwise would not be available except for
the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> against such
third-party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us
to spend substantial resources and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other
legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of
the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation
or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other
resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our
clinical trials, continue our research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our current or future product candidates, if approved. Any of
the foregoing events would harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to damages or settlement
costs resulting from claims that we or our employees have violated the intellectual property rights of third parties, or are in breach of our agreements. We may be accused of, allege or otherwise become party to lawsuits or disputes alleging
wrongful disclosure of third-party confidential information by us or by another party, including current or former employees, contractors or consultants. In addition to diverting attention and resources to such disputes, such disputes could
adversely impact our business reputation and/or protection of our proprietary technology. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intellectual property landscape relevant to our
product candidates and programs is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and
could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without
infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical
industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination, <I>inter partes</I> review and post grant review proceedings before the USPTO or oppositions and other comparable
proceedings in foreign jurisdictions. We or any of our current or future licensors or strategic partners may be party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other
intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our current or future
product candidates and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by
third parties. For example, many of our employees were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT
STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such
individual&#146;s former employer. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants and advisors, even those related to one or more of our current or future product
candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While certain
activities related to development and clinical testing of our current or future product candidates may be subject to safe harbor of patent infringement under 35 U.S.C. &#167;271(e)(1), upon receiving FDA approval for such candidates we or any of our
future licensors or strategic partners may immediately become party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that such product
candidates infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing
our current or future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our current or future product candidates may give rise to claims of infringement of the patent
rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent
applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual property
rights, we may face a number of issues, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be
expensive and time-consuming to litigate and may divert our management&#146;s attention from our core business and may impact our reputation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court
decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#146;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent
owner&#146;s attorneys&#146; fees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a court prohibiting us from developing, manufacturing, marketing or selling our current product candidates,
including <FONT STYLE="white-space:nowrap">IK-930,</FONT> <FONT STYLE="white-space:nowrap">IK-007,</FONT> <FONT STYLE="white-space:nowrap">IK-175,</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> or future product candidates, such as
against our Ras signaling target, ERK5, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other
amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which would permit third parties to use the same intellectual property to
compete with us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesigning our current or future product candidates or processes so they do not infringe, misappropriate or
violate third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there could be public announcements of the results of hearings, motions or other interim proceedings or
developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Some of our competitors may be able to sustain the costs of complex patent
litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise
the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect
on our business, financial condition, results of operations or prospects. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may choose to challenge the patentability of claims in a
third-party&#146;s U.S. patent by requesting that the USPTO review the patent claims in an <FONT STYLE="white-space:nowrap">ex-parte</FONT> <FONT STYLE="white-space:nowrap">re-exam,</FONT> <I>inter partes</I> review or post-grant review proceedings.
These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#146;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition
proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be
infringed by our current or future product candidates or proprietary technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary
technology without authorization. Patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted in U.S. courts only with evidence that is &#147;clear and convincing,&#148; a heightened standard of proof. There may be issued
third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current or future product candidates. Patent applications can
take many years to issue. In addition, because some patent applications in the U.S. may be maintained in secrecy until the patents are issued, patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months
after their earliest priority filing date, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our current or future product candidates or
technology. If any such patent applications issue as patents, and if such patents have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
priority over our patent applications or patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> we may be required to obtain rights to such patents owned by third parties which
may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis. There may be currently pending third-party patent applications which may later result in issued patents that our current or future
product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our current or future product candidates or other technologies, could be found to be
infringed by our current or future product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant
patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our current or
future product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a
license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our
formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we
obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary
license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our current or future product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a
license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties making claims against us may seek
and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our current or future product candidates. Defense of these claims, regardless of their merit, could involve substantial
litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including
treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We
cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to
advance our research or allow commercialization of our current or future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and
commercialize our current or future product candidates, which could harm our business significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to obtain patent or other
intellectual property protection for our current or future product candidates or our future products, if any, in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the
jurisdictions where we seek protection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to pursue patent coverage of our current or future product candidates in all countries.
Filing, prosecuting and defending patents on current or future product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the U.S. can be less extensive than
those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our
inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our current or
future product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates and in jurisdictions where we do not have any issued patents our patent applications or other intellectual property rights may not be effective or sufficient to prevent them from
competing. Much of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult
for us to stop the infringement of any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce any rights we may have in our
patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any
patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a
patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies,
which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we may own or license that are relevant to our business, our competitive position may be impaired, and our
business, financial condition, results of operations, and prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not obtain or grant licenses or sublicenses
to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It may be necessary for us to use
the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area,
and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size,
capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire
third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our
business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected current or future product candidates, which could materially harm our business, and the third parties
owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Even if we are able to obtain a license, it may
be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third
parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time be party to license and collaboration agreements with third parties to advance our research or allow commercialization of current or
future product candidates. Such agreements may impose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us
and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might conclude that we
have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any termination of these licenses, or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and
could harm our ability to commercialize our current or future product candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease
our development and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate
intellectual property rights of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our current or future product candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of any patented technology; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our future licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we
may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that
may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a
material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future licensing arrangements on
acceptable terms, we may be unable to successfully develop and commercialize the affected current or future product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any granted patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> covering our current or future product candidates or other
valuable technology could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad, including the USPTO and the EPO. A patent asserted in a judicial court could be found invalid or
unenforceable during the enforcement proceeding. Administrative or judicial proceedings challenging the validity of our patents or individual patent claims could take months or years to resolve. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our licensors or strategic partners initiate legal proceedings against a third-party to enforce a patent covering one of our current or future product
candidates, the defendant could counterclaim that the patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are
commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of
patentable subject matter, lack of written description, lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld relevant information from the USPTO, or made a misleading statement, in the process of obtaining the patent during patent prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or
abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter partes</I> review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition
proceedings). Such proceedings could result in revocation or amendment to our patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in such a way that they no longer cover our current or future product
candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any
rights we may have from our patent applications or any patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> allow third parties to commercialize our current or future product candidates or other technologies and compete directly
with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine
priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our future licensors&#146; priority of invention or other features of patentability with respect to our patent
applications and any patents we may own or <FONT STYLE="white-space:nowrap">in-license.</FONT> Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our current or future product candidates and other technologies. With respect to the
validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our future licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion
of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent
protection could have a material adverse impact on our business and our ability to commercialize or license our technology and current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is
favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other
priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and maintain such licenses, we may need to
cease the development, manufacture, and commercialization of one or more of the current or future product candidates we may develop. The loss of exclusivity or the narrowing of our patent application claims could limit our ability to stop others
from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent reform legislation in the U.S. and other countries, including the
Leahy-Smith America Invents Act, or Leahy-Smith Act, signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions
that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#147;first inventor to file&#148; system. The <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> provisions, however, only became effective on March&nbsp;16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have
on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the U.S. and other countries that, if adopted, could impact our ability to obtain patent
protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies
in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might
subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot
guarantee that any of our or our licensors&#146; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we
have identified each and every third-party patent and pending patent application in the U.S. and abroad that is relevant to or necessary for the commercialization of our current or future product candidates in any jurisdiction. For example, U.S.
patent applications filed before November&nbsp;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. As mentioned above, patent applications in the U.S.
and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our current or
future product candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our current
or future product candidates or the use of our current or future product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution history. Our
interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our current or future product candidates. We may incorrectly determine that our current or future
product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or
abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our current or future product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our
ability to develop and market our current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to identify and correctly interpret relevant patents, we may be
subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we
may be temporarily or permanently prohibited from commercializing any of our current or future product candidates that are held to be infringing. We might, if possible, also be forced to redesign current or future product candidates so that we no
longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our
business and could adversely affect our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not guarantee commercial success of current or future product
candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights, whether owned or <FONT STYLE="white-space:nowrap">in-licensed,</FONT> is
uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover,
if a third-party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications that we own or may <FONT STYLE="white-space:nowrap">in-license</FONT> may not lead to issued
patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents, should they issue, that we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> may not
provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to develop and/or practice technology, including compounds that are similar to the chemical
compositions of our current or future product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or <FONT STYLE="white-space:nowrap">in-license,</FONT> should
any patents issue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a
patent application that we own or may <FONT STYLE="white-space:nowrap">in-license;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future licensors or collaborators, might not have been the first to file patent applications covering
a particular invention; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies without infringing, misappropriating or
otherwise violating our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the U.S. and other countries that provide a
safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products
for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may
preclude us from exercising exclusive rights, or any rights at all, over that intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third-party may subsequently file a patent covering such trade secrets or <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop or <FONT STYLE="white-space:nowrap">in-license</FONT> additional proprietary technologies that
are patentable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for
approval of product candidates with which we must comply prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and
could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable regulatory approvals, our target market will be reduced and our
ability to realize the full market potential of our product candidates will be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our product
candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on
the regulatory approval process in others. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the
product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies
or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In
many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject
to approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation,
and even if we do, such designation may not lead to a faster regulatory review or approval process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA determines that a product candidate
offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that
the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant
priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result
in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the <FONT
STYLE="white-space:nowrap">six-month</FONT> review cycle or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek orphan drug designation for certain of our product candidates, and
we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our business strategy, we may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful. Regulatory authorities
in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is a product
intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no
reasonable expectation that the cost of developing the product will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, in Europe, the European Commission, upon
the recommendation of the EMA&#146;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically
debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a
life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, orphan
drug designation entitles a party to financial incentives such as reduction of fees or fee waivers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, if a product with an orphan drug
designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing
application for the same product and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if
a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for one of our product candidates, that exclusivity may not effectively protect our product candidate from
competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically
superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for
which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantity of the product to meet the needs of patients with the rare disease or condition or if another product with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care.
Orphan drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in the regulatory review or approval process. While we may seek orphan drug designation for our product
candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A breakthrough therapy designation and fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster
development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug or biologic that is intended,
alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over
existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and
communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough
therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for
designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process,
review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the
FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek fast track designation for some of our product candidates. If a drug or biologic is intended for
the treatment of a serious or life-threatening condition and the drug or biologic demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation. The FDA has broad discretion whether or
not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a
faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track
designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accelerated approval by the FDA, even if granted
for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive </I></B>regulatory<B><I> approval.
</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek accelerated approval of our current or future product candidates using the FDA&#146;s accelerated approval pathway. A product may be
eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably
likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval,
the FDA requires that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently
requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated
approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory
pathway. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively
the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with <FONT
STYLE="white-space:nowrap">an&nbsp;FDA-licensed&nbsp;reference</FONT> biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first
licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During
<FONT STYLE="white-space:nowrap">this&nbsp;12-year&nbsp;period</FONT> of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#146;s own
preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#146;s product. The law is complex and is still being interpreted and implemented by the FDA. As a
result, its ultimate impact, implementation, and meaning are subject to uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that any of our product candidates approved as a biologic
product under a BLA should qualify for <FONT STYLE="white-space:nowrap">the&nbsp;12-year&nbsp;period</FONT> of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA
will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA
exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic
substitution <FONT STYLE="white-space:nowrap">for&nbsp;non-biologic&nbsp;products</FONT> is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If competitors are able to obtain regulatory approval for biosimilars referencing our products, our products
may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA, the EMA and other
regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA, the EMA and regulatory authorities in other countries have each expressed interest in further regulating biotechnology products. Agencies at both the
federal and state level in the United States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent
commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates.
These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in
regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to
consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review
and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could
negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these
agencies&#146; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from
performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of
the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy
changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the
political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new
product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies,
such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and
process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize
and continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA
announced its intention to postpone most inspections of foreign manufacturing facilities and products while local, national and international conditions warrant. On March&nbsp;18, 2020, the FDA announced its intention to temporarily postpone routine
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials which the FDA continues to update. As of June 23, 2020, the FDA noted
it was continuing to ensure timely reviews of applications for medical products during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign
inspections to ensure compliance of manufacturing facilities with FDA quality standards. On July&nbsp;16, 2020, the FDA noted that it was continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may
not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions, the FDA is unable to
complete such required inspections during the review period. As of July 2020, utilizing a rating system to assist in determining when and where it is safest to conduct such inspections based on data about the virus&#146; trajectory in a given state
and locality and the rules and guidelines that are put in place by state and local governments, FDA is either continuing to, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, conduct only
mission critical inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which generally include <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections. Foreign
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections that are not deemed mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. FDA will use similar data to inform resumption of prioritized operations abroad as it becomes feasible and advisable to do so. The FDA may not be able to maintain this pace and delays or
setbacks are possible in the future. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, FDA has stated that it generally intends to issue a
complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced
receipt of complete response letters due to the FDA&#146;s inability to complete required inspections for their applications. Additionally, regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response
to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely
review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by
delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative
reform measures may have a material adverse effect on our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. and many foreign jurisdictions have enacted
or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay regulatory approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell a product for which we obtain regulatory approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i)&nbsp;changes to our manufacturing arrangements, (ii)&nbsp;additions or modifications to product labeling, (iii)&nbsp;the recall or discontinuation of our products or (iv)&nbsp;additional record-keeping requirements. If any such changes were to
be imposed, they could adversely affect the operation of our business. In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable
Care Act, or the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological
products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or
injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on
manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of
2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part&nbsp;D. Since then, the ACA risk adjustment program
payment parameters have been updated annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the United States Congress and the current administration have expressed intent to pass
legislation or adopt executive orders to fundamentally change or repeal parts of the ACA. While Congress has not passed comprehensive repeal legislation to date, the Tax Cuts and Jobs Act of 2017, or TCJA, essentially repealed, effective
January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred
to as the &#147;individual mandate.&#148; In addition, various portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court. Litigation and legislation over the ACA are likely to continue, with
unpredictable and uncertain results. We will continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, on January&nbsp;20, 2017, an Executive Order was signed directing federal agencies with authorities and responsibilities under the ACA to waive,
defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or
manufacturers of pharmaceuticals or medical devices. On October&nbsp;13, 2017, an Executive Order was signed terminating the cost-sharing subsidies that reimburse insurers under the ACA. The current administration has concluded that cost-sharing
reduction, or CSR, payments to insurance companies required under the ACA have not received necessary appropriations from Congress and announced that it will discontinue these payments immediately until those appropriations are made. The loss of the
CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a
restraining order was denied by a federal judge in California on October&nbsp;25, 2017. The loss of the cost share reduction payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Further, on
June&nbsp;14, 2018, the United States Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay to third-party payors more than $12&nbsp;billion in ACA risk corridor payments that they argued were owed to
them. This decision was appealed to the United States Supreme Court, which on April&nbsp;27, 2020, reversed the United States Court of Appeals for the Federal Circuit&#146;s decision and remanded the case to the U.S. Court of Federal Claims,
concluding the government has an obligation to pay these risk corridor payments under the relevant formula. The U.S. federal government has since started sending third-party payors owed payments. It is not clear what effect this result will have on
our business, but we will continue to monitor any developments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, on January&nbsp;22, 2018, a continuing resolution on appropriations for fiscal
year 2018 was approved that delayed the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including the so called &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee
imposed on certain health insurance providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices; however on December&nbsp;20, 2019, the Further Consolidated Appropriations
Act (H.R. 1865) was signed into law, which repeals the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future. The Bipartisan Budget Act
of 2018, also amended the ACA, effective January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in
Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and
health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, CMS has published a final rule that would
give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through
such marketplaces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. In August 2011, the Budget Control Act
of 2011, among other things, created measures for spending reductions by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach
required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative
amendments, will remain in effect through 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, these Medicare sequester reductions were suspended from
May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The American Taxpayer Relief Act of 2012 among other things, reduced Medicare payments to several providers, including hospitals,
imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have
been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the current administration&#146;s budget for fiscal year 2021 includes a $135&nbsp;billion allowance to
support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost
generic and biosimilar drugs. On March&nbsp;10, 2020, the current administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. Additionally, the current administration released a &#147;Blueprint&#148; to lower drug
prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their
products and reduce the out of pocket costs of product candidates paid by consumers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;24, 2020, President Trump signed four Executive Orders
directing the Secretary of the U.S. Department of Health and Human Services, or HHS, to: (1)&nbsp;eliminate protection under an Anti-Kickback Statute safe harbor for certain retrospective price reductions provided by drug manufacturers to sponsors
of Medicare Part D plans or pharmacy benefit managers that are not applied at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale;</FONT></FONT> (2)&nbsp;allow the importation of certain drugs from other countries
through individual waivers, permit the <FONT STYLE="white-space:nowrap">re-importation</FONT> of insulin products, and prioritize finalization of FDA&#146;s December 2019 proposed rule to permit the importation of drugs from Canada; (3)&nbsp;ensure
that payment by the Medicare program for certain Medicare Part B drugs is not higher than the payment by other comparable countries (depending on whether pharmaceutical manufacturers agree to other measures); and (4)&nbsp;allow certain <FONT
STYLE="white-space:nowrap">low-income</FONT> individuals receiving insulin and epinephrine purchased by a Federally Qualified Health Center, or FQHC, as part of the 340B drug program to purchase those drugs at the discounted price paid by the FQHC.
On October&nbsp;1, 2020, the FDA issued its final rule allowing importation of certain prescription drugs from Canada. On September&nbsp;13, 2020, President Trump signed an Executive Order directing HHS to implement a rulemaking plan to test a
payment model, pursuant to which Medicare would pay, for certain high-cost prescription drugs and biological products covered by Medicare Part B, no more than the most-favored-nation price (i.e., the lowest price) after adjustments, for a
pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and development that has a comparable <FONT STYLE="white-space:nowrap">per-capita</FONT> gross domestic product. Although a
number of these, and other proposed measures will require authorization through additional legislation to become effective, Congress and the current administration have each indicated that it will continue to seek new legislative and/or
administrative measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HHS has already started the process of soliciting feedback on some of these measures and, at the same
time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning
January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change that was effective January&nbsp;1, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, on May&nbsp;30, 2018, the Right to Try Act, was signed into law. The law, among other things,
provides a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible
patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its product candidates available to
eligible patients as a result of the Right to Try Act. <B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the state level, individual states are increasingly aggressive in passing legislation
and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what
pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In particular any policy changes through CMS as well as local state
Medicaid programs could have a significant impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue prospects could be affected by changes in healthcare spending and policy
in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or
payment for healthcare products and services could negatively impact our business, operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been, and likely will
continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be
adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of
healthcare and/or impose price controls may adversely affect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for our current or future product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain coverage and reimbursement approval for a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may
adversely affect our future profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and third-party payors will be subject to applicable anti-kickback,
fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future
earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be subject
to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our future arrangements
with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and
distribute our product candidates for which we obtain regulatory approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting,
offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made
under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to
civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment of up to ten years, and exclusion from government healthcare programs. The Anti-Kickback Statute has been interpreted to apply
to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims
Act, or FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are
false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if
they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false
of fraudulent claim for purposes of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil
liability for executing a scheme to defraud any healthcare benefit program (e.g. public or private), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the
delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a
violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#147;Sunshine Act&#148;
under the ACA, require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report to HHS information related to transfers of value made to
physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members. Effective
January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and its implementing regulations, impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of
individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to
government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state laws and regulations, such as state anti-kickback and false claims laws may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. Some state laws require pharmaceutical companies to
comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to
physicians and other health care providers or marketing expenditures. Further, many state laws governing the privacy and security of health information in certain circumstances, differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that our future business arrangements with third parties comply with
applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment
or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions,
including exclusions from government funded healthcare programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations,
we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of
hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot
eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation
insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance
for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for any of our product candidates, we will be subject to
ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling
restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging,
distribution, import, export, adverse event reporting, storage, advertising, promotion, monitoring, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our
product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4
clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or
additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance
requiring remediation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings,
contraindications or other safety information, including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a REMS which may include distribution or use restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct additional post-market clinical trials to assess the safety of the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial holds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or other regulatory enforcement action; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit or
delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to
additional privacy restrictions. The collection, use, storage, disclosure, transfer, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR. The GDPR is wide-ranging in
scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing
information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party
processors. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to
fines and penalties, litigation, and reputational harm in connection with our European activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laws and regulations governing any international
operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each
jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign
official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are
listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise
and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult,
particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other
hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it
will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth
potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may result in substantial civil
and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#146;s accounting
provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on many of our key employees and members of our executive management team as well as the other principal members of our
management, scientific and clinical team. Although we have entered into employment letter agreements with certain of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#147;key person&#148;
insurance for any of our executives or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy.
Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain
high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing
and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and
commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to
hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, we have experienced a very competitive hiring environment in Boston, Massachusetts, where we are headquartered. Many of the other
pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better
chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we
can discover and develop product candidates and our business will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to adequately protect our information systems from
cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations. In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email addresses,
phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information
and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial
espionage, wire fraud and other forms of cyber fraud, the deployment of harmful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">malware,&nbsp;denial-of-service,&nbsp;social</FONT></FONT> engineering fraud or other means to threaten
data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business
information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be
no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any
failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#146; personal data could result in significant liability under state (e.g., state breach notification laws), federal
(e.g., HIPAA, as amended by HITECH), and international law (e.g., the GDPR) and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on our third-party providers to implement effective security measures and identify and correct for
any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our
information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in the losses described above as well as disputes with physicians,
patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenue or other adverse consequences, any of which could have a material adverse effect on our business, results of operations,
financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to
prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. By way of example, the California Consumer
Privacy Act, or CCPA, which went into effect on January&nbsp;1, 2020, creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for
civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. In March 2020, the California State Attorney General has proposed varying versions of companion draft
regulations which are not yet finalized. Despite the delay in adopting regulations, the California State Attorney General will commence enforcement actions against violators beginning July&nbsp;1, 2020. The CCPA may increase our compliance costs and
potential liability, and many similar laws have been proposed at the federal level and in other states. By way of example regarding foreign laws and regulations with respect to data privacy and security, the GDPR went into effect in the EU in May
2018 and introduces strict requirements for processing the personal data of EU data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection
requirements and potential fines for noncompliance of up to &#128;20&nbsp;million or 4% of the annual global revenue of the noncompliant company, whichever is greater. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with U.S. and international data protection laws and regulations, it could
result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we
or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights,
failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to successfully integrate acquisitions, which may adversely impact our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have in the past and in the future may continue to acquire complementary businesses or technologies. Acquired technologies, products or businesses may not
perform as we expect, and we may fail to realize anticipated synergies or results. In addition, our acquisition strategy may divert management&#146;s attention away from our existing business, and expose us to unanticipated problems or legal
liabilities, including responsibility as a successor for undisclosed or contingent liabilities of acquired businesses or assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have successfully
integrated our past acquisitions of Arrys Therapeutics or Amplify Medicines, however, if we are unsuccessful in integrating any future acquisitions, it could impede us from realizing all of the benefits of those acquisitions and could weaken our
business operations or future prospectus. The integration process may disrupt our business and, if new technologies, products or businesses are not implemented effectively, may preclude the realization of the full benefits expected by us and could
harm our results of operations. In addition, the overall integration of new technologies, products or businesses may result in unanticipated problems, expenses, liabilities and competitive responses. The difficulties of integrating an acquisition
include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issues in integrating the target company&#146;s technologies, product candidates or capabilities with ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining employee morale and retaining key employees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrating the culture of the target company with ours; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preserving important strategic relationships and collaborations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consolidating corporate and administrative infrastructures and eliminating duplicative operations.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, even if the operations of an acquisition are integrated successfully, we may not realize the full benefits of the
acquisition, including the synergies, pipeline expansion or growth opportunities that we expect. These benefits may not be achieved within the anticipated time frame, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a
result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of November&nbsp;30, 2020, we had 29
full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, regulatory affairs and, if any
of our product candidates receives regulatory approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities
and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of
our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or
augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our
business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related
to Our Common Stock and This Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the public market could cause our stock
price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market
after the <FONT STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the market price of our common stock could decline. Based upon the number of shares of common stock, on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, outstanding as of December&nbsp;31, 2020, upon the completion of this offering, we will have outstanding a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, and assuming no exercise of the underwriters&#146; option to purchase additional shares. Of these shares, as of the date of
this prospectus, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, plus any shares sold upon exercise of the underwriters&#146; option to purchase additional
shares, will be freely tradable, without restriction, in the public market immediately following this offering, assuming that current stockholders do not purchase shares in this offering. The representatives of the underwriters, however, may, in
their sole discretion, permit our officers, directors and other stockholders who are subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering
will expire 180 days from the date of this prospectus. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, based upon the number of shares of common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding as of December&nbsp;31, 2020, up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be
eligible for sale in the public market,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of which shares are held by directors, executive officers and other affiliates and will be subject to certain
limitations of Rule 144 under the Securities Act of 1933, as amended, or the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this
offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are either subject to outstanding options or reserved for future issuance under our equity incentive plans will
become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act. If these
additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After this offering, the holders of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. Registration of these shares under the
Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the
market our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors, principal stockholders and their affiliates will continue to exercise significant
control over our company after this offering, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following the completion of this offering, and disregarding any shares of common stock that they purchase in this offering, the existing holdings
of our executive officers, directors, principal stockholders and their affiliates, including entities affiliated with Atlas Ventures, OrbiMed, Fidelity Management&nbsp;&amp; Research Company, Celgene Corporation (BMS) and Omega Funds, will represent
beneficial ownership, in the aggregate, of approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock, assuming no exercise of the underwriters&#146; option to acquire additional common stock in this offering and assuming we issue the
number of shares of common stock as set forth on the cover page of this prospectus. As a result, these stockholders, if they act together, will be able to influence our management and affairs and control the outcome of matters submitted to our
stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These stockholders acquired their shares of common stock for substantially less than the price of
the shares of common stock being acquired in this offering, and these stockholders may have interests, with respect to their common stock, that are different from those of investors in this offering and the concentration of voting power among these
stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delaying, deferring or preventing a change of control of us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impeding a merger, consolidation, takeover or other business combination involving us; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Principal Stockholders&#148; in this prospectus for more information regarding the ownership of our outstanding common stock
by our executive officers, directors, principal stockholders and their affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase our common stock in this offering, you will
incur immediate and substantial dilution in the book value of your shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will suffer immediate and substantial dilution in the net tangible
book value of the common stock you purchase in this offering. Assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range
set forth on the cover page of this prospectus, purchasers of common stock in this offering will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share in net
tangible book value of the common stock. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, investors purchasing common stock in this offering will contribute&nbsp;&nbsp;&nbsp;&nbsp;% of the total amount invested by stockholders since inception but will only
own&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding. In the past, we issued options and other securities to acquire common stock at prices significantly below the initial public offering price. To the extent these outstanding
securities are ultimately exercised, investors purchasing common stock in this offering will sustain further dilution. See &#147;Dilution&#148; for a more detailed description of the dilution to new investors in the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of
operations and cause our stock price to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will have considerable discretion in the application of the net proceeds of this offering. We
intend to use the net proceeds from this offering to fund discovery and clinical development efforts as well as further expansion of our manufacturing capabilities, and infrastructure to support our pipeline, and to fund new and ongoing research
activities, working capital and other general corporate purposes, which may include funding for the hiring of additional personnel, capital expenditures and the costs of operating as a public company. As a result, investors will be relying upon
management&#146;s judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at
all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change&#148; (generally
defined as a greater than 50 percentage point change (by value) in the ownership of its equity over a three year period), the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards
and certain other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as
a result of this offering or subsequent shifts in our stock ownership, some of which are outside our control. As of December&nbsp;31, 2020, we had federal net operating loss carryforwards of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and our ability to utilize those net operating loss carryforwards could be limited by an &#147;ownership change&#148; as described above, which could
result in increased tax liability to us. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As a result, the amount of the net operating loss
and tax credit carryforwards presented in our consolidated financial statements could be limited and may expire unutilized. Federal net operating loss carryforwards generated in taxable years beginning after December&nbsp;31, 2017 will not be
subject to expiration. However, any such net operating loss carryforwards may only offset 80% of our annual taxable income in taxable years beginning after December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the
Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and
changes are likely to continue to occur in the future. For example, the TCJA was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of
21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses from taxable years beginning after December&nbsp;31,
2017 to 80% of current year taxable income and the elimination of net operating loss carrybacks generated in taxable years ending after December&nbsp;31, 2017 (though any such net operating losses may be carried forward indefinitely), and the
modification or repeal of many business deductions and credits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on March&nbsp;27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and
Economic Security Act, which, among other things, suspends the 80% limitation on the deduction for net operating losses in taxable years beginning before January&nbsp;1, 2021, permits a <FONT STYLE="white-space:nowrap">5-year</FONT> carryback of net
operating losses arising in taxable years beginning after December&nbsp;31, 2017 and before January&nbsp;1, 2021, and generally caps the limitation on the deduction for net interest expense at 50% of adjusted taxable income for taxable years
beginning in 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations
and rulings may be promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#146; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any
adverse effects of changes in tax law or in the interpretation thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law
could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fourth amended and restated certificate of incorporation and amended and restated bylaws, which are to become effective at or prior to the completion of
this offering, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of
the board will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken
at a meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that special meetings of the stockholders may be called only by the board of directors acting
pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for
cause and, in addition to any other vote required by law, upon the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of all outstanding shares of our voting stock then entitled to vote in the election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement of approval of not less than a majority of all outstanding shares of our voting stock to amend any
bylaws by stockholder action and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of all outstanding shares of our voting stock to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors
without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding
voting stock. These anti-takeover provisions and other provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control
of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests
and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors
could cause the market price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our bylaws to be effective upon the consummation of this offering designate certain courts as the sole
and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or
employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our bylaws that will become effective upon the completion of this offering provide that, unless we consent in writing to an alternative
forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of fiduciary
duty owed by any of our directors, officers, and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of
incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of
Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange
Act. Our bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of
action arising under the Securities Act, or the Federal Forum Provision. In addition, our bylaws that will become effective upon the completion of this offering will provide that any person or entity purchasing or otherwise acquiring any interest in
shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and
regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that the Delaware Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing
any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a forum that
they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In
addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#147;facially valid&#148; under Delaware law, there is
uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also
impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or
results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to certain U.S. and
foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are
collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing,
soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties,
imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies
or government-affiliated hospitals, universities, and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the
corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in 2008,
the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused significant volatility and uncertainty in U.S. and
international markets. See &#147;Risks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates<I>&#151;</I>The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or a similar pandemic, epidemic, or
outbreak of an infectious disease may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.&#148; A severe or prolonged economic downturn could result in a
variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly
resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market
conditions could adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, principal investigators, CROs and consultants may engage in misconduct or other
improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity.
Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the
reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict
or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the
course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We intend to adopt, prior to the completion of this offering, a
code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in
controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a
person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our
business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm,
diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop, and you may not be able to resell your
shares at or above the initial public offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for shares of our common stock.
Although we anticipate that our common stock will be approved for listing on The Nasdaq Global Market, or Nasdaq, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of
our common stock will be determined through negotiations between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading
market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; as defined in the JOBS Act and will be able to avail ourselves of reduced disclosure requirements
applicable to emerging growth companies, which could make our common stock less attractive to investors and adversely affect the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging
growth company until the earlier of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the
completion of this offering; (iii)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules
of the Securities and Exchange Commission, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th. For so long as we remain an
emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, or Section&nbsp;404; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing only two years of audited financial statements in addition to any required unaudited interim financial
statements and a correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. In this prospectus, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not all, of the available exemptions
available to us so long as we qualify as an &#147;emerging growth company.&#148; We have taken advantage of reduced reporting burdens in this prospectus. In particular, we have provided only two years of audited financial statements and have not
included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or
revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected to avail ourselves of this exemption and, therefore, we are not subject to the same new or
revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of
existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our independent registered public accounting firm will not be required to provide an attestation report on the
effectiveness of our internal control over financial reporting so long as we qualify as an &#147;emerging growth company,&#148; which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial
reporting go undetected. Likewise, so long as we qualify as an &#147;emerging growth company,&#148; we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of
our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. We cannot predict if investors will find
our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile
and may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if
any, will be your sole source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of
our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be
your sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result
in substantial losses for purchasers of our common stock in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market in general,
and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your
common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advancement of our preclinical programs, such as our targeted oncology programs, into clinical testing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical trials of our product candidates or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our programs and product candidates or preclinical and clinical
development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
additional product candidates or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur
significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies,
including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover,
these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive
for us to obtain director and officer liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404, we will be required to furnish a report by our management on our
internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be
required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a
process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a
detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a
continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed
timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
In additional, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls
and procedures may not prevent or detect all errors or acts of fraud. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will become subject to the periodic
reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is
accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and
procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be
faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls.
Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If
securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We
may never obtain research coverage by industry or financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our
business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to
decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to
securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#146;s attention from other business concerns, which
could seriously harm our business. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our
management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking
statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and
future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to efficiently discover and develop product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture our drug substances and product candidates for
preclinical use, for clinical trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability and willingness of our third-party strategic collaborators to continue research and development
activities relating to our development candidates and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization
of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize our products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, and strategic plans for our business and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our future expenses, revenue, capital requirements, and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations
or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future agreements with third parties in connection with the commercialization of product candidates and any other
approved product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing
cost; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> including mitigation
efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;should,&#148;
&#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable
terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and
which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus.
If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking
statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement, of which
this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not
rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus also
contains estimates, projections and other information concerning our industry, our business and the markets for our programs and product candidates. Information that is based on estimates, forecasts, projections, market research or similar
methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business,
market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications,
government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are
subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in full their option to purchase additional shares,
assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our net proceeds from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our net proceeds from
this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. This information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. We do not expect that a change in the initial price
to the public or the number of shares by these amounts would have a material effect on uses of the proceeds from this offering, although a decrease in the initial offering price without a corresponding increase in the number of shares offered may
accelerate the time at which we will need to seek additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to use our net proceeds from this offering, together with our existing
cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the continued development of <FONT STYLE="white-space:nowrap">IK-930;</FONT> including the completion of
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and completion of Phase 1 clinical trial(s); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the development of our ERK5 program; including nomination of a development candidate and initiation of Phase 1 clinical trial(s); </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> our two programs partnered
with BMS, through the completion of the ongoing Phase 1b clinical trials for each of program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance the clinical development of <FONT STYLE="white-space:nowrap">IK-007;</FONT> including the completion of the ongoing Phase 1b clinical trial in MSS CRC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund further development of our preclinical programs towards IND filings and/or into clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The remaining proceeds for general corporate purposes, which may include the hiring of additional personnel,
capital expenditures, the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of assets in line with our strategy and the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this
prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above and we expect that we will
require additional funds in order to fully accomplish the specified uses of the proceeds of this offering. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary
businesses or technologies to continue to build our pipeline, research and development capabilities and our intellectual property position, although we currently have no agreements, commitments, or understandings with respect to any such
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current plans, we believe that our existing cash and cash equivalents, together with the anticipated net proceeds from this
offering, will enable us to fund our operating expenses and capital expenditure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The expected net proceeds from this offering will not be sufficient for us to
fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the many inherent uncertainties in the development of our programs and product candidates, the amounts and timing of our actual expenditures may vary
significantly depending on numerous factors, including the progress of our research and development, the timing of patient enrollment and evolving regulatory requirements, the timing and success of preclinical studies, our ongoing clinical trials or
clinical trials we may commence in the future, the timing of regulatory submissions, any strategic alliances that we may enter into with third parties for our product candidates or strategic opportunities that become available to us, and any
unforeseen cash needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation
instruments, including short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return.
Our management will retain broad discretion in the application of the net proceeds we receive from our initial public offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the
growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on
our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash
dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of September&nbsp;30, 2020: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the acquisition of Amplify, which occurred on October&nbsp;1,
2020, which includes the issuance of 7,863,094 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock and 3,048,764 shares of common stock, the recognition of $10.7&nbsp;million of expense related to the <FONT
STYLE="white-space:nowrap">write-off</FONT> of acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets with no future alternative use, and the recognition of other assets acquired and liabilities assumed,
(ii)&nbsp;the issuance of 85,806,214 shares of our Series B preferred stock which occurred on December&nbsp;21, 2020 for net proceeds of $116.4&nbsp;million, and (iii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock
into an aggregate of 169,396,576 shares of common stock immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect to our sale in this offering of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the
price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on
the actual initial public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table should be read together with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Description of Capital Stock,&#148; and the consolidated financial statements and related notes appearing elsewhere in this prospectus.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2020</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actual&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><br><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro&nbsp;Forma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><br><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As&nbsp;Adjusted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 55,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A and <FONT STYLE="white-space:nowrap">A-1),</FONT>
$0.001 par value, 75,727,268 shares authorized, issued and outstanding, actual (liquidation preference of $75,727,268 as of September&nbsp;30, 2020); no shares authorized, issued and outstanding, pro forma&nbsp;and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value, no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, no shares issued outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 113,795,082 shares authorized, 19,021,056 issued and outstanding,
actual; 230,000,000 shares authorized, 191,466,396 issued and outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
adjusted amount of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity, and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. A 1.0&nbsp;million share increase (decrease) in the number of shares offered by us would increase (decrease) the pro forma as adjusted amount of cash and cash equivalents, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming an initial public offering price
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, assuming no change in the assumed initial public offering price per share and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. This information is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the
actual initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actual, pro forma, and pro forma as
adjusted information set forth in the table excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19,046,758 shares of common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2020, at a weighted average exercise price of $0.48 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock that will
become available for future issuance under our 2021<B> </B>Stock Option and Incentive Plan, which will become effective in connection with the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock that will
become available for future issuance under our 2021<B> </B>Employee Stock Purchase Plan, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial
public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of September&nbsp;30, 2020 was $(78.6) million, or $(4.13) per share of our common stock. Our historical
net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and preferred stock, which is not included within stockholders&#146; (deficit) equity. Historical net tangible book value (deficit) per share
represents our historical net tangible book value (deficit) divided by the 19,021,056 shares of our common stock outstanding as of September&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of September&nbsp;30, 2020 was $119.2&nbsp;million, or $0.62 per share of our common stock. Pro forma net tangible
book value represents the amount of our total tangible assets less our total liabilities, after giving effect to (i) ) the acquisition of Amplify, which occurred on October&nbsp;1, 2020, which includes the issuance of 7,863,094 shares of our Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred stock and 3,048,764 shares of common stock, the recognition of $10.7&nbsp;million of expense related to the <FONT STYLE="white-space:nowrap">write-off</FONT> of acquired
<FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets with no future alternative use, and the recognition of other assets acquired and liabilities assumed, (ii)&nbsp;the issuance of 85,806,214 shares of our Series B
preferred stock which occurred on December&nbsp;21, 2020 for net proceeds of $116.4&nbsp;million, and (iii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 169,396,576 shares of common stock
immediately prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding as of September&nbsp;30, 2020, after giving effect to
the automatic conversion of all outstanding shares of our preferred stock into common stock immediately prior to the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After
giving further effect to our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2020 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in pro forma as adjusted net tangible book value
per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed initial public
offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to the pro forma adjustments described
above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September&nbsp;30, 2020, before giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in pro forma as adjusted net tangible book value per share to new investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, our pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and dilution per share to new investors purchasing shares in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A 1.0&nbsp;million share increase
in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and decrease the dilution per share to new investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no
change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A 1.0&nbsp;million share decrease in the number of shares offered by us, as set
forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and increase the dilution per share to new investors
participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net
tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing an immediate increase in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to new investors purchasing common stock in this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. If any shares are issued upon exercise of outstanding options, you will experience further dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
summarizes, on the pro forma as adjusted basis described above, the differences between the number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid by existing stockholders and by
new investors purchasing shares of common stock in this offering. The calculation below is based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the
price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,466,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">214,446,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. A 1.0&nbsp;million share increase
(decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points and, in the case of a decrease, would
decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; percentage points, assuming no change in the assumed initial public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the underwriters&#146; option to
purchase additional shares is exercised in full, the number of shares of our common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock held by existing stockholders would be reduced to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering, and the number of shares of
common stock held by new investors participating in the offering would be increased to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 191,466,396 shares of our common stock outstanding as of
September&nbsp;30, 2020, which assumes (i)&nbsp;the automatic conversion of all of our outstanding preferred stock into 169,396,576 shares of common stock immediately prior to the completion of this offering, which includes 7,863,094 shares of our
Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock issued on October&nbsp;1, 2020 and 85,806,214 shares of our Series B preferred stock issued on December&nbsp;21, 2020 and (ii)&nbsp;the issuance of 3,048,764 shares of common stock
issued on October&nbsp;1, 2020, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19,046,758 shares of common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2020, at a weighted average exercise price of $0.48 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that will
become available for future issuance under our 2021<B> </B>Stock Option and Inventive Plan, or 2021 Plan, which will become effective in connection with the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that will
become available for future issuance under our 2021<B> </B>Employee Stock Purchase Plan, which will become effective in connection with the completion of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options are exercised or shares are issued under our 2021 Plan, you will experience further dilution. In addition, we may
choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity
or convertible debt securities, the issuance of these securities may result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_10"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following summary financial data together with our consolidated financial statements and the related notes appearing at the end of this
prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. We have derived the statement of operations data for the years ended December&nbsp;31, 2018 and
2019 and the balance sheet data as of December&nbsp;31, 2018 and 2019 from our audited financial statements appearing elsewhere in this prospectus. The statement of operations data for the nine months ended September&nbsp;30, 2019 and 2020 and the
balance sheet data as of September&nbsp;30, 2020 have been derived from our unaudited financial statements appearing elsewhere this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of
management, the unaudited data reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of
results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full year. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended<BR>September&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="15" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share and&nbsp;per&nbsp;share&nbsp;data)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue under collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue (related party)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,193,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,945,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,938,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,013,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 16 and to our consolidated financial statements appearing elsewhere in this prospectus for details on
the calculation of basic and diluted net loss per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma basic and diluted net loss per share attributable to common stockholders have been prepared to give
effect to the automatic conversion of all shares of preferred stock outstanding into shares of common stock as if the conversion had occurred on the later of the beginning of the period presented or the date the preferred shares were issued.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 18,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 82,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 90,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 55,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations
together with the &#147;Selected Consolidated Financial Data&#148; section of this prospectus and our consolidated financial statements and the related notes included elsewhere in this prospectus. Some of the information contained in this discussion
and analysis or set forth elsewhere in this prospectus includes forward-looking statements that involve risks and uncertainties, such as statements of our plans, strategies, objectives, expectations and intentions. As a result of many factors,
including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion
and analysis. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a targeted
oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack
approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep
pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates.
Since we commenced operations in 2016, we have discovered or developed five oncology programs that include four product candidates in either <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead targeted oncology product candidate, <FONT STYLE="white-space:nowrap">IK-930,</FONT> is an oral small molecule inhibitor of the transcriptional
enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is widely accepted as a key and prevalent driver of cancer pathogenesis and is genetically altered in approximately 10% of all cancers, and
such genetic alterations are generally associated with poor clinical outcomes. We intend to pursue clinical development of <FONT STYLE="white-space:nowrap">IK-930</FONT> across a wide range of tumor types with known Hippo pathway mutations, and plan
to focus our initial development efforts on indications that provide the potential for rapid clinical development to achieve <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> such as mesothelioma and
soft tissue sarcomas. We intend to submit an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for <FONT STYLE="white-space:nowrap">IK-930</FONT> in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our second targeted oncology program, we have discovered and plan to develop oral small molecule inhibitors of extracellular signal-related kinase 5, or
ERK5, a downstream enzyme in the RAS signaling pathway, which have the potential to bring therapeutic benefit to cancer patients with a mutation in the kirsten rat sarcoma, or KRAS, gene, which is an oncogene implicated in many cancers. We
anticipate nominating a development candidate for the ERK5 program and initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021 with the goal of submitting an IND in the second half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our targeted oncology programs, we have three product candidates designed to modulate the tumor microenvironment in specific patient
populations by leveraging biomarker-driven patient enrichment strategies. Two of these product candidates, <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> are partnered with Bristol-Myers Squibb
Company, or BMS, which we believe validates our ability to rapidly advance internally developed product candidates into clinical development using biomarker-driven patient enrichment strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated as a Delaware corporation on March&nbsp;2, 2016, and our headquarters is located in Boston, Massachusetts. On December&nbsp;3, 2019, we
formally changed our name to Ikena Oncology, previously Kyn Therapeutics. Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, acquiring intellectual property, business planning, raising
capital, conducting discovery, research and development activities, and providing general and administrative support for these operations. We do not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have any products approved for sale and have not generated any revenue from product sales. To date, we have funded our operations primarily through private placements of preferred stock, payments
from a collaboration arrangement and related party revenue. Through September&nbsp;30, 2020, we have raised an aggregate of approximately $122.8&nbsp;million, of which $95.0&nbsp;million is related to aggregate upfront consideration related to our
master collaboration agreement with BMS, or BMS Collaboration Agreement, which consisted of approximately $80.5&nbsp;million in cash and an equity investment of approximately $14.5&nbsp;million for which we issued shares of our Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock pursuant to a separate stock purchase agreement, and $27.8&nbsp;million of net proceeds from the issuance of redeemable convertible preferred stock to other investors. We
also obtained $11.3&nbsp;million in cash from our acquisition of Arrys Therapeutics, Inc., or Arrys. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to September&nbsp;30, 2020, we obtained
$3.7&nbsp;million in cash from our acquisition of Amplify Medicines, Inc., or Amplify, and raised $116.4&nbsp;million of net proceeds from the issuance of Series B redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred significant net losses in every year since our inception and expect to continue to incur significant expenses and increasing net losses for
the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful
development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $40.9&nbsp;million and $16.8&nbsp;million and&nbsp;for the years ended December&nbsp;31, 2018 and 2019, respectively and
$11.7&nbsp;million and $18.2&nbsp;million for the nine months ended September&nbsp;30, 2019 and 2020, respectively. As of September&nbsp;30, 2020, we had an accumulated deficit of $85.3&nbsp;million. We anticipate that our expenses will increase
significantly as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance the development of our product candidate pipeline; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and continue research and preclinical and clinical development of potential new product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our infrastructure and facilities to accommodate our growing employee base and ongoing development
activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish agreements with contract research organizations, or CROs, and contract manufacturing organizations, or
CMOs, in connection with our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the manufacture of larger quantities of our product candidates for clinical development and potential
commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals for our product candidates that successfully complete clinical trials, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may
obtain marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
research and development programs, any future commercialization efforts and our transition to operating as a public company following the completion of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can
generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity instruments, debt financings, or other capital sources, which may include collaborations with other companies or other strategic
transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to
significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not generate revenue from product sales unless and until we successfully complete clinical
development and obtain marketing approval for our product candidates. The lengthy process of securing marketing approvals for new drugs requires the expenditure of substantial resources. Any delay or failure to obtain regulatory approvals would
materially adversely affect the development efforts of our product candidates and our business overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased
expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a
continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise
additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future
commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2020, we had cash and cash equivalents of $55.9&nbsp;million. We believe the existing cash and cash equivalents on hand as of December&nbsp;31, 2020, together with the anticipated net proceeds from this offering, will enable us to
fund our operating expenses and capital expenditure requirements through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have based this estimate on assumptions that may prove to be wrong, and we
could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and capital resources.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of <FONT
STYLE="white-space:nowrap">COVID-19&nbsp;Pandemic</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization declared the outbreak of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> a global pandemic, which continues to spread throughout the United States and worldwide. The ultimate extent of the impact of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> on our
business, financial condition and results of operations is highly uncertain and will depend on future developments that cannot be predicted, including new information that may emerge concerning the severity of
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> and actions taken by government authorities and businesses to contain or prevent the further spread <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19.&nbsp;For</FONT> instance,
a recurrence or continuation <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;cases</FONT> could cause a more widespread or severe impact on commercial activity depending on where infection rates are highest. If we or any of the third parties
with whom we engage were to experience any shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially negatively affected, which could have a
material adverse impact on our business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been carefully monitoring the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its potential impact on our business and have taken important steps to help ensure the safety of our employees and their families and to reduce the spread
<FONT STYLE="white-space:nowrap">of&nbsp;COVID-19.</FONT> We have established a work-from-home policy for all employees, other than those performing or supporting business-critical operations, such as certain members of our laboratory and facilities
staff. For those employees, we have implemented stringent safety measures designed to comply with applicable federal, state and local guidelines instituted in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We have also
maintained efficient communication with our partners and clinical sites as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation has progressed. We have taken these precautionary steps while maintaining business continuity so that we can
continue to progress our programs. While we have experienced some delays in enrollment and site closures at certain of our third-party clinical trial sites, these delays have not had a material impact on our development timelines for our product
candidates. We will continue to monitor developments as we address the disruptions and uncertainties relating to <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> See &#147;Risk Factors&#148; for a discussion of the potential
adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from
product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval and successful commercialization
efforts, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory
approval for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our revenue has been derived from research and development revenue under our BMS Collaboration
Agreement and service revenue related to our service agreements with related parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Agreement and Stock Purchase Agreement with BMS
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, we entered into the BMS Collaboration Agreement with Celgene Corporation (which was acquired by BMS in November 2019), pursuant
to which BMS may elect in its sole discretion to exclusively license rights to develop and commercialize compounds (and products and diagnostic products containing such compounds) that modulate the activity of two collaboration targets, kynurenine
and aryl hydrocarbon receptor, or AHR, excluding AHR agonists for inverse agonists, which we are developing as <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> respectively. On a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis, through the completion of a Phase 1b clinical trial for each of <FONT STYLE="white-space:nowrap">IK-175</FONT> and
<FONT STYLE="white-space:nowrap">IK-412,</FONT> BMS has the exclusive license to develop, commercialize and manufacture the relevant product candidate worldwide. Concurrent with execution of the BMS Collaboration Agreement, we entered into a stock
purchase agreement with Celgene Corporation (now BMS) in November 2019, or the Stock Purchase Agreement, pursuant to which we issued Celgene Corporation 14,545,450 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMS paid a total of $95.0&nbsp;million in aggregate upfront consideration related to the BMS Collaboration Agreement and Stock Purchase Agreement. We are
eligible to receive $50.0&nbsp;million, in case of an exercise of its option with respect to <FONT STYLE="white-space:nowrap">IK-175,</FONT> and $40.0&nbsp;million, in case of an exercise of its option with respect to
<FONT STYLE="white-space:nowrap">IK-412.</FONT> If we do not complete a Phase 1b clinical trial by the end of the research term, we may elect to provide a data package to BMS upon which BMS may exercise the foregoing option for an additional
$0.25&nbsp;million fee. Upon the exercise of the delivery of each license, we become eligible to receive up to $265.0&nbsp;million in regulatory milestones and $185.0&nbsp;million in commercial milestones as well as a tiered royalties at rates
ranging from the high single to low double digit percentages based on worldwide annual net sales by BMS, subject to specified gross sale reductions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operating expenses since
inception have consisted solely of research and development costs and general and administrative costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for our research and development activities. These efforts and costs include external
research costs, personnel costs, consultants, supplies, license fees and facility-related expenses. We expense research and development costs as incurred. These expenses include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, related benefits and stock-based compensation expense, for
employees engaged in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with CROs which are primarily engaged to support our clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with CMOs, which are primarily engaged to provide drug substance and product
for our preclinical research and development programs, nonclinical studies and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of acquiring and manufacturing preclinical study materials, including manufacturing registration and
validation batches; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance
of facilities and insurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets that have no
alternative future use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with quality and regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments made under third-party licensing agreements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development,
primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical development activities in the near term and in
the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of, or obtain regulatory approval for, any of our current or future product
candidates. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to add and retain key research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our successful enrollment in and completion of clinical trials, including our ability to generate positive data
from any such trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and cost of any future clinical trials for existing or future product candidates in our pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with the development of any additional programs we identify
<FONT STYLE="white-space:nowrap">in-house</FONT> or acquire through collaborations and other arrangements and the success of such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of any additional collaborations, license or other arrangement, including the timing of any
payments thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain agreements and operate with third-party manufacturers for clinical supply
for our clinical trials and commercial manufacturing, if any of our product candidates are approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to manufacturing of our product candidates or to account for any future changes in our
manufacturing plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patents, trade secret and other intellectual property protection and
regulatory exclusivity for our product candidates, both in the United States and internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain third-party insurance coverage and adequate reimbursement for our product
candidates, if and when approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other products if our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations, including the timing and enrollment of patients in
our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> or similar public health crisis; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain a continued acceptable safety profile for our therapies following approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change
the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and
allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, auditing, tax services and insurance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will increase as our organization and headcount needed&nbsp;in the future to support continued research
and development activities and potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, attorneys and accountants, among
other expenses. Additionally, we expect to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT>
services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the Years
Ended December&nbsp;31, 2018 and 2019 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2018 and 2019:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Change&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center"><B>(in thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue under collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue (related party)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Related party
revenue of $1.0&nbsp;million for the year ended December&nbsp;31, 2018 was related to services performed on behalf of related entities. We had no related party revenue for the year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had no research and development revenue under collaboration agreement in the year ended December&nbsp;31,
2018. The research and development revenue under collaboration agreement of $13.8&nbsp;million for the year ended December&nbsp;31, 2019 related to the BMS Collaboration Agreement for the <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT
STYLE="white-space:nowrap">IK-412</FONT> programs which was executed in January 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses for each period presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Change&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center"><B>(in thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-930</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-175</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-412</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-007</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other discovery stage programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development personnel and overhead expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense was $39.0&nbsp;million for the year ended December&nbsp;31, 2018, compared to
$24.9&nbsp;million for the year ended December&nbsp;31, 2019. Included within research and development personnel and overhead expenses is stock-based compensation expense of $0.1&nbsp;million and $0.5&nbsp;million for the years ended
December&nbsp;31, 2018 and 2019, respectively. The decrease in research and development expense was primarily attributable to expense recognized during 2018 related to the acquisition of in process research and development assets of
$28.5&nbsp;million as a result of the acquisition of Arrys in December 2018. Excluding the expense associated the acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development, research and development expenses increased
by $14.4&nbsp;million. This was primarily due to initiation of clinical activities for <FONT STYLE="white-space:nowrap">IK-007,</FONT> completion of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and manufacturing development costs for
<FONT STYLE="white-space:nowrap">IK-175,</FONT> preclinical and manufacturing development costs for <FONT STYLE="white-space:nowrap">IK-412,</FONT> discovery and preclinical activities for <FONT STYLE="white-space:nowrap">IK-930</FONT> and research
activities for other discovery stage programs. In addition, research and development expenses related to personnel and overhead expenses increased due to an increase in headcount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expense was $2.9&nbsp;million for the year ended December&nbsp;31, 2018, as compared to $7.3&nbsp;million for the year ended December&nbsp;31, 2019. General and administrative expense includes $0.2&nbsp;million and $0.7&nbsp;million
of stock-based compensation expense for the years ended December&nbsp;31, 2018 and 2019, respectively. The increase was primarily attributable to an increase in compensation expense due to an increase in headcount, as well as general increases in
legal and consulting expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the Nine Months Ended September&nbsp;30, 2019 and 2020 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the nine months ended September&nbsp;30, 2019 and September&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Change&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center"><B>(in thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue under collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,079</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development revenue under collaboration agreement was $10.9&nbsp;million for the nine months ended September&nbsp;30, 2019, compared to $9.1&nbsp;million for the nine months ended September&nbsp;30, 2020. This decrease was primarily attributable to
a decrease in the amount of activities related to our <FONT STYLE="white-space:nowrap">IK-412</FONT> program under the BMS Collaboration Agreement due to timing of drug substance availability and partially offset by an increase in the amount of
activities related to the <FONT STYLE="white-space:nowrap">IK-175</FONT> program. The BMS Collaboration Agreement commenced in the nine months ended September&nbsp;30, 2019 and program setup costs were incurred in this period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
summarizes our research and development expenses for each period presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Change&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-930</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-175</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-412</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-007</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other discovery stage programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development personnel and overhead expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense was $19.0&nbsp;million for the nine months ended September&nbsp;30, 2019, as compared to
$21.4&nbsp;million for the nine months ended September&nbsp;30, 2020. Included within research and development personnel and overhead expenses is stock-based compensation expense of $0.3&nbsp;million and $0.5&nbsp;million for the nine months ended
September&nbsp;30, 2019 and 2020, respectively. The increase in research and development expense was primarily attributable to the initiation of clinical activities for <FONT STYLE="white-space:nowrap">IK-175,</FONT> completion of studies to support
drug candidate and initiation of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">IK-930</FONT> and expenses related to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research activities for other discovery stage programs. In addition, research and development personnel and overhead expenses increased due to an increase in headcount. This increase was offset
by a decrease attributable to timing of drug substance availability for <FONT STYLE="white-space:nowrap">IK-412.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative
Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense was $5.0&nbsp;million for the nine months ended September&nbsp;30, 2019 as compared to $6.2&nbsp;million
for the nine months ended September&nbsp;30, 2020. General and administrative expense includes $0.5&nbsp;million and $0.6&nbsp;million of stock-based compensation expense for the nine months ended September&nbsp;30, 2019 and 2020, respectively. The
increase in general and administrative expenses was primarily attributable to an increase in&nbsp;compensation expenses due to an increase in headcount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses. We have not
yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for several years, if ever. To date, we have financed our operations primarily through private placements of preferred stock and from
upfront payments from the BMS Collaboration Agreement. Through September&nbsp;30, 2020, we have raised an aggregate of $122.8&nbsp;million, of which $95.0&nbsp;million related to aggregate upfront consideration related to the BMS Collaboration
Agreement, which consisted of approximately $80.5&nbsp;million in cash and an equity investment of approximately $14.5&nbsp;million for which we issued shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred
stock pursuant to a separate stock purchase agreement, and $27.8&nbsp;million of net proceeds from the issuance of redeemable convertible preferred stock to other investors. We also obtained $11.3&nbsp;million in cash from our acquisition of Arrys.
Subsequent to September&nbsp;30, 2020, we obtained $3.7&nbsp;million in cash from our acquisition of Amplify and raised $116.4&nbsp;million of net proceeds from the issuance of Series B redeemable convertible preferred stock. As of
September&nbsp;30, 2020, we had cash and cash equivalents of $55.9&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our sources and uses of cash for the years ended December&nbsp;31, 2019 and 2018, and nine months ended September&nbsp;30, 2019
and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="15" ALIGN="center"><B>(in thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, we used $11.6&nbsp;million of cash in operating activities primarily resulting from cash utilized to fund our net
loss of $40.9&nbsp;million. The net loss included $28.5&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> research and development expense for the <FONT STYLE="white-space:nowrap">write-off</FONT> of acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development and $0.7&nbsp;million of other <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses. Operating assets and liabilities changed by $0.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, operating activities provided $47.9&nbsp;million primarily related to $78.7&nbsp;million of upfront
consideration from the BMS Collaboration Agreement, of which $13.8&nbsp;million was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized during the period and $65.0&nbsp;million was deferred as of December&nbsp;31, 2019. We utilized cash to fund our net loss of $16.8&nbsp;million, which includes the $13.8&nbsp;million
of revenue recognized as a result of the BMS Collaboration Agreement and $1.3&nbsp;million of other <FONT STYLE="white-space:nowrap">non-cash</FONT> expense. In addition, there was a net use of $1.5&nbsp;million to fund changes in prepaid expenses,
other current assets, accounts payable, accrued expenses and other current liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019, operating
activities provided $56.0&nbsp;million primarily related to $78.7&nbsp;million of upfront consideration related to the BMS Collaboration Agreement, of which $10.9&nbsp;million was recognized during the period and $67.8&nbsp;million was deferred as
of September&nbsp;30, 2019. We utilized cash to fund our net loss of $11.7&nbsp;million, which includes the $10.9&nbsp;million of revenue recognized as a result of the BMS Collaboration Agreement and $0.9&nbsp;million in other <FONT
STYLE="white-space:nowrap">non-cash</FONT> expense. In addition, there was a net use of $1.0&nbsp;million to fund changes in prepaid expense and other current assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2020, we used $25.3&nbsp;million in operating activities which primarily related to cash utilized to fund our
net loss of $18.2&nbsp;million, which includes $9.1&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> revenue recognition and $2.1&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2018 net cash provided by investing activities was $11.0&nbsp;million due to $11.3&nbsp;million of cash obtained in the acquisition of Arrys, and partially offset by $0.3&nbsp;million of cash used in purchases of property and
equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019 we used $0.3&nbsp;million of cash in investing activities related to purchases of property and
equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019 we used $0.2&nbsp;million of cash in investing activities which was related to purchases
of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2020 we used $0.1&nbsp;million of cash in investing activities which was
related to purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018 there was no net cash provided in or used by financing activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019 net cash provided by financing activities was $16.3&nbsp;million which related to the proceeds of issuance of
preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019 net cash provided by financing activities was $16.3&nbsp;million which related to
the proceeds of issuance of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2020 there was minimal net cash provided by financing
activities related to the proceeds from exercises of stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for, initiate clinical
trials for, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing,
manufacturing and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive
terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the net
proceeds from this offering, together with our existing cash and cash equivalents as of December&nbsp;31, 2020, will enable us to fund our operating expenses and capital expenditure requirements
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently
expect. Our future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical
trials for other potential product candidates we may develop, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration
agreements we might have at such time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing
and distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our
product candidates receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of assets in line with our strategy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our business operations and our research and development
activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt
financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your
ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Any debt financing, if available, may involve agreements that include
restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required
to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our significant contractual obligations as of payment due date by period at December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;to&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligation<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents future minimum lease payments under our <FONT STYLE="white-space:nowrap">non-cancelable</FONT>
operating lease which expires in February 2021. The minimum lease payments above do not include any related common area maintenance charges, operating expenses or real estate taxes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;21, 2020, we entered into an operating lease agreement for 20,752 square feet of office, lab and animal care facility space located in Boston,
Massachusetts for our new corporate headquarters. The commencement date of the lease is estimated to be February&nbsp;1, 2021 and the lease term is 63 months. The lease provides a three-month free rent period, which will commence on the lease
commencement date. The base rent is $145&nbsp;thousand a month and escalates by 3% annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business
with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon
prior notice of 30&nbsp;days and, as a result, are not included in the table of contractual obligations above. Payments due upon cancelation consist only of payments for services provided and expenses incurred up to the date of cancelation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or that we may be required
to make royalty payments under license agreements we have entered into with various entities pursuant to which we <FONT STYLE="white-space:nowrap">have&nbsp;in-licensed&nbsp;certain</FONT> intellectual property such as our patent license agreement
with the University of Texas at Austin and our license agreement with AskAt, Inc. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable
at this time and have not been included in the table above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material
changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ
materially from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in the
notes to our consolidated financial statements appearing elsewhere in this prospectus, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and
estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2 to our consolidated audited financial statements appearing at the end of this prospectus, we adopted Accounting Standards Codification
(ASC) 606, <I>Revenue from Contracts with Customers</I> (&#147;ASC 606&#148;) as of January&nbsp;1, 2018. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration which the entity expects to receive in exchange for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements that are
within the scope of ASC 606, we perform the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the
transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess
the goods or services promised within each contract and determine those that are performance obligations, then assess whether each promised good or service is distinct. When we offer options for additional goods or services, such as to receive a
license for intellectual property or for additional goods or services, we evaluate whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, we then
recognize as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation
is satisfied over time, we recognize revenue based on the use of an input method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each reporting date, we calculate the measure of progress for the
performance obligations transferred over time. The calculation generally uses an input measure based on <FONT STYLE="white-space:nowrap">costs&nbsp;incurred&nbsp;to-date&nbsp;relative&nbsp;to</FONT> estimated total costs to complete the transfer of
the performance obligation. The measurement of progress is then used to calculate the total revenue earned, including any cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have two performance obligations in the BMS Collaboration Agreement, which are research and development services for
<FONT STYLE="white-space:nowrap">IK-412</FONT> and for <FONT STYLE="white-space:nowrap">IK-175.</FONT> We recognize revenue related to each of its performance obligations as the research and development services are performed. We recognize revenue
related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part
of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable
personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The
majority of our service providers invoice us in arrears for services performed, on <FONT STYLE="white-space:nowrap">a&nbsp;pre-determined&nbsp;schedule</FONT> or when contractual milestones are met; however, some require advance payments. We make
estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers
and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vendors, including research laboratories, in connection with preclinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CROs and investigative sites in connection with preclinical studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CMOs in connection with drug substance and drug product formulation of preclinical studies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We base the expense recorded related to external research and development on our estimates of the services received and efforts
expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conduct and manage nonclinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows.
There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the
level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our
estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that
are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We apply the fair value
recognition provisions of ASC 718, <I>Compensation&#151;Stock Compensation</I>, or ASC 718, for stock-based awards granted to employees and directors for their services on the board of directors. Determining the amount of stock-based compensation to
be recorded requires us to develop estimates of the fair value of stock options as of their grant date. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the fair value of stock-based
awards requires that we make subjective assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to ASC 718, we measure stock-based awards granted to employees and members of the board of
directors at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award.
We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Black-Scholes option-pricing model uses the following inputs: the fair value of our common stock, the expected volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the
expected term of our stock options and our expected dividend yield. Due to the lack of a public market for our common stock and a lack of company-specific historical and implied volatility data, we have based our computation of expected volatility
on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product development, life science industry focus, length of trading history and similar vesting provisions. The
historical volatility data is calculated based on a period of time commensurate with the expected term assumption. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock
price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the
calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&nbsp;107, <I>Share-Based Payment</I>, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise
data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the weighted-average expected option term is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years)
of our stock options. We utilize this method due to lack of historical exercise data and the &#147;plain-vanilla&#148; nature of our stock-based awards. The expected term is applied to the stock option grant group as a whole, as we do not expect
substantially different exercise or post-vesting termination behavior among our employee population. For options granted to <FONT STYLE="white-space:nowrap">non-employees,</FONT> we utilize the contractual term of the arrangement as the basis for
the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid cash dividends
and have no current plans to pay any cash dividends on our common stock.&nbsp;The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Determination of Fair Value of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as
of the date of each option grant with input from management, considering our most recently available third-party valuations of common stock, and our board of directors&#146; assessment of additional objective and subjective factors that it believed
were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public
Accountants&#146; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
probability-weighted expected return method, or PWERM, the value of an enterprise, and its underlying common securities, are estimated based on an analysis of future values for the enterprise, assuming various outcomes. The value of the common
securities is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes and the rights of each class of equity. The future values of the common securities under the various
outcomes are discounted back to the valuation date at an appropriate risk-adjusted discount rate and then probability weighted to determine the value for the common securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The option pricing method, or OPM, treats common securities and preferred securities as call options on the enterprise&#146;s equity value, with exercise
prices based on the liquidation preferences of the preferred securities. Under this method, the common securities have value only if the funds available for distribution to shareholders exceed the value of the liquidation preferences at the time of
a liquidity event. The Black-Scholes model is used to price the call option, and the model includes assumptions for the time to liquidity and the volatility of equity value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The hybrid method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the
allocation of value within one or more of those scenarios. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Valuations performed in the year ended December&nbsp;31, 2018 and 2019 and the nine months
ended September&nbsp;30, 2019 used the OPM, and the nine months ended September&nbsp;30, 2020 used a hybrid of the PWERM and OPM when allocating our enterprise value to classes of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When using the hybrid method, we assumed two scenarios: an IPO scenario and a remain private scenario. Both scenarios estimated an equity value based on the
guideline public company method under the market approach. The guideline public companies considered for these scenarios consist of biopharmaceutical companies with recently completed initial public offerings. The IPO scenario assumed the conversion
of our preferred shares to common stock. In the remain-private scenario, value was allocated using the OPM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the OPM, volatility is estimated based on
the trading histories of selected guideline public companies. The relative probability of each scenario was determined based on an assessment of then-current market conditions and our expectations as to timing and prospects of an IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations were highly complex and subjective and represented management&#146;s best estimates, which involved inherent
uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could be materially different.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary
for our board of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted
market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Awards granted </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes each equity award grant between January&nbsp;1, 2018 through September&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type of<BR>Award</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;Price<BR>of Award per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;of<BR>Common&nbsp;Stock<BR>per Share on<BR>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Estimated&nbsp;Fair<BR>Value&nbsp;of&nbsp;Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;24, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,403,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;15, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;20, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,136,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;10, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;9, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;18, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,862,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,633,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;16, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,898,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;11, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">875,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;18, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,338,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;6, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">654,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;6, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;23, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,388,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the time of grant of each of the stock options listed above, our board of directors determined that the values included
under &#147;Per share exercise price of awards&#148; reasonably reflected the per share fair value of our common shares as of the grant dates. However, for certain dates, the fair value of the common shares at the date of these grants was adjusted
to the amounts included under &#147;Fair Value of Common Stock per Share on Grant Date&#148; in connection with retrospective fair value assessments for financial reporting purposes. These reassessed values were based, in part, upon third-party
valuations of our common stock prepared as of each grant date on a retrospective basis. The third-party valuations were prepared using the hybrid method and used market approaches to determine our enterprise value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as
defined under applicable SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risk related to changes in interest rates. As of December&nbsp;31, 2018 and 2019, our cash equivalents consisted of interest-bearing
checking accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term nature and the low risk profile of our interest-bearing accounts, an
immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents or on our financial position or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our costs. We do not believe that inflation had a material effect on our business, financial condition or results
of operations during the years ended December&nbsp;31, 2018 and 2019, and the nine months ended September&nbsp;30, 2019 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&nbsp;107 of the JOBS Act provides that an &#147;emerging
growth company,&#148; or an EGC, can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. Thus,
an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which
we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company
until the earliest to occur of: (1)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (2)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700.0&nbsp;million of
equity securities <FONT STYLE="white-space:nowrap">held&nbsp;by&nbsp;non-affiliates;&nbsp;(3)&nbsp;the&nbsp;date</FONT> on which we have issued more than
<FONT STYLE="white-space:nowrap">$1.0&nbsp;billion&nbsp;in&nbsp;non-convertible&nbsp;debt&nbsp;securities</FONT> during the prior three-year period; and (4)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial
public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a targeted oncology company focused on
developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective
therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned
and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. Since we commenced
operations in 2016, we have discovered or developed five oncology programs that include four product candidates in either <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead targeted oncology product candidate, <FONT STYLE="white-space:nowrap">IK-930,</FONT> is an oral small molecule inhibitor of the transcriptional
enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is widely accepted as a key and prevalent driver of cancer pathogenesis and is genetically altered in approximately 10% of all cancers, and
such genetic alterations are generally associated with poor clinical outcomes. We intend to pursue clinical development of <FONT STYLE="white-space:nowrap">IK-930</FONT> across a wide range of tumor types with known Hippo pathway mutations, and plan
to focus our initial development efforts on indications that provide the potential for rapid clinical development to achieve <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> such as mesothelioma and
soft tissue sarcomas. We intend to submit an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for <FONT STYLE="white-space:nowrap">IK-930</FONT> in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our second targeted oncology program, we have discovered and plan to develop oral small molecule inhibitors of extracellular signal-related kinase 5, or
ERK5, a downstream enzyme in the RAS signaling pathway, which have the potential to bring therapeutic benefit to cancer patients with a mutation in the kirsten rat sarcoma, or KRAS, gene, which is an oncogene implicated in many cancers. We
anticipate nominating a development candidate for the ERK5 program and initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021 with the goal of submitting an IND in the second half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the programs described above, we have ongoing discovery programs in targeted oncology focused on the development of novel drug candidates that
target key nodes within the RAS pathway, and expect to nominate the first development candidate resulting from these discovery programs in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition to our targeted oncology programs, we have three product candidates designed to modulate the tumor microenvironment in specific patient populations by leveraging biomarker-driven patient enrichment strategies. Two of these product
candidates, <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> are partnered with Bristol-Myers Squibb Company, or BMS, which we believe validates our ability to rapidly advance internally developed
product candidates into clinical development using biomarker-driven patient enrichment strategies. The programs are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">IK-175</FONT> is an oral inhibitor of aryl hydrocarbon receptor, or AHR. We are
currently enrolling patients with bladder cancer with activated AHR in a dose expansion cohort of a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">IK-175</FONT> as a monotherapy. Additionally, we plan on assessing <FONT
STYLE="white-space:nowrap">IK-175</FONT> in combination with nivolumab in patients with bladder cancer in the first half of 2021 in the Phase 1b portion of the clinical trial. We expect to complete enrollment in both treatment arms in the second
half of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">IK-412</FONT> is an enzyme therapy designed to lower levels of immunosuppressive
kynurenine in the tumor microenvironment. We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">IK-412</FONT> and intend to submit an IND in the second half of 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Finally, we are evaluating <FONT STYLE="white-space:nowrap">IK-007,</FONT> an oral antagonist of prostaglandin E2
receptor 4, or EP4, in a Phase 1b clinical trial in biomarker-enriched patients with microsatellite stable colorectal cancer, or MSS CRC, who express high levels of an EP4 pathway metabolite called PGE2 Metabolite, or PGEM. We expect to complete
enrollment for the Phase 1b clinical trial in the second half of 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current pipeline of discovery and clinical programs is shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g93v29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Leading Investors and Partners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2020, we have raised over $160&nbsp;million from leading life sciences investors and companies, including $120.0&nbsp;million from our
issuance of Series B preferred stock in December 2020 led by Omega Funds and including participation from Fidelity Management and Research Company, Surveyor Capital (a Citadel company), Invus, Farallon Capital Management, BVF Partners, L.P., Cowen
Healthcare Investments, Logos Capital, and HealthCor Management. Existing investors Atlas Venture, OrbiMed and BMS all participated in the financing. In addition to the equity investments noted above, we received an aggregate of $80.5&nbsp;million
in January 2019 as part of our strategic collaboration with Celgene Corporation (now BMS). This collaboration covers two of our tumor microenvironment programs, an AHR antagonist <FONT STYLE="white-space:nowrap">(IK-175)</FONT> and a recombinant
human kynurenine-degrading enzyme <FONT STYLE="white-space:nowrap">(IK-412).</FONT> If BMS elects to license each of our programs, we are entitled to an aggregate of $90.0&nbsp;million in <FONT STYLE="white-space:nowrap">opt-in</FONT> fees, and up
to $265.0&nbsp;million in regulatory milestones and $185.0&nbsp;million in commercial milestones for each program as well as a tiered royalties at rates ranging from the high single to low double digit percentages based on worldwide annual net
sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dedicated to bringing
next generation targeted oncology therapies to cancer patients. We plan to achieve this goal by leveraging our deep understanding of complex biologic pathways and biomarker-driven discovery and clinical development. The key components of our
strategy are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Rapidly advance <FONT STYLE="white-space:nowrap">IK-930</FONT> through clinical development. </B>We are
developing <FONT STYLE="white-space:nowrap">IK-930,</FONT> an oral small molecule inhibitor of TEAD to evaluate its potential to bring single agent therapeutic benefit to patients with tumors harboring genetic mutations in the Hippo signaling
pathway. Our clinical development strategy is designed to rapidly achieve clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> and to leverage the potential for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fast-to-market</FONT></FONT> opportunities in orphan indications, and to expand in broader indications through </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
combination treatments with other targeted therapies to address therapeutic resistance, such as with epidermal growth factor receptor, or EGFR, inhibitor. We are conducting <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">IK-930</FONT> and intend to submit an IND in the second half of 2021 and expect to begin a Phase 1 clinical trial shortly thereafter. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expeditiously progress a development candidate for the RAS signaling program through clinical development.
</B>We have discovered small molecule inhibitors of ERK5 in the RAS signaling pathway that we believe may have the potential to bring therapeutic benefit to patients with KRAS mutant cancers, which have a high unmet medical need. We plan to pursue
clinical development of oral ERK5 inhibitors both as single agent in KRAS mutated pancreatic and lung cancer and in combination with other targeted therapies to address resistance to mitogen-activated protein kinase, or MEK, inhibitors. We
anticipate nominating a development candidate and initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021 and anticipate submitting an IND in the second half of 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deepen our pipeline of biomarker-driven targeted oncology programs. </B>We are currently pursuing
discovery-stage programs against targets that are key drivers of cancer progression and in indications with high unmet medical need, in addition to TEAD and ERK5, in particular in the RAS pathway. In addition to internally identified targets, we
plan to opportunistically <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire discovery and clinical programs for which we can leverage our expertise in drug discovery and structural biology-guided chemistry, with a focus on mechanisms of
actions targeting cancer drivers that complement our existing targeted oncology programs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the value of our pipeline by retaining commercial rights to our targeted oncology programs. </B>As we
seek to expand our targeted oncology pipeline and advance it rapidly through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trials, we plan to build a fully integrated, biotechnology
company. We hold worldwide development and commercial rights to our targeted oncology programs, and we intend to continue to develop our capabilities in late stage clinical development and commercialization to maximize the potential value of these
programs. Given that our targeted oncology programs have broad applicability, we may also opportunistically enter into strategic partnerships to maximize the value potential, as well as clinical and commercial impact of our overall pipeline.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> our
<FONT STYLE="white-space:nowrap">BMS-partnered</FONT> programs, through Phase 1b clinical trials and achieve key near-term financial milestones</B>. BMS, our strategic partner, has the exclusive right to license each of <FONT
STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412</FONT> worldwide through completion of the Phase 1b clinical trials. If BMS exercises both licenses, we would receive $90&nbsp;million in <FONT
STYLE="white-space:nowrap">opt-in</FONT> fees, which would provide a meaningful source of <FONT STYLE="white-space:nowrap">non-dilutive</FONT> capital. We would have the right to receive clinical, regulatory and commercial milestone payments and
royalties on worldwide net sales. We are currently conducting a dose expansion cohort of the open-label Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">IK-175</FONT> in bladder cancer patients with activated AHR enriched with an AHR
biomarker using our proprietary assay. For <FONT STYLE="white-space:nowrap">IK-175,</FONT> we anticipate initiating the Phase 1b combination arm with nivolumab in patients with bladder cancer in the first half of 2021 and completing enrollment in
both treatment arms in the second half of 2022. For <FONT STYLE="white-space:nowrap">IK-412,</FONT> we intend to submit an IND in the second half of 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Research&nbsp;&amp; Development Expertise </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ
a patient-centric R&amp;D approach across discovery chemistry and biology, translational science and clinical development for our targeted oncology and tumor microenvironment therapies. Using this approach, we have discovered or developed five
oncology programs that include four product candidates since we commenced operations in 2016: two of which are currently in clinical development, two of which are in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and one program in
discovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We select new programs based on two key strategic principles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cancer driver targets must have a compelling biological rationale, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tumor intrinsic changes such as mutations, gene fusions, and gene amplifications; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong clinical rationale with the potential to develop a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapeutic. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Alignment with a translational path in disease indications with high unmet medical need, including:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No currently approved therapies, or patient populations that are underserved by current treatments; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A biomarker-driven
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical development plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We pursue
the discovery and development of small molecule modulators of targets in any target classes that meet these key strategic principles. To date, we have pursued programs and product candidates against transcription factors, kinases, receptors and
tumor microenvironment metabolites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our expertise, capabilities and experience in discovering small molecules using structural biology-guided
chemistry and <I>in vivo</I> systems to optimize pharmaceutical properties to rigorously select the best molecules, is key to our progress to date. In parallel to selecting lead small molecules, we are generating translational insights and
discovering biomarkers to select patients who we believe may be most likely to benefit. We take a holistic view of the entire R&amp;D process to design a focused clinical strategy to maximize the probability of success for each program, integrating
collective knowledge of discovery and translational science, in order to select what we believe are the most relevant tumor types and the patients who may benefit the most. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Early in the R&amp;D process, we identify biomarkers to support which tumor types we may pursue in the clinic and to help determine which patients with the
selected tumor types may be better suited for our therapies. Because our pipeline has been focused on programs where there are no approved product candidates, we have had to discover novel biomarkers internally to enable indication and patient
selection strategies, as well as develop new assays to measure these biomarkers in the clinic. We are currently using these biomarkers across our pipeline using techniques and assays such as <FONT STYLE="white-space:nowrap">LC-MS/MS</FONT> for
metabolites analysis, RNASeq for gene signature, immunohistochemistry, or IHC, next generation sequencing, or NGS, and chemokine/cytokine profiling. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For TEAD, we plan on using NGS to select patients with genetic alterations in the Hippo signaling pathway, such
as Neurofibromatosis 2, or NF2, loss and/or YAP1 and TAZ gene fusions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For <FONT STYLE="white-space:nowrap">IK-175,</FONT> we are currently enrolling bladder cancer patients selected
for a new IHC biomarker we developed that measures activated AHR. We are also using an internally discovered <FONT STYLE="white-space:nowrap">AHR-activated</FONT> gene transcription signature, measured by RNASeq, to inform indication selection.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For <FONT STYLE="white-space:nowrap">IK-007,</FONT> we identified PGEM as a biomarker that we believe correlates
with clinical benefit. We then generated a validated <FONT STYLE="white-space:nowrap">LC-MS/MS</FONT> assay to enable prospective patient enrollment in our ongoing clinical study. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of our R&amp;D leadership and executive teams bring 23 years of experience on average and have contributed to over 50 INDs and 14 regulatory approvals
throughout their careers at both biotech and pharma companies. In addition, we have recently formed a multidisciplinary scientific advisory board, or SAB, that will bring extensive strategic, clinical, translational and drug development expertise.
Our SAB members include George Demetri, M.D., (Chair) Director of the Ludwig Center at Dana-Farber/Harvard Cancer Center, Kevan Shokat, Ph.D., Professor and Vice-Chair, Department of Cellular and Molecular Pharmacology at the University of
California San Francisco, and Josep Tabernero, M.D., Ph.D., Head of the Medical Oncology Department at the Vall d&#146;Hebron Barcelona Hospital and Director of the Vall d&#146;Hebron Institute of Oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are continuing to execute our patient-centric R&amp;D approach as planned and we are currently working on a number of early stage discovery programs in the
targeted oncology space. Moreover, we are developing a preclinical-stage <FONT STYLE="white-space:nowrap">gut-preferred</FONT> AHR agonist program for treatment of inflammatory bowel disease, or IBD, including in patients who have caspase
recruitment domain-containing protein 9, or CARD9, polymorphisms. We plan on exploring a partnership for this <FONT STYLE="white-space:nowrap">non-core</FONT> program in the second half of 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Our Programs </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Targeted Oncology Programs </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">IK-930,</FONT> a TEAD inhibitor </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-930</FONT> is an internally discovered oral small
molecule inhibitor of the TEAD family of transcription factors in the Hippo signaling pathway that is undergoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. We believe that <FONT STYLE="white-space:nowrap">IK-930</FONT> is one of
the most advanced TEAD inhibitors currently in development for this important, but historically undruggable, target. TEAD functions as the ultimate step in the Hippo signal transduction pathway by driving expression of genes involved in cell
proliferation and survival. The Hippo pathway is widely accepted as a key and prevalent driver of cancer pathogenesis and is genetically altered in approximately 10% of all cancers, and such genetic alterations are often associated with poor
clinical outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-930</FONT> is a novel inhibitor of TEAD that exploits a recently discovered and promising binding
pocket on TEAD to enable the inhibitory effect upon the Hippo pathway. TEAD activity is dependent on binding of the fatty acid palmitate to a central lipid pocket. <FONT STYLE="white-space:nowrap">IK-930</FONT> blocks palmitate from binding TEAD,
thereby disrupting TEAD-dependent gene transcription. The mechanism of action of <FONT STYLE="white-space:nowrap">IK-930</FONT> is differentiated from historically unsuccessful attempts that targeted <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">protein-to-protein</FONT></FONT> interactions, or PPIs, using either small molecules or cyclic peptides. Using structural biology-guided chemistry, we were able to generate novel TEAD inhibitor compounds across several
chemical series directed to this binding pocket in TEAD and profile them using various <I>in vitro</I> and <I>in vivo</I> assays assessing potency, selectivity, tolerability and activity. By selecting <FONT STYLE="white-space:nowrap">IK-930</FONT>
based upon these characteristics, we believe <FONT STYLE="white-space:nowrap">IK-930</FONT> has the potential to bring therapeutic benefit to patients with tumors harboring genetic mutations in the Hippo signaling pathway. Moreover, activation of
the Hippo pathway confers resistance to certain targeted therapies, such as EGFR inhibitors and MEK inhibitors, which supports the potential for <FONT STYLE="white-space:nowrap">IK-930</FONT> to be combined with these therapies to overcome
therapeutic resistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">IK-930</FONT>
and intend to submit an IND in the second half of 2021 and expect to begin a Phase&nbsp;1 clinical trial shortly thereafter. In our Phase&nbsp;1 clinical trial, we expect to evaluate <FONT STYLE="white-space:nowrap">IK-930</FONT> as a monotherapy in
orphan Hippo-mutated cancers in order to establish <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> and in combination with other targeted agents to address therapeutic resistance in more prevalent
tumor indications characterized by genetic alterations, including EGFR. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Role of the Hippo pathway and TEAD in oncology </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Hippo pathway is a highly conserved developmental signaling pathway that modulates the regulation of multiple biological processes including cell
proliferation, survival, differentiation, organ size, and tissue homeostasis. Dysregulation of the Hippo pathway is associated with the induction of hyperproliferation, cellular invasion, metastasis, cancer cell maintenance and therapeutic
resistance and has been linked to other <FONT STYLE="white-space:nowrap">pro-tumorigenic</FONT> activities such as activation of regulatory T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Hippo signaling cascade begins with NF2, a gene that encodes the scaffold protein merlin, which links multiple extracellular cues to an intracellular signaling cascade. Merlin activates the kinases MST1 and MST2, or MST1/2, which subsequently
phosphorylate and activate the kinases LATS1 and LATS2, or LATS1/2. LATS1/2 phosphorylates two key transcriptional coactivators of TEAD: YAP1 and TAZ. When phosphorylated, YAP1 and TAZ are sequestered to the cytoplasm where they are targeted for
proteasome-mediated degradation. When the upstream portion of the signaling cascade is inactivated through normal regulation or through inactivating mutations, YAP1 and TAZ are not phosphorylated and can shuttle into the nucleus. Once inside the
nucleus, YAP1 and TAZ bind TEAD to enable the transcription of TEAD target genes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schematic diagram of the Hippo pathway </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g88z21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the role of certain Hippo pathway alterations in driving cancer, several pathway components are known to drive
resistance to targeted therapies such as EGFR inhibitors. Published data from patient tumor samples shows that, upon acquired resistance to EGFR inhibitors through specific mutations in EGFR, there is an increase in nuclear YAP1 in tumors as
compared to baseline. In EGFR mutant lung cancer cell lines <I>in vitro</I>, the increase in nuclear YAP1 was observed to lead to increased TEAD activity as measured by higher levels of TEAD gene transcription. These data suggest that the addition
of a TEAD inhibitor to an EGFR inhibitor regimen in patients with EGFR resistant tumors may be able to overcome therapeutic resistance to EGFR inhibition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that blocking TEAD-mediated cell proliferation through direct TEAD inhibition could be an important therapeutic intervention for patients with
Hippo pathway mutations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Epidemiology of Hippo pathway driven cancers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Published literature suggests that approximately 10% of all cancers have dysregulation of the Hippo pathway and subsequent activation of TEAD. Dysregulation
can occur at multiple nodes within the pathway. For example, NF2 can undergo inactivating mutations and YAP1 and TAZ can undergo gene amplification. These genetic alterations lead to tumor formation in mouse models and therefore are believed to be
genetic drivers of cancer. Moreover, there is cross-talk between the Hippo pathway and multiple other signal transduction pathways, such as EGFR, which can lead to aberrant TEAD activation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that approximately 125,000 newly diagnosed cancer patients annually within the United States have tumors which harbor genetic alterations in the
Hippo pathway, based on the incidence of cancers with YAP1 and TAZ gene amplification or fusion as well as NF2 loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figure below illustrates the
incidence of individuals with newly diagnosed cancers that harbor Hippo pathway genetic alterations in the United States on an annual basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Incidence of Hippo pathway genetic alterations </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g02m26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genetic alterations in the Hippo pathway are present in diverse cancer types but there are certain cancers, including more
prevalent indications such as lung squamous cell carcinoma, and rarer indications such as mesothelioma and sarcoma, which are reported to have a particularly high incidence of genetic alterations in the Hippo pathway and where alterations are
considered to drive tumor formation and growth and are associated with a poor patient prognosis: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Hippo pathway is one of the most dysregulated signal transduction pathway in cancer. Loss of function
mutations in NF2 are found in approximately 40% of cases of malignant mesothelioma and are associated with poor prognosis, including a significantly shorter progression free survival and overall survival. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Multiple soft tissue sarcomas have YAP1 and TAZ gene fusions. For example, approximately 90% of epithelioid
hemangioendothelioma, or EHE, have <FONT STYLE="white-space:nowrap">TAZ-CAMTA1</FONT> fusions and the remaining 10% have YAP1-TFE3 fusions, which are directly linked to the etiology of these cancers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In squamous lung cancer, YAP1 and TAZ amplifications are found in approximately 6% and 29%, respectively, based
on internal analysis of The Cancer Genome Atlas (TCGA) using the Genome Data Commons and cBioportal tools. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the role of certain
Hippo pathway alterations in driving cancer, several pathway components are known to drive resistance to targeted therapies such as EGFR inhibitors. Approximately 30% of patients with <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung
carcinoma, or NSCLC, will have EGFR mutations. Tagrisso (osimertinib) is an EGFR inhibitor approved for the first-line treatment of patients with NSCLC whose tumors have certain EGFR mutations. Despite the robust clinical activity exerted by
osimertinib, patients often develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological options available to date. Early use of osimertinib raises the question of the optimal
management of osimertinib resistance and the role of targeted agent combinations in this patient population. We believe this population also represents a substantial opportunity for TEAD inhibitors. Published data from patient tumor samples shows
that, upon acquired resistance to EGFR inhibitors through specific mutations in EGFR, there is an increase in nuclear YAP1 in tumors as compared to baseline. In EGFR mutant lung cancer cell lines <I>in vitro</I>, the increase in nuclear YAP1 was
observed to lead to increased TEAD activity as measured by higher levels of TEAD gene transcription. These data suggest that the addition of a TEAD inhibitor to an EGFR inhibitor regimen in patients with EGFR
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resistant tumors may be able to overcome therapeutic resistance to EGFR inhibition. We have generated preclinical data supporting our belief of the clinical opportunity to treat EGFR resistant
patients with <FONT STYLE="white-space:nowrap">IK-930.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disease Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The epidemiology findings in mesothelioma, EHE, soft tissue sarcomas as well as other solid tumors including menangioma point to the critical role of the Hippo
pathway in tumor formation. In addition to the strong biological rationale for pursuing development of <FONT STYLE="white-space:nowrap">IK-930</FONT> in these cancers, we believe that these are areas of high unmet medical need in which <FONT
STYLE="white-space:nowrap">IK-930</FONT> has the potential to provide meaningful clinical benefit to patients. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Malignant mesothelioma is a rare cancer in the tissue lining the lungs, and is a very aggressive cancer with a
poor prognosis. After initial diagnosis, patients are reported to have a median life expectancy of 15 months. Approximately 3,000 people in the United States are diagnosed with mesothelioma each year. On average, about 2,500 mesothelioma-related
deaths occur in the United States each year. There are few effective treatment options for advanced unresectable malignant mesothelioma and to date only two treatment have been approved by the FDA for the treatment of this condition. The combination
of cisplatin and pemetrexed was the first systemic treatment approved by the FDA in 2004, followed only by the May 2020 FDA approval of Nivolumab in combination with ipilimumab. Even with this newly approved treatment, the median overall survival of
these patients is 18 months, with most of the patients eventually progressing and dying from their disease. Approximately 40% of malignant mesothelioma patients are associated to NF2 deficiency and this genetic alteration has been described to
contribute to asbestos-induced mesotheliomagenesis in animal models, showing that NF2 drives the malignant behavior of this subset of mesothelioma cases. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition to mesothelioma, menangioma also has high frequency of NF2 deficiency. Menangioma is the most common
central nervous system, or CNS, tumor, accounting for approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of primary CNS tumors. Surgery and/or radiation therapy, or RT, constitute the initial therapeutic approach for meningiomas.
Furthermore, surgery and/or RT can control disease in some patients with recurrence. Unfortunately, despite the appropriate use of surgery and RT for initial disease management and management of recurrent disease, there is a subset of patients in
whom disease cannot be controlled with local approaches. Experience with systemic treatments is limited and although several agents have been studied, none have an established role in prolonging progression-free survival or overall survival. The
outcome of this subset of patients with persistent or recurrent meningiomas continue to be poor, underscoring the substantial need for new therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Soft Tissue Sarcomas, or STS, represent a rare and heterogeneous group of solid tumors derived from mesenchymal
progenitor cells and characterized by a variety of genetic alterations. Recent molecular and genetic studies in large cohorts of STS cases have demonstrated an essential role of YAP1/TAZ in sarcomagenesis, implying that a YAP1/TAZ directed
therapeutic approach could represent a rational strategy in a selected subgroup of these tumors. STS account for 1% of all adult malignancies. While the clinical outcome of these diseases has improved in the last decade with the use of
anthracycline-based chemotherapy and the introduction of novel therapies targeting different cell pathways and the use of immune checkpoints, the prognosis for a significant subgroup of patients with STS is still poor and there is an unmet medical
need for these patients. For these reasons, the identification of novel molecular targets is important in these rare malignancies. Recent studies in a large cohort of STS tumors showed that myxoid liposarcomas, synovial sarcomas and angiosarcomas,
in addition to EHE, expressed the highest levels of YAP1/TAZ gene expression, potentially driving tumorigenesis in these subsets of STS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EHE is a rare STS that grows from the cells that make up the lining of blood vessels with an incidence of one
case per million people. This cancer can occur anywhere in the body with the most common sites being the liver, lungs, and bone. It usually occurs in people between 30 and 50 years of age but can occur in young children and older people. Surgery and
radiotherapy have been used as treatment for localized disease and several interventions have been used with palliative intent in the recurrent or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
metastatic cases, including steroids, interferon, and others, but there is currently no specific targeted therapy approved for the treatment of EHE. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Despite the successful expansion of personalized oncology using targeted therapies to selectively treat patients
with specific mutations in key oncogenic drivers, intrinsic and acquired resistance to targeted agents is a growing clinical problem. Activation of YAP1/TAZ has been associated with the development of resistance to various targeted agents, including
in EGFR mutant NSCLC, and in KRAS mutant tumors such as pancreatic carcinoma, CRC, and NSCLC. In EGFR mutant NSCLC, the successful development of anti-EGFR inhibitors has improved the clinical outcome for these patients in not only advanced but also
early disease and has become a new therapeutic paradigm for this patient population. However, the most efficient approach to managing emerging resistance to EGFR inhibitors remains to be determined. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Solution, <FONT STYLE="white-space:nowrap">IK-930</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-930</FONT> is an oral small molecule inhibitor of TEAD that binds to a recently discovered lipid binding pocket on TEAD
itself. TEAD activity is dependent on binding of the fatty acid palmitate to a central lipid pocket. <FONT STYLE="white-space:nowrap">IK-930</FONT> blocks palmitate from binding TEAD, thereby disrupting TEAD-dependent gene transcription. The
mechanism of action of <FONT STYLE="white-space:nowrap">IK-930</FONT> is differentiated from historically unsuccessful attempts that targeted PPIs using either small molecules or cyclic peptides. It is often difficult to discover compounds that
disrupt PPIs with sufficient potency due to the typically undruggable shallow PPI pockets and large surface areas that make up tight PPIs. We believe that targeting the lipid binding pocket of TEAD has the potential to yield more potent and
selective molecules as compared to these historical attempts. Using structural biology-guided chemistry, we were able to generate novel TEAD inhibitor compounds across several chemical series directed to this binding pocket in TEAD and profile them
using various <I>in vitro</I> and <I>in vivo</I> assays assessing potency, selectivity, tolerability and activity. We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and we intend to submit an IND in the second
half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">IK-930</FONT> is one of the most advanced TEAD inhibitors in development and compares
favorably to other TEAD inhibitors based on publicly available information. Moreover, we believe we are well positioned given our ongoing translational work, the planned breadth of our strategy for clinical development and ability to prospectively
enrich programs to select patients most likely to benefit from <FONT STYLE="white-space:nowrap">IK-930</FONT> using our biomarkers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated
preclinical data supporting our belief of the clinical opportunity to treat EGFR resistant patients with <FONT STYLE="white-space:nowrap">IK-930.</FONT> Based on our preclinical studies, we believe <FONT STYLE="white-space:nowrap">IK-930</FONT> is a
potent, well tolerated and selective TEAD inhibitor with favorable pharmacologic properties. In a TEAD reporter cell line, <FONT STYLE="white-space:nowrap">IK-930</FONT> inhibited TEAD-dependent transcription with an EC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB> of 25 nM, and inhibited proliferation of H226 cells, an NF2 mutant mesothelioma cell line, with an EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> of 21 nM, demonstrating that <FONT
STYLE="white-space:nowrap">IK-930</FONT> has high potency in inhibiting activated Hippo signaling in cultured cancer cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figure below illustrates
the inhibition of TEAD by <FONT STYLE="white-space:nowrap">IK-930.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inhibition of TEAD by <FONT STYLE="white-space:nowrap">IK-930</FONT> blocks TEAD-dependent
transcription and proliferation in H226 cells containing an NF2 mutation </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g30q34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of <FONT STYLE="white-space:nowrap">IK-930</FONT> to selectively inhibit proliferation in Hippo pathway mutated
cells was demonstrated in the H28 mesothelioma cell line which does not have any Hippo pathway mutations. This cell line is insensitive to <FONT STYLE="white-space:nowrap">IK-930.</FONT> However, knockdown of NF2 using CAS9-CRISPR converts H28 into
an <FONT STYLE="white-space:nowrap">IK-930</FONT> sensitive tumor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figure below illustrates <FONT STYLE="white-space:nowrap">IK-930</FONT> blocking
the proliferation of cells with NF2 loss but not in cells with normal NF2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">IK-930</FONT> blocks
proliferation in cells with NF2 loss but not in cells with normal NF2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g04v89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also observed that IK-930 was significantly selective for TEAD as assessed in these cell-based assays relative to a
safety panel of 45 receptors, enzymes and ion channels, a human ether-a-go-go related gene, or hERG, assay and a panel of Cytochrome P450, or CYP, inhibition assays. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We observed favorable PK/PD of <FONT STYLE="white-space:nowrap">IK-930</FONT> in preclinical studies. We observed that
<FONT STYLE="white-space:nowrap">IK-930</FONT> exhibited anti-tumor activity in tumor models with Hippo pathway mutations. <FONT STYLE="white-space:nowrap">IK-930</FONT> dosed in a H226 NF2 mutant mouse xenograft
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
model led to antitumor activity throughout the treatment period. We observed similar activity in a xenograft model using a LATS1 fusion/LATS2 deleted tumor model.
<FONT STYLE="white-space:nowrap">IK-930</FONT> dosed in NF2 mutant and LATS1 fusion/LAT2 deleted mouse xenograft models led to tumor growth inhibition compared to vehicle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figures below illustrate the antitumor activity of <FONT STYLE="white-space:nowrap">IK-930</FONT> in Hippo mutant xenograft models. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Antitumor activity of <FONT STYLE="white-space:nowrap">IK-930</FONT> in Hippo mutant xenograft models </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g31l85.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g84y44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to potential for single agent activity in tumors with genetic alterations in the Hippo pathway, we believe
there is an opportunity for <FONT STYLE="white-space:nowrap">IK-930</FONT> to be beneficial in combination with other targeted therapies in the therapeutic resistance setting. For example, YAP1 activation (nuclear localization) has been shown to
drive resistance to EGFR targeted therapies. NSCLC patients who develop resistance to EGFR inhibitors have higher levels of nuclear YAP expression in their tumors compared to baseline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated robust preclinical data supporting our confidence in the clinical opportunity to treat EGFR resistant patients with <FONT
STYLE="white-space:nowrap">IK-930.</FONT> We observed <I>in vitro</I> that inhibitors of EGFR (osimertinib) promote YAP1 nuclear localization in EGFR mutant NSCLC cells. Moreover, we observed that <FONT STYLE="white-space:nowrap">IK-930</FONT> is
able to kill EGFR resistant lung cancer cells <I>in vitro</I> in combination with osimertinib. We observed increased apoptosis <I>in vitro</I> and activity <I>in vivo</I> of <FONT STYLE="white-space:nowrap">IK-930</FONT> combined with EGFR
inhibition. In the H1975 EGFR mutant lung cancer xenograft mouse model, we observed meaningful tumor growth inhibition in the group treated with <FONT STYLE="white-space:nowrap">IK-930</FONT> in combination with osimertinib, as well as complete
regressions in the group treated with <FONT STYLE="white-space:nowrap">IK-930</FONT> in combination with osimertinib </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and trametinib, a MEK inhibitor, supporting that shutting down the mitogen-activated protein kinase, or MAPK, survival pathway further leads to robust anti-tumor activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figure below illustrates <I>in vitro</I> (top) and <I>in vivo</I> (bottom) models of <FONT STYLE="white-space:nowrap">IK-930</FONT> in EGFR resistant lung
cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IK-930 in EGFR resistant lung cancer </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g42g02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g04v02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-930</FONT> clinical development strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the broad role of the Hippo signaling pathway on tumor biology and cancer progression, we plan to focus development of
<FONT STYLE="white-space:nowrap">IK-930</FONT> on biomarker selected patient populations based on NF2 loss, and/or YAP1 and TAZ gene fusion or gene amplification in patients with solid tumors. We plan to utilize a comprehensive clinical development
strategy focused on genetically defined patient populations targeting indications of high unmet medical need, which includes the following components: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Assessing potential in rapid
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> opportunities of
<FONT STYLE="white-space:nowrap">IK-930</FONT> monotherapy for patients with genetic alterations in the Hippo pathway; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expanding our clinical development plan into combinations with other targeted therapies as well as larger
indications. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our Phase 1 clinical trial(s) of <FONT STYLE="white-space:nowrap">IK-930</FONT> will explore <FONT
STYLE="white-space:nowrap">IK-930</FONT> as a monotherapy and in combinations with other targeted therapies. In the monotherapy arm of the trial, we plan to evaluate the safety and activity of <FONT STYLE="white-space:nowrap">IK-930</FONT> in rare
and orphan tumors associated with specific genetic alterations such as NF2 loss. As illustrated in the figure below, in the dose escalation part of the monotherapy arm, we plan to enroll patients with tumors known to have high incidence of Hippo
pathway alterations to determine the maximum tolerated dose and the recommended Phase 2 dose. In the dose expansion cohort, we plan to select patients prospectively based on specific Hippo genetic alterations such as NF2 loss and/or YAP1 and TAZ
gene fusion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Rapid clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">POC/Fast-to-Market</FONT></FONT>
opportunities with <FONT STYLE="white-space:nowrap">IK-930</FONT> as single agent </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with planned expansion into combinations for
broader indications </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g18u29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the combination arm of the Phase 1 clinical trial, we plan to explore indications based on emerging efficacy data from
the monotherapy arm, as well as genetically defined tumors with known mechanisms of therapeutic resistance where <FONT STYLE="white-space:nowrap">IK-930&nbsp;may</FONT> be able to overcome resistance to targeted therapies, such as EGFR resistant
NSCLC, and potentially improve effectiveness of targeted therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ERK5 inhibitor / RAS signaling pathway inhibitor program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing a novel small molecule inhibitor program of ERK5 in the RAS signaling pathway with potential for treating patients with KRAS mutant tumors.
We anticipate nominating a development candidate and initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021 and plan to submit an IND in the second half of 2022. We believe that ERK5 provides an
opportunity to address unmet medical need in the RAS pathway by modulating a key target that is downstream of RAS and therefore applicable to cancers with a broad range of KRAS mutations such as G12C, G12D, G12V, and G13. We believe that positive
clinical data for KRAS G12C inhibitors currently in clinical development provide support for modulating targets in the KRAS pathway, including potentially G12D, G12V, G13 and others that are not being addressed by current product candidates or
approved therapies. We believe that ERK5 inhibition represents a differentiated approach to address mutations in the KRAS pathway more broadly, with potential to demonstrate both potent monotherapy activity, as well as potentially broader and more
durable activity in combination other targeted agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical models, we observed that knockout of ERK5 prevented tumor formation and improved
survival in genetically engineered KRAS mutant lung and pancreatic cancer models in mice. Small molecule inhibition of the target using an ERK5 inhibitor tool compound with suboptimal pharmacokinetics blocked tumor growth in patient-derived KRAS
mutated xenograft models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that inhibition of ERK5 has potential as a monotherapy in cancers with specific genetic alterations, including KRAS.
In studies using a KRAS primary human tumor model of lung and pancreatic cancer, we observed synergistic effects on tumor inhibition by combining this inhibitor tool compound of ERK5 and a MEK </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inhibitor and therefore we believe there is an opportunity to pursue development of our ERK5 inhibitor in combination with other targeted therapies such as MEK inhibitors to overcome or delay
therapeutic resistance to those therapies and thereby improve the effectiveness of these therapies. We are not aware of other ERK5 inhibitors in development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ERK5 Rationale </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ERK5 is a member of the MAPK
family. It is composed of an <FONT STYLE="white-space:nowrap">N-terminal</FONT> kinase domain and a <FONT STYLE="white-space:nowrap">C-terminal</FONT> tail responsible for <FONT STYLE="white-space:nowrap">sub-cellular</FONT> localization and
transcriptional activation. ERK5 can be activated in response to a range of mitogenic stimuli such as growth factors, G protein-coupled receptor agonists, cytokines and cellular stresses (e.g., hypoxia, shear stress). Through the MAPK signaling
cascade, mitogen-activated protein kinase 5, or MEK5 activates ERK5 by phosphorylating the <FONT STYLE="white-space:nowrap">N-terminal</FONT> domain, thereby enabling ERK5 kinase activity. ERK5 is an important mediator of tumorigenesis and
metastatic progression, and a fundamental component of drug resistance in cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have found an association between activated ERK5, as measured by an
internally discovered ERK5 gene expression signature, and cancer types with high incidence of KRAS mutations, including pancreatic cancer, lung cancer and CRC. In our preclinical KRAS mutant tumor models of lung and pancreatic cancer, we observed
that knocking out the target blocked tumor formation. For example, in a transgenic lung tumor model driven by KRAS G12D and p53 loss, in the absence of the ERK5 gene, only three of six mice formed one to two tumors over an 80-day period, while over
100 tumor lesions were observed in the lungs of mice that retained the ERK5 gene over the same 80-day period. In addition, we observed that, in the absence of the ERK5 gene in this model, survival of these mice was significantly improved. Moreover,
in the same transgenic lung tumor model in which the MEK5 enzyme responsible for activating ERK5 was itself activated (MEK 5 DD), a large number of tumors formed and the survival of the mice was greatly reduced. These data, as illustrated in the
figures below, suggest that ERK5 is an essential component to transduce signals in the RAS pathway and validate its key role in cancer formation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ERK5 knockout prevents tumor formation and improves survival in KRAS mouse lung tumor model </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g01k09.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g24k76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As illustrated in the figure below, we observed single agent anti-tumor activity in both a pancreatic and lung patient
derived xenografts in mice using a small-molecule ERK5 inhibitor. This inhibitor is a potent and selective tool compound with high selectivity for ERK5 but has a short half-life and short PD effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ERK5 inhibition reduces tumor growth in patient-derived mouse xenograft models of pancreatic and lung cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g71u06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, in preclinical studies in KRAS primary human tumor models of lung and pancreatic cancer, we observed synergistic
effects on tumor inhibition by combining this inhibitor tool compound of ERK5 and trametinib. These models contained high unmet medical need mutations in the RAS pathway. These data, as illustrated in the figure below, suggest that, in addition to
single agent potential in KRAS-mutated cancers, there is potentially a clinical opportunity for ERK5 inhibitors to be used in combination with MEK inhibitors and other targeted therapies to address therapeutic resistance in these patient
populations. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Synergistic combination of MEK inhibitor and ERK5 inhibitor in KRAS mutant pancreatic (left) and lung (right) primary
human tumor xenografts </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g63f26.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ERK5 Opportunity and Disease Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite continuous industry efforts in the past several decades to develop therapies for KRAS mutant cancers, therapies directly targeting KRAS G12C are only
now beginning to show clinical promise. For example, Amgen recently reported <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in topline Phase 2 clinical trial results of their KRAS G12C inhibitor
Sotorasib in advanced NSCLC. In the United States, about 13% of patients with NSCLC harbor the KRAS G12C mutation. Although there has been recent progress with these compounds that directly inhibit mutant KRAS, the majority of the KRAS space remains
open. At this time, 85% of KRAS mutations (G12D, G12V, G13, others) are not being addressed by current product candidates or approved therapies. KRAS mutations are estimated to occur in about 26% of all cancers, including 25% of lung cancers, 90% of
pancreatic cancers and between 27% and 56% of colorectal cancers. We believe that ERK5 represents a differentiated opportunity to address these high unmet medical need segments by modulating a key node downstream in the RAS signaling pathway. The
three indications we plan to initially focus on are NSCLC, pancreatic cancer and CRC, which we believe are indications where there is strong biologic rationale for ERK5 inhibition and significant unmet medical need. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>NSCLC</I>: There are an estimated 228,000 new cases of lung cancer diagnosed and approximately 135,000 deaths
in the United States annually. NSCLC is estimated to account for approximately 80% to 85% of lung cancer cases and KRAS mutations are estimated to occur in about 25%. Previously, patients were treated primarily with radiation therapy or combinations
of cytotoxic drugs. In the past 15 years, a number of targeted agents have been developed based on alterations in the genes for EGFR and anaplastic lymphoma kinase gene, or ALK, significantly improving the outcome of patients with NSCLC harboring
these genetic alterations. Furthermore, in the last five years, the introduction of immunotherapy for the treatment of NSCLC patients has also improved the outcome of the treatment in patients, especially those with high <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression. However, a significant proportion of NSCLC patients are ineligible for these novel therapies or develop resistance to existing treatments, representing an important unmet medical need.
Approximately <FONT STYLE="white-space:nowrap">two-thirds</FONT> of NSCLC patients are ineligible for treatment with EGFR or ALK targeted therapies, representing an important unmet medical need. Despite the availability of these new therapies, the
prognosis in NSCLC remains poor, with an overall five-year survival for all patients diagnosed with NSCLC estimated to be approximately 19% and until recently there were no specific therapeutic options for this subset of patients. Even with the
emergence of KRAS inhibitors targeting G12C mutations, most NSCLC patients with KRAS mutations will eventually progress and die due to their disease. An ERK5 inhibitor potentially could provide significant clinical benefit to patients with KRAS
mutations as a monotherapy as and in combination to patients whose tumors have developed resistance to EGFR therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pancreatic cancer</I>: The American Cancer Society estimates that about 57,600 patients will be diagnosed with
pancreatic cancer in 2020. The tendency of pancreatic cancer to spread silently before diagnosis makes it one of the deadliest cancer diagnoses. In metastatic pancreatic cancer, surgery and radiation are used only for symptom control. Chemotherapy,
such as gemcitabine and <FONT STYLE="white-space:nowrap">5-FU/leucovorin/oxaliplatin/irinotecan,</FONT> can help improve pancreatic cancer symptoms and survival. The drug olaparib (Lynparza) has been approved for metastatic patients with the BRCA
gene mutation whose cancer has responded well to chemotherapy. Unfortunately, in spite of the development of new treatments for pancreatic cancer, deaths due to this tumor are on the rise. The National Cancer Institute has identified targeting
oncogenic RAS as one of the four major priorities for pancreatic cancer research. In that context, the development of an ERK5 inhibitor potentially could represent a promising strategy to achieve improvement in outcomes for patients with advanced
pancreatic cancer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>CRC</I>:<B> </B>CRC is the second leading cause of cancer deaths in the United States. Despite the reduction
of incidence and improvement of early detection in the United States, approximately 86% of patients are diagnosed after the onset of symptoms when their disease is relatively advanced. Patients with advanced CRC are treated with radiation and
chemotherapy drugs such as <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> oxaliplatin and capecitabine, as well as recently approved antibodies, that inhibit angiogenesis, such as bevacizumab. In a subset of CRC patients, treatment with
antibodies targeting epidermal growth factor receptor, or EGFR, (for example, the agent cetuximab) has been shown to be effective both as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
monotherapy and in combination with chemotherapy. However, approximately 40% of patients have a mutation in the KRAS gene that renders cetuximab ineffective. We believe an ERK5 inhibitor could
restore sensitivity to EGFR inhibitors when given in combination. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution, ERK5 inhibitor program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing oral small molecule inhibitors of ERK5 and we believe there are currently no other ERK5 inhibitors in development. We plan to initially focus
our development efforts in lung and pancreatic cancer due to the strong biological rational and large market opportunity. Lead optimization is ongoing using structural biology-guided chemistry and we anticipate nominating a development candidate and
initiating <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in the second half of 2021. Our goal in lead optimization is to identify a novel, potent, selective, oral inhibitor of ERK5 with an optimized pharmacokinetic profile as compared
to the existing ERK5 inhibitor tool compound. In addition, we have developed <I>in vitro</I> assays to determine the best compound to take forward into clinical development. We are also developing reagents that will allow us to look at the
pharmacodynamics of selected compounds, including antibodies that detect active ERK5. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earlier stage RAS programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond TEAD and ERK5, we are developing early stage discovery programs in targeted oncology and applying our patient-centric research and development approach.
We have efforts underway to explore additional programs in the RAS pathway. We are focused on well-known targets and mutations in this pathway that lack approved or effective therapies and therefore represent high unmet medical needs and expect to
nominate the first development candidate resulting from these discovery programs in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Tumor Microenvironment Programs </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">BMS-Partnered</FONT> Programs: <FONT STYLE="white-space:nowrap">IK-175</FONT> and
<FONT STYLE="white-space:nowrap">IK-412</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have two programs partnered with BMS which validates our capabilities and approach to rapidly
advance internally developed product candidates into clinical development using biomarker-driven strategies. <FONT STYLE="white-space:nowrap">IK-175</FONT> is an inhibitor of AHR and patients with activated AHR are currently being enrolled in the
dose expansion cohort of a Phase 1 clinical trial of patients with locally advanced or metastatic solid tumors, including bladder <FONT STYLE="white-space:nowrap">cancer.&nbsp;IK-412</FONT> is an enzyme therapy designed to lower levels of
immunosuppressive kynurenine in the tumor microenvironment, and we are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. BMS, our strategic partner, has the exclusive right to license each of <FONT
STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412</FONT> through completion of the Phase 1b clinical trials. If BMS exercises both licenses, we would receive up to $90&nbsp;million in
<FONT STYLE="white-space:nowrap">opt-in</FONT> fees, which could provide a meaningful and <FONT STYLE="white-space:nowrap">non-dilutive</FONT> source of capital. We would have the right to receive clinical, regulatory and commercial milestone
payments and royalties on worldwide net sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Developments with the IDO1/TDO2 Pathway and Differentiation of Our Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our tumor microenvironment programs explore promising immunosuppressive pathways including the IDO1 pathway. We have developed two programs in the IDO1 pathway
<FONT STYLE="white-space:nowrap">(IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412),</FONT> each of which are partnered with BMS, which are differentiated from IDO1 inhibition preclinically by inhibiting bypass mechanisms to IDO1, including
the TDO2 pathway which epacadostat or linrodostat do not modulate. We believe the IDO1 pathway remains a promising immunosuppressive pathway in cancer with strong clinical and translational rationale, based on recent supportive emerging data
indicating that epacadostat was severely underdosed (by <FONT STYLE="white-space:nowrap">six-fold)</FONT> in the Phase 3 clinical trial in melanoma patients, suggesting that the IDO1 pathway has not yet been adequately tested.&nbsp;In addition, BMS
is developing an IDO1 inhibitor, linrodostat, which is in Phase 3 clinical trials in combination with nivolumab and/or neoadjuvant chemotherapy in muscle invasive bladder cancer, which we believe has the potential to further validate our approach.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on preclinical data, both <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT
STYLE="white-space:nowrap">IK-412</FONT> were observed to provide greater immune stimulation and tumor growth inhibition <I>in vivo</I> compared to epacadostat. In addition, we have identified certain proprietary biomarkers expressed in cancer
patients which we believe indicates a higher likelihood of responding to our therapies. For <FONT STYLE="white-space:nowrap">IK-175,</FONT> for example, we are currently enrolling bladder cancer patients selected for a novel IHC biomarker we
developed internally that measures activated AHR. For <FONT STYLE="white-space:nowrap">IK-412,</FONT> we are exploring an enrichment strategy based on high serum kynurenine levels in these patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">IK-175,</FONT> an AHR antagonist </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-175</FONT> is a potent, selective oral antagonist of AHR. We observed evidence of potent antitumor activity of <FONT
STYLE="white-space:nowrap">IK-175</FONT> as a monotherapy and in combination with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody in preclinical models. We are currently enrolling patients with
bladder cancer with activated AHR in a dose expansion cohort of a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">IK-175</FONT> as a monotherapy. We also plan to evaluate <FONT STYLE="white-space:nowrap">IK-175</FONT> in combination with
BMS&#146; nivolumab in the Phase 1b portion of the clinical trial. Pursuant to our master collaboration agreement with Celgene Corporation (now BMS), or the BMS Collaboration Agreement, we are responsible for development of <FONT
STYLE="white-space:nowrap">IK-175</FONT> through the completion of a Phase 1b clinical trial, through the completion of which BMS has an exclusive right to license <FONT STYLE="white-space:nowrap">IK-175</FONT> worldwide. See &#147;&#151;License and
Collaboration Agreements&#151;Master Collaboration Agreement with Bristol-Myers Squibb&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dual role of AHR in cancer
progression </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AHR is a ligand-dependent transcription factor that drives tumor progression through direct cancer cell and immunosuppressive effect
in the tumor microenvironment. In some tumors, such as bladder cancer, high levels of AHR lead to constitutive, <FONT STYLE="white-space:nowrap">always-on</FONT> activation and direct stimulation of tumor cell growth. AHR is also a critical
component of a dominant immunosuppressive pathway in cancer, a pathway that modulates the function of cells in both the innate and adaptive components of the immune system. AHR is, in its inactive form, found in the cytosol, outside the nucleus.
Upon binding of a signaling molecule or ligand, AHR migrates to the nucleus and functions as a transcription factor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AHR is overexpressed and
constitutively activated in a number of tumors, including, but not limited to, bladder cancer and advanced breast cancer. Constitutive activation of AHR also has been reported in head and neck squamous cell carcinoma as well as castration-resistant
prostate cancer. In melanoma, constitutive activation of AHR is believed to represent a significant mechanism of resistance to approved inhibitors of BRAF kinase. Inhibition of constitutively active AHR in patient-derived acute myeloid leukemia
cells has been shown to sensitize these cells to killing by natural killer cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bladder cancer overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We prioritized patients with bladder cancer as a lead indication for the development of <FONT STYLE="white-space:nowrap">IK-175</FONT> based on the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Poor prognosis of patients with bladder cancer is associated with a high AHR transcript profiling score;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">High levels of AHR mRNA and protein as measured by immunohistochemistry and RNAscope are found in bladder
cancers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AHR amplifications have been described in approximately 5% to 22% of bladder cancer patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nuclear localization of AHR is high in bladder cancers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bladder cancer is the most common malignancy involving the urinary system and there were an estimated 81,400 new cases of bladder cancer and 17,980 deaths in
the United States in 2020. The five-year survival for patients with early stage disease is 88%; however, for patients with metastatic disease or cancer that has spread to other parts of the body, the five-year survival drops to 5%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most common treatment for patients diagnosed with advanced or metastatic bladder cancer is chemotherapy
with platinum-based drugs such as carboplatin or cisplatin in combination with gemcitabine. Patients with metastatic disease that progresses during or after platinum-based chemotherapy are increasingly being treated with checkpoint immunotherapy. A
number of <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">PD-L1</FONT> checkpoint inhibitors have been approved by the FDA for the treatment of patients with refractory bladder cancer. Objective response rates in
clinical trials with checkpoint inhibitors have generally been between 13% and 29%. The median overall survival of patients with advanced or metastatic bladder cancer from the start of initial therapy is 12.7 months.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We began our ongoing trial of <FONT STYLE="white-space:nowrap">IK-175</FONT> with enrolling patients
with solid tumors with a specific focus on urothelial (bladder) cancer patients based on the high unmet medical need in bladder cancer and the biological rationale of the role of AHR in this tumor type. We are currently enrolling bladder cancer
patients, irrespective of prior <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, and have a biomarker for AHR that can help identify patients whose pathway is activated. For the combination arm with
nivolumab that we expect to initiate in the first half of 2021, bladder cancer patients will have been treated with nivolumab or other <FONT STYLE="white-space:nowrap">PD-1</FONT> therapy prior to be enrolled onto that arm. Moreover, we will seek to
enroll a subsection of patients who are AHR biomarker positive in the combination arm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution, <FONT STYLE="white-space:nowrap">IK-175</FONT>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-175</FONT> is an internally discovered small molecule AHR antagonist that we are developing for the treatment
of advanced or metastatic solid tumors, including bladder cancer where <FONT STYLE="white-space:nowrap">AHR-activation</FONT> is known to lead to poor prognoses. We observed that <FONT STYLE="white-space:nowrap">IK-175</FONT> is potent and selective
for AHR in multiple <I>in vitro</I> assays and species. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently enrolling patients with locally advanced or metastatic solid tumors in an
open-label Phase 1 clinical trial evaluating <FONT STYLE="white-space:nowrap">IK-175</FONT> as a monotherapy, including a dose expansion cohort for patients with bladder cancer. Clinical pharmacokinetic and pharmacodynamic data supports once-daily
clinical dosing in patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-175</FONT> preclinical data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preclinical studies, we observed that inhibition of AHR by <FONT STYLE="white-space:nowrap">IK-175</FONT> has potent antitumor activity in <FONT
STYLE="white-space:nowrap">AHR-dependent</FONT> tumors and led to immune-driven antitumor responses. <FONT STYLE="white-space:nowrap">CAL-27</FONT> is an oral squamous cell carcinoma in which AHR is constitutively active. Over 92% of <FONT
STYLE="white-space:nowrap">CAL-27</FONT> cultured cells <I>in vitro</I> were found to have AHR localized in the nucleus compared to less than 13% of cells from normal tissue. Based upon these findings, we assessed the direct antitumor effect of <FONT
STYLE="white-space:nowrap">IK-175</FONT> in a <FONT STYLE="white-space:nowrap">CAL-27</FONT> xenograft model. This model uses an immunocompromised mouse, which allows us to minimize the potential role of
<FONT STYLE="white-space:nowrap">IK-175</FONT> in tumor immune regulation and isolate the direct antitumor function of <FONT STYLE="white-space:nowrap">IK-175.</FONT> In this model illustrated in the figure below, monotherapy treatment with 25 mg/kg
of <FONT STYLE="white-space:nowrap">IK-175</FONT> arrested tumor growth. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Direct anti-tumor activity of <FONT STYLE="white-space:nowrap">IK-175</FONT> in a <FONT
STYLE="white-space:nowrap">CAL-27</FONT> immunocompromised mouse model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g53q79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also assessed the tumor immune activity of <FONT STYLE="white-space:nowrap">IK-175</FONT> alone and in combination with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody in a <FONT STYLE="white-space:nowrap">CT-26</FONT> colon cancer model in immune competent mice. Four days after inoculation of <FONT
STYLE="white-space:nowrap">CT-26,</FONT> we initiated once daily oral dosing with vehicle control or 25 mg/kg <FONT STYLE="white-space:nowrap">IK-175</FONT> and continued for 53 days. Concurrently, 10 mg/kg of an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody was administered twice a week for a total of 5 doses. Monotherapy with <FONT STYLE="white-space:nowrap">IK-175</FONT> resulted in an approximately 41% inhibition of tumor growth. Treatment
with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody alone resulted in tumor growth inhibition of approximately 72% and four complete responses out of ten mice. The combination of <FONT
STYLE="white-space:nowrap">IK-175</FONT> and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody resulted in an approximately 87% inhibition of tumor growth including complete responses in seven out
of ten mice. Mice with complete responses were <FONT STYLE="white-space:nowrap">re-challenged</FONT> with <FONT STYLE="white-space:nowrap">CT-26</FONT> tumor cells after 95 days and were found to be resistant to tumor formation with only one small
tumor (&gt;104 mm<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>) detected in one mouse of the seven tested. We believe that the improved antitumor activity and long-term antitumor memory observed in these studies is due to the ability of
both <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody to overcome independent mechanisms of tumor immunosuppression. In contrast to <FONT
STYLE="white-space:nowrap">IK-175,</FONT> epacadostat does not have activity in the <FONT STYLE="white-space:nowrap">CT-26</FONT> model (see &#147;&#151;<I><FONT STYLE="white-space:nowrap">IK-412</FONT> preclinical data&#148;).</I><B><I> </I></B>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immune-stimulated anticancer activity of <FONT STYLE="white-space:nowrap">IK-175</FONT> in
a <FONT STYLE="white-space:nowrap">CT-26</FONT> immunocompetent mouse model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g70s36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Phase 1 clinical trial </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently enrolling patients with locally advanced or metastatic solid tumors in an open-label Phase 1 clinical trial evaluating <FONT
STYLE="white-space:nowrap">IK-175</FONT> as a monotherapy, including a dose expansion cohort for patients with bladder cancer. The primary endpoint of this trial is safety and tolerability. As of January&nbsp;1, 2021, we have dosed patients in the
200 mg, 400 mg, 800 mg, 1200 mg and 1600 mg once daily monotherapy dose escalation cohorts. We have not observed any dose limiting toxicities, or DLTs, to date and have not reached the maximum tolerated dose. In the first four dose cohorts, we
observed dose responsive target gene inhibition in whole blood assay from patient samples, as set forth in the graph below. We have also recently initiated monotherapy expansion at 1200 mg in urothelial carcinoma patients with activated AHR in their
tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">IK-175</FONT> target modulation in patients </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g07v02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to initiate the Phase 1b portion of the clinical trial design, evaluating the combination of <FONT
STYLE="white-space:nowrap">IK-175</FONT> with nivolumab, BMS&#146; <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor, in patients with bladder cancer, in the first half of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-175</FONT> indication and patient selection strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">IK-175</FONT> clinical development strategy is focused on enrolling patients who are most likely to respond to an AHR
antagonist. We have explored three tumor profiling technologies centered on AHR to help guide indication selection and/or candidate patients: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AHR gene amplification: Increases in the number of copies of the AHR gene as assessed by Fluorescent In Situ
Hybridization, or FISH, are observed in over 5% of multiple cancers such as esophageal, bladder and lung cancers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nuclear localization of AHR: Constitutive activation of AHR leads to its localization to the nucleus, which can
be directly measured by a proprietary immunohistochemical staining assay that we developed. In the monotherapy expansion cohort, we are prospectively enriching for patients with tumors that exhibit activated AHR using this assay.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">AHR-dependent</FONT> gene transcription: Activation of AHR leads to changes in
transcription of many genes which can be quantified by standard mRNA transcription profiling technologies. We discovered this gene transcription expression signature. We generated a profile of the transcriptional changes induced by AHR activation
across a panel of cell lines. We then used this profile to score tumors based on available transcript profiling data in public databases. We found that bladder cancer patients with transcriptional profiles that scored highest using our activated AHR
profile had poorer prognoses compared to those with low scores, as illustrated in the figure below. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">AHR-activated</FONT> gene transcription signature is
associated with poor overall survival in bladder cancer patients </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g08v01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-175</FONT> development plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently enrolling patients with locally advanced or metastatic solid tumors in an open-label Phase 1 clinical trial evaluating <FONT
STYLE="white-space:nowrap">IK-175</FONT> as a monotherapy, including a dose expansion cohort for patients with bladder cancer. We have recently initiated the monotherapy dose expansion cohort at 1200 mg in bladder cancer patients with tumors that
exhibit activated AHR, using an assay that we developed. We plan to initiate the Phase 1b portion of the clinical trial in the first half of 2021 by opening a combination arm of the ongoing trial to combine
<FONT STYLE="white-space:nowrap">IK-175</FONT> with nivolumab, BMS&#146; <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitor, in patients with bladder cancer and expect to complete enrollment in both treatment arms in the second half of 2022.
Moreover, we plan to initiate a clinical trial in a second solid tumor indication in the second half of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">IK-412,</FONT> a recombinant human kynurenine-degrading enzyme </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-412,</FONT> is a recombinant human kynurenine-degrading<B><I> </I></B>enzyme intended to catalyze the degradation of
kynurenine, an immunosuppressive metabolite that is present in tumors and in the blood of certain cancer patients and is generated by the enzymes IDO1 and TDO2. We believe <FONT STYLE="white-space:nowrap">IK-412</FONT> inhibits the IDO1 pathway in a
manner that selective IDO1 inhibitors are able to achieve, by degrading kynurenine regardless of whether it is synthesized by IDO1 or TDO2. In preclinical studies, <FONT STYLE="white-space:nowrap">IK-412</FONT> was observed to lead to durable and
profound depletion of over 95% of serum levels of kynurenine, as compared to 50% for the IDO1 inhibitor epacadostat. <FONT STYLE="white-space:nowrap">IK-412</FONT> has been optimized for enzymatic activity and stability in plasma which we observed
in <FONT STYLE="white-space:nowrap">non-human</FONT> primates to be consistent with weekly or biweekly dosing in humans. Based on preclinical data, we also believe <FONT STYLE="white-space:nowrap">IK-412</FONT> has the potential to overcome <FONT
STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitor resistance. We have also observed antitumor activity when dosed both as a monotherapy and in combination with checkpoint inhibitors and increased overall survival when dosed in combination
with checkpoint inhibitors in preclinical studies. We intend to submit an IND application with the FDA for <FONT STYLE="white-space:nowrap">IK-412</FONT> in the second half of 2021. To inform indication selection, we have developed several
translational assays, including an immunohistochemistry screen using IDO1 and TDO2 antibodies to help prioritize solid tumors. We are working to detect kynurenine in tumors and in the blood of certain patients with solid tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immunosuppressive activity of kynurenine and role in <FONT STYLE="white-space:nowrap">PD-1</FONT>
resistance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tumors take several routes to suppress destruction by the immune system. One such mechanism involves the formation of kynurenine from
its precursor tryptophan by the enzymes IDO1 and TDO. TDO, which is known to be capable of metabolizing tryptophan to form kynurenine, is typically expressed in the liver, but it can also be overexpressed in multiple tumors. Various published
studies indicate that there is a correlation between kynurenine production and immune suppression. Multiple therapeutic programs have been directed at inhibiting the formation of kynurenine primarily through the inhibition of the enzyme IDO1.
Selective IDO1 inhibitors that have been tested in the clinic include epacadostat, developed by Incyte Corporation, or Incyte. It was recently disclosed that epacadostat was severely underdosed (by <FONT STYLE="white-space:nowrap">six-fold)</FONT>
in a Phase 3 clinical trial in patients with metastatic melanoma when used in combination with pembrolizumab, suggesting that the IDO1 pathway has not yet been tested adequately in humans. We believe <FONT STYLE="white-space:nowrap">IK-412</FONT>
may provide a more potent and robust way of impinging on this important pathway by inhibiting the downstream of IDO1 and TDO2, where the pathways converge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Another important aspect of kynurenine is the way that tumors appear to use it to resist or lessen the impact of treatment with checkpoint inhibitors. As
illustrated in the figure below, treatment of melanoma patients with BMS&#146; nivolumab was found to increase the levels of multiple metabolites, but not more significantly than kynurenine. Using the ratio of kynurenine to tryptophan as a metric of
the relative conversion of tryptophan to kynurenine, it was observed that this ratio spanned a range of eight-fold among patients. Strikingly, melanoma patients in which this ratio increased over four weeks of nivolumab treatment, consistent with
the formation of kynurenine, had significantly reduced survival, 15.7 months, compared to patients with a decreasing ratio, over 85% of which survived over 38 months. A similar trend was observed in renal carcinoma cancer with patients with
increasing ratios having a 16.7 month mean overall survival and those with decreasing ratios with a mean 31.3 month overall survival. These results suggest that reducing the ratio of kynurenine to tryptophan may improve the therapeutic efficacy of
checkpoint inhibitors such as nivolumab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Increased serum kynurenine to tryptophan ratio is associated with worse overall survival in
melanoma </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g08v02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution, <FONT STYLE="white-space:nowrap">IK-412</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-412,</FONT> our therapeutic candidate, is a recombinant human enzyme that breaks down kynurenine, leading to durable
elimination of over 95% of serum levels of kynurenine in animal models after a single dose. We believe that <FONT STYLE="white-space:nowrap">IK-412&#146;s</FONT> robust ability to degrade kynurenine in a durable manner, regardless of its source from
IDO1 or TDO2, has the potential to be differentiated from other selective kynurenine-reducing approaches such as IDO1 inhibition. Moreover, given the emerging role of kynurenine in checkpoint resistance,
<FONT STYLE="white-space:nowrap">IK-412</FONT> may be able to overcome <FONT STYLE="white-space:nowrap">PD-1</FONT> resistance in tumors with high IDO1/TDO2 expression. TDO2 is expressed, in addition to IDO1,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in many tumors and may make selective IDO1 inhibition insufficient to relieve the full immunosuppressive effect of kynurenine. We believe <FONT STYLE="white-space:nowrap">IK-412</FONT> may
provide a more potent and robust way of impinging on this important pathway by inhibiting the downstream of IDO1 and TDO2, where both pathways converge, as illustrated in the figure below. <FONT STYLE="white-space:nowrap">IK-412</FONT> is undergoing
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and we intend to submit an IND in the second half of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A kynureninase
acts downstream of IDO1/TDO2 thereby being able to block kynurenine irrespective of its source. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g08v03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-412</FONT> preclinical data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-412</FONT> is a highly active and stable human enzyme which is the product of protein engineering efforts. <FONT
STYLE="white-space:nowrap">IK-412</FONT> contains 14 mutations compared to the native human enzyme to optimize enzymatic activity and stability in plasma required for the enzyme to be used as an oncology therapeutic. It is pegylated for stability
and to reduce potential immunogenicity. <FONT STYLE="white-space:nowrap">IK-412</FONT> was not immunogenic after repeat dosing as assessed by Anti-Drug Antibody, or ADA, analysis in rats. As illustrated in the figure below, a single dose of 100
mg/kg of <FONT STYLE="white-space:nowrap">IK-412</FONT> administered to <FONT STYLE="white-space:nowrap">non-human</FONT> primates led to rapid elimination of serum kynurenine with levels decreased by over 95% within 15 minutes. These reduced levels
were maintained for at least 14 days and serum kynurenine levels were still less than half of the starting concentrations after 21 days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A single dose of 100mg/kg <FONT STYLE="white-space:nowrap">IK-412</FONT> reduced kynurenine levels by over 95&nbsp;percent for over two
weeks in <FONT STYLE="white-space:nowrap">non-human</FONT> primates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g09v01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potential of <FONT STYLE="white-space:nowrap">IK-412</FONT> to overcome resistance of tumors to checkpoint inhibition
was tested in a <FONT STYLE="white-space:nowrap">CT-26</FONT> syngeneic colon cancer mouse model. Dosing of these mice with a <FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitor led to approximately 63% tumor growth inhibition. Dosing
with an <FONT STYLE="white-space:nowrap">IK-412</FONT> tool enzyme as a monotherapy had no significant effect. However, when we combined the <FONT STYLE="white-space:nowrap">IK-412</FONT> tool enzyme with the checkpoint inhibitor, we observed that
tumor growth was significantly inhibited. In parallel, we dosed mice with a combination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
epacadostat and a <FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitor and observed that addition of epacadostat did not lead to any improvement in antitumor activity, as illustrated
in the figure below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The addition of an <FONT STYLE="white-space:nowrap">IK-412</FONT> tool enzyme to a
<FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitor improved antitumor activity in a <FONT STYLE="white-space:nowrap">CT-26</FONT> model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g01k13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-412</FONT> indication selection strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exploring multiple strategies to guide selection of tumor types for the upcoming Phase 1 clinical trial with
<FONT STYLE="white-space:nowrap">IK-412:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We assessed gene expression databases with the goal of identifying tumors that have high levels of expression of
the genes for TDO and IDO1, the two enzymes responsible for kynurenine levels. Based on these analyses, we believe certain solid tumor types may represent attractive potential indications. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are also conducting an immunohistochemistry screen of a panel of tumors using IDO1 or TDO antibodies to guide
selection of tumors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Finally, we are working to identify those tumors where increases in kynurenine levels may be associated with
development of resistance to checkpoint inhibitors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-412</FONT> clinical development
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-412</FONT> is undergoing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and we plan to submit an
IND in the second half of 2021. As our translational studies continue, we will finalize our plans for clinical development. Our Phase 1 clinical trial will be designed as an open-label clinical trial to explore safety, PK/PD and preliminary efficacy
of <FONT STYLE="white-space:nowrap">IK-412</FONT> as monotherapy and in combination with nivolumab in solid tumors. The tumors will be selected based on the presence of high levels of IDO1 and TDO2 tumor expression. We also plan to assess kynurenine
levels in the blood of patients in the expansion cohorts of the study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">IK-007,</FONT> an EP4 antagonist </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-007</FONT> is an oral selective antagonist of the EP4 receptor. <FONT STYLE="white-space:nowrap">IK-007</FONT> has been
well tolerated in over 900 subjects to date in <FONT STYLE="white-space:nowrap">non-oncology</FONT> clinical trials. We are conducting a Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab for
the treatment of patients with MSS CRC, which represents approximately 85% of patients with CRC. In this Phase 1b clinical trial, we observed encouraging preliminary evidence of antitumor activity in the initial dose escalation cohort and have not
observed any DLTs. In addition, we have identified higher baseline levels of urinary PGEM, a metabolite in the EP4 pathway, as a biomarker that we believe is associated with clinical benefit. We are enrolling patients in a dose expansion cohort
using baseline levels of urinary PGEM to enrich for MSS CRC patients who may be more likely to respond to treatment. We anticipate completing enrollment in the Phase 1b clinical trial in the second half of 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Role of EP4 Pathway in cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prostaglandin-endoperoxide synthase 2, or COX2, is an enzyme that is responsible for the production of prostaglandins during inflammation, including
Prostoglandin E<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> or PGE<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>. PGE<SUB STYLE="font-size:85%; vertical-align:bottom">2 </SUB>sends its signals through four distinct receptors,
known as EP1 through EP4, and these receptors in immune cells can have either stimulatory or suppressive activities. We believe that blocking immunosuppressive activity by inhibiting EP4, the higher affinity immunosuppressive receptor of PGE<SUB
STYLE="font-size:85%; vertical-align:bottom">2</SUB>, could be valuable in treating cancer. We also believe that selectively blocking PGE<SUB STYLE="font-size:85%; vertical-align:bottom">2 </SUB>signaling through EP4 could lower the likelihood of
toxicities that may result from fully blocking this fundamental pathway. The figure below illustrates the mechanism of action of <FONT STYLE="white-space:nowrap">IK-007.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">IK-007</FONT> selectively blocks EP4, the high affinity immunosuppressive receptor in the COX2/PGE2
pathway. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g10v01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A large body of literature demonstrates that activation of the PGE<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>
pathway in cancer augments tumor initiation, progression and therapeutic resistance. Increased expression of pathway components, including EP4, is associated with decreased survival, therapeutic and preventive precedent in a number of cancer types,
including CRC. When activated, EP4 affects the activity of a broad range of cells within the innate and adaptive immune system culminating in an immunosuppressive tumor microenvironment. Preclinical studies suggest that a selective antagonist of EP4
has the potential to bring therapeutic benefit to tumors such as CRC by changing the immunosuppressive tumor microenvironment so that tumors can become more accessible to the penetration of immune cells and more susceptible to the activity of
checkpoint inhibitors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MSS CRC Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRC
is the second leading cause of cancer deaths in the United States. The National Cancer Institute estimates that there were 147,950 new cases of CRC and 53,200 CRC related deaths in the United States in 2020. Approximately 35% of patients newly
diagnosed with CRC will die within five years. <FONT STYLE="white-space:nowrap">PD-1</FONT> checkpoint inhibitors have been approved in a subset of CRC known as microsatellite instability-high, or <FONT STYLE="white-space:nowrap">MSI-H,</FONT>
tumors. <FONT STYLE="white-space:nowrap">MSI-H</FONT> tumors are found in about 15% of CRC patients, with microsatellite stability, or MSS, tumors representing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remaining 85% of patients. The prognosis of MSS CRC patients is significantly poorer than that of <FONT STYLE="white-space:nowrap">MSI-H</FONT> patients. MSS CRC represents a large unmet clinical
need. Interim data of single agent treatment with pembrolizumab showed an overall response rate in MSS CRC of 0% (0/18). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our solution, <FONT
STYLE="white-space:nowrap">IK-007</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-007</FONT> is a selective EP4 antagonist originally discovered by
Pfizer that we licensed to explore as a potential cancer therapy. <FONT STYLE="white-space:nowrap">IK-007</FONT> has been dosed in over 900 adults in previous <FONT STYLE="white-space:nowrap">non-oncology</FONT> clinical trials, including in two
Phase 2 clinical trials on the treatment of osteoarthritic knee pain. In normal healthy volunteers studies, <FONT STYLE="white-space:nowrap">IK-007</FONT> was found to be well tolerated when administered as a single dose up to 1000 mg and as
multiple doses up to 300 mg twice a day for 14 days. Based on the biological rationale for PGE<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>/EP4 in CRC and the high unmet medical need in MSS CRC, in particular given that single agent
pembrolizumab is inactive in these patients, we are currently conducting a Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab for the treatment of patients with MSS CRC. Signs of antitumor
activity and a potential predictive PGE2 metabolite biomarker, called PGEM, are emerging from the ongoing trial. As of January&nbsp;1, 2021, we have 45 patients enrolled in our Phase 1b clinical trial and we plan to complete enrollment of our Phase
1b clinical trial in the second half of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are conducting a single arm Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab in patients with MSS
CRC patients who have received at least two lines of prior systemic therapy and progressed, and therefore unlikely to respond to pembrolizumab monotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2021, we observed evidence of clinical benefit (complete response, or CR, partial response, or PR, and stable disease, or SD, for 16
weeks) in four out of 20 evaluable patients treated at 300 mg bid p.o. as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One patient had a CR and remained on study for 22 months; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One patient experienced 29% tumor shrinkage that was close to meeting the criteria for a PR;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One patient had durable stable disease for over six months (prolonged SD); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One patient had a mixed response with shrinkage of some but not all tumors and stable disease for 17 weeks
(prolonged SD). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patient who reached a CR had received five prior lines of therapy. This highly refractory patient&#146;s tumor also
exhibited low tumor mutational burden, or TMB, reducing the likelihood that the antitumoral response could be due to pembrolizumab treatment alone as high TMB is often associated with response to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapies. Antitumor activity was observed soon after commencement of dosing with <FONT STYLE="white-space:nowrap">IK-007.</FONT> A significant shrinkage of 48% of the tumor size was observed by CT
scan after approximately two months of combined therapy. With additional cycles of treatment, evidence of tumor in this patient disappeared and the patient was classified as a complete responder, as illustrated in the figure below. This patient was
on treatment for 22 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Complete response in an MSS CRC patient treated with 300 mg
<FONT STYLE="white-space:nowrap">IK-007</FONT> and 200 mg pembrolizumab, and association with high urinary PGEM levels. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g01k14.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g86d56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, we have identified a biomarker in the EP4 pathway, higher baseline levels of urinary PGEM, that we believe can
help us select for patients who may benefit the most from <FONT STYLE="white-space:nowrap">IK-007.</FONT> An ad hoc analysis of the first 33 patients enrolled in the study showed that there was a significant correlation between higher baseline
levels of urinary PGEM and clinical benefit observed and with prolonged time on treatment (defined as over 16 weeks on study drug). High urine levels of PGEM (&gt; 50 ng/mg creatinine) were present in approximately 20% (21.2% with 95% CI <FONT
STYLE="white-space:nowrap">9.0-38.9)</FONT> of the first 33 CRC patients tested for PGEM in the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most common related adverse events were Grade
1 or Grade 2 fatigue, pruritus and Grade 3 or Grade 4 increased gamma-glutamyl transferase, a liver enzyme. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the early positive tolerability profile of <FONT STYLE="white-space:nowrap">IK-007</FONT> in the first
two cohorts (300 mg BID) in combination with pembrolizumab as well as encouraging signs of activity at this dose, we amended the protocol to explore three more dose escalation levels of <FONT STYLE="white-space:nowrap">IK-007:</FONT> 450 mg, 600 mg
and 900 mg BID in combination with pembrolizumab. No DLTs in the three additional dose escalation cohorts were observed up to 900 mg BID. Most adverse events observed included myalgia, anemia, decrease appetite, insomnia and diarrhea, mostly Grade 1
or Grade 2. We also observed transient elevations of liver function tests, or LFTs, that in a few cases required <FONT STYLE="white-space:nowrap">IK-007</FONT> dose modifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these data, we selected the dose of 900 mg BID of <FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab (200 mg) every
three weeks for the dose expansion cohort. The trial is ongoing and will enroll up to 53 patients total, including at least ten patients with high baseline levels of urinary PGEM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In selecting patients to receive <FONT STYLE="white-space:nowrap">IK-007,</FONT> our objective is to focus treatment on patients who are most likely to
respond. We generated a validated urine PGEM biomarker assay. We are currently using it to measure baseline PGEM urinary levels to select patients who are more likely to respond in our MSS CRC dose expansion cohort. We expect that the enrollment of
the ongoing MSS CRC clinical trial will be completed in the second half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also conducted a second open-label single arm Phase 1b clinical trial
of <FONT STYLE="white-space:nowrap">IK-007</FONT> in combination with pembrolizumab in patients with advanced or metastatic post <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/L1</FONT></FONT> treatment in NSCLC. Based
on the combined data generated in the interim period for efficacy and safety, we decided not to further explore this combination in NSCLC and terminated this clinical trial in December 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that <FONT STYLE="white-space:nowrap">IK-007</FONT> may have the potential to bring therapeutic benefit beyond MSS CRC and we may expand into
certain additional indications in which there is high unmet medical need and biological rationale for the key role of EP4 pathway in cancer progression. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical
industries are characterized by rapid innovation of new technologies, fierce competition and strong defense of intellectual property. While we believe that our pipeline and our knowledge, experience and scientific resources provide us with
competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compete in the segments of the pharmaceutical, biotechnology, and there are other companies focusing on structural biology-guided chemistry-based drug
design to develop therapies in the fields of cancer and other diseases. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. Any product candidates that we successfully develop and
commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted oncology therapeutics. Key
product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe principal competitive factors to our business include, among other things, our ability to identify promising biomarkers, our ability to
successfully transition research programs into clinical development, our ability to raise capital, and the scalability of our pipeline and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors
may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their
products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable
cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available
drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are
ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers
and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded
generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are
developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-930</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are not aware of any TEAD inhibitor in clinical development. Other companies that have publicly disclosed that they are developing preclinical stage TEAD inhibitors are: Vivace Therapeutics, Inc., Inventiva Pharma, Kyowa Kirin, and Roche/Genentech.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ERK5 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not aware of any other ERK5
inhibitor in development. Efforts over the past several decades have failed to develop approved therapies for KRAS mutant cancers. Therapies directly targeting KRAS G12C are beginning to show clinical promise and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> such as <FONT STYLE="white-space:nowrap">AMG-510</FONT> being developed by Amgen Inc. and MRTX849 being developed by Mirati Therapeutics, Inc., both in Phase 3 in KRAS G12C mutant NSCLC.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-175</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of one other AHR antagonist in clinical development under development by Bayer AG, or Bayer. Bayer is currently enrolling patients with advanced
solid tumors in a Phase 1 trial for <FONT STYLE="white-space:nowrap">BAY-2416964</FONT> in advanced solid tumors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-412</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are not aware of any other kynurenine degrading enzyme product candidates in development. The closest competitors are IDO/TDO inhibitors which have shown limitations in recent clinical trials. As a consequence, activity in the IDO/TDO inhibitor
space has been low recently, with the exception of Incyte&#146;s epacadostat and BMS&#146;s lindorostat. BMS is actively recruiting for several clinical studies, including one Phase 3 to assess lindorostat, alone and in combination with nivolumab,
in bladder cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">IK-007</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IK-007</FONT> is one of the EP4 antagonists currently in clinical development. The other programs in clinical development are
from BMS/Ono Pharmaceutical <FONT STYLE="white-space:nowrap">(BMS-986310</FONT> / <FONT STYLE="white-space:nowrap">ONO-4578),</FONT> Adlai Nortye/Eisai <FONT STYLE="white-space:nowrap">(AN-0025</FONT> /
<FONT STYLE="white-space:nowrap">E-7046)</FONT> and Tempest Therapeutics (TPST-1495), all of which are in Phase 1 clinical trials in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy
in advanced solid tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Master Collaboration Agreement with Bristol-Myers Squibb </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, we entered into the BMS Collaboration Agreement with Celgene Corporation (which was acquired by BMS in November 2019) under which BMS may
elect in its sole discretion to exclusively license rights to develop and commercialize compounds (and products and diagnostic products containing such compounds) that modulate the activity of two collaboration targets, kynurenine and AHR, excluding
AHR agonists except for inverse agonists, or the Collaboration Candidates, which we are developing as <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412.</FONT> The BMS Collaboration Agreement triggered an
upfront payment of $95.0&nbsp;million, which consisted of approximately $80.5&nbsp;million in cash and an equity investment of approximately $14.5&nbsp;million for which we issued 14,545,450 shares of our Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock pursuant to a separate stock purchase agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis, through the completion of a Phase 1b clinical trial for each of <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412,</FONT> BMS has the
exclusive right with respect to such Collaboration Candidate to a worldwide exclusive license with us to develop, commercialize and manufacture the compound (and products and diagnostic products containing such compounds) underlying such
Collaboration Candidate. Additionally, if we do not complete a Phase 1b clinical trial by the end of the research term (as defined below), we may elect to provide a data package to BMS upon which BMS may exercise the foregoing option for an
additional $0.25&nbsp;million fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If and when BMS exercises its rights for a Collaboration Candidate, and as a result of the timing of our submission of
INDs with respect to each Collaboration Candidate, BMS is required to pay us $50.0&nbsp;million, in the case of an exercise of its option with respect to <FONT STYLE="white-space:nowrap">IK-175,</FONT> and $40.0&nbsp;million, in the case of an
exercise of its option with respect to <FONT STYLE="white-space:nowrap">IK-412.</FONT> The option exercise fees are payable within fifteen (15)&nbsp;days after the execution of each license agreement. Upon the execution of each license agreement, we
will become eligible to receive up to $265.0&nbsp;million under such license agreement in regulatory milestones and $185.0&nbsp;million in commercial milestones as well as a tiered royalties at rates ranging from the high single to low double digit
percentages based on worldwide annual net sales by BMS, subject to specified reductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMS will continue to pay royalties on a Collaboration <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Candidate-by-Collaboration</FONT></FONT> Candidate and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the latest of
(i)&nbsp;there being no valid claim under the licensed patents covering the Collaboration Candidate, (ii)&nbsp;expiration of all regulatory exclusivity for the Collaboration Candidate in such country, and (iii) twelve (12)&nbsp;years after the first
commercial sale of the Collaboration Candidate in the applicable country (the Royalty Term), after which the applicable license granted to BMS in such country will become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> perpetual, irrevocable and royalty-free. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research term under the BMS Collaboration Agreement continues for
a period of five (5)&nbsp;years from its effective date. The term of any license agreement described above would continue on a Collaboration <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Candidate-by-Collaboration</FONT></FONT>
Candidate and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of all Royalty Terms under such agreement, unless earlier terminated as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BMS Collaboration Agreement may be terminated (i)&nbsp;by either party on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis if the other party remains in material breach of the BMS Collaboration Agreement following a cure period to remedy the material breach,
(ii)&nbsp;by BMS at will on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis or in its entirety, (iii)&nbsp;by either party, in its entirety, upon bankruptcy or insolvency of the other party,
or (iv)&nbsp;automatically, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis if BMS fails to timely deliver an <FONT STYLE="white-space:nowrap">opt-in</FONT> notice to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each license agreement may be terminated (i)&nbsp;by either party if the other party remains in material breach of the license agreement following a cure
period to remedy the material breach, (ii)&nbsp;by BMS at will, (iii)&nbsp;by either party, in its entirety, upon bankruptcy or insolvency of the other party, or (iv)&nbsp;by us, in its entirety, if BMS challenges a patent licensed by us to BMS
under the license agreement or any jointly-owned collaboration patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon our termination of a license agreement for BMS&#146; breach, bankruptcy or insolvency or patent
challenge, we would receive (i)&nbsp;upon our timely request, a nonexclusive worldwide license under BMS&#146; <FONT STYLE="white-space:nowrap">know-how</FONT> and patents covering the applicable licensed compound to the extent that such compound
(or product or diagnostic product containing such compound) has been or is in active development or commercialization as of termination; and (ii)&nbsp;subject to determination of an applicable license payment in accordance with the license
agreement, an exclusive license for the foregoing. If BMS terminates a license agreement for our breach or bankruptcy or insolvency, BMS&#146; license will survive for six (6)&nbsp;months. Additionally, in the event of our material breach, BMS may
elect to have the license agreement continue, with all future payments under that license agreement reduced by 50%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent License Agreement with
the University of Texas at Austin </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2015, we entered into an exclusive patent license agreement, or the License Agreement, with the
University of Texas at Austin, or the University, pursuant to which the University granted us a worldwide license to certain technology and IP rights relating to a kynurenine-degrading enzyme, which we are developing as <FONT
STYLE="white-space:nowrap">IK-412.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the License Agreement, and we pay a license fee of approximately $40,000 per year. We will also be
obligated to make milestone payments to the University of up to an aggregate of $0.7&nbsp;million upon meeting certain development milestones and up to an aggregate of $4.0&nbsp;million upon meeting certain regulatory milestones, as well as low
single digit royalties based on worldwide annual net sales on any licensed product, subject to specified reductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be obligated to continue to
pay royalties on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, as
long as there is an existing valid claim under the licensed patents in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Licensed Agreement expires on licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the expiration of all royalty
terms, unless earlier terminated as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The License Agreement may be terminated (i)&nbsp;by either party if the other party remains in
breach of the license agreement following a cure period to remedy the breach, (ii)&nbsp;by us at will, (iii)&nbsp;by the University, in its entirety, upon our bankruptcy or insolvency, or (iv)&nbsp;by the University, in its entirety, if we challenge
a patent licensed by the University to us under the license agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with AskAt </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection of our acquisition of Arrys Therapeutics, Inc., or Arrys, in December 2018, we acquired <FONT STYLE="white-space:nowrap">in-process</FONT>
research and development assets related to AskAt Inc.&#146;s, or AskAt, selective EP4 antagonists, namely <FONT STYLE="white-space:nowrap">IK-007</FONT> which we are currently developing in a Phase 1b clinical trial in MSS CRC and <FONT
STYLE="white-space:nowrap">IK-008</FONT> which is a backup molecule, based on the intellectual property associated with a License Agreement, or the AskAt Agreement, between Arrys and AskAt, dated December&nbsp;14, 2017. Pursuant to the AskAt
Agreement, AskAt granted Arrys an exclusive license worldwide, other than China and Taiwan, to the research and development of the licensed compounds in human diseases. AskAt controls the prosecution and maintenance of all intellectual property
rights pertaining the licensed technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the AskAt Agreement, we are obligated to make milestone payments to AskAt, including up to
$4.0&nbsp;million upon the achievement of certain clinical development milestones, as well as milestone payments of up to an aggregate of $600&nbsp;million upon the achievement of certain worldwide annual net sales milestones. We are also obligated
to pay low single-digit royalties on annual worldwide net sales on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">licensed-product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, for the period beginning upon the first commercial sale in such country and ending upon the later of (i) 10 years from the first commercial sale in such country, or (ii)&nbsp;the
expiration of valid claims in such country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the AskAt Agreement expires on licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the expiration of the royalty term for such licensed product,
unless earlier terminated as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The License Agreement may be terminated (i)&nbsp;by either party if the other party remains in material
breach of the license agreement following a cure period to remedy the breach, (ii)&nbsp;by us for convenience upon 180 days&#146; notice or (iii)&nbsp;by either party, in its entirety, upon bankruptcy or insolvency of the other party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We seek to protect the
intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and future products, and methods of using the same, as well as any other
relevant inventions and improvements that we believe to be commercially important to the development of our business. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop
and maintain our proprietary and intellectual property position. Our commercial success depends, in part, on our ability to obtain, maintain, enforce and protect our intellectual property and other proprietary rights for the technology, inventions
and improvements we consider important to our business, and to defend any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future, prevent others from infringing any patents we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> in the future, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of
third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Protection </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As with
other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates, future products, and proprietary technologies will depend on our success in
obtaining effective patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents
and any issued patents we may obtain do not guarantee us the right to practice our technology or commercialize our product candidates. We also cannot predict the breadth of claims that may be allowed or enforced in any patents we may own or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future. Any issued patents that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future may be challenged, invalidated, circumvented, or have the scope of their claims
narrowed. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent
may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the
countries in which they are obtained. In most countries, including the United States, the patent term is 20&nbsp;years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United
States, a patent&#146;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an
earlier expiring patent. The term of a patent claiming a new drug product may also be eligible for a limited patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The term extension period
granted on a patent covering a product is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the
time between the submission date of an application and the ultimate approval date. The term extension period cannot be longer than five years, and the term extension period may not extend the patent term beyond 14 years from the date of FDA
approval. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Additionally, the application
for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension
in consultation with the FDA. In the future, if our product candidates receive approval by the FDA, we expect to apply for patent term extensions on any issued patents covering those products, depending upon the length of the clinical studies for
each product and other factors. There can be no assurance that our pending patent applications, and any patent applications that we may in the future file or license from third parties, will issue or that we will benefit from any patent term
extension or favorable adjustments to the terms of any patents we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. In addition, the actual protection afforded by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country,</FONT></FONT> and depends upon many factors, including the type of patent, the scope of its
coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our
products for an adequate amount of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;28, 2020, our overall patent portfolio includes forty-three (43)&nbsp;patent families
comprising issued patents, pending U.S. and PCT International patent applications,&nbsp;and pending patent applications in foreign jurisdictions. The patents and patent applications have claims relating to our current product candidates, methods of
use and manufacturing processes, as well as claims directed to potential future products and developments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>TEAD Inhibitor Patent Families </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2020, we solely own seven patent families related to TEAD inhibitors and degraders, compositions thereof, and methods of their use. Any
U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2040 to 2041, not including any patent term adjustment, patent term extension, or supplementary
protection certificate (SPC). </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current lead TEAD inhibitor, <FONT STYLE="white-space:nowrap">IK-930,</FONT> compositions thereof, and methods of the
use, are covered by pending U.S., PCT international, Taiwanese, and Argentinian patent applications that, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term
extension, or supplementary protection certificate, or SPC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>EP4 Antagonists Patent Families </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;28, 2020, we have an exclusive license to seven patent families directed to EP4 antagonists, crystal forms thereof, compositions thereof,
and methods of their use. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2021 to 2036, not including any patent term adjustment, patent term
extension, or SPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2020, we and AskAt Inc. jointly own three patent families directed to EP4 antagonist compositions, methods of
making certain EP4 antagonists and their formulations, and methods of their use. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including
any patent term adjustment, patent term extension, or SPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;28, 2020, we solely own two patent families directed to EP4 antagonist
salts and crystal forms, and methods of using EP4 antagonists. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2039 to 2041, not including any
patent term adjustment, patent term extension, or SPC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;28, 2020, our current lead EP4 antagonist,
<FONT STYLE="white-space:nowrap">IK-007,</FONT> salts and crystal forms thereof, compositions thereof, and methods of the use, are covered by over ten (10)&nbsp;issued U.S. patents, and by a number of pending U.S. and PCT international patent
applications, and issued patents and pending patent applications in foreign jurisdictions that, if granted and all appropriate maintenance fees paid, are expected to expire from 2021 to 2041, not including any patent term adjustment, patent term
extension, or SPC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AHR Antagonists Patent Families </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2020, we solely own nine patent families related to AHR antagonists, compositions thereof, and methods of their use. Any U.S. or
foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2038 to 2041, not including any patent term adjustment, patent term extension, or SPC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2020, our current lead AHR antagonist <FONT STYLE="white-space:nowrap">IK-175,</FONT> salts and crystal forms thereof, compositions
thereof, and methods of the use, are covered by two issued U.S. patents, and by a number of pending U.S. and PCT international patent applications, and pending patent applications in Europe, Japan, Australia, Canada, China, and other foreign
jurisdictions that, if granted and all appropriate maintenance fees paid, are expected to expire in from 2038 to 2041, not including any patent term adjustment, patent term extension, or SPC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">IK-412</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;20, 2020, we have an exclusive license to or solely own multiple patent families related to <FONT STYLE="white-space:nowrap">our&nbsp;IK-412</FONT> <FONT STYLE="white-space:nowrap">program.&nbsp;The&nbsp;IK-412&nbsp;biologic</FONT>
drug product is covered by eight granted patents that are expected to expire between August 2034 and April 2035, not including any patent term extension, SPC, or data exclusivity. <FONT STYLE="white-space:nowrap">The&nbsp;IK-412</FONT> biologic drug
product is also covered by an additional granted U.S. patent, and by at least three pending patent application families in a number of jurisdictions covering both the drug product and methods of treatment currently in clinical development, that are
expected to expire between August 2035 and October 2040, if issued, not including any patent term adjustment, patent term extension, SPC or biologic market exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ERK5 and RAS Signaling Pathway Program Patent Families </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2020, we exclusively own six patent families related to inhibitors targeting the ERK5 and Ras signaling pathway, compositions thereof,
and methods of their use, along with one patent family relating to methods for identifying cancer patients to be treated with an ERK5 inhibitor. Each patent family contains one U.S. provisional patent application. Any U.S. or foreign patents that
issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO or other foreign jurisdiction are
often significantly narrowed by the time they issue, if they issue at all. Any of our pending PCT patent applications are not eligible to become issued patents until, among other things, we file national stage patent applications within 30 months in
the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent applications and any patent protection on the inventions disclosed in
such PCT patent applications. Our provisional patent applications may never result in issued patents and are not eligible to become issued patents until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
application and/or PCT patent application within 12 months of filing the related provisional patent application. If we do not timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we may lose our priority date with
respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. While we intend to timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> and national stage
patent applications relating to our provisional and PCT patent applications, we cannot predict whether any of our current or future patent applications will issue as patents. If we do not successfully obtain patent protection, or, if the patent
protection scope is not sufficiently broad, we may be unable to prevent others from using our proprietary technology or from developing or commercializing technology and products similar or identical to ours or other competing products and
technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secret Protection </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition to patents, we rely on unpatented trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential <FONT
STYLE="white-space:nowrap">know-how</FONT> are difficult to protect. In particular, we anticipate that with respect to the building of our compound library, our trade secrets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and <FONT STYLE="white-space:nowrap">know-how</FONT> will over time be disseminated within the industry through independent development and public presentations describing the methodology. We
seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors and <FONT STYLE="white-space:nowrap">non-competition,</FONT>
<FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected consultants,
scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of
technologies that are developed through our relationship with the respective counterparty. We cannot guarantee that we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us adequate
protection of our intellectual property and proprietary information rights. In addition, our trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> may become known or be independently developed by a third party or
misused by any collaborator to whom we disclose such information. These agreements may also be breached, and we may not have an adequate remedy for any such breach. Despite any measures taken to protect our intellectual property, unauthorized
parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary
information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual
property, please see &#147;Risk Factors&#151;Risks Related to our Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademark Protection </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed for and obtained Notices of Allowance for trademark protection with the U.S. Patent and Trademark Office for the IKENA and IKENA ONCOLOGY word
marks for goods and services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the
United States to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed. The
responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine. Outside the United
States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any manufacturing
facilities. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical testing, as well as for clinical testing and commercial manufacture if our product candidates
receive marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our drug candidates are small molecules and are manufactured in synthetic processes from available starting materials.
The chemistry appears amenable <FONT STYLE="white-space:nowrap">to&nbsp;scale-up&nbsp;and</FONT> does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced
cost-effectively at contract manufacturing facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If necessary, we expect to rely on third parties for the manufacture of companion diagnostics for
our products, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governmental Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the
research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval
reporting of drugs and biologics. We, along with our vendors, contract research organizations, or CROs, clinical investigators and contract manufacturing organizations, or CMOs will be required to navigate the various preclinical, clinical,
manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and
biologics and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, where we are initially focusing our drug development, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or
FD&amp;C Act, and biologics under the FD&amp;C Act and the Public Health Service Act, or PHSA, as amended, their implementing regulations. Both drugs and biologics are also subject to other federal, state and local statutes and regulations. If we
fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other regulatory requirements relating to product manufacture, processing, handling, storage, quality
control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include,
among other things, the FDA&#146;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product
seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates must be approved for therapeutic indications by the FDA before they may be marketed in the United States. For drug product candidates
regulated under the FD&amp;C Act, FDA must approve a New Drug Application, or NDA. For biologic product candidates regulated under the FD&amp;C Act and PHSA, FDA must approve a Biologics License Application, or BLA. The process is similar and
generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive preclinical studies in accordance with applicable regulations, including studies
conducted in accordance with good laboratory practice, or GLP, requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug
substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an investigational new drug application, or IND, which must become effective before
clinical trials may begin and must be updated annually and when certain changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site
before each trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good
clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of an NDA or BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> or <FONT
STYLE="white-space:nowrap">pre-license</FONT> inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to
preserve the drug or biological product&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees for FDA review of the NDA or BLA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA or BLA, including, where applicable, consideration of the views of any FDA
advisory committee, prior to any commercial marketing or sale of the drug in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical studies and clinical
trials for drugs and biologics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing any drug or biologic in humans, the product candidate must undergo rigorous preclinical testing.
Preclinical studies include laboratory evaluations of product chemistry, formulation and stability, as well as<I></I><I>&nbsp;in vitro</I>&nbsp;and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The
conduct of preclinical studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical
data, must be submitted to the FDA as part of an IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND is a request for authorization from the FDA to administer an investigational product to
humans and must become effective before clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes the results of animal and <I>in
vitro</I> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the
investigational product. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA, within the
<FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or
partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence
or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until the deficiencies articulated by FDA are corrected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified
investigators, who generally are physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their
participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be
used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each
institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent
form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various
grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about
clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of
Health. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA
authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP
requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials to evaluate therapeutic
indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;1</I>&#151;Phase&nbsp;1 clinical trials involve initial introduction of the
investigational product in a limited population of healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the
investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;2</I>&#151;Phase&nbsp;2 clinical trials typically involve administration of the
investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#146;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and
safety risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase</I><I></I><I>&nbsp;3</I>&#151;Phase&nbsp;3 clinical trials typically involve administration of the
investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial
sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. Generally, two adequate and well-controlled Phase 3
trials are required by the FDA for approval of an NDA or BLA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FDA released a draft guidance entitled
&#147;Expansion Cohorts: Use in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-In-Human</FONT></FONT> Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#148; which outlines how drug developers can
utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial)
to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort
trials can potentially bring efficiency to drug development and reduce development costs and time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as
Phase&nbsp;4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly
intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase&nbsp;4 clinical trials as a condition of NDA or BLA approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety
reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal
or<I></I><I>&nbsp;in vitro</I>&nbsp;testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The
sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#146;s initial receipt of the information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and
physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity,
strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration
over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. marketing approval for drugs and biologics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information
relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA package requesting approval to market the product for one or more indications. An NDA is a
request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#146;s safety and efficacy for the requested indications. A BLA is a request for approval to market a new biologic for one or more
specified indications and must contain proof of the biologic&#146;s safety, purity and potency for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical
trials, as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data may come from company-sponsored clinical trials intended to
test the safety and efficacy of a product&#146;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the
safety and efficacy of the investigational drug, or the safety, purity and potency of the investigational biologic, to the satisfaction of the FDA. FDA must approve an NDA or BLA before a drug or biologic may be marketed in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs and BLAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing and may
request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the
submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review of the NDA or BLA. The FDA reviews an NDA or BLA to determine, among other things, whether the product is safe and effective for
the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards designed, including cGMP requirements, designed to assure and preserve the product&#146;s continued identity, strength, quality
and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA or BLA and
respond to the applicant, and six months from the filing date of a new molecular entity NDA or BLA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs or BLAs, and the review process is often extended
by FDA requests for additional information or clarification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, under PDUFA, as amended, each NDA or BLA must be accompanied by a substantial user
fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees
are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it believes that a risk evaluation and mitigation strategy is
necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use,
such as restricted distribution methods, patient registries, special monitoring or other risk-minimization tools. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug or biologic to an advisory committee. An advisory
committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound
by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA,
the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and
are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and
the integrity of the clinical data submitted to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After evaluating the NDA or BLA and all related information, including the advisory committee
recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review
cycle of the application is complete and the application is not ready for approval. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA or BLA, except that
where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing
proposed labeling. In issuing the Complete Response Letter, the FDA may require additional clinical or preclinical testing or recommend other actions, such as requests for additional information or clarification, that the applicant might take in
order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been
met to the FDA&#146;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require
that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess a product&#146;s safety after approval, require testing
and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and
profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new
indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan
drug designation and exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a
rare disease or condition, which is a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States when there is no
reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA or
BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the
regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or
condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in
limited circumstances, such as a subsequent product&#146;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive
approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan
product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is
clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United States
may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited development and review programs for drugs and biologics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs and biologics to address unmet medical needs in the
treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the
development or review of important new drugs and biologics to get them to patients more quickly than standard FDA review timelines typically permit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
new drug or biologic is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track
designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical
development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the FDA may review portions of the marketing application before the sponsor submits the complete application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a new drug or biologic may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or
condition and preliminary clinical evidence indicates that the drug or biologic, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient product development
program beginning as early as Phase&nbsp;1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional
FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA or BLA is submitted, if the product that is the subject of the
marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#146;s goal date to take action on
the marketing application is six months compared to ten months for a standard review. Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical
benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence
of the condition and the availability or lack of alternative treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accelerated Approval is usually contingent on a sponsor&#146;s agreement to
conduct, in a diligent manner, adequate and well-controlled additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. The FDA may withdraw approval of a drug or an indication approved under Accelerated
Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, as a condition for Accelerated Approval, that all advertising and promotional materials intended
for dissemination or publication within 120&nbsp;days of marketing approval be submitted to the agency for review during the <FONT STYLE="white-space:nowrap">pre-approval</FONT> review period. After the
<FONT STYLE="white-space:nowrap">120-day</FONT> period has passed, all advertising and promotional materials must be submitted at least 30&nbsp;days prior to the intended time of initial dissemination or publication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or
the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the
quality of evidence necessary to support approval, though they may expedite the development or review process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric information and pediatric
exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, as amended, certain NDAs and BLAs and certain NDA and BLA supplements must contain
data that can be used to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is
safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires that a sponsor who is planning to submit a marketing application for a product candidate that includes a new
active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an
outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any
request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit
amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. Unless otherwise
required by regulation, PREA does not apply to a drug or biologic for an indication for which orphan designation has been granted, except that PREA will apply to an original NDA or BLA for a new active ingredient that is orphan-designated if the
drug or biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A drug can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods
and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an
<FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. post-approval requirements for drugs and
biologics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drugs and biologics manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including,
among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;)
and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe approved products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. The FDA
and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, including not only by company employees but also by agents of the company or those speaking on the
company&#146;s behalf, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability, including investigation by federal and state authorities. Failure to
comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties, including liabilities under the False Claims Act where products are obtain
reimbursement under federal health care programs. Promotional materials for approved drugs and biologics must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug or
biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or BLA or NDA or BLA supplement, which may require the development of
additional data or preclinical studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of approval of an
NDA or BLA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. In addition, manufacturers and
their subcontractors involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA
and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements on sponsors and their CMOs. Changes to the manufacturing process are strictly regulated,
and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third
party manufacturers that a sponsor may use. Accordingly, manufacturers must continue to expend time money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure
to comply with statutory and regulatory requirements may subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution.
There is also a continuing, annual program user fee for any marketed product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval of a product if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or
imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications
containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation
of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or
mandated modification of promotional materials and labeling and issuance of corrective information. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of companion
diagnostics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely
to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety
or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FD&amp;C Act, and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical
device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market
surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization
applicable to a medical device are clearance of a premarket notification, or 510(k), and approval of a premarket approval application, or PMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain
510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a
previously cleared 510(k) device or to a <FONT STYLE="white-space:nowrap">pre-amendment</FONT> device that was in commercial distribution before May&nbsp;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a
PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device and assesses whether the subject device is comparable to the predicate device with respect
to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing.
The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A PMA must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing
data, to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will
conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities to ensure compliance with the quality system regulation, or QSR, which requires manufacturers to follow design, testing, control,
documentation and other quality assurance procedures. The FDA&#146;s review of an initial PMA is required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete. If the
FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final
approval of the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the
application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards
is not maintained or problems are identified following initial marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2014, the FDA issued a final guidance document addressing the
development and approval process for &#147;In Vitro Companion Diagnostic Devices.&#148; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential
for the safe and effective use of the corresponding therapeutic product, the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when
contemporaneous development may not be possible. However, in cases where a drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cannot be used safely or effectively without the companion diagnostic, the FDA&#146;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic
device. The FDA also issued a draft guidance in July 2016 setting forth the principles for <FONT STYLE="white-space:nowrap">co-development</FONT> of an in vitro companion diagnostic device with a therapeutic product. The draft guidance describes
principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding <I>in vitro</I> companion diagnostic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of the FDA&#146;s QSR, adverse
event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of
the product(s) and the company&#146;s facilities for compliance with its authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other regulatory matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also subject
to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, the
Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and local
governments and governmental agencies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other healthcare laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain
marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may
constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and
federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity need not have
actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the
remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the civil False Claims Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, prohibit
individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or
used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay
money to the federal government. Manufacturers can be held liable under the FCA even when they do not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a
&#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil False Claims Act, the government may
impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or
remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner, or supplier of services reimbursable by
Medicare or a state health care program, unless an exception applies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability
for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully
obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or
services. Similar to the federal Anti-Kickback Statute, a person or entity may be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their respective business associates relating to the privacy and security of individually identifiable health information
including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to
business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing
federal civil actions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available
under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, for certain payments and &#147;transfers of value&#148; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors)
and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.&nbsp;Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made in the
previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities
that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analogous state and foreign laws and regulations, including, but not limited to, state anti-kickback and false
claims laws, may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and
relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of
marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are
not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, which may complicate compliance efforts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current
environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare
providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future
statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us,
we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight
and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the curtailment or restructuring of our
operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring
business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#146;s attention from its business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insurance Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare
costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health
insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to
follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process
for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are
increasingly challenging the prices charged, examining the medical necessity, reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an
approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to secure coverage
and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional
expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless,
product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our
operations and financial condition. Additionally, a third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage
for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the
prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic
products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved
products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory
approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future healthcare reform
legislation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and certain foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and
regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the
United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. The ACA includes provisions of importance to our potential product candidates that:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum
rebate for both branded and generic drugs and revising the definition of &#147;average manufacturer price,&#148; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded the types of entities eligible for the 340B drug discount program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale-discounts</FONT></FONT> off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the
manufacturers&#146; outpatient drugs to be covered under Medicare Part D; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been numerous
judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently facing
legal and constitutional challenges in the United States Supreme Court. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business. Additionally, the Trump administration issued various
Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of
pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot
predict what effect further changes to the ACA would have on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act
was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent
legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020 and is designed
to provide financial support and resources to individuals and businesses affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, suspended these reductions from May&nbsp;1, 2020 through December&nbsp;31, 2020. In January 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in
healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, including bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review
the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. For example, at the federal level, the current administration&#146;s budget for fiscal year
2021 includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for
patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the current administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things,
cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. Additionally, the current administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of
drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of
pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019,
CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change that was effective
January&nbsp;1, 2019. Although a number of these and other measures may require additional authorization to become effective, Congress and the current administration have each indicated that it will continue to seek new legislative and/or
administrative measures to control drug costs. Additionally, on October&nbsp;1, 2020 the FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in
certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits challenging
multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September&nbsp;25, 2020, CMS stated drugs imported by States under this rule will not be eligible for
federal rebates under Section&nbsp;1927 of the Social Security Act and manufacturers would not report these drugs for &#147;best price&#148; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS
further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The regulatory and market implications of the final rule and guidance are
unknown at this time. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2020, CMS and the HHS Office of the Inspector General issued two final rules
implementing changes to the Physician Self-Referral Law, or Stark Law, and the Anti-Kickback Statute. These new rules codify new value-based exceptions and safe harbors to the Stark Law and the Anti-Kickback Statute, as well as offer additional
clarification in the form of updated definitions. We continue to analyze and monitor the potential impact of these new and amended exceptions and safe harbors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access
certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and
without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an
internal policy and respond to patient requests according to that policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring coverage and adequate payment for a product
also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may
require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after
a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or
<FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which
their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or may instead adopt a system of direct or indirect
controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit
prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the
severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being
erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various
European Union member states, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls
or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance with other federal and state laws or requirements; changing legal requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any products that we may develop are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional
laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, labeling, packaging, distribution, sales, promotion and other activities also are
potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which we may be subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or regulatory requirements may subject firms to legal or
regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure
of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including government contracts. Any claim or action against us
for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Prohibitions or restrictions on marketing,
sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the
interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling or packaging; (iii)&nbsp;the
recall or discontinuation of our products; or (iv)&nbsp;additional recordkeeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. environmental, health and safety laws and regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use,
storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce
hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination
or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines
and penalties for failure to comply with such laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain workers&#146; compensation insurance to cover us for costs and expenses
that we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted
against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government regulation of drugs and biologics outside of the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding
safety and efficacy and governing, among other things, clinical trials, marketing authorization, manufacturing, commercial sales and distribution of our products. For instance, in the United Kingdom and the European Economic Area, or the EEA
(comprised of the 27 EU Member States plus Iceland, Liechtenstein and Norway), medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Centralized procedure</I>&#151;The centralized procedure provides for the grant of a single marketing
authorization by the European Commission that is valid throughout the EEA. Pursuant to Regulation (EC) No.&nbsp;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological
processes, products designated as orphan medicinal products, advanced therapy products (gene therapy, somatic cell therapy and tissue engineered products) and products with a new active substance indicated for the treatment of certain diseases,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
which includes products for the treatment of cancer. For medicines that do not fall within one of the mandatory categories, an applicant still has the option of submitting an application for a
centralized marketing authorization to the European Medicines Agency, or EMA, as long as the medicine concerned contains a new active substance not yet authorized in the EEA, is a significant therapeutic, scientific or technical innovation, or if
its authorization would be in the interest of public health in the EEA. If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, the EMA&#146;s Committee for Medicinal Products for
Human Use, or CHMP, is responsible for conducting an initial assessment of whether a product meets the required quality, safety and efficacy requirements, and whether a product has a positive benefit/risk ratio. Under the centralized procedure the
maximum timeframe for the evaluation of a marketing authorization application, or MAA, by the EMA is 210&nbsp;days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked
by the CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the
final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#146;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of
major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150&nbsp;days, excluding clock stops, but it is possible that the
CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>National authorization procedures</I>&#151;There are also two other possible routes to authorize products for
therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Decentralized procedure</I>&#151;Using the decentralized procedure, an applicant may apply for simultaneous
authorization in more than one EEA Member State for a medicinal product that has not yet been authorized in any EEA Member State and that does not fall within the mandatory scope of the centralized procedure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Mutual recognition procedure</I>&#151;In the mutual recognition procedure, a medicine is first authorized in
one EEA Member State, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EEA Member States in a procedure whereby the countries concerned recognize the validity of
the original, national marketing authorization. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In both cases, as with the centralized procedure, the competent
authorities of the EEA Member States assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy before granting the marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EEA, new products for therapeutic indications that are authorized for marketing (i.e.,&nbsp;innovator products) qualify for eight years of data
exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from referencing the preclinical and clinical trial data contained in the dossier of
the innovator product when applying for a generic or biosimilar marketing authorization in the EEA during a period of eight years from the date on which the innovator product was first authorized in the EEA. The additional <FONT
STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EEA until ten years have elapsed from the initial authorization of the
reference product in the EU. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an
authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered
to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company obtained marketing authorization based on a MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for designating an &#147;orphan medicinal product&#148; in the EEA are similar in principle to those in the United States. Under Article 3 of
Regulation (EC) 141/2000, in the EEA a medicinal product may be designated as orphan if it meets the following criteria (1)&nbsp;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition;
and (2)&nbsp;either (a)&nbsp;such condition affects no more than five in 10,000 persons in the EEA when the application is made, or (b)&nbsp;it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient
return in the EEA to justify the investment needed for its development; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition, or if such a method exists, the product will be of significant benefit
to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the
approved therapeutic indication. During this <FONT STYLE="white-space:nowrap">ten-year</FONT> orphan market exclusivity period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a similar
medicinal product for the same indication, although similar, is safer, more effective or otherwise clinically superior than the authorized product; (ii)&nbsp;the marketing authorization holder of the authorized product consents to a second orphan
medicinal product application; or (iii)&nbsp;the marketing authorization holder of the authorized product cannot supply enough orphan medicinal product. An orphan product can also obtain an additional two years of market exclusivity in the EU for
pediatric studies. The <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for
example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. The application for orphan drug designation must be submitted before the application for marketing authorization. The applicant will receive a fee
reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of
<FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research in the European Union are subject to significant regulatory controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system,
an applicant must obtain prior approval from the national competent authority, or NCA, of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after
the competent ethics committee, or EC, has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting
information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, and the provisions of the individual EU Member States&#146; legislation implementing the Clinical Trials Directive. Under the current regime (the EU Clinical Trials Directive
2001/20/EC and corresponding national laws) all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted. It is expected that the new Clinical Trials
Regulation (EU) No 536/2014 will apply following confirmation of full functionality of the Clinical Trials Information System (CTIS), the centralized European Union portal and database for clinical trials foreseen by the regulation, through an
independent audit. The regulation becomes applicable six months after the European Commission publishes notice of this confirmation. The Clinical Trials Regulation will be directly applicable in all the EU Member States, repealing the current
Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the European Union will continue to be bound by the Clinical Trials Directive and the Member States&#146; national implementing legislation until the new Clinical
Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three
years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. The new Clinical Trials Regulation aims to simplify and streamline the approval of
clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point, the &#147;EU portal&#148;; a single set of documents to be prepared and submitted for the
application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part&nbsp;I is assessed by the competent
authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part&nbsp;II is assessed separately by each Member State concerned. Strict deadlines have been
established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related
timelines will be defined by the Clinical Trials Regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government regulation of data collection outside of the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event we conduct clinical trials in the European Union, we will be subject to additional privacy restrictions. The collection and use of personal health
data in the European Economic Area, or EEA (being the European Union plus Norway, Iceland, and Liechtenstein), is governed by the General Data Protection Regulation, or the GDPR, which became effective on May&nbsp;25, 2018. The GDPR applies to the
processing of personal data by any company established in the EEA and to companies established outside the EEA to the extent they process personal data in connection with the offering of goods or services to data subjects in the EEA or the
monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how
personal data is used, enhanced requirements for securing personal data, requirements to conduct privacy impact assessments for &#147;high risk&#148; processing, limitations on retention of personal data, mandatory data breach notification and
&#147;privacy by design&#148; requirements, and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate
level of protection, like the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States and Norway, Iceland and Liechtenstein, which may deviate slightly from
the GDPR, may result in fines of up to 4% of a company&#146;s global revenue for the preceding financial year, or &#128;20,000,000, whichever is greater. Moreover, the GDPR grants data subjects the right to claim material and <FONT
STYLE="white-space:nowrap">non-material</FONT> damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will require significant time, resources and
expense, and we may be required to put in place additional controls and processes ensuring compliance with the new data protection rules. There has been limited enforcement of the GDPR to date, particularly in biopharmaceutical development, so we
face uncertainty as to the exact interpretation of the new requirements on any future trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. Further, the
United Kingdom&#146;s decision to leave the European Union, means that it has in force its own legislation which is aligned with the GDPR, known as the Data Protection Act 2018. The requirements are similar except that the United Kingdom is now
regarded as a &#147;third country&#148; for the purposes of transfers of personal data from the EEA. Transfers continue to flow freely from the UK to the EEA; however, as part of the agreement between the UK and the EU, the UK intends to obtain an
adequacy decision from the European Commission to ensure personal data can continue to flow freely from the EU to the UK. The UK hopes to obtain this decision by the end of June 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data protection authority activity differs across the EU, with certain authorities applying their own agenda which shows there is uncertainty in the manner in
which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed
by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results of operations and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should we utilize third party distributors, compliance with such foreign governmental regulations would
generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we had 29 full-time employees, of which 16 have M.D. or Ph.D. degrees. Within our workforce, 21 employees are engaged in research
and development and eight are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our
relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining,
incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based
compensation awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate
headquarters is located in Boston, Massachusetts, where we lease and occupy approximately 13,170 square feet of office and laboratory space, or the Boston Lease. The term of our Boston Lease expires on February&nbsp;28, 2021. Additionally, we have
entered into a lease to move our corporate headquarters and occupy approximately 20,752 square feet of office, laboratory and animal care space, or the New Lease. We expect the commencement date of the New Lease to be February&nbsp;1, 2021 and the
term is expected to expire on May&nbsp;31, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our existing facilities, including the facilities we expect to occupy under the New Lease,
are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially
reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to
time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.
Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executives and directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth
the name, age and position of each of our executives and directors as of December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Manfredi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas R. Carlson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Ecsedy, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Scientific Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sergio Santillana, M.D., M.Sc., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maude Tessier, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Business Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald C. Renaud, Jr.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Bonita, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iain D. Dukes, D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela,
M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Otello Stampacchia, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each executive officer serves at the discretion of our board of directors and holds office until his or her successor is duly elected and qualified or until
his or her earlier resignation or removal. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark Manfredi, Ph.D.</I></B> is a founding member of Ikena Oncology and has served as our President and Chief Executive Officer, and as a
member of our board of directors since December 2017. Previously, Dr.&nbsp;Manfredi served as our Chief Scientific Officer from March 2016 until December 2017. Prior to that, from April 2015 to September 2017, Dr.&nbsp;Manfredi was an <FONT
STYLE="white-space:nowrap">in-house</FONT> oncology expert at Atlas Venture, a company that has founded multiple biotechnology companies and Dr.&nbsp;Manfredi currently serves as an advisor to Atlas Venture. Concurrently, from April 2015 to April
2016, Dr.&nbsp;Manfredi was the Chief Scientific Officer of Raze Therapeutics, Inc., a biotechnology company focused on oncology therapeutics that target key metabolic pathways. He also previously held roles of increasing responsibility at
Millennium Pharmaceuticals, Inc., as well as its parent company, Takeda Pharmaceutical Company from April 2001 to April 2015. Dr.&nbsp;Manfredi holds a Bachelor of Science in Zoology from the University of Rhode Island, and a Doctorate of Philosophy
from Boston College. We believe that Dr.&nbsp;Manfredi is qualified to serve as our President and Chief Executive Officer and as a member of our board of directors because of his significant scientific and industry knowledge, as well as valuable
experience gained from prior service as President and Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Douglas R. Carlson </I></B>has served as our Chief Financial Officer
since January 2019. Prior to this, from March 2013 to January 2019, he held roles of increasing responsibility at Collegium Pharmaceutical, Inc. (NASDAQ: COLL), or Collegium, a publicly-traded, specialty pharmaceutical company, including Vice
President, Corporate and Business Development and Vice President, Commercial Operations, Corporate Strategy&nbsp;&amp; Business Development. Prior to joining Collegium, Mr.&nbsp;Carlson was Senior Director of Business Development at BTG
International, Inc. (LSE: BTG), or BTG, a publicly-traded, international specialist healthcare company, where he was responsible for global specialty pharmaceutical M&amp;A and licensing, from August 2011 to March 2013. Prior to BTG,
Mr.&nbsp;Carlson was Senior Director and Head of Business Development for Lundbeck Inc., or Lundbeck, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the U.S. Headquarters of H. Lundbeck A/S, from December 2009 to August 2011. Prior to Lundbeck, Mr.&nbsp;Carlson was Director of Corporate Development and M&amp;A at Ovation Pharmaceuticals,
Inc., or Ovation, where he played an integral role in the sale of Ovation to H. Lundbeck A/S in March 2009. Prior to Ovation, Mr.&nbsp;Carlson was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital
Management, Inc. Mr.&nbsp;Carlson began his career in the healthcare investment banking group of Cowen. Mr.&nbsp;Carlson graduated from Trinity College in Hartford, Connecticut with a B.A. in American Studies in 2001. We believe that
Mr.&nbsp;Carlson is qualified to serve as our Chief Financial Officer because of his extensive experience in the pharmaceutical industry, including his prior service in senior management roles with both private and public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jeffrey Ecsedy, Ph.D.</I></B> has served as our Chief Scientific Officer since March 2019. Prior to this, he served as our Senior Vice President of
Research and Development from October 2017 to February 2019. Previously, from June 2013 to October 2017, Dr.&nbsp;Ecsedy served as the Senior Director and Head of Oncology Translational Medicine at Takeda Pharmaceuticals Company Limited.
Dr.&nbsp;Ecsedy holds a Bachelor of Science in Biological Sciences from the University of Connecticut and a Doctorate of Philosophy from Boston College. We believe that Dr.&nbsp;Ecsedy is qualified to serve as our Chief Scientific Officer because of
his significant scientific and industry knowledge, and his prior service in senior management roles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sergio Santillana, M.D., M.Sc., MBA</I></B>
has served as our Chief Medical Officer since July 2020. Prior to this, he served as Senior Clinical Consultant for Ikena from September 2019 to June 2020. Dr.&nbsp;Santillana is also founder and President of his own oncology consulting firm, SLSS
Consulting LLC, where he provides strategic consultancy services since April 2019. From June 2017 to April 2019 Dr.&nbsp;Santillana served as Senior Vice President and Chief Medical Officer at Merrimack Pharmaceuticals, Inc., a company focused on
developing biologics and nanotherapeutics for solid tumors. Before joining Merrimack Pharmaceuticals, Inc., from March 2016 to June 2017, he was Head of Clinical Research and then Chief Medical Officer for ARIAD Pharmaceuticals, a commercial-stage
biotechnology company focused on developing targeted therapies for cancer, that was acquired by Takeda Pharmaceutical Company. From August 2014 to March 2016, Dr.&nbsp;Santillana served as the Senior Medical Director of Oncology and Clinical
Research at Takeda Pharmaceuticals International Limited, where he was the Global Clinical Lead of early development programs. Prior to joining Takeda Oncology, he served in various oncology clinical development roles at GlaxoSmithKline and Eli
Lilly Oncology. Before joining the biopharmaceutical industry, Dr.&nbsp;Santillana was a practicing medical oncologist for more than a decade. Dr.&nbsp;Santillana holds a Bachelor of Science, Medical Degree (MD)&nbsp;and specialty/residence in
Medical Oncology from the Universidad Nacional Federico Villarreal, a Master of Science from Kellogg College at Oxford University, and Master of Business Administration from Sloan School of Management at the Massachusetts Institute of Technology. We
believe that Dr.&nbsp;Santillana is qualified to serve as our Chief Medical Officer because of his executive experience in the life sciences industry and his extensive medical knowledge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maude Tessier, Ph.D.</I></B> has served as our Chief Business Officer since December 2019. Prior to this, she served as our Vice President of Business
Development and Corporate Strategy from July 2018 to December 2019. Prior to that, from September 2014 until July 2018, Dr.&nbsp;Tessier held roles of increasing responsibility at Merck&nbsp;&amp; Co., including Executive Director of Business
Development&nbsp;&amp; Licensing, and Director, Business Development&nbsp;&amp; Licensing for oncology partnering. Prior to joining Merck&nbsp;&amp; Co., from June 2008 until September 2014, Dr.&nbsp;Tessier held roles of increasing responsibility
at Boston Children&#146;s Hospital, including Assistant Director of Business Development and Strategic Initiatives. In this role, she forged discovery alliances with industry partners and also built and managed the Marketing&nbsp;&amp;
Communications team. Maude began her business development career at Xanthus Pharmaceuticals, a small venture-backed oncology biotech company in Cambridge, Mass., where she had key roles in Business Development and Program Management of a Phase 3
asset leading to its eventual FDA approval. Dr.&nbsp;Tessier holds a Bachelor of Science in Biochemistry from McGill University and a Doctorate in Medical Biophysics from the University of Toronto. We believe that Dr.&nbsp;Tessier is qualified to
serve as our Chief Business Officer because of her extensive industry knowledge and experience. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ronald C. Renaud, Jr.</I></B> has served as Chairman of our board of directors and as a member of our audit and compensation committees since March 2018.
Since November 2014, Mr.&nbsp;Renaud has served as President and Chief Executive Officer and as a member of the board of directors of Translate Bio, Inc. (Nasdaq: TBIO). Mr.&nbsp;Renaud currently serves as a member of the board of directors of Atara
Biotherapeutics, Inc. (Nasdaq: ATRA) and Axial Biotherapeutics, Inc. Formerly, Mr.&nbsp;Renaud served as President and Chief Executive Officer of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from October 2010 until Idenix was acquired
by Merck&nbsp;&amp; Co., a pharmaceutical company, in August 2014. He was previously Chief Financial Officer and Chief Business Officer of Idenix Pharmaceuticals, Inc. from May 2007 until October 2010. Mr.&nbsp;Renaud has also previously served as a
member of the boards of directors of Akebia Therapeutics, Inc. (Nasdaq: AKBA), PTC Therapeutics, Inc. (Nasdaq: PTCT), and Chimerix, Inc. (Nasdaq: CMRX). Mr.&nbsp;Renaud received a Bachelor of Arts from St. Anselm College and a Master of Business
Administration from the Marshall School of Business at the University of Southern California. We believe that Mr.&nbsp;Renaud is qualified to serve on our board of directors because of his executive experience, his service on the boards of other
private and public life sciences companies and his extensive knowledge of the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>David Bonita, M.D.</I></B> has served as a
member of our board of directors since March 2016. Dr.&nbsp;Bonita is a member of OrbiMed Advisors LLC, an investment firm. Dr.&nbsp;Bonita currently serves on the boards of directors of Acutus Medical Inc. (Nasdaq: AFIB), IMARA Inc. (Nasdaq: IMRA),
Prelude Therapeutics, Inc. (Nasdaq: PRLD), Repare Therapeutics Inc. (Nasdaq: RPTX), and Tricida, Inc. (Nasdaq: TCDA), as well as several private companies. Dr.&nbsp;Bonita also previously served on the boards of directors of Clementia
Pharmaceuticals Inc., Loxo Oncology, Inc., <FONT STYLE="white-space:nowrap">SI-BONE,</FONT> Inc., and ViewRay Inc. Prior to OrbiMed, Dr.&nbsp;Bonita&nbsp;worked as a corporate finance analyst in the healthcare investment banking groups of Morgan
Stanley and UBS. He has published scientific articles in peer-reviewed journals based on signal transduction research performed at Harvard Medical School. He received his B.A. in biology from Harvard University and his joint M.D./M.B.A. from
Columbia University. We believe that Dr.&nbsp;Bonita is qualified to serve on our board of directors based on his roles on several public and private boards of directors as well as his extensive experience in investing in healthcare companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Iain D. Dukes, D.Phil</I></B><B>.</B> has served as a member of our board of directors since November 2016. Dr.&nbsp;Dukes is a Venture Partner at
OrbiMed Advisors LLC, which he joined in August 2016. Dr.&nbsp;Dukes has served as the Chief Executive Officer of Viriom Inc. since February 2019 and has also served as the Executive Chairman of Angiex Inc. since February 2020. In June 2018,
Dr.&nbsp;Dukes <FONT STYLE="white-space:nowrap">co-founded</FONT> Theseus Pharmaceuticals, Inc. and currently serves as the Chief Executive Officer. In September 2017, Dr, Dukes <FONT STYLE="white-space:nowrap">co-founded</FONT> Kartos Therapeutics,
Inc. and currently serves as President. Dr.&nbsp;Dukes previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories from August 2013 through May 2016. Prior to joining Merck,
Dr.&nbsp;Dukes was Vice President of External Research&nbsp;&amp; Development at Amgen, Inc. from August 2010 to August 2013. From October 2017 to July 2020, Dr.&nbsp;Dukes was a board member and Chairman of KaNDy Therapeutics, which was acquired by
Bayer AG in September 2020. From January 2020 to June 2020, Dr.&nbsp;Dukes served as supervisory board member of Themis BioScience GmbH, until it was acquired by Merck&nbsp;&amp; Co. Dr.&nbsp;Dukes also
<FONT STYLE="white-space:nowrap">co-founded</FONT> Telios Pharmaceuticals, Inc., where he serves as President. Dr.&nbsp;Dukes currently serves on the boards of directors of NeRRe Therapeutics, ReViral Limited, and ENYO Therapeutics. Since August
2016, Dr.&nbsp;Dukes has also served as chairman of the board of directors of Iovance Biotherapeutics Inc. (Nasdaq: IOVA). Dr.&nbsp;Dukes holds Master of Jurisprudence and Doctor of Philosophy degrees from the University of Oxford, a Master of
Science degree in Cardiovascular Studies from the University of Leeds and a Bachelor of Science degree in Pharmacology from the University of Bath. We believe that Dr.&nbsp;Dukes is qualified to serve as a member of our board of directors because of
his extensive experience in the pharmaceutical industry, including his service in senior management roles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Jean-Fran&ccedil;ois Formela,
M.D.</I></B><I> </I>has served as a member of our board of directors and as a member of our audit committee since March 2016. Dr.&nbsp;Formela is currently a Partner at Atlas Venture and focuses on novel drug discovery approaches and therapeutics.
Dr.&nbsp;Formela joined Atlas Venture in 1993 to build the U.S. life sciences </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
franchise. Dr.&nbsp;Formela is a director and <FONT STYLE="white-space:nowrap">co-founder</FONT> of IFM Therapeutics, Inc., Intellia Therapeutics, Inc. (Nasdaq: NTLA), Korro Bio, Inc., Triplet
Therapeutics, Inc. and Translate Bio, Inc. (Nasdaq: TBIO). Dr.&nbsp;Formela also serves on the board of Spero Therapeutics, Inc. (Nasdaq: SPRO). Dr.&nbsp;Formela is a member of the Partners Healthcare Innovation Growth Board and a former trustee of
the Boston Institute of Contemporary Art. Dr.&nbsp;Formela received his Doctor of Medicine from Paris University School of Medicine and his Master of Business Administration from Columbia University. We believe Dr.&nbsp;Formela&#146;s experience in
the life sciences industry, as well as his practice of medicine, provides him with the qualifications and skills to serve as a director of our Company </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Otello Stampacchia, Ph.D</I></B><B>.</B> has served as a member of our board of directors since December 2020. Dr.&nbsp;Stampacchia is founder, Managing
Director, and member of the investment committee at Omega Funds. Dr.&nbsp;Stampacchia currently serves on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Morphic Holding, Inc. (Nasdaq: MORF), and Replimune Group, Inc. (Nasdaq: REPL), and
private companies: Amunix Pharmaceuticals, Inc. and Scorpion Therapeutics, Inc. Prior to founding Omega in January 2004, Dr.&nbsp;Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the
portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Dr.&nbsp;Stampacchia was a member of the HealthCare corporate finance
and M&amp;A team at Goldman Sachs. Before Goldman, he helped <FONT STYLE="white-space:nowrap">co-found</FONT> the healthcare investment activities at Index Securities (now Index Ventures). Dr.&nbsp;Stampacchia received a Masters of Science in Plant
Genetics from the University of Pavia, a Masters of Science in Molecular Biology and a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbourg. We
believe Dr.&nbsp;Stampacchia is qualified to serve on our board of directors because of his venture capital experience in the life sciences industry and his service on the boards of other public and private life sciences companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of our board of directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board consists
of six<B> </B>members, each of whom are members pursuant to the board composition provisions of our certificate of incorporation and agreements with our stockholders, and is chaired by Mr.&nbsp;Renaud. These board composition provisions will
terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board of
directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is
identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our
business, understanding of the competitive landscape, professional and personal experiences, and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of
their resignation or removal. Our fifth amended and restated certificate of incorporation that will become effective upon the closing of this offering and amended and restated bylaws that will become effective upon the effectiveness of the
registration statement of which this prospectus is a part, also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that all our
stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our
directors then in office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common stock on The Nasdaq Global Market. Under the Nasdaq listing rules, independent directors must comprise a majority of a
listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating
and governance committees be independent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule
<FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not
have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1)&nbsp;accept, directly or indirectly, any
consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be
considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining
whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of
compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that all members of the board of directors, except Mark Manfredi, Ph.D., are independent directors, including for
purposes of the rules of The Nasdaq Global Market and the SEC. In making such independence determinations, our board of directors considered the relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with us and
all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. In
considering the independence of the directors listed above, our board of directors considered the association of our directors with the holders of more than 5% of our common stock. Upon the completion of this offering, we expect that the composition
and functioning of our board of directors and each of our committees will comply with all applicable requirements of The Nasdaq Global Market and the rules and regulations of the SEC. There are no family relationships among any of our directors or
executive officers. Dr.&nbsp;Manfredi<B> </B>is not an independent director under these rules because he is our President and Chief Executive Officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of
our fifth amended and restated certificate of incorporation that will become effective upon the closing of this offering and amended and restated bylaws that will become effective upon the effectiveness of the registration statement of which this
prospectus is a part, our board of directors will be divided into three staggered classes of directors and each will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a
three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the
years 2022 for Class&nbsp;I directors, 2023 for Class&nbsp;II directors and 2024 for Class&nbsp;III directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;II directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fifth amended and restated
certificate of incorporation that will become effective upon the closing of this offering and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> that will become effective upon the effectiveness of the registration statement of
which this prospectus is a part provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The division of our board of directors into three classes with staggered three-year terms may delay or
prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board leadership structure and board&#146;s role in risk
oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, the role of chairman of our board of directors is separated from the role of Chief Executive Officer. Our Chief Executive Officer
is responsible for recommending strategic decisions and capital allocation to the board of directors and to ensure the execution of the recommended plans. The chairman of our board of directors is responsible for leading the board of directors in
its fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort, and energy that the Chief Executive Officer is required to devote to his position in the current business
environment, as well as the commitment required to serve as our chairman, particularly as the board of directors&#146; oversight responsibilities continue to grow. While our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> and
corporate governance guidelines will not require that our chairman and Chief Executive Officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and
demonstrates our commitment to good corporate governance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk is inherent with every business, and how well a business manages risk can ultimately
determine its success. We face a number of risks, including the four risks more fully discussed in the section entitled &#147;Business&#148; appearing elsewhere in this prospectus. Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of
directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as disclosed
in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee) discusses
with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairman of the
relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly
with respect to risk interrelationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of our board of directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will
operate pursuant to a charter to be adopted by our board of directors and will be effective upon the effectiveness of the registration statement of which this prospectus is a part. The board of directors may also establish other committees from time
to time to assist us and our board of directors. Upon the effectiveness of the registration statement of which this prospectus is a part, the composition and functioning of all of our committees will comply with all applicable requirements of the
Sarbanes-Oxley Act of 2002, Nasdaq and SEC rules and regulations, if applicable. Upon our listing on The Nasdaq Global Market, each committee&#146;s charter will be available on our website at www.ikenaoncology.com. The reference to our website
address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be part of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serve on the audit committee, which is chaired
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that&nbsp;each are &#147;independent&#148; for audit committee purposes as that term is defined by the rules of
the SEC and Nasdaq, and that each has sufficient knowledge in financial and auditing matters to serve on the audit committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Our board of directors has determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;qualifies as an &#147;audit committee financial
expert,&#148; as defined under the applicable rules of the SEC. The audit committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and assessing the independence of, our independent registered public
accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and
quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending, based upon the audit committee&#146;s review and discussions with management and our independent
registered public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as
they relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serve on the compensation committee, which is chaired
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that each member of the compensation committee is &#147;independent&#148; as defined in the applicable Nasdaq
rules. The compensation committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and,
based on such evaluation, recommending to the board of directors the cash compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the cash compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the
evaluation of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retaining and approving the compensation of any compensation advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the grant of equity-based awards; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to the board of directors the compensation of our directors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the compensation committee report required by SEC rules, if and when required, to be included in our
annual proxy statement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of our compensation committee is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director,
as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and corporate governance committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the effectiveness of the registration statement of which this prospectus forms a
part,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will serve on the nominating and corporate governance committee, which will be chaired
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that a majority of the nominating and corporate governance committee is &#147;independent&#148; as defined in
the applicable Nasdaq rules. The nominating and corporate governance committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees
recommended by stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the
appropriate skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to the board of directors appropriate corporate governance guidelines; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the evaluation of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation committee interlocks and insider participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the compensation committee consisted of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. None of the
members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors
or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of
Business Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors will adopt a Code of Business Conduct and Ethics in connection with this offering. The Code of
Business Conduct and Ethics will apply to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions. Upon the
completion of this offering, the full text of our Code of Business Conduct and Ethics will be posted on our website at www.ikenaoncology.com. The information on our website is deemed not to be incorporated in this prospectus or to be a part of this
prospectus. If we make any substantive amendments to, or grant any waivers from, our Code of Business Conduct and Ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on
Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, provisions in our fifth amended and restated certificate of incorporation, which will become effective immediately prior to the
closing of this offering, and amended and restated bylaws, which will become effective upon the effectiveness of this registration statement, limit or eliminate the personal liability of directors for a breach of their fiduciary duty of care as a
director. The duty of care generally requires that, when acting on behalf of the corporation, a director exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director will not
be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payments of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek
<FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, such as injunctive relief or rescission. These provisions will not alter a director&#146;s liability under other laws, such as the federal securities laws or other state or federal laws.
Our fifth amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under
Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, our amended and restated bylaws to be effective upon the effectiveness of this registration statement will
provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other
agents, in connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then the liability
of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director, employee or
other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our bylaws permit such indemnification. We have obtained such insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the indemnification that will be provided for in our fifth amended and restated certificate of incorporation and amended and restated bylaws,
we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification
agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or executive officer in any
action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to
attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This description of the indemnification provisions of our fifth
amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement
of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our
directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is,
therefore, unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being
sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding
future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers, or NEOs, for the year ended December&nbsp;31, 2020, which consist of our principal executive officer and the next two most
highly compensated executive officers, are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mark Manfredi, Ph.D., our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Douglas R. Carlson, our Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sergio Santillana, M.D., M.Sc., MBA, our Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the compensation of our NEOs has consisted of a combination of base salary, cash bonuses and long-term incentive compensation in the form of stock
options. Our NEOs, like all full-time employees, are eligible to participate in our health and welfare benefit plans. As we transition from a private company to a publicly traded company, we intend to evaluate our compensation values and philosophy
and compensation plans and arrangements as circumstances require. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the total compensation earned by, or paid to, our NEOs for services rendered to us in all capacities during the fiscal year ended
December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and principal position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Manfredi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas R. Carlson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sergio Santillana, M.D., M.Sc.,
MBA<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586,700</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,250</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">778,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash bonuses for performance during the year ended December&nbsp;31, 2020 are not calculable as of the latest
practicable date prior to the filing of this prospectus. We expect that such amounts will be determined later in the first quarter of the fiscal year ending December&nbsp;31, 2021. For more information on these bonuses, see the description of the
annual performance bonuses under &#147;2020 bonuses&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Santillana joined our company as our Chief Medical Officer in July 2020. Pursuant to the terms of his
employment agreement with us, Dr.&nbsp;Santillana devotes approximately 50% of his full working time to our company and his annual base salary for 2020 was $275,000, which reflects his 50% commitment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents the aggregate grant date fair value of the option award granted to Dr.&nbsp;Santillana
during our fiscal year ended December&nbsp;31, 2020, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note to our financial statements for the year ended
December&nbsp;31, 2020, included elsewhere in this prospectus. This amount does not correspond to the actual value that may be recognized by Dr.&nbsp;Santillana upon exercise of the applicable award or sale of the underlying shares of stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount reported for Dr.&nbsp;Santillana represents fees paid to Dr.&nbsp;Santillana for his services as a
consultant in 2020 prior to becoming our Chief Medical Officer in July 2020. Pursuant to the consulting agreement between us and Dr.&nbsp;Santillana, he was paid $500 per hour for consulting services. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our NEOs each receive a base salary
to compensate them for services rendered to our company. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. Base salaries are
reviewed annually, typically in connection with our annual performance review process, approved by our board of directors or the compensation committee, and may be adjusted from time to time to realign salaries with market levels after taking into
account individual responsibilities, performance, and experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For fiscal year 2020, the annual base salary for each of Dr.&nbsp;Manfredi,
Mr.&nbsp;Carlson, and Dr.&nbsp;Santillana were $409,500, $330,372, and $275,000, respectively. For Dr.&nbsp;Santillana, his 2020 base salary reflects that he devoted approximately 50% of his full working time to our company during the time that he
served as our Chief Medical Officer in 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 bonuses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&nbsp;31, 2020, each NEO was eligible to earn an annual cash bonus based on the achievement of certain corporate and
individual performance milestones. The target annual bonus for each of Dr.&nbsp;Manfredi, Mr.&nbsp;Carlson, and Dr.&nbsp;Santillana for the fiscal year ended December&nbsp;31, 2020 were 35%, 35% and 35% of annual base salary, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual cash bonus earned by each NEO for the fiscal year ended December&nbsp;31, 2020 has not been determined as of the date of this filing, but once
determined will be reported in the <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148; column of the &#147;2020 Summary Compensation Table&#148; above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-based compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not have
a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the
interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of
directors or our compensation committee periodically review the equity incentive compensation of our NEOs and may grant equity incentive awards to them from time to time. In July 2020, in connection with his appointment as our Chief Medical Officer,
we granted Dr.&nbsp;Santillana an option to purchase 1,128,269 shares of our common stock, with an exercise price per share equal to the fair market value of our common stock on the date of grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2020 Fiscal Year End </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table lists all outstanding equity awards held by our NEOs as of December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Manfredi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681,818</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/15/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,274</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,089</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/8/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/19/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">811,692</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,558</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/14/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640,156</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">823,046</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/19/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas R. Carlson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">556,822</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715,905</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/28/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/19/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sergio Santillana</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,128,269</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/22/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of the outstanding equity awards in the table above was granted pursuant to our 2016 Stock Incentive Plan,
as amended, or the 2016 Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase shares of our common stock granted on August&nbsp;24, 2016. The shares
underlying this option vest as follows: 25% of the shares vested on April&nbsp;15, 2017 and the remainder vested over the next three years in equal monthly installments on the last day of each succeeding calendar month. All shares underlying this
option have vested and are exercisable by Dr.&nbsp;Manfredi. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase shares of our common stock granted on February&nbsp;20, 2018. The shares
underlying this option vest in equal monthly installments on the last day of each calendar month following the vesting commencement date and will become fully vested on the fourth anniversary of the vesting commencement date, subject to continued
service to us through the applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase shares of our common stock granted on December&nbsp;18, 2018. The shares
underlying this option vest as follows: 25% of the shares vested on December&nbsp;14, 2018 and the remainder vest over the next three years in equal monthly installments on the last day of each succeeding calendar month (with the option becoming
fully vested on the fourth anniversary of the vesting commencement date), subject to continued service to us through the applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase shares of our common stock granted on March&nbsp;20, 2019. The shares
underlying this option vest as follows: 25% of the shares vested on March&nbsp;20, 2020 and the remainder vest over the next three years in equal monthly installments on the last day of each succeeding calendar month thereafter (with the option
becoming fully vested on the fourth anniversary of the vesting commencement date), subject to continued service to us through the applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase shares of our common stock granted on March&nbsp;20, 2019. The shares
underlying this option vest as follows: 25% of the shares vested on January&nbsp;19, 2020 and the remainder vest over the next three years in equal monthly installments on the last day of each succeeding calendar month thereafter (with the option
becoming fully vested on the fourth anniversary of the vesting commencement date), subject to continued service to us through the applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an option to purchase shares of our common stock granted on July&nbsp;23, 2020. The shares
underlying this option vest as follows: 25% of the shares vest on July&nbsp;1, 2021 and the remainder vest over the next three years in equal monthly installments on the last day of each succeeding calendar month thereafter (with the option becoming
fully vested on the fourth anniversary of the vesting commencement date), subject to continued service to us through the applicable vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
this offering, we intend to enter into new employment agreements with each of Dr.&nbsp;Manfredi, Mr.&nbsp;Carlson, and Dr.&nbsp;Santillana. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Arrangements in Place Prior to the Offering for Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark Manfredi, Ph.D. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective December&nbsp;8,
2017, we entered into an amended and restated employment agreement with Dr.&nbsp;Manfredi, or the Manfredi Employment Agreement, for the position of Chief Executive Officer. The Manfredi Employment Agreement provides for Dr.&nbsp;Manfredi&#146;s <FONT
STYLE="white-space:nowrap">at-will</FONT> employment. Dr.&nbsp;Manfredi&#146;s current annual base salary is $409,500, and he is eligible for an annual bonus with a target amount of 35% of his current annual base salary. Dr.&nbsp;Manfredi is
eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Manfredi
Employment Agreement, in the event that Dr.&nbsp;Manfredi&#146;s employment is terminated by us without &#147;cause&#148; (as defined in the Manfredi Employment Agreement), subject to the execution and effectiveness of a severance and release of
claims agreement within 60 days of such termination, Dr.&nbsp;Manfredi will be entitled to receive (i)&nbsp;six months of base salary continuation, (ii)&nbsp;accelerated vesting of the portion of the stock options and restricted stock awards held by
Dr.&nbsp;Manfredi that would have vested in the six months </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following termination had Dr.&nbsp;Manfredi remained employed, and (iii)&nbsp;subject to the Dr.&nbsp;Manfredi&#146;s timely election to continue COBRA health coverage and copayment of premium
amounts at the applicable active employees&#146; rate, we will continue to pay the share of the premiums that we would have paid to provide health insurance to Dr.&nbsp;Manfredi until the earlier of (A)&nbsp;six&nbsp;months following termination or
(B)&nbsp;Dr.&nbsp;Manfredi&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan. In the event that such termination occurs within six months after a &#147;change in control&#148; (as defined in the
Manfredi Employment Agreement), Dr.&nbsp;Manfredi will, subject to the execution and effectiveness of a general severance and release of claims agreement within 60 days of such termination, be entitled to receive (x)&nbsp;a lump sum payment equal to
six months of base salary, (y)&nbsp;accelerated vesting of 100% of any stock options and restricted stock awards held by Dr.&nbsp;Manfredi, and (z)&nbsp;the benefits set forth in clause (iii)&nbsp;of the preceding sentence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Douglas R. Carlson </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2018, we
entered into an employment offer letter with Mr.&nbsp;Carlson, or the Carlson Offer Letter, to serve as our Chief Financial Officer. The Carlson Offer Letter provides for Mr.&nbsp;Carlson&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT>
employment. Mr.&nbsp;Carlson&#146;s current base salary is $330,372 and he is eligible for an annual bonus with a target amount of 35% of his base salary. Mr.&nbsp;Carlson is eligible to participate in the employee benefit plans available to our
employees, subject to the terms of those plans. Pursuant to the Carlson Offer Letter, in the event that Mr.&nbsp;Carlson&#146;s employment is terminated by us without &#147;cause&#148; or by Mr.&nbsp;Carlson for &#147;good reason&#148; within one
year of a &#147;change of control&#148; (as all such terms are defined in the 2016 Plan), then the unvested portion of the stock option granted to Mr.&nbsp;Carlson in March 2019 shall immediately vest in full. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sergio Santillana, M.D. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective July&nbsp;1,
2020, we entered into an employment agreement with Dr.&nbsp;Santillana, or the Santillana Employment Agreement, for the position of Chief Medical Officer. Pursuant to the terms of the Santillana Employment Agreement, Dr.&nbsp;Santillana devotes
approximately 50% of his full working time to our company. The Santillana Employment Agreement provides for Dr.&nbsp;Santillana&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, his initial annual base salary of $275,000 (subject to
adjustment), and his eligibility for an annual bonus with a target amount of 35% of his annual base salary. Dr.&nbsp;Santillana is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Santillana Employment Agreement, in the event that Dr.&nbsp;Santillana&#146;s employment is terminated by us without &#147;cause&#148; or
by Dr.&nbsp;Santillana for &#147;good reason&#148; (as such terms are defined in the Santillana Employment Agreement), subject to the execution and effectiveness of a separation agreement and a general release of claims within 60 days of such
termination, Dr.&nbsp;Santillana will be entitled to receive (i)&nbsp;six months of base salary continuation, (ii)&nbsp;acceleration of vesting of 50% (or in the event that Dr.&nbsp;Santillana converts to full time employment 100%) of the unvested
portion of any time-based stock options and other stock-based awards subject to time-based vesting held by Dr.&nbsp;Santillana, and (iii)&nbsp;subject to the Dr.&nbsp;Santillana&#146;s timely election to continue COBRA health coverage and copayment
of premium amounts at the applicable active employees&#146; rate, a monthly cash payment equal to the amount that we would have paid to provide health insurance to Dr.&nbsp;Manfredi until the earliest of (A) six&nbsp;months following termination,
(B)&nbsp;Dr.&nbsp;Santillana&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end of Dr.&nbsp;Santillana&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Santillana has also entered into an Invention and <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement with us that contains <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> provisions that apply during and following his employment with us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Equity
Compensation Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2016 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our 2016 Plan was adopted by our board of directors on March&nbsp;4, 2016, approved by our stockholders on March&nbsp;4, 2016 and most recently amended on
December&nbsp;18, 2020. As of December&nbsp;31, 2020, under the 2016 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan, we have reserved for issuance an aggregate of 37,264,008 shares of our common stock. The number of shares of common stock reserved for issuance shall be equitably adjusted by our board of
directors in the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock underlying awards that are terminated, surrendered or cancelled, are forfeited in whole or in part or otherwise result in
shares of common stock not being issued are currently added back to the shares of common stock available for issuance under the 2016 Plan. Following this offering, such shares will be added to the shares of common stock available for issuance under
the 2021 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has acted as administrator of the 2016 Plan. The administrator has full power to select, from among the individuals
eligible for awards, the individuals to whom awards will be granted, and to determine the specific terms and conditions of each award, subject to the provisions of the 2016 Plan. Persons eligible to participate in the 2016 Plan are employees,
officers and directors of, and consultants and advisors to, our company as selected from time to time by the administrator in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2016
Plan permits the granting of (1)&nbsp;options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code, and (2)&nbsp;options that do not so qualify. The per share exercise price of each option is
determined by our board of directors but may not be less than 100% of the fair market value of the common stock on the date of grant. The term of each option is fixed by our board of directors but may not exceed 10 years from the date of grant. Our
board of directors determines at what time or times each option may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the 2016 Plan permits the granting of stock appreciation
rights, restricted shares of common stock, restricted stock units and other stock-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2016 Plan provides that upon the occurrence of a
&#147;reorganization event,&#148; as defined in the 2016 Plan, our board of directors may take any one or more of the following actions as to all or any (or any portion of) outstanding awards (other than restricted stock awards) except as provided
otherwise in an award agreement or other agreement between us and a participant: (i)&nbsp;provide that all such awards will be assumed or substituted with substantially equivalent awards by the acquiring or succeeding corporation (or affiliate
thereof); (ii) upon written notice to a participant, provide that all unexercised awards will terminate immediately prior to the consummation of such reorganization event unless exercised (to the extent then exercisable) within a specified period
following the date of such notice; (iii)&nbsp;provide that outstanding awards shall become exercisable, realizable or deliverable, or that applicable restrictions shall lapse in whole or in part prior to or upon such reorganization event;
(iv)&nbsp;in the event of a reorganization event under the terms of which holders of common stock will receive a cash payment for each share surrendered in the reorganization event, or the &#147;acquisition price,&#148; provide for a cash payment to
participants with respect to each award equal to the number of shares subject to the vested portion of such award (after giving effect to any acceleration of vesting in connection with such reorganization event) multiplied by the excess, if any, of
the acquisition price over the exercise price of such award and any applicable withholdings, in exchange for the termination of such award; (v)&nbsp;provide that in connection with a liquidation or dissolution of the company, awards shall convert
into the right to receive liquidation proceeds net the exercise price thereof and any applicable withholdings; and (vi)&nbsp;any combination of the foregoing. Upon a reorganization event other than a liquidation or dissolution of the company, the
repurchase and other rights of the company with respect to outstanding restricted stock shall inure to the benefit of the company&#146;s successor and shall, unless our board of directors determines otherwise, apply to the cash, securities or other
property which the common stock was converted into or exchanged for pursuant to such reorganization event in the same manner and to the same extent as they applied to such restricted stock; provided that the board of directors may provide for
termination or deemed satisfaction of such repurchase or other rights under the applicable award agreement. Upon a reorganization event involving the liquidation or dissolution of the company, except as specifically provided in an award agreement or
other agreement with the participant, all restrictions and conditions on all restricted stock then outstanding shall automatically be deemed terminated or satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors may amend or discontinue the 2016 Plan at any time, subject to stockholder approval
where such approval is required by applicable law. The administrator of the 2016 Plan may also amend or cancel any outstanding award, provided that no amendment to an award may materially adversely affect a participant&#146;s rights without his or
her consent. The administrator of the 2016 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding awards or effect the repricing of such awards through cancellation and
<FONT STYLE="white-space:nowrap">re-grants.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2016 Plan will automatically terminate upon the earlier of 10 years from the date on which the
2016 Plan was initially adopted by our board of directors or 10 years from the date the 2016 Plan was initially approved by our stockholders. As of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021, options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock were outstanding under the 2016 Plan. Our board of directors has determined not to make any further
awards under the 2016 Plan following the closing of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our 2021 Stock Option and Incentive Plan, or 2021 Plan, was adopted by our board of directors on,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, approved by our stockholders on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and will
become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The 2021 Plan will replace the 2016 Plan as our board of directors has determined
not to make additional awards under the 2016 Plan following the closing of our initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The 2021 Plan allows us to make equity-based and
cash-based incentive awards to our officers, employees, directors and consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initially reserved
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock for the issuance of awards under the 2021 Plan, or the Initial Limit. The 2021 Plan provides that the number of shares
reserved and available for issuance under the 2021 Plan will automatically increase on January&nbsp;1, 2022 and each January&nbsp;1 thereafter, by &nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding number of shares of our common stock on the immediately
preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee, or the Annual Increase. The number of shares reserved under the 2021 Plan subject to adjustment in the event of a stock split, stock dividend or
other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares we issue under the 2021 Plan will be authorized but unissued shares or shares that we reacquire. The
shares of common stock underlying any awards under the 2021 Plan and the 2016 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting,
satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum number of shares of common stock that may be issued in the form of incentive stock options shall not exceed the Initial Limit, cumulatively
increased on January&nbsp;1, 2022 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grant date fair value of all awards made under our 2021 Plan and all other cash compensation paid by us to any
<FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; provided, however,
that such amount shall be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan will be administered by our compensation committee. Our compensation committee has the full power to select, from among the individuals eligible
for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the
specific terms and conditions of each award, subject to the provisions of the 2021 Plan. Persons eligible to participate in the 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan will be those full or part-time officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation
committee in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options
under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date
of grant unless the option is granted (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code or (ii)&nbsp;to individuals who are not subject to U.S. income tax. The term of each option will
be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee may award stock appreciation rights under the 2021 Plan subject to such conditions and restrictions as it may determine. Stock
appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right may not be less than 100% of the
fair market value of our common stock on the date of grant. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what
time or times each stock appreciation right may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee may award restricted shares of common stock and restricted stock
units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period.
Our compensation committee may also grant shares of common stock that are free from any restrictions under the 2021 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be
issued in lieu of cash compensation due to such participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee may grant dividend equivalent rights to participants that entitle
the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
compensation committee may grant cash bonuses under the 2021 Plan to participants, subject to the achievement of certain performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan
provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2021 Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under the 2021 Plan. To the extent that awards granted under the
2021 Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the sale event, such awards shall terminate. In such case, except as may be otherwise provided in the relevant award certificate, all awards
with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become
vested and nonforfeitable in connection with a sale event in the administrator&#146;s discretion or to the extent specified in the relevant award certificate. In the event of such termination, (i)&nbsp;individuals holding options and stock
appreciation rights will be permitted to exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind,
to participants holding vested and exercisable options and stock appreciation rights equal to the difference between the per share consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation
rights and we may make or provide for a payment, in cash or in kind, to participants holding other vested awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may amend or
discontinue the 2021 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the
holder&#146;s consent. Certain amendments to the 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan require the approval of our stockholders. The administrator of the 2021 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options
and stock appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2021 Plan after the date that is 10 years
from the effective date of the 2021 Plan. No awards under the 2021 Plan have been made prior to the date of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee Stock
Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our 2021 Employee Stock Purchase Plan, or ESPP, was adopted by our board of directors on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, approved by our stockholders on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and will
become effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148;
within the meaning of Section&nbsp;423 of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common
stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January&nbsp;1, 2022 and each January&nbsp;1 thereafter through January&nbsp;1, 2031, by the least of
(i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, (ii) &nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding number of shares of common stock on the immediately preceding
December&nbsp;31, or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other
change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All employees who are customarily employed by us or one of our designated subsidiaries for more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hours per week and who we have employed for at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; days are eligible to participate in the ESPP.
However, any employee who owns&nbsp;5% or more of the total combined voting power or value of all classes of our stock will not be eligible to purchase shares of common stock under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may make one or more offerings each year to our employees to purchase shares under the ESPP. Offerings will usually begin on each
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and will continue for <FONT
STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least&nbsp;15&nbsp;business days before the applicable offering
date </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to 15% of his or her
eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of
the offering period at a price equal to&nbsp;85% of the fair market value of the shares of our common stock on the first business day or the last business day of the offering period, whichever is lower, provided that no more $25,000 worth of common
stock (or such other lesser maximum number of shares as may be established by the administrator) may be purchased by any one employee during any offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of
shares of our common stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accumulated payroll deductions of any
employee who is not a participant on the last day of an offering period will be refunded. An employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of our common stock authorized
under the ESPP and certain other amendments require the approval of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Senior Executive Cash Incentive Bonus Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 our board of directors adopted the Senior Executive
Cash Incentive Bonus Plan, or the Bonus Plan. The Bonus Plan provides for annual cash bonus payments based upon the attainment of company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and individual performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our company,
or the Corporate Performance Goals, as well as individual performance objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee may select Corporate Performance Goals from
among the following: cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or after interest,
taxes, depreciation and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions or strategic transactions, including collaborations, joint ventures or promotion arrangements; operating income (loss);
return on capital assets, equity, or investment; stockholder returns; return on sales; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per share of
our common stock; bookings, new bookings or renewals; sales or market shares; number of customers, number of new customers or customer references; operating income and/or net annual recurring revenue; or any other performance goal as selected by the
compensation committee, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, as compared to results of a peer group, against the market as a whole, compared to applicable market indices and/or
measured on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">post-tax</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each executive officer who is
selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The
Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and
individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period, but no later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the
rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to
approve additional bonuses to executive officers in its sole discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently maintain a 401(k) retirement savings plan for our employees, including our NEOs, who satisfy certain eligibility requirements. Our NEOs are
eligible to participate in the 401(k) plan on the same terms as other full-time employees. Our 401(k) plan is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash or deferred feature that is
intended to meet the requirements of Section&nbsp;401(k) of the Code. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) plan adds to the overall desirability of our
executive compensation package and further incentivizes our employees, including our NEOs, in accordance with our compensation policies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_15"></A><FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTOR
COMPENSATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation for each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT>
member of our board of directors during the year ended December&nbsp;31, 2020. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or
<FONT STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2020. During fiscal year 2020, Mark Manfredi, our
President and Chief Executive Officer served as a member of our board of directors and received no additional compensation for his services as a member of our board of directors. See the section titled &#147;Executive Compensation&#148; for more
information about Dr.&nbsp;Manfredi&#146;s compensation for fiscal year 2020. We reimburse <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors for reasonable travel and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in attending meetings of our board of directors and committees of our board of directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or&nbsp;Paid<BR>in Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Bonita, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iain Dukes, D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Francois Formela, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Georgiou, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald Renaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Otello Stampacchia, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There were no options or other equity awards granted to directors in 2020. Except as noted below, none of our
directors held options to purchase our common stock or any other stock awards as of December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Number&nbsp;of&nbsp;Shares<BR>Subject to Stock Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iain Dukes, D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,691,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald Renaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">901,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will become
effective upon the completion of this offering and will be designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who is not
an employee will be paid cash compensation from and after the completion of this offering, as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide that, upon
initial election to our board of directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock, or Initial Grant. The Initial Grant will vest in equal installments on the first, second, and third anniversaries of the grant date, subject to continued service through the applicable vesting date. Furthermore, on the
date of each annual meeting of stockholders following the completion of this offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director following such
meeting will be granted an annual option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, or Annual Grant. The Annual Grant will vest in full on the earlier of
(i)&nbsp;the first anniversary of the grant date or (ii)&nbsp;our next annual meeting of stockholders, subject to continued service through the applicable vesting date. Such awards are subject to full accelerated vesting upon the sale of the
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will reimburse all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred
by <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in attending meetings of the board of directors and committees thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_16"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of transactions or series of transactions since January&nbsp;1, 2018, to which we were or will be a party, in which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount involved in the transaction exceeds, or will exceed, the lesser of $120,000 or one percent of the
average of the Company&#146;s total assets for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in which any of our executive officers, directors or holders of five percent or more of any class of our capital
stock, including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation arrangements for our named executive officers and our directors are described elsewhere in this prospectus under &#147;Executive
Compensation&#148; and <FONT STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, we entered into a master collaboration agreement, or the BMS Collaboration Agreement, with Celgene Corporation (which was acquired by
Bristol-Meyers Squibb Company, or BMS, in November 2019) under which BMS may elect in its sole discretion to exclusively license rights to develop and commercialize compounds (and products and diagnostic products containing such compounds) that
modulate the activity of two collaboration targets, kynurenine and AHR excluding AHR agonists except for inverse agonists, or the Collaboration Candidates. The BMS Collaboration Agreement triggered an upfront payment of $95.0&nbsp;million, which
consisted of approximately $80.5&nbsp;million in cash and an equity investment of approximately $14.5&nbsp;million for which we issued 14,545,450 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock pursuant to a separate
share purchase agreement. See &#147;&#151;Private Placements of Securities&#151;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock Financing&#148; and &#147;Business&#151;Master Collaboration Agreement with Bristol-Myers Squibb&#148;
for additional information. BMS is a holder of five percent or more of our capital stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements of Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, in connection with the BMS Collaboration Agreement, we sold 14,545,450 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock at a purchase price of $1.00 per share to Celgene Corporation (now BMS) for an aggregate purchase price of $14.5&nbsp;million. Celgene Corporation (BMS) is a holder of five percent or more of our capital stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Shares&nbsp;of&nbsp;Series&nbsp;A-1</FONT><BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation (BMS)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,545,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,545,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2020, we sold an aggregate of 85,806,214 shares of our Series B preferred stock at a purchase price of $1.3985 per share for aggregate proceeds of
$120.0&nbsp;million. The following table summarizes purchases of our Series B preferred stock by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series B<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with FMR LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,876,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,999,999.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed Advisors
LLC<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,088,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,499,998.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omega Fund VI, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,870,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,999,999.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Opportunity Fund I,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,362,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,499,998.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation (BMS)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">999,998.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entities affiliated with FMR LLC collectively beneficially own more than five percent of our outstanding
capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entities affiliated with OrbiMed Advisors LLC, or OrbiMed Advisors, collectively beneficially own more than
five percent of our outstanding capital stock. Dr.&nbsp;Bonita is a member of OrbiMed Advisors and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Omega Fund VI, L.P. is a holder of five percent or more of our capital stock. Mr.&nbsp;Stampacchia is a
Managing Director and <FONT STYLE="white-space:nowrap">co-founder</FONT> of Omega Fund Management, LLC, is one of three directors of Omega Fund VI GP Manager, Ltd., the sole general partner of Omega Fund VI GP, L.P., which is the sole General
Partner of Omega Fund VI, L.P. and is a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Atlas Venture Opportunity Fund I, L.P. is an affiliate of Atlas Venture. Entities affiliated with Atlas Venture
collectively beneficially own more than five percent of our outstanding capital stock. Dr.&nbsp;Formela is a partner at Atlas Venture and a member of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Agreements with Our Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
with our Series B convertible preferred stock financing, we entered into investors&#146; rights, voting and right of first refusal <FONT STYLE="white-space:nowrap">and&nbsp;co-sale&nbsp;agreements</FONT> containing registration rights, information
rights, voting rights and rights of first refusal, among other things, with certain holders of our preferred stock and certain holders of our common stock. These stockholder agreements will terminate upon the closing of this offering, except for the
registration rights granted under our investors&#146; rights agreement, as more fully described in &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2018, we entered
into an agreement and plan of merger with Arrys Merger Sub, Inc., Arrys Therapeutics, Inc., and OrbiMed Private Investments VI, LP. We refer to this agreement as the Arrys Merger Agreement. Under the Arrys Merger Agreement, we agreed to merge with
the other parties party thereto, resulting in Arrys Merger Sub, Inc. ceasing to exist and Arrys Therapeutics, Inc. becoming our wholly owned subsidiary. For more information regarding the Arrys Merger Agreement, see &#147;Note 3 &#150; Arrys
Acquisition,&#148; to our financial statements for the year ended December&nbsp;31, 2019, included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2020,
we entered into an agreement and plan of merger with AMI Merger Sub, Inc., Amplify Medicines, Inc., and Atlas Venture Fund XI, L.P. We refer to this agreement as the AMI Merger Agreement. Under the AMI Merger Agreement, we agreed to merge with the
other parties party thereto, resulting in AMI Merger Sub, Inc. ceasing to exist and Amplify Medicines, Inc. becoming our wholly owned subsidiary. For more information regarding the AMI Merger Agreement, see &#147;Note 17&#151;Subsequent
Events,&#148; to our financial statements for the year ended December&nbsp;31, 2019, included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these
individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken
by such person on our behalf or that person&#146;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies for approval of related party transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related
party&#146;s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the transaction is not considered approved by our board of directors unless a majority of the
directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#146;s relationship or interest in the
transaction are disclosed to the stockholders, who must approve the transaction in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, we have adopted a
written related party transactions policy that such transactions must be approved by our audit committee. This policy will become effective on the date on which the registration statement of which this prospectus is part is declared effective by the
SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_17"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of December&nbsp;31, 2020, as adjusted
to reflect the sale of common stock offered by us in this offering, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to be the beneficial owner of more than five percent of
our capital stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under
those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power with respect to the securities as well as any shares of common stock that the individual or entity has the
right to acquire within 60 days of December&nbsp;31, 2020 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the
percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, we believe,
based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each individual or entity shown on the table has furnished information with respect to beneficial ownership. Unless otherwise indicated, the address for each
beneficial owner is c/o Ikena Oncology,&nbsp;Inc., 50 Northern Avenue, Boston, MA 02210. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The percentage of beneficial ownership prior to this offering in the table below is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock deemed to be outstanding as of&nbsp;December 31, 2020, assuming the conversion of all outstanding shares of our preferred stock
immediately prior to the completion of this offering, and the percentage of beneficial ownership at this offering in the table below is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of common stock assumed to be outstanding after the closing of the offering. The information in the table below assumes no exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of Shares<BR>Outstanding<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed Advisors
LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,512,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Atlas
Venture<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,193,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with FMR LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,876,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation (Bristol-Meyers
Squibb)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,260,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omega Fund VI, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,870,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Manfredi, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,139,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas R. Carlson<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sergio Santillana, M.D., M.Sc., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Renaud<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">528,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Bonita, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iain D. Dukes, D.Phil.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela,
M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Otello Stampacchia, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (10 persons)<SUP
STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,729,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 18,500,001 shares of our common stock issuable upon conversion of our Series A preferred stock
held by OrbiMed Private Investments VI, LP, (&#147;OPI VI&#148;), (ii) 21,923,701 shares of our common stock issuable upon conversion of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock held by OPI VI, (iii) 8,938,148 shares of
our common stock issuable upon conversion of our Series B preferred stock held by OPI VI, (iv) 5,720,414 shares of our common stock issuable upon conversion of our Series B preferred stock held by Worldwide Healthcare Trust PLC (&#147;WWH&#148;),
and (v) 1,430,103 shares of our common stock issuable upon conversion of our Series B preferred stock held by OrbiMed Genesis Master Fund, L.P. (&#147;OrbiMed Genesis&#148;). Dr.&nbsp;Bonita is a member of OrbiMed Advisors and is a member of our
board of directors. OrbiMed Capital GP VI LLC (&#147;OrbiMed GP VI&#148;) is the general partner of OPI VI and OrbiMed Advisors is its managing member. OrbiMed Capital LLC (&#147;OrbiMed Capital&#148;) is the portfolio manager of WWH. OrbiMed
Genesis GP LLC is the general partner of OrbiMed Genesis and OrbiMed Advisors is its managing member. By virtue of such relationships,&nbsp;OrbiMed Genesis GP LLC, OrbiMed GP VI, OrbiMed Capital, and OrbiMed Advisors may be deemed to have voting
power and investment power over the securities held by OPI VI, WWH, and OrbiMed Genesis (collectively, the &#147;OrbiMed Funds&#148;), and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Capital is a relying
advisor of OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. Each of OrbiMed Advisors, OrbiMed GP VI,
OrbiMed Capital, OrbiMed Genesis GP LLC, Dr.&nbsp;Bonita, Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein disclaims beneficial ownership of the shares held by the OrbiMed Funds, except to the extent of its or his pecuniary interest
therein if any. The principal business address of&nbsp;the OrbiMed Funds is c/o&nbsp;OrbiMed Advisors, 601 Lexington Avenue 54th Floor, New York, NY 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,209,707 shares of common stock held by Atlas Venture Fund XI, L.P. (&#147;Atlas XI&#148;),
(ii)&nbsp;9,499,999 shares of our common stock issuable upon conversion of our Series A preferred stock held by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Atlas Venture Fund X, L.P. (&#147;Atlas X&#148;), (iii)&nbsp;11,258,117 shares of our common stock issuable upon conversion of our Series A-1 preferred stock held by Atlas X, (iv)&nbsp;7,863,094
shares of our common stock issuable upon conversion of our Series A-2 preferred stock held by Atlas XI and (v) 5,362,888 shares of our common stock issuable upon conversion of our Series B preferred stock held by Atlas Venture Opportunity Fund I,
L.P. (&#147;Atlas Opportunity&#148;). Atlas Venture Associates X, L.P. (&#147;Associates X&#148;) is the General Partner of Atlas X, and Atlas Venture Associates X, LLC (&#147;X LLC&#148;) is the general partners of Associates X. Atlas Venture
Associates XI, L.P. (&#147;Associates XI&#148;) is the General Partner of Atlas XI, and Atlas Venture Associates XI, LLC (&#147;XI LLC&#148;) is the general partners of Associates XI. Atlas Venture Associates Opportunity I, L.P. (&#147;Associates
I&#148;) is the General Partner of Atlas Opportunity, and Atlas Venture Associates Opportunity I, LLC (&#147;I LLC&#148;) is the general partners of Associates I. Dr. Formela is one of the members of X LLC, XI LLC and I LLC and collectively with
other members of each respective LLC makes investments decisions for such LLC. Dr. Formela is also a member of our board of directors. The address of&nbsp;Atlas Venture Fund VIII LP is 300 Technology Square, Cambridge, MA 02139. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 10,131 shares of common stock issuable upon conversion of the Series B Preferred Stock held by
Fidelity Capital Trust: Fidelity Flex Small Cap Fund&#151;Small Cap Growth Subportfolio, (ii) 3,645,400 shares of common stock issuable upon conversion of the Series B Preferred Stock held by Fidelity Securities Fund: Fidelity Small Cap Growth Fund,
(iii) 822,200 shares of common stock issuable upon conversion of the Series B Preferred Stock held by Fidelity Securities Fund: Fidelity Small Cap Growth K6 Fund, (iv) 2,022,700 shares of common stock issuable upon conversion of the Series B
Preferred Stock held by Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund, (v) 1,024,065 shares of common stock issuable upon conversion of the Series B Preferred Stock held by Fidelity Capital Trust: Fidelity Stock Selector Small Cap
Fund, (vi) 4,068,100 shares of common stock issuable upon conversion of the Series B Preferred Stock held by Fidelity Securities Fund: Fidelity Series Small Cap Opportunities Fund, and (vii) 6,283,700 shares of common stock issuable upon conversion
of the Series B Preferred Stock held by Fidelity Select Portfolios: Biotechnology Portfolios (collectively, the &#147;Fidelity Funds&#148;). The Fidelity Funds are managed by direct or indirect subsidiaries of FMR LLC. Edward C. Johnson 3d is a
Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, the Vice Chairman and the President of FMR LLC. Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through
trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series B
voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the
Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Edward C. Johnson 3d nor Abigail P. Johnson has the sole power to vote or direct the voting of the
shares owned directly by the various investment companies registered under the Investment Company Act (Fidelity Funds) advised by Fidelity Management&nbsp;&amp; Research Company (FMR Co), a wholly owned subsidiary of FMR LLC, which power resides
with the Fidelity Funds&#146; Boards of Trustees. Fidelity Management&nbsp;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#146; Boards of Trustees. The address of FMR LLC and
associated funds is 245 Summer Street Boston, MA 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 14,545,450 shares of our common stock issuable upon conversion of our Series <FONT
STYLE="white-space:nowrap">A-1</FONT> preferred stock and (ii) 715,051 shares of our common stock issuable upon conversion of our Series B preferred stock. Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene
disclaims beneficial ownership of these shares, except to the extent of its pecuniary interest therein. The principal address for Celgene is 86 Morris Avenue, Summit, NJ 07901. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 12,870,933 shares of our common stock issuable upon conversion of our Series B preferred stock.
Dr.&nbsp;Stampacchia is founder, Managing Director, and a member of the five-member investment committee at Omega Funds. Dr.&nbsp;Stampacchia is one of three directors of Omega Fund VI GP Manager, Ltd., the sole general partner of Omega Fund VI GP,
L.P., which is the sole General Partner of Omega Fund VI, L.P.&nbsp;Dr.&nbsp;Stampacchia may therefore be deemed to be the beneficial owner of the shares held by Omega </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Fund VI, L.P.&nbsp;Omega Fund VI GP Manager, Ltd., Omega Fund VI GP, L.P. and each of the directors of Omega Fund VI GP Manager Ltd. disclaim beneficial ownership of the shares held by Omega Fund
VI, L.P. except to the extent of their pecuniary interest therein.&nbsp;The address of Omega Fund VI, L.P. is 888 Boylston Street, Suite 1111, Boston, MA 02199. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 3,139,350 shares of our common stock that are exercisable within 60 days of
December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 609,852 shares of our common stock that are exercisable within 60 days of
December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 528,499 shares of our common stock that are exercisable within 60 days of
December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 1,043,235 shares of our common stock that are exercisable within 60 days of
December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 6,729,835 shares of our common stock that are exercisable within 60 days of
December&nbsp;31, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_18"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following descriptions are summaries of the material terms of our fifth amended and restated certificate of incorporation, which will be effective upon
the closing of this offering and amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this prospectus is a part. The descriptions of the common stock and preferred stock give effect to
changes to our capital structure that will occur immediately prior to the completion of this offering. We refer in this section to our fifth amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our
amended and restated bylaws as our bylaws. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our authorized capital stock will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, par value $0.001 per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock will be undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020,
22,155,319 shares of our common stock were outstanding and held by 21 stockholders of record. This amount assumes the conversion of all outstanding shares of our preferred stock into common stock, which will occur immediately prior to the closing of
this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our
common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably
any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other
subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our common stock
will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and
paid for, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock. Upon the
consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting
power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change
in control of our Company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this
offering, the holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, including those issuable upon the conversion of preferred stock, will be entitled to rights with
respect to the registration of these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities under the Securities Act. These rights are provided under the terms of our Investor Rights Agreement between us and the holders of our preferred stock. The Investor Rights Agreement
includes demand registration rights, short-form registration rights, and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including
underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand registration rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning six months after the completion of this offering, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, including those issuable upon the conversion of shares of our preferred stock upon closing of this offering, will be
entitled to demand registration rights. Under the terms of the Investor Rights Agreement, we will be required, upon the written request of a majority of holders of the registrable securities then outstanding that would result in an aggregate
offering price of at least $10.0&nbsp;million, to file a registration statement and to use commercially reasonable efforts to effect the registration of all or a portion of these shares for public resale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Short-form registration rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the
completion of this offering, the holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, including those issuable upon the conversion of shares of our preferred stock
upon closing of this offering, are also entitled to short-form registration rights. Pursuant to the Investor Rights Agreement, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written
request of at least 20% in interest of these holders to sell registrable securities at an aggregate price of at least $3.0&nbsp;million, we will be required to use commercially reasonable efforts to effect a registration of such shares. We are
required to effect only two registrations in any twelve-month period pursuant to this provision of the investor rights agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback
registration rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, including those issuable upon the conversion of shares of our preferred stock upon closing of this offering, are entitled to
piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain
exceptions contained in the Investor Rights Agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not
jeopardize the success of the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our investor rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities
in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of registration rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The demand
registration rights and short-form registration rights granted under the Investor Rights Agreement will terminate on the fifth anniversary of the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover effects of our certificate of incorporation and bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from
acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover
attempts. These provisions include the items described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board composition and filling vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class
being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares
then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a
majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to
change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No written consent of stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting,
and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our
stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of
stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to
those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance notice requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new
business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally,
to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form
and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to certificate of incorporation and bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of
incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the
provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less
than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any
limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating
to notice of stockholder business and nominations and special meetings must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereon as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the
amendment, in each case voting together as a single class. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated preferred stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our certificate of incorporation will provide for
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage
an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best
interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed
acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The
issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these
holders and may have the effect of delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that, unless we consent in writing to the selection of an alternative form, the Court of Chancery
of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for: (1)&nbsp;any derivative
action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a
claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (including the interpretation, validity or
enforceability thereof) or (4)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our <FONT STYLE="white-space:nowrap">by-laws</FONT> of incorporation also provide that any person or entity purchasing or otherwise acquiring
any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated
certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our <FONT
STYLE="white-space:nowrap">by-laws</FONT> provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the exclusive forum for any private action asserting violations
by us or any of our directors or officers of the Securities Act or the Exchange Act, or the rules and regulations promulgated thereunder, and of all suits in equity and actions at law brought to enforce any liability or duty created by those
statutes or the rules and regulations under such statutes. If any action the subject matter of which is within the scope of the preceding sentence is filed in a court other than the federal district courts of the United States, the plaintiff or
plaintiffs shall be deemed by this provision of the bylaws (i)&nbsp;to have consented to removal of the action by us to the federal district courts of the United States, in the case of an action filed in a state court, and (ii)&nbsp;to have
consented to transfer of the action to the federal district courts of the United States </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that the Delaware Forum Provision in our bylaws may
impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated bylaws may limit
our stockholders&#146; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an
action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities Act be brought in federal court were &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the
Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not
enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an
action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general,
Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested
stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the
assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as any entity
or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to list
our common stock on The Nasdaq Global Market under the trading symbol &#147;IKNA.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer agent and registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
The transfer agent and registrar&#146;s address is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and its telephone number is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_19"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of such
shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal
restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to
raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the number of shares outstanding as of December&nbsp;31, 2020, upon the completion of this offering,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will be outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of
outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in
compliance with the limitations described below, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock are restricted shares of common stock subject to time-based vesting
terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, a person who has
beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a
sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or
any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after this offering assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of
shares outstanding as of December&nbsp;31, 2020; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we are subject to the Exchange
Act periodic reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and
notice provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule&nbsp;701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without
compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive officers, or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on
the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after the effectiveness of the registration statement of which this prospectus forms a part before selling their shares. However,
substantially all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and under &#147;Underwriting&#148; included elsewhere in this prospectus and will become eligible for sale upon the
expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for
our capital stock have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any of our common stock or any securities convertible into or
exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the date of this prospectus without the prior written consent of the representatives, subject to certain exceptions. See the section entitled
&#147;Underwriting&#148; appearing elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the
Securities Act.&nbsp;Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration statement.&nbsp;See
the section entitled &#147;Description of Capital Stock&#151;Registration rights&#148; appearing elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity incentive plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to file one or more
registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to
be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are
subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_20"></A>MATERIAL U.S. FEDERAL INCOME TAX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSIDERATIONS <FONT STYLE="white-space:nowrap">FOR&nbsp;NON-U.S.&nbsp;HOLDERS</FONT> OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. For purposes of this discussion,
a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or any other organization taxable as a corporation for U.S. federal income tax purposes that is
created or organized in or under laws other than the laws of the United States, any state thereof, or the District of Columbia;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is not subject to U.S. federal income tax on a net income basis; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1) (a) has not made an election to be treated as a U.S. person under applicable U.S. Treasury
regulations and (b)&nbsp;either (i) is not subject to the primary supervision of a court within the United States or (ii)&nbsp;is not subject to the substantial control of one or more U.S. persons or (2)&nbsp;the income of which is not subject to
U.S. federal income tax on a net income basis . </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities or
arrangements that are treated as pass-through entities for U.S. federal income tax purposes or persons that hold their shares of our common stock through partnerships or such other pass-through entities. The tax treatment of a partner in a
partnership or other entity or arrangement that is treated as a pass-through entity for U.S. federal income tax purposes generally will depend upon the status of the partner and the activities of the partnership. A partner in a partnership or an
investor in any other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through
entity, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the Code, existing and proposed U.S. Treasury regulations promulgated
thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or
differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below.
There can be no assurance that the IRS will not challenge one or more of the tax consequences described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a
&#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code, which is generally property held for investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not
address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual
circumstances, including the alternative minimum tax, the Medicare tax on net investment income, the rules relating to &#147;qualified small business stock,&#148; any U.S. federal tax other than the income tax (including, for example, the estate or
gift tax), or any aspects of U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">regulated investment companies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension
fund&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons that hold or receive our common stock pursuant to the exercise of any employee stock option or
otherwise as compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders
of our common stock should consult their tax advisors with respect to the U.S. federal, state, local, estate and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on our common stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the
&#147;Dividend Policy&#148; section above, we do not intend to pay any dividends in cash or property on our common stock to our stockholders stock in the foreseeable future. Distributions of cash or property, if any, on shares of our common stock
generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and
accumulated earnings and profits, the excess will be treated as a return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s adjusted tax basis in the shares of common stock. Any remaining
excess will be treated as capital gain, subject to the tax treatment described below in &#147;Gain on sale, exchange or other taxable disposition of shares of our common stock.&#148; Any such distributions will also be subject to the discussion
below under the section titled &#147;Withholding and information reporting requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion in the following two
paragraphs in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by
an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends that are treated as effectively
connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed
base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable
certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the
Code). Any U.S. effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate
or such lower rate as specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of shares of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a
properly executed IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or a successor form) to the applicable withholding agent and satisfy
applicable certification and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may generally obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim
with the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on sale, exchange or other taxable disposition of shares of our common stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;Withholding and information reporting requirements&#151;FATCA,&#148; a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#146;s sale, exchange or other taxable disposition of shares of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
conduct of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in
which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on our common stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30%
tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital
losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed
U.S. federal income tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition
(or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market, within the
meaning of the relevant provisions of the Code, and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the
five-year period ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a &#147;U.S. real property holding corporation&#148; only if the
fair market value of its &#147;U.S. real property interests&#148; (as defined in the Code and applicable U.S. Treasury regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other
assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes, or that we are likely to
become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup withholding and information reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We must
report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on shares of our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable
rate with respect to dividends on shares of our common stock. Generally, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will comply with such procedures if it provides a properly executed IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8),</FONT> or otherwise meets
documentary evidence requirements for establishing that it is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, or otherwise establishes an exemption. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to
withholding of U.S. federal income tax, as described above in &#147;Distributions on our common stock,&#148; generally will be exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding will generally apply to the proceeds of a disposition of shares of our common stock by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> unless the holder certifies its status as a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or
operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the
information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated
under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded
or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding and information reporting requirements&#151;FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common
stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the
foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Such withholding may also apply to payments of
gross proceeds of sales or other dispositions of shares of our common stock, although under proposed U.S. Treasury regulations (the preamble to which specifies that taxpayers, including withholding agents, are generally permitted to rely on them
pending finalization), no withholding will apply to payments of gross proceeds. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An
intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the
possible implications of this legislation on their investment in our common stock and the entities through which they hold our shares of common stock, including, without limitation, the process and deadlines for meeting the applicable requirements
to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_21"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021, among us and Jefferies LLC, Cowen and Company, LLC, Credit Suisse Securities (USA) LLC and William Blair&nbsp;&amp; Company, L.L.C., as the
representatives of the underwriters in this offering named below, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock
shown opposite its name below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions
precedent such as the receipt by the underwriters of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of
common stock if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have
agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of
those liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common
stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no
assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The
underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they
exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commission and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the
cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. The underwriters may allow, and
certain dealers may reallow, a discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock to certain brokers and dealers. After the offering, the initial public offering price,
concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, the underwriting discounts and commissions that we are
to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions
referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to pay the filing fees incident to, and the fees and disbursements of counsel for the underwriters in connection with, the required
review by the Financial Industry Regulatory Authority, Inc. in an amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of
Offering Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for
our common stock will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies
that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market
subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common stock on The Nasdaq Global Market under the trading symbol &#147;IKNA.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted to
the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the
underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above.
This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales
of Similar Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, our officers, directors and holders of all or substantially all our outstanding capital stock and other securities have
agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Securities Exchange Act of 1934, as amended; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or
securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this
prospectus without the prior written consent of certain of the representatives.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This restriction terminates after the close of trading of the common stock on and including the 180th day after the date of this prospectus </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the representatives<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>may, together in their sole discretion and at any time or from time to
time before the termination of the <FONT STYLE="white-space:nowrap">180-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between
the underwriters and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have advised us
that, pursuant to Regulation M under the Securities Exchange Act of 1934, as amended, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of
penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales
positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Covered&#148; short sales are sales made in an
amount not greater than the underwriters&#146; option to purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of
our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase
in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Naked&#148; short
sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the
common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase
transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a
result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member
in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described
above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters may also engage in passive market making transactions in our common stock on The Nasdaq
Global Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market
maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits
are exceeded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus
in electronic format may be made available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may
view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online
distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained
by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and
certain of their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research,
principal investment, hedging, financing and brokerage activities. The underwriters and certain of their respective affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial
advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. Jefferies LLC acted as a placement agent in connection with the private placement of our Series&nbsp;B preferred stock and received
cash compensation in connection therewith. Affiliates of Cowen and Company, LLC, an underwriter of this offering, beneficially own an aggregate of approximately 1% of our common stock, on an as-converted basis and fully diluted basis, as of
December&nbsp;31, 2020. Such shares were acquired during the sale of our Series&nbsp;B preferred stock in December 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of their
various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank
loans) for their own accounts and for the accounts of their respective customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective
affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into
transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could
adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Resale Restrictions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of shares of our
common stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt from the requirement that we prepare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares of common stock in Canada must be made under
applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities
regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Representations of Canadian Purchasers
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By purchasing shares of our common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer
from whom the purchase confirmation is received that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchaser is entitled under applicable provincial securities laws to purchase the shares of common stock
without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;</FONT><I>Prospectus Exemptions</I>,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conflicts of Interest </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canadian purchasers are hereby
notified that the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;</FONT><I>Underwriting Conflicts</I> from having to provide certain
conflict of interest disclosure in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Statutory Rights of Action </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus
(including any amendment thereto) such as this prospectus contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Enforcement of Legal Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of
our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a
substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian
courts against us or those persons outside of Canada. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation and Eligibility for Investment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Canadian purchasers of our shares of common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the
shares in their particular circumstances and about the eligibility of the shares for investment by the purchaser under relevant Canadian legislation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is not a disclosure
document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You confirm and warrant that you are either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you
have provided an accountant&#146;s certificate to the company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor or professional investor under
the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You warrant and agree that you will not offer any
of the shares issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the
Corporations Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area and United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, each referred to herein as a Relevant State, no offer of any securities which are the subject
of the offering contemplated by this prospectus has been or will be made to the public in that Relevant State other than any offer where a prospectus has been or will be published in relation to such securities that has been approved by the
competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the relevant competent authority in that Relevant State in accordance with the Prospectus Regulation, except that an offer of such
securities may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a &#147;qualified investor&#148; as defined in Article 2(e) of the Prospectus
Regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Regulation), as permitted under the Prospectus Regulation, subject to obtaining the prior consent of the representatives<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>of the underwriters for any such offer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall require the Company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to any securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor
to decide to purchase or subscribe the securities, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129 (as amended). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This European Economic Area selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been and will not be
circulated or distributed in the PRC, and no securities may be offered or sold, or will be offered or sold, to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, to any resident of the PRC except
pursuant to applicable laws and regulations of the PRC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary
business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or SFO, and any rules made under that Ordinance; or
in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong, or CO, or which do not constitute an offer to the public for the purpose of the CO or the SFO. No
document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the
contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside
Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been
registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each
person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and
that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by
the Israel Securities Authority. In the State of Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with section 15A of
the Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers,
investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals&#148;, each as defined in the Addendum (as it may be amended from
time to time), collectively referred to as qualified investors (in each case purchasing for their own accounts or, where permitted under the Addendum, for the accounts of their respective clients who are investors listed in the Addendum). Qualified
investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering has not been and will not be
registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended), or FIEL, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan (which term as used herein means, unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for
<FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any
other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been and will not be lodged or registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document
or material in connection with the offer or sale, or the invitation for subscription or purchase of the securities may not be issued, circulated or distributed, nor may the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other
than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person as defined under Section&nbsp;275(2), or any person pursuant to
Section&nbsp;275(1A) of the SFA, and in accordance with the conditions, specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor as defined under Section&nbsp;4A of the SFA) the sole business
of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares of common stock pursuant to an offer made under Section&nbsp;275 of
the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person
arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated
trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or
the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this prospectus nor any other offering or marketing
material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised
by, the Swiss Financial Market Supervisory Authority FINMA and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of
interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article
2(e) of the Prospectus Regulation that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the Order, and/or
(ii)&nbsp;high net worth entities falling within Article 49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully be communicated. Any investment or investment activity to which this prospectus relates is available only to
relevant persons and will only be engaged in with relevant persons. Any person who is not a relevant person should not act or rely on this prospectus or any of its contents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_22"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain legal
matters related to this offering will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_23"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements at December&nbsp;31, 2018 and
December&nbsp;31, 2019, and for each of the two years in the period ended December&nbsp;31, 2019, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration statement in reliance on
Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom197729_24"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File Number
<FONT STYLE="white-space:nowrap">333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</FONT> under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus does not contain all
of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our
contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and current
reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at www.ikenaoncology.com. Upon completion of this
offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and any amendment to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or
furnished to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom197729_25"></A>Index to Consolidated Financial Statements
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited financial statements for the years ended December&nbsp;31, 2018 and 2019:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_2">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_3">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_4">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_5">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_6">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_7">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited financial statements for the nine months ended September&nbsp;30, 2019 and
2020:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_9">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_10">Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_11">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and
 Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_12">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin197729_13">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_1"></A><A NAME="fin197729_2"></A>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Ikena Oncology, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Ikena Oncology, Inc. (the Company) as of December&nbsp;31, 2018 and 2019, and the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and
stockholders&#146; deficit and cash flows for the years then ended, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company at December&nbsp;31, 2018 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of
America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst and Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;8, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_3"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A and <FONT STYLE="white-space:nowrap">A-1),</FONT>
$0.001 par value, 61,181,818&nbsp;shares authorized, issued and outstanding (liquidation preference of $61,181,818) as of December&nbsp;31, 2018 and 75,727,268 shares authorized, issued and outstanding (liquidation preference $75,727,268) as of
December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 90,909,088 shares authorized, 18,818,179 issued and outstanding as
of December&nbsp;31, 2018 and 113,372,392 shares authorized, 18,967,681 issued and outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_4"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue under collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue (related party)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,193,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,945,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_5"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable</B><br><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of preferred stock in connection with the acquisition of Arrys Therapeutics,
Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in connection with the acquisition of Arrys Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,818,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,818,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of preferred stock in connection with private placement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,545,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,967,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(67,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_6"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> research and development expense for <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development acquired in acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> rent expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash obtained in asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock in connection with private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT>
activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets obtained in asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities assumed in asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of equity instruments issued in connection with asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs for asset acquisition in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_7"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. Description of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a
targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company&#146;s programs focus on key cancer driver pathways that are well-validated in
scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging the Company&#146;s deep understanding of discovery chemistry, translational science, and
patient-centric drug development, it has built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables it to target specific patient populations that the Company believes are
most likely to respond to treatment with its product candidates. Since the Company commenced operations in 2016, it has discovered or developed five oncology programs that include four product candidates in either
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to
early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government
regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and
regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Because of the numerous risks and uncertainties
associated with product development, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Even if the Company is able to generate revenue from
product sales, the Company may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then the Company may be unable to continue its operations at planned levels and be forced to
reduce or terminate its operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Codification (&#147;ASC&#148;) <FONT STYLE="white-space:nowrap">205-40,</FONT> <I>Going Concern</I>, the Company has
evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the consolidated financial statements
are issued. As of December&nbsp;31, 2019, the Company had an accumulated deficit of $67.1&nbsp;million.&nbsp;During the year ended December&nbsp;31, 2019, the Company incurred a loss of $16.8&nbsp;million and provided $48.0 of cash in operations.
The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash and cash equivalents of $82.1&nbsp;million at December&nbsp;31, 2019, together with the $3.7&nbsp;million of cash received
through the acquisition of Amplify Medicines, Inc. (&#147;Amplify&#148;) on October&nbsp;1, 2020 and the net proceeds of $116.4&nbsp;million from the issuance of Series B redeemable convertible preferred stock on December&nbsp;21, 2020, will be
sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from issuance of the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company expects that it will seek additional funding through public or private financings, debt financing, collaboration agreements or
government grants. The inability to obtain funding, as and when needed, could have a negative impact on the Company&#146;s financial condition and ability to pursue its business strategies, which may include amending, delaying, limiting, reducing,
or terminating planned activities related to its product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation: </B>The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys
Therapeutics, Inc. (&#147;Arrys&#148;) and Ikena Oncology Securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#147;ASU&#148;) of
the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates: </B>The preparation of the Company&#146;s financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses
during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable
under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses, research and development revenue under a
collaboration agreement, stock-based compensation expense and the determination of fair value of equity instruments and intangible assets acquired in an asset acquisition. The Company utilized various valuation methodologies in accordance with the
framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid,<I>&nbsp;Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>, to estimate the fair value of its equity awards. The Company
evaluates its estimates and assumptions on an ongoing basis. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segments: </B>Operating segments are defined as components of an entity for which separate financial information is available and that is regularly
reviewed by the Chief Operating Decision Maker (&#147;CODM&#148;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#146;s CODM is its Chief Executive Officer. The Company has determined it
operates in a single operating segment and has one reportable segment. All long-lived assets of the Company reside in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration
of Credit Risk and of Significant Suppliers: </B>Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. At December&nbsp;31, 2019 and 2018, substantially all of
the Company&#146;s cash and cash equivalents were deposited at one highly rated financial institution. The Company maintains balances in operating accounts above federally insured limits. The Company has not experienced any losses on such accounts
and does not believe it is exposed to any significant credit risk on cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers and
clinical research organizations to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with
its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated
drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments: </B>The amounts reported for cash equivalents, accounts payable and accrued expenses approximate fair
value because of their short maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level&nbsp;1, defined as observable inputs such as quoted
prices in active markets for identical assets; Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&nbsp;3, defined as unobservable inputs in which little or no
market data exists, therefore requiring us to develop our own assumptions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents: </B>The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition
date to be cash equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment: </B>Property and equipment are recorded at cost and depreciated using the
straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over five years. Electronic equipment and software are depreciated over three years. Leasehold improvements are amortized over the shorter of their
useful life or lease term. When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and
maintenance costs are expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-lived Assets: </B>Long-lived assets consist of property and equipment.<B> </B>The Company reviews the
recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such
assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash
flows arising from the assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes: </B>The Company utilizes the asset and liability method of accounting for income taxes. Under this
method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more
likely than not in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition: </B>The Company has generated revenue from a collaboration agreement as well as service
agreements with related parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> <I>Revenue from Contracts
with Customers</I> <I>(Topic 606),</I> or Topic 606, which amended the guidance for accounting for revenue from contracts with customers. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services
in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company adopted Topic 606 in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements that are within the scope of Topic 606, the entity performs the following five steps: (i)&nbsp;identify the
contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize
revenue when (or as) the entity satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determine
those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods
or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the
transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company
recognizes revenue based on the use of an input method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected
to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12
months following the balance sheet date are classified as deferred revenue, net of current portion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company recognized
$1&nbsp;million of service revenue from related parties for fees associated to services performed by the Company, which was generally based on the cost of providing such services and which may have included a profit margin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company had one collaborative agreement with Bristol-Myers Squibb
(&#147;BMS&#148;), which the Company entered into in January 2019 (the &#147;BMS Collaboration Agreement&#148;). For a complete discussion of the accounting related to BMS Collaboration Agreement, see Note 8, Collaboration Agreement with BMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expense: </B>Research and development costs are expensed as incurred. Research and development expenses are comprised of costs
incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged
to conduct preclinical development activities and trials. Research and development expense also includes the <FONT STYLE="white-space:nowrap">write-off</FONT> of acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development
(&#147;IPR&amp;D&#148;) assets with no alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset Acquisitions:</B><B><I> </I></B>In 2018, the Company adopted ASU <FONT
STYLE="white-space:nowrap">2017-01,</FONT> <I>Business Combinations (ASU <FONT STYLE="white-space:nowrap">2017-01)</FONT></I>, which clarified the definition of a business. The Company measures and recognizes asset acquisitions that are not deemed
to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset
acquisitions. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-based Compensation: </B>The Company&#146;s stock-based compensation program grants awards that may include stock options, restricted stock awards,
restricted stock units, and other stock-based awards. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units
are based on the fair value of the Company&#146;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards
that are subject to graded vesting, companies have the option to recognize compensation expense either on a straight-line or accelerated basis. The Company has elected to recognize compensation expense for these awards on a straight-line basis. The
Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#146;s salary and related
costs are classified or in which the award recipient&#146;s service payments are classified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes significant estimates and assumptions
in determining the fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, <I>Valuation of
Privately-Held Company Equity Securities Issued as Compensation</I> (the &#147;Practice Aid&#148;), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#146;s
judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the superior rights and preferences of securities senior to the Company&#146;s common stock at the time of, and the
likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly
available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. No dividend yield was assumed
as the Company does not intend to pay dividends on its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Loss: </B>Comprehensive loss includes net loss as well as other
changes in stockholders&#146; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&nbsp;31, 2019 and 2018, there were no differences between net loss and comprehensive
loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Issuance Costs: </B>Deferred issuance costs consist of legal, accounting and other third-party
fees that are directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings and remain deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are
recorded as a reduction to the proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated
statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status: </B>The Company is an emerging growth company, as defined in the
Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as
those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier
of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that
comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842)</I> (&#147;ASU
<FONT STYLE="white-space:nowrap">2016-02&#148;).</FONT> The guidance in ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> supersedes the current leasing guidance, which will require lessees to recognize
<FONT STYLE="white-space:nowrap">right-of</FONT> use assets and lease liabilities on the balance sheet for all leases with terms longer than 12 months. As amended, ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for financial
statement periods beginning after December&nbsp;15, 2021. The Company adopted ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> as amended, by applying the modified retrospective approach for leases existing at, and entered into after,
January&nbsp;1, 2020. The adoption of this standard resulted in the recognition of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and&nbsp;operating lease liabilities of $1.0&nbsp;million and
$1.0&nbsp;million respectively, on the Company&#146;s consolidated balance sheet upon adoption on January&nbsp;1, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued <FONT
STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-13,</FONT><I>&nbsp;Financial Instruments&#151;Credit Losses (Topic 326)&#151;Measurement of Credit Losses on Financial Instruments</I>,&nbsp;which has been subsequently amended <FONT
STYLE="white-space:nowrap">(&#147;ASU&nbsp;2016-13&#148;).</FONT> The provisions of <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-13&nbsp;modify</FONT> the impairment model to utilize an expected loss methodology in place of the currently used
incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company early adopted <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-13</FONT> as of
January&nbsp;1, 2020 and it did not have a significant impact on its financial position or results of operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued <FONT
STYLE="white-space:nowrap">ASU&nbsp;2018-13,</FONT><I>&nbsp;Fair Value Measurement (Topic 820):</I> <I>Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement </I>(&#147;ASU
<FONT STYLE="white-space:nowrap">2018-13&#148;).</FONT> The Company adopted ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> as of January&nbsp;1, 2020 and it did not have a significant impact on its financial position or results of operation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-15,</FONT><I>&nbsp;Customer&#146;s Accounting for Implementation Costs
Incurred in a Cloud Computing Arrangement That Is a Service Contract </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2018-15&#148;)</FONT><I>.</I> The new standard will align the requirements for capitalizing implementation costs for hosting
arrangements (services) with costs for <FONT STYLE="white-space:nowrap">internal-use</FONT> software (assets). As a result, certain implementation costs incurred in hosting arrangements will be deferred and amortized. The Company adopted ASU <FONT
STYLE="white-space:nowrap">2018-15</FONT> as of January&nbsp;1, 2020 and it did not have a significant impact on its financial position or results of operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2019, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2019-04,</FONT><I>&nbsp;Codification Improvements to Topic 326, Financial
Instruments&#151;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2019-04&#148;).</FONT> This update provides clarifications for three topics related to financial
instruments accounting, some of which apply to the Company. The Company adopted ASU <FONT STYLE="white-space:nowrap">2019-04</FONT> as of January&nbsp;1, 2020 and it did not have a significant impact on its financial position or results of
operation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income Taxes
(Topic 740)</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;)</FONT> as part of its initiative to reduce complexity in the accounting standards. The amendments in <FONT STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;eliminate</FONT>
certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. <FONT
STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;also</FONT> clarifies and simplifies other aspects of the accounting for income taxes. The Company adopted ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> effective January&nbsp;1, 2020 and it did
not have a material impact on the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT> <I>Statement of Cash Flows (Topic 230): Restricted Cash
Payments</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-15&#148;)</FONT> to clarify how entities should present restricted cash and restricted cash equivalents in their statements of cash flows. Under this new update, entities are required to
show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in their statements of cash flows. The Company adopted ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> in 2019 and there was not a material
impact on the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies
and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements
and disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Arrys Acquisition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;18, 2018 (the &#147;Acquisition Date&#148;), the Company acquired Arrys. Pursuant to the terms and conditions of the Agreement and Plan of Merger (&#147;the Arrys Merger Agreement&#148;), each share of Arrys common and preferred stock,
issued and outstanding immediately prior to the Acquisition Date, was cancelled and converted into 1.5801 fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of the Company&#146;s common stock or Preferred Series <FONT
STYLE="white-space:nowrap">A-1</FONT> stock, respectively. In addition, each outstanding and unexercised option to acquire Arrys common stock was cancelled and converted into 1.5801 options to acquire the Company&#146;s common stock with a
corresponding adjustment to the exercise price. As a result of the Arrys Merger Agreement, the Company issued equity instruments with a total fair value of $38.8&nbsp;million consisting of 6,818,179 shares of common stock, 33,181,818 shares of
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, and options to purchase 644,713 shares of common stock. In addition, the Company also issued options to purchase 2,218,227 shares of its common stock which were unvested at the
Acquisition Date. The unvested options require the recipients to perform future services on behalf of the Company in order to vest in the awards. As the unvested options represent payments for future services, they are not considered as part of the
initial purchase price consideration and will be expensed as the services are provided consistent with the Company&#146;s stock-based compensation accounting policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company first assessed if the acquisition represented a transaction which was under common control or common ownership under both the variable interest
entity guidance and the voting interest entity guidance. While Arrys is a related party to the Company, it is not under common control or common ownership with the Company. The Company next assessed if Arrys represented an asset or a business under
FASB ASC Topic 805, <I>Business Combinations ASC 805, </I>as amended by ASU <FONT STYLE="white-space:nowrap">2017-01.</FONT> Under ASC 805, the Company determined that Arrys did not constitute a business since substantially all of the fair value of
the gross assets acquired is concentrated in a single asset, the intellectual property for the lead product candidate in development by Arrys, which is in Phase 1 clinical trials. The intellectual property acquired from Arrys is at an early stage of
development and will require a significant investment of time and capital for development. There is no assurance that the Company will be successful in completing the additional research and development activities. The intellectual property acquired
is considered to have no alternative future use, and therefore is expensed as incurred. The total transaction price, which includes consideration issued and the issuance costs of $284&nbsp;thousand </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was allocated to the assets acquired and liabilities assumed on a relative fair value basis. The transaction price was determined and allocated as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of equity instruments issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total transaction price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction Price Allocation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities assumed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total transaction price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the consideration issued and the fair value of the assets acquired and liabilities assumed was based on a
probability weighted model that utilized three different scenarios that considered both a scenario that utilized an asset approach and two scenarios that utilized a market approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development of $28,463&nbsp;thousand did not have an alternative future use and
was charged to research and development expense at the acquisition date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s&nbsp;financial assets measured at fair value on a recurring basis and indicate the level of
the fair value hierarchy utilized to determine such fair values (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements as of</B><br><B>December&nbsp;31, 2018 using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements as of</B><br><B>December&nbsp;31, 2019 using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition of Arrys required the determination of fair value on a <FONT STYLE="white-space:nowrap">non-recurring</FONT>
basis. The fair value of the equity consideration issued is considered to be a level three estimate in the fair value hierarchy. In addition, the consideration was allocated to the assets acquired and liabilities assumed on a relative fair value
basis. The determination of the fair value of the assets acquired and liabilities assumed is also considered to be a level three estimate in the fair value hierarchy. Reasonable changes in the assumptions used in the valuation models, including the
weighting between the three scenarios utilized to value the equity instruments, could result in materially different values. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following at December&nbsp;31, 2018 and 2019 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical, manufacturing and scientific development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following at December&nbsp;31, 2018 and 2019 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Electronic equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2019 was $179&nbsp;thousand and
$243&nbsp;thousand, respectively. There were no impairments for the years ended December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Accrued Expenses and Other
Current Liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following at December&nbsp;31, 2018 and 2019 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Collaboration Agreement and Stock Purchase Agreement with BMS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, the Company entered into the BMS Collaboration Agreement with Celgene Corporation, which was acquired by BMS in November 2019, whereby the
Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the BMS Collaboration Agreement, the Company entered into a stock
purchase agreement with BMS, which resulted in the issuance of 14,545,450 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (the &#147;Stock Purchase Agreement&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Agreement Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BMS Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for
certain targets, which are the kynurenine, which the Company is developing as <FONT STYLE="white-space:nowrap">IK-412,</FONT> and the aryl hydrocarbon receptor (&#147;AHR&#148;), which the Company is developing as
<FONT STYLE="white-space:nowrap">IK-175.</FONT> The Company is obligated to complete research and development activities through completion of a Phase 1b clinical trial for each program. BMS has the option to receive a global-development,
manufacture and commercialization license for the product candidate. Subsequent to the delivery of a license, BMS is responsible for the worldwide development, manufacturing and commercialization of these product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMS paid the Company a total of $95.0&nbsp;million in aggregate upfront consideration related to the BMS Collaboration Agreement and Stock Purchase Agreement.
The Company is eligible to receive $50.0&nbsp;million, in case of an exercise of its option with respect to <FONT STYLE="white-space:nowrap">IK-175,</FONT> and $40.0&nbsp;million, in case of an exercise of its option with respect to <FONT
STYLE="white-space:nowrap">IK-412.</FONT> If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to BMS to support the decision to exercise the option for an additional
$0.25&nbsp;million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $450&nbsp;million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low double digits.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting Considerations of the Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BMS
Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock was initially accounted for at fair value. The
purchase price for the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock was considered to be at a discount from fair value, and therefore $1.8&nbsp;million of the upfront from the BMS Collaboration Agreement was allocated to the
equity arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined that the BMS Collaboration Agreement represented a contract with a customer and should be accounted for in
accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412.</FONT> The options to
receive worldwide development and commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be
performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
identified $78.7&nbsp;million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential
milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the distinct performance obligations identified above, the Company allocated the $78.7&nbsp;million transaction price based on relative estimated
standalone selling prices of each of its performance obligations as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$41.2&nbsp;million for research and development services for <FONT STYLE="white-space:nowrap">IK-175;</FONT> and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$37.5&nbsp;million for research and development services for <FONT STYLE="white-space:nowrap">IK-412.</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined the estimated standalone selling price for the research and development services based on internal estimates of
the costs to perform the services, including expected internal expenses and expenses with third parties, marked up to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development
activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is recognizing revenue related to each of its performance obligations as the research and
development services are performed. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, the Company recognized revenue of $13.8&nbsp;million from the BMS Collaboration Agreement. During the year ended
December&nbsp;31, 2018, the Company did not recognize any research and development revenue under the BMS Collaboration Agreement. The consolidated balance sheet at December&nbsp;31, 2019 included deferred revenue of $65.0&nbsp;million related this
agreement, of which $20.7&nbsp;million and $44.3 million were classified as current and <FONT STYLE="white-space:nowrap">non-current,</FONT> respectively. This amount is expected to be recognized as performance obligations are satisfied through the
completion of the research and development services for <FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412</FONT><I>.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Redeemable Convertible Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2019, the authorized capital stock of the Company includes 75,727,268 shares of redeemable convertible preferred stock, consisting of 28,000,000 shares of Series A Redeemable Convertible Preferred Stock (&#147;Series A Preferred
Stock&#148;) and 47,727,268 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redeemable Convertible Preferred Stock (&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148;), collectively known as Redeemable
Convertible Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Issued</B><br><B>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Issued</B><br><B>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the Company entered into a Series A Preferred Stock Purchase Agreement. Upon execution of the agreement, the
Company issued 6,000,000 shares of Series A Preferred Stock for a purchase price of $1.00 per share. The agreement also provided for the issuance of additional shares of Series A Preferred Stock upon the occurrence of certain contingent events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2017, the Company modified the terms of the agreement and issued 2,400,000 shares of Series A Preferred Stock for a purchase price of $1.00 per
share. The amendment decreased the number of shares that would be issued upon the occurrence of the contingent events by the same number of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2017, the contingent events were achieved, and the Company issued the remaining 19,600,000 shares of Series A Preferred Stock for a purchase price of $1.00 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, the Company issued 33,181,818 <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT>
Preferred Shares pursuant to the acquisition of Arrys. The shares were recorded at fair value of $34.7&nbsp;million (Note 3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, the
Company issued 14,545,450 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred shares to BMS as part of a stock purchase agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
obligation to issue the additional shares of Series A Preferred Stock was assessed and not considered to be a freestanding instrument. As a result, the feature was embedded within the shares, however, did not meet the characteristics to be
bifurcated and accounted for separately apart from the underlying shares of Series A Preferred Stock. The Preferred Stock is eligible to be redeemed upon certain deemed-liquidation events which are outside of the Company&#146;s control. As a result,
the shares are presented outside of stockholders&#146; deficit. The shares will be accreted to redemption value if the events that would result in a deemed-liquidation event are considered probable. As of December&nbsp;31, 2019, these events are not
considered probable of occurring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Stock has the following characteristics as of December&nbsp;31, 2019: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Voting </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written
consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such
holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Company&#146;s Amended and Restated Certificate of Incorporation, holders of
Preferred Stock shall vote together with the holders of Common Stock as a single class and have other special voting rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of outstanding
shares of Preferred Stock shall be entitled to elect three directors of the Company. The investors have agreed that two of the directors are to be named by one investor and the other director is to be named by a separate investor. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dividends </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Stock are entitled to an 8% <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend. Dividends are payable only when, as and
if declared by the Board. No dividends are payable to the common stockholders unless a dividend is also paid to Preferred Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were converted into common
stock.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2019, no dividends have been declared or paid by the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liquidation Preference </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed liquidation
events, holders of shares of Preferred Stock then outstanding shall be entitled to receive the greater of (i)&nbsp;an amount per share equal to the Preferred Stock original issue price, plus any dividends declared but unpaid thereon or (ii)&nbsp;the
amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Conversion </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of one for one and are
automatically converted upon a qualified initial public offering or upon written consent of at least 75% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for
certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain dividends and distributions, and mergers and reorganizations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2018 and 2019, the Company had 90,909,088 and 113,372,392, shares of common stock authorized, respectively, of which 18,818,179 and
18,967,681 were issued and outstanding as of December&nbsp;31, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting: </B>The holders of shares of common stock are
entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two
directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation: </B>After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining
assets of the Company are distributed to the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted stock: </B>A total of 6,000,000 shares of the Company&#146;s common
stock were issued in 2016 and were subject to repurchase agreements upon issuance. The repurchase right lapsed ratably over a period of 24 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
changes in the unvested restricted stock during the year ended December&nbsp;31, 2018 was: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(750,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no unvested restricted stock outstanding during the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11. Stock-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, in
conjunction with the acquisition of Arrys, the Company increased the number of shares available for issuance under the Company&#146;s 2016 Stock Incentive Plan (the &#147;Plan&#148;) to up to 10,909,091, as approved by the Board of Directors. On
March&nbsp;30, 2019, the number of shares reserved under the Plan was increased by 7,372,392 shares to 18,281,483, as approved by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, 616,065 shares were available for grant under the Plan. The Plan provides that equity awards may be granted to employees and
nonemployees. The vesting periods for equity awards, which generally is four years, are determined by the Board of Directors. The contractual term for stock option awards is ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recorded during the years ended December&nbsp;31, 2018 and 2019 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average fair value of the stock options granted during the year ended December&nbsp;31, 2018 and 2019 was $0.42
and $0.36 per share, respectively. As of December&nbsp;31, 2019, the total unrecognized stock-based compensation balance for unvested options was $4.4&nbsp;million which is expected to be recognized over 2.5 years. The Company recognized
$0.7&nbsp;thousand of stock-based compensation expense for the year ended December&nbsp;31, 2018 related to the vesting of restricted common stock. There was no stock-based compensation expense related to the vesting of restricted common stock for
the year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity under the Plan for the year ended December&nbsp;31,
2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term&nbsp;(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,038,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,400,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,773,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,516,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,215,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,301,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intrinsic value of options exercised for the years ended December&nbsp;31, 2018 and 2019 was zero and $70&nbsp;thousand,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of each option award granted during the years ended December&nbsp;31, 2018 and 2019 is estimated on the date of grant using
the Black-Scholes option pricing model and the weighted average assumptions noted in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected option term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#146;s loss before income taxes as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax effected at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.3</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-taxable</FONT> incentives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14.6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.8</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36.1</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s total deferred tax assets at December&nbsp;31, 2018 and 2019 are as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized <FONT STYLE="white-space:nowrap">start-up</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation Allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets and liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has had no income tax expense due to operating losses incurred since inception. ASC 740 requires a valuation
allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that some portion or all of the deferred tax assets will not be realized. The Company
has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the
deferred tax assets is not determined to be more likely than not. During 2019, the valuation allowance increased by $5.7&nbsp;million primarily due to the increase in the Company&#146;s net operating loss during the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company had approximately $47.2&nbsp;million of Federal operating loss carryforwards, of which $8.9&nbsp;million begin to
expire in 2036 and $38.3&nbsp;million are not subject to expiration. These loss carryforwards are available to reduce future federal taxable income, if any. As of December&nbsp;31, 2019, the Company had approximately $46.9&nbsp;million of state
operating loss carryforward, of which $46.9&nbsp;million will begin to expire in 2036. As of December&nbsp;31, 2019, the Company also has federal and state research and development tax credit carryforwards of approximately $1.9&nbsp;million and
$538&nbsp;thousand respectively, to offset future income taxes, which will begin to expire in December 2031. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss
carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the company&#146;s ultimate parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company follows the provisions of ASC <FONT STYLE="white-space:nowrap">740-10,</FONT> <I>Accounting for Uncertainty in Income Taxes</I>, which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in
financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions.
The Company&#146;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income. As of December&nbsp;31, 2019, and 2018, the Company had no reserves
for uncertain tax positions. For the years ended December&nbsp;31, 2019 and 2018, no estimated interest or penalties were recognized on uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development
credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allowance has been provided against the Company&#146;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation
allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s federal
and Massachusetts income tax returns for the years ended December&nbsp;31, 2017 to December&nbsp;31, 2019 remain open and are subject to examination by the Internal Revenue Service and state taxing authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13. Research License Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2015, the
Company entered into an exclusive patent license agreement (the &#147;UT Austin License&#148;) to license certain technologies and intellectual property rights from the University of Texas at Austin (the &#147;University&#148;), an entity affiliated
with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License
Maintenance fees annually of $40&nbsp;thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $4.7&nbsp;million upon meeting certain development
milestones during the term of the UT Austin License. The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.
The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended
December&nbsp;31, 2018 and 2019, the Company incurred expenses totaling $20&nbsp;thousand and $100&nbsp;thousand, respectively, related to license maintenance fees and $80&nbsp;thousand and $126&nbsp;thousand related to patent reimbursement costs,
respectively, related to the UT Austin License, which are included in research and development expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, the Company acquired IPR&amp;D on an
Arrys&#146; immune-oncology candidate based on the intellectual property associated with Arrys&#146; AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $28.5&nbsp;million and was recognized as
research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make
additional milestone payments to AskAt upon meeting certain development milestones totaling $4&nbsp;million, as well as certain sales event milestones ranging from $50&nbsp;million to $250&nbsp;million contingent on sales in a calendar year, during
the term of the AskAt License. The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14. Commitments and Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017,
the Company entered into an operating lease agreement with Obsidian Therapeutics, Inc. to sublease approximately 4,156 square feet of office space located at 1030 Massachusetts Avenue, Cambridge, Massachusetts, as amended, which expired in November
2018. The monthly rent per the lease, exclusive of operating expenses, real estate taxes and parking, was $24&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, the
Company entered into an operating lease with Vertex Pharmaceuticals Inc. (&#147;Vertex&#148;) to lease approximately 13,170 square feet of office, laboratory and vivarium space at 50 Northern Ave, Boston, Massachusetts, expiring in December 2020. In
July 2020, the Company extended the term of the lease through February 2021. The monthly rent per the lease, exclusive of operating expenses and real estate taxes, is $93&nbsp;thousand, with the first payment of rent paid in January 2019. Under the
terms of the lease, Vertex contributed $160&nbsp;thousand towards a tenant improvement allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded rent expense of $535&nbsp;thousand
and $996&nbsp;thousand for the years ended December&nbsp;31, 2018 and 2019, respectively. The Company recognizes rent expense on a straight-line basis over the lease period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and has recorded deferred rent for rent expense incurred but not yet paid and for tenant improvement allowance paid by the lessor, which resulted in a deferred balance of $243&nbsp;thousand and
$121&nbsp;thousand at December&nbsp;31, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the future minimum lease payments under the
Company&#146;s operating leases as of December&nbsp;31, 2019 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is also party to various agreements, principally relating to licensed technology, that require future payments
relating to milestones not met at December&nbsp;31, 2019 or royalties on future sales of specified products that have not yet occurred as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 15. Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered
into several agreements with investors and entities affiliated with an investor: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has entered into a lease agreement with an investor and a separate lease agreement with an
affiliate of the investor for office and laboratory space located in Massachusetts. The Company paid the related parties approximately $319&nbsp;thousand in total rent during the year ended December&nbsp;31, 2018. The Company had no rent payments to
related parties in the year ended December&nbsp;31, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company performs services on behalf of entities affiliated with the investor. The Company recognized
$990&nbsp;thousand during the year ended December&nbsp;31, 2018. As of December&nbsp;31, 2018, the Company was owed $6&nbsp;thousand related to these activities. The Company did not perform services on behalf of entities affiliated with the investor
in 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company received consulting services from an investor for $100&nbsp;thousand and $161&nbsp;thousand during
the years ended December&nbsp;31, 2018 and 2019, respectively. The Company has accrued for $75&nbsp;thousand of service costs as of December&nbsp;31, 2018. There was no accrual for the year ended December&nbsp;31, 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As discussed in Note 13 above, the Company recognized $28.5&nbsp;million as expense upon the acquisition of
IPR&amp;D associated with the Arrys&#146; AskAt License. The Company also incurred expenses of $17&nbsp;thousand during the year ended December&nbsp;31, 2018 related to the AskAt consulting services agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into several agreements with a director and an entity affiliated with a director: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As discussed in Note 13 above, the Company has entered into a license agreement with the University, which was
affiliated with a director of the Company at the time of the agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has engaged the University to perform certain research services. The Company incurred expenses
totaling $100&nbsp;thousand and $20&nbsp;thousand, respectively, related to license maintenance fees and $126&nbsp;thousand and $80&nbsp;thousand, respectively, related to patent reimbursement costs in the years ended December&nbsp;31, 2019 and
2018, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company received consulting services from a director for $101&nbsp;thousand during the year ended
December&nbsp;31, 2019. The Company did not receive consulting services from a director during the year ended December&nbsp;31, 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 16. Net Loss per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the
weighted-average common shares outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s potentially dilutive securities, which include convertible preferred stock, restricted
stock, and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic
and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders because including them would have had an
anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,038,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,516,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,220,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,243,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 17. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated all events or transactions that occurred from December&nbsp;31, 2019 through January&nbsp;8, 2021, the date the consolidated financial
statements were issued. The Company has concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements, other than the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Lease </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On July&nbsp;21, 2020, the Company entered into an operating lease agreement for 20,752 square feet of office, lab and animal care facility
space located in Boston, Massachusetts for the Company&#146;s new corporate headquarters. The commencement date of the lease is estimated to be February&nbsp;1, 2021 and the lease term is 63 months. The lease provides a three-month free rent period,
which will commence on the lease commencement date. The base rent at commencement is $145&nbsp;thousand a month and escalates by 3% annually. The Company provided a letter of credit to secure their obligations under the lease in the initial amount
of $0.9&nbsp;million. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Common Stock and Preferred Stock Authorized for Issuance</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2020, the Board Amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of
shares of Common Stock authorized for issuance to 200,000,000 shares. In addition, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of Preferred Stock authorized for issuance to
83,590,362 shares, of which 28,000,000 are designated Series A Preferred Stock, 47,727,268 are designated Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and 7,863,094 are designated Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Amplify Medicines, Inc. Acquisition</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2020 (the &#147;Acquisition Date&#148;), the Company acquired Amplify, a related party. Pursuant to the terms and conditions
of the Agreement and Plan of Merger (&#147;the Merger Agreement&#148;), the Company issued a total of 7,863,094 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock at a fair value of $1.31 for
aggregate fair value of approximately $10.3&nbsp;million, net of issuance costs and 3,048,764 shares of Common Stock with a fair value of $1.03 for a total fair value of $3.1&nbsp;million related to the Common Stock issued to the shareholders of
Amplify as part of the Merger Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U><I>Voting Rights</I></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each holder of outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock shall be
entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.
Except as provided by law or by the other provisions of the Company&#146;s Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Dividends</U></I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock are entitled to an 8% <FONT
STYLE="white-space:nowrap">non-cumulative</FONT> dividend. Dividends are payable only when, as and if declared by the Board. No dividends are payable to the common stockholders unless a dividend is also paid to Preferred Stockholders equal to at
least the amount that would be received if the shares of Preferred Stock were converted into common stock.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Liquidation
Preference</U></I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event
of certain other deemed liquidation events, holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock then outstanding shall be entitled to receive the greater of (i)&nbsp;an amount per share equal to
$0.8266466, plus any dividends declared but unpaid thereon or (ii)&nbsp;the amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Conversion</U></I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each
share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of one for one and are automatically converted upon a qualified initial public offering or upon written consent of at
least 75% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain
dividends and distributions, and mergers and reorganizations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Preferred Stock is eligible to be redeemed upon certain
deemed-liquidation events which are outside of the Company&#146;s control. As a result, the shares will be presented outside of stockholders&#146; deficit. The shares will be accreted to redemption value if the events that would result in a
deemed-liquidation event are considered probable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company first assessed if the acquisition represented a transaction which was under
common control or common ownership under both the variable interest entity guidance and the voting interest entity guidance. While Amplify is a related party to the Company, it is not under common control or common ownership with the Company. The
Company next assessed if Amplify, represented an asset or a business under FASB ASC Topic 805, <I>Business Combinations ASC 805, </I>as amended by ASU <FONT STYLE="white-space:nowrap">2017-01.</FONT> Under ASC 805, the Company determined that
Amplify did not constitute a business since substantially all of the fair value of the gross assets acquired is concentrated in a single asset, which is the intellectual property for the lead product candidate in development by Amplify. The
intellectual property acquired from Amplify is at an early stage of development and will require a significant investment of time and capital for development. There is no assurance that the Company will be successful in completing the additional
research and development activities. The intellectual property acquired is considered to have no alternative future use, and therefore the cost of the acquisition allocated to it will be expensed as incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The transaction price was determined and allocated as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of equity instruments issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction Price Allocation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities assumed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total transaction price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The fair value of the consideration issued was based on a probability weighted model that
utilized two different scenarios that utilized a market approach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company will recognize the
<FONT STYLE="white-space:nowrap">write-off</FONT> of the acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development intellectual property of $10.7&nbsp;million within Research and development expense upon the closing of the
transaction. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Common Stock and Preferred Stock Authorized for Issuance</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2020, the Company amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of
shares of Common Stock authorized for issuance to 230,000,000 shares. In addition, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of Preferred Stock authorized for issuance to
169,396,576 shares, of which 28,000,000 are designated Series A Preferred Stock, 47,727,268 are designated Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, 7,863,094 are designated Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and 85,806,214 are designated Series B Preferred Stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Series B Redeemable Convertible Preferred Stock Issuance </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2020, the Company issued a total of 85,806,214 shares of Series B Redeemable Convertible Preferred Stock at a purchase
price of $1.3985 per share for aggregate proceeds of approximately $116.4&nbsp;million, net of issuance costs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Voting Rights</U>
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each holder of outstanding shares of Series B Redeemable Convertible Preferred Stock shall be entitled to cast the number of votes
equal to the number of whole shares of Common Stock into which the shares of Series B Redeemable Convertible Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.
Except as provided by law or by the other provisions of the Company&#146;s Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Dividends</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The
holders of Series B Redeemable Convertible Preferred Stock are entitled to an 8% <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend in seniority to the Series A, <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT
STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock. Dividends are payable only when, as and if declared by the Board. No dividends are payable to the common stockholders unless a dividend is also paid to Preferred
Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were converted into common stock.<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Liquidation Preference</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed
liquidation events, holders of shares of Series B Redeemable Convertible Preferred Stock then outstanding shall be entitled to receive the greater of (i)&nbsp;an amount per share equal to $1.3985, plus any dividends declared but unpaid thereon or
(ii)&nbsp;the amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Conversion</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each
share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of one for one and are automatically converted upon a qualified initial public offering or upon written consent of at
least 75% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain
dividends and distributions, and mergers and reorganizations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Preferred Stock is eligible to be redeemed upon certain
deemed-liquidation events which are outside of the Company&#146;s control. As a result, the shares will be presented outside of stockholders&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
deficit. The shares will be accreted to redemption value if the events that would result in a deemed-liquidation event are considered probable. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Option Plan Increase</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2020, the number of shares reserved under the Plan was increased by 18,014,373 shares to 37,264,008, as approved by the
Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_8"></A><A NAME="fin197729_9"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A and <FONT STYLE="white-space:nowrap">A-1),</FONT>
$0.001 par value, 75,727,268 shares authorized, issued and outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020 (liquidation preference of $75,727,268 as of December&nbsp;31, 2019 and September&nbsp;30, 2020);</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 113,372,392 shares authorized, 18,967,681 issued and outstanding
as of December&nbsp;31, 2019; 113,795,082 shares authorized, 19,021,056 issued and outstanding as of September&nbsp;30, 2020;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_10"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development revenue under collaboration agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stocks outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,938,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,013,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_11"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable</B><br><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity&nbsp;(Deficit)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,181,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,818,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(50,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of preferred stock in connection with private placement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,545,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,967,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(56,715</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable</B><br><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity&nbsp;(Deficit)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,967,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(67,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,021,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(85,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(78,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_12"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(422</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock in connection with private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash included in other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT>
activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment in accrued expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets recognized upon adoption of ASC 842</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset
obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred transaction costs in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin197729_13"></A>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note&nbsp;1. Description
of Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the
formation and spread of cancer. The Company&#146;s programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical
needs. By leveraging the Company&#146;s deep understanding of discovery chemistry, translational science, and patient-centric drug development, it has built a deep pipeline of wholly owned and partnered programs focused on genetically defined or
biomarker-driven cancers, which enables it to target specific patient populations that the Company believes are most likely to respond to treatment with its product candidates. Since the Company commenced operations in 2016, it has discovered or
developed five oncology programs that include four product candidates in either <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by
competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under
development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional
capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Because of the numerous risks and uncertainties associated with product development, the Company is unable to predict the timing or amount of increased
expenses or when or if the Company will be able to achieve or maintain profitability. Even if the Company is able to generate revenue from product sales, the Company may not become profitable. If the Company fails to become profitable or is unable
to sustain profitability on a continuing basis, then the Company may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations. The Company expects to incur substantial operating losses and negative
cash flows from operations for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Codification (&#147;ASC&#148;) <FONT
STYLE="white-space:nowrap">205-40,</FONT> <I>Going Concern</I>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going
concern within one year after the date that the condensed consolidated financial statements are issued. As of September&nbsp;30, 2020, the Company had an accumulated deficit of $85.3&nbsp;million. The Company expects to continue to generate
operating losses in the foreseeable future. The Company has funded these losses principally through the sale of common and convertible preferred stock and from cash proceeds received in connection with the Company&#146;s collaboration with
Bristol-Myers Squibb (&#147;BMS&#148;) entered into in January 2019 (the &#147;BMS Collaboration Agreement&#148;). The Company expects that its cash and cash equivalents of $55.9&nbsp;million at September&nbsp;30, 2020, together with the
$3.7&nbsp;million of cash received through the acquisition of Amplify Medicines, Inc. (&#147;Amplify&#148;) on October&nbsp;1, 2020 and the net proceeds of $116.4&nbsp;million from the issuance of Series B redeemable convertible preferred stock on
December&nbsp;21, 2020, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from issuance of the condensed consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company expects that it will seek additional funding through public or private financings, debt financing, collaboration agreements or
government grants. The inability to obtain funding, as and when needed, could have a negative impact on the Company&#146;s financial condition and ability to pursue its business strategies, which may include amending, delaying, limiting, reducing,
or terminating planned activities related to its product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of presentation: </B>The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys
Therapeutics, Inc. (&#147;Arrys&#148;) and Ikena Oncology Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with
accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification
(&#147;ASC&#148;) and Accounting Standards Update (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim
Condensed Consolidated Financial Statements:</B> The accompanying condensed consolidated balance sheet as of September&nbsp;30, 2020 and the condensed consolidated statements of operations and comprehensive loss, redeemable convertible preferred
stock and stockholders&#146; equity (deficit) and cash flows for the nine months ended September&nbsp;30, 2019 and 2020 are unaudited. The financial data and other information contained in the notes thereto as of and for the nine months ended
September&nbsp;30, 2019 and 2020 are also unaudited. The condensed consolidated balance sheet data as of December&nbsp;31, 2019 was derived from the Company&#146;s audited consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed in <I>Recently Adopted Accounting Pronouncements,</I> the unaudited interim condensed consolidated financial statements have been prepared
on the same basis as the audited consolidated financial statements as of and for the year ended December&nbsp;31, 2019, and, in the opinion of management, reflect all adjustments necessary, all of which were normal and recurring, for the fair
presentation of the Company&#146;s financial position as of September&nbsp;30, 2020, and the results of operations and cash flows for the nine months ended September&nbsp;30, 2019 and 2020. These unaudited condensed consolidated financial statements
should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&nbsp;31, 2019, and the notes thereto, included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates: </B>The preparation of the Company&#146;s financial statements requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on
historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from
estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses, research and development revenue under collaboration agreement, stock-based compensation expense and the
determination of fair value of equity instruments and intangible assets acquired in an asset acquisition. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public
Accountants Technical Practice Aid,<I>&nbsp;Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>, to estimate the fair value of its equity awards. The Company evaluates its estimates and assumptions on an ongoing basis.
All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segments:
</B>Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#147;CODM&#148;) in deciding how to allocate resources to an
individual segment and in assessing performance. The Company&#146;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment. All long-lived assets of the Company reside
in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments: </B>The amounts reported for cash equivalents, accounts payable and accrued expenses
approximate fair value because of their short maturities. The Company reports its investment securities at their estimated fair value based on a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These
tiers include: Level&nbsp;1, defined as observable inputs such as quoted prices in active markets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for identical assets; Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&nbsp;3, defined as unobservable
inputs in which little or no market data exists. The Company has not historically held any Level&nbsp;2 or Level&nbsp;3 investments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in
circumstances that caused the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents: </B>The Company considers all short-term, highly liquid investments with original
maturities of 90 days or less at acquisition date to be cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash:</B> Restricted cash is composed of amounts held on deposit
related to the Company&#146;s lease arrangements. Restricted cash is classified as other assets as of September&nbsp;30, 2020 based on terms of the underlying arrangement. There was no restricted cash as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk: </B>Financial instruments which potentially expose the Company to concentrations of credit risk include cash equivalents,
marketable securities and accounts receivable. All of the&nbsp;Company&#146;s cash deposits are maintained at large, creditworthy financial institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment: </B>Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of
each asset. Lab equipment is depreciated over five years. Electronic equipment and software are depreciated over three years. Leasehold improvements are amortized over the shorter of their useful life or lease term. When an item is sold or retired,
the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations and comprehensive loss. Repairs and maintenance costs are expensed as incurred.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-lived Assets: </B>Long-lived assets consist of property and equipment.<B> </B>The Company reviews the recoverability of its long-lived assets,
including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an
impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets. To date, the
Company has not recorded any impairment losses on long lived assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes: </B>The Company utilizes the asset and liability method of
accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the
enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of
management, realization is considered more likely than not in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition: </B>The Company has generated revenue from a
collaboration agreement as well as service agreements with related parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> <I>Revenue from Contracts with Customers</I> <I>(Topic 606),</I> (&#147;Topic 606&#148;), which amended the guidance for accounting for revenue from contracts with customers. Under Topic 606,
an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. The Company adopted Topic 606 in
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements that are within the scope of Topic 606, the entity performs the following five steps:
(i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract;
and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determine those that are
performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services,
the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price
that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue
based on the use of an input method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as
revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the
balance sheet date are classified as deferred revenue, net of current portion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, the Company had one collaborative
agreement, the BMS Collaboration Agreement, which the Company entered into in January 2019. For a complete discussion of the accounting related to the BMS Collaboration Agreement, see Note 7, Collaboration Agreement with BMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expense: </B>Research and development costs are expensed as incurred. Research and development expenses are comprised of costs
incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged
to conduct preclinical development and discovery activities and trials. Research and development expense also includes the <FONT STYLE="white-space:nowrap">write-off</FONT> of acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research
(&#147;IPR&amp;D&#148;) and development assets with no alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asset Acquisitions:</B><B><I> </I></B>The Company measures and
recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value
methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to IPR&amp;D assets with no alternative future use is charged to research and development expense at the acquisition date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation: </B>The Company&#146;s stock-based compensation program grants awards that may include stock options, restricted stock awards,
restricted stock units, and other stock-based awards. The fair values of stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units
are based on the fair value of the Company&#146;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards
that are subject to graded vesting, companies have the option to recognize compensation expense either on a straight-line or accelerated basis. The Company has elected to recognize compensation expense for these awards on a straight-line basis. The
Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#146;s salary and related
costs are classified or in which the award recipient&#146;s service payments are classified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes significant estimates and assumptions
in determining the fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, <I>Valuation of
Privately-Held Company Equity Securities Issued as Compensation</I> (the &#147;Practice Aid&#148;), to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#146;s
judgment. These estimates and assumptions include a number of objective and subjective factors, including external market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions, the superior rights and preferences of securities senior to the Company&#146;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial
public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly
available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. No dividend yield was assumed
as the Company does not intend to pay dividends on its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Loss: </B>Comprehensive loss includes net loss as well as other
changes in stockholders&#146; equity (deficit) that result from transactions and economic events other than those with stockholders. For the nine months ended September&nbsp;30, 2019 and 2020, there were no differences between net loss and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Issuance Costs: </B>Deferred issuance costs consist of legal, accounting and other third-party fees that are directly
associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings and remain deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the
proceeds generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leases: </B>The Company adopted ASC Topic 842,<I>&nbsp;Leases</I>&nbsp;(&#147;ASC 842&#148;) on January&nbsp;1, 2020. At the
inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases that are economically similar to the purchase of assets are generally classified as
finance leases; otherwise the leases are classified as operating leases. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. Options to renew a lease are not included in the Company&#146;s
assessment unless there is reasonable certainty that the Company will renew. Leases with a term greater than one year are recognized on the balance sheet
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as&nbsp;right-of-use&nbsp;assets,</FONT></FONT> lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">corresponding&nbsp;right-of-use&nbsp;assets</FONT></FONT> are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">the&nbsp;right-of-use&nbsp;asset</FONT></FONT> may be required for items such as incentives received. The Company has elected as an accounting policy to combine lease and <FONT STYLE="white-space:nowrap">non-lease</FONT>
components, such as common area maintenance, for all classes of underlying assets. The interest rate implicit in lease contracts has not historically been readily determinable. As a result, the Company utilizes its incremental borrowing rates, which
are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. To estimate its incremental borrowing rate, a credit rating applicable to the Company is
estimated using synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to adoption of ASC
842, the Company recognized lease expense straight line based the average of the remaining term of payments with an adjustment to deferred rent asset or liability based on the timing in payments in relation to straight line rent expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status:</B> The Company is an &#147;emerging growth company,&#148; (&#147;EGC&#148;) as defined in the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;), and the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. As an EGC, the Company can elect to take
advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards,
and as a result of this election, the Company&#146;s consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#146; effective dates. The Company will remain an EGC until the last day of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fiscal year in which the fifth anniversary of the date of the first sale of common equity securities of the Company under an effective Securities Act registration statement occurs, although if
the market value of the Company&#146;s common stock that is held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;exceeds</FONT> $700&nbsp;million as of any June&nbsp;30 before that time or if the Company has annual gross revenue of
$1.07&nbsp;billion or more in any fiscal year, the Company would cease to be an EGC as of December&nbsp;31 of the applicable year. The Company would cease to be an EGC if it issued more than $1&nbsp;billion
<FONT STYLE="white-space:nowrap">of&nbsp;non-convertible&nbsp;debt</FONT> over a three-year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-02,</FONT><I>&nbsp;Leases (Topic 842)</I><FONT
STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2016-02&#148;),&nbsp;as</FONT> subsequently amended which requires an entity to recognize assets and liabilities arising from a lease for both financing (formerly referred to as capital) and operating
<FONT STYLE="white-space:nowrap">leases.&nbsp;ASU&nbsp;2016-02&nbsp;also</FONT> requires new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash
flows arising from leases. The Company adopted this ASU as of January&nbsp;1, 2020 using the required modified retrospective approach and utilizing the effective date as its date of initial application. As a result, prior periods are presented in
accordance with the previous guidance in ASC 840, Leases (&#147;ASC 840&#148;). In addition, the standard allows for certain practical expedients in transition to ASC 842, including the package of practical expedients. The Company elected to utilize
the package of practical expedients which allowed the Company to not reassess the following: (i)&nbsp;whether any expired or existing contracts contained leases; (ii)&nbsp;the lease classification for any expired or existing leases; and
(iii)&nbsp;the treatment of initial direct costs for any existing leases. The adoption of this standard resulted in the recognition of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets
and&nbsp;operating lease liabilities of $1.0&nbsp;million and $1.0&nbsp;million respectively, on the Company&#146;s consolidated balance sheet at adoption as of January&nbsp;1, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326)
&#151;Measurement of Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;)</FONT></I>. The provisions of ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> modify the impairment model to utilize an
expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company early adopted ASU <FONT
STYLE="white-space:nowrap">2016-13</FONT> as of January&nbsp;1, 2020 and it did not have a significant impact on its financial position or results of operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-13,</FONT><I>&nbsp;Fair Value Measurement (Topic 820):</I> <I>Disclosure
Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2018-13&#148;).</FONT> The Company adopted ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> as of January&nbsp;1,
2020 and it did not have a significant impact on its financial position or results of operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued <FONT
STYLE="white-space:nowrap">ASU&nbsp;2018-15,</FONT><I>&nbsp;Customer&#146;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </I>(&#147;ASU
<FONT STYLE="white-space:nowrap">2018-15&#148;)</FONT><I>.</I> The new standard will align the requirements for capitalizing implementation costs for hosting arrangements (services) with costs
<FONT STYLE="white-space:nowrap">for&nbsp;internal-use&nbsp;software</FONT> (assets). As a result, certain implementation costs incurred in hosting arrangements will be deferred and amortized. The Company adopted ASU
<FONT STYLE="white-space:nowrap">2018-15</FONT> as of January&nbsp;1, 2020 and it did not have a significant impact on its financial position or results of operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2019, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2019-04,</FONT><I>&nbsp;Codification Improvements to Topic 326, Financial
Instruments&#151;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2019-04&#148;).</FONT> This update provides clarifications for three topics related to financial
instruments accounting, some of which apply to the Company. The Company adopted ASU <FONT STYLE="white-space:nowrap">2019-04</FONT> as of January&nbsp;1, 2020 and it did not have a significant impact on its financial position or results of
operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2019-12,</FONT><I>&nbsp;Income Taxes (Topic
740)&#151;Simplifying the Accounting for Income Taxes</I><I></I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2019-12&#148;),</FONT><I></I>&nbsp;as part of its initiative to reduce complexity in the accounting standards. The amendments in <FONT
STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;eliminate</FONT> certain exceptions related to the approach for intraperiod tax allocation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences.
<FONT STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;also</FONT> clarifies and simplifies other aspects of the accounting for income taxes. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> as of January&nbsp;1, 2020
and it did not have a significant impact on its financial position or results of operation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date.
Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
presents information about the Company&#146;s&nbsp;financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements as of</B><br><B>December&nbsp;31, 2019 using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements as of</B><br><B>September&nbsp;30, 2020 using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash equivalents:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019 and nine months ended September&nbsp;30, 2020, there were no transfers between
Level&nbsp;1, Level&nbsp;2 and Level&nbsp;3. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following at December&nbsp;31, 2019 and September&nbsp;30, 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical, manufacturing and scientific development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following at December&nbsp;31, 2019 and September&nbsp;30, 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Electronic equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for the nine months ended September&nbsp;30, 2019 and 2020 was $0.2&nbsp;million and $0.2&nbsp;million,
respectively. There were no impairments for nine months ended September&nbsp;30, 2019 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6. Accrued Expenses and Other Current Liabilities
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following at December&nbsp;31, 2019 and September&nbsp;30, 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7. Collaboration Agreement and Stock Purchase Agreement with BMS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, the Company entered into the BMS Collaboration Agreement with Celgene Corporation, which was acquired by BMS in November 2019, whereby the
Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the BMS Collaboration Agreement, the Company entered into a stock
purchase agreement with BMS, which resulted in the issuance of 14,545,450 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (the &#147;Stock Purchase Agreement&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Agreement Structure </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BMS Collaboration
Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are the kynurenine, which the Company is developing as
<FONT STYLE="white-space:nowrap">IK-412,</FONT> and the aryl hydrocarbon receptor (&#147;AHR&#148;), which the Company is developing as <FONT STYLE="white-space:nowrap">IK-175.</FONT> The Company is obligated to complete research and development
activities through completion of a Phase 1b clinical trial for each program. BMS has the option to receive a global-development, manufacture and commercialization license for the product candidate. Subsequent to the delivery of a license, BMS is
responsible for the worldwide development, manufacturing and commercialization of these product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BMS paid the Company a total of
$95.0&nbsp;million in aggregate upfront consideration related to the BMS Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $50.0&nbsp;million, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case of an exercise of its option with respect to <FONT STYLE="white-space:nowrap">IK-175,</FONT> and $40.0&nbsp;million, in case of an exercise of its option with respect to <FONT
STYLE="white-space:nowrap">IK-412.</FONT> If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to BMS to support the decision to exercise the option for an additional
$0.25&nbsp;million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $450&nbsp;million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low double digits.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accounting Considerations of the Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BMS
Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock was initially accounted for at fair value. The
purchase price for the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock was considered to be at a discount from fair value, and therefore $1.8&nbsp;million of the upfront from the BMS Collaboration Agreement was allocated to the
equity arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined that the BMS Collaboration Agreement represented a contract with a customer and should be accounted for in
accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for <FONT STYLE="white-space:nowrap">IK-412</FONT> and for <FONT STYLE="white-space:nowrap">IK-175.</FONT> The options to
receive worldwide development and commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be
performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
identified $78.7&nbsp;million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential
milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the distinct performance obligations identified above, the Company allocated the $78.7&nbsp;million transaction price based on relative estimated
standalone selling prices of each of its performance obligations as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$41.2&nbsp;million for research and development services for <FONT STYLE="white-space:nowrap">IK-175;</FONT> and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$37.5&nbsp;million for research and development services for <FONT STYLE="white-space:nowrap">IK-412.</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined the estimated standalone selling price for the research and development services based on internal estimates of
the costs to perform the services, including expected internal expenses and expenses with third parties, marked up to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development
activities include, the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed. The Company
recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2019 and 2020, the Company recognized revenue of $10.9&nbsp;million and $9.1&nbsp;million from the BMS
Collaboration Agreement, respectively. The consolidated balance sheet at September&nbsp;30, 2020 included deferred revenue of $55.8&nbsp;million related this agreement, of which $23.1&nbsp;million and $32.7&nbsp;million was classified as current and
<FONT STYLE="white-space:nowrap">non-current,</FONT> respectively. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for
<FONT STYLE="white-space:nowrap">IK-175</FONT> and <FONT STYLE="white-space:nowrap">IK-412</FONT><I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and September&nbsp;30, 2020, the authorized capital stock of the Company includes 75,727,268 shares of redeemable convertible
preferred stock, consisting of 28,000,000 shares of Series A Redeemable Convertible Preferred Stock (&#147;Series A Preferred Stock&#148;) and 47,727,268 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redeemable Convertible Preferred
Stock (&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148;), collectively known as Redeemable Convertible Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Issued</B><br><B>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Issued</B><br><B>and&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Stock has the following characteristics as of September&nbsp;30, 2020: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Voting </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written
consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such
holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Company&#146;s Amended and Restated Certificate of Incorporation, holders of
Preferred Stock shall vote together with the holders of Common Stock as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of outstanding shares of Preferred Stock shall be
entitled to elect three directors of the Company. The investors have agreed that two of the directors are to be named by one investor and the other director is to be named by a separate investor and have certain other special voting rights. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dividends </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Stock are entitled to an 8% <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend. Dividends are payable only when, as and
if declared by the Board. No dividends are payable to the common stockholders unless a dividend is also paid to Preferred Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were converted into common
stock.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through September&nbsp;30, 2020, no dividends have been declared or paid by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Liquidation Preference </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed liquidation
events, holders of shares of Preferred Stock then outstanding shall be entitled to receive the greater of (i)&nbsp;an amount per share equal to the Preferred Stock original issue price, plus any dividends declared but unpaid thereon or (ii)&nbsp;the
amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Conversion </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of one for one and are
automatically converted upon a qualified initial public offering or upon written consent of at least 75% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for
certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain dividends and distributions, and mergers and reorganizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Stock is eligible to be redeemed upon certain deemed-liquidation events which are outside of the Company&#146;s control. As a result, the shares
are presented outside of stockholders&#146; deficit. The shares will be accreted to redemption value if the events that would result in a deemed-liquidation event are considered probable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2019 and
September&nbsp;30, 2020, the Company had 113,372,392 and 113,795,082 shares of common stock authorized, respectively, of which 18,967,681 and 19,021,056 were issued and outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting: </B>The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of
stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation: </B>After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining assets of the Company are
distributed to the holders of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the number of shares reserved for issuance under the Company&#146;s 2016 Stock Incentive Plan (the &#147;Plan&#148;) was
18,281,483. On July&nbsp;23, 2020, the number of shares reserved under the Plan was increased by 968,152 shares to 19,249,635, as approved by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, no shares were available for grant under the Plan. The Plan provides that equity awards may be granted to employees and
nonemployees. The vesting periods for equity awards, which generally is four years, are determined by the Board of Directors. The contractual term for stock option awards is ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recorded during the nine-month periods ended September&nbsp;30, 2019 and 2020 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average fair value of the stock options granted during the nine months ended September&nbsp;30, 2019 and 2020,
was $0.36 and $0.49 per share, respectively. As of September&nbsp;30, 2020, the total unrecognized stock-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based compensation balance for unvested options was $4.1&nbsp;million which is expected to be recognized over 2.0 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity under the Plan for the nine months ended September&nbsp;30, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term&nbsp;(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,516,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,828,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled or forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(244,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,046,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,497,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,549,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intrinsic value of options exercised for nine months ended September&nbsp;30, 2019 and 2020 was $70&nbsp;thousand and
$13&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of each option award granted during the nine months ended September&nbsp;30, 2020 is estimated on the
date of grant using the Black-Scholes option pricing model and the weighted average assumptions noted in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected option term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes for the nine months ended September&nbsp;30, 2019 and 2020 have been calculated based on an estimated annual effective tax rate and certain
discrete items. For the nine months ended September&nbsp;30, 2019 and 2020, the Company recorded an income tax expense of $0&nbsp;million. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, the CARES Act was enacted in response to <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> Among other
things, the CARES Act permits corporate taxpayers to carryback net operating losses (&#147;NOLs&#148;) originating in 2018 through 2020 to each of the five preceding tax years. Further, the CARES Act retroactively and temporarily (for taxable years
beginning before January&nbsp;1, 2021) suspends application of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">80%-of-income</FONT></FONT> limitation on the use of NOLs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has never been examined by the Internal Revenue Service or any other jurisdiction for any tax years and, as such, all years within the applicable
statutes of limitations are potentially subject to audit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12. Research License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2015, the Company entered into an exclusive patent license agreement (the &#147;UT Austin License&#148;) to license certain technologies and
intellectual property rights from The University of Texas at Austin (the &#147;University&#148;), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or
abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $40&nbsp;thousand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, the Company shall make additional milestone payments in the aggregate of $4.7&nbsp;million to the University upon meeting certain development milestones during the term of the UT
Austin License. The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits. The Company will also be responsible
for reimbursing the University for certain patent-related costs incurred on its behalf. The Company incurred expenses totaling $87&nbsp;thousand and $55&nbsp;thousand related to patent reimbursement costs in the nine months ended September&nbsp;30,
2019 and 2020, respectively, and incurred $40&nbsp;thousand in expense related to licenses obtained from the party in the nine months ended September&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, the Company acquired IPR&amp;D on an Arrys&#146; immune-oncology candidate based on the intellectual property associated with Arrys&#146; AskAt
License Agreement (the &#147;AskAt License&#148;) as part of the acquisition of Arrys. Total consideration allocated to the technology was $28.5&nbsp;million and was recognized as research and development expense upon the acquisition. The AskAt
License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain
development milestones totaling $4&nbsp;million, as well as certain sales event milestones ranging from $50&nbsp;million to $250&nbsp;million contingent on sales in a calendar year, during the term of the License. The Company will pay the AskAt
royalties a percentage in the low single digits as defined in the License on any commercialized product sales related to the licensed technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
13. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2018, the Company entered into an operating lease to lease approximately 13,170 square feet of office, laboratory and vivarium
space at 50 Northern Ave, Boston, Massachusetts, expiring in December&nbsp;31, 2020. In July 2020, the Company extended the term of the lease through February 2021. The monthly rent per the lease, exclusive of operating expenses and real estate
taxes, is $93&nbsp;thousand, with the first payment of rent paid in January 2019. Under the terms of the lease, the Company received $160&nbsp;thousand towards a tenant improvement allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded rent expense of $0.8&nbsp;million for the nine months ended September&nbsp;30, 2019. The Company recognizes rent expense on a
straight-line basis over the lease period and recorded deferred rent for rent expense incurred but not yet paid and for tenant improvement allowance paid by the lessor, which resulted in a deferred balance of $151&nbsp;thousand at September&nbsp;30,
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2020, the Company adopted ASC 842. The components of the lease costs which are included in the condensed consolidated statements
of operations and comprehensive loss for the nine months ended September&nbsp;30, 2020 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental cash flow information relating to the Company&#146;s leases for the nine months ended September&nbsp;30, 2020 was
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities (operating cash
flows)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the weighted average remaining lease term and discount rate for its operating
lease as September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining lease term:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount Rate:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undiscounted future lease payments for the Company&#146;s operating lease as of&nbsp;September 30, 2020, were as follows
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Fiscal Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>Leases</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 (excluding the nine months ended September&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less amounts representing interest or imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;21, 2020, the Company entered into an operating lease agreement for 20,752 square feet of office, lab and animal
care facility space located in Boston, Massachusetts for the Company&#146;s new corporate headquarters. The commencement date of the lease is estimated to be February&nbsp;1, 2021 and the lease term is 63 months. The lease provides a three-month
free rent period, which will commence on the lease commencement date. The base rent at commencement is $145&nbsp;thousand a month and escalates by 3% annually. The Company provided a letter of credit to secure their obligations under the lease in
the initial amount of $0.9&nbsp;million that is recognized in other assets on the accompanying condensed consolidated balance sheets. The Company will recognize the right of use asset, operating lease liability and related lease costs beginning upon
the commencement of the lease in 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met at
September&nbsp;30, 2020 or royalties on future sales of specified products that have not yet occurred as of September&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 15. Related
Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into several agreements with investors and entities affiliated with an investor: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company received consulting services from an investor for $135&nbsp;thousand during the nine months ended
September&nbsp;30, 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into several agreements with a director and an entity affiliated with a director: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As discussed in Note 12 above, the Company has entered into a license agreement with the University, which was
affiliated with a director of the Company at the time of the agreement </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has engaged the University to perform certain research services. The Company incurred expenses
totaling $87&nbsp;thousand and $55&nbsp;thousand, respectively, related to patent reimbursement costs in the nine months ended September&nbsp;30, 2019 and 2020, respectively and incurred $40&nbsp;thousand in expense related to licenses obtained from
the party in the nine months ended September&nbsp;30, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company received consulting services from a director for $101&nbsp;thousand during the nine months ended
September&nbsp;30, 2019. The Company did not receive consulting services from a director during the nine months ended September&nbsp;30, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 16. Net Loss per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s potentially dilutive securities, which include redeemable convertible preferred stock, restricted stock, and stock options, have been
excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share
attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders at September&nbsp;30, 2019 and 2020 because including them would have had an
anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,727,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,759,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,046,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,486,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,774,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 17. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated all events or transactions that occurred from September&nbsp;30, 2020 through January&nbsp;8, 2021, the date the condensed consolidated
financial statements were available to be issued. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Common Stock and Preferred Stock Authorized for Issuance</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2020, the Board Amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of
shares of Common Stock authorized for issuance to 200,000,000 shares. In addition, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of Preferred Stock authorized for issuance to
83,590,362 shares, of which 28,000,000 are designated Series A Preferred Stock, 47,727,268 are designated Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and 7,863,094 are designated Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Amplify Medicines, Inc. Acquisition</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I></I>On October&nbsp;1, 2020 (the &#147;Acquisition Date&#148;), the Company acquired Amplify, a related party. Pursuant to the terms and
conditions of the Agreement and Plan of Merger (&#147;the Merger Agreement&#148;), the Company issued a total of 7,863,094 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock at a fair value of $1.31
for aggregate fair value of approximately $10.3&nbsp;million, net of issuance costs and 3,048,764 shares of Common Stock with a fair value of $1.03 for a total fair value of $3.1&nbsp;million related to the Common Stock issued to the shareholders of
Amplify as part of the Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Voting Rights </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U></U></I>Each holder of outstanding shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock
shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on
such matter. Except as provided by law or by the other provisions of the Company&#146;s Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Dividends </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U></U></I>The holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock are entitled to an 8% <FONT
STYLE="white-space:nowrap">non-cumulative</FONT> dividend. Dividends are payable only when, as and if declared by the Board. No </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
dividends are payable to the common stockholders unless a dividend is also paid to Preferred Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were
converted into common stock.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Liquidation Preference </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed
liquidation events, holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock then outstanding shall be entitled to receive the greater of (i)&nbsp;an amount per share equal to $0.8266466, plus any
dividends declared but unpaid thereon or (ii)&nbsp;the amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Conversion </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each
share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of one for one and are automatically converted upon a qualified initial public offering or upon written consent of at
least 75% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain
dividends and distributions, and mergers and reorganizations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Preferred Stock is eligible to be redeemed upon certain
deemed-liquidation events which are outside of the Company&#146;s control. As a result, the shares will be presented outside of stockholders&#146; deficit. The shares will be accreted to redemption value if the events that would result in a
deemed-liquidation event are considered probable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company first assessed if the acquisition represented a transaction which was under
common control or common ownership under both the variable interest entity guidance and the voting interest entity guidance. While Amplify is a related party to the Company, it is not under common control or common ownership with the Company. The
Company next assessed if Amplify, represented an asset or a business under FASB ASC Topic 805, <I>Business Combinations ASC 805, </I>as amended by ASU <FONT STYLE="white-space:nowrap">2017-01.</FONT> Under ASC 805, the Company determined that
Amplify did not constitute a business since substantially all of the fair value of the gross assets acquired is concentrated in a single asset, which is the intellectual property for the lead product candidate in development by Amplify. The
intellectual property acquired from Amplify is at an early stage of development and will require a significant investment of time and capital for development. There is no assurance that the Company will be successful in completing the additional
research and development activities. The intellectual property acquired is considered to have no alternative future use, and therefore the cost of acquisition allocated to it will be expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The transaction price was determined and allocated as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of equity instruments issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Transaction Price Allocation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities assumed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total transaction price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The fair value of the consideration issued was based on a probability weighted model that utilized two
different scenarios that utilized a market approach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">During the three-months ended December&nbsp;31, 2020, the Company recognized the <FONT
STYLE="white-space:nowrap">write-off</FONT> of the acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development intellectual property of $10.7&nbsp;million within Research and development expense. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Common Stock and Preferred Stock Authorized for Issuance</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2020, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of
shares of Common Stock authorized for issuance to 230,000,000 shares. In addition, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of Preferred Stock authorized for issuance to
169,396,576 shares, of which 28,000,000 are designated Series A Preferred Stock, 47,727,268 are designated Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, 7,863,094 are designated Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and 85,806,214 are designated Series B Preferred Stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Series B Redeemable Convertible Preferred Stock Issuance</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I></I>On December&nbsp;21, 2020, the Company issued a total of 85,806,214 shares of Series B Redeemable Convertible Preferred Stock at a
purchase price of $1.3985 per share for aggregate proceeds of approximately $116.4&nbsp;million, net of issuance costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Voting
Rights </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each holder of outstanding shares of Series B Redeemable Convertible Preferred Stock shall be entitled to cast the number
of votes equal to the number of whole shares of Common Stock into which the shares of Series B Redeemable Convertible Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such
matter. Except as provided by law or by the other provisions of the Company&#146;s Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Dividends </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The
holders of Series B Redeemable Convertible Preferred Stock are entitled to an 8% <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend in seniority to the Series A, <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT
STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Stock. Dividends are payable only when, as and if declared by the Board. No dividends are payable to the common stockholders unless a dividend is also paid to Preferred
Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were converted into common stock.<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Liquidation Preference </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed
liquidation events, holders of shares of Series B Redeemable Convertible Preferred Stock then outstanding shall be entitled to receive the greater of (i)&nbsp;an amount per share equal to $1.3985, plus any dividends declared but unpaid thereon or
(ii)&nbsp;the amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I><U>Conversion </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each
share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of one for one and are automatically converted upon a qualified initial public offering or upon written consent of at
least 75% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain
dividends and distributions, and mergers and reorganizations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Preferred Stock is eligible to be redeemed upon certain deemed-liquidation events which
are outside of the Company&#146;s control. As a result, the shares will be presented outside of stockholders&#146; deficit. The shares will be accreted to redemption value if the events that would result in a deemed-liquidation event are considered
probable. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Option Plan Increase</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2020, the number of shares reserved under the Plan was increased by 18,014,373 shares to 37,264,008, as approved by the
Board of Directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:62pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197729g65g59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:62pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:62pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY
PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:62pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Credit&nbsp;Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE> <P STYLE="font-size:62pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:62pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information Not Required in Prospectus </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the fees and expenses, other than underwriting discounts and commissions, payable in connection with the registration of the
common stock hereunder. All amounts are estimates except the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>to&nbsp;be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and mailing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be completed by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law, or DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising
out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including
attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay expenses
(including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain insurance on
behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to
indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted provisions in our fifth amended and restated certificate
of incorporation to be in effect upon the closing of this offering and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> to be in effect upon the effectiveness of this registration statement of which this prospectus forms a part
that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for
monetary damages or breach of fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations of liability do not alter director liability under the federal securities laws and do not
affect the availability of equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the <FONT STYLE="white-space:nowrap">by-laws</FONT> to be
in effect upon the effectiveness of this registration statement provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to
the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of
our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our executive officers. These
agreements provide that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146; fees (but excluding
judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or
proceeding arising out of that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of
expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein.
Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the
expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also maintain general liability insurance which covers certain liabilities of our
directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended, or the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement filed as Exhibit&nbsp;1.1 to this registration statement provides for indemnification of us and our directors and officers by the
underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recent Sales of Unregistered Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities
Act: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Issuances of Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding securities we have issued within the past three years that were not registered under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2019, we sold an aggregate of 14,545,450 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock to Celgene
Corporation (now Bristol-Myers Squibb Company) at a purchase price of $1.00 per share for $14.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2020, we issued 7,863,094 shares
of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock and 3,048,764 in connection with the AMI Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2020, we
sold an aggregate of 85,806,214 shares of Series B convertible preferred stock to 23 investors at a purchase price of $1.3985 for $120.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing sales of securities. Unless otherwise stated, the sales of
securities described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities Act, including Regulation&nbsp;D and Rule&nbsp;506 promulgated thereunder, as transactions by an issuer not involving a public
offering. All of the purchasers in these transactions represented to us in connection with their purchase that they were acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold
the securities for an indefinite period of time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption
from such registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(b)
Grants and Exercises of Stock Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2020, we have granted stock options to purchase an aggregate of 21,277,935 shares of
our common stock, with an exercise price of $0.16 to $0.63 per share, to employees, directors and consultants pursuant to the 2016 Stock Inventive Plan, or the 2016 Plan. Since January&nbsp;1, 2018, 288,376 shares of common stock have been issued
upon the exercise of stock options pursuant to the 2016 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuances of the securities described above were deemed to be exempt from registration
pursuant to Section&nbsp;4(a)(2) of the Securities Act or Rule&nbsp;701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of options are deemed to be
restricted securities for purposes of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibits </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Fifth Amended and Restated Certificate of Incorporation of Registrant, to be in effect immediately prior to the completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws of Registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of Registrant, to be in effect upon the effectiveness of this registration statement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Common Stock Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Investors&#146; Rights Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Goodwin Procter LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2016 Stock Incentive Plan, and form of award agreements thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Stock Option and Grant Plan, and form of award agreements thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2021 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Employment Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and between the Registrant and AskAt, Inc., dated December&nbsp;14, 2017, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Collaboration Agreement by and between the Registrant and Celgene Corporation (now Bristol-Myers Squibb), dated January&nbsp;14, 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Patent License Agreement by and between the Registrant and The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas System, dated March&nbsp;29, 2015, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of Subsidiaries of Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst&nbsp;&amp; Young, independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Goodwin Procter LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page).</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the
Securities and Exchange Commission. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financial Statements Schedules: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes
thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Act, may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant hereby undertakes that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) For
purposes of determining any liability under the Act, the information omitted from a form of prospectus filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in the form of prospectus filed by the Registrant
pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Act, shall be deemed to be part of this registration statement as of the time it was declared effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a
form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IKENA ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Mark Manfredi, Ph.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: President
and Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY AND SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each individual whose signature appears below hereby constitutes and appoints Mark Manfredi, Ph.D. and Douglas R. Carlson as such person&#146;s true and
lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent with full power of substitution and resubstitution, for such person in such person&#146;s name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule&nbsp;462(b) under the
Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or any substitute
or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as
amended, this registration statement and power of attorney have been signed by the following persons in the capacities and on the date indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Manfredi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Principal Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Douglas R. Carlson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>Principal Financial
Officer and Principal Accounting Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ron Renaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David Bonita, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Iain D. Dukes, D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Otello Stampacchia, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FOURTH AMENDED AND RESTATED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IKENA ONCOLOGY, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ikena
Oncology, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DOES HEREBY CERTIFY: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. That the name of this
corporation is Ikena Oncology, Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law on March&nbsp;2, 2016, under the name Kyn Therapeutics Inc., that an Amended and Restated Certificate of Incorporation
was filed on December&nbsp;18, 2018, that a Second Amended and Restated Certificate of Incorporation was filed on January&nbsp;11, 2019 and that a Third Amended and Restated Certificate of Incorporation was filed on October&nbsp;1, 2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. That the Board of Directors of this corporation duly adopted resolutions proposing to amend and restate the Third Amended and Restated
Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit
the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">RESOLVED,
that the Third Amended and Restated Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of this corporation is Ikena Oncology, Inc. (the &#147;<B>Corporation</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209&nbsp;Orange
Street, in the City of Wilmington, County of New&nbsp;Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD: </B>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH: </B>The total number of shares of all classes of stock which
the Corporation shall have authority to issue is (i) 230,000,000 shares of Common Stock, $0.001 par value per share (&#147;<B>Common Stock</B>&#148;), and (ii) 169,396,576 shares of Preferred Stock, $0.001 par value per share (&#147;<B>Preferred
Stock</B>&#148;), of which 28,000,000 shall be designated Series A Preferred Stock (the &#147;<B>Series A Preferred Stock</B>&#148;), 47,727,268 shall be designated Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (the
&#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#148;), 7,863,094 shall be designated Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock (the &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred Stock</B>&#148;) and 85,806,214 shall be designated Series B Preferred Stock (the &#147;<B>Series B Preferred Stock</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges and rights, and
the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. COMMON STOCK
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the
rights, powers and preferences of the holders of the Preferred Stock set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of the Common Stock
are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such,
shall not be entitled to vote on any amendment to the Fourth Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, this &#147;<B>Certificate of Incorporation</B>&#148;) that relates solely to the terms
of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation
or pursuant to the General Corporation Law. There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote
of the holders of one or more series of Preferred Stock that may be required by the terms of this Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes
represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28,000,000
shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>S</B><B>eries A Preferred Stock</B>&#148; 47,727,268 shares of authorized Preferred Stock are hereby designated &#147;<B>Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#148;, 7,863,094 shares of authorized Preferred Stock are hereby designated &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</B>&#148;, and 85,806,214 shares
of authorized Preferred Stock are hereby designated &#147;<B>Series B Preferred Stock</B>&#148; with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. The Series A Preferred Stock, the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock are referred to collectively herein as the &#147;<B>Series <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock</B>&#148;. Unless otherwise indicated, references to &#147;sections&#148; or &#147;subsections&#148; in this Part B of this Article Fourth refer to sections and subsections of Part B
of this Article Fourth. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1 The holders of Series B Preferred Stock, prior and in preference to the holders of each series of Series <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock and the holders of Common Stock, shall be entitled to receive, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the
Series B Original Issue Price (as defined below) per annum on each outstanding share of Series B Preferred Stock. Such dividends shall be payable only when, as and if declared by the Board of Directors of the Corporation (the
&#147;<B>Board</B>&#148;) and shall be <FONT STYLE="white-space:nowrap">non-cumulative</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2 The holders of each series of Series <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock, prior and in preference to the holders of Common Stock, shall be entitled to receive on a <I>pari passu</I> basis, but only out of funds that are legally available therefor, cash
dividends at the rate of eight percent (8%) of the Series A Original Issue Price (as defined below), the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price (as defined below), or the Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price (as defined below) as applicable, per annum on each outstanding share of Series A Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, and Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, respectively. Such dividends shall be payable only when, as and if declared by the Board and shall be <FONT STYLE="white-space:nowrap">non-cumulative.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.3 The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the
Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to obtaining any consents required elsewhere in this Certificate of Incorporation) the holders of Preferred Stock then outstanding
shall first receive, or simultaneously receive, in addition to the dividends payable pursuant to <U>Subsection 1.1</U> and <U>Subsection 1.2</U>, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (A)&nbsp;in the
case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of the applicable series of Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such
class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Preferred Stock, in each case
calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of the applicable series of
Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Applicable Original Issue Price (as defined below);
<U>provided</U> that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of the applicable series of
Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest dividend. The &#147;<B>S</B><B>eries A Original Issue
Price</B>&#148; shall mean $1.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock. The &#147;<B>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Original Issue Price</B>&#148; shall mean $1.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. The &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price</B>&#148; shall mean $0.8266466 per share, subject to appropriate adjustment in the event of any
stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. The &#147;<B>Series B Original Issue Price</B>&#148; shall mean $1.3985 per share,
subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock. The &#147;<B>Applicable Original Issue Price</B>&#148; shall mean, as the
context so requires, the Series A Original Issue Price with respect to the Series A Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price with respect to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and the Series B Original Issue Price with respect to the Series B
Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset
Sales</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Series B Preferred Stock</U>. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Corporation (a &#147;<B>Liquidation Event</B>&#148;) or Deemed Liquidation Event (as defined below), the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of
the assets of the Corporation available for distribution to its stockholders before any payment shall be made to the holders shares of each series of Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT>
Preferred Stock and Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;one (1) times the Series B Original Issue Price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per
share as would have been payable had all shares of Series B Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such Liquidation Event or Deemed Liquidation Event (the amounts payable
pursuant to this sentence is hereinafter referred to as the &#147;<B>S</B><B>eries B Liquidation Amoun</B><B>t</B>&#148;). If upon any such Liquidation Event or Deemed Liquidation Event, the assets of the Corporation available for distribution to
its stockholders shall be insufficient to pay the holders of shares of Series B Preferred Stock the full amount to which they shall be entitled under this <U>Subsection</U><U></U><U>&nbsp;2.1</U>, the holders of shares of Series B Preferred Stock
shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with
respect to such shares were paid in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Preferential Payments to Holders of Series <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock</U>. In the event of any Liquidation Event or Deemed Liquidation Event (as defined below), after the payment in full of the Series B Liquidation Amounts for all shares of Series B
Preferred Stock, the holders of shares of each series of Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock then outstanding shall be entitled to be paid out of the assets of the
Corporation available for distribution to its stockholders before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;(A) in the case of Series A
Preferred Stock, one (1)&nbsp;times the Series A Original Issue Price, plus any dividends declared but unpaid thereon, (B)&nbsp;in the case of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, one (1)&nbsp;times the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Original Issue Price, plus any dividends declared but unpaid thereon, and (C)&nbsp;in the case of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, one (1)&nbsp;times the Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Original Issue Price, plus any dividends declared but unpaid thereon or (ii)&nbsp;such amount per share as would have been payable had all shares of such series of Series <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such Liquidation Event or Deemed Liquidation Event (the amounts payable pursuant
to this sentence is hereinafter referred to as the &#147;<B>Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Liquidation Amounts</B>&#148;). If upon any such Liquidation Event or Deemed Liquidation
Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred
Stock the full amount to which they shall be entitled under this <U>Subsection</U><U></U><U>&nbsp;2.2</U>, the holders of shares of Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock
shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with
respect to such shares were paid in full. The &#147;<B>Applicable Liquidation Amount</B>&#148; shall mean, as the context so requires, the Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Liquidation
Amount with respect to the Series A Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, or Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, as applicable, or the Series B Liquidation Amount with
respect to the Series B Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Payments to Holders of Common Stock</U>. In the event of any Liquidation Event or
Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Series B Preferred Stock and to the holders of shares of Series
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock as set forth in <U>Subsections 2.1</U> and <U>2.2</U> above, the remaining assets of the Corporation available for distribution to its
stockholders shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4 <U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.1 <U>Definition</U>. Each of the following events shall be considered a &#147;<B>Deemed Liquidation Event</B>&#148; unless the Required
Holders (as defined below) voting or consenting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, elect otherwise by written notice sent to the Corporation at least five (5)&nbsp;days prior to the effective
date of any such event: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) a merger or consolidation in which </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation involving the Corporation or a subsidiary in which
the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or
consolidation (in substantially the same proportions and with substantially the same rights and privileges), a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or
resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the
Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries
of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a
wholly owned subsidiary of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all purposes of this Certificate of Incorporation, the term &#147;<B>Required Holders</B>&#148; shall
mean the affirmative consent or vote of the holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, which majority must
include the affirmative consent or vote of the holders of at least seventy percent (70%) of the outstanding shares of Series B Preferred Stock, voting as a separate class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 2.4.1(a)(i)</U> unless the
agreement or plan of merger or consolidation for such transaction (the &#147;<B>Merger Agreement</B>&#148;) provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the
Corporation in accordance with <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event referred
to in <U>Subsection 2.4.1(a)(ii)</U>, or <U>2.4.1(b)</U> above, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90)&nbsp;days after such Deemed Liquidation Event, then (i)&nbsp;the
Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Deemed Liquidation Event advising such holders of their right (and the
requirements to be met to secure such right) pursuant to the terms of the following <U>clause (ii)</U>&nbsp;to require the redemption of such shares of Preferred Stock, and (ii)&nbsp;if the Required Holders so request in a written instrument
delivered to the Corporation not later than one hundred twenty (120)&nbsp;days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained
liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board (the &#147;<B>Net Proceeds</B>&#148;)), all to the extent permitted by Delaware law governing distributions to stockholders, on the one
hundred fiftieth (150<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after such Deemed Liquidation Event (the &#147;<B>Redemption Date</B>&#148;), to redeem all outstanding shares of each series of Preferred Stock at a price per share
equal to the Applicable Liquidation Amount (the &#147;<B>Redemption Price</B>&#148;). Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Net Proceeds are not sufficient to redeem all outstanding
shares of Preferred Stock, or if the Corporation does not have sufficient lawfully available funds to effect such redemption, the Corporation shall first ratably redeem each holder&#146;s shares of Series B Preferred Stock to the fullest extent of
such available amounts based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the available amounts were sufficient to redeem all such shares, and second, ratably redeem each holder&#146;s shares
of Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock to the fullest extent of such remaining available amounts after the payment to holders of Series B Preferred Stock of all amounts
owed thereto pursuant to this <U>Subsection 2.4.2(b)</U> based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the available amounts were sufficient to redeem all such shares. Prior to the
distribution or redemption provided for in this <U>Subsection 2.4.2(b)</U>, the Corporation shall not expend or dissipate the consideration received from such Deemed Liquidation Event, except to discharge expenses incurred in connection with such
Deemed Liquidation Event or, to the extent approved by the Required Holders, to discharge expenses incurred in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) The Corporation shall send written notice of a required redemption pursuant to
<U>Subsection 2.4.2(b)</U> (the &#147;<B>Redemption Notice</B>&#148;) to each holder of record of Preferred Stock not less than forty (40)&nbsp;days prior to the Redemption Date. The Redemption Notice shall state: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of shares of each series of Preferred Stock held by the holder that the Corporation shall redeem on
the Redemption Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Redemption Date and the Redemption Price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date upon which the holder&#146;s right to convert such shares terminates (as determined in accordance with
<U>Subsection 4.1.2</U>); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner
and at the place designated, his, her or its certificate or certificates representing the shares of each series of Preferred Stock to be redeemed. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) On or before the Redemption Date, each holder of shares of Preferred Stock, unless such holder has exercised his, her or its right to
convert such shares as provided in <U>Section</U><U></U><U>&nbsp;4.1</U>, shall, if a holder of shares in certificated form, surrender the certificate or certificates representing such shares (or, if such registered holder alleges that such
certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged
loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the Redemption Price for such shares shall be payable to the order of the person whose name appears
on such certificate or certificates as the owner thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the Redemption Notice shall have been duly given, and if on the
applicable Redemption Date the Redemption Price payable upon redemption of the shares of Preferred Stock to be redeemed on the Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available
therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, dividends with respect to such shares of Preferred Stock shall cease to
accrue after the Redemption Date and all rights with respect to such shares shall forthwith after the Redemption Date terminate, except only the right of the holders to receive the Redemption Price without interest upon surrender of any such
certificate or certificates therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.3 <U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the
holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid or distributed to such
holders by the Corporation or the acquiring person, firm or other entity. The value of such property, rights or securities shall be determined in good faith by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.4.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed
Liquidation Event pursuant to <U>Subsection 2.4.1(a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B>Additional Consideration</B>&#148;), the
Merger Agreement shall provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;) shall be allocated among the holders of capital stock of the Corporation
in accordance with <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes
payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U> after taking into
account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Subsection 2.4.4</U>, consideration placed into escrow or retained as a holdback to be available for satisfaction of
indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.
<U>Voting</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at
any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of
Common Stock into which the shares of the applicable series of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other
provisions of the Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the
number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of
capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation
Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. The holders of record of the shares of Series B Preferred
Stock, exclusively and as a separate class, shall be entitled to elect two (2)&nbsp;directors of the Corporation (the &#147;<B>Series B Preferred Directors</B>&#148;), the holders of record of the shares of Series <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock, exclusively and as a separate class, shall be entitled to elect three (3)&nbsp;directors of the Corporation (the &#147;<B>Series A Preferred Director</B><B>s</B>&#148;, together
with the Series B Directors, the &#147;<B>Preferred Directors</B>&#148;) and the holders of record of the shares of Common Stock, exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation. Any director
elected as provided in the preceding sentence may be removed only by the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such
stockholders duly called for that purpose or pursuant to a written consent of stockholders. If the holders of shares of Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for
which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this <U>Subsection</U><U></U><U>&nbsp;3.2</U>, then any directorship not so filled shall remain vacant until such time as the
holders of the Preferred Stock or Common Stock, as the case may be, elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the
stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate<B> </B>class. The holders of record of the shares of Common Stock and of any other class or series of voting stock
(including the Preferred Stock), exclusively and voting together as a single class, shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose of electing a director, the presence
in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. A vacancy in any directorship filled by the
holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series. The rights of the holders of the Preferred Stock and the rights of the holders of the Common Stock under the
first sentence of this <U>Subsection 3.2</U> shall terminate on the first date following the Series B Original Issue Date on which there are no shares of Preferred Stock issued or outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when at least 33,879,315 shares of Preferred Stock (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger,
consolidation or otherwise, do any of the following, or permit or cause any subsidiary of the Corporation to do any of the following, without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or
affirmative vote of the Required Holders, given in writing or by vote at a meeting, consenting or voting (as the case may be) as a single class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void
<I>ab initio</I>, and of no force or effect.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business and
affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 amend, alter, repeal or waive any provision of the Certificate of Incorporation or Bylaws of the Corporation in a manner that adversely
affects any of the designations, preferences, rights, privileges or powers of the Series A Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock or
Series B Preferred Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional
class or series of capital stock that ranks senior to or pari passu with the Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of
redemption or voting, or increase the authorized number of shares of Preferred Stock or increase the authorized number of shares of any additional class or series of capital stock that ranks senior to or pari passu with the Preferred Stock with
respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption or voting; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 (i) reclassify, alter or amend any existing security of the Corporation that is
<I>pari passu</I> with the Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption or voting, if such reclassification, alteration or
amendment would render such other security senior to the Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to the Preferred Stock in
respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption or voting, if such reclassification, alteration or amendment would render such other security
senior to or <I>pari passu</I> with the Preferred Stock in respect of any such right, preference or privilege;<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any
shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii)&nbsp;distributions upon a Liquidation Event or Deemed Liquidation Event in
accordance with <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U> of the Certificate of Incorporation, (iii)&nbsp;dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and for which an
appropriate adjustment is made to the Applicable Conversion Price (as defined below) and (iv)&nbsp;repurchases of Common Stock approved by the Board (including all of the Preferred Directors) from former employees, officers, directors, consultants
or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at no greater than the original purchase price thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 create, or authorize the creation of, or issue, or authorize the issuance of, or guarantee or assume, or authorize the guarantee or
assumption of, any debt security if the aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would exceed $250,000, other than (i)&nbsp;equipment leases or bank lines of credit and (ii)&nbsp;any
debt security that has received the prior approval of the Board, including the approval of a majority of the Preferred Directors; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7
hire, terminate or change the compensation of the executive officers of the Corporation or its subsidiaries, unless such hiring, termination or change was approved by the Board (including approval by a majority of the Preferred Directors); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 sell, transfer, license, pledge or encumber all or substantially all of the Corporation&#146;s technology or intellectual property,
other than licenses granted in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 enter into or be a party to any transaction with any officer or
employee of the Corporation or any of its subsidiaries or any &#147;associate&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Securities Exchange Act of 1934, as amended) thereof, unless such transaction
was approved by the Board (including approval by a majority of the Preferred Directors, other than any Preferred Director that is an interested party with respect to such transaction); such transaction was conducted on an arms-length basis and upon
fair and reasonable terms that were approved by the Board; or a preferred equity financing in which the Corporation complies with Section&nbsp;4 of the Fourth Amended and Restated Investors&#146; Rights Agreement, by and among the Company, the
investors listed therein and certain stockholders; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 increase the number of shares of Common Stock available for issuance under the
Corporation&#146;s 2016 Stock Incentive Plan, as amended (the &#147;<B>2016 Plan</B>&#148;) or to adopt any new stock incentive or stock option plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.11 create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one or more other subsidiaries)
by the Corporation, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose
(in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.12
increase or decrease the authorized number of directors constituting the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Series A Preferred Stock Protective Provision</U>.
At any time when at least a majority of the shares of Series A Preferred Stock issued and outstanding on or about the date that this Certificate of Incorporation is filed are issued and outstanding, the Corporation shall not, either directly or
indirectly (including through any subsidiary of the Corporation) by amendment, merger, consolidation, reclassification, reorganization or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate
of Incorporation and without prejudice to any other rights available to the holders of Series A Preferred Stock) the written consent or affirmative vote of holders of at least seventy percent (70%) of Series A Preferred Stock, given in writing or by
vote at a meeting, consenting or voting (as the case may be) as a single class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect: (a)&nbsp;alter, amend
or waive any provision of this Certificate of Incorporation of the Corporation, as amended from time to time, or Bylaws of the Corporation in a manner that disproportionately and adversely affects the rights, preferences, privileges or powers of the
Series A Preferred Stock or (b)&nbsp;increase the number of authorized shares of Series A Preferred Stock, <U>provided</U>, that the creation or issuance of a new series of senior preferred stock and correlative amendments to this Certificate of
Incorporation shall not in and of itself be considered disproportionately adverse to the rights, preferences or privileges of the Series A Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock Protective Provision</U>. At any time when at least a majority of
the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issued and outstanding on or about the date that this Certificate of Incorporation is filed are issued and outstanding, the Corporation shall not, either directly or
indirectly (including through any subsidiary of the Corporation) by amendment, merger, consolidation, reclassification, reorganization or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate
of Incorporation and without prejudice to any other rights available to the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock) the written consent or affirmative vote of holders of at least sixty-five percent (65%) of
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (which holders shall include Atlas Venture Fund X, L.P., and its affiliates) given in writing or by vote at a meeting, consenting or voting (as the case may be) as a single class,
and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect: (a)&nbsp;alter, amend or waive any provision of the Certificate of Incorporation of the Corporation,
as amended from time to time, or Bylaws of the Corporation in a manner that disproportionately and adversely affects the rights, preferences, privileges or powers of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock or
(b)&nbsp;increase the number of authorized shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, <U>provided</U>, that the creation or issuance of a new series of senior preferred stock and correlative amendments to this
Certificate of Incorporation shall not in and of itself be considered disproportionately adverse to the rights, preferences or privileges of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.6 <U>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock Protective
Provision</U>. At any time when at least a majority of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock issued and outstanding on or about the date that this Certificate of Incorporation is filed are issued and
outstanding, the Corporation shall not, either directly or indirectly (including through any subsidiary of the Corporation) by amendment, merger, consolidation, reclassification, reorganization or otherwise, do any of the following without (in
addition to any other vote required by law or this Certificate of Incorporation and without prejudice to any other rights available to the holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock) the written consent or
affirmative vote of holders of at least sixty-five percent (65%) of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock (which holders shall include Atlas Venture Fund XI, L.P., and its affiliates) given in writing or by vote at a
meeting, consenting or voting (as the case may be) as a single class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect: (a)&nbsp;alter, amend or waive
any provision of the Certificate of Incorporation of the Corporation, as amended from time to time, or Bylaws of the Corporation in a manner that disproportionately and adversely affects the rights, preferences, privileges or powers of the Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock or (b)&nbsp;increase the number of authorized shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, <U>provided</U>, that the creation or issuance of a new series of
senior preferred stock and correlative amendments to this Certificate of Incorporation shall not in and of itself be considered disproportionately adverse to the rights, preferences or privileges of the Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.7 <U>Series B Preferred Stock Protective Provision</U>. At any time when
at least a majority of the shares of Series B Preferred Stock issued on or about the date that this Certificate of Incorporation is filed are issued and outstanding, the Corporation shall not, either directly or indirectly (including through any
subsidiary of the Corporation) by amendment, merger, consolidation, reclassification, reorganization or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate of Incorporation and without
prejudice to any other rights available to the holders of Series B Preferred Stock) the written consent or affirmative vote of holders of at least seventy percent (70%) of Series B Preferred Stock given in writing or by vote at a meeting, consenting
or voting (as the case may be) as a separate class (the &#147;<B>Series B Required Holders</B>&#148;), and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect:
(a)&nbsp;alter, amend or waive any provision of the Certificate of Incorporation of the Corporation, as amended from time to time, or Bylaws of the Corporation in a manner that disproportionately and adversely affects the rights, preferences,
privileges or powers of the Series B Preferred Stock or (b)&nbsp;increase the number of authorized shares of Series B Preferred Stock, <U>provided</U>, that the creation or issuance of a new series of senior preferred stock and correlative
amendments to this Certificate of Incorporation shall not in and of itself be considered disproportionately adverse to the rights, preferences or privileges of the Series B Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional</U><U> Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B>Conversion Rights</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from
time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the applicable
Original Issue Price with respect to such share of Preferred Stock by the Applicable Conversion Price applicable to such share, in each case as in effect at the time of conversion; provided that such holder may waive such option to convert pursuant
to this <U>Subsection 4.1.1</U> upon written notice to the Company. The &#147;<B>Applicable</B> <B>Conversion Price</B>&#148; shall initially be equal to (w)&nbsp;with respect to each share of the Series A Preferred Stock, the Series A Original
Issue Price, (x)&nbsp;with respect to each share of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Original Issue Price, (y)&nbsp;with respect to each share of the
Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price and (z)&nbsp;with respect to each share of the Series B Preferred Stock, the Series B Original Issue
Price. Such initial Applicable Conversion Price, and the rate at which shares of each series of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a Liquidation Event or a Deemed Liquidation Event, the Conversion Rights shall
terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu of any
fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not
fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock
issuable upon such conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own
transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b)&nbsp;surrender the certificate or certificates for such
shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any
claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation
serves as its own transfer agent). Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation, any certificates surrendered for
conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of
business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of
conversion (the &#147;<B>Conversion Time</B>&#148;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the
Conversion Time, (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the
provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in
<U>Subsection</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock so converted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall, at all times when the Preferred
Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time
to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the
Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation,
engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action which would cause an adjustment reducing an Applicable Conversion Price below the then
par value of the shares of Common Stock issuable upon conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally
issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted Applicable Conversion Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no
longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to
receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in <U>Subsection</U><U></U><U>&nbsp;4.2</U> and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred Stock so
converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number
of shares of Preferred Stock accordingly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no adjustment to such Applicable
Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes
that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax
which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be
made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments</U><U> to Applicable Conversion Price for Diluting Issues</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this Certificate of Incorporation, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Option</B>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or
Convertible Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>S</B><B>eries B Original Issue Date</B>&#148; shall mean the date on which the first share of Series
B Preferred Stock was issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Convertible Securities</B>&#148; shall mean any evidences of indebtedness, shares or other
securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Additional
Shares of Common Stock</B>&#148; shall mean all shares of Common Stock issued (or, pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Series B Original Issue Date, other than (1)&nbsp;the
following shares of Common Stock and (2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;<B>Exempted Securities</B>&#148;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Preferred
Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to the 2016 Plan, any other stock incentive or stock option plan approved by the Required Holders in accordance with <U>Subsection 3.3.9</U> or a plan, agreement or arrangement approved by the Board,
including the approval of a majority of the Preferred Directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board, including the approval of a majority of the Preferred Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued pursuant to the acquisition of another
corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or pursuant to a joint venture agreement, <U>provided</U> that such issuances are approved by the Board, including the approval of a
majority of the Preferred Directors; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board, including the approval of a majority of the Preferred Directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Applicable Conversion Price</U>. No adjustment in any Applicable Conversion Price shall be made as the result of the
issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Required Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional
Shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Series B Original Issue Date shall issue any Options or Convertible
Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities,
then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained
therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be
Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to any Applicable Conversion Price
pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms
pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any
such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the
Applicable Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Applicable Conversion Price as would have obtained had
such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause&nbsp;(b) shall have the effect of increasing any Applicable
Conversion Price to an amount which exceeds the lower of (i)&nbsp;such Applicable Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;such
Applicable Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security)
between the original adjustment date and such readjustment date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding
Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to any Applicable Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U> (either because the consideration
per share (determined pursuant to <U>Subsection 4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than any Applicable Conversion Price then in effect, or because such Option or Convertible Security was
issued before the Series B Original Issue Date), are revised after the Series B Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding
automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or
exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the
Additional Shares of Common Stock subject thereto (determined in the manner provided in <U>Subsection 4.4.3(a)</U>) shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option or unconverted or
unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to any Applicable Conversion Price pursuant to the terms of
<U>Subsection</U><U></U><U>&nbsp;4.4.4</U>, such Applicable Conversion Price shall be readjusted to such Applicable Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or
the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment
to any Applicable Conversion Price provided for in this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions
for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c) of this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>). If the number of shares of Common Stock issuable upon the exercise, conversion
and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended,
any adjustment to any Applicable Conversion Price that would result under the terms of this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or
amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to such Applicable Conversion Price that such issuance or amendment took place at the time such calculation
can first be made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Applicable Conversion Price Upon Issuance of Additional Shares of Common Stock</U>. In the
event the Corporation shall at any time or from time to time after the Series B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
<U>Subsection</U><U></U><U>&nbsp;4.4.3</U>), without consideration or for a consideration per share less than such Applicable Conversion Price in effect immediately prior to such issue, then such Applicable Conversion Price shall be reduced,
concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> = (CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> &times; (A + B))
&divide; (A + C). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>&#148; shall mean the Applicable Conversion Price in effect immediately
after such issue of Additional Shares of Common Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148; shall mean the
Applicable Conversion Price in effect immediately prior to such issue of Additional Shares of Common Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;A&#148; shall mean
the number of shares of Common Stock outstanding immediately prior to such issue of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately
prior to such issue or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had
been issued at a price per share equal to CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;C&#148; shall mean the number of such Additional Shares of Common
Stock issued in such transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of <U>Subsection 4.4</U>, the consideration
received by the Corporation for the issue of any Additional Shares of Common Stock shall be computed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and
Property</U>: Such consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii) above, as determined in good faith by the Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration)
payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities, by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are
a part of one transaction or a series of related transactions and that would result in an adjustment to any Applicable Conversion Price pursuant to the terms of <U>Subsection 4.4.4</U>, and such issuance dates occur within a period of no more than
ninety (90)&nbsp;days from the first such issuance to the final such issuance, then, upon the final such issuance, such Applicable Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first
such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any time or from time to time after the Series B Original
Issue Date effect a subdivision of the outstanding Common Stock, each Applicable Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of
each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Series B Original Issue Date combine the
outstanding shares of Common Stock, each Applicable Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series
shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or combination becomes
effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation
at any time or from time to time after the Series B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in
additional shares of Common Stock, then and in each such event each Applicable Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as
of the close of business on such record date, by multiplying each Applicable Conversion Price then in effect by a fraction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the
numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made
on the date fixed therefor, such Applicable Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter such Applicable Conversion Price shall be adjusted pursuant to this subsection as of the time
of actual payment of such dividends or distributions; and (b)&nbsp;no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number
of shares of Common Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the Series B
Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of
Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock
shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have
received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of
<U>Subsection 2.4</U>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for
securities, cash or other property (other than a transaction covered by <U>Subsections 4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred
Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the
Corporation issuable upon conversion of one share of the applicable series of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such
transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board) shall be made in the application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of
the holders of the Preferred Stock, to the end that the provisions set forth in this <U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to changes in and other adjustments of any Applicable Conversion Price) shall thereafter be
applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of any Applicable Conversion Price pursuant
to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10)&nbsp;days thereafter, compute such adjustment or readjustment in accordance with the
terms hereof and furnish to each holder of the applicable series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the Preferred Stock is
convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of such series of Preferred Stock (but
in any event not later than ten (10)&nbsp;days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the Applicable Conversion Price then in effect, and (ii)&nbsp;the number of shares of Common Stock and
the amount, if any, of other securities, cash or property which then would be received upon the conversion of the applicable series of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or
to receive any other security; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the Common Stock of the
Corporation, or any Liquidation Event or Deemed Liquidation Event, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or
other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange
applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10)&nbsp;days prior to the record date or effective date for the event specified in such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. Upon either (a)&nbsp;the closing of the sale of shares of Common Stock to the public at a price of at least 2.0978
per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended, resulting in at least $75,000,000 of gross proceeds to the Corporation, with the Company shares being listed on the New York Stock Exchange or NASDAQ (a &#147;<U>Qualified
IPO</U>&#148;) or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the Required Holders for the conversion of all outstanding shares of Preferred Stock (the date and time specified or the time of the
event specified in such vote or written consent is referred to herein as the &#147;<B>Mandatory Conversion Time</B>&#148;), then (i)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the
then effective conversion rate as calculated pursuant to <U>Subsection 4.1.1.</U> and (ii)&nbsp;such shares may not be reissued by the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory
Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time.
Upon receipt of such notice, each holder of shares of Preferred Stock shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost
certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the
Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the
Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <U>Subsection 5.1</U>, including the rights, if any, to receive
notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights
of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Subsection 5.2</U>. As soon as
practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder,
or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b)&nbsp;pay cash as provided in
<U>Subsection</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted
Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized
number of shares of Preferred Stock accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redeemed or Otherwise Acquired Shares</U>. Any shares of Preferred Stock that are
redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may
exercise any voting or other rights granted to the holders of Preferred Stock following any redemption or acquisition of Preferred Stock by the Corporation or any of its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Waiver</U>. Any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all
holders of Preferred Stock by the affirmative written consent or vote of the Required Holders; provided, however, that the waiver of any approval or consent rights specifically granted hereunder to the holders of Series B Preferred Stock shall
additionally require the affirmative written consent or vote of the Series B Required Holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Notices</U>. Any notice required or
permitted by the provisions of this Article Fourth to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication
in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH: </B>Subject to any additional vote required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation of
the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH: </B>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH: </B>Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide.
The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH: </B>To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Eighth to authorize corporate action
further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article Eighth by the
stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such
director occurring prior to, such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH: </B><B></B>To the fullest extent permitted by applicable law, the
Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification)
through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by <U>Section</U><U></U><U>&nbsp;145</U> of
the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this Article Ninth shall not adversely
affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH: </B>The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being
offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the
possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such
holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, &#147;<B>Covered Persons</B>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or
otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.
The foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. This Fourth Amended and Restated Certificate of Incorporation, which restates and integrates and amends the provisions of this corporation&#146;s
Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Fourth Amended and Restated Certificate of Incorporation has
been executed on this 18th day of December, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Manfredi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Manfredi, Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>B<SMALL>YLAWS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>OF</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>K<SMALL>YN</SMALL> T<SMALL>HERAPEUTICS</SMALL> I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARTICLE I STOCKHOLDERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Place of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annual Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Special Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notice of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Voting List</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Quorum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Adjournments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Voting and Proxies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Action at Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Conduct of Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">1.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Action without Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARTICLE II DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Powers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Number, Election and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board; Vice Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Quorum</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Action at Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Removal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vacancies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Resignation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regular Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Special Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notice of Special Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Meetings by Conference Communications Equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Action by Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Committees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">2.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Compensation of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARTICLE III OFFICERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>7</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Titles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Election</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tenure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Resignation and Removal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vacancies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President; Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice Presidents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Secretary and Assistant Secretaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Treasurer and Assistant Treasurers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Salaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delegation of Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARTICLE IV CAPITAL STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Issuance of Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock Certificates; Uncertificated Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transfers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lost, Stolen or Destroyed Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Record Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regulations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARTICLE V GENERAL PROVISIONS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>12</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fiscal Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Corporate Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Waiver of Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Voting of Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Evidence of Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pronouns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARTICLE VI AMENDMENTS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By the Stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCKHOLDERS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<U>Place of Meetings</U>. All meetings of stockholders shall be held at such place as may be designated from time to time by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President or, if not so designated, at
the principal office of the corporation. The Board of Directors may, in its sole discretion, determine that a meeting shall not be held at any place, but may instead be held solely by means of remote communication in a manner consistent with the
General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Annual Meeting</U>. The annual meeting of stockholders for the election of
directors and for the transaction of such other business as may properly be brought before the meeting shall be held on a date and at a time designated by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the
President (which date shall not be a legal holiday in the place where the meeting is to be held). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Special Meetings</U>. Special
meetings of stockholders for any purpose or purposes may be called at any time by only the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President, and may not be called by any other person or persons. The Board
of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of
meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Notice of Meetings</U>. Except as otherwise provided by law, notice of each meeting of stockholders, whether annual or
special, shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. Without limiting the manner by which notice otherwise may be given to stockholders, any notice shall
be effective if given by a form of electronic transmission consented to (in a manner consistent with the General Corporation Law of the State of Delaware) by the stockholder to whom the notice is given. The notices of all meetings shall state the
place, if any, date and time of the meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting. The notice of a special meeting shall state, in
addition, the purpose or purposes for which the meeting is called. If notice is given by mail, such notice shall be deemed given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s
address as it appears on the records of the corporation. If notice is given by electronic transmission, such notice shall be deemed given at the time specified in Section&nbsp;232 of the General Corporation Law of the State of Delaware. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Voting List</U>. The Secretary shall prepare, at least 10 days before every meeting
of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be
open to the examination of any stockholder, for any purpose germane to the meeting, for a period of at least 10 days prior to the meeting: (a)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access
to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the principal place of business of the corporation. If the meeting is to be held at a physical location (and not solely by means of remote
communication), then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote
communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the
notice of the meeting. The list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 <U>Quorum</U>. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, the holders of a majority in voting
power of the shares of the capital stock of the corporation issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board of Directors in its sole
discretion, or represented by proxy, shall constitute a quorum for the transaction of business; provided, however, that where a separate vote by a class or classes or series of capital stock is required by law or the Certificate of Incorporation,
the holders of a majority in voting power of the shares of such class or classes or series of the capital stock of the corporation issued and outstanding and entitled to vote on such matter, present in person, present by means of remote
communication in a manner, if any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum entitled to take action with respect to the vote on such matter. A quorum, once established at a
meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 <U>Adjournments</U>. Any meeting of
stockholders may be adjourned from time to time to any other time and to any other place at which a meeting of stockholders may be held under these Bylaws by the chairman of the meeting or by the stockholders present or represented at the meeting
and entitled to vote, although less than a quorum. It shall not be necessary to notify any stockholder of any adjournment of less than 30 days if the time and place, if any, of the adjourned meeting, and the means of remote communication, if any, by
which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which adjournment is taken, unless after the adjournment a new record date is fixed for the adjourned
meeting. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8
<U>Voting and Proxies</U>. Each stockholder shall have one vote for each share of stock entitled to vote held of record by such stockholder and a proportionate vote for each fractional share so held, unless otherwise provided by law or the
Certificate of Incorporation. Each stockholder of record entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action without a meeting, may vote or express such consent or dissent in person (including by means
of remote communications, if any, by which stockholders may be deemed to be present in person and vote at such meeting) or may authorize another person or persons to vote or act for such stockholder by a proxy executed or transmitted in a manner
permitted by the General Corporation Law of the State of Delaware by the stockholder or such stockholder&#146;s authorized agent and delivered (including by electronic transmission) to the Secretary of the corporation. No such proxy shall be voted
or acted upon after three years from the date of its execution, unless the proxy expressly provides for a longer period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 <U>Action at Meeting</U>. When a quorum is present at any meeting, any matter other than
the election of directors to be voted upon by the stockholders at such meeting shall be decided by the vote of the holders of shares of stock having a majority in voting power of the votes cast by the holders of all of the shares of stock present or
represented at the meeting and voting affirmatively or negatively on such matter (or if there are two or more classes or series of stock entitled to vote as separate classes, then in the case of each such class or series, the holders of a majority
in voting power of the shares of stock of that class or series present or represented at the meeting and voting affirmatively or negatively on such matter), except when a different vote is required by law, the Certificate of Incorporation or these
Bylaws. When a quorum is present at any meeting, any election by stockholders of directors shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 <U>Conduct of Meetings</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Chairman of Meeting</U>. Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in the Chairman&#146;s
absence by the Vice Chairman of the Board, if any, or in the Vice Chairman&#146;s absence by the Chief Executive Officer, or in the Chief Executive Officer&#146;s absence, by the President, or in the President&#146;s absence by a Vice President, or
in the absence of all of the foregoing persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen by vote of the stockholders at the meeting. The Secretary shall act as secretary of the
meeting, but in the Secretary&#146;s absence the chairman of the meeting may appoint any person to act as secretary of the meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<U>Rules, Regulations and Procedures</U>. The Board of Directors may adopt by resolution such rules, regulations and procedures for the conduct of any meeting of stockholders of the corporation as it shall deem appropriate including, without
limitation, such guidelines and procedures as it may deem appropriate regarding the participation by means of remote communication of stockholders and proxyholders not physically present at a meeting. Except to the extent inconsistent with such
rules, regulations and procedures as adopted by the Board of Directors, the chairman of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of
such chairman, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting, may include, without limitation, the following:
(i)&nbsp;the establishment of an agenda or order of business for the meeting; (ii)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present; (iii)&nbsp;limitations on attendance at or participation in the
meeting to stockholders of record of the corporation, their duly authorized and constituted proxies or such other persons as shall be determined; (iv)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; and
(v)&nbsp;limitations on the time allotted to questions or comments by participants. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance
with the rules of parliamentary procedure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 <U>Action without Meeting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Taking of Action by Consent</U>. Any action required or permitted to be taken at any annual or special meeting of stockholders of the
corporation may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that
would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such action were present and voted. Except as otherwise provided by the Certificate of Incorporation, stockholders may act by written consent to
elect directors; provided, however, that, if such consent is less than unanimous, such action by written consent may be in lieu of holding an annual meeting only if all of the directorships to which directors could be elected at an annual meeting
held at the effective time of such action are vacant and are filled by such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Electronic Transmission of Consents</U>. A
telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written,
signed and dated for the purposes of this section, provided that any such telegram, cablegram or other electronic transmission sets forth or is delivered with information from which the corporation can determine (i)&nbsp;that the telegram, cablegram
or other electronic transmission was transmitted by the stockholder or proxyholder or by a person or persons authorized to act for the stockholder or proxyholder and (ii)&nbsp;the date on which such stockholder or proxyholder or authorized person or
persons transmitted such telegram, cablegram or electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted shall be deemed to be the date on which such consent was signed. No consent given by
telegram, cablegram or other electronic transmission shall be deemed to have been delivered until such consent is reproduced in paper form and until such paper form shall be delivered to the corporation by delivery to its registered office in the
State of Delaware, its principal place of business or an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a corporation&#146;s registered office shall be
made by hand or by certified or registered mail, return receipt requested. Notwithstanding the foregoing limitations on delivery, consents given by telegram, cablegram or other electronic transmission may be otherwise delivered to the principal
place of business of the corporation or to an officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded if, to the extent and in the manner provided by resolution of the Board of
Directors. Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy,
facsimile or other reproduction shall be a complete reproduction of the entire original writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Notice of Taking of Corporate
Action</U>. Prompt notice of the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would
have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DIRECTORS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1
<U>General Powers</U>. The business and affairs of the corporation shall be managed by or under the direction of a Board of Directors, who may exercise all of the powers of the corporation except as otherwise provided by law or the Certificate of
Incorporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Number, Election and Qualification</U>. Subject to the rights of holders of any series of Preferred Stock to elect
directors, the number of directors of the corporation shall be established from time to time by the stockholders or the Board of Directors. The directors shall be elected at the annual meeting of stockholders by such stockholders as have the right
to vote on such election. Election of directors need not be by written ballot. Directors need not be stockholders of the corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3
<U>Chairman of the Board; Vice Chairman of the Board</U>. The Board of Directors may appoint from its members a Chairman of the Board and a Vice Chairman of the Board, neither of whom need be an employee or officer of the corporation. If the Board
of Directors appoints a Chairman of the Board, such Chairman shall perform such duties and possess such powers as are assigned by the Board of Directors and, if the Chairman of the Board is also designated as the corporation&#146;s Chief Executive
Officer, shall have the powers and duties of the Chief Executive Officer prescribed in Section&nbsp;3.7 of these Bylaws. If the Board of Directors appoints a Vice Chairman of the Board, such Vice Chairman shall perform such duties and possess such
powers as are assigned by the Board of Directors. Unless otherwise provided by the Board of Directors, the Chairman of the Board or, in the Chairman&#146;s absence, the Vice Chairman of the Board, if any, shall preside at all meetings of the Board
of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Tenure</U>. Each director shall hold office until the next annual meeting of stockholders and until a successor is
elected and qualified, or until such director&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Quorum</U>. The greater of (a)&nbsp;a
majority of the directors at any time in office and <FONT STYLE="white-space:nowrap">(b)&nbsp;one-third</FONT> of the number of directors fixed pursuant to Section&nbsp;2.2 of these Bylaws shall constitute a quorum of the Board of Directors. If at
any meeting of the Board of Directors there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be
present. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Action at Meeting</U>. Every act or decision done or made by a majority of the directors present at a meeting of the Board
of Directors duly held at which a quorum is present shall be regarded as the act of the Board of Directors, unless a greater number is required by law or by the Certificate of Incorporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Removal</U>. Except as otherwise provided by the General Corporation Law of the State of Delaware, any one or more or all of the
directors of the corporation may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except that the directors elected by the holders of a particular class or series of
stock may be removed without cause only by vote of the holders of a majority of the outstanding shares of such class or series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 <U>Vacancies</U>. Subject to the rights of holders of any series of Preferred Stock to
elect directors, unless and until filled by the stockholders, any vacancy or newly-created directorship on the Board of Directors, however occurring, may be filled by vote of a majority of the directors then in office, although less than a quorum,
or by a sole remaining director. A director elected to fill a vacancy shall be elected for the unexpired term of such director&#146;s predecessor in office, and a director chosen to fill a position resulting from a newly-created directorship shall
hold office until the next annual meeting of stockholders and until a successor is elected and qualified, or until such director&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <U>Resignation</U>. Any director may resign by delivering a resignation in writing or by electronic transmission to the corporation at its
principal office or to the Chairman of the Board, the Chief Executive Officer, the President or the Secretary. Such resignation shall be effective upon delivery unless it is specified to be effective at some later time or upon the happening of some
later event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <U>Regular Meetings</U>. Regular meetings of the Board of Directors may be held without notice at such time and place as
shall be determined from time to time by the Board of Directors; provided that any director who is absent when such a determination is made shall be given notice of the determination. A regular meeting of the Board of Directors may be held without
notice immediately after and at the same place as the annual meeting of stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <U>Special Meetings</U>. Special meetings of
the Board of Directors may be held at any time and place designated in the manner specified in Section&nbsp;2.12 of these Bylaws by the Chairman of the Board, the Chief Executive Officer, the President, two or more directors, or by one director in
the event that there is only a single director in office. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 <U>Notice of Special Meetings</U>. Notice of the date, place, if any, and
time of any special meeting of directors shall be given to each director by the Secretary or by the officer or one of the directors calling the meeting. Notice shall be duly given to each director (a)&nbsp;in person or by telephone at least 24 hours
in advance of the meeting, (b)&nbsp;by sending written notice by reputable overnight courier, telecopy, facsimile or electronic transmission, or delivering written notice by hand, to such director&#146;s last known business, home or electronic
transmission address at least 48 hours in advance of the meeting, or (c)&nbsp;by sending written notice by first-class mail to such director&#146;s last known business or home address at least 72 hours in advance of the meeting. A notice or waiver
of notice of a meeting of the Board of Directors need not specify the purposes of the meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 <U>Meetings by Conference
Communications Equipment</U>. Directors may participate in meetings of the Board of Directors or any committee thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can
hear each other, and participation by such means shall constitute presence in person at such meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14 <U>Action by Consent</U>. Any action required or permitted to be taken at any meeting
of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent to the action in writing or by electronic transmission, and the written consents
or electronic transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are
maintained in electronic form. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.15 <U>Committees</U>. The Board of Directors may designate one or more committees, each committee to
consist of one or more of the directors of the corporation with such lawfully delegable powers and duties as the Board of Directors thereby confers, to serve at the pleasure of the Board of Directors. The Board of Directors may designate one or more
directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members of the committee present at any
meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any
such committee, to the extent provided in the resolution of the Board of Directors and subject to the provisions of law, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs
of the corporation and may authorize the seal of the corporation to be affixed to all papers which may require it. Each such committee shall keep minutes and make such reports as the Board of Directors may from time to time request. Except as the
Board of Directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is
provided in these Bylaws for the Board of Directors. Except as otherwise provided in the Certificate of Incorporation, these Bylaws, or the resolution of the Board of Directors designating the committee, a committee may create one or more
subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.16 <U>Compensation of Directors</U>. Directors may be paid such compensation for their services and such reimbursement for expenses of
attendance at meetings as the Board of Directors may from time to time determine. No such payment shall preclude any director from serving the corporation or any of its parent or subsidiary entities in any other capacity and receiving compensation
for such service. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OFFICERS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1
<U>Titles</U>. The officers of the corporation shall consist of a Chief Executive Officer, a President, a Secretary, a Treasurer and such other officers with such other titles as the Board of Directors shall determine, including one or more Vice
Presidents, Assistant Treasurers and Assistant Secretaries. The Board of Directors may appoint such other officers as it may deem appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election</U>. The Chief Executive Officer, President, Treasurer and Secretary shall
be elected annually by the Board of Directors at its first meeting following the annual meeting of stockholders. Other officers may be appointed by the Board of Directors at such meeting or at any other meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Qualification</U>. No officer need be a stockholder. Any two or more offices may be held by the same person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Tenure</U>. Except as otherwise provided by law, by the Certificate of Incorporation or by these Bylaws, each officer shall hold office
until such officer&#146;s successor is elected and qualified, unless a different term is specified in the resolution electing or appointing such officer, or until such officer&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Resignation and Removal</U>. Any officer may resign by delivering a written resignation to the corporation at its principal office or to
the Chief Executive Officer, the President or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some later time or upon the happening of some later event. Any officer may be removed at any
time, with or without cause, by vote of a majority of the directors then in office. Except as the Board of Directors may otherwise determine, no officer who resigns or is removed shall have any right to any compensation as an officer for any period
following such officer&#146;s resignation or removal, or any right to damages on account of such removal, whether such officer&#146;s compensation be by the month or by the year or otherwise, unless such compensation is expressly provided for in a
duly authorized written agreement with the corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <U>Vacancies</U>. The Board of Directors may fill any vacancy occurring in any
office for any reason and may, in its discretion, leave unfilled for such period as it may determine any offices other than those of Chief Executive Officer, President, Treasurer and Secretary. Each such successor shall hold office for the unexpired
term of such officer&#146;s predecessor and until a successor is elected and qualified, or until such officer&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 <U>President; Chief Executive Officer</U>. Unless the Board of Directors has designated another person as the corporation&#146;s Chief
Executive Officer, the President shall be the Chief Executive Officer of the corporation. The Chief Executive Officer shall have general charge and supervision of the business of the corporation subject to the direction of the Board of Directors,
and shall perform all duties and have all powers that are commonly incident to the office of chief executive or that are delegated to such officer by the Board of Directors. The President shall perform such other duties and shall have such other
powers as the Board of Directors or the Chief Executive Officer (if the President is not the Chief Executive Officer) may from time to time prescribe. In the event of the absence, inability or refusal to act of the Chief Executive Officer or the
President (if the President is not the Chief Executive Officer), the Vice President (or if there shall be more than one, the Vice Presidents in the order determined by the Board of Directors) shall perform the duties of the Chief Executive Officer
and when so performing such duties shall have all the powers of and be subject to all the restrictions upon the Chief Executive Officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8 <U>Vice Presidents</U>. Each Vice President shall perform such duties and possess such powers as the Board of Directors or the Chief
Executive Officer may from time to time prescribe. The Board of Directors may assign to any Vice President the title of Executive Vice President, Senior Vice President or any other title selected by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9 <U>Secretary and Assistant Secretaries</U>. The Secretary shall perform such duties and
shall have such powers as the Board of Directors or the Chief Executive Officer may from time to time prescribe. In addition, the Secretary shall perform such duties and have such powers as are incident to the office of the secretary, including
without limitation the duty and power to give notices of all meetings of stockholders and special meetings of the Board of Directors, to attend all meetings of stockholders and the Board of Directors and keep a record of the proceedings, to maintain
a stock ledger and prepare lists of stockholders and their addresses as required, to be custodian of corporate records and the corporate seal and to affix and attest to the same on documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Assistant Secretary shall perform such duties and possess such powers as the Board of Directors, the Chief Executive Officer or the
Secretary may from time to time prescribe. In the event of the absence, inability or refusal to act of the Secretary, the Assistant Secretary (or if there shall be more than one, the Assistant Secretaries in the order determined by the Board of
Directors) shall perform the duties and exercise the powers of the Secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of the Secretary or any Assistant Secretary
at any meeting of stockholders or directors, the chairman of the meeting shall designate a temporary secretary to keep a record of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10 <U>Treasurer and Assistant Treasurers</U>. The Treasurer shall perform such duties and shall have such powers as may from time to time be
assigned by the Board of Directors or the Chief Executive Officer. In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including without limitation the duty and power to keep and be
responsible for all funds and securities of the corporation, to deposit funds of the corporation in depositories selected in accordance with these Bylaws, to disburse such funds as ordered by the Board of Directors, to make proper accounts of such
funds, and to render as required by the Board of Directors statements of all such transactions and of the financial condition of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assistant Treasurers shall perform such duties and possess such powers as the Board of Directors, the Chief Executive Officer or the
Treasurer may from time to time prescribe. In the event of the absence, inability or refusal to act of the Treasurer, the Assistant Treasurer (or if there shall be more than one, the Assistant Treasurers in the order determined by the Board of
Directors) shall perform the duties and exercise the powers of the Treasurer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11 <U>Salaries</U>. Officers of the corporation shall be
entitled to such salaries, compensation or reimbursement as shall be fixed or allowed from time to time by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.12
<U>Delegation of Authority</U>. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CAPITAL STOCK </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1
<U>Issuance of Stock</U>. Subject to the provisions of the Certificate of Incorporation, the whole or any part of any unissued balance of the authorized capital stock of the corporation or the whole or any part of any shares of the authorized
capital stock of the corporation held in the corporation&#146;s treasury may be issued, sold, transferred or otherwise disposed of by vote of the Board of Directors in such manner, for such lawful consideration and on such terms as the Board of
Directors may determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Stock Certificates; Uncertificated Shares</U>. The shares of the corporation shall be represented by
certificates, provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of the corporation&#146;s stock shall be uncertificated shares. Every holder of stock of the corporation
represented by certificates shall be entitled to have a certificate, in such form as may be prescribed by law and by the Board of Directors, representing the number of shares held by such holder registered in certificate form. Each such certificate
shall be signed in a manner that complies with Section&nbsp;158 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each certificate
for shares of stock which are subject to any restriction on transfer pursuant to the Certificate of Incorporation, these Bylaws, applicable securities laws or any agreement among any number of stockholders or among such holders and the corporation
shall have conspicuously noted on the face or back of the certificate either the full text of the restriction or a statement of the existence of such restriction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the corporation shall be authorized to issue more than one class of stock or more than one series of any class, the powers, designations,
preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the
face or back of each certificate representing shares of such class or series of stock, provided that in lieu of the foregoing requirements there may be set forth on the face or back of each certificate representing shares of such class or series of
stock a statement that the corporation will furnish without charge to each stockholder who so requests a copy of the full text of the powers, designations, preferences and relative, participating, optional or other special rights of each class of
stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within a reasonable time
after the issuance or transfer of uncertificated shares, the corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to Sections 151, 202(a) or
218(a) of the General Corporation Law of the State of Delaware or, with respect to Section&nbsp;151 of the General Corporation Law of the State of Delaware, a statement that the corporation will furnish without charge to each stockholder who so
requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Transfers</U>. Shares of stock of the corporation shall be transferable in the manner
prescribed by law and in these Bylaws. Transfers of shares of stock of the corporation shall be made only on the books of the corporation or by transfer agents designated to transfer shares of stock of the corporation. Subject to applicable law,
shares of stock represented by certificates shall be transferred only on the books of the corporation by the surrender to the corporation or its transfer agent of the certificate representing such shares properly endorsed or accompanied by a written
assignment or power of attorney properly executed, and with such proof of authority or the authenticity of signature as the corporation or its transfer agent may reasonably require. Except as may be otherwise required by law, by the Certificate of
Incorporation or by these Bylaws, the corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect to such
stock, regardless of any transfer, pledge or other disposition of such stock until the shares have been transferred on the books of the corporation in accordance with the requirements of these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Lost, Stolen or Destroyed Certificates</U>. The corporation may issue a new certificate of stock in place of any previously issued
certificate alleged to have been lost, stolen or destroyed, upon such terms and conditions as the Board of Directors may prescribe, including the presentation of reasonable evidence of such loss, theft or destruction and the giving of such indemnity
and posting of such bond as the Board of Directors may require for the protection of the corporation or any transfer agent or registrar. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>Record Date</U>. The Board of Directors may fix in advance a date as a record date for the determination of the stockholders entitled to
notice of or to vote at any meeting of stockholders or to express consent (or dissent) to corporate action without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights in respect of any change,
conversion or exchange of stock, or for the purpose of any other lawful action. Such record date shall not precede the date on which the resolution fixing the record date is adopted, and such record date shall not be more than 60 nor less than 10
days before the date of such meeting, nor more than 10 days after the date of adoption of a record date for a consent without a meeting, nor more than 60 days prior to any other action to which such record date relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If no record date is fixed, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall
be at the close of business on the day before the day on which notice is given, or, if notice is waived, at the close of business on the day before the day on which the meeting is held. If no record date is fixed, the record date for determining
stockholders entitled to express consent to corporate action without a meeting, when no prior action by the Board of Directors is necessary, shall be the day on which the first consent is properly delivered to the corporation. If no record date is
fixed, the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating to such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the
meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Regulations</U>. The issue, transfer, conversion and registration of shares of stock
of the corporation shall be governed by such other regulations as the Board of Directors may establish. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GENERAL PROVISIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Fiscal Year</U>. Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the corporation shall
begin on the first day of January of each year and end on the last day of December in each year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Corporate Seal</U>. The corporate
seal shall be in such form as shall be approved by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Waiver of Notice</U>. Whenever notice is required to be
given by law, by the Certificate of Incorporation or by these Bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before, at or after the time of the
event for which notice is to be given, shall be deemed equivalent to notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in any such waiver. Attendance of a person at a meeting shall
constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Voting of Securities</U>. Except as the Board of Directors may otherwise designate, the Chief Executive Officer, the President or
the Treasurer may waive notice of, vote, or appoint any person or persons to vote, on behalf of the corporation at, and act as, or appoint any person or persons to act as, proxy or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for this corporation (with or without power of substitution) at, any meeting of stockholders or securityholders of any other entity, the securities of
which may be held by this corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Evidence of Authority</U>. A certificate by the Secretary, or an Assistant Secretary, or a
temporary Secretary, as to any action taken by the stockholders, directors, a committee or any officer or representative of the corporation shall as to all persons who rely on the certificate in good faith be conclusive evidence of such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Certificate of Incorporation</U>. All references in these Bylaws to the Certificate of Incorporation shall be deemed to refer to the
Certificate of Incorporation of the corporation, as amended and in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Severability</U>. Any determination
that any provision of these Bylaws is for any reason inapplicable, illegal or ineffective shall not affect or invalidate any other provision of these Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Pronouns</U>. All pronouns used in these Bylaws shall be deemed to refer to the
masculine, feminine or neuter, singular or plural, as the identity of the person or persons may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDMENTS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1
<U>By the Board of Directors</U>. These Bylaws may be altered, amended or repealed, in whole or in part, or new bylaws may be adopted by the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>By the Stockholders</U>. Except as otherwise provided by the Certificate of Incorporation, these Bylaws may be altered, amended or
repealed, in whole or in part, or new bylaws may be adopted by the affirmative vote of the holders of a majority of the shares of the capital stock of the corporation issued and outstanding and entitled to vote at any annual meeting of stockholders,
or at any special meeting of stockholders, provided notice of such alteration, amendment, repeal or adoption of new bylaws shall have been stated in the notice of such special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#147;[***]&#148;. SUCH IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I)&nbsp;NOT MATERIAL AND (II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOURTH AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS&#146; RIGHTS AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TABLE OF CONTENTS </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registration Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demand Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting Requirements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligations of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furnish Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses of Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delay of Registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reports Under Exchange Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitations on Subsequent Registration Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Market <FONT STYLE="white-space:nowrap">Stand-off&#148;</FONT> Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restrictions on Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Registration Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Information Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delivery of Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inspection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Information Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidentiality</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rights to Future Stock Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of First Offer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Covenants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Stock Plan; Employee Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Successor Indemnification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right to Conduct Activities.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CFIUS Filing Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of Covenants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Successors and Assigns</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Counterparts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Titles and Subtitles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments and Waivers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aggregation of Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dispute Resolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delays or Omissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publicity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Schedule A</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Schedule of Investors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Schedule B</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Schedule of Key Holders</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOURTH AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FOURTH AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT (this &#147;<B>Agreement</B>&#148;), is made as of the 18th day of December,
2020, by and among Ikena Oncology, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), each of the investors listed on <U>Schedule A</U> hereto (the &#147;<B>Investors</B>&#148;) and each of the stockholders listed on <U>Schedule B</U>
hereto, each of whom is referred to herein as a &#147;<B>Key Holder</B>&#148;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company, certain of the Investors and the Key Holders entered into that certain Third Amended and Restated Investors&#146;
Rights Agreement dated as of October&nbsp;1, 2020 (the &#147;<B>Prior Agreement</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and certain
Investors are parties to that Series B Preferred Stock Purchase Agreement, of even date herewith (the &#147;<B>Series B Purchase Agreement</B>&#148;), pursuant to which such Investors have agreed to purchase shares of the Company&#146;s Series B
Preferred Stock (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Key Holders and the Company desire to further induce such Investors to purchase
Series B Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Investors and the Company hereby agree that this Agreement shall govern the rights of the
Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set
forth in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and certain stockholders representing the Required Holders (as defined in the
Prior Agreement) desire that the Prior Agreement be amended and restated as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of
the mutual promises and obligations contained herein, the parties hereby agree to amend and restate the Prior Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Definitions</U>.<B> </B>For purposes of this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1 &#147;<B>Affiliate</B>&#148; means, with respect to any specified Person,
any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing partner, member, manager, officer or director of such Person or any
venture capital fund or other investment fund now or hereafter existing that is controlled by one or more general partners or managing members, or shares the same management company or investment adviser with, such Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2 &#147;<B>Celgene</B>&#148; means Celgene Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 &#147;<B>Certificate of Incorporation</B>&#148; means the Fourth Amended and Restated
Certificate of Incorporation of the Company, as amended and/or restated from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4 &#147;<B>Common Stock</B>&#148; means
shares of the Company&#146;s common stock, par value $0.001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5 &#147;<B>Competitor</B>&#148; means a Person engaged, directly
or indirectly (including through any<B> </B>partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in any business or enterprise that is competitive with the
Company&#146;s business; provided, however, the term &#147;<B>Competitor</B>&#148; shall not include (i)&nbsp;as of the date of this Agreement and subject to the last sentence of this definition, Celgene, and (ii)&nbsp;any financial investment firm
or collective investment vehicle (including any venture capital fund or other investment fund). For purposes of clarity, if Celgene or a financial investment firm or collective investment vehicle (including any venture capital fund or other
investment fund) owns a portfolio company (or an interest in a portfolio company) that is competitive with the Company&#146;s business, Celgene or such financial investment firm or collective investment vehicle (including any venture capital fund or
other investment fund) shall not be deemed to be a &#147;Competitor&#148; but such portfolio company shall be deemed to be a &#147;Competitor&#148;. Subject to the foregoing sentence, the Board of Directors of the Company (the &#147;<B>Board of
Directors</B><B>&#148;</B><B>)</B> may make a unanimous determination (in good faith) that Celgene should be deemed a Competitor at any future time if Celgene or any Affiliate thereof engages in any competitive activities including, but not limited
to research, development or commercialization of products that bind or modulate the targets to which the products the Company is researching, developing or commercializing bind or modulate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6 &#147;<B>Damages</B>&#148; means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under
the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a
material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii)&nbsp;an omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii)&nbsp;any violation or alleged violation by the indemnifying<B> </B>party (or any of its agents or Affiliates)<B> </B>of the Securities
Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.7 &#147;<B>Derivative Securities</B>&#148; means any securities or rights convertible into, or exercisable or exchangeable for (in each case,
directly or indirectly), Common Stock, including options and warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.8 &#147;<B>Exchange Act</B>&#148; means the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.9 &#147;<B>Excluded Registration</B>&#148; means (i)&nbsp;a registration relating to the
sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii)&nbsp;a registration relating to an SEC Rule 145 transaction; (iii)&nbsp;a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv)&nbsp;a registration in which the only Common Stock being registered is Common Stock issuable
upon conversion of debt securities that are also being registered. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.10 <B>&#147;Fidelity Investors</B>&#148; means the Investors advised
or <FONT STYLE="white-space:nowrap">sub-advised</FONT> by Fidelity Management&nbsp;&amp; Research Company LLC or affiliated investment advisers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.11 <B>&#147;</B><B>FOIA Party</B>&#148; means a Person that, in the reasonable determination of the Board of Directors, may be subject to,
and thereby required to disclose <FONT STYLE="white-space:nowrap">non-public</FONT> information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (&#147;<B>FOIA</B>&#148;), any state public records access
law, any state or other jurisdiction&#146;s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.12 &#147;<B>Form S</B><B><FONT STYLE="white-space:nowrap">-1</FONT></B>&#148; means such form under the Securities Act as in effect on the
date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.13 &#147;<B>Form S</B><B><FONT
STYLE="white-space:nowrap">-3</FONT></B>&#148; means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.14 &#147;<B>GAAP</B>&#148; means generally accepted
accounting principles in the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.15 &#147;<B>Holder</B>&#148; means any holder of Registrable Securities who is a party to
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.16 &#147;<B>Immediate Family Member</B>&#148; means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT><B>
</B>or<B> </B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including, adoptive relationships, of a natural person referred to herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.17 &#147;<B>Initiating Holders</B>&#148; means, collectively, Holders who properly initiate a registration request under this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.18 &#147;<B>IPO</B>&#148; means the Company&#146;s first underwritten public offering of its Common Stock under the Securities Act.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.19 &#147;<B>Key Holder</B> <B>Registrable Securities</B>&#148; means (i)&nbsp;any Common
Stock currently held or hereafter acquired by the Key Holders (including any shares of Common Stock issued to Key Holders pursuant to that certain Restricted Stock Agreement, dated as of the January&nbsp;11, 2019 (the &#147;<B>AskAt RSA</B>&#148;)
by and between the Company and those persons affiliated with AskAt, Inc. or pursuant to other Restricted Stock Agreement by and between the Company and certain Key Holders); and (ii)&nbsp;any Common Stock issued as (or issuable upon the conversion
or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced above; and excluding for purposes of Section&nbsp;2 any shares
for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.20 &#147;<B>Major Investor</B>&#148; means
any Investor that, individually or together with such Investor&#146;s Affiliates, holds at least 2,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof) and each Person to whom any of the right of any such Investor are assigned pursuant to Section&nbsp;6.1 of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.21 &#147;<B>New Securities</B>&#148; means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.22 &#147;<B>Person</B>&#148; means any individual, corporation, partnership, trust, limited liability company, association or other entity.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.23 &#147;<B>Preferred Director</B>&#148; means any<B> </B>director<B> </B>of the Company that the holders of record of the Preferred
Stock are entitled to elect pursuant to the Company&#146;s Certificate of Incorporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.24 &#147;<B>Preferred Stock</B>&#148; means
the Series A Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and the Series B Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.25 &#147;<B>Registrable Securities</B>&#148; means (i)&nbsp;the Common Stock issuable or issued upon conversion of Preferred Stock;
(ii)&nbsp;any Common Stock, or any Common Stock<B> </B>issued or issuable<B> </B>(directly or indirectly)<B> </B>upon conversion and/or exercise of<B> </B>any other<B> </B>securities<B> </B>of the Company, acquired by the Investors after the date
hereof; (iii)&nbsp;the Key Holder Registrable Securities, <U>provided</U>, <U>however</U>, that such Key Holder Registrable Securities<B> </B>shall not be deemed Registrable Securities and the Key Holders shall not be deemed Holders for the purposes
of <U>Subsections</U> <U>2.10</U>, <U>3.1</U>, <U>3.2</U>, <U>4.1</U> and <U>6.6</U>; and (iv)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or
other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses <U>(i)</U>&nbsp;and <U>(ii)</U> above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in
which the applicable<B> </B>rights under this Agreement are not assigned pursuant to <U>Subsection 6.1</U>, and excluding for purposes of <U>Section&nbsp;2</U><B> </B>any shares for which registration rights have terminated pursuant to <U>Subsection
2.13</U><B> </B>of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.26 &#147;<B>Registrable Securities then outstanding</B>&#148; means the number of shares determined
by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of<B> </B>Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are
Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.27 &#147;<B>Restricted Securities</B>&#148; means the securities of the Company required
to be notated with the legend set forth in <U>Subsection </U><U>2.12(b)</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.28 &#147;<B>SEC</B>&#148; means the Securities and
Exchange Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.29 &#147;<B>SEC Rule 144</B>&#148; means Rule 144 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.30 &#147;<B>SEC Rule 145</B>&#148; means Rule 145 promulgated by the SEC under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.31 &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.32 &#147;<B>Selling Expenses</B>&#148; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in <U>Subsection 2.6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.33 &#147;<B>Series A Preferred Stock</B>&#148; means shares of the Company&#146;s Series A Preferred Stock, par value $0.001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.34 &#147;<B>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</B>&#148; means shares of the Company&#146;s Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, par value $0.001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.35 &#147;<B>Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</B>&#148; means shares of the Company&#146;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, par value $0.001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.36 <B>&#147;Series B Preferred Stock</B>&#148; means shares of the Company&#146;s Series B Preferred Stock, par value $0.001 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Registration Rights</U>. The Company covenants and agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Demand Registration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand</U>. If at any time after one hundred eighty (180)&nbsp;days after the
effective date of the registration statement for the IPO, the Company receives a request from Holders of at least forty percent (40%) of the Registrable Securities then outstanding (excluding any Key Holder Registrable Securities) that the Company
file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement<B> </B>with respect to at least twenty percent (20%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net
of Selling Expenses, would exceed $10 million), then the Company shall (x)&nbsp;within ten (10)&nbsp;days after the date such request is given, give notice thereof (the &#147;<B>Demand Notice</B>&#148;) to all Holders other than the Initiating
Holders; and (y)&nbsp;as soon as practicable, and in any event within sixty (60)&nbsp;days after the date such request is given by the Initiating Holders, file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement under the
Securities Act covering all Registrable Securities that the Initiating Holders requested<B> </B>to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within twenty (20)&nbsp;days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Subsection</U><U>s</U><U> </U><U>2.1(c)</U> and <U>2.3.</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand</U>. If at any time when it
is eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable Securities then outstanding (excluding any Key Holder
Registrable Securities) that the Company file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling
Expenses, of at least $3&nbsp;million, then the Company shall (i)&nbsp;within ten (10)&nbsp;days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii)&nbsp;as soon as practicable, and
in any event within forty-five (45)&nbsp;days after the date such request is given by the Initiating Holders, file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement under the Securities Act covering all Registrable Securities
requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20)&nbsp;days of the date the Demand Notice is given, and in each case, subject to the limitations of
<U>Subsections 2.1(c)</U> and <U>2.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a
registration pursuant to this <U>Subsection 2.1</U> a certificate signed by the Company&#146;s chief executive officer stating that in the good faith judgment of the Company&#146;s Board of Directors it would be materially detrimental to the Company
and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i)&nbsp;materially interfere
with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature disclosure of material information that the Company has a bona fide business purpose for preserving as
confidential; or (iii)&nbsp;render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect
to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90)&nbsp;days after the request of the Initiating Holders is given; <U>provided</U>, <U>however</U>, that the Company may not invoke this right
more than once in any twelve (12)&nbsp;month period; and <U>provided</U> <U>further</U> that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90)&nbsp;day period other than an
Excluded Registration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
<U>Subsection </U><U>2.1(a)</U>, (i) during the period that is sixty (60)&nbsp;days before the Company&#146;s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180)&nbsp;days after the effective date of,
a Company-initiated registration, <U>provided</U> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii)&nbsp;after the Company has effected two
(2)&nbsp;registrations pursuant to <U>Subsection </U><U>2.1(a)</U>; or (iii)&nbsp;if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
pursuant to a request made pursuant to <U>Subsection 2.1(b)</U>. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Subsection </U><U>2.1(b)</U>&nbsp;(i) during the period that is thirty
(30)&nbsp;days before the Company&#146;s good faith estimate of the date of filing of, and ending on a date that is ninety (90)&nbsp;days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has effected two registrations pursuant to <U>Subsection </U><U>2.1(b)</U> within the twelve
(12)&nbsp;month period immediately preceding the date of such request. A registration shall not be counted as &#147;effected&#148; for purposes of this <U>Subsection </U><U>2.1(d)</U> until such time as the applicable registration statement has been
declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to <U>Subsection
2.6</U>, in which case such withdrawn registration statement shall be counted as &#147;effected&#148; for purposes of this <U>Subsection </U><U>2.1(d)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Company Registration</U>. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20)&nbsp;days after such notice is given by the Company, the Company shall, subject to the
provisions of <U>Subsection 2.3</U>, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this <U>Subsection 2.2</U> before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with <U>Subsection 2.6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Underwriting Requirements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If, pursuant to <U>Subsection 2.1</U>, the Initiating Holders<B> </B>intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Subsection 2.1</U>, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&#146;s Registrable Securities in such registration shall be conditioned upon such
Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in <U>Subsection 2.4(e)</U>) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this <U>Subsection 2.3</U>, if
the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that
otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; <U>provided</U>, <U>however</U>, that (i)&nbsp;the number of Registrable
Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting and (ii)&nbsp;any Registrable Securities which are not Key Holder Registrable
Securities shall not be excluded from such underwriting unless all Key Holder Registrable Securities are first excluded from such offering. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100)&nbsp;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In connection with any offering involving an underwriting of shares of the
Company&#146;s capital stock pursuant to <U>Subsection 2.2</U>, the Company shall not be required to include any of the Holders&#146; Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders; <U>provided</U>,
<U>however</U>, that any Registrable Securities which are not Key Holder Registrable Securities shall not be excluded from such underwriting unless all Key Holder Registrable Securities are first excluded from such offering. To facilitate the
allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100)&nbsp;shares. Notwithstanding the foregoing, in no event shall
(i)&nbsp;the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii)&nbsp;the number of Registrable
Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters
make the determination described above and no other stockholder&#146;s securities are included in such offering. For purposes of the provision in this <U>Subsection 2.3(b)</U> concerning apportionment, for any selling Holder that is a partnership,
limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and
retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single &#147;selling Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate
number of Registrable Securities owned by all Persons included in such &#147;selling Holder,&#148; as defined in this sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) For purposes of <U>Subsection 2.1</U>, a registration shall not be counted as
&#147;effected&#148; if, as a result of an exercise of the underwriter&#146;s cutback provisions in <U>Subsection 2.3(a)</U>, fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in
such registration statement are actually included. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4 <U>Obligations of the Company</U>. Whenever required under this
<U>Section</U><U></U><U>&nbsp;2</U> to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120)&nbsp;days or, if earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U>, <U>however</U>, that (i)&nbsp;such one hundred twenty (120)&nbsp;day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii)&nbsp;in the case of any registration of
Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120)&nbsp;day period shall be
extended for up to an additional one hundred twenty (120)&nbsp;days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) provide a transfer agent and registrar for all Registrable Securities registered
pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company&#146;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#146;s directors may implement a trading program under Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.5 <U>Furnish Information</U>. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder&#146;s Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.6 <U>Expenses of Registration</U>. All expenses (other than Selling Expenses) incurred in
connection with registrations, filings, or qualifications pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, including all registration, filing, and qualification fees; printers&#146; and accounting fees; fees and disbursements of counsel for the
Company; and the reasonable fees and disbursements of one counsel for the selling Holders<B> </B>(&#147;<B>Selling Holder Counsel</B>&#148;), shall be borne and paid by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant to <U>Subsection 2.1</U> if the registration request is subsequently withdrawn at the request of the Initiating Holders (in which case all selling Holders shall bear such
expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Initiating Holders agree to forfeit their right to one registration pursuant to <U>Subsections </U><U>2.1(a)</U> or
<U>2.1(b)</U>, as the case may be; <U>provided</U> <U>further</U> that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the
Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one
registration pursuant to <U>Subsections 2.1(a)</U> or <U>2.1(b)</U>. All Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> shall be borne and paid by the Holders pro rata on the basis
of the number of Registrable Securities registered on their behalf. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.7 <U>Delay of Registration</U>. No Holder shall have any right to
obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
<U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.8 <U>Indemnification</U>. If any Registrable Securities are included in a registration statement
under this <U>Section</U><U></U><U>&nbsp;2</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company will indemnify and hold harmless each
selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel, accountants and investment advisers for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder;
and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that
the indemnity agreement contained in this <U>Subsection </U><U>2.8(a)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be
unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such
Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person
of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on
behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Subsection </U><U>2.8(b)</U> shall not apply to
amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and <U>provided</U> <U>further</U> that in no event shall the aggregate
amounts payable by any Holder by way of indemnity or contribution under <U>Subsections 2.8(b)</U> and <U>2.8(d)</U> exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case
of fraud or willful misconduct by such Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this <U>Subsection 2.8</U><B>
</B>of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this <U>Subsection 2.8</U>, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>, <U>however</U>, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i)&nbsp;any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Subsection 2.8</U> but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this <U>Subsection 2.8</U> provides for indemnification in such case, or
(ii)&nbsp;contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this <U>Subsection 2.8</U>, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; <U>provided</U>, <U>however</U>, that, in any such case
(x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y)&nbsp;no Person guilty of
fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided</U> <U>further</U> that in no
event shall a Holder&#146;s liability pursuant to this <U>Subsection 2.8(d)</U>, when combined with the amounts paid or payable by such Holder pursuant to <U>Subsection 2.8(b)</U>, exceed the proceeds from the offering received by such Holder (net
of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; <U>provided</U>,
<U>however</U>, that any matter expressly provided for or addressed by the foregoing provisions that is not expressly provided for or addressed by the underwriting agreement shall be controlled by the foregoing provisions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this <U>Subsection 2.8</U> shall survive the completion of any offering of Registrable Securities in a registration under this <U>Section</U><U></U><U>&nbsp;2</U>, and otherwise shall survive the termination of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.9 <U>Reports Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the Company shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) use commercially reasonable efforts to file with
the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90)&nbsp;days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any
time after the Company so qualifies); and (ii)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time
after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to use such form). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.10 <U>Limitations on Subsequent Registration Rights</U>. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that
would (i)&nbsp;allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the
extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii)&nbsp;allow such holder or prospective holder to initiate a demand for registration of any securities held
by such holder or prospective holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.11 <U>&#147;</U><U>Market
Stand</U><U><FONT STYLE="white-space:nowrap">-off</FONT></U><U>&#148;</U><U> Agreement</U>. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the
final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180)&nbsp;days), (i) lend; offer; pledge; sell; contract to sell; sell any option or
contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable (directly or indirectly) for Common Stock held by such Holder immediately prior to the IPO or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of such securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this <U>Subsection 2.11</U><B>
</B>shall apply only to the IPO, and shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, the sale of any shares purchased in connection with the IPO, transactions (including, without limitation, any
swap, hedge or similar agreement or arrangement) or announcements, in each case, relating to securities acquired in the IPO or securities acquired in open market or other transactions from and after the IPO or that otherwise do not involve or relate
to securities of the Company owned by a Holder prior to the IPO, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, <U>provided</U> that the trustee of the trust agrees
to be bound in writing by the restrictions set forth herein, and <U>provided</U> <U>further</U> that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and stockholders
owning 1% or more of the Company&#146;s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such registration are
intended <FONT STYLE="white-space:nowrap">third-party</FONT> beneficiaries of this <U>Subsection 2.11</U> and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees
to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this <U>Subsection 2.11</U> or that are necessary to give further effect thereto. In the event that the
Company or the managing underwriter waives or terminates any of the restrictions contained in this <U>Subsection 2.11</U> or in a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with respect to the securities of any Holder, officer,
director or <FONT STYLE="white-space:nowrap">one-percent</FONT> or greater stockholder of the Company (in any such case, the &#147;<B>Released Securities</B>&#148;), the restrictions contained in this <U>Subsection 2.11</U> and in any <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements executed by the Holders shall be waived or terminated, as applicable, to the same extent and with respect to the same percentage of securities of each Holder as the percentage of Released
Securities represent with respect to the securities held by the applicable Holder, officer, director or <FONT STYLE="white-space:nowrap">one-percent</FONT> or greater stockholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.12 <U>Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144 to be bound by
the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each certificate, instrument, or book entry representing (i)&nbsp;the Preferred Stock, (ii)&nbsp;the
Registrable Securities, and (iii)&nbsp;any other securities issued in respect of the securities referenced in clauses (i)&nbsp;and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless
otherwise permitted by the provisions of <U>Subsection 2.12(c)</U>) be notated with a legend substantially in the following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE
SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE
REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE
WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this <U>Subsection 2.12</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to
comply in all respects with the provisions of this <U>Section</U><U></U><U>&nbsp;2</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering
the proposed transaction or, following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder&#146;s intention to effect such sale, pledge, or transfer. Each such notice shall
describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder&#146;s expense by either (i)&nbsp;a written opinion of legal
counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii)&nbsp;a &#147;no
action&#148; letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or
(iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the
Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or
&#147;no action&#148; letter (x)&nbsp;in any transaction in compliance with SEC Rule 144; or (y)&nbsp;in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration or (z)&nbsp;in any
internal transaction in which such Holder transfers Restricted Securities to an Affiliate of such Holder that is an entity and that is ultimately controlled by the same parent company as the Holder (or is the ultimate parent company of the Holder);
<U>provided</U> that, in the case of clauses (y)&nbsp;and (z); other than in connection with a transaction in compliance with SEC Rule 144 following the IPO, each transferee agrees in writing to be subject to the terms of this <U>Subsection
2.12</U>. Notwithstanding the foregoing, the Company shall be obligated to reissue promptly unlegended certificates or book entries at the request of any Holder thereof if the Company has completed its IPO and the Holder shall have obtained an
opinion of counsel (which counsel may be counsel to the Company) to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend, provided that the second legend listed above
shall be removed only at such time as the Holder of such certificate is no longer subject to any restrictions hereunder. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be
notated with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in <U>Subsection 2.12(b)</U>, except that such certificate instrument, or book
entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.13 <U>Termination of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to <U>Subsections 2.1</U> or <U>2.2</U> shall terminate upon the earliest to occur of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the closing of a Deemed
Liquidation Event (as defined in the Company&#146;s Certificate of Incorporation); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) such time following the IPO as SEC Rule 144 or
another similar exemption under the Securities Act is available for the sale of<B> </B>all of such Holder&#146;s shares without limitation during a three-month period without registration; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the fifth anniversary of the IPO. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Information Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>Delivery of Financial Statements</U>. The Company shall deliver to each Major Investor: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) as soon as practicable, but in any event within one hundred twenty (120)&nbsp;days after the end of each fiscal year of the Company,
(i)&nbsp;a balance sheet as of the end of such year, (ii)&nbsp;statements of income and of cash flows for such year, and a comparison between (x)&nbsp;the actual amounts as of and for such fiscal year and (y)&nbsp;the comparable amounts for the
prior year and as included in the Budget (as defined in <U>Subsection 3.1(e)</U>) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and
(iii)&nbsp;a statement of stockholders&#146; equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) as soon as practicable, but in any event within <FONT STYLE="white-space:nowrap">forty-five</FONT> (45)&nbsp;days after the end of each of
the first three (3)&nbsp;quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders&#146; equity as of the end of such fiscal
quarter, all prepared in accordance with GAAP (except that such financial statements may (i)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments; and (ii)&nbsp;not contain all notes thereto that may be
required in accordance with GAAP); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) as soon as practicable, but in any event within forty-five (45)&nbsp;days after the end of each
quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the
Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock
options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief
executive officer of the Company as being true, complete, and correct; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) as soon as practicable, but in any event within thirty
(30)&nbsp;days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders&#146; equity as of the end of such month, all prepared in accordance with
GAAP (except that such financial statements may (i)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and (ii)&nbsp;not contain all notes thereto that may be required in accordance with GAAP); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) as soon as practicable, but in any event thirty (30)&nbsp;days before the end of each fiscal year, a budget and business plan for the next
fiscal year (collectively, the &#147;<B>Budget</B>&#148;), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any
other budgets or revised budgets prepared by the Company; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) such other information relating to the financial condition, business, prospects, or
corporate affairs of the Company as any Major Investor may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this <U>Subsection 3.1</U> to provide information (i)&nbsp;that the
Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); (ii) that the Company reasonably determines in good faith
would give rise to a conflict of interest between the Company, on the one hand, and such Major Investor, on the other hand; or (iii)&nbsp;the disclosure of which would adversely affect the attorney-client privilege between the Company and its
counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of
such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else in this <U>Subsection 3.1</U> to the contrary, the Company may cease providing the information set forth in this
<U>Subsection 3.1</U> during the period starting with the date forty-five (45)&nbsp;days before the Company&#146;s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC
rules applicable to such registration statement and related offering; <U>provided</U> that the Company&#146;s covenants under this <U>Subsection 3.1</U> shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Inspection</U>. The Company shall permit each Major
Investor at such Major Investor&#146;s expense, to visit and inspect the Company&#146;s properties; examine its books of account and records; and discuss the Company&#146;s affairs, finances, and accounts with its officers, during normal business
hours of the Company as may be reasonably requested by the Major Investor; <U>provided</U>, <U>however</U>, that the Company shall not be obligated pursuant to this <U>Subsection 3.2</U> to provide access to any information that it reasonably and in
good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company), would give rise to a conflict of interest between the Company, on the one hand,
and such Major Investor, on the other hand, or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Termination of Information Rights</U>. The covenants set forth in <U>Subsection 3.1</U> and <U>Subsection 3.2</U> shall terminate and
be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO,<B> </B>(ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of the Exchange Act, or
(iii)&nbsp;upon a Deemed Liquidation Event (as defined in the Company&#146;s Certificate of Incorporation), whichever event occurs first. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Confidentiality</U>. Each Investor agrees that such Investor will keep confidential
and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company&#146;s
intention to file a registration statement), unless such confidential information (a)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this <U>Subsection 3.4</U> by such Investor), (b) is or has been
independently developed or conceived by such Investor without use of the Company&#146;s confidential information, or (c)&nbsp;is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; <U>provided</U>, <U>however</U>, that an Investor may disclose confidential information (i)&nbsp;to its attorneys, accountants, consultants, and other professionals to the extent necessary to
obtain their services in connection with monitoring its investment in the Company; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this
<U>Subsection 3.4</U>;<B> </B>(iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, <U>provided</U> that such Investor informs such Person that
such information is confidential and directs such Person to maintain the confidentiality of such information and, in the case of any such prospective Person of the type identified in this clause (iii), such prospective Person has agreed in writing
to maintain the confidentiality of information received from such Investor; (iv)&nbsp;to the extent required in connection with any routine or periodic examination or similar process by any regulatory or self-regulatory body or authority not
specifically directed at the Company or the confidential information obtained from the Company pursuant to the terms of the Agreement, including, without limitation, quarterly or annual reports or other filings required by national securities
exchanges; or (v)&nbsp;as may otherwise be required by law, <U>provided</U> that, with respect to this clause (v), the Investor promptly notifies the Company of any such required disclosures and takes reasonable steps to minimize the extent of any
such required disclosures, in each case with respect to any such required disclosures that are specifically targeted at the information regarding the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Rights to Future Stock Issuances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right of First Offer</U>. Subject to the terms and conditions of this <U>Subsection 4.1</U> and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it, in such proportions as it
deems appropriate, among (i)&nbsp;itself, (ii)&nbsp;its Affiliates and (iii)&nbsp;its beneficial interest holders, such as limited partners, members or any other Person having &#147;beneficial ownership,&#148; as such term is defined in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Exchange Act, of such Major Investor (&#147;<B>Investor Beneficial </B><B>Owners</B>&#148;); <U>provided</U><I> </I>that each such Affiliate or Investor Beneficial Owner (x)&nbsp;is not a
Competitor or FOIA Party, unless such party&#146;s purchase of New Securities is otherwise consented to by the Board of Directors and (y)&nbsp;agrees to enter into this Agreement and each of the Fourth Amended and Restated Voting Agreement (the
&#147;<B>Voting Agreement</B>&#148;) and the Fourth Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement of even date herewith among the Company, the Investors and the other parties named therein,
as an &#147;<B>Investor</B>&#148; under each such agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company shall give notice (the &#147;<B>Offer Notice</B>&#148;) to
each Major Investor, stating (i)&nbsp;its bona fide intention to offer such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any, upon which it proposes to offer such New Securities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) By notification to the Company within twenty (20)&nbsp;days after the Offer Notice is
given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major
Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total
Common Stock of the Company then held by all the Investors (including all shares of Common Stock issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities<B> </B>then
held by the Investors). At the expiration of such twenty (20)&nbsp;day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a &#147;<B>Fully Exercising
Investor</B>&#148;) of any other Major Investor&#146;s failure to do likewise. During the ten (10)&nbsp;day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to
purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the
proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the
Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities<B> </B>then held, by all Fully Exercising Investors who wish to purchase
such unsubscribed shares. The closing of any sale pursuant to this <U>Subsection 4.1(b)</U> shall occur within the later of ninety (90)&nbsp;days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to
<U>Subsection 4.1(c)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as
provided in <U>Subsection 4.1(b)</U>, the Company may, during the ninety (90)&nbsp;day period following the expiration of the periods provided in <U>Subsection 4.1(b)</U>, offer and sell the remaining unsubscribed portion of such New Securities to
any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if
such agreement is not consummated within thirty (30)&nbsp;days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in
accordance with this <U>Subsection 4.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The right of first offer in this <U>Subsection 4.1</U> shall not be applicable to
(i)&nbsp;Exempted Securities (as defined in the Company&#146;s Certificate of Incorporation), (ii) shares of Common Stock issued in the IPO, and (iii)&nbsp;the issuance of shares of Series B Preferred Stock pursuant to the Series B Purchase
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2 <U>Termination</U>. The covenants set forth in <U>Subsection 4.1</U> shall terminate and be of no further force or effect
(i)&nbsp;immediately before the consummation of the IPO or (ii)&nbsp;upon a Deemed Liquidation Event (as defined in the Company&#146;s Certificate of Incorporation), whichever event occurs first. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Additional Covenants</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Insurance</U>. The Company has obtained from financially sound and reputable insurers Directors and Officers liability insurance in an
amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should
be discontinued. The Directors and Officers liability insurance policy shall not be cancelable by the Company without prior approval by the Board of Directors (including all of the Preferred Directors). Notwithstanding any other provision of this
<U>Section</U><U></U><U>&nbsp;5.1</U> to the contrary, for so long as a Preferred Director is serving on the Board of Directors, the Company shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least
five million dollars ($5,000,000) unless approved by all of the Preferred Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Employee Agreements</U>. The Company will
cause each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure
and proprietary rights assignment agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.3 <U>Employee </U><U>Stock</U><U> Plan; Employee Stock</U>. Unless otherwise approved by
the Board of Directors (including a majority of the Preferred Directors), all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company&#146;s capital stock after the date
hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (a)&nbsp;vesting of shares over a four (4)&nbsp;year period, with the first twenty-five percent (25%) of such shares vesting following twelve
(12)&nbsp;months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;months and (b)&nbsp;a market <FONT
STYLE="white-space:nowrap">stand-off</FONT> provision substantially similar to that in <U>Subsection 2.11</U>. In addition, unless otherwise approved by the Board of Directors (including all of the Preferred Directors), the<B> </B>Company shall
retain a &#147;right of first refusal&#148; on employee transfers until the Company&#146;s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.4 <U>Board Matters</U>. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall
meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel
expenses incurred (consistent with the Company&#146;s travel policy) in connection with attending meetings of the Board of Directors. Each Preferred Director shall be entitled in such person&#146;s discretion to be a member of any committee of the
Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.5 <U>Successor Indemnification</U>. If the Company or any of its successors or assignees consolidates with or
merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company&#146;s Bylaws, its Certificate of Incorporation,
or elsewhere, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.6 <U>Indemnification</U><U> Matters</U>. The Company hereby acknowledges that one
(1)&nbsp;or more of the directors nominated to serve on the Board of Directors by the Investors (each a &#147;<B>Fund Director</B>&#148;) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of
the Investors and certain of their Affiliates (collectively, the &#147;<B>Fund Indemnitors</B>&#148;).&nbsp;The Company hereby agrees (a)&nbsp;that it is the indemnitor of first resort (<I>i.e.</I>, its obligations to any such Fund Director are
primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of
expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by
the Company&#146;s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c)&nbsp;that it
irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.&nbsp;The Company further agrees that no
advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a
right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.7 <U>Right to Conduct Activities.</U><B></B><B>&nbsp;</B>The Company hereby agrees and acknowledges that<B> </B>each of OrbiMed Private
Investments, VI, LP, Atlas Venture Fund X, L.P., Atlas Venture Fund XI, L.P., Atlas Venture Opportunity Fund I, L.P., Omega Fund VI, L.P., the Fidelity Investors, Invus Public Equities, L.P., Citadel Multi-Strategy Equities Master Fund Ltd.
(&#147;<B>Surveyor</B>&#148;), Zone II Healthcare Holdings, LLC, Cowen Healthcare Investments II LP, CHI EF II LP, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. and Celgene (together
with each of their respective Affiliates) (&#147;<B>Funds</B>&#148;) is a professional investment fund or makes professional investments, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the
Company&#146;s business (as currently conducted or as currently propose to be conducted).&nbsp;The Company hereby agrees that, to the extent permitted under applicable law, such Funds shall not be liable to the Company for any claim arising out of,
or based upon, (i)&nbsp;the investment by any of such Funds in any entity competitive with the Company, or (ii)&nbsp;actions taken by any partner, officer or other representative of such Funds to assist any such competitive company, whether or not
such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x)&nbsp;any of
such Funds from liability associated with the unauthorized disclosure of the Company&#146;s confidential information obtained pursuant to this Agreement, or (y)&nbsp;any director or officer of the Company from any liability associated with his or
her fiduciary duties to the Company. The Company acknowledges that the execution of this Agreement and and the access to the Company&#146;s confidential information shall in no way be construed to prohibit or restrict the Funds from maintaining,
making or considering investments in other companies, or from otherwise operating in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.8 <U>CFIUS Filing Even</U><U>t</U>. If and only if (i)<U></U>&nbsp;the Committee on
Foreign Investment in the United States or any member agency thereof acting in its capacity as a member agency (&#147;<B>CFIUS</B>&#148;) requests or requires that the Company and an Investor to file a notice or declaration with CFIUS pursuant to
the Defense Production Act of 1950, as amended, including all implementing regulations thereof (the &#147;<B>DPA</B>&#148;), with respect to an Investor&#146;s investment in the Company (the &#147;<B>Covered Transaction</B>&#148;), or (ii)&nbsp;the
Company or an Investor determine in good faith that a filing with CFIUS with respect to the Covered Transaction is advisable or required by applicable law, then in either case, (i)&nbsp;or (ii) (either to constitute a &#147;<B>CFIUS Filing
Event</B>&#148;) the Company and such Investor shall, and shall cause any Affiliates of such Investor to, cooperate and promptly make a CFIUS filing in the requested, required or advisable form in accordance with the DPA. This <U>Subsection 5.8</U>
shall only be applicable to Investors who are Foreign Persons or are managed or controlled by Foreign Persons. &#147;<B>Foreign Person</B>&#148; means a Person or government that is a &#147;foreign person&#148; within the meaning of the DPA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.9 <U>Termination of Covenants</U>. The covenants set forth in this <U>Section</U><U></U><U>&nbsp;5</U>, except for <U>Subsection
</U><U>5.5</U>, shall terminate and be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g) or 15(d) of
the Exchange Act, or (iii)&nbsp;upon a Deemed Liquidation Event, whichever event occurs first. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1 <U>Successors and Assigns</U>. The rights under this Agreement may be<B> </B>assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i)&nbsp;is an Affiliate of a Holder; (ii)&nbsp;is a Holder&#146;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&#146;s Immediate Family Members;
or (iii)&nbsp;after such transfer, holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) or, if less, all of the Registarble
Securities held by such Holder; <U>provided</U>, <U>however</U>, that (x)&nbsp;the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with
respect to which such rights are being transferred; and (y)&nbsp;such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of
<U>Subsection 2.11</U>. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1)&nbsp;that is an Affiliate or stockholder of a Holder; (2)&nbsp;who is a Holder&#146;s
Immediate Family Member; or (3)&nbsp;that is a trust for the benefit of an individual Holder or such Holder&#146;s Immediate Family Member shall be aggregated together and with those of the transferring Holder; <U>provided</U> <U>further</U> that
all transferees who would not qualify individually for assignment of rights shall have a single <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of exercising any rights, receiving
notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.2 <U>Governing Law</U>. This Agreement shall be governed by the internal law of the State
of Delaware, without regard to any conflicts of laws principles that would require the application of laws of any other jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3
<U>Counterparts</U>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes<B>.</B><B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Titles and Subtitles</U>. The titles and subtitles used in
this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5 <U>Notices</U>.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when
sent, if sent by electronic mail or facsimile during the recipient&#146;s normal business hours, and if not sent during normal business hours, then on the recipient&#146;s next business day; (iii)&nbsp;five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid; or (iv)&nbsp;one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying
<FONT STYLE="white-space:nowrap">next-day</FONT> delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on <U>Schedule A</U> or <U>Schedule B</U> (as applicable)
hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance
with this <U>Subsection 6.5</U>. If notice is given to the Company, a copy shall also be sent to Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210, Attention: Richard A. Hoffman, Esq., Fax: (617)
<FONT STYLE="white-space:nowrap">977-9449,</FONT> email: [***]; and if notice is given to OrbiMed Private Investments VI, LP, Atlas Venture Fund X, L.P., Atlas Venture Fund XI, L.P. or Atlas Venture Opportunity Fund I, L.P., a copy shall also be
given to Greenberg Traurig, P.A., 401 E. Las Olas Boulevard, Suite 2000, Fort Lauderdale, FL 33301, Attn: Mathew B. Hoffman, Fax: (954) <FONT STYLE="white-space:nowrap">759-5532,</FONT> email: [***]; and if notice is given to Omega Fund VI, L.P., a
copy shall also be given to Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP, 1 Marina Park Drive, Suite 900, Boston, MA 02210, Attention: Jeffrey Engerman, email: [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each Investor and Key Holder consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the
&#147;<B>DGCL</B>&#148;), as amended or superseded from time to time, by electronic transmission pursuant to Section&nbsp;232 of the DGCL (or any successor thereto) at the electronic mail address set forth below such Investor&#146;s or Key
Holder&#146;s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of electronic transmission is returned or undeliverable for any
reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each Investor and Key
Holder agrees to promptly notify the Company of any change in its electronic mail address, and that failure to do so shall not affect the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.6 <U>Amendments and Waivers</U>. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Required Holders (as defined in the Company&#146;s
Certificate of Incorporation); <U>provided</U> that the Company may in its sole discretion waive compliance with <U>Subsection </U><U>2.12(c)</U> (and the Company&#146;s failure to object promptly in writing after notification of a proposed
assignment allegedly in violation of <U>Subsection </U><U>2.12(c)</U> shall be deemed to be a waiver); and <U>provided</U> <U>further</U> that any provision hereof may be waived by any waiving party on such party&#146;s own behalf, without the
consent of any other party. Notwithstanding the foregoing, (a)&nbsp;this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor,
unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that any waiver of the provisions of <U>Section</U><U></U><U>&nbsp;4</U> shall be effective (i)&nbsp;only if all Investors that have rights
under <U>Section</U><U></U><U>&nbsp;4</U> are provided the opportunity to participate in such offering to the same extent (on a percentage basis) of their pro rata share and on similar terms as the other Investors who are participating in such
offering or (ii)&nbsp;if none of the Investors elect to participate in such offering), (b) <U>Subsection 5.7</U> and this clause (b)&nbsp;of this <U>Subsection 6.6</U>) may not be amended, modified, terminated or waived without the written consent
of Surveyor and (c)<U>&nbsp;Subsections 3.1</U>, <U>3.2</U> and <U>4.1</U> and any other section of this Agreement applicable to the Major Investors (including this clause (c)&nbsp;of this <U>Subsection 6.6</U>) may not be amended, modified,
terminated or waived without the written consent of the holders of a majority of the Registrable Securities then outstanding and held by the Major Investors. Further, Section&nbsp;2 of this Agreement may not be amended, and no provision of
Section&nbsp;2 hereof may be waived, in each case, in any way which would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to any adverse effect such amendment or waiver would have on the rights of the Investors
hereunder, without also the written consent of the holders of a majority of the Registrable Securities then outstanding held by the Key Holders; provided, however, any amendment to this Agreement to grant registration rights senior or pari passu to
the Investors in connection with any future issuance of securities of the Company shall not be deemed to adversely affect the rights of the Key Holders hereunder in a manner disproportionate to the Investors. The Company shall give prompt notice of
any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this <U>Subsection 6.6</U> shall
be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a
further or continuing waiver of any such term, condition, or provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.7 <U>Severability</U>. In case any one or more of the provisions contained in this
Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision
shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.8
<U>Aggregation of Stock</U>. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may
apportion such rights as among themselves in any manner they deem appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.9 <U>A</U><U>dditional Investors</U>. Notwithstanding
anything to the contrary contained herein, if the Company issues additional shares of Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an
additional counterpart signature page to this Agreement, and thereafter shall be deemed an &#147;Investor&#148; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an &#147;Investor&#148; hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.10 <U>Entire Agreement</U>. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties, including the Prior Agreement, is expressly canceled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.11 <U>Dispute Resolution</U>. The parties (a)&nbsp;hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b)&nbsp;agree not to commence any suit, action or
other proceeding arising out of or based upon this Agreement except in the state courts of Delaware<I> </I>or the United States District Court for the District of Delaware, and (c)&nbsp;hereby waive, and agree not to assert, by way of motion, as a
defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or
proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WAIVER OF JURY TRIAL:<B> </B>EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT,
THE SECURITIES OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS
TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE
PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS
FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">CONFIDENTIAL </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.12 <U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.13 <U>Publicity</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The
Company shall not use the name or logo of Celgene or its Affiliates, or refer to Celgene or its Affiliates, directly or indirectly, in connection with Celgene&#146;s or its Affiliates&#146; relationship, agreements or arrangements with the Company
in any advertisement, press release, professional or trade publication, or in any other manner, except (i)&nbsp;as may be required by law, (ii)&nbsp;on a confidential basis to potential financing sources, including lenders, investors, investment
bankers or acquirors but only as to the fact of Celgene&#146;s equity investment in the Company and documentation relating thereto, (iii)&nbsp;on a confidential basis to the Company&#146;s lawyers, contractors, accountants and other advisors who
have a need to have access and knowledge of such information, or (iv)&nbsp;with Celgene&#146;s prior written consent, which may be withheld in Celgene&#146;s sole discretion. If the Company believes public disclosure of Celgene&#146;s or its
Affiliates&#146; relationship, agreements or arrangements with the Company is required by law, the Company shall at a reasonable time before making any such disclosure, consult with Celgene regarding such disclosure, permit Celgene to review such
disclosure not less than ten (10)&nbsp;business days prior to its proposed disclosure (unless the Company is legally obligated to make such disclosure on fewer than ten (10)&nbsp;business days&#146; notice, in which case the Company shall give
Celgene as much time to review such disclosure as is reasonably practicable), revise such disclosure as reasonably requested by Celgene, and if requested by Celgene, seek confidential treatment for any portion of any agreements or documents intended
to be filed with the Securities and Exchange Commission or other regulatory authority as may be reasonably requested by Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)
Except as provided in <U>Section</U><U></U><U>&nbsp;6.13(a)</U> hereof, the Company may not, without the express prior approval of Celgene (which may be given or withheld in Celgene&#146;s sole discretion) issue any press release, advertisement or
announcement (in whatever form) disclosing that Celgene has invested in the Company or make any other disclosure regarding Celgene or its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IKENA ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Manfredi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Manfredi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">50 Northern Avenue, 7th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Boston, MA 02210</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>GEORGE GEORGIOU, PH.D.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ George Georgiou&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>MARYJEAN DOTIS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Maryjean Dotis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>AKIHIRO FURUTA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Akihiro Furuta&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SHINICHI KOIZUMI</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Shinichi Koizumi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ATSUSHI NAGAHISA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Atsushi Nagahisa&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TAKAKO OKUMURA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Takako Okumura&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>YOSHIYUKI OKUMURA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Yoshiyuki Okumura&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ANDREW M. SAIDEL</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Andrew M. Saidel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>YUKINORI TAKE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Yukinori Take&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>MARK MANFREDI</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Mark Manfredi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SILVIA BUONAMICI</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Silvia Buonamici&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SIMONE HAUSMANN</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Simone Hausmann&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SHANE LOFGREN</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Shane Lofgren&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>KEY HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>SERENA LUNARDI</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Serena Lunardi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PAWEL MAZUR</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Pawel Mazur&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PETER SMITH</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Peter Smith&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>DOMINIC REYNOLDS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U> /s/ Dominic Reynolds&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CELGENE CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel O&#146;Connell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Daniel O&#146;Connell</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ORBIMED PRIVATE INVESTMENTS VI, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">OrbiMed Capital GP VI LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">OrbiMed Advisors LLC, its Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Bonita</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Bonita</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Member</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTOR:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ORBIMED GENESIS MASTER FUND, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Genesis GP LLC, its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Advisors LLC, its Managing Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ C. Scotland Stevens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: C. Scotland Stevens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Member</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTOR:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>WORLDWIDE HEALTHCARE TRUST PLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OrbiMed Capital LLC, solely in its capacity as</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Portfolio Manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ C. Scotland Stevens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: C. Scotland Stevens</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Member</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATLAS VENTURE FUND X, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atlas Venture Associates X, L.P., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atlas Venture Associates X, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ommer Chohan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Ommer Chohan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: CFO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATLAS VENTURE FUND XI, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atlas Venture Associates XI, L.P., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atlas Venture Associates XI, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ommer Chohan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Ommer Chohan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: CFO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATLAS VENTURE OPPORTUNITY FUND I, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atlas Venture Associates Opportunity I, L.P., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atlas Venture Associates Opportunity I, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ommer Chohan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Ommer Chohan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: CFO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>OMEGA FUND VI, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Omega Fund VI GP, L.P., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Omega Fund VI GP Manager, Ltd., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Otello Stampacchia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Otello Stampacchia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FIDELITY CAPITAL TRUST: FIDELITY FLEX SMALL CAP FUND &#150; SMALL CAP GROWTH SUBPORTFOLIO</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY SECURITIES FUND:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY SMALL CAP GROWTH FUND</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to Fourth Amended and Restated Investors&#146; Rights Agreement</I>]<I>
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY SECURITIES FUND:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY SMALL CAP GROWTH K6 FUND</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY ADVISOR SERIES VII:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY ADVISOR BIOTECHNOLOGY FUND</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FIDELITY CAPITAL TRUST: FIDELITY STOCK SELECTOR SMALL CAP FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY SECURITIES FUND:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY SERIES SMALL CAP</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>OPPORTUNITIES
FUND</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FIDELITY SELECT PORTFOLIOS:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>BIOTECHNOLOGY PORTFOLIO</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVUS PUBLIC EQUITIES, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Raymond Debbane</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Raymond Debbane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President of its General Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEALTHCOR THERAPEUTICS MASTER FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">HealthCor Therapeutics GP, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anabelle Perez Gray</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Anabelle Perez Gray</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: General Counsel</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Citadel Advisors, LLC, its portfolio manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shellane Mulcahy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Shellane Mulcahy </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ZONE II HEALTHCARE HOLDINGS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Farallon Capital Management, L.L.C., its Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Philip Dreyfuss</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Philip Dreyfuss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COWEN HEALTHCARE INVESTMENTS II LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cowen Healthcare Investments II GP LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Raidy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Kevin Raidy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHI EF II LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cowen Healthcare Investments II GP LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Raidy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Kevin Raidy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LOGOS OPPORTUNITIES FUND II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Logos Opportunities Fund GP, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Graham Walmsley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Graham Walmsley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LOGOS OPPORTUNITIES FUND II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Logos Opportunities Fund GP, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arsani William</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Arsani William</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Partner</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">Title:&#8201;&#8202;Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology
Value Fund, L.P.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">Title:&#8201;&#8202;Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology
Value Fund, L.P.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">Title:&#8201;&#8202;Chief Executive Officer BVF Partners L.P., itself sole member of BVF Partners
OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
</I><I>Fourth</I><I> Amended and Restated Investors&#146; Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Investors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Celgene Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">86 Morris Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summit, NJ 07901 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Daniel O&#146;Connell and Andrew Fedder </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***];
[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI, LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue, 54th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York,
NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worldwide Healthcare Trust PLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue, 54th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orbimed Genesis Master Fund, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue, 54th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund X, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">300 Technology Square, 8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Ommer Chohan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund XI, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">300 Technology Square, 8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Kevin Bitterman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlas Venture Opportunity Fund I, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">300 Technology Square, 8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Ommer Chohan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Omega Fund VI, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">888 Boylston Street, Suite 1111 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02199 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Capital Trust: Fidelity Flex Small Cap Fund &#150; Small Cap Growth Subportfolio </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State Street Bank&nbsp;&amp; Trust </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 5756 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02206 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: ISLANDMOORING CO FBO Fidelity Capital
Trust: Fidelity Flex Small Cap Fund - Small Cap Growth Subportfolio </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-988-9110</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Securities Fund: Fidelity Small Cap Growth Fund </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers Harriman&nbsp;&amp; Co.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions/Vault </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Securities Fund: Fidelity Small Cap Growth K6 Fund </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNY
Mellon </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 392002 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pittsburgh, PA 15230 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Advisor Series VII: Fidelity Advisor
Biotechnology Fund </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State Street Bank&nbsp;&amp; Trust </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO
Box 5756 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02206 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Bangle&nbsp;&amp; Co fbo
Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-988-9110</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Capital Trust: Fidelity Stock Selector Small Cap Fund </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers Harriman&nbsp;&amp; Co.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions/Vault </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Securities Fund: Fidelity Series Small Cap Opportunities Fund </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers Harriman&nbsp;&amp; Co.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions/Vault </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Select Portfolios: Biotechnology Portfolios </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers Harriman&nbsp;&amp; Co.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions/Vault </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o The Invus Group, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">750 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Raymond Debbane </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With cc to [***], [***], [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citadel
Advisors, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Noah Goldberg and Harry Greenbaum </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]; [***]; [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With copies to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Choate, Hall&nbsp;&amp; Stewart, LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two International Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Brian P. Lenihan and Tobin P. Sullivan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]; [***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zone II Healthcare Holdings, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Farallon Capital
Management, L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Maritime Plaza, Suite 2100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Francisco, CA 94111 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Philip Dreyfuss </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***];
[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HealthCor Therapeutics Master Fund, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o HealthCor Management, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 Hudson Yards, 28<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Anabelle Perez Gray </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen Healthcare Investments II LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o CHI Advisors LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Ave., 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Kevin Raidy and Tim Anderson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***]; [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHI EF II LP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o CHI Advisors LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Ave., 19<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Kevin Raidy and Tim Anderson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***]; [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BVF Partners L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">44 Montgomery Street, 40<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Gorjan Hrustanovic </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund II, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BVF Partners L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">44 Montgomery Street, 40<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Gorjan Hrustanovic </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biotechnology Value Trading Fund OS, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BVF Partners L.P.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">44 Montgomery Street, 40<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Gorjan Hrustanovic </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Logos Opportunities Fund II, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Letterman Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building D, Suite <FONT
STYLE="white-space:nowrap">D3-7300</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94129 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Virginia Yee </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Key Holders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">George
Georgiou, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maryjean Dotis </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Akihiro Furuta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o AskAt, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-37-2</FONT></FONT> Hirojihonmachi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Showa-ku,</FONT> Nagoya, Japan, <FONT STYLE="white-space:nowrap">466-0841</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shinichi Koizumi </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o AskAt,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-37-2</FONT></FONT> Hirojihonmachi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Showa-ku,</FONT> Nagoya, Japan, <FONT STYLE="white-space:nowrap">466-0841</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Atsushi Nagahisa </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o AskAt,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-37-2</FONT></FONT> Hirojihonmachi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Showa-ku,</FONT> Nagoya, Japan, <FONT STYLE="white-space:nowrap">466-0841</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Takako Okumura </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o AskAt, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-37-2</FONT></FONT> Hirojihonmachi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Showa-ku,</FONT> Nagoya, Japan, <FONT STYLE="white-space:nowrap">466-0841</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yoshiyuki Okumura </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o AskAt,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-37-2</FONT></FONT> Hirojihonmachi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Showa-ku,</FONT> Nagoya, Japan, <FONT STYLE="white-space:nowrap">466-0841</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Andrew M. Saidel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yukinori Take </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c/o AskAt, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-37-2</FONT></FONT> Hirojihonmachi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Showa-ku,</FONT> Nagoya, Japan, <FONT STYLE="white-space:nowrap">466-0841</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mark Manfredi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Silvia Buonamici </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simone Hausmann </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shane Lofgren </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Serena Lunardi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pawel Mazur </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Peter Smith </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dominic Reynolds </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries of Ikena Oncology, Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction of Incorporation or Organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arrys Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amplify Medicines, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ikena Oncology Securities Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Massachusetts</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g197729g01k09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g01k09.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #\ C<# 1$
M A$! Q$!_\0 'P !  (" P$! 0$           @)!@<$!0H# 0(+_\0 5A
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M%>K,3INK,#9@!O>P''H[X^[IV5G&WQMBL:[9QVW\D7TXQG./_P"<*:?]&/\
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M:?41WT5WURKMC,!CYY<IQ+C9LUGYH,3>I159)LM8DG++./ALR"65^^?4CCR
M-8&M.M'NM+^R'X%P_&&*]$/I)K6,GP)D^->$,T,S@?1O<'!W"(GX?XLRV*J7
M:F!Q\)CAO6:@8W(6I)YI+3H83MC8VL4IOW@HW^=WWQ_M32S]@]M7VC;_ -*Y
MS_.<O\U?,O\ 4QA_?UZ3?]-+W_AI^\%&_P [OOC_ &II9^P>?:-O_2N<_P Y
MR_S4_J8P_OZ])O\ II>_\-/W@HW^=WWQ_M32S]@\^T;?^E<Y_G.7^:G]3&']
M_7I-_P!-+W_AI^\%&_SN^^/]J:6?L'GVC;_TKG/\YR_S4_J8P_OZ])O^FE[_
M ,-/W@HW^=WWQ_M32S]@\^T;?^E<Y_G.7^:G]3&']_7I-_TTO?\ AI^\%&_S
MN^^/]J:6?L'GVC;_ -*YS_.<O\U/ZF,/[^O2;_II>_\ #46YV(BO,O2O*S0-
MVA>LK:F[8DL=M>(7!U"[E\?& 6]9R@JPVD\<>OF#<;IDTF,RBJ=2RWV<[--4
MD\.-D-O8V9D6.R.,#,O=E#[,L=F*WDG2QM8*TCF^)&YS0WV^77.-;UH;TM,R
M4%+@_B[@ME?T@\2766,W;JYNAGN,I+]6&JW$7)HS<J2RQLA'K AY766\O.6<
MHYRTJUTK:]6@A(8\;LJ !P<C366CQDK,8Z/$GDF_V7VZH8B[(HLRB:'VR/VV
M[%9?5/[5+Z^=?M-/IV=UFLQK'OL0-9("8WNEC:UX&MECBX!P&QOE)UL;[KML
MV;PU:"O9L9?&5ZUL.=5L37ZD4%EK>7F=7E?*V.8-YF\QC<X#F;O6PL>QT+06
MV?HUO&G]L_\ HQ9<+SG_ /U@W]/H>O4O^>5?\HA_GKR?LIX8_?'@?\[X_P#X
MA?W^^"H7/^J[JB_1^C/_ /$F&?HS_P"C_P M>>O4O^>5?\HB_GJO[*.&?WQ8
M+_.^/_XA;("'0DF%M#D<,BI %?ZJ;L# 0@T*BWNB2RC=7=H08+.&CG5-PBJ@
MILBMOC19)1+;.-]-M<>ACV2-#XWM>QWWKV.#FG1(.G-)!T01T/<$++5[-:Y#
M'9J6(+5>4$Q3UY8YX9 UQ8XQRQ.<QX#FN:2UQTYI!Z@A86:N6GXV4=A)%:U;
M 30_?5)^(-3J+BRC)3=+1;1-V/?%$';;?=%5-7719+3;9)313&,Z[ZYS9?;J
MQN+)+-=CV]',?-&UP.MZ+7.!'0@]1V6/L<08&I-)6MYO$5;$1 E@L9*G#-&2
MT. DBDF:]A+7!P#F@EI![$+J_P!\%0N?]5W5%G_7C_G)AG^O&?HSC_RU_P!&
M?T9__/T?7J7_ #RK_E$7\]6?V4<,_OBP7^=\?_Q"^BE^44CM]1:Z:E2W^JGO
M]12QH?IM]17355+?ZNQG&?JJ);Z*)[?1]&^F^N^N<Z[8SEZ]2_YY5_RB+S[?
MW:J>)^&VG3N(<&TZ!T<M0!TX!S3HV.SFD.![$$$="OG^^!H7_P#&ZHO[R89_
M^]>>O4O^>5?\HB_GJG[*.&?WQ8+_ #OC_P#B%]%;\HI!3=%:Z:F153VSJHDK
M8T/34TVQ_KUWTW,XVUVQ_P!.-L8SC_T>>O4O^>5?\HB_GJKN)^&VDM=Q#@VN
M!T6NRU $$=P0;&P?@45ORBD=\IK734R2F,:;9T5L:'I[XU4TU4TVSKL9QMC&
MZ>VN^F?H^C;3;7;'TXSC.7KU+_GE7_*(O/M_=H>)^&VG3N(<&T]#HY:@#H@$
M'1L;Z@@CW@@K9@XD.,#V180_9%11)J@^'$QSI!\/(,G26JS5XR>-E%6SIJY1
MWT50<(**(K);ZJ)[[:;8SGTM<U[0YC@YK@'-<TAS7-(V""-@@CJ"#HCLLQ#-
M%8BCG@ECF@F8V6*:%[9(I8WM#F21R,+F/8]I#FO:2US2""05S?55Q/$3Q$\1
M/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$SG&,9SG.,8QCZ<YS^C&,
M8_UYSG_HQCQ%YL.A^[*0H;JVY[*Y+^3;@ ,>NK$#'WQ471HF>67"@=@5C'$X
M )F4/L^B9:*WC1):)C@D<ED*DJA,4F]CN""+X,2>D$TRN!I(&VN/FTCX_#1W
M[^_;KU"M@^/ZNV(&KIO<R_04#ZCG/5=E.KUL:Z:F;"AU1'3F(9#*L!1VJA0B
M0RU)C!X)!JTBL/'[$I.>D9-\()%Y$1_%'Z[%D47'KK6M#0![CN>O;KLD]A\
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MW8 @L2'(BG+%R[*F@"-G8V-D;[>?< _H7G$;[<@_G.G_ -V97Y*<<"[0Y?\
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MBO2_23PE*[ K7IE]/&KJ86$T.VMH7$,R53 8F_$M=(RV9N7@UJ4.%7V7'6G
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M!LC>]^9&O+R\_P!6O>I#\.VA9MM0KH"I.@'-=61*.<KRDO-INS:]BV([65W
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MV5,?F<=<LO9'D8GR.;!6LR2N:QH+GN#"&M!+B -K_5R]V=?E6GB)XB>(GB*
M79-#,B5:WS/8_"^G;DE5BB*A#2"JJ+Z7DM-RQQ'JZG#$FH0I]Z^GT+BL'E+0
M8]*&9.B#-1<E:@X3I#BA)YN]9(>*H/4=A\2 1U]_0[^?>O)5P<KQKXU3=W5Z
M%:W]WO2_2T9E<>D8+F?LSJ?K.M)T;D 8NT?C0VM:6W/_ ,F72(?.D$$W@R$$
M;"C)\<JJW65>L5U==BD>;79I'O:UGT@;!^717H<\4$\1/$3Q$\14>=$?KZ_C
MK_J?=;?[X7XK@_!._*:KP_%;5;E@?K6><?ZG'0/_ 'DU9[=Z?]K[-_XRX?\
MB5]96+]IK?\ A]7_ &-A61^TA8I/$3Q$\1/$47.R;HK.D.>+*D-GRIE%QT@B
M<FAD?PX3=.GIV52*.%FH@&)',$'+UZ]<[X464^Q0RBR9-W1%^LU8-'+E+7N*
M<K0Q.#R$^0LLKQSUK%6'F#G.FL3UY6Q0QL8USWO<=DZ;IC0Y[RUC7.'4_0QP
M5Q/QSZ1>&<=POB9\I9QV6Q>:R)C=%#!0Q6.R5.6Y>N6;$D4$$,32UC>>023S
MR15J[);$T43]5_&M<]9VQR)3 B RID>,596M?U[8 A--TT)QB5!(J/9NF+]D
M^0;+Y;.%6CC<85;Z+"RB:"^S!XXV;.M$<=P%E<?DN&<5%2LLFEQU"E1NQ .;
M)7LPUF,<Q['M:>5Q:XQR-!CD =R/=RN VO[)?@KB?A+TP<:W.(,5/0I\5\3<
M0\1</7'.BFJY3$WLM9FBGKSP22QB6-LL8M5)#';J.?&+$,8EB<^>_MR7 4\1
M/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q
M$\1/$3Q$\1/$3Q$\1/$3Q%!2]:M^0F46(4,\]]<T'4E9K,1:8B#S[DXS:TC8
MD&[!%(NZ>39E?T"0>MR1'59VU;:1=ML.;JZ--E7NR67"A5'+Y@D_!P'Z.4_2
ML?\ CSMZ^[& ]+0/INP*ZLFYN=NGI-3)^25/ UX' 5 R5:558<51$MW,ME[D
MH2V"3YN]E"CU<._CLG>%H.L*=H19K*9*57 #6M@$;ZG9[D>X>[Y^_GH0L[HE
MW&V>EYE6DDYYOVV)A>HGF'E/JRQ*HESV$U#5C"^+LAP7FB1V2Y=S8"/(7M#9
M@0$2>LST#B<BLV%P]_LN^,B(V2%MEBJW>NXT"7 'ST-G73L0.OD=:*EO\88R
MD0U26X(JQGT*SL$3T%,A73>G64E>3+HQ>]1T9A+7=Y8DJ<$2C&0,7U6)UB\K
MTM''FT:?5RXBSD>D@[5)(Z%1V]C>NW370:V>P^7?SJ=]E@II)X!+X[74[UK"
M<F@) ;%K$VBXV:YA9AVCLBTD:43,N6@>0.!>^WWIL,*K?AKAPFEJ^2<-OM6Z
MI15-'QDPQWSC)/EWCB,UG]OEZZZJ0/NIS:AI.13V>2+?D>E)@4*R0DR9#&>S
M@J;>N\-AP@<-$AAV[0*%8,AC!FV2*;SOE.@/9[#H/OG*!NU,UQ7'PO\ -7R(
MQ^*QW;M@5)>7.N2G2J8EBG<<VL^[NA*\3M03,)\BBG)I/%YK%;(DM=DH65).
MHTJ 4&"=1.&PD>B@^OU^OYU7^[+2?9',T ^0&]?/TWOW]3W*G]6G.E'=O]M?
M*@\ZHJV&74UKB6TMRW6(>Q@(^38J^KM^=X794BS7>Q9!RM"3$TG=E')2_D\:
MV&'E'K(&JB2TR%8;)%0DAK-'70DZ/<\Q V/@!T4=J^Z^Z@ ?"QS^<CO-5F]D
MR"945T%4EC3>/SN,1TC!8O4SV;55'K)FCF686=RM0Y' "95\JQ4W*/W(U^\=
M+K.'^JNP'?95Y07GVM:(/7KO>B1T_1[U-#X?(-#;-^&SD"O+#C .:P6:\[[1
MJ6Q*2CFQ<!(@!<I(69,26&/$U6SQB\;*J(K(K)[:[:[?3CZ-L8S@HNZ/<1WY
MC])5<OSJ_&KP-07Q6=3VU2_)%'5G9<31IK:-3>(0<8(D03)OH*J(X6R.(M],
M+-\D 1<F*=?4SC[5D^<H;?\ )4V\5R)SB\ N)!WT))\B?-6ZQ?XCOC(!N8](
MA7#/-K,T(7$FAI#2LP6ZK4H/4;OF;S359!1+=1!VBFOKA5/=/;;7&-]-M<YQ
MDK9>X[VYW7OU.OS*R'Q13Q$\1/$3Q%"+Y$+IE-!\L2R?PRP'-42%>;4U!6EG
MMZQ#6\G7Z%FW!!Z](RQ]"I-,8#%W X..DCMR\+R:4L0D?3Q^,O&9W+), 4*K
M1L@?+YZ\M]]'^GL%K:L_C*J =/83=_1%F75VK>T".CYE!K$Z)G2I2*UW+F2R
M3YM(:DI"%MHG2-=N6K]%N^#D!4'=R$6HW;*(2)19+*^Y"X]AT'P]WN)[GMY^
M:LF\5$\1/$3Q$\14>=$?KZ_CK_J?=;?[X7XK@_!._*:KP_%;7GDOSY,.0ZU^
M3R(2.73LZP$T72]ZT78ZZ$%E[[<39#ZPH2X;"&B#,2LL6:;I1LMML6':.!NF
M4--=G.-ET<;]EQ' _$=[@2S!6J1/DRN3Q.6I VZS!)293M-=(XND C<#-']S
MDY7G9TTZ*VBMB+TV'>V.)I=9L5K$0,L8YH6Q2@N)+@&G;V^R=.Z]NBO;JFSX
M?=-;PJV*^?KE(38,>'2F+D73!X+</0Q1'"[)PL.((MWS-11+;&=F[I!)9//Z
M-],9_1[DV0H6<9=M8^XP1VJ<SZ\[&O;(&RQGE< ]A<QP!_NFD@^16N30R5Y9
M()0&R1/+'@$. <TZ(V"0?E!TM@>\:M)XB>(GB*LGY0N)IIVA4L/%UL?$"IU7
M$F?2 2*D;IRQ 21@6':CRHY9\U;/-AY9+[NS<B'B[55GG.CQBYW:)O\ +]KH
M'I"X3M\5XRK'0FBCN4;#YXHYW.9#.R5@9(PO:UQ9(.5KHG%I;T<QQ:'\[?I_
M[%KTWX3T*\79FUQ+C[EK \28R#'V[>-BBGR&,L4[)L5++()9(18J/\2:*Y#'
M*R;K!8B$KJ_@2P.^,;E"Y>,NQ5J_M*1BOO=G<RS&=D(C$SA(B":[QNSH)'P+
M@[MN@Q&$SS%,G(/N*R#9YH)9&'B+0CML3((Z:=P!PWE.%>*#2R%B/FR& M7)
M*U::1\+37R%.&$S$AD<DS!)-R%K7")DKPR0^(\#O?V4'I9X+]-/H99Q#PKC;
M?@\+^D_#X&OE\O1K5K\HR?"^=R&0CH!LEBU5H3NK8_UADDL+K<].%\U8"K7>
M[T3^[@OSE3Q$\1/$3Q$\1/$3Q$\1/$3Q%\TUD5=E=4E4E=D5/LEM4U-=]DE<
M:Z[935QKG.4U,:[:[?4W^C;ZNVN?H^C.,^H"#O1!UT.CV/N/N4BUS0TN:YH<
M.9I((#F[(YF[[C8(V-C8(\E_*#ENYQOLV<(N-4E-D5-D%4U<)K:?1G=+?*>V
MV-%-,;:YV3V^C;7Z<?3C'TX\!!WH@Z.CH@Z/N.O/X(]CV$![',+FAS0]I:2T
M[TX; VTZ.B.AT=%?;U5%/$3Q$\1/$7YG.,?Z\XQ__?.,?_KXB?6U^C.WTX^C
M'TYSGZ<?1C&/]><Y_P!7Z/\ I\1?-!=!REHNV62<(*8SE-9!315+?&,YQG.B
MB>VVFV,9QG&<ZYS]&<9Q_KQZ@((!!!![$'8/R$*3V/8XL>US'MZ.:]I:X'OH
MM(!'3KU"^OJJ*>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB\^79M<<_]!]?
MV]&HA\5\][EM^JP58,[TL]IT6 H"'QDI+(@W.P&$L-IC;D00E)Y"!?A)HMF.
MQW[J*9E!&I%^L^?9UU*;=@#V@T'?EL_*= _)\WN5E7Q]U^E5]#.82TXG8\&C
M1$\/[C:?9V)7EI*R) @- $7-EDYA79D^T?DY 4=$ ;G62%GDJQK%TEGBGX6N
M'Q@J.[_?<W3OHCYNNE7=TUS9972?5W2<>XPZ,@4$G<(L[@^Y.HJAORGI9*H(
M[M"FR$6M[GR?U]-XC*XF<;IR.,5A&H39D;33+BR@B/X2'%(I)--R7BJ#H#8W
MT< 0=$ @@C77>M[';KOKHJSOD'FZ6<^QJS3%J6>E<U[7Y:3VYKLL5A%48-&B
M$L5AT-KH!'(/#DR9Q:.P>#U[7T.B,?9D3IHN]T$N394BH_++HH%$G>M= !H>
M?39/4]-]2?)2Y\5%%2A.84:1M#KRQU)CK+4^K;I#6^N 6C6@A*%:"JAKVJ=X
MSL^V-E]90F[3@?XWN4W8 <)X+;"\C%=67W]V52=Z^ U^DG]:@O&/BSL01&*W
MYE.=2M)#\?U0V]'K7A7/V:8196N_$06P-+3K6D)Q>N]BO1,BI^"3MD$(M&[.
MI0TR,@P(F,$Y1]T:[O'!5YAU.O:/<[WW&B0-=R>N]G7D MT6WQ3?6MZ7/>'(
MW4P+G,ETY%(5'+\#3"CDKH;N)'7H!Q#8E;]5NM+*KG:$6:,@ZC.+.L'T)O#3
M+<''"!",[/ __P!,)L: (WK>M'7?W]#T'7MKNMGOJ%@G+GQZ2[GJLTGVD'J+
MEB?PH"N57T=&":0JN3VKTZ;=))-T7)V0DMWIPVY0;MFZY4B\5;MFR.^B"9 =
MN!/<NV?G*T3\(7ZIWAC^A,?_ ,>.^(_[]WY3OI*Q7KSX6^;NV+ L"<W-=G9:
M8VRMH]O(ZKBG11<93.GY98!&@Q,76Q8&=!L&^CN/CSN[333=KK(L*EVR+=SO
MKG0C7N;VT._7E;OK\=;_ $_H4C^-. :[XE=SMY!;HZFM?:?M8^S?MNB+UD-M
MC@:<=5**ME8J-)-6#$*[>Y*JIDWB;=9TZ0;,V^JJ**6^BI4+B>^O/L ._OT!
MM3M\5$\1/$3Q$\11,[C@X2R.8;)A4CYMDO7(,_B+M2G/L1G >N3D^::3 "NJ
MFA+3\SK\0P: L)?F0FU>RL<F7&"'8C5(CN^U&NQ&^BJWN.NOCK>NGN&U0[65
M.<QT!?7+KF0_"#>O,SF27Y6,-K>XI)U+"Y+ Z\GS@\V>1(D;;1WI66C$ONST
M?KN!CY4;OM,S2+"&1X<<D9L2#(4T![_SG]94R=@_= [OTY2-^_N/K^<KU*^J
MK:>(GB)XB>(J/.B/U]?QU_U/NMO]\+\5P?@G?E-5X?BMKP\]\_%_UC(^[)&Y
M&1^'[I=>7U=1.E\K344CDFT$M#MCO-CNNV/I ;ZQ=JJNGH\^G*CO&K/'_C=L
M>^I^$./.'H.$X&R36=\.8C&,R>JLA\-TCX:3?"_]\/'> 2WLW;NH70\9F:3,
M:P.=)NC6KBQJ,G1<YD(Y?QO;('3RZKUT<659+J1Y.Y]J*>MV329UW5T6BDF;
M#GR1)B@8%,-&[Q-J_0_\2[0U4USC1=/_ )"F/TX_1[YUXGOULIQ#F,C4<YU6
M[?L6('/86/,<CRYI<P]6G7<'J%I&0F98NVIXB3'+,]["1HEKCL;'D?@I/>P2
M\:>(GB)XB>(J7I9VMS*)^46+HO[2$H-(_0<QH(X<^YE-XZ*M<U:\2--(P].Z
M,MAJ6J+<.\;$C6'&P$22TR/)$VKE)SHARJSQ7@(_2%6#\C$UL&&M8::;ED,$
M>1FR-:5E=\P9X8TV)[7R\W@QR#DDD:X$#[6Q/H2])]O[%C*/K\*VY)LCQ_AO
M2!1H>-4&2M\)4N$\M2ERD-!TXLO+Y+D,M:CX8R%NL?6*M66-\1DNA]U5?%*>
M(GB)XB>(GB+\VSC77.V?I^C7&<Y^KKMMM]&,?3GZ-=<9VVS_ .C77&=LY_1C
M&<_H\^OO^A5 V0.G4ZZD =?>3H ?$D >:KX/_)CSB"%FB.PF]7.X=@2>Y;;\
M]W&,T<;CVZR^4-WQ6&LV0_57*/V>SHDLU:M,;96>*())J;:Z3-Q]@X8Y7^%F
M7&)DCN7[292,.+&DZYY*K6L!UKF>6M;O;B #KZ&H?8Q^DB]:I5A<X#B%RQ6@
M$C?2)P;:,8L2,CYQ!4S,TU@L#^815F2RS$<D+9'N:#4+2/SG7"?OH&.M6OH;
MK3LMD: 38/!@4F(3B)LRCK#,4^&.$B1)S,'[)19ON4&(Q_5V=^JLF!9#72K9
MGGF6)]+V4GS,,>1I5/M79G$7A4X;$ERLR1W+&^-PDD=:>PEIDC$'--U$+8W%
MK5]@\<?8)\'4. ;UCA/B'-'C/$8V2\+N=OXRO@LO-5B,UN"U$ZK6BP\$[62"
MI:?D#%0VQV0GM1,EG%W]<]RT;:,T P*+L[@3/2-RLU&[GZ+MN.!]5D&CA[OE
M^<,1%H*&(_8M5?\ Z2_=-VVN_P!351;3ZV,^ZW0XOQ&1MPTJ[,H)IW.;&9\/
MDH(MM8YYYYI:S8XQRM/M/<UN] D;7PWQ)Z"N.N%<)?S^4GX.=0QL;);+<?QY
MPCDKA9)-' T5Z-/+S6[3^>5OW*O%)*6[+6.UI3"SG&N,[;9QKKKC.=MLYQC&
M,8Q].<YSG]&,8Q^G.<_HQCVT+C8!)T!LGH .Y/N7F7YVZ,GMQ:YK>(.YS0]9
M=L=C= ')]U?@1]U6)%S+XE^2J*I,VZWRV&2F25K" 8-I8[U-T@"(;N 4;9O9
M6Q4V1Y;C<G8N[JP&?'U<[F\B^SE^0@N>]SO Q]"1Q]F:6K!'&+3@6QNYHXFN
ME;T^[N->"</PR?MYDX\3Q?GO19Z,N#JF']'GK/.V"M5B@&4XMXKJ1CQ)\=1S
MN5MVY,'$Z-]N ,MWI8L?* ^U>:'B?*!_F'D+CRI*^RM9 ZV2&6<F>&F(&'1V
M  0RSVP):8%J.CI1R^EDJ"+&GSY(L=F;W+@.F]8$BOYA$[;/(_$28K#86G6W
M:;<=J5TC8X8Z\;"ZS,]FY'ETTT9>YW/),X\@<US_ !&?/>+IU_2'3X]])/I+
MXDS(;@Y^'8?%H159;F3NYBY99%AL;6L-CIUXXL=C[;:L,3J]3%Q!EHPS05O4
MK.*6[UA=-8R5" 2FTN$Z<D,:@,7,2.0W'83M).SIR98N'AD/5U5![$8V-%(<
M"W02:XE$XW)%RZ[]+8)%2;1HL[6M7,O?JRBM+;X?I215XGRRW;)'K5A[2Z1E
M2FRRVS#!'H#Q9^9[RX%D+@-G(<-^CSA?/47YC'X#TM\3TKV8R%:C2X8PL;G8
M'$U9F15K.?XALX67"9'*6P\R?:_$B"M79"_UO(UY)&Q,_N8]WRIGRERYT"RC
M$1K/'1+^*,I3-+.TD\@J>C&!^-&S6DEF.\5P&-D0ALJ)81V,.79&)BOO,D&/
MI >$-T5-'"?B"88C$Y%L4%7[9/A;-/:\66GCV2122>+.8>1[HWO8V*)SG0LW
M*QTLC #NF,]$6/E](?'_  ;+?R6=/!4.1EQ^+P)H4N(N+9J=ZI5-'&#(>M58
M+56O9FO7V10Y*QX=&Q%2J67N#F2 KZ?=13>E)T5;1NA7EK,BRK6H)J+F1,AS
MY<,6<H!7XBPFJD;>S";Q<6LW?%Q;N//%2;_\8!X78EG@4HV()9&M8RT]&P\1
M8YUMKR*4[)WNQMV$B-S+(,3IIXF$.>QT9+W<\>VO=&\.&G9G#\ XKBG$UWW>
M+XN'I:S9.)<58Q<$'&?#.08^U#9PLC;T6-Q60L-?#6L178V00^K6^2:O':KR
M0NEIIMNFWTV=J(X431UV<JZ8RDWQOKIC*RFFJFZFR2/UL;;:X45WSII]&-]]
MLXSMG,=AU(V!U/8?$]>P^4KG) <\B,.Y2XAC3IS]$^R"6@!SM:!TT GL!V52
M GMSJ)6@(IV&:KJF&'/Y*Q!8E_$TG<US;!VJIA<*=:Q"QXZ14?9BXHEAB:CY
MG:(D1I?$D9)O";0['LDF(9GIS,[ECCH<T^M1;CGVFL=$'3^MR4Y[OJL%J)W,
M8F.Y9(G^"YK_ !1S/;)'S-8WZ-L^BK@%O&.1]&E7-\3S<8P86Q9AR+HL6.':
MG$.,X9=G<G@[T B&0L0>-5NU1DH)ZWJ$IB@EIW? FM2<CL6F+9O/IX XVY0B
M?1M-U%1A3  /:5G-ZPA12U;$ES!Z?7$.$([,"!R1"(A P8<7J\#C@#!>3$UB
M9QCLFU3?2S5&Y?RL;OM1#DZ5/'O\-ENV*D#[=F=KI2PB.=TDK(:\;&![&1M,
MKBZ0= 8>C/BCAWA/@*XP>D3)<$<3\2<6US<L\/X"3/Y2OP]A<;-%3998^[C(
M:E*SDLQ;LV/"LV+D[*%=L%27<ABV;65;4#TGQ15>E?P:7511:Q9S/Y'0L(RS
M8K2MU$)#)DIQ3,L22QLL>CY2?#R"!9D-)"/S2N*8-W#I((^>C%_55JX[*8.I
MZO7GIT"\V)<?!IAF=#)*)Z4P'62-UAK@]K7L\4L:"?#<YAP6>SG&/ WI3X@=
MF<MC>(>+65H\/1XOROBS-QT>2I478GB?&N=IM.[!AIH7UI9X+/VO99F>R-UN
M**PS#_CS;1AW;'7YZJX ^H&H6TLKF#LN;38YO%)#"K'B\;(OIM/7]:C%W4?K
MQC8@J01' 1O'W;EK+&$>Q)'>47"NJ6+'#8B=;S4E2L['4Q-6KMQ<C&PRP688
MG.GL.K,)CK-M,EA\,1N(F;%XIZD+)>FA]^/A[T:U.(,S%QCQ))C<WE9N.*L[
M\C2RN$R%Z"+$X>'.3LCN9J;"V*62-I]R-DF.FNFC'SL:7*U#VVKY^3Q$\1/$
M3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$59UM\'W=)^D;'Z,HGO*V>7WUIQJ!1N80
M>"U!0LXBYG->BW0P*=*)6C"95A_)L(OW;?,C4;Z'-0^!L<V(J@085@Q*0(UH
MM!Z]#L@CX?)W_.I;<[5C;M40DI';HZ0EW4,I>2E\:83^9U]5E;E! !R)",6L
M/0!U%%HC&G3 >1'%3219Z-7.+N) Z9N7RK!B-0;%0Z\AKY]JB/Y&'G$[GL*8
MG9!QCV]T?>$=SSU2=D6GS_TE.Z/@40DUX/&0VB*:PYTZ7J(/D]*G!T(2<L@,
M=P#:OID"('S'XQ(%LZ%-O-K6V@'9TYH)(&]G[UQT-'O[E8Y\4Q6OR%%VFQKR
MB+\YR:1?HB;Q*2UITM=TAO"V&DO Q"O&Q<F6(2JR[3.P@4^0RPTC\.<R!HS?
MB&S6QP@U0#8(PX:*+NXZM/3NT:'T-Z_-\/)6=^**>(GB)XBT=T[_ !:^A?Z#
MK9_P$?\ %5O<?*/I4'OA"_5.\,?T)C_^/'?%5_W[ORG?25:EXHIXB>(GB)XB
M>(GB*.?6ADW&^?+&D@'HZ'<E.XZ/&G'704_B$;G<1KX.,.BW9QP9C$MD$7 $
M$C8E)Y&VV[PVT49O3#9XR3>/T&S)P51K8V"?@#HGW>1\_@J:G2+:Q.L*!YAZ
MV^9&&78?C]B4WT3&^8X3R]!*/7L27PYTA;E'CY/:(>0S-FW2?$@0F?"JWU)!
MY--Q0QBZ9-%ASANYV*?31+6$="-EQ.O(]-#RV#W'YEZ(?%;3Q$\1/$3Q%1YT
M1^OK^.O^I]UM_OA?BN#\$[\IJO#\5M5N=;_QV_B[_I5Z3_\ EKE_MUX=_<QQ
MW_!V%_ERJLK2_:_,?WBI_'(E9'[2EBD\1/$3Q$\1/$7D2O\ ^):R(1U# P;^
M<Q]:H^@[U5B<4F#==V[EX9 ZF=E[EJ>C[ELW24+C0HHDV2?-23D<3>Z,W*N[
M'#Q=HR^9LUZ-;U3B&G"^Y <9F\P:U:R'/=:B;,)K3FS0N: 9611R-#VR.9(\
M,<2SF<UGZ_>C[[+GAK-^BW/7Z^"R#.,/1YP&S+Y;#21Q0X>Y)0?0P\4N/R$4
MKWLIV;MNK*Z"2M%9JP.FB8VQX,<T_KF:M]&C9NU2RILFV01;I[*J;*J[:(IZ
MIZ945WSG=13.NN,[J;9SMOM].VV<YSGWTNUH:UK1O36AHV=G0&AL^9Z=3YK\
MA99'32R2O#0Z61\C@UH:T.>XN(:T:#6[)TT#0&@.@7W])6T\1/$3Q$\1/$7R
M<-T'2"S5TBDY;.4E&[ANX3T60706TV361614UV35253VVT43WUVTWTVVUVUS
MKG./4<UKFEK@'-<"US7 %KFD:((/0@CH0>A'0J<<DD4C)8GOBEB>V2.2-SF2
M1R,<',>Q[2',>QP#FN:0YK@"""% NKOC+XZIZWT[L@]9*LY>/?N"T<9OY 9*
M1B)%7/VGUB,<C[UTJT:N6_VRF1GWS9\B%WRFL&2'K-FBB&FX[@#A?%Y,9:GC
MRVTQ[I(&/GEDKU9';V^"%[BUKF[/A\W.(M@Q!A:TM[[Q5]D[Z9>,N#W<$9WB
M=DV'L5XZF2GKXZE4RF8J1\NJ^2R$$3998Y.1HM>"*[[S>=EU]ADLS9)\^W-?
M/ZPRQX^:EE>3R*QLRE')%)H9*(^ D*[91Z@!-&0CX<+,K,T5VJKM(6^<H/E&
MJ3ENHXT0REHNCMOA36Q9CDFK6(HGB*66"6..0@N$<CXW-8\M!!(8XAQ ()UH
M$=UE,)<JX[-8C(7JKKM*AE,?<N4F2-B?;JU;<,]BJR5S)&QNL0L?$V1S'M87
MAQ8X#1B^9XPB9SBN*<AKFE1^T'K:#QV(6(*:;,R\:LFO& US&;3#(IN=7#(L
MTF(Q*2K-VY!%5TDX?BE'NJ#U??;%28.&3!PX8O+?5ZM>*"RP:?%:K-:8K;!O
M;7MG8)2 X$@N9S:<5OM7TH9&IZ4<CZ26U6S#+9S+7<EA;$HDK7\'FIIV7^'K
M3S&62UI,98=08]\#FQN9#9;$7Q, RZ$45-6EYQR^+(FX24R<'S0$HU5J$CS@
M*R7E#F8XF%CSIGHX)/=1S*8NA$11:1Y/17<0F%4T4*/]%4L(WH,?.V_%D+4\
M<TL>+CH$1Q%C3*9_&LSM!<[D;.YD($8V6>'U>[IK&Y7BW%R<)WN$,'BK>/Q]
MOCJUQ8V2W>9:E90CQAQN$Q,I9!%X\N,CLY)TEUQ:+)M M@A(=S1QD/%EWHN.
MJX_6USUK$(CU'()U,"LV*U.3D%Z14A.8HTCCR("Y=I-Q@)Q$1NS%+2/OG@)8
MO&P3M\*$H)D-1QYAC),'?!R\=6]5AARTEB=\[Z;Y+\+[$+8C"R;QVQF%G*/#
M<Z,OBC+F, =RR-W>EZ4>%'-]'MW.\+YS)Y+@"GB<97Q5?B*"GPGD(,3D9+T6
M2L8TXFQ;9D9A,XW(HKC:UZW'#9L/= 9Z<VSG_-UTPT#1C*DK8B8YG5='#Z)E
ME469%Y')J2L$&Q%QQDTDVL;!RP$\C\N$J 5FK(HKD[AY'BKP"\231V476]3L
M7>@CQ[:%R%K:=!N/FIVHI9:-F-K(FME\*.:-T<[#&0UY\3FC>Z-P ))P,/''
M"V3N<6R\5<.Y&>3B#BR?B['<0X&_1H<58:W+8O2R4#=MXZY%<QMD7&R35VBH
M8KM>*Y&YSFM8WIJBH:T>98E4%55G(01#25=!3JT;L=":\4"5U'H)*-9/*Y)#
M:V!J'G[2M8ZVDCV+1Z&"<$Y$:<?:O7R#/#+,A(@XT\?;Q<-.I5DC=XV1L6[S
MF5O#K1UYO&FE@JQ^(YM6,2NACA;SRR';G!O+XCHO3Q)Q?@..\EQ)Q#G:5N$X
M_@W$</\ "T=C--M9N[EL><?CJ.3SML4X9,[=?1AR%S*6/5Z55G+#"^4R^I0V
M]S]ESHE6W*/0LR"(/'4A%U+-&T8;CT%G+U:5FPSD!%4VZ"&NZRN^TA*#<?52
MUVWSK]/U<?3^GWMS=A]7$9*>,.,K*<XB#02XS/88X0  2?NCV]EK'HQQ$&=]
M(?!F+MOBCI6.(\6_(/F<UD3<=5M1W,@7N>0QK12KS]7$-![]%%RM^([>2@%"
M45;EO1"1\[4.YK^2#(;'H$0#3^>EJ[W9F81%+-E2\M)1E]$(7)FC)]NG'(D*
M=S/\!"9+;,/J$,$,55P5P5L=C[ER&7&X\UI6P1UW,L6'UM25X;4QF=$Z&"8-
M=]RA89_#CY^3VN;?\YZ5>&W9GC#B[AOAK)4>-.+X\S1GR=W+PVL/AZ^:$E7*
MY' X]F.@OPY/*T))H0;N2L1XOURWZN)]PF';,NH?IT58=N'*+Z!B<5AMXKAB
MAD=94%D5A2"HI(PCC"*%#U.KMIT "X;&AHUF5Q%Y..=!14I15+(?>6;]Z)4]
M<V/RK+-R2AD888+Y8Z1MJ"6S)3E;$V%TE(B>.,![6M?X4K3&V4%XV'.:=<QO
M%W =C"\-U.+.#<CD<GPHRU7JS8/+TL+2XDHS7ILC!3XF:_$7+1DJSSRUOMAC
MYX[4^/>VN_DEABL-^*/*,[J"-T0.Y8M;$1WI"%R" O(=:B$DF%:VL'E+@<6+
M2.:AHY)(NNRLA&4,%Y,/FPK7=;18S( RPU005PDTH,18I1X]N)M^#ZA!)6=!
M<$L]6W',6O?+.R*6(BUXS?%;89UV^5A86/T)N](>(XEO<73^D#A[[9#BO*4L
MQ%D^'G4,9G.'K./9/7K4<5:NT;[)<&['S-H38JP0PLK4[3)VV:_/)M+G:AC%
M2+VC.)],FE@W)>4P8S6SI6) [16,Z*@XX,B,2B4.C:I,T[&16'QD2T%CE"ID
MN<*.-WQ4J0W6>:-FGKQN/?3-NQ8G%F[D)FSVI61^%$#'$R"&&"(N>610Q,:U
MI>]\CSS/>[;@&Z_QKQ?6XC9@,3A\9)AN&.$\9-BL#CK%L9"^6V[UC)9'(Y.\
MVO5CL9#)W[,MB<5ZM:I78(:]> -B,DLE?91:,GB)XB>(GB)XBH<^9&B8H&(<
MS]:@9+:\=N!GV%Q+4'VD=MZQP4&>P0Y?@Q P,*5J*DC2"E')-L9?-'Q-^"<$
M'339%JNX40;H)Z%-I/5O31:\]AWY3YZWY#S5S4BM^M8G-X=7$BEHX7,YZA+W
M46#+)O%,OT(&)$'99NZ((-5A07\(#GPY#?4X^&[NVY!OLPU=YSMKJ4->?N_6
MMD^(GB)XBI.#J=(TA\O-45)(.N+:N2E.B:1ZIN7]R6<A:[8QFMG\1F\!TB$=
MB+V,103('0>-#9@[%,53I8@^5:,VV[U=RXV55W*70M)T 06C8)Z@AW<$D>7E
MI78^**>(GB)XBJ4G_6?6//G8?0,</\F=;]1\V2&/4\7HXU0%<T^\'UP?:Q)T
MTM*,NGDMG]>&98V/F]A9_4X_//M@Y#+^.,(\/9L<F#CZ_7Z_TS#00#S-!WU!
M)ZCW]NFE/#G6\2]_0DI,3-!WSSHZ&RE]&DX1T/'89&9J4;LQ(0II*1C"#3VQ
M!*L7?*&51+)VX-M2*A8(;16%H-D&CMZ42-'N#\1O7Z0%$WH/X\'5RRKI:0Q:
M^I%68[I**4X:*QM&$1V4M(CTWS?,8!*J'Z* %'KL<5VS&FE;QF.RZMG"V0LS
M8"QCM(S'7S-95\50[6NF];\R-@]Q_2/TK<O''.%ET&(N627A< N[KPZ$MW]U
MZSIG&8$G6$+;OQM:5S3\5C4.A&A^4+# X"!5;%VBSXB=(EC)7) D]7UPL@W0
M*A(.M#0 T/,^_J=#?4GR^"F1XJ)XB>(GB+1W3O\ %KZ%_H.MG_ 1_P 56]Q\
MH^E0>^$+]4[PQ_0F/_X\=\57_?N_*=])5J7BBGB)XB>(GB)XB>(H9][T%-^C
M^='\#K?6&/YS';/HFY(U%K)7?-JUL$E1-TP.X=*WL%P.&&GC:*3Q.%J1E^]2
M#E=1JI!L26&OT&:C18JM.CU]Q'YP1OYM[UY^\*MR(<$]>ET(X\LL)20^<]%_
M(M%.]NL)R'G9V0.:2B'.\NJ@YSUSW3>[F%!R-ADWT9K@;"2TW?[0T1$1SB;_
M '48<2D(W&A2+A\H#2UH[=P07'YR3[^PWTVK[_%!/$5-_P F?;4RYXNCF"DX
M7U!SWR,/M"(7M95G71T-#F<[CL?C-9?N;A(@!#1IY8M9?B)^;RR>+LF:#,^J
M^PS"%'B3%PDP7TV*;6[WT)UH #H=G?P/30/E\ZY\RZRNZH^+*SF\7Z"YX[,N
M_I[H6L.?N<;EKZ [0FA-S5U2QC%1)F0QZ,6I8KDZ)K(<-FTKD>HB;LGIQ<+K
M&E$@2^CEZF5-#9Z$  D@GKT'R#SUY=ELNAKEZ4K'LEYQ7U!8\&O+:<\]$.C:
M7N:)5A^XZ6W3A,Z!5_:E9S&&M)9,03Q84YF$,D\//B'H]=8._-C339Z['MGZ
MI-=-CWZ.SON-CR'N*CET1^OK^.O^I]UM_OA?BD/P3ORFJ\/Q6UY_._?D/YBJ
MKO7DJ/S&2R-F2Y2L&T#%R)-(>;?IAV-H<[NV,1W$K-F^^A[=VXE8;5TF.RKN
MQU65W<8UPW5^CK_"'!F=R'"7$,U:"!T?$%*C%C2ZS$PR/H9IC[ D#B#"&MK2
M\I?H/( ;OF"V;&8JY/C;KXV,+;L4+8"9&CF,-MIDY@3[.A&[6^^NG<*YSGR_
M*WZ>J*)WA4A$@6KZ:Y.X OR@EZ#?+YCDD+Q0I]N+()INVWV1D&012^UTQ]LB
MFFX3^E-73.>9YC$7L%D;&*R+&1W*O@^,R.1DK!X\$5B/4C"6NW%*PG1Z$EIZ
M@K VJTM.>2O. )8^7G#7!P',QKQIPZ'V7#Y^BW/[&+SIXB>(GB)XB@+V=_SK
M\"_UMF'_ '5V1[3.*OVRX,_QE9_)U]=_]"W[D_3_ /\ 9%8__*^&E/KVYK@"
M>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB
M*H3YH?XN_.?_ +P_A#_Y@8OXI-[G\E_^HY5[]X0WX_+ ^6>G&UKM3Z%O;, +
MTS$VO*4FEL<L8U7,@K)HL*L"/_N8%7?40VW:ZL$1$XC8P@B3BW,N*%-FE2R#
MM-\Q:%)I<&DCMU'<=-[_ #'IV[G?1>H/Q6T\1/$50=V?KL.%?ZE?9'^,Z2\4
MA]X[\IOT/5OGBBGB)XB>(J&K_<TK='>'0-0]N]?6)SI!JL@]-F.9:?!]-R'D
MF'V3$Y7%79.P[M7DD9E$%+6O)@UDH&Z^P/\ S*]%U^-B;=98"FO*E'R[Z_7Z
M_J4AL $ '??;0[6OE!';7Q[]5*GXM9^1FE:7\##7-,.DJ(JWIF85OS)T+.S^
M9E)+0J49 ZV-%L*V+NEKO:PROK=/6=5X2T-G!',M&0QOML4)*L%7[DCAHC8T
M2-D:UH[/37ETT?G73S_H_P"0"9=9WK0_)-5<DR2O*& UAM+;"OBRK<AK]"=V
M/$=)BC 4A4%K^9*OBC( Y$21P0:L] 38#) :>Q=P?R3##RIH:ZDCYM_IV/KO
MW==/<W_(GV"3MD7 ^N.<Z,A$7*=2R7C O*J/M^7R\[6U_#:W_=;A;29Q"7P$
M&S+P&U(&Y!EXI+XA+2;P/M*(\SE\="D%RK(,4BT:Z$[UOJ  1\-$]1UV/@>O
MD;M?%!/$3Q$\1:.Z=_BU]"_T'6S_ ("/^*K>X^4?2H/?"%^J=X8_H3'_ /'C
MOBJ_[]WY3OI*M2\44\1/$3Q$\1/$3Q%73W1\DM6<([1%C.JXNR;F)A(*N'L,
MP*H[.D\12"S^U@5:EGJ\_BD)E$71ED:;E'1X96[IVUETX=HA(Q'6NQ.6!55"
MDUI=VUT![D#L-]B=_#?8>:UTW^62M9S,:LKRB^>>NK,F-C6U74")(2;E[H6F
MXQ!(/*)*R&3BUY).+!JAG&6X6M8VJ_E3T2Z>L%CFC# MN1';N<OFY.7OLM&@
M3]\TDGR&@2>IZ?#NK6_%%/$5;73=GMJ)ZJJNTYUQB=M^M%J;F$2']/4M2<CO
MV]Z@GB\G'O\ >N3,+@,7DECB:FG<>^N];R>+L2;)&7L%!<B:#F)!(@H4AU&@
M==>Q.@?CU(&Q\?>->:JZ$\IWTESO9'24)YZG40:BOES@?R14WQUL(' +6VH^
M$_E"&3T8U@F[U =#[5LR/:6):8^K5';=TU+.Q8-=/64%G([4I;&];'WA;OR)
M.W#\QTWX:WV4\Z7(2?K3Y%PO6(>H[LJ^B:"Y+FE(QPS?543.CY58EN719D%E
M\FTC$ L84"FRT2KZ)UJQ&%9,2!#1923R7+*/+E&P9Z\W*)Z-UL'9!T"#K0/?
M1UUWV^"AE(^>Q],?Z0YR[,V=JW?8:UZT!US8;Z/6O8*LSBE:.%-FB>8I3H90
M8PU@L&T^\YWTCJ:Y'77=%OM]Z_\ %8QDI@[B=T T6CH.I[GJ?/O\WDO2)XK2
M\D_R8?$+V)T3V%?G0U<#:Z7KF5_E,J)6,SE 49V:1:KHA'BN7 O<<ML@IJ1C
MY#5OIE;;[9'5%7&=<*XQCZ'X&](W#6%X:Q&&NR71=K^LQR-BJ.DCYK%^S-'R
MR!X!!9,S9T-'8\EN^(SM"I0K593*)6>(UP;'S-V^>1[=.V-^RX;]Q5S?PT1L
MG%OC4YA'%=4=7+P).Y(AA!7"VF1DNM:=2D/MMOC77ZJVPHPSV<)?1G*"^5$<
M[;93^MGF?I,G98XXSSX]\K9:<!YAH\];'5*\NAL]/$B=RGS;HZ&UK^><'Y>Z
M1V#XV]?>R&-CO_N:=>\=59[[1%B$\1/$3Q$\10%[._YU^!?ZVS#_ +J[(]IG
M%7[9<&?XRL_DZ^N_^A;]R?I__P"R*Q_^5\-*?7MS7 $\1/$3Q$\1/$3Q$\1/
M$3Q$\1:+CW25-R,7=I]"8,Q49YWG$BKRVI3)$U([&HS)HD""R*3-]S9?#5@Z
M9A!I\9D@1;+;LD72JK/[;+E!5/6RVQ$X3.#P&P/='*YVVM:YH:YW4Z! #ALC
MIO8[A8J'-8V9F4F%AL<&'M34\A8G!A@@GKQ133CQ9.5CFQ,F9SO:2T.);OF:
M0.\I2YH=?U>A[2KY"3XA,DV<*Q@I*HJ<AKF1B$M\:MI&*#21F.-;1TMKG+@(
M3=CVB9=E]0BQT68.&KE>44K)F"1G-R.^]+FN:7#R< X \I[@ZZCJ%=QF2K9:
MG'>J"?U68N,$D]>6LZ:,'V9XXYFLE,,G>*1S&B1OMM!86N.V/7%D$\1/$3Q$
M\11QO?JRFN<2<)!V81F&T@L1&3.HC'(%65C6I(RK&'8"9DI+(&M8O*BK,8)V
MD81-R1?-&[/"Q%NCHMLIG;77SS68JY8V0OYI XM;'%)*XAG+S'EB8\@#F;LD
M =>ZPV5SV-PSZT5U]DS7!.ZO#4HW;\TC*WA>._PJ->Q(UD9GB#GO:UNY&@$E
M<=QUQ2 ZD\= R S+(C72I=./,,32L['B,W,R)T8Q'Q<> UC((J/L8X=/&=M6
M,>$"HN[?G=ML+"T'37&R^'K,(A\=Q<R,GE'/'(QY<7<H:(W,$A<YW1H#27>6
MU0\08MF,^V\TEBO3,@A9ZS1NU[,DSI/!CBBHS5V799993R0QQP.=*>L8<.J[
MBD.EZLZ <3(3!W$L$RZNG@EG/J]L:!S&L+$B&TA:+$(X[-PN=A01U 5(V#9P
M[!&46BXHFFV=IM7F[ED\0;RAL13%X87!\>N>-['QR,YMEO,QX:=. )! (.CH
M]"KF+S=#+FS'5-B.Q2=&RW3NU+-&Y7,S2^%TM:U%%*(YF NBD#3&\!P:XN:X
M#D= ]&UIS/%8Y+;,4E"C27S<+7$4#PJ'2.?2N2S20,BY$4!!16)CRATH]=,@
M11QJDR9+;8T:[_H^MG7&:3V(Z[6ODY].>V-H8QTCG/<"0 U@+B2 >P5<OF:6
M$KPV+OK!;8M14J\56M/;L3V9FR/CABKUV22R/<V*0@-:3II6LJY[7KNS9J!@
M@6JNJP9.1.5VS4M/.5+V@,19;-V;E\HJ;E\LA(J/!&^46JB:2Y(@W37=;H,T
M<J.G*"2EN.Y'*]K&Q66EV]%]6>-@T"?:>]@:WMYD;.AW*\-/B:I=LQ58\?GX
M7S.+6R6\!E:=9FFN<3+9L58X8AII +WM#G%K1MS@#*"82P% HC*9S*7N!L9A
MD<-RR1$=DU%=6 *.C'1@N]V22UW54PU'LW"^4T]=E-\)_5TUSMG&,^E[FL:Y
M[CIK&ESC[FM!)/S $K.V;$52O/:G?R05H9;$SR"0R*%CI)'D#9/*QKCH#9UT
M7'@<S"6/!X;849W>*1N>16/3*/J$6+D8_4!R@0S-B5'PUYHF\'.]V#YOLY8N
MTTW31;.[=PGHLGOI@Q[9&,D;OE>UKV[&CRN (V#V.CV\E&I9BNU:UR N,-NO
M#9A+V.C>8IXVRQE[' .8[D>.9C@'-.P0""HJM?D YR)3\A6P->WI,>%6(3JM
M^3BO.]\R6$(3<))58@:%[6($KI]!<M@\A0<#BIC$@R&';-G*SM^BV056U\PO
M0%YC;XSG"0Q$LKSN9SM=R.'B-C,?1P()YM#1V1I8%O%V&?;?2B.1GECN24'O
MKX;+3U1:BG->6/UR*D^IRQS!S))/&\-A:XN> "1-7WK6S*H3YH?XN_.?_O#^
M$/\ Y@8OXI-[G\E_^HY1%ZKD5J-OETIM$5R-6,X'L7M:#DKX(S^W6S"/24\D
M<WYT=3>1BZ&D!"KST8&"NPP[>!U<>-599G[JL,1OL_'W&T81>E4 %IZZ(ZZZ
M;^.AS#8URD[Z['3?5>C7Q03Q$\15!W9^NPX5_J5]D?XSI+Q2'WCORF_0]6AQ
MZRH+*Y9.X-'9*P*RRLGL=&SL*W^\8<QQ]+(VTE\=;.]U44VZRA6-/FAAO]S6
M<ZZM%]<K;)J8VTP4?UK.?$3Q$\14G=)L.C^ONKKEYRBH3@./P'FT%4Y^.H=@
M\X&.DIW8SBTXRN>)6%# :]AP,)%H %+#G5?(DF#0P^(2^*2=%Z1;ZM&K)$IC
M0&_:V?Q3R@=^A.CL_#W*R#EB%WO7]8[16_YC1LQD0L\NWB*O/=4&::K^/P!
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MFLY'QIC- <^('1.X4C&P8Z+M2@-R& 2!-\+=!1 _=XP529O&Q%)PLW^_IO\
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M-\3_ $(Q$RV=LBPP8O-K&/N8RJ19O7+5X2C2PDHNW4PCN\SIIIKK1M*!C96
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M7=G$4]GU^NE4;V-=3[O?[P?@1W^"IYK#GZ<0N]J(C'9_=P62UMU5TZ%[:K:
M0_D:;4@ROGHB*@:X.5E%[0LN32*6@:S>BWT"B$]!4$OI'Y%,I4 ?C]'SK(S0
M'XI[&CRM(T-$EP/0D[T !WZ@GJ-?+M>ESQ6T\1/$3Q$\14>=$?KZ_CK_ *GW
M6W^^%^*X/P3ORFJ\/Q6UC$V_\S)=_P!6#_\ PIWZ_5_LFO\ W^'_ &C5./\
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MZ:[XQMC&^NNV,;Z[:;XQMC&<8VTVQC;3;'T_1MKMC&VN?IQG&,XSCV!^OO\
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M %YKGV/X&X8CXDS3(;QDBQ=9\7K[V.$<CWSR>#5IQO(/++8EYG.(!='5@M3
M'P=*QA<:W(6PV8N96B+3.X'E<7/=R1PM)[/>[9/FV)DK_P"Y6UBO5,,IH'6<
M(N8I*93?!.L([+9I"ZBJFP;0D[;5 8U:2N:DX?5\9E3^)0_>2)$V[%\828L7
M*Z*XT0H_<LUT4\='P_:RDU^WBXZ]?$1WYZU6UDLC2Q]=Q+W/K5([.0L5V6;/
M@&,N9$7O:'-DE#&O#C8;0ELOGEK-C95;.^..6Q8A@C.W$QQ-EG?&)).3E)#=
MD AS@T$%8W?O3V4Z?H&:<[R>/R%?I*^:*K"OY7]RR6$J1^;RM,E."N!CK#9?
M#L57,<F^Z[-\B@^"D6:NKYFB^'JMM?1A\!O)YBKFJ\T(P>'R^0NUN?PY!-4K
M%E2,R-YAR27IZ@#F$LE8\<CBUX<9U*/]<VXKD;V>I5;4\T>^5W/%&1$WF&QI
MTSXM$$AS2-$AP*S"==AU$!JOIBRHJ>S*V?,D>ESB9$6H<ZG$5IE&0#LKM" L
MR<#VT7E)] BDT!G!T6,%EXZ8>H"#N1I)31M[S4^&<E-D<#0L0^KNS\]856.E
MA-D5;$S8_6Y:K7NL5X2PNFB?8BC$\33+#XD8+A:BQUA\]*![/#-U\?A@N;X@
MB>\-\5T8)>QA;M[7/:T/:"YG, 2H4<\]:61*8A*;8EO:_+EOL:CI4_;-PTC5
M-1+AI4"V80%^:5;-)TI=$CU?@(_(]$F:TG'0Q88>^YZLTE!:Q)+[':<WPY1K
MV:^.K<*\0XQV2RL..QF6R63;+7F#[C(@YU,8F#PYYH#SBN^WSP\_,1(&'>3N
M8^".2.O'C;]<V++*]>U8L!T3@9@W9B%9FGOCV?#,H<S>SS!IWFDLLN[^;8V#
MUD%OR^W)VYY!M>SK&B<K%U[G$9LB&QJ%-X@>C6\4A<8?A6LOLXZ^A V.2-Z9
M''-G/UQ&B"T5..%_)7H8K.3S>!C:V.J-XEQV/HV:TES[O1M3VW689_6;4[)7
M5J$3+;YX&121!NI218A:VW'#5NO?R5XZ\0R->"&2,R^W!*^4R-D$DKVN,<#!
M*Y[ PLUIW21H$A:V<6/ N@8M3IBXI9<P\A0$DGED_F]C!<.X%,P\NKJ.P9\,
M?0R'1%TQ%VD@6M7= +(LE\*_N;[.0*H_#$YJ1PUYM&YAK&2BQM;&2,S,%2CZ
ML^WRW*LM:]-;9(RU:LM?)CW18X&6$1D>O<LPDYXC'XYA#-4DLMK1UBVVR&'P
MW2ZEC=',^5KFRRR N@Y:^WLY=>, \.+F$3/]JZQJ\MM"<RWKUI\4=E4G0=FE
MZT/6!V]VU 9L]U>0[6&.JHL#I"S8G9;Z< 9-!I86F#>/Q$B4*1F-PD]7$G<2
MS AZUG(M-COA0KFP' D;TUA^<,;H=^Q\^A^17^\@P^ZH1SO6X7HN7R*:W>J)
M5+V:5D9N$2+9G+3+M<B7!Q\I7E>5;%U(:&=+J,H@T:0U@X&1Y-@,>.2#AGN]
M6*!UOIV^OO)^E08NS]=APK_4K[(_QG27BJ/O'?E-^AZM\\44\1/$6E^D*<:]
M$<\WQS^]/+Q9E>5-6?3[N3-6"95U'6UEPDW#%SK88LZ8I$5Q*1K=^BP5>M$W
M:C?5ONZ;ZJ95T*H.B"/(@_F6=P"*)P."0J#HO=R24,B4;BB1%1#5LH_3CH9D
M(T>J-M5%M6^[K5GA?=#5975+93*>%%,:XVR5%EOB*GFVG_R%T!V-=ECTW!:/
MM^@K^'TD%B,6O_L0]4SF-6;$(R[C!)E5$5Q5<Q QUG,U'K#!B/LFQ<_*Y(,T
MD&YI-%XRCXDI#E(&R01OLT'Y/[H'?]'QW8'S7-.@Y[ 7Q[I"J*TI^9;25VW
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M$Z$H8'51R#2A\2:N!DBD18??=JOG(8@+'FF IFXCPP>956W)#CCC42LV6(X
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M.7?7?7KL*073OR>_+SQ_1D[Z,O7XPZ*CE55ND 6EAH9V*!DCYDG)I4#A@C*
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MBX3K&ML'UI::=%6XZ,?@:B9+!ATS5:+H;Z8<)V9WQLAD=(7!G*0>3FYCS>R
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M)39#F\7/<?%3IW)N7)8HV'LL8F6U$V"7DRM".,N8 .2P6LVP.D:.UIBU)9W
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M?$3\UQ;^4H#^V!W[3XB?FN+?RE ?VP._:?$3\UQ;^4H#^V!W[3XB?FN+?RE
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M/TK.4PH,.,T4V_3AF.:(X_Y*6OMB:QC"]S6AID<'R$#J]X8R,.=[R&1L9O\
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M0G )(D6I#Y!(]8ME&%I%571\*TJ.J)&;:L5,4K<+/<:2WJYD2U:H[BXO<XH
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M6G2%+W\8 RN[.1>@C%'RJ?QJ.IQ 9:46?0V'6;6-EJQ%N\(,(J<D<(G(UG*
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MBHQNR-]M@'KUZG0U^OX?,N3?/2-]/0_QXT#34S"P&\.X47)&2727AXB7:5M
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M#'3YA&1+HFLW'-B)QT@D-9KO5TVR3ARGNMM]37.,Q>XM8]S6EY:US@QNN9Q
M)#1O0V3T&_-6+4LD%:Q/%7DM2PP2RQU8BQLMB2-CG,@C=(6L:^5P#&EQ#07
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MYO:VT@@#???;8UT([GMU'0E;.V)=!\2R_P"1&KXGRE>]^:]671->C^7)O4@
M&=@KZ:7354(ALDKRW9&_D(IK3^D*LN(N#+N2RQ-,$1A!O4H+=NR;%4)E]?U*
MG1P:=@:&B//H>_0==@_'LNAA?,EJ_'9(_CGMT36$_P"A(U2'"!_A?I(51H32
M93N.D2Q6I[- 6?$(,H[&FYI$LV1 I/'SC0)JXD 81( I=,40;HDL-2;YN8$@
M;=S#?S['GKH1\.FE,OX]*VLQ*1=D=26Q7TBJ,_V+T0RL*(5?,\#4IU$:@K>J
MH#3=9[S\<)?E6 ":R<?"B,M+1E$F_5CS0V,%$%]2S8BW0*CC]Z-[Y1K?ELDD
M_3KYMA64>**ZTS@QL'*XCVXU,_D:^P#4,I.E@Z9C+57 S<JBQ5;O51NKW[#9
M\DS71=*-<*Z-U4U<Z;ZD7G@NUOT)VH#YU@9GX_[ HGY X/?5%RRRNK4H3'(_
M3E)CZDG@8I9\\JOH'23%3MF1"PH,*-Q.%5@,)'C!$5,M!4S;-/P19ZJ5S0:3
M[0+2#T\SL'6QK6P='KT!&QUTMD,X2>XAZ8^1PN<X@MOJ6(=S2D#:->2^F8%&
M;#;R[5[68Z&R_G2Z,E"X]2O [":-C)P(>E39:NR<9G))X[+-BHQ\)W*G<- .
MBW8Z].[M[!^?W[Z=O?A54<O]%\(13XJ;ED-;SN^2?-/,-K<M=/PFFT6]@6'#
M0%OJ0&<PTK!8\H39N;!CU23"!-*Z/-(T[(&E8T]8'P PDP%.DO$)#N8;UMP<
M-_..NMZ)WL^73Y%.W@6O[+*6OV]V#9M<2NFU>N;;K=Q7%63] >RL$!4%%5#&
MZJB!^=AQS\DE&)+.R[262K>).'BY( (?!VY39(@JX9-"HXC30.N@=GR)))Z>
M?3MOX=.G>S'Q13Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$6!6!6$!M1C'QM@Q<=*&
M<4F<7L*-ID,+:J!)I#":9>-R$<X;+(.&SX<\3SC.4U<(O&2[P8_2=#7SQHOY
M[-2O;;&RS$V5L,\5F(.WN.>!X?%*T@@AS'#WZ<TN:X%KG-.7P^>S'#\UR?#7
MY\?+D,9D,+>="6D6L7E(#6O4IV2->R2&>(@Z<TNBE9%8A='/#%*S/?>A8A8\
M7ET4CY($&/2>/!"\H=[L(R*+FAHTE(GZ6NNZC($Q>N471=VGIOIMNV'I.%M-
M=]=MM,8VQG,2YK2T.<T%QTT$@%Q]S03LGX!69+%>%\44L\,4D[BR".25C'S/
M'4MB8YP=(X#J6L!/P5*2)_K"&VW8=R2#E+IJV+AKF:7&2<GY%U6!HSD!I2B)
M&2M*Z!5M$D)8?!3=OBM- )TCO*:L3D*=D8>EY-)&*K1I@?B=V6RR2NK6)98W
MRGF=9;#5$(+Q&(V!Q:\>'RN//%S>)U<X=-<T$N?K9"YDI<#F\ADJ=G(O=--G
MHL7PZW&!\S:<5*N+,L5H>I"*5_CT!,V[S23SL+6EDV-B)_KJ.P9&50L-(.,.
MNN7A3PA$284LSM&"RV7@UIC^(2DSHJYCK<&O%R0<0$5'[-SPB?L6A04JX:Z_
M?4O7MUIK.9C75+58$L+2)&/>WGVX_>AO*0!V<'@$>];-SS<0P518K1R\-\0X
M.-SZ[XI&WZEBQ$;///*"Z%L3H'QQQ%O++';8U\9</:$D^?H%.ZMIN US9-A[
MVO+H4&S&W=AKB]PY"4"Q3UVUC+XVUW?$=EY$G&$P[21E<NL_CAUL0,_8MOO_
M -V2]$#'QQ,CDD\5[&\IDUHN )#21L^URZYCYNV?-9G$5+5#&U*5VX<A8JQ^
M"ZXYAC?/'&YS8'RM+WDS" 1MGDYONLH?)IO/RC<?KJR2>(GB)XB>(GB)XB>(
MGB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)X
MB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(G
MB)XB>(GB)XB>(N"4*#0@TB:,D&(@.(8NRA8J3=H,!HP:P;J.WQ @^=*)-F;%
MDU25<NW;E5-!N@DHLLIHGIMMBA( ))  !)).@ .I))Z  =RHO>R)CY)'MCCC
M:Y\DCW!C&,8"Y[WN<0UK6M!<YSB T DD *.=Y]2P&FZNCE@,-FU@GK,5BPJC
M*["G@P>1W1)YR2 BHF$B*AU=JA]@\7DPA\7+*IJ-@ )5P8?I91;_ &2EB:RR
M*-L@^Z.DY1#&US0Z9SRT-#.8@=>8$GLUO4^Y8;*YVIC:,-MO+;ENFO'BZ<<L
M<<V2GM/BCKQ5S*6C3C/&^20@MAB)D>-#1JQZ(YSQ<]]V[4%F.($,MFW5'O0#
M+HTZJ@3E?)_'=-J0$3 (_4^Y;1BVAMDEK<;28D<*Q0GH!&"W<DFLH-%2R\<"
MXQL\'C32Q2%@EEW.)W:<^M5BY P1\W1DAEY^8M/*!S.<22 M$S&&^V>6R&.N
MFHS(9'FR[<S*1)8P'#N-]4CIPX\R!K:UV3(MG?+)7?X4<;I[,\DDCH8A(?G:
MFL]U432%W=B06THQ8JM<!(K*XF-N*6QVI+]A/V3241V9RFL8/,FT<-1>;8+X
M/O8C-X^+*H$%B49DH8C'1H?1:_!%ZY##-:9*U_AM:YHE<V*=GWS7OBC?R.:_
M?,6O:"#MI!:!O+X;'?LJQ6+RG$=2_!=]2C@G@9D;$&/RU4AL\-F>C4LM@E@M
M>()G5K4+'AY?!-$^%D8-K35JV8MF[)DW0:,VB"+5HT:HIMVS5LW3U20;MT$M
M=$D$$$M-$D44M-4TT]==--===<8QDP !H#0'0 =@/<M^:UK6M:UH:UH#6M:
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M:-M14FKT^;8,R49V=D2;P$1:RA/1$8IOJEB[]KEBNUW-Y'&H]\+M@B5K@62
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2Q$\1/$3Q$\1/$3Q$\1/$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g197729g01k13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g01k13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %[R^8'8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!V"C$@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  +$   &[          !                          $
M!NP   +$                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   +$     %)G:'1L;VYG   &[     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "Q     !29VAT
M;&]N9P  !NP    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     8X0DE-! P     #9     !    H    $    '@  !X    #70
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M3].K]$S9]'97^C5?J?[?]2C]D_9/3WM^T_:O4P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ P0'B P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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MI2M3DDN/VY=]&,[Z11\;![XX/8^N.]*_6I P[?AQ73VT;E!;07(!QO3DBV_
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M .3@X%59@N,YY.!@$_?\AZD\5N>AK[K;I*OPV55CFY.$=!*)I"7),^,;M&)
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M$021M^C_ -%E?.$9G^LB*JLR[6;;'N&/S:LB\X(P69N"1G;D'[3 KFA)(4Y
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MD2[*3E\9V+LSMC+$DX[<^0^0[#Y5NH"@*.P&.>_WUOC*U-,4IBE<9;_4U?\
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MI&'$&;A0W(/4JRW$DFKF31AS4D-:B,1M=7LQD:S33)MQDI I"H,/VB*@/O\
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M14C\Z]7)KXJ/ZN?_ /<F_P#[!9*]Q]1^^J2?FY/U&_\ XFM/<\?_  +P'_\
M"E'^J+\^QU#_ .NK_P#^*O\ ]J.NG>SS_P!B^G__ )-__P"S/6Y\^-7=*8I3
M%*8I3%*8I3%*Q:10B(2YPASK*(VS/[E7LGW-8.N=4!"Q5$Y:*.2&(;D;"<<
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M6,.E<@21>$6+]6T34N&P5^L!I+;7&4MZMO?WA$Y:2*B[RJ@D>!]H8QOC8O\
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M@!]=B&+W#$(6Z$DDDDDDY)/<FI    & . !5<GA#_LG.%?\  YI_UEZS2?\
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M,=^QX[&KZ^1BO@YGI0G:;H5)\<!9@?3=8K1N/2)'H6/_ '=SKC%:X:J=A_\
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M;1-.OWMKNYZGU#2Y[621XK2WZ;M-2BC9HI(#)[U+K5D\GB12-E&MP(V/PLV
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MH<K<2N' 7F6&E3:K E]?74O3O3;@O%=B/.NZX@/*:%8R;6@MGY4ZO>!(%)S
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MH%HEQ"\S!7(41FME!C:E1L! ]1"V-SD1KZOD$]OLH 7;OY#'SK,R#.%!<_\
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M\6\TD O;?K?HJU@NQ$[(+F&UO.I5N[>.;;XB07($\*L(Y?C4UWO^W+S_ /\
MURRO_P!$[>__ ,7G)_GSTW_^HU#U_P#4.O?_ .9^SO6'_8'[3/\ W=T[Z?\
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MF:V)B9&X@:I>[.KFK,*2(F]&F ,]2J/- 244$1@QZ#K>\@ D@ $DG  Y))[
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MTSTI'@ YP"NB>?8^H)]:[A-P3RJE#[":V6Z!_3L K!LH8=B_^GL(I?O6Q_\
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M25E5<\ES4V)D;S.7.M(\6ODBY-KV;>%*1RV_#2+5( EB4_&X&@V?HP9&B"1
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M;ZF)+\B;V]L;BX[(2F-M;DK:<<J3[1(B&TS11XEBD]8<>(P9IB@W8O=H 2P
MZ7KG0.@=0:@FIW_OPN8HXHH?=KKW>.)8G:13&BQG#&1VD9R2Q8YS@ #VWH;^
M4'U_[/>GINF=!&A2:;=7-U=7;:GICW]U=RW<<<$HN)Y+I2\8MXHX(XPJHD28
M +,[-*Q-%X\E))* RM(]DE@+T<-K;M&F;"'0=FF;*2E@^0S?J,S8  #L0A;"
M .M^FNW+:VZ!0((<J -WA1AC@8R2J 9/G@ >@ KQZ75=2E=V-]> .Q;8+NY*
M*"<A5WS.Q5> NYF; &6)YKG :6HKT^-L;R_3?NU[$28'H+U]?77M*UZ;]?S]
M=?GZYJ(HQVC0?1%'^5<=KR[?.^ZN&R,'=/*V1Z'+'CY5S"RBBM;T4667K?Y[
MT6 (-;WK^C>_;K7KZ?\ ?+  =@!] !^ZL69F^TS-CMN)./Q)K3?05.)[]JF2
M52LE#S$$$G$V <'=B 2:NVC;W-(Y&H-E*!!)-2K]I IE98]^T9 QAWH0=[#O
MXG46B)U%I%UI$EW/9Q7?A"6:VVF7PXY4E:/#Y4I)L"."""I(Q7>/9OUQ+[.>
ML-*ZPM])L-:N=)%VUM9:B9%MA/<VDUJEQNB_I%FMA,9867E9%4@@C-:NY+Y*
M9N36:8L+!.I',&Z7.;6["3/B5"C(:5K>E5(SSD)*'>P;-<B#4@%A@_00@MJ0
M.O70/R^5T?T?;]'V][;6M_=WD-Y-%/LN1&JPR(C1LT:Q@#,J[!(3R1$@\J[9
M[9/;+?\ MDU#1-2U/I_2M$N]&L[JQ$NG27$LEY;W$T<\4=Q)<$MLM)%G:!%X
M4W4Y[M4N<[C7C-,4IBE:YE=>&2IS Y GUC1C0$A27[=%) E:VP>RC#3/J1IC
MFI:,2LSY?8:;\VM"+**#H&O9O>_H6M^+6,QFQT^YRY?Q+J!Y9!D*-H994 0;
M<@8X)8YYKKFK=/-JMRMR-?ZCTL+"L7N^DZA%:VS;6=O%:-[6<F9M^UF#@%40
M;002="Q/DMMC$PDLB2SV<-Q:P1(6!6R.R!"^E$JRM'/@'=:)D,(.VH7Z#M-]
M$0E#I.'83]#$+TU]Z[ZKDNK.UMFL+%S&";A9HG>!F0E8/"3Q@5"1_:W,V6/&
M *Z#I'LDMM+UG5-2BU_7;=9S&+"6RO((;]$E0/?B[G-DR2&6Y ,?@I'B-</D
MDU)F)QD45;36X<CD\GV:K,5_<)8YE.KD7HPHDKZ4I02C1  D+^'Y"ROAV()I
MQP]CWH>M!ZU=7(NI!(+>VML($\.UC:*,X+'>59W.\[L$@@$*O&02?3M)TPZ5
M;-;'4=3U0M,\WO&K7*75RNY(U\)9$A@ A79N5-A(=Y#N.X 5L^2*E)?:<VXK
MEC12]RW?"*AN6R9/9D:H.SVNIK,0LLDH2QH/'W-EE*VXZ+6@3AES^RDNJ1IG
MB10H:S%9:I&N0B4)3LXV4+(I*J650I92PR'4GLK>0/EZ5SW!RIP2 3D#OV./
M,>?^^U0[N1N;F.7^/!M2\*])/;>Q]?W*_I:*Z+MFMK=LF7+".-[D<1S&%2"Q
M.F+@AZLJ+";BW-EC,SLZ(IR'EF5KF)"C>36Y:NNHXE(D4? N2JLH'](HP0%4
M\\?94_OQ4GE?@;N>&/)(7RY/D/,C/:M;2OC'KIMC]9LS-S<:V15[8NTG)MBU
M1(^-YI.:$,Z1Z,76?#.>W]]Z=42&K854C?7ZMJ)F4@HZ#V&X():SK8]&M*8>
MTQH#_.]/B^('\V/B\0*VU-I<! &+;AD;BO?)!).!#?"=OF>VTX!8D DY  'F
M!]_'.5T7R5?]7PF+QNV.%6;IF9V3SGP'#&B53:>5&G8>>I5SM5T.B4VA5FR!
MUE9U@,;+";#8WRX8J_44QV7N3R"0+RB24+N64J50[JQ)5]H#2G&TY;>200 ,
M'(PI#$8 QG'8%( !7=D(.XXP.0>> .<$>?D3DG2X.&NZYS9L/+'54AI!Q22;
MO!L?YQ%$O)$5I"!+>BJ2Z/BD!L2M7>O7)[ZXLDEVFDS@\EE[W;,D0N2%_5%*
M]P$]<G LAMO$C /9N(\?;+':R$@[L(HVJ0 H[<9QWC:Y/; ^+L1Y[L'@ECW!
M.3]QK8TGXMO.SU&S(9P.R\\((?Q]5%02N(.4PHA*R]#NU.=3\\V[**4(/KJ5
MR1"97EC5M7\_@L3E=B$,>GA/*W1'.V",,_MTXU#A?TRQW,0?B^'<C*&Y PRL
M0WP]B 02>UMI/Z.. #VYVL">1GN,XS^[FLGM?C^XK0>K0O%@Y#M2E8X_V]SE
M*X!3-7SKDYNN^%RNHZNO.#3/I$=:RURL/D>=N,M1VA$JR<*UELV(<W>OX43,
MP.R"6LL78Q0K@ +N!X8$L'VD%E(7(PX *[LCS..Q)H5SDX(YX P#P",]L$GM
MSY=OGA*WBKKALA<1=!\?4U-;->. NP>=4;>1'Z*B<0B#_,+L)G56M-K16/3E
MAC:&1V)3AKVP2M!3[H]U47;DDDD=6.\>JU]52$,ATR1O('BQMD%CV!#%206P
MIY&X;MH'&>*C8<?9!)##' \\C/<9(X)SC.!SWK#$G#73SXZ7O.I;S#8TW8%T
MS\5=BQ"!VBU<'Q::S1+RIU-8<QO-C8('0CO&J2C"]+4$F^S1Q',Y0N?97'UR
MAB=9V:D6IXHQ6\1,(NX# G!(\0K\<85?M MDL.<# [@ 54HQ)(!QE#@D#.UR
M3P..W8GN,>>:NW[WY/<.R.9++IYAG$QKN4R>NYK'(N-GL&6PB)J'F4L FQ&E
MLMOAAQX97%T9WQ[4M"U"[I EB5? E.^<6AXQOX;JV <,I^> <G!\C\ZU==RD
M9(R"//'WXP?VUWUNTQ,8[QM>-04X!?<\^>JCM%DA#1T3/Y/.4TSDLHCCNE;X
MQ-)?('HM[41MP5K M0DRA\;DJ9N.TCVX-J/0U)$*1O5F^$;E)VC! !&2!ZXY
M'SJ2/A(')(/?G)(\_E5$C#P5U1,I-8>Y30-A KB>-?C9C2^.6PV\1P<MW8^?
M>YH]9%O,@ZWY95E0E+"8M4"Y_/9")B]S.72)G(>FDE;O2IH8%.WB( O(R/&^
MSXAY:+:IR^3DL!G  '?&*S*MD\'G:/T?)\DX&/+_ )FI?3+BB=,'5R:TXWS.
MS2>JHKY1*^OQ@88RGJ5$-'5LD\:K1S]-K)CK%(Y#'4"%*P='_:9#+FDDQ%+7
M%1$S)JQ,$A7-[0:JIO&S&X@^$5.<\GQ=X7C/<9^63@GOB2IW9P"H;./J@4GM
MZ_[[U]V/BWKE-XMGJDC+%EC?+C^ ;AI7_9)!'J44,#O:,GIF?1%B0&VH-O.D
M214LE#VT+PGD3\B.E*22B%2@IH&M!N?$3Q@^./%5MWQ9VA@3Q] ?+- K;,9_
M1(V\=R#CGR^^I 3CQYQ0GGRP7-M'<MM]!)>3KFJ^J4UPWO/K*10V66;3[C#G
M=!!FB;RY5!8J\R,X:>+JI0G2IEI+$H5M('M*Q+G$E102'(!VJNY6.U0,X/G@
M9P/3MGRR!4[!C/).T@9)XXQP/+]]:X:8-TQT;&.&Z:>.;K1YDC/,LJJBT;-M
MFUY)0SLI62"F*M?(W%XK4\5K&U;77/JY[GSHU.3J\S-#&(^AAC2[I3"75T=T
M[67;*)O.\.64A0H8 98$EBRKQM!'&3DCMWH-S;1@J 1G.,G XQR?/U_Y5(#I
M[G6])9PCTC3AUC/W3EPS>'R1!!WF1Q>K*Z>/:ZD,1*>)(RX@T0R)D) 'MJQ?
MMR<M$K%!B\:=8N,3)$)1-490ZMC:!G(Y/D1GU\_*I()4C.3Y' 'F/X58P7K8
M2RP[UZ;T &MZ_P##>@ZUO7_MS.KU^\4IBE,4IBE,4IBE5]=Z\\W#;RKE2W:"
M0P:1VMR5T<BN]GK^R9:[P.(6.PN-9V+5DKBI\S9HE.E46>@M=@:?&!Z,B3VD
M+6LPD"E,44X[5IM8W5=ZMG;(FTD $K\2L" 2,_9P1D<'CT-'4G:1R4;(!. >
M"#S@X[Y[5H>D_%/!A\7T+SYTX]39ZG-8N5P6 ]+*(OJ]:9CI<^O>QI):,S:$
M3I6DPKAXET887:1[8XV=+4>O1&WB<D[2S'.BQ+JQF82,Z8PP5<,B-E5 49#!
M@"0.<'[ZJ(P5 8D$$D[6(Y8Y[@\X[5&7@OP=TI$./.?HSTNR]'Q6^&: HT=G
MQZ']Q].L,9:9,%<N&>D9F>J[U25XWHPIQIA 3Q-,2U!&(8BP:-$;O>DETY=R
MI0J6.W,4?;R[IG\>:JD("KNW X&0'. ?/L<?AQ4NOU+W$/[;K/\ ?Z[=_C[F
M?O,OJG^%%_HJW@KZO_?;^-<)?X3.$74C29S3=3.*;1@3=)U_=_:RPC1H=""$
MS12B^C"]&!",80CT'W:T(6M;UH6_6DDGBKMEC@E7(.V2W@=00" <-&1GD\^6
M3C%<BVEGLY#+:75W:RE2ADMKF:"0H2"4+Q.K%254E<X)4$C(%?EO\)/!K268
M2U(^I&PHT?R&E-_=O:B(LPSVZ#\A@$U\EA&/VZT'WBUL7MUK7KZ:UK(C?P05
MACMXE)R5CMH$!.,9(6, D =SSZY%3<S7-ZRO>7=Y=NB[4>YNIYV5<D[5:5W*
MKDDX! R2<9KG_J7N(?VW6?[_ %V[_'W-?>9?[/\ PHO]%<;P5]7_ +[?QI^I
M>XA_;=9_O]=N_P ?<>\R_P!G_A1?Z*>"OJ_]]OXT_4O<1?MNL_W^>W/X^X]Y
ME_L_\*+_ $4\%?5_[[?QJ*D4\*M9:[%N(4G!U%KDL-'TP.H1E]Y=3:7:NW<K
MM3],0CC$-]:GWQ?AC58;)^_"_#NA[.W'_1;MZP9SL7 B\3>Y8^!%G;A-G_EX
MSG?VY[9\JG$A+*99MFU0!XTF#G.X8W=L8';'EZU*O]2]Q#^VZS_?Z[=_C[D>
M\R^J?X47^BH\%?5_[[?QI^I>XA_;=9_O]=N_Q]Q[S+ZI_A1?Z*>"OJ_]]OXT
M_4O<0_MNL_W^NW?X^Y/O,O\ 9_X47^BG@KZO_?;^-/U+W$/[;K/]_KMW^/N/
M>9?[/_"B_P!%/!7U?^^W\:?J7N(?VW6?[_7;O\?<>\R_V?\ A1?Z*>"OJ_\
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M$KFU@V-()1,Y2]'-C,T-1*EX>U6D34UM[8@+2H49"<N68N03C@8  "@#).
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MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*@+Y/\
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MD=-2EV*CT2LVN8M-8DU/UCQ25R12@C3$HAJ!W7*Y$[,C(8@(<7MI3K7@R94
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MBX6LBN[)5VS*6VS37URD4U=W6U!J6QWTC10]"R-A"@*R%EC0D+&VUHV1LO\
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14IBE,4IBE,4IBE,4IBE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g197729g01k14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g01k14.jpg
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MEK2UMK?3U-4U<Q@9(K,C,5%7="0S,C1"UB9!0V&7L;+_Q  > 0$  00# 0$
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M1 VK"Q<M?I?XEMB/-H;8!/Q6Q]13:'NQ)64N&BHAW:+HR>--@XS '(F3GO\
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M%(BD12(I$4B*1%(BD12(I$KC+82['3DIG$-\J:L*[7<I%2<4<"X.>>G# ,$
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M+,0(G(L19CL29PHI=$8&'7>+(V>EB*N.23$<V[5X[4M?!NBIE:]JC@$WL";
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MFS^U:O"K!LX3[3<,_4P[1%9?!3#KIYX*8=;&W6PRQSMTXY6O?6CI#!.]^UK
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M_5ZO\U7GB3X2_P >?2']::+[EV9-<NX/>YMR"^?$,^X2M?..EOX=L;]4U/\
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M3(?#\92_>7S6D*T>:I"%2=W%QUK,K-\;1:SM4J,S/G8E5.51U"@G%4:J6J8
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MVKM/93[E[3K/LS:&MV>]9=K:1%JMHM35TS550Z0E5J&F6"DDJ" 22+R\-*Y
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MT_\ FGF8KQ^F4GI=XM^;OIWYB!/L]>O?0Q\56X/V:V=_"F+J^^O](SS5O?\
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M_P#=F<ZKWM?IC]UI(G=1/Z]IWY(F7VV.UVOPR_SEN#^H[P?S&R91I/\ G/\
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MIJBK[GIZC6[(K;.2O4Q1JG!2I5%1\4+X V4M82&'8.&X9L&!\9;VO?OF2O\
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MKTNH;>G==EH:BA6957:V3+2JJY"WT %R%(%R!?M,E'67!'!?F+>,G_%-2-Y
MIMM/4\VU^)A;\:1DXM-@T?$3,8NR;J8/V;N^;BS8TLOU+X-LL;=FEGEULL?8
MZ.F]MS>D?=;5;Z;D;Q;KZ'5:;2:O;.C334-3JQ6]STG754*Y:KP:=2KB5I%>
MHC&Y'*US(:5&5U8TVL#?DRWY?XS*K_+IWS_UC?K=I^O6E7^AWOI_M7NMZNU_
M_#Y,]V?]2_K)_P 4UAGPN:2W44LUVSA)%L2D$!*Q)N^<F8OWB@\( UA2;I?L
MC2CCO9-52RN?9I9*]G:_5POE[%;O;S[N:G;NXVW-U=/J=/1U>U-V==L.CJ:P
MJ^YJ=?5;.J:)*U3"FU7@J[AVQ1GP!LI/*0UJ,'#<-K!@WC+?D;V[9D]_ET[Y
M_P"L;];M/UZTA_T.]]/]J]UO5VO_ .'R9[L_ZE_63_BFH1J*3HGQ\=:?2ASQ
M,TOJA+7^)10S&O!>)%.+I@KO<K8F;N^\KN,+K6M9"Z_8WM_PNO\ Z:W*VAN=
MK-9T6UMPTUFD3:%3<A-UQK6%?W&-6NQDV;[H(%(U_<YJKQ.5/B\,^)EU9$6H
MRU W#8@-?QEO:_S_ -9E[_ET[Y_ZQOUNT_7K37_0[WT_VKW6]7:__A\E^[/^
MI?UD_P"*:HDX_-WVB"&J$X8^P+O-2.]>8$LS,9\&XDG$.4C>+[.V)J[KO'%U
MG9QE:R%U^PM?H2NI_HK?W=#1MNYLO=?0:FHE>IL+0;$TFH>@'PK/LO3Z:C5>
MCQ%1L:C4&-/,*;,,@IO;K&\VSZ^V]W]X-CT,*-;:^QMJ[-HU:Q_)4JNT-%J-
M+3J50F3\-'K!GP#-B#B";">=QOW%#E$BX06RD.O+XI+)*7M8LMTWMAGCE>UN
ME.UNF]K=%NGV.FMAVZ6-D$$?V;M#F"/&T_E'^\GF[3\!G?Y*E-SO=ND0CJQ
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MA020.R_+SD"6ZE6G2 -1T0$V!=@MS:]A?ML.9[AS/*=I"S&+R,D7$ 3H\N0
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M.B-51551961R22CA@5%A:Q(L5O>Q\;R$&P8VZ-2H]1@72I35 !4IE"KMD>9
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M1<#K?W\@>5R,;<HBC4J49ZA(RI# K24$/[[G87NE[4\&%R #F"3-(JCR9,A
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MK*2\0ERK9S&U]ID6*.O-AP0IDJ.66(%W+=N@/<U4PI5@4-1BR !20X6SY%;
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M2IA6/:5P&)/G(L3*-[7BX&8\AMT$ >G.;&]KQ]Q (U.$]4<HW6E]=0.9MM?
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MC'T;3Q-"$F#LP@X:-V#IVA13#EOR=\K'L[O+?R6/98\CR':1+E8T@GY:V!(
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M^'AQ <W#8DR-.8/"#,?A+Z^:*4H1; AI@^&$LY"#4(55@]U+,&R1;6J"H>0
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M\!@YE)@RR[Z0%524G'$(T!D'5'!SS&1&5@E5-2R'E48*X.--06!(/6)YD V
M[+$CF00+T5WPJKSI(6ID%ZSE48!AU%7D&87))+ @'L8$V[=W/_&!XZ4D%]<A
M(F,CM]L3M+$IK6<'=B:AEKIFH,'WD.G9-($D75M;I-&C.-AHTPLM'H,]CQ2#
MQEZ2 1T<2=\5\LQF6O@O)U"N+W-G [6N22>UKAC8D@<Z3'A' +;B/S1R]-NS
MG38\\+6 47"6*J2 #/P<M=GH:HVEHDZS):5UY)BL4W3'AFZN0TX-0[5T:#.W
M^H"!O6O>H]<8.E$XV0]%QZ2QH,3D0!9$/JF6E!SEYDQ=#W/-)<TJ"S, 4."
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MP.1ZO)%8(7.2]6Y!%AS>UB3C86/,<ZEF14*X@\0 U'IM4%(%7Z^*D&Y][OD
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MF,90)5>12-Q)^N$8&I84"N,#S,L+%-2'-$%LQ=K8@E44,[6=;6!(M8\R1<@
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MP+:CQW'=4\@-'Z57@DE0ET3Y$;_CF\R\NV>ZD,,6ADDA.(G<6_B,98!8\SV
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M+D];CK <28EU'#;HH/R!7:CJR6+4W:XPX=,H5'ER)1 01Y.L;\[CRQJ%-DJ
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4D12(I$4B*1%(BD12(I$4B*1/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g197729g02m26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g02m26.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $F D8# 1$  A$! Q$!_\0
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M<[5T$;$K5?CB-#'@26)];$;)%+.+^:$IMF996,W3T_6'] 61M=D!)!>=*&@
M=1LWSYF@#0HF\VG7WR.'$+0"(QK9.8DMS"@!5:@<]3?=K8[!YMU >#/RH5#Z
M!&*@1QUDRDW%IWRJFVR)=>P<PK]>MS@:\DITSZQ=$XI< 4>?18UO%Q(R1Q8L
M2%#)Z9K4B$V 7-UJJO4%K76+;V->#UJ/8H,[0/%=>H-@4UV9[ '4ZS;F.'5L
M:62 5Q*\YZ$Q-<KR:-T&RVR.R*2D;35\W)P#DQ^G]1N)Y((O.Z2.&QM56)QR
M[PCPZU3:Z?@%8\$1\J?(/2F8;@N.N9H'>[,*U:!?5O7.VB 16MTGA#>65Q-
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M('C$D@ZC7R?FNR 2!0T65[\?N#;'C1.^)\DV+"PK$-#C=\XIVX H=;VML6R
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MQX[$Q>#2/C+L^0 YLN6[:'<K/?7-8,+\T.16.+0GJI$MEEE=%DU:$%%QXE>
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M>>5])7[O=$7_ *C#_"&]:G9O/%_R4_IH5WE]1Z)V:@=FO,BKB>C="KTFA#U
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M=;*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBC+M=?+VWC?6ZK7X?S
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M?W0X!S7<))'5A@3><."%,-U2%-F*JS,:3X/K0L6ZO'S<WY<VH&6LG+K7STM
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M9GUS/U(Q>.B_)XU92&JO3HG>B[ 5L,F5S^P2 )"&X-GSR)8M#"6GFL.]KYW
M.5218K#=?JP=@J PI%C)%ENFZG5N07?6%CL %M)&:B &V#96,139B"755-=G
M- 6"0>^Q; <MBR:JE,(OQ1[^NZ@IUAZQ**48 URUR."L?4K?>YI"30>W>-G6
MFY)Z/+H-5#$[(%C<NZM7@-RA1PJ2 J[U^'/J8PLU<[9:*\6/*:8 XYA8:&@!
MT<C-.L2 <S"6ZZM/6H@#((I,PM]M&70O+M6R1/\ 4@$@-> 16C@,H.9QR+H_
MCUY&V2#=1U5Z+'"D3W2CMM&7Y/9>M"SB0,QR\SZ0):IS $O2ZC$YFL[5JR^
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MP@"V!T!L,:B0)66+8!0 !#&$C2+LT!O(\6=>N3J;"<*37KW9L@O>+UEK74M
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MZG]1DO\ Q#/N52=R/A-1].^W[&W]R_\ @NFM*]YN1_2?9]Y_0X2QWJW%[&"
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M!-@-:WD1X@H4,V6B+S M=9)((L5()7P2HA4K9S'UBDBB!HC"D@"H.O"1E@H
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M5)#+8"Q F(>YP!MS0";!-@AUV6ENI L!H'FYJ3 "QK"X$-<2 0:HM+:H/#M
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M%3:8J(L&[U.JHDDY$^>&>@3XQ%DKM3KT.*X3B 11O^,VCJX --ZDY3IH4,S
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M_'5%>?CM/+0R\]%4I:HSKK:4K<CJ6I3*U;;VI6T[WOG&DEK20 2T$@&P"1J
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M5[B70]R7R;,1D0ZS7%$7&D&"&P,<$UHX$W5 .N[:T]G87MJK)UH:"Y$X[6$
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M&84YRSFUS(;0I;[@MJ+)5.V]';&KE25P$,K0F&N0^J/IO;SFU0,-A@US1AX
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M]5KW 4'$'E(66_#XQ.IE;!;X4-:XL4S6B!4U&C*<$PX8N%&)AI+Z&MK&#QT
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M!HAC&W1 ([B%KSF\N&3"+=FT>(\,$)D$!EUEV"0W62,W<2.)%*U#L<5WDBX
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MCBQQ9UB[*'4"7-;J:&H<!Q<VS<1#)AX;CEGQ,39F0PN+WM8Y@D;G):U@);9
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MCEQ!"TS*HL\2I>JQ5HM=G5:5:[M7F2&PQC3%F+&EQD:UIST?&&;,,U-91JR
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M-;B(7.(:T/LEQ  %'4DZ!= 7W >Z_L+]7_>\MW\49^77S,.DO['F_/Y);?\
MB]=B\(P_K\/X5GPD^X#W7]A?J_[WEN_BC'S,.DO['F_/Y);?^+T\(P_K\/X5
MGPD^X#W7]A?J_P"]Y;OXHQ\S#I+^QYOS^26W_B]/",/Z_#^%9\)/N ]U_87Z
MO^]Y;OXHQ\S#I+^QYOS^26W_ (O3PC#^OP_A6?"3[@/=?V%^K_O>6[^*,?,P
MZ2_L>;\_DEM_XO3PC#^OP_A6?"3[@/=?V%^K_O>6[^*,?,PZ2_L>;\_DEM_X
MO3PC#^OP_A6?"3[@/=?V%^K_ +WEN_BC'S,.DO['F_/Y);?^+T\(P_K\/X5G
MPD^X#W7]A?J_[WEN_BC'S,.DO['F_/Y);?\ B]/",/Z_#^%9\)/N ]U_87ZO
M^]Y;OXHQ\S#I+^QYOS^26W_B]/",/Z_#^%9\)/N ]U_87ZO^]Y;OXHQ\S#I+
M^QYOS^26W_B]/",/Z_#^%9\)/N ]U_87ZO\ O>6[^*,?,PZ2_L>;\_DEM_XO
M3PC#^OP_A6?"3[@/=?V%^K_O>6[^*,?,PZ2_L>;\_DEM_P"+T\(P_K\/X5GP
MD^X#W7]A?J_[WEN_BC'S,.DO['F_/Y);?^+T\(P_K\/X5GPEBM-\>>^Q?.KP
M MTGB'78]4IO7[N3M]F?YO<6J_51TOFIN!%GV,RX&2."0I,YYJ''E$I,9AZ4
MZW';6IU:4;^PO0B[K;S[M[4W\DWBW<V]L"/&;'V1%A'[:V1M#93,5)'CL2^2
M/#.QV'@$[XV.:Y[8BYS&N:7  @G@-MN;-)LXQ.;*&3REYC<'Y 8Q1=E)R@T0
M":!.G->J?/M5:B81,(F$3")A$PB81,(F$6,EZ73K![7SZIUDW[?K[?S<"+)>
MWZ_A]KXV*][7K^/U]?7\>9H\1B(OH4\T?W.5[/ZK@L,F&P\OT7#PR_=(HW_U
MFE1:7\7?'$[[>R/#N6[6OU]MZ%2@0J0O>_O[4J2*A0G]J_\ 2VY[7[>;D>V-
MJQ>)M'& =SL1(\>T]SA[RT)-A;&ELOV7@"3S+<+$QQ_]S&M=[ZBPQ]'[XDF/
M;4YR9@>\KU]'@]IN@SV-[_&B-&L28/WOQ:5%4G7Y/3-V/>?;D?+'%X[I(<.^
M_.3%F]IP*T)-T=WI>>SVL/?'/B8Z]ALP;[;2HM,?1;^,Q+VMP9/2:_O?K[.A
M5J'R$HW^+TT=KQE6]:_)M?KO7_C>OW\W(]\MKLK,,)+]O"X7^#EC]Y:$FXFP
MWWE.-B[N'B&FOPL4GOJ+2_T2/.G_ &_D'7+J-]?7V/FX0$<]G\GM_!+K_M^G
MX_3V/7]K-V/?C%CZ+@<._OX<DD?];BU[ZT).CW!'Z%M#%,[N)'%+_5X-^\HL
M+_1%V=GV]@>V@2'X?827I9 /Z_DTM<*P'?3\FU:1O\OL_BS<CWYB-<79TC>\
MQXAK_:#HH_SK0DZ/)Q?!VI$_N$F%?'[9;-+[=>PHL,?14^1$'VUC+)RLXWKU
M]A#!ZQ09:M:_![34^J,Q4;W^+6IR]?EWK-V/?393M'PXV/RF*)S?;;.7?]*T
M)=P=L,^ASX"4>269CO:=A\O_ %*+3'T='EJ*]K;'.H!MM'KZNA[I35^NM?C2
MP0.#I:_7\241U*_]'-V/>O8;ZO%/C)[),//[Y9&]H]M:$NYF\,?BX..4?^5B
M</[=221D^P"?)S46&/$'R=!^W\;P[H;WL>OM?* ,BP:^]^'V=@=DM+U^3:/:
MUO\ #KUUFXS;NQY/%VCA1]O((OTF1:,F[FW8KS;+Q9KUN/C>UPB^_8M1:7Y9
MTZO>W\_YQ? ?N_7V_F]0L(WV/3\/M_&CF/9]/Q^OIZ9NQXW!R_0L7AI+Y<.>
M)]_>O*X^39^/A^BX+%Q5SXF&F97WS L%6A;:E(<0I"T;VE2%IVE25:_#I25:
MUO6]?CUO6MZS9!!%@@@\B-0?96J002"""-""*(/<0>2^<*$PB81,(OW7X?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g197729g04v02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g04v02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '+Z^<U@X0DE-! 0      &8< 5H  QLE1QP!6@ #&R5'' (   *H !P"
M4  (<G(S,S,Q-C@< @4 /4UI8W)O<V]F="!7;W)D("T@26ME;F$@($)U<VEN
M97-S(%-E8W1I;VX@4RTQ($EM86=E<R!/;FQY+F1O8W@X0DE-!"4      !!V
M"##6+KN6'1/X#;A^Q4#H.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'"0
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              F\
M  3V          $                          0             $]@
M F\                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M F\     4F=H=&QO;F<   3V    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MI_NU,V_S?Z']_P!;U=G-ZQTW L;5EWMJL<PV!I!/L#JZ7/\ :'>U
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ X@', P$1  (1 0,1 ?_$ !\
M 0 " 04! 0$            ("0<!! 4&"@,""__$ %,0   '  (! @0# @@(
M"0D)  $" P0%!@< "!$)$A,4%2$6,5$B01<C,CAA=9&W"A@967&!F/ D,T)2
MH;'1UO$E)S17EL'5U^$F-38Y8G)SDJ+_Q  = 0$!  $% 0$
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M(&4FSS1)J4T:-^IOFI7,TG'QZ4&\(DDY<_3I0CA98B"14W7]>OAYT_'XCF/
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MI'_Y<[D[AT<#JV8/&K =DS]J!0+XJ0A[_*@SX?LB ^2===?DI!>I)WL5]/3
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MJV,>QD\,7#(UD@X7M!). X;''@5W_5/IL]*VM;/-8-5:XO=[LU1+!-/;ZR6
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M@ZK'%)\)L\F ; D5NW*4H$BX5L9-_*BF8C4&[)!Y(,\Q# QK ]X[*G8.!C6
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MB_/2"/OA32\4@HLW<%9?#$BSKEF097A]/C:!CV=TO,:5$I$2CJO1JY$UF%;
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MLT55%2P1,XY#FO,\D%,RF]'4K8)*;?.JW3#IE6:'%&<M IE<1\ ;[>]DR3,
MH2EB\"(@S\G9Q?["\OY.9M'O>Z-C;&ULLX)#MXH02'RC;#W$;QP[[N_F?RCV
M#GL\BC@CAC;450/"X<4%.#PR3C_.XXS'3^;_ .:3E%ME[>SP-?C*XR^2CTS
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M97JY7XUE#04#"L6T9#PT1&MDV<=&1<<S31:,6#%HBDV:-&R2:#=!,B21"D*
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MB(.9TS4[0PJ=6&R2K1L\>QU6B%WJU@M#MBT</48"(D1:)"Y%(0(HOO=>[?\
M5B\X^\[4Z!ANOXQM-Z8Y=-V;-\ULF03>(:!8HB5DZFZ.C-Z%H+&[YI*/H9Q7
M7\B_4KME@GCV-E%QDV:KILT==<D\^NC^/AOLMW8O4EQ6WX+L6H4*=U?,86CY
MBCJ$#K>@]:-,5IL]1GTHQC8[0,_8S[>HQFG0;Q1ZV,T81MDCI%=D^:RORY8\
MY%E">[GX*5G813LB_JU.A.LJV?PMIM%MCH^VZ/I$:\L,'FM#"(E)&5M<?0V$
MY6WEYL;J0:1-?A:^-AB6+=::4FI-VJSB5&3LBQ9TCWG1=FSO50UE[2Y^U8EO
M&HX=(:/G$;(PE$TY'-W3%(]S@X&3E)YQ N"*O5Z[9H1*>G&,=;*_.MX^379E
M1(FZZV_HG[=?IYJ&?I]=W;SVBTN/7NG:C+%1M['3KA6.KS3KO:J);TZ/&7&2
MBJJ[A=ALMS&-O\A5:^->=WYO5ZR^&.D94S:0",(0BHSK\?/\1S^";Y\/GT/J
MIF]A?4$Z\=9+Y)9OI:FENK3!YFQV:PM:%E-ZT-M6LI<3DY7Y&_V)[48>50A*
MU6WM??JV.0D3-R1[0S54@.#N4TN7KK'YJXZZY_!=6BO4\ZC2<9H<RM:;O!1N
M?U"KZ"@XL^5Z'7E=*HUXL:=-I=LQF/E*\WDM5AK;<%VE6K:U09R"\Q-2$6@R
M;JHRD>X<E%TBQ^I!0;]E^XEP!E<F.XY?9<7RM6C;!F5PH,M6M1[$62&JV<L9
M^K65G$R[LC(9I.R2S9O\- \*U%PD^%HY3=@ZZWZ\PG76/ZK3K;Z@==L\;;87
M;9Z,;WR*W#N)")-ZO!NB1E.POK9J-PJ@:;I;OYITRJ%991$ TCGEIFG;%K/6
M58S&%:+N2.F[0BRIA?J)=<^PNKPV+43^%.-OMESB:V"L,-!R&_YRTL^5Q$K7
MX="_5Y_<H6(1F*U//+*P"OO67Q1?IHOC'3;F;>PY%.GA$X1.$3A%"+O9V7U3
MK3G><O<3R>"U[4M>VNCXC3(.X7$:#1H>7N;2=?IV"YVPL?)GC8=LE *L&Z23
M;YB1F9&,CFQQ<ND452+D>J%Y[N7!>ZE[?8UA.3H,4X(:*?&=8FM-4FU7!Y0)
M\L^26K4 $.1B1&*-''1,Z%X+IV50J7RQ1.3KKKYJ7LJ"8QK\%G(LD19N@5>
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MJDTKJ1_I1[&:LNU-81G478.N4\L;8#-ZM"]\<IB+C6_=F)KG 4X.'.P7J\D
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MU=A.IFCZEIW;BYUU>JIL=P]/M3J[2S2<@Z;OFN@*3>RR1UY@J48X!E6%$KY
M>]^V6>.3*MW?NC1^61,M#X]?U]RH."#Y'Z;?NH)=S>K]RRRI9)V#M5QH]2B^
ML_6+J70V\Q+M;98*HGM&+]C,XOS0;VE6:W)RL+C,J6&6C+'H2;0RE-:.@M#^
M-391*Q@$9\_AU^"BX'I97M5[D]Q=H[-SQLC<Y#';WA5R?262VNP7O-[3.8UU
MIN]+J]=I%_E:U66>F*5"[Z%&6&VV2.B(J%A[17&<-')/7L8X<$#\#[_Z<]O9
MY9VOS]GS/M/R]OSYASZ9UYQBG=K]%:S43#&[-2/>6,[5(5QS9[8]L.!ZO+:3
M>,8O52KK:)=NY+6L:-+)-$Z-#1[=G;(FX7*%([>S'TETLY#? _!,_3 ^2V'0
MS9] [2]Z,7O+Z9P&X57 ^C5^SJ6L?72QW"[UU"<N][QLT*M>)2QU"GML_M-J
M9424?1V.&1EK)4&<+)JS<FL1XS*FZZ/Y>'R4ZZ_+S7HAY43A$X1.$52/K(AE
M$AULH=2TSK=8.V$K>-VIU>RG&*_J+_'336EMZU=;*QE)*]1[QLI&,8.MUZRO
MT$CHR NI8D:BW9?-&;NF\/SZ^ON_-49\/:?EOUC\,J+?H?SM+DIS<T*SU+7Z
MH.)C,>N6HLXF6[273LG+:#0]4CKU.46W,U[ @$+6X9-NQE(U9O&N3S83J$G'
M6!HR/&LBK7KK\OR4Z_#KYX7H"ECG3C) Z8@"B;)V<GEN9Y^V5NH8GEH004=!
M[@#_ (.00.O_ ,440$_D"+R&>GY:']>G,,J5TW3UD*1<PU[VS&.L.M<U7NIB
M#^4TIZ\+!QSASEK@U1Q"33=I"#->?C/P_7'2R*A(GY82).NL)O[/+<_AY^?[
M+V! (#^\//\ O_O]_P#7PBUX1.$4>NVFRR77CK)O6XP<&K9[!EN4W:YUNM(,
M7TDI8;+"P+UU7(,&$9_Y0=EE9LK!BHBS$C@R:YOAJ)F_C"D5/-)]3W>Y#KU%
M2GXPP[0^T.B[WUIZY169FP?;,,0Z_7C>&991_):_3=(O;R]7*MQ<"25FJK,U
M\M1C;@$,9"/>B1RNM'NNOJG777O6[A?4W[4Z,&<]?*#4,.B.VC_>^X6*:/;+
M&QN<KBT>VZ>5EC:I.T5ZK1MIC[6F;3VMDIK*,C7]N=?A)1_,N72\X5BU17*X
MV)/P]_Y\CR4VL*]3SK-;NJG6WL5V"U_&^M<CV H[N=95?3=.J]125L=5?A7=
M!C:NXM,G&+3L77[,F=N5XB510C)Y&*._AJNR <F#G&"?<"?Z?''ES72NA^O9
M7N7;_P!2/1,9T:DZK0I.R]6&<?<L]L\/;ZR]>1>(K,Y%JUFX)X^CEW#!VF=L
M[13<&4;K%,DJ4AP$O"BM;X1.$3A$X1.$3A$X1.$3A$X1.$6$V'9/KS*Z':\D
MC=TR)]J-%CG$O=,[::-47%UJD6S3*J]D+%64Y8TQ#,V21R*/'$@T02:)G*=P
M9,I@$2+#LWV!L&H2)ZQA"#\L-[C)2FGIP?UEZN@(^W_S<UV0%I%J_-$,)XV_
MZ ZB*()11?P3&_-1<(M^0RED<T2/+8(CREF/ UWGP @OEQXB)CR-LXRN;%03
MR,$LG!30'&)ZEW9L=_\ I-P99R!S$$<A&V<9&<=S=NH/7\5(2<MD?6K[<R$>
MOH**GVMNWG0W*8&(W?7*^2Z)U6S<WQ#H,8R&@S R*/TNB"J<&D4&[%&Z60P6
MJVU=[K& .>&1EE+3 YQ-5R%S8*. 8)[>NJ8F/:'\,+RUS3V2V6&"2F%TJ98J
M&SQR.C??+R)(J*:5A':4UIML/'7WNM8'-)IJ7M&Q%['5PI*<F8?JL06@W=0)
M:(QMR]1?'*NFZU%Y*4.AIF((':O9F%F6DML^IRK0?"H*7J J,$JH"1X>.AU1
M.X3W'V:GD+9-4WV"H,9!CL=A:+A2P$8/#).'06R5X.W:B:IC! >*)CV[[U7K
M(4#'4>D*>HHV<)CDU#<!'#>ZAI;P/;014X,&GJ60%V:>WM%<YCC'57:K8XM;
M%;U+>K7>7?LHJ.?9G9FE_:3,XYD-%JE="HY=16,?"(LW%8CV;&R33RS37Q98
MRKM9:2N,@S25B8]5*'9G$53>I^C74^B=/W2JK[E1OM[H(&1VVIG%7<ZU[YG/
M;4R.?30,I8 V$-8UD5%$\B5[3*X8 \LOM'<+A3"&GF#C+(7U'$0P/ ]9H=Q%
MSG$R8<7%[MV@XR2I8>F5E.\8=U;@<D[ UJ*KEEH]BL$;6THR3A)<S^F/%6TO
M&.Y%W O'S(7R$C(R\87WK Z,P8,3KD$XF55ZOZ2;I8KWJFHNU@GEJ*:NIJ>6
MI,L<\0CK&A\,K&,J&1O##%'"_P!5I:'OD (&PY-HIZFEH8J>JX.TA+F-+"#F
M/8LXL$CB&2T[Y(:"=RK">=#633A%^#*$(43'.0I2AY,8Q@*4H!^8B(B  '](
MCR$@ DD #F2=A[RBQA)[+GK!VI&M)TMFF$CBF>$I;-_<Y=)0!$OM=,:RUE%6
M >X (9:0!HW3,(%46)^?,1+?K7&]T4=3WN=KN$T]OCEN,X/+UXJ)DSHAG(+I
M>!K3_,X+%R7FVQO=$RH%5,TX-/0QR5T[3Y/CI&3.C'AQ2<# =BX%5;^IO?JE
M8\XK\%;&9LTM[5R\M>>*7.82CYVS,V7P(^?C(J!KZ-@$J;U)VQ,(6&2KZR+M
MLV]Z( 4Q3>5>E"X4M9;Z."LIC;:IDCZJW&X31QU%7&W$53%%34XJ@ \/A<!5
M2TKQ(P-+<9STCTA:0U)KC25QJ[-8*XNT\V2Z=Y=40LJ>RB@DDJ8(J*F?//+V
M],Q[VQN,4O:0L 878:[N?IQPM:FL67A,YW\KR20=L;#I4=2ZXU+,P,_9V0@R
MAI*>N4;+HK_*QT5\H!HF*;%(LT=*).3>\BQ^;Z-J6":RRP6W4?WO:,JKE!;Z
M6+MZ6>ICX8H):FMBJ(W<,4' 1!#&&O8\MD<2UYY^C?1WJ+1NF+73W:IJK;-=
MXA=9F,IZ?O)EJ(H'&.2:J[V6F"$PQ.:*>!S7AV/6#L6$EQ.GN1]UD>6RZG$?
M)@M]MGI5B<?W>Z#3?-*\'C[@ EB"B #X ?'VYZ(-/T+Q_I<E;<">??JZJGC=
MSYTW:MI!@G8BG'D<A=D%DHW_ /.GUE<3S[Y65$L9]].U[*7;PQ %WJ!I]4JR
M/R]<K<#!)"/D21$0PC0.;_G*?*()"H<?WG/[CB/D1,(CYYDJ:AHJ-O#24E-3
M [D4\$4()\R(VMR?:<D^))7/@HZ2E'#34M/3M\H88XLGS/ UN3[3DGS7.N5T
M6B"SI<Q4D6Z2BRRA@'PFDD0RBAQ]H"/@I"F,/@!'P ^ $?L/(<6M:YSMFM!<
M3Y ;D_#&5R@"XAH&22 !YDG 'S4+B>HATL,Y*F7=ZG\P=4K,IOIMF 15,L"(
M(_&^@>WP*P@3^7[/?^_]_.E__:+HDN(_B"CXP[@_NZG.<XX<]AC&=COC.^<;
MKLO\&:F#3)]CS@</$7<=/GAQQ9QVW$1C?&%-1)4BR2:R9@,FJF14AOOX,0Y0
M.4WW\#X$H@/W !_7G=00X!P.0X @^8(R#OOR\UUH@@D'F#@^\+K=UN$#G]0L
M]YL[H[.N4^!EK+/.T6Z[Q5K$0C%>1D7";1JFJY<G1:MU3E002465,4")D,<0
M >-75D%OHZJOJGF.FHZ>6IG>&N>6PP,=)(X,:"YY#&N(:T%Q.P!.RWJ6FEK*
MF"D@:'35,T<$32X-#I)7!C 7.(:T%Q R2 /$J(5?]1+K-99JKP3"8OB#NYSD
M+7:ZYE<JT.(BG\K87*32'0"6D:ZWCDRO5EDP364<$2$@BI[OAE,8.H4_I$TQ
M4S4D$<UP:^MG@IJ=TMGND,+YJES60M[:6E9$ ]SAAQ<&X];.-UV&?1U]IXJB
M:2*CX*6*2:9K+C0R2-CB#G2$1QU#GNX0#D!I.V "2IQE,!@\_P"G[?Z!\<[R
MNKK#NX6/<:O4&TA@&84;6;J>::-G5:T#4)#)(-O *-GIWTLE9HW/M)77?M72
M4>@A$F@44W2+MPX&20,S*@Y(H5]7N]FE:9E[/L#V>S+!NJ_7Z=8OD*UH,EV>
M)9G3BUL[@YJ*5?G(ZRY1FD+"(OUXR678/R6B1<.#MVC8D9[W9SM7T5]VZE(7
MN3U,/8Z!4"]F,&&UZK&0\WF=;'6:,$Y?HBPE]\#)5&+&;![/LIPOWAW$:BX2
MD@_]",O^0E.NODLD.==H[378G#5Y%P71YS/9W4HV(".?G:+4RMV*!JLM(FER
MMQBT5T)JRQ#8D>JZ*^7374<(H'0054*18<[)]EY/&)?,\US?,I#;-YVAW9$L
MXS1G8XZFQ7T6EL6+^ZWJ\764:R+6I4:IIRT(UDI)*)FI5Y+3T+#PT+(OY!-,
MI.NNOR6.LR[K+M+3?LR[>T*N=4=*SS/DM?>.I358*X8]:<D^LEKLG?*EJ;R)
MI)?DZK85X^$N,5::W69:">34"O\ +NX^:8O%'ADHLM0_:+,K_)XJYQK2,-U&
MBZY9+E7D;5![-7G#EXYJ52D;&Y9YQ$PS.>;:-.LUF1/Q+!MYB$<5N %U87"C
ME-K\DJ126611<)*(KI)K(JD,FJDL0JB2B9@$IB*)G Q#D, B!BF 2B B @(#
MPB^31DSCVZ31@T;,FB)1*BV:()-FZ11$3"5)%$A$TRB81,($* "(B/CR/"+<
M_G^?"+9,XV.CBJECV#)@5=4SA<K-J@U*LN<?)UE003("BIQ^YE#^3F'\S#PB
MWO")PB<(G"*M#U0;)"0>4XG'%R&'V;6+-VDR"-ZZP-CNTKG-9KFWPP6*Z5R[
M6>XP23B:CJY 0=7LP34;%LWSJTL'BU5!HHE,JJ)/A^GN\_HG7+/L\=O';)"A
MQZ*@XI'RNL(YWBB677+3,&ZC]C+5(--)N&A0J<+LE?T5[%YA4V-Q<OG.>TC,
M;%#VM"G5%B\.V-"S[=Z*:10;D+/IY#\OZ)]?;Y[_ *JV3M!B>B[C08^!RCL/
MH?66_P!>L\=;*[HN?Q]=L!%G4>RD6)J]=*?:F3N%N5+DDI(ZLG .%&"JCQI'
M/6T@V79$]U10._Q?O6>DT4ZM*>H)U:@H$I@1<:/5>GSY73G;,1]IU$H*=TUW
M0(^2%,PB1P1BZ;)+$(<K42F,F4FW6V_U5D."Y=/XWEM9S^U:U?\ <[+$!*.)
MW4].7BE;A;)6:F'\V]=/48..BH>-CVJ\@>/@86,9(LH.":1T2W%5-H"QR+,7
M")PBQOL%6O5VS&[57,M&7R/09N ?,J?I3>N0UO/3I\Y/='3*E8L":D3.M4%R
ME(\C70HBY:*+D;NV;H47:)%4-/>E-L&D2FF;SJ'8NC+=Q+5K75[5:;>*1E$W
M!8S5ENI:<BG0Z]+9U(:'*6:P,+B6QVW\=/DKQ$O0"::HP(,F\0FF\GG\_CT$
M_0CY]?+;RQ^6'I0:S3HO.M/SKL32XWMM6]K[1[7=+Y8LKF)3(K?)=NX)O6M%
MK;2A1]_B[;#Q%2BHBK'H+H]\D'A'M?$\\$@C)JI-:GP\ /'Y_%3=POT^.N&4
M]:\$ZY7G-<ZW>.P:EC682SZQG=4MT@YE)9P$M<Y]DWL;";""-;+$=>6>,&+D
MR:9?E&JBSDK%%7A%B#I3GU"R_N=ZD]/S6D5'/:DQL751PRJ](K</5*\T</L.
M5<O5VT-!,V$<BL[<'.NY53;E.NL8RBIC'$1X16B\(G")PB<(G")PB<(G")PB
MZK<KU3,[@7EHOMKKU,K<>4#/9ZT3$?!1#8!\^T%9"3<-FQ#&\>"$%3WJ&_9(
M4P_;FIC'R.X6,<]V,X:"XX'C@9..>^,#!RM36.>0UC7.<>0:"3]%$+1.X::E
M3EYC*:9)NZ[]-> GLVKR2>&XZQ4,@M\-Y%3=SC7%XNRI4RF>1@T7.K'"RIDD
MT"3K<%153Y<%#/.]T<4<M1*QKI'4])$^JGX& N>2R$.#0T Y+G#!VYKE04AE
MJ(*9TL3):B>&GB87M),LT@C8USLB./+B >)X+1N6K^<_TXZS[U#^I3F%XN:)
M;37VV_MK'9;S/3CA"(TZ.E+0JLY3E5DF5CLJC>\"Z!.;;*5N7DF[9^Z^8C';
MDA&ZWGMJ])VA:JJMS7WN:G-94BG;'';9ZJMIY7!S6<=(711Y<_AC8XU(;QO:
MYKW<)(^C:[^R;Z=;++?99M+T<5-IR@JKK+=Y+S;1:JR"EB?,6V^>21TD\QC:
MYS62TL(B+":EU."UQ_HL5?->P6EILT;!=T,%RU'P*=)QVLMZA:K W-]SMG-F
MFQF+%78]5,"@G*QS.E6MPFJL"T#6WQ$'2?H4MSII^/N%MGC:_+1<K[**FXRC
MDV2GML7#0T (]8"O^U)>0X(",N\;E;9K#(9:^I@U=?VD$T\,LC],V^4#^6JK
M,LJ=13Q.)'943J*SM>T$U=V@<Z$2=H.*97F1G+JETB#AYB1,528LAD#R=MGG
M!2B7YJP6Z54>V6>=& QO<YEY1XL/O/Y/^T;SL&HJ'01TIFE[M$2YE.)'-@:]
MV[Y!$TMC,CSN^0MXWG=[B5UNZ7>XWJK=77.I=4SE@BC]2.*&F@9GLZ6CI861
MTU%20@D0TE)%#3Q-)$<3 2%E$  /L'-E8Y1K[ ]K\EZTC6R:4ZF@7M0R Q;2
M 8-95Z"4;\N#ARY9GD&;A%J8S@J:3D$U$3JD42$Y3E H]8U#JVTZ9-*VX]Y<
MZK[4Q-I8XYG 1%@<Z1KI8RUI+P&D @D.',+K&J=6VK1U)2UUY96MI*NH=2Q5
M%-2NJ(Q4-C,W8R.#FACWQASV-))<UCR!ZI6WRSN!A&MU)[<H&W(0T8PFE8%5
MI;%(^%FU'Z;5J[(5O#A(.WJZ;I-V0C,4TQ4=*IK)HIG%/[Z+7K/3]VHWUL58
MVEB94&F+*YT-/.Z0,8\<$/:O>\/$@:PL!+WAS0,A:;+K&QWRULO--4/IZ&:>
M:G@?7QBE?4R0%K9#3QN<YTS&O<8LQAQ,K'L XFKOI]5>2H@2D9]=[04X?L2<
MA&ITB */D?!S/KDI$R3E$P!]EHB$E2" #]P-X >=]LR3G%OM=QK!@GMIH1;:
M;ED$R7!U/.YIV]:"FG'N.QR7VJ^7 H;;7U0/*62(4-./(E]<Z"5S3_FA@F'/
MQV729R\V=#W(W+5LHRE-10J(QD&Z1M=I*<X^"I-IBS&B(X'1Q]OA,:&_]WO%
M-(HF]BW.#/6UX]6NO%GLP)P8J0BMK&DYP&5%9V,(<?)UKD\6CB.'KDQ6[4U>
M.("&BCQDMHJ6:OF#1S(JZED-.W8;EU!(T D9V#CU\C7-9807>Q&P[>\. F*,
MY#6=W77!B>!]J,=--JCE[;W_ & IP:-B+D$!465(03\XX@M4_K30WN_R'_VR
M*KDIG<\8IYVT5G:,$@%D3.,8RYYP5O#2D!(-SJ6U3B1G[4N#:B/?!_YA3%U,
MW'CP48=OA^3LLE1LI?T6J3&GX[!U2/2 A44[/;(>"101$ * HQ5'B;BF91("
ME#Y<[IF0X !2N2AX$,O$^O8P1T5FIZ.)H :VIJX:=K1C +8J&"LW:/\ "7L&
M, .63BH[93,$8J0&- #8J&B^[  Y#MGTC6MQL.%CL?Y<#>!W9=QK%-[+8GH]
MBJEOM\#'Y=J5;>/<)R)]H3RO/)V7J2S-N\0L;Z1BS.'J;!91N]=1R)4"MU?$
M>[!810Z%J9UVHM36.Z5-'65D$=JNE+(ZPV=]P=3OGFHWL:]M3)+$YSPR3$CH
MV!H&S'\1X>Y61M!56.YT45134TKZ^@G NMQ91ME;%'4M<6.B9&\-'&W,8D))
M(^\&!G>=3H#1;QKW9J_-I+<,G@K,XR-*&7OV64.G3=F&%JTQ'2"QHB0I3F+3
M3BW1?ETCPR3<%$G"2D@55PJ0P;FDJ>XU]XU/<6R7VT053K0V%UPM5#13U7=Z
M:HCD/82T3X@V)VP,(&0YKI,N(QHO\U'2VZR49CM=?+"+BZ04EPJJJ*'M)XW,
M':1U#7\3VX)$I=RPSA#2%/#^#[0__7M>?_9G*/\ Y>\[[]GW#_MZO_[K:/\
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M4  \>>-D8.Y>?1D=?:$OEHIKM>+C<!74E300U4U!;K;35T5/4B*N?0T_!VO
MV1],]\M1,^**H>Z)A=Q+-WIV9[4I>P]@CYEH\N-,AI?+XB*M-7IS.IO+(=O0
M6J<XZ*:ZP<U/1Q7,P1]\^5HJU!TZ.J[1.@!TBIYWT<VZEEJ-0?9USG-)!+:X
M(:RGI&4LM21;V.J'#O\ !/40M=4&8R1QEC7/)D'#D 9IFD;/H+3^E;12V"V4
M]=!;)HJZI+(WU55.RH<'U5544;XN\2SDF4=M)-V3'-A!+(P%:.&,4ER40GRV
M*X";W H2WVRR6!DJ!_Y1%8A])GA3I&'S_$_3@1( B5-,A/V>>I_8M"X8G%35
M\\BKK*JH8<\P8I)3"1X\/9X!Y#FN.;C4C^Z,-./#NT$,+A[0]C!)G?GQY]NP
MQW.!IU3JR8)5NLP$ F! 3 D-#Q\87V!Y\%\,FZ(B4/(^ $1\>1_7G-@HZ2E&
M*:FIX!C'W,$<6WD>!K=O9L%QI:BHG.9IY9CS^]D>_?S]8E=D$ '\P ?]/.2M
ME.$3P'Z<(G")PB<(G")X#].$3A$X1.$3A%H(@'Y\(GN#SX\_?A$\A_1]O_?_
M -OG_IX1/<7]0_7\_/"((E_?X_U_G_9^?"( @/Y>!_+_ .G^_P"[A%KX#] _
M\?S_ +>$6@B ?F(?[_\ N_I_+A$ 0'\A_IX1!$ _,?'[^$6OY\(G")PB<(G"
M+SE^HOUO]:7=>S-E;X!HM9;]*/I%<;0>;5W='/7V[3KT8&,_%86.\5.BS=T^
M3<6%*0*@W0F2I#&J%(@#8QQ$"NWMS_7]OJI)>D/TIN?3J-UV.NG4#".M4E<3
M51PM;\HWG0MTL^INX]U9G#D]YD]"C&LA''@AE"K1YVSUT207F)%15% 4$Q-/
M?UUUC*AZRKHN5$X1.$3A$X1.$3A$X1;.1D6$0Q=RDH]:1T:P;JNWS]\Y19LF
M;5$HG6<NG3E1)!N@B0#'5664(FF0!,8P  CS1))'#&^661D44;2^221S61L8
MT9<Y[W$-:UHW<YQ  W) 6IC'R.:R-CGO>X-8Q@+G.<XX#6M:"7.)V  ))V"K
M,ZS7BEI=XO4'E%+=6"1MZL751O2GYI^)!G;G#'%#1KU"LN1> C.K-) Q6+E.
M+.Z.@\,5LJ!5A G,7#J"PU$W=J>]VB>IXN#N\%RHY9N,NX SLF3%X>7>J&EO
M$7; $K*5%AOE+31UM39KK3T<S7/BJI[?5PTTK&?SNCGDA;&]K,'B+7$#Q(5G
M_,NL2G"+8OY2-BFZCN3?LXYJD'E5R^=(-&Z90#R)CK.%$TR% /S$Q@#FIK7.
M.&M<X^302?D,K6R.20AL;'R.)P&L:YQ)\@&@DE1VN_<SJ7FZGP+UV3Q"K.?8
M<X,Y?3J<V?*%3 1."+$9<7BYR@'W320.I^A?/V'>%)5'BS!(S@:'/,@[-K&_
MYG.DX0UO^L[ Y;K(QV2[R=GPVVM':N#(R^GDC#W.W :Z1K 2<[8.Z@_NGK+]
M&:EFN@NLX["05OOC*HVH:BA3*[8KB 6UM"OSP)7"#"%=)&;#*D:_$66348F2
M]QE3F0]XAJJK+>Y[75U-LA+I'4E2ZCJHXW5E*VH$3^R=)+2LJ(>%D@!>'N P
MTAV!E9ZT:6JA>J"GO-,V*FCKZ(W*A-;!!<)J%U1'WF.EA#WU#YY:<O;$(HI'
MA[FEK'' 7D:ZX_X2+ZF=_P"S=2JDC*4VXUJ_7"(KT7GPTZH5\6OQ'H),VY[$
M2+(HU(Y)Y2G7JIVQ2)&4=IKQX-@,7JE0VMI+;;Y:J_L@[E/3272OFAHH(:ZG
M=-&VIB>_NTK:-KP2V":&.22(D99.X^MG:&YZ&K[_ 'R&MT=36K3]927D6Q\=
MYO3:O2G84TT]+=JRKFFJVW.*WMIS-<H*FD;'-$)S"ZD#06^F C[M!V-2^8W7
M19N.C) 3&'*L32:S$ U;G3,<C29;TVVM965<-C*?"6&8>:/7W;A 7"\ =N=N
MU:637='$\LL]+'58']]2127!SS_A<V9DD-:6 C!=3T5*^1CWL+(2TEV-&HO1
M/:0&T-PN6I)PW/%1@6X%QSR^S*75-PG;PGE3UMH.V,/#BLR4?J]78UJP8H]8
MKCHS-BO\W'1^C6U:!H[%83^1<QN7,ZMF>=1:I@ "G(C7P7<)E22>/G14$3DX
M[]6ZJJP^.FM%T;'*#VC(ZEUJ94,(X0*EW8VZ>I]4X+*ZHJ#PD\3G.))QKO2)
M31.XM/Z==;79+V5-'IFFEN#79>0^.\ZQNM7<X9>(@]K2/I"QP:Z.-G" IA5V
ML]DXMF:/I5'P?*8Q8"B1!I'+I/$A H)E%TG#*3+!VJ0O@#']H#[?!!/X ##P
M(6:MX7-I:"PVMC\$%SG]KN"!QBG;4,<\  <6_%@G*Z_<]3W^]S-GN-+7W&5H
M+6RW[5,M0]C,Y#60T]MJQ" 2?4CJG,!)Y_S'M0Y+V,G"@-B[(?1DU"_QL?2L
M_A&94Q$!]P)R[Y8S\1_+VG32;>T/S(8P 8.1]D:IJ,]ZU/'3M<-XJ"UQ-+>>
M<5$LI>2,[$1Q\AEOGBS+=7XX/L:DW)^[H*RLD SL#)67(P/('^+N;!G.68P!
MU>Z]0E;72;5"S&U[3:9F5K,Y%QWUW09*)KA9&0C'+5H>3BJRWCC/XPCA5,SI
MF_5D4U42F(*9_/MYQJS1LE71U44^H+]632TT\4;9[@Z"E[22)S&&6&CCA,D8
M<1Q1R.D:6Y:0X%;D#:OO$,E7=KCV+98W21VZ.W6IX8UP+Q!-0T4%4QY /"YU
M4YS7'(</"FG/>ED@[TB&H2&H]8Y*78/Z9'/HA@ZO3Q53\%RT"^GOPT>2A@A7
M5CF4(-TA*-22#UK\.5D6S5DS1_91^=K)#IZNU)'IBDUAI"JNL513T[J*&:Y.
M;-)13P/K(:">:E%%55<K:>5DE/%43MQ42LBB:QH#<]#_ &>HM.:CU%Z5;GHR
M_5FF[M:F36Z"]P4MSDH;E<VU#:^[W3ODM16&&9SJ>:DJZB%DQDJ*ATTFT3I?
M2S'0\3#M4F43&,(MDB7VHM(YFW9-4B^1'VI-VR:229?(B/@A #R(CX\\^O(H
M88&"."&*&-HPV.*-D;&CR#6!K0/8 L%%#% P1PQ1PQM #61,;&QH'(!K &@#
MP "Y "E 1$ #R/Y\W,#R"W%KRHMA(.(UBW4>R:S1JU0#W*NGJJ*"")1$ $RB
MZYB)IE$1\>3& !$0 /OS8J)Z:DB=/530T\$8S)/42,BAC'(%\DA:Q@S@9<0/
M;D[[L,,]1*R"GBEGFD)#(88WRRO/B&1QASW' W !7V:G:+(IKLS(*(+%!1-5
MN8ATE2&#]E0ATQ$ARF#[E.41 Q?N B \UQ212QMEA?')%(T/9)$YKXY&D9:Y
MKV$M>TC<.!((Y%:7QOB>Z.1CXY&.+7L>TL>QP."US7 .:X'8@@$'FMSS<6A.
M$3A$X18EU378C+TH)JI"V"V6BUO'+&K4^JLDWT[-K,D =2"R22RJ"#=A'-S$
M6?OG"I$6Y5$P'W&.!0Z/K37-#HYEM@=;[I?+S>ZB6FLUALL#:BY7"2FC$U4]
MC7OCCAIJ6(M?45$CPV)KV;.SMW'2.C*W5LEPE97VVS6FSP15-WOEXG=3VZ@C
MGD,-,Q[F,DDEJ:J4.93T\;"^4M?N TE;C+-7A-4C99=C&S5>FZW)C"VFIV9E
M].L%>E 1(X(@_:@HJF9%TW4(X8O&ZJC9V@(G3/[B*$)NZ+UK;M:4==+34EQM
M5QM58;?>K)>(.[72U5O9ME;%40ASVF.:)PEIYHWNCF821PN:YK=K5ND*_2-7
M1Q5-507.@N=(*^T7FTS]ZMESHR]T3I*>8M8X20RM=%402,;+#(.%S<.:YV4N
M=S74TX1.$6&@["8R:\_P;AH, -R^=&,^D?'5\?5 \!]*"0%((P93W#\,8\'@
MNP7 S<4?C%%,.@#THZ .H_X3&J+;]O\ >!1]Q[1^.^$\/<N]\'<N^<7J&E[Q
MVXDS$6=H"Q=V/HWUR-/C5)TU<OL(P=Z[[V;,]SW/?#3<?>Q28!=WDP"#L_O.
MT[,AQS( ^0\_T>?_ *#^[S^OWYW_ ,,_O^'Y+I*QO?=1K= A;)*RAGZRM;@Y
M"<79MHN36^828L%GX()O462K(IUB) 3WF7]B0F\JB4"F\=0U-K2T:7H+M5UI
MJI);5;JJXOIX:&N>)FT],^I$3:IE*^F9VH9P=H^0-CSQ2%H!QV?3NDKKJ2MM
M5)1BGC9=+C36^.>:KI(^S?45+*8R/@?4,G+6.?Q<(CXG@88'$C,1*YV,U:(>
M9Q;M!<4U_1=.F(J*-7:Y7K2VGJ0%F;G<UYQ]8>(J,K.0A 21E4VJ!%A,H=5@
M50A 'GAEI]+.M*"ITK>]436"JTYK"OH:(VFU6B]P7+3HN\1FMLK;A/ ZGO(8
MT,;61P,,A+GNIN)K O:+GZ,=(5T.J+-IN.^4VH-)4-76?:=TNEGEM]_-IE;%
M<HNXP2MGM)<XO?2/FD<P-:QE3PO>5.B$L<382KGBE7*Q6QB%5%Q'R##P8X")
M0(#]JV%7[ /D4@.!?M[A 1#S](6V[4-V;*^B?+(V%S6R&6EJZ7#G D!HJH("
M_8')8' ;9P3A?/\ 7VRLMKHVU;(F&9KG,$=335.6M(!)---*&;D8#RTGP!PH
M%^J19K'4>H<W-U2?F:U,IZ]UM9)RT#)O8B2(RE.PN9QLFT(^CUF[DK:1C7;I
M@^0*J";IFY7:KE.BLH0V2.WT^IPN -_K]!E50R_:C4Y[LIV=Z8#;=<RC-]:]
M0N;S2\]MSDEC5O)JQ8L7S.0I> 9+;WKA6/I^E:_*Q-A@X>;2(E%9\><;O6R"
MUNM==3!UUU^*N1L1Y='\]_=OA6E]M=EB,^ZS;YU\ZIZE6'/;>@8#8T<PRB(O
M459]R9+PU.2>-)*.J\E+2%QF;4UK0C.Q#N1:O7LI*&8/5SNU'7N5**!/6RR5
M+2=AO/5/J+V5[,-LHU;I@6^3FI:)):?;KE0M@A=*K%2LT[0[!LYT9N&O5@J5
MM>-+Q'1 HP%6N#>&E6,<TL#658C/'WCK;X_17ES\QMYYZ'+S6-IJUZAC3KLK
MU>B+)V&Q>)T'L+T=S>@5B_:[9=3TVN8OL^FJ9IJ.W9UKKZP65U766IJ1LG!L
MX)A:'<[GUE;J3KIM"R5A9M25-O?L>OSS]-M[..F+&1R;LAW,ZNQEPNMNRK*R
M=?\ 0\T;Z#=K)HEEI*>Q5&V'M5+):[<_EK&YKR,S1RV&!C964?K11+$\;MW!
M6!F;=LQC^I/XJ=>7[+IO^4%O =^''7(>NW90^>)Y*D\(X3QQH8_XO'8G-(/I
MHSOXH^(./'A4B"E-?+ 85/<[^0\_L\)X9^GBLD]R7%KTC<.J/4^.OUUR^A[6
MOL%VU6S9U8'E.O%FJV-UJ"?,LOKMUBU6\W50MLY;&$G8I*NNF=A5JU9EX^-D
M(\KUR[3)UUU^2C5HMBL'IN;*:'R VS[GEFA]8>Q.N-^OMGT"Y:C/0.D=?ELZ
M>L'^>6:XN+C=8>#O$7>GL59JZBI,L$GT8TG(*(/*&=,)(K[]M_+KY+KM:]11
M3;<TRRVS<7U^T KWNMU:R5@YZZ]C[Q-MZ^\TVPJHF=WZOO*7GEZJ]AI#]NJW
M>9_=X=2!NJ)3*.TD$D7<:V**\D/L !^@!PBUX1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$46.\0N?\3CM #(4P?&PK32,!5^Z7SYZG*$8_%#P/E,78H@</ ^2^
M0\#YYUO6 #M+7\.#BPVNK[0-!<XQ=D[M0P#<O,?$& ;\6,;KN?HZ;4/U[HUM
M'V/?':FLHI#48-,*O[0@[LZISD=W;/V;I\@CL@\D$9"_F8>FS7^X;?U"<=6A
MAGJ_;1UNN!8)S2X"?F**E*'G6XQ:U@CR2D E*M3S0LC,$8V:8'$@@JT=),R*
M@/6KC4:)EH+!%0FVS2-NEF%DBM\E.VL@E[[3\+\-9)-'%&SB=6,F8TRL:^)[
MXYG,D9ZS9;?Z7SJ'TC#4+]04T#[#J,>DFHNL-1/22V]]/,^3A;))%2U=:^I$
M4EC[G(1QB.6E!HVR,=[]Y[.?4/D5G);_ -QKUGT>HN"JH9#U9RAU&)I <ASH
MQDTD_P!IMK)L4H&2(O+1B3L"G]WO<F*;W]KJ(M7$3"CJ-)\7%]PZIIKN#V?$
M2WM6&M8WM' 8+HY"UA=Q-:2 #T..Q:7J8:,V>ZV2LK8\=XCK*V:WF?+0.%]%
MJ!]HI0\NRYHH[O.T;!Y8-UUUMT[EM*4!G;?4([.WM^N8A75<0[)KX^Z.80$3
M-7%8H6:5&28B/DPG:*L".0(8"&.0"E-S;,^OXI*:84FDF"G80^.!]PCIZDYX
MA+-)5VRZR%X)W[-[&D!H&""5CKCIJMH(YI9_XLM=&\]HVLMND]+5=%&T8'%2
MW5_?GR0D@X<+M-$3G/'NMTIZ.O6F3=IR5LS9]J4@8I?CO--[*;#< =@4I0]S
MEO.UZ79N!4]ODX_ 3 ?<(>!\AXC[IZ1A') V'3;J>:4ROB?=(VEDAS@PU$N@
MZNKB W<WLZB,L.[<')6"<;=+*9IM=^D6*4PF!W=*&UT<<D1_F9)!;;W;(,'D
M<Q.<=]\<LMU'TR.J]&*(UWJ%AS%8P "AV]TM0)J^/'CXB(4]NW4$/'V]S8/'
MD2E\%^W-+KIZ1I'B63A;-P=FY]-Z1-44@<P# :126*E:0&X;@Q@ #;P*QDEA
MT=/&8)]1ZWJ:<O+S3U4=3)3EY))>:3^,S2AQ._$V/(SL>><A7GJS06N5:!7*
M[UVH$.$E1K5%MC5RR*GDT5W< _:-UHM)U5Q1/((F4*9B"P"7XY4BB4?L7G5]
M3#4\]FN]5/IBCNU9#:[@^)M3JVZW&>:1M+,]D;!/;F32.DD#6\#)X7OXB&R,
M>6N&3TSI?0%-J*PSMN=73NCO-KD-5462,M@$==!)VKY)KS5- B+1(720RQMX
M<N:Y@(=0UBGI']5,KT?$>P6:2<G/Z[8]"S=^E6D[;4EGHRC60&1OC>3@FE+.
M[K[0'C8GU!RBUCSQC5N^2=*R9I!-0GGM;Z:WZ@TAH6V6W17HSJ+K?KKIVABM
MENO&J)+M13,>^2YN%%+J&LJ*%ULDC:YDMXAKJ6AC@?V]/6B2(L^BF:5NMLUQ
MZ7+Q=[W=Z2T5&GM1LJ;E-HW3]-3S4U?!)#Q?:;;?#;ZS^(&SL!98H+/5U3II
M&FI:'2KU-H.-*1*5)O5:&U0\#X\W.;,)/T\((T--,0$/MX!8G@?(_M  >?91
M4:R& RR:9B9C_%J.YN<#RV8S2X:1RYR@@;+YT;3:28W_ -::@<X<FLL%M8P^
M?KG49(_W6_L7U'^%)4!]HT)B(_D!B6&5 OG]_D%8;W^S\O'@GQ//N\I^/;RG
M^-GC(.EJ8GP+;M78S[>*W<7#RQAG'SRS&#1_"3.8U%48\C;*/._D17\.1OG+
MN$[8=S7X^1U!3_C+#24?S\_ J<RJ(>?M]OC7 H#[?L(>?S$/ _;FGNVM7XX[
MOIJ$^<5@N,I!_P#Y-0MVV!&V_(@*]XTFT^K:[_(/ 27J@9GW\%C)WY$#&!N#
MG8/H>B''^,O$(F7P/V:T@2' WV\#[W-H=E$/'G["EY]P@/N H"!J;;JUQ/%J
M>V-! _N-,EC@1S/%->ZD$>0+"0=\X]5._:9:/5T]<''/.;4 <W&_^&*SPG.<
M?X\8SMG=<;-4FYRL1*1X:=-LUGT<\9IK,(*IMRIG<-U$2*"+B&D%R !C^5#H
MJIJ@0/*)D5 !3G$K].:AK:"MI3K2Y0R5-+4P-?36NQ0-:Z:%\;7%TENJ96AI
M<.-T<C7\(S&6/PY<JAOUCHJRCJ?X2H)V4U3!.]E1<KU*7MBE;(YN(Z^FC)(;
MAH>PLR</:]F6JOZ#S'6I6O9=BAJ)=:O(Y[;J]*2M]<(4$*)&LZW)&=N+)4I=
MM"&GI66G2$$R+)V<ZPJO% F!>(@J!OF&VZ/US6VO1WH]?IS45FJM+WVV5E;J
M.:+3(TQ14]JK'3276R5T=L^U*ZMKV@F.">61Y?,17]XCXFKZ-N&J]&4EQU;K
MT:AL%WIM366Z4E'IV&74IU%5SW6F$,=JO5%+<!;J*BMSB!)40-:S@A8:'L'E
MN+$2U.W)!_%Z985A#R("_@J2L B/_/!C78T1* ?R0*8A@'[F.8/V>?5(L=^8
M/4UG=I#G([S:]./&?)PIK31Y;CD&EIS@N)Y+YH==[,\GBTG;(P=L4]QO["/:
MTU%UJL$GGQ!PQL&@[K]&@- *  C?8\_CSX%]36RYA#[?R_DYJ-*)OW )0(4
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M5Z[4V:A[C1KO QMAK4_%.$).#L==FV2+^-DF+@GO0=L'[)PDLD;P)3IG #
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MT#A8 'R3W> ,'@?(>0\#QVTW_6?_  C]EJ_CG56 /MBHY8/W=*<^\&G*W?\
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MLHQFUCHYHU8,&3=)JS9,FZ+5HT;($!-!NV;-R)H(((IE*1)%(A$TR% I"E*
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-3A$X1.$3A$X1.$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g197729g04v89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g04v89.jpg
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M3-_42_O(?[LRK2?M5?\ =6?[8%>(A5E 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M3MLC@%< Q1;L0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$7YR8N/+)BXS_#.<?\
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MVH:>0C5892F:MK5*?(66S*2J32E+:UD(J248ODHQH\D8.\,H(\MD+@X['PN
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MT#786M?C.SV#B\,^9<!W4UO_ $P>F)YVM$:/TOR%WK-%-DB"51H>&\:N?/\
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M65/VW3MP?&#8)@^"%(4N_P"SPRC;GDLV>=\:?-*09'B:G&"0T-&F1VF1M[-
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M/ZQCE$;KW7HP^1N>F<?VKNQH]<9_'SU*;S_CC'7I^.< .$X#Y\]P8_H; ?\
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MZ1!U_L7HW99#K^[X[9S4O3/_ #96AF&/_&>S_P!?(/Y+\*;]/G$;O_$H./\
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M)/8Z18/&YU$';)\T71<M7*!SHKH*IJIG,0Y<YK$$$@C1!((/J".Q!_H5L$$
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MTP8YS6D^7/%)$[8&G,(^]9:*R[9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 18#M':%#TO0;+L_9MB;56C5%DD^G9MRW?/>X(Y>-HU@T9QT6
MU?2TO+2TH]8Q$+"Q#%]+S4N^8Q44Q>2#QLV5^FM<]P:T;<?0=A_M.@ !W))
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M#8^(F"21C"2 YP!(]=?/7KWUZ=O522O,<;W@;+6D@$Z&_EL_5OU6E-/W#>=
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M2_O(?[LRK2?M5?\ =6?[8%>(A5E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M.8I"XZ=3&S@I<=<],=<YSC&.N<XQCS^W/0?+WLC:7R/;&P:VY[@UHV=#;G$
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M]9?0C<"TLJNE<80&NVYC>C72QQZF-TUWQ K)1G*ZQ 1 1 1 1 1 1 1 1 1
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M9F@BI+3)XB&B(L\H_,X>FCHJ-8F7RV8M4DN22=;).AH;/H-DZ'U#9)U]9*X
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M)P>X#S6-+1K3@X]^HZV>W8 $#Y]^VI'Y(; VNZ@/2/\ (F#V_LVFV+@]=Z_
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g197729g07v02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g07v02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0"^="0X0DE-! 0      %X< 5H  QLE1QP"   "J  < E  "')R,S,S
M,38X' (% #U-:6-R;W-O9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T
M:6]N(%,M,2!);6%G97,@3VYL>2YD;V-X.$))300E       0;%J4L4I>6(Q[
M:?&?<Q#;4SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              X0   5J          $
M 0             %:@   X0                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   X0     4F=H=&QO;F<   5J    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      2A     $   "@    :
M >   ,,    2:  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ : "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M/YC]+8K_ %2Q]73LFRMK7.94XAKVE[#I_A*V>Y[/WT#I55=_2,9E[*K6[00
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M>F75/#7.+V50#,_I'[/:[W./\Y^>J#\OHC2&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_A0!IH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME
M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P
M-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*
M(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#$M,#54,#(Z-#8Z,3<K
M,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O
M;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 Q+3 U5# U.C0Q
M.C V*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A
M9&%T841A=&4^,C R,2TP,2TP-50P-3HT,3HP-BLP-3HS,#PO>&UP.DUE=&%D
M871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W
M<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^
M"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3YR<C,S,S$V.#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @
M(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @
M(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O
M9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T:6]N(%,M,2!);6%G97,@
M3VYL>2YD;V-X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C@R1$$U.#(W14$T145",3$Y148T0S$X0SDX.3A$,T0P/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.C@P1$$U.#(W14$T145",3$Y148T0S$X0SDX.3A$,T0P/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z.#!$034X,C=%031%14(Q,3E%1C1#,3A#.3@Y.$0S1# \+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C@P1$$U.#(W14$T
M145",3$Y148T0S$X0SDX.3A$,T0P/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Q+3 U5# U.C0P.C4Y
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z.#%$034X,C=%031%14(Q,3E%1C1#,3A#.3@Y
M.$0S1# \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C$M,#$M,#54,#4Z-#$Z,#8K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C@R1$$U.#(W14$T
M145",3$Y148T0S$X0SDX.3A$,T0P/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Q+3 U5# U.C0Q.C V
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C@Q1$$U.#(W14$T145",3$Y148T0S$X0SDX.3A$,T0P
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.C@P1$$U.#(W14$T145",3$Y148T0S$X0SDX.3A$,T0P
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/GAM<"YD:60Z.#!$034X,C=%031%14(Q,3E%1C1#,3A#
M.3@Y.$0S1# \+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T
M;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\
M+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!
M( &\ P$1  (1 0,1 ?_$ !X  0 " @(# 0             ("0<* P8!! 4"
M_\0 31    8#   $ @4'"04&! <  0(#! 4&  <("1$2%!,A%3%5E-(*%B(S
M05'3&CA7<WB8LK?6%Q@C)'$R0F&6U? 9)H'1)2@T-9&A\?_$ !T! 0 !!0$!
M 0             & 0,%!P@$ @G_Q !-$0 " @$# P(#! 8%!@L) 0   0(#
M! 4&$0<2(1,Q%")!"%%Q\!46(V&1L20R@:'!%S-5E-'A)31"4E=BEM+3U/$)
M)D-$15-4@J*R_]H # ,!  (1 Q$ /P#?XP!@%:,Y%>*7*[TV37J[LGF"GZ50
M083FJ[=*Z0N%PDWS%XLHW?U.VE;[TK3EO9X94A%R/V$(,+*1JA%RKM'H*,"
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MMLM&*E>-B?#]9V@JI#Y'2.F8/,0_/Y_B;AJ7S23']Z9/\(8!R8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & !'R^8X
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M)_A#!4Y, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M0WA/<T/5,NT;.6CZ<>3$I'LG%AD%%UFL-7&"JSV259N5?-NV BQP/CW'Q':
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MYA%+_MD\D?YK,,%/JOP?\XE\*/ZI+^K)_A#!4Y, 8 P!@# & , 8 P!@# &
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M:P=,;US; :&V%^?K>;BS5RVQ#J9<?[6JB6&(Z]\V\[+.+*4QX9H9=Z9DO]-
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M$#U^(M+=?Z'LFS&NT*IH-"I;AW)=]P6)76URM/MJH[M"+!%K!5"H2-29,TT
M".37EG:\L0[Z0<.7OPR^LJ0 6A?^_P#W]> , 8!0U^45_P PBE_VR>2/\UF&
M"GU7X/\ G$OA1_5)?U9/\(8*G)@'X4(51,Z9RE.0Y#$.4X 8IBF 0,4Q1 0,
M4P"(" @(" B AC\'P_HU[K]Y5-IIQ;33333:::?*::X::^C7L_)1YK#3L6GL
M7LCP_)]8\9&R$LETASW)JG:@K"%LZB2CAU'J(@FH"D3:")$%DBB()QI7P' 2
MK&]6LLC0ZLV>YMH6MTJVR&Y=OW15R>*\NR7J^C-\=D<35:[._P!*:^3,?'#;
M:Z<^T]M^CK9T-Z7=6DX_I66FOIQNW,JC:K</=.UU._;VI-3]1)VX/$Y72F_6
M<H5N,H\(P;R#N6:XJV\[JMY1/ Z VWL-6B7Z,<J&)'\_=+F+\))Z8JI@)%Z\
MVZR;IRK!T?X;-O)>X*0R+>,,+G?6S]>MZO[)G5J$>WJAT_IEI^MX[@EDZ_I.
M)S&O,A!).W*JCYDX12G*-T*U*+@SA;9&O7W8D\?48_#YF%F2TG6<9R;>#K%:
M7;<ER^,35:5#)ILDES99)\Q<NU;&Q3%.4IRF Q3% Q3%$!*8!#S 0$!$! 0^
M8" B'_CD2^]?5>&ON?W,V8?K & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P#C612<)*(KIIK(JD,11)4A5$U"& 0,0Y#@)3E, B!BF
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M0MX?"EQ)>))EI.:X,P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MM2<XI_1M+DLQR<>=T\>-],KX)2G3&R#MA%\I.5:DY17A^6D?:R^7A@# & ,
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MHLL<J:21#***'$"D(0A1,<YC#\@*4H"8PC\@ !$?D&4;23;?"2;;?LDO+;_
M^HQE.480BY3G)1C&*YE*4GQ&*2\MMM))>[*FH[QE.39/H,FAD'4^":]A+5FN
MQC$B_P T5Y@Z_LTU03"1^ETX59\)6B<P=B" G'W!DRL?)UD&AOW3YY45^C=9
MCHT\[]&U[F>!:M!GG<]OH+.X]/ES^5/G_K-*/DZTR?L<=2\;9-FZ):IM>>O4
M:(]QY'3V&I2>\*='4/6E=+!]+L>1"C]M+&4^>$ZHV2R/V);.0Y3E*<@@8I@
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MFON:?N0PV+Q/09F=<7[4$W.:#V>J853V?7:I&,3+*^KXGP[-4Q (29:J*_\
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MELW<&XY*[>^NREBR\_JYH$[<'2^WE_)F9:<<W-YCPIISJKYYX3C[R@@F^AM
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M7?1;7=3;!3JMJG&==D)+F,H3BW&46O*:;3/HY=+@P!@# & , 8 P!@# & ,
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MI.&VW]FN&ZZ9545T.>-VK(K)' #$4253I)B*)G*(&(<AC%,40$HB ^> <O\
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MI.6RR2Z"Z9%D5D5"*HJI*% R:B2I!,11,Y1 Q#D$2G*(&*(@(#@'+@# & ,
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M:JIK))"B4N"C%XDLTH-I,L9ZI[A<#8Z;MT&B"+9JBDV;-TR(H-T$R)(HHIE
MB:2228%(FF0H 4A"% I2@    & <V 41>,_UCU9S$RH;[4CRSZVTLO1[[8KK
MNRJ:E+N$[?:T0I&M=6:EML4X7(RJ%&V"]?+MYRY/$C)MP2*R*NU%4RV 5L\J
M:&<[8W[NNCQO(2=6@MIQ6J=?^)AQ!M)U7F%;HY]BPCJS0'47*EECI:2B6E47
MG"SLB_IL?(,Y<CY,LE'-V\HBE\(#9NYDY;U]R[KVLT:JNYZXRM;K3&F#L_82
MT=/;5L-3A)"2>5>OVJZ(QK&2GHZIMI)2*KZ+\5181R2213&4%50X$E< AGV!
MVWKCCZ*I2$[4]C[:V=LZ6?0VK](:8K"MTVI?G$.R/*6!W"5])=L4D17HQ,SV
M8EWKANQ:%,@B987#E%,X%56].>O$ D^AK#XI7+<])0,RMI'3;)IPULIP]8?[
M6J)&M;)+;1UYL>'7.M&TW9S920AU*)*Q3AP1G+MWS&26!)VNBN!VG0'A>:"W
MS>M<]@1S3>FE-$;!F(CH2W^'C=6*]2UTSZ>@G1D(_8-HIQU"^W-$.DG;]6KM
M4OS9L,TC#6@2*())-E +]RE*4 *4H%*    4    /J  #Y  ?L /D& >I(R#
M&)8/923=H,(V-:.'S]ZZ4*BV9LVB)UW+EPJ<0(DB@BF=550P@4A"&,(@ #@%
M'6R-L?\ Q@*:^T=H^O;TUIS]%;-UU<;EOFXU:=HNH.G]+56Z(IW_ %UK6WQ$
MJRM+^/M[5LX1)*-4X]F]CVIA.Y]@] Q@*FM:T?3>V=R;Y\*2OT_=<K>=,=GW
M6Y\S[4H#Y^I9?#ZUBG0JG.Q&PF^QK4Z%8]7?W]^]CHVAJRCY>PMG$@W42/\
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M^S3+YO8G>^-SL-@QS-R.UEF)(JNP<0PC&\51X!D:*AQ014%NG4%X@%*4
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MO.;*PIKKI/AOWE?GH/:MAVW &E*7>7VW:PZ=)V>B*U@KIQ!LX-2&E(>RQPO
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M622D=$WA*OMXWX&Y+A!S<0W*YVA.OFCI=J_8'3)'03PC1V=X]4<*@!<>
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M(]JV8L&S=DR9H)-6C1JBFW;-6R! 30;MT$2D21013*5-)),I2)D*!2E   ,
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M9".W?J4?G\_E@V)TTTT4R))$(DDD0J:::90(1,A  I"$(4 *4A2@!2E*  4
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MHWBXX57Y58Z5/[V&52^EX27*K'KO !1W&_'13^&!-? & 0L\0+C:"[QY=O\
MSG.7*Q4$]G+'RD'::ZX, QUE@'9)."^GHLP^TLM66D$44[!6WY3-):/%5 WH
M4^&H4"J7PK]>7V3['ZKD>YZ>>-[=UYJBEZ$8LZS14X#G.7Y*:K-W%8F=5N&R
M1XJP(W6RLGLA:(^4.20@G*)(4D<V9HF(#\_G^X%Y&B>?=/\ ,]$#6.C:1&:\
MH2<]8;*WJ\,H\&*9RUIE7$U-JL&[MRX*P;NI)TNX(Q9_ 8MOB"1LW2('IP#,
MN ?,EI>/A62KZ1=MFJ!!*F07+A!L"[A4?0W:(G<*))G=.E1*BV1]8'65,4A
M$1# -5O>UCWAXOZVW)[65A;:F8\,[ANM1=<GW76IKUMZ\MW%/@Q9;%G=465^
MQKS+9,5,C--M+NI@96F>EZYEY$@/&S8Q0+A?"PU=U)K'GZ?;=37+8UFE[-L6
M<LFMJ_N*8K]CVI0=;N6,8TBZ[>YFKMFU?4FGDFTE;#]%115FE>:3*$(1<YV2
MA2@6,1-;KT"M*.(."AX9>;>C)3*T5&LX]66D12(@+^2.T11,]>"BFFD+ER*B
MPIID()_24  #[6 , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8!%/ICL3GWF)"!@-K[OU?JB_[(2>Q6J8W8\NNQ9SUE4 K&(,
M\18)+OD8()MTP:2$B8J#<@+"@FY!R8A! U_=O=>^(/UC(;IY4M&A-!1-WT9K
MI![T9PW?"R$V^[?UM-2#E*?N'->PE'+5./J1:^DU<U-Z)'4PWMPI-I4&WPTT
MR@6%>&'R_(*\OPE,W.Q1V]RVWE8"\\B:]Z/UT7_;KHVN)I.17UQM%A863B+?
MRFOIXKJ.I]@:$4=JPA4%3+ F=N! +HB)D2(5-,A$TR% I"$*!"$*4  I2E*
M%*4H          !Y8!^L 8 P!@# & , \" & 2F #%$/(0$ $!#]P@/R$/\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'I+K/$U/2
M@R!PGZ0'U^Y31\C?/S#TF*81\OW_ %#Y_+ZAP#A]U)?98??D?P8 ]U)?98??
MD?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)
M?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P
M8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98
M??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]
MU)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D
M?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?
M98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8
M ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98?
M?D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U
M)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?
MP8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?9
M8??D?P8 ]U)?98??D/P8![Z1E#IE,JG\)00_23]0'](^8_+UE^1OEY#YA^_
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g197729g08v01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g08v01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2K>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *L*^$)1CA"24T$!       9AP!6@ #&R5'' %:  ,;)4<< @   J@ '
M)0  AR<C,S,S$V.!P"!0 ]36EC<F]S;V9T(%=O<F0@+2!):V5N82 @0G5S:6
MYE<W,@4V5C=&EO;B!3+3$@26UA9V5S($]N;'DN9&]C>#A"24T$)0      $'
M8(,-8NNY8=$_@-N'[%0.@X0DE-!#H      .4    0     0      "W!R:6
MYT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86
MUE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P
M!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96
MYU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F
M]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M  0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&
M)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M   P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M  0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M!";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <)
M    IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U
M!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M           %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G
M1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296
M-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F
M]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $)     0 ! 0D    !
M$X0DE-!"8       X             /X   #A"24T#\@      "@  ______
M__   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M  "0           0 X0DE-)Q        H  0         ".$))30/U
M!( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %
MH    &       ! #4    ! "T    &       !.$))30/X      !P  #___
M__________________________ ^@     __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@  #A"24T$"       $     $   )    "0
M X0DE-!!X       0     .$))300:      ,U    !@             #'@
M   TD          0                         !              -)
M #'@                     !                         !     !
M      ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M    !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M #'@    !29VAT;&]N9P   TD    &<VQI8V5S5FQ,<P    %/8FIC     0
M      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&
MQO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&
M]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M  !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M0H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M0    ).$))300,     " G     0   *    "8   !X  !'0   " + !@  ?
M_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\
MX  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /
M;6  $     TRU(4" @
M                     18W!R=    5     S9&5S8P   80   !L=W1P=
M   ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48E
MA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M"&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M    !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;G
MD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U
M)'0B!)14,V,3DV-BTR+C$
M                           %A96B        #S40 !     1;,6%E:(
M                    !865H@        ;Z(  #CU   #D%A96B
M!BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14
M,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=R
MYI96,N8V@
M          9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B
M!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2
M!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=V
MEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M            !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M%865H@      !,"58 4    %<?YVUE87,          0
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MR8_2G]NOY+_MS_;?___^T #$%D;V)E7T--  +_[@ .06
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!(0$Q P$1  (1 0,1 ?_$ !X  0 !! ,! 0
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MQG"4H[<RC*+<>9;KF2;:W75;I;KJMRC2>VM60K%>3F-DT*)C6TPXKSE_)6Z
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M^#@UTJG)MG9EY\L6NB_4,F3LR\F/,[I=K8^K3ME*<8+:,-^6*44DI79@&Q&
M, 8 P!@# & , 8 P!@# & , 8 P!@'Y.7M$,7\("&1]4U[>@[FG[&G]CW\_>
M:0*5Y,[FMIJ2V8UT!Y1D^K:+L;9EPV6K4!XWT:TGC96X/A=OB$G)V=7D%A3(
M"21#@**?:3!1-),PB \M/:Q=#T71,KFRZM$PI8&-;%^CS6/9DWY-J_-\SYY3
MR+)1DY2E"36S<8Q2Z\ZM9&LZQK.*EBW:SF1S<FMMW0[6O&JQJNDTEM&%%<9*
M*BIQ3W2E*4GGB#\F+4:OP]Y$<:8K9MLF;[R?C;*YVSOF[()6*TV*[6E@5F[L
M;F+(XCVQ8]C]>6,@T7::;1L/<F=*JB=<_+495Y6)H^FX5,<#2]#U''SL+%3=
MLYRJU"K/NLR;I*,KLO+=-<+\IQ4IN"GRM[M\M+[7#U++UG.L]/U/4,>./F7J
M*HK[.O#LQ**,:F&ZHQ<96V.BCFGRQER.;6W+UMQ>39D;WJWBG%ZXWU8=0;YX
MAQ4=&:UW7"UB-F4'2!(-& G&D_29-X+&1C)AHD*OH]21["*XE%4SE,!3',S-
M0NNXESN(\6,<:S4L._2\[&G^?KNTO(LKNLQ_648QM5]5=D+U#FBX]%ORN.%A
MZ?13P]5P_EIY5>)EQU/!R8MX]V)J=4['5E5N#D^5U6SHLJ<FIURELXMO?J<>
MO)R;$UAREB>76X^55OY";4/K&R:WLXV&GQ%:@%6<K)QCR*"FPD*]&/I\5'-H
M\0>Q2*#[TI).5Y$[I 3B@'*C,Q</!UK3L/"5>/K4M-R,F=MLKLF6=AO)[:ZR
MZ47VF/9"^-&+B*,(85-481=B::MV-D95NEY&5EN=^E963+'552IQUAVT2IJJ
M5,9-1RE*3LR<QRE+*DDW"&R+.E_)<[,J^T-JRG&OF9L3CIHO?=D5MFW=,5NG
M5V<<*3LN55"UO];7656\_P!<N[ U.7MNXN/<.6CHH+$44!%JBC@X3KKTO&T3
M483S]+T[MH:71":Q;<;&MGVT<&S(K4IVX-=VZCCI03HG*O>,IV6RS<MV6ZC;
MK.)..'JN371'+R'7'(HOMQH<E>7+$L_-/+DG*=UTW)V6-2ENHQ@LC:1\EKJ;
M5W$O=O#>TV&6V%JS<-SO%F,X>HJ,[%!-+8=FJQ3)*K/9%:1GX1TS3?ISZHHJ
M.WH"J=HF03)#RU7(MU3"T*CU<++X?HQH8&7B0C4L?)P<[(S,#(QJ-G&F.+VM
M=,*^:3==;?.I237/#:P=2U'.JYLB&IJN.71FR>0\E2P:\3->79))7O-LC9D3
MBZXPA*:A&/)"*47;CY';=VW].K:*WWY0'9^T=;U.+8,=-UH]$@ZXSKCN)732
MB)/9#F(E22NU7$1$((LXY&8D&*"#PRS\Q%!,FB38?.:EJ6'KMN)3;K>-J&)G
M3R>51Q$Z;:K<F>)@)=CC9>3R6U^E.5CA7?8E%N3D\/$Q5A4V:=1?D+1[*;J9
MX3FGD75NJV.+1=GRC*[T2BZR%]F-6H*]T45RG&J"B35Y3<!$-_1.D;11MMVC
M1_(CCJ@@CJO=E48MY%9F@JP9QLY#V2K/7*;&QUN=;M"F=0SIT1,IP HJJ('<
M(KX/I-].LY^L84HX]FJTVX>I8]D(Y&/F8%F1+(A1=7-)2MQIV62Q;^CIMF[%
M%RY>7LHQZ5HN/HN7%Y-.(J;<3(B^PR<7-HHC3')QYKF=2M48+(IBTK:XQ@YI
MQC)5;C7Q?Y.ZZN\M?>1W-6Y<CG@UUS6:S56E K&JJ%$M'ZI'+Z6EJU6E':=@
ML8+(HI1TLY<(&CV7?MDTE06$Q63+#MP,[%JQ.SOU"I47Y-MT\A40K=CI>%2U
M".-.2MFLJ2<GD15<7RJM'5&G)])P[;,N4J<.=ML:*ZX5=O9=&-<GDV)RE;77
M&*E15LHUV\UF[WV+SX.\2QX<:HL>LOJW/??3^U]E;.&84A"P MAV%9GMB]#@
MS(_D@5"+\[\U\\%<@NNQWHH(]KL!W9.:\C"T+#[-06BZ'I^C*SFW>1Z#6X=N
MX[)0[1O=0WERI)-M[M=TJ^;4M8U#?9ZMGO.=6W2ENBJEUJ6_K+\US;[+]+;;
MH2NM-7@+M6YRH6J*:3E:LL4^A)V'?I%792<5)-E&CUDZ2. E41<-U3IG*/CT
M-U 0$ '-5E8M.9CVXU\7*JZ#A-)[/9]THR7K1E%I2C*+3C))I[HRJ+[<:ZK(
MHFZ[J9QLKFN^,HO=/KT?L::::W36S-.%:\ESR.TFE*ZZXK^4+V=ICCA)2+QV
MQU-+Z\JNQYJE,)ATNK+P>O[]/NDI.L1B:3A0L"1NS44B' E>G4=N $Y]DLNS
M,IKQ]<E;J,:HQHKR:;'AZA+$KHKJJJORZU-V65.N*A:E&,:MZH5Q75X-F/&G
M)NR]+C7@69$E=9CSCZ3@K*WFYVU8LW&-<+')2LK<I<\TY2E^BHY2V_Y,1&Q4
MCCBEI#D%LK46Z^+CJ97UWO"?(VV?8ILMK35);B[ 83ZK5O:!GE%UW2W;7:H)
M.E.HH*(@5$O%Y5L-9MU;$JQ<-96D1T#+PJ:5Z'9H\)QMACUU2;==L+JX7QO<
MI2=JYFFTFN2QJK=)EIN?9DY]D-36N8N?=<UE8^L*+I>4IQBOS=F+*6+.B/+'
ML-H)_I<WZXY>3FV#J3E(ARYVYRHN7(+:LEJZ:UQ:U+'5(FO0RB3V78/XL]-B
M(5Z#"GPL:W8]A:#0;O0?2#EU(F>I"KW 9-.7C8>!K&FX.$J*-8NTW+NMLMG=
ME/.PUD+(OMNFM[:K5?&K%QTJX8>/5"J+LWE)]-V/D95NF9&9DNV_3+LSLE77
M&G%]#NIE5CT1QX[\E\'.5F3E<\GES>\H5[(D7Q&XE&XMK<@5OJW/<QWIO6Y[
MI$IX0D/]3@VXR!OJ? 22#X9(&'<] D#>:&7[74S9/L]<PE9MP_HNA\N_S/AY
M.)Z3O_I'I-]EW.ZVER<G/RM*<N;;?==QEY2])UO4=8ZP]/Q])H]'3W5?S7AQ
MQ.;GZ<W;<KGR\BY$^5N6R9A+7'DS=?P?&OD;QCV?:G>QJ=R(VML[9LC(,XE.
MLRE76V#-&FV+>(5(]E ])U=V"*S&8$4^_71*HHS(03IFZLA=MI/#&GURGCY'
M"^/B1P-0J>UT<S"R9Y-&97!I]G)2FX.'-+FA*4>9-[K*>3/Y^U[65"N5>O0Q
MZLG!NBK:.PKTRC3;:+&]NVA:J(W+FA%0GR=)<N[LW27D[^1%1MNL WISSV9O
M+4&E'S63UUJU.FP%"4=O89(S.M#LFW0[UU,[ ;0S$2'%I)=PF[DT4GBI@3*9
ML?;_ #E39DW:IDX-5^LVU9-5>2G*K"QWGT3Q\_(AIL=Z995M,W71;8Y+&C;D
M2BG99&4-'/3G''AI>+DW4:-&W&MECS?:YUBP<FK+PZ):B^6U8T+H-W4**C=&
M-$/5C5LZ//>35WIKG:&S[KPFYK6CC!3]RV1Q?+UJ^2UA6-N5-*_OQ.$M8JDE
M9GS0:NG,=4UI%DT34[]P0IA< BFW;HZW#MLQ]/Q-(R'Z5IFG*=>F5M*O*PL:
MVV5EF)#+BG.6-6Y-XU3BNPDY3WG*3;V>=&&7ERU*N*Q]0R*XUY]L.M&8ZHQC
M5D68_2/I;7-VV1S.5J:Z1:;>4]O^3[L.XN+^LN/UMY$7>UV6C[>H.WY_;5ZB
MVMCG[9+5&V$MK^*+&H.XMI#1+YT"C&':-U5TH&.!NU2*[*@';S<;-IP^(N']
M:QL2-5'#]>153ANR4[<JN[!OPE9EY<ES69?+=SVWN&]TH_HP\,=4VSTO7\#)
MR9WW:]1D567\D:ZL1Y$ZI<N+C1VC5CU*I*NE2Z.4Y.6\FELK;)=R@DEUZ]V0
MB?7IV>O8(4O7L]1Z=>G7IU'I^$?AS7M[MOVMO[7OY^WIW'="/)"$/]F,8]VW
MZ,4O.S9]\AS& , 8 P!@# & , 8 P!@% M%HK]+@).T6J5:0E?AFQG<G*/3B
M1LS;E,4@J*"4ISB G.4A2D(8YS&*4I3&$ $##)>5G'\Q0,&QH_H8 , C%6$.
MI3  E$/_ $1X@(" @/P" X!S[ZO0'K&C_DJP^R, >^KT!ZQH_P"2K#[(P![Z
MO0'K&C_DJP^R, >^KT!ZQH_Y*L/LC 'OJ] >L:/^2K#[(P![ZO0'K&C_ )*L
M/LC 'OJ] >L:/^2K#[(P![ZO0'K&C_DJP^R, >^KT!ZQH_Y*L/LC 'OJ] >L
M:/\ DJP^R, >^KT!ZQH_Y*L/LC 'OJ] >L:/^2K#[(P![ZO0'K&C_DJP^R,
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MAX ]&QWY R_94/X> /1L=^0,OV5#^'@#T;'?D#+]E0_AX ]&QWY R_94/X>
M/1L=^0,OV5#^'@#T;'?D#+]E0_AX ]&QWY R_94/X> /1L=^0,OV5#^'@#T;
M'?D#+]E0_AX ]&QWY R_94/X> /1L=^0,OV5#^'@#T;'?D#+]E0_AX ]&QWY
M R_94/X> /1L=^0,OV5#^'@#T;'?D#+]E0_AX ]&QWY R_94/X> 6!9=@:OI
M\P: LTS78:7+59R["Q>IHIK!5:V7M3DWT! P"SC2B N3@(F+U\"C@&)JMRQX
MP72ZLM?UF_UN4LTH])&1:"<4^2CI.64CBRY(B/FEXQ*(=RHQAP>^CD'IW?<]
MH>Z$2F  W_$DH+*)^N &<<(E 1,'<-NI0+_G"( 01 "_]81^ .HC\& 8H1W+
MHYU2;1L=E=*3(46ER4O"V>T1SID_B(B8@5R-9:*7<M"+%/(,7:J319H@"J_G
M2A6Y"'6$""!UH#>&A[0&N_0-VIDDKMDLP?7+5!5N#VV!7T?.)TL8R40(Z,>'
M2 1DDU4DCLSAW:Y2'^MP"H/-N:6CK"PJDA;J:RL<M:ST:(AG3ABB_EK<E'%E
MEZ_&('*!WTDVCCD=NT&P*BU2, KB0WUN 4&Q\@^/51MTS1+->Z=#6NO0BUAF
M8E\4J2K&+00!RJ=1;S46QW8-1*Y+&IK'D3H'(J5J)#%$0+XUU>=;;9J[*Z:\
MDX*T5E^HY0;RD>W)V =,U10>,W""[=%TS>-5@%-PT=(HN43!T52((EZ@6_L/
M<6E-3RU7@]BVJK5.4N3P&-=:RI")F?K&<-VA3F.FV439M1=NVK0'KX[9H+IR
M@W[_ +U4A1 Z,YO71%:MM@HTY;ZQ'6:J5LUNLL>NV-V(&O@B+@LA+/2,S,&)
M5D@[3=!=T5TYZE!!%03E 0*QKK:VH-L)=_KV?K]D)Z.;RHE:-11<%8.E5$$'
M)VKMJW<ID,LDHB;MI%,FJ44U"E,( (%B<?$TTK-R&*DFFD4-SR/UJ1"IE^YZ
M"\>R0 #J/QCTZC\8B.3Q?N7W_@7P3^E_PV_$DQE(, 8!8>SJE,7NA6FH5^Y3
MNO)J?B'4?&7>L@S-.UEZL7HA+1J;]%PS4<-C@!@3<H*)' 1*8OCU "QM):9F
M-1LI!&;V_LO;C^40CB.)'8LA$O5&B[)#NUU8PD7$QH-$GZHF<+MSF733.)2H
M]@H#U PGY1>!0G.&V]8HB*2;J<J[2&*[(U35<)FDYV(9$,4>[.J8Q16 2E(
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M#'2(-TTWB=E29D?H"F<.]^R'.($B]2<:'U,W?<]Y$W#/7"#OB4FXCZBN95:
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M*V-U:R*I.%RC;!*,U&Q27,DD]M]CU%YV&(, 8 P!@# & , 8 P!@# & , 8
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ME>LSF%!VDDY5!)<AR"<1#-J>!+YP!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , C5H#[J.0_P"F>2^CT%D\7[E\9%\%[W\(DE<I!@#
M& , B=S?^]GV!^<TWZ;UW(^^/O\ N8).QA.\A8Y/M"7MQC,O:*/0Q1%JF &*
M/Q&+\)1Z#T$ 'H/P8:W375;K;==Z]WTEB^62ELGLT]I+>+V>^S7BGW->*-2'
M)_C567+3D=#;@K-]W)J?9U+2F(6-0;L)52O7@C=.&<33.2>L^Y@K"T2*Q/$R
MYC)E:-D3@*@=K/+0KEH^J9F5?;G786575/=1=M=5V\:YN:CL^L=MGW)1]KZ_
MH#/SL/Y2^ .$]#TO X8T[BWAW+S\"<9V1P,W-TR:GG8E6!VMDXSB[I7]K7%<
MUETHQCMU,2^2N\H/39?5U!X];KA8+2^S8G8=ST;1F)UH:.8;#FZ$X6309-H^
M/5.=I:7%>09OI!1T1)O-/A<N(]=<YS$#U$9QG%3A*,X22<90DI1:>SW3BVGT
M?79[^'?T/@5U-^-=;CY--V-D4S<+:+ZYTW5RBVG&=<TI1>Z;6Z6ZV:Z--[W
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MDL1&8>O9F*610KSIG$RKIXX543 LN+4J+A0.IS#M3YP>C?B3OVB\E-#4+:-
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MN0HK F)@.)A3TB$4(H "0P& 0Z@)1 0'^@0$0'^SX/C\< _> , 8 P!@# &
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MI\RU7,U?0.*L"VF%F1IFMY"HRU*5:3MKH:I<9.*6/"MN*E*<MIOINWLC]U<
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MNJTA'+S#&PP[R*:E1.XD6T@V69($<ID5;F5<IJ&2(59)5-1,3& #D4(8O4#
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MNG_)G;JTO/-:VBW,QL\<E!D/#Q44P< Z04K8KJ) JQ4\V IP$$.X(IVC 81
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MFL'P(H(N:ZY;M3R2);80L@DJ\$J;1,.[\U<&*X'M]CH(AG(*CRFZ!UW%KCJ
M!U'W,'8=1Z>(@ V?PZCX]/BP7ZD_?O\ <T<C4.4W0>FXM;]>@]!'6#OH ]/
M1#ZJ Z@ ^/3KX_!@;_0E]OWMF$J%KCG.QV/LZ0L>[-:J5N2?0!X(!U<_[IPD
MA")I.3QZ9K8<&":3D!3<IB*AG"P&6^L[0@$\O^/T?A]Q//XF1KI2.7[RJS[6
MO[HUHA+KQ,BDR.IJYX?M+J,ETTDT^S:DQ36.J9,$EA,)4C]#B4P (#09(XX5
M_:U9U+4(G<=@CK#<VL'&(OW+"*5BSH*I,TB+MW@*OGYG;HBP'%1T"A 4$?\
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MY!_^O$]S'_Z;V+P7&-.R]G_P>\S5FS/## & , 8 P!@# & , 8 P!@# & ,
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M?]1'_?U\?Z< R1KNZ7RU+2:=RU9):[29D;F8K/[##S@29E1,"Q$RQ74S<6X
M41%;P/VNA>G0< A7R9Y?7_0V]@I<=$P$A5I;7$1,Q[^UJNH.K0L\1_:',D::
MLS9JY,1S+QL(A$5Z+* "YFG38H^"G0P>?/GP+0T=Y1^S;>W?6-*R''ZU4N0L
M9UFXS$LJ[\Q8O8F.-9+"U<&/'(I$%E5'4')M%C+%3>N)4&1/LR"@ !M6P!@#
M & , 8 P!@# '3_'40_[L _'=I_]@GZH?NP!W:?XLGZI?W8 [M/\63]4O[L
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MD1;(P)!LSD2$3?,CD76:.V;LJ1U$N_:/&R[=0R2ATSF3$Z9S$,41 R)@# &
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M=-W4C$R+!NN>FU\2(K.V:R"2IP+']1*0ZA3& ! 1 !Z#C9+N20.KK?2=*I]
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M(=_66CMA7GL;7(EF[A&3]057K2+<(-2*L6[I01.NDW.F10XB8P"(C@&0L 8
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M3$1$B:CE54R1!$>PD)"?]7!3*. , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
$!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g197729g08v02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g08v02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %R*^62(X0DE-! 0      %X< 5H  QLE1QP"   "J  < E  "')R,S,S
M,38X' (% #U-:6-R;W-O9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T
M:6]N(%,M,2!);6%G97,@3VYL>2YD;V-X.$))300E       0;%J4L4I>6(Q[
M:?&?<Q#;4SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D
M("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U
M8D!OX            $)R9%15;G1&(U)L=                $)L9"!5;G1&
M(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E8W1O
M<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F
M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              L$   =C          $
M 0             '8P   L$                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   L$     4F=H=&QO;F<   =C    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      ,I0    $   "@    /
M >   '"    ,B0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ / "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]2MK]2I]>YS-[2W>PPX2/I,/[S55PVW4Y#L5]S[VUTUN#K(+BXNM#W[@/S]K
M58L%%[;,9Y#@YNVQ@,':X1^:=[-RI]/JQJLIS<5V^C[/5L=O+P1OOX>7.\4E
M.BDDDDI2H6T]:^T6NHRJ!0X@ULLI<XMT#37NKMJW-W;K=_\ UM7TDE.+U#+Z
METG%LZCGYE+L3'VFUE>,[>6EVW;7^L^RRS=6S>_]%6B]-_:&51CYGVX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6'&WN-76\"0G@9.4)3(SP2DT1U-58I66I^'Q_\0 '0$!  (# 0$! 0
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MXX7#%RTG2@E0+(JYQ8FM'!*G9?4$:J&0/-LNHZ^ULT8? $7HH6K2[";4EY9
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M)D+)W/K$F\_,I]?,W8$N0&U]N(PWXLQ7'HZNCZ3\R2>LFJ$E>R$ 8\E>2@9
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MY\\?IQ_9[>W\O:/RC\,?KS_;[^_\_>?SG\<K/VX[4Z8Z5Z2LN_MUG/@U>O+
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MMYRAQI:5ISG&<<8SO_.GY_\ #/Y<8QYT_/\ X9_+C&/.GY_\,_EQC'G3\_\
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M?+F,640=@F<NLUX0*;VPE;*>NJ0I8K0473B#AHW'N4]<G: 7&(FB)4"5D,#
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M5NW1LCLR^:_F=.R)TS2M*5!IL"?FW]D![7 1BPVVUO@URF#+I+@R7W94HI!
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MW[K8VMDZJBMTTU*&W&DYB5,.ZLS6LRD5D8"9#$24=W.9W[1V_P#_ ,*ZX?\
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MK7^%;$A5(R^T?Z)=F;JJ,6#[G127;GU(5>_PBZ /M^S7VXLQ%MRGOB"-+8L
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M;S@-8AP\_8IO=6MSNM\?); VLY&5L6LQ$6[O;;<< 12Q*_&E"6L4*I1,PJ1
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MTOKV'1#'UG*$&5W2(0U!+,%K A ;,^&/FQ]G.7ES//ACYL<8SQX8Q^S&,?\
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MQQC'&,<8QQC'&,<8QQC/GT]+ALL S9FF==3M0VAKY]TRTB5;=M$K5,8V;DE
M-=,7G2VR[)V%U/6*4\2H]T$M=P$ES2SHM_V2KG ,Y)=I4AE^W;*V6JUA=$9\
M-,TU[EI*KMD)%S70]+Z1]@N&LNO8;"V%+Q1+1D;SY\&KDI&M94=M$E-H&OJ(
M8RNZ?] H5.&VN![?--A*1[@\9N*)&-U^A$DHTKJU!IU^DRT4:N((D=IG5R3V
M.<ZB,'2HN[2-0(*JYUE(\,.RQ4 2_%/EJ<<"=6RI"L]S9S$W[4P%5?+9GLI@
MU=8)D8F14MP@T(&>8(3$9@X*(B(XSBT/^RK^)Q^[9@[!+)I1+F2,\JD@E<QQ
MX>)DH3V0<]\%DN<H9<QQC'&,H;VQ_E%^CB_O0;!_W2.Q?&8^^/Y3_B.7RSGP
MQG/S8\>,SFI8?TB-^G>W)FCZ92-56?7D1V-:ZYRJ(Z^RQF\&S@]=HNMOV.NE
M"0ST'$T*E'.M1,D5,2H[IZ%^M">P6I@0C&EF=D"VNCQIMJZI?6?7F')JU^G7
M,JU[.Q84A !N+Z&:ZHI7+ALNK'VL49R.=O$Z_N!,BQM<.FR>MT^,K#>H'!)5
MJ !WFQFMH-#8VF,B%^)5@)[)"#F8D=ZAU=IL]:_<.IO6XL[E<]Z8[ Q.;UXM
MQRY#UO[E>*-@[V[P3Y51?PDRM+/B3DG*,>3.-9/UB#BC@?%%^9\$^JB?0FT/
MB[97V=_BGR_O>GF2@N_LGEL8FA"YF.>^*,_;?LW'JY3SQ)>3N[8;/BXX\_ =
MOCED=M$=F=XNPM7[YWRG%V/X(ZIU[LRMZHK-!,D]9CP%W:G]/DW_ #<KM#2<
M&5MT"M/3:G!B-L52?:J5* BO4RE0F\IE#&:VJL2RE?N68%C"9U<"ZS60I-=/
M30J-!384/=KGW$"RPAFQ&PC9.<BD@*@N1998V:)6ZC7KS*UQ6Z:LMLK#O;;9
MO=@VG84M3Y@+@5#E==M6B2K584OO$]_:=0)'O/??9G83H]VPW/HK)76VVZ2K
M#I8;MY@X^U7Q14=7,3TN:W3B38L.$K-B:>85K:]&$2S-BA_&S,P&1G6!,S[!
M3$4]3L!88HM[VK6;3)7BN!4^LJ=)E#93,G]5;CNL2=[7]EEM.M*OM9.T)JET
MRU7-P>I:*R9%,^VXIHV*#+!@\PO:T@\?UKJX!,BFW#:P/LRQ?:/I3AV!;H[9
M[_C-TG1<'NDFE%4DGJ+5Z1H@:O4@L_L+&[]0./L2]-F3\%(V<D^M*-D<0#]1
M+!AJ\?3CR+,!*"F.,-W:R!?O;529DUV>NMUTP^LJ(&=!IJ&@3M4;B)@29#?4
M&;2LV_)0917Z,5!:ACQXK'$KIZA<B8)X="4>IO4%!R5_=-WCM8>K;\E&DJR*
M_P"RU87>BQ?&R5@:T N;F(Z6[.9[@Z[['O[OF+7$5& <A)+-Q.(79"X5V)L(
M9-. J57B:YJ]J,D9:6C;$_<7X15X"(A\PXI[D1(/--Q:PPHGNR-8E&VJ0CD"
M81-,"HE6-WF,QK#1BM8\<4(3%WU<Q=%GB646KPQ:5K 'GOH/-T24^,4]Y-EI
M*A405J;*F"@UWB8%>(AU65F,@S8_R/-L<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8R--Q:[_=9UC=-<^^7*]FW0A$2B;:!;DUQ;KBVGF#,1[SXS1N&7V6U+
M&60QAY'F;]<WE6%XJ7ZOKJ=BIY/%YUR$,[8/LF9B8+LF1@N)B.1[HYCVYC/2
M=(=0STIU-I>H_1CL(U%Y=LJ)O.J-H @A-/J !IHDP(HAHK9(%P787'$Q\FB]
METIPG&_=?8PG&,8Q^X*3^S&/#'_VM\K>GVW_ +SJ_P#],+_C\[T[KZ-9F9GH
M#?S,SS/_ +?*_P#^/R)]YZQ[A3FJ+K$TK>5)/LI\.MB+#CM2$U:3((R0.K#<
M?8L[5*;B",MI<S[4Z*0G"<*1AOQ<PI-'94]\VC875V-8G&' 0-&4G,]PS\+9
MO3 3Q$\S,3[<QQ,S&>KZ&ZE^A^AU7I+>[Z&W=?65[D,M-?U<K:U07XV#W6-=
M'2:2N+@I'E(-7,SP7=\/&2=IJR;43L796MMG6BKW!ZH5G6]@C)FMTXJF>55O
M5;V#P"PB+3:<&)'56QW1BTD"KS[2^VXPK"4+S;U[KOJ[E.ZY#RKIIN!B*Y5^
M)L>H@P(2L/[NV4C(SR,_%///MGF>L-;TK/3O374?3&LVNG#;;+J/7VJ6SW*=
MU$QJ(U!UK"GKU6J)),C9-%J96T8\2R%D21#EEN=?/G&.,8XQCC&.,8XQCC&.
M,8XQCC&?E:$N(4A:<+0O&4K2K&%)4G./!258SXXRE6/'&<9QX9QG..8(1,2$
MH@A*)$HF(F)B8XF)B>8F)CYQ,<9F)F)B8F8F)YB8]IB8^4Q/W3&?--<NT%JZ
MOV#;;.A-%^C\@:EK_MA8->QE'OEGOT%V%D)">,:LMKV<J*:@)1,7"O&2<A-B
MOQZUQ#%=:<EAWQPV<B<IT+<U]5HF-XFF-'<BM%!LD_6:O2'M2&M;)D22K3PJ
M2D@LEVH=?I 3'+<$9;NTX;L-OVG,6FAJ=@YMX8A6QV.VK:X9FF 3PQ2X< JA
M'O8*I:& 4T#+/H/TSL5&W=2ZWVDB',KZ-@TNNV],'(9\3(K$]%C2/L+ZO(WZ
MQ0^7_5I=]6WZU&$N>1'F\N.WLZ?U??MTO)Y?3.-4'V]LE$3S'</,]AQ$Q#!Y
MF!."&)F(YSBZVY]84*MWL\?J%"SL@NZ(F9F)D2XCN ICN IB)()&9B)GC),S
MG&/ESGPQ\^>4<O9U<=-P\NY)-14K'23D.>[%2S8!HQBXR39;:>>CCTCNN*#.
M:9?8=<$(PV^AMYI:F\)<3G*/<!9'N!]_8<>X'V&2C["CV+L:!K/B9[6 03P0
MS&)]BD9]B&!F1GV*(,8,)F)]X@PF"&9C@AF"CF)B<I;9OYR/3G]O3'?WA_;_
M -\W7WC&7FXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&:'/3&7MROVC354V;K_<>X^KUKINPOW4M4
M:@+(@U66=CS:\Y!KO$V/6IITBGHC5R[)D,Q*UTA;[C1WM9+8ZF$\N"JSLKP[
M.OZBO7U^OM49<<A1K61N6XM-L#RKR'X1KL2WSE%<T3'@GS>4.E$/'6).B^*]
MEFT*M9((B;3:ATR)2ZL\,D.ZQ'C>,JX<IG$-"5R#-K_4Z6U]/=9]%3.J*LFD
M:TDM7T\NB5!)^93%:JSL,+F%A<2*GB%&>[P?4C>T*?=4[ZOSJ<5G.<Y]1NPM
MAM;PWG^IMP[[9\# 0TY$9[H&(B(B(F(CB..(B8^>>>UG@]$J*R90D3> JF9*
M1('M!G,E,S,DT3.>>.)+CB)CB(4W+WSI6G-P&ZR/UY?K+ 4Y>L&MP;1@<UI-
M0U*_N:P.UG7+$\')S85CFW)>3;:7*?!F)E,5Z--!D9/+;!&,IY6MYV5KTZ^%
M W;ET]5L,F)78WH:I6Y+70(23%1Z"Q4XM-$4%:MHK04F1=E^Y'I*_EY\[PUK
M=TZDJ)FPG2IM'39L2@H@#'S(N$" .7&BC<=V]JA@_9N7O)$:5VQ#T&P:<VF=
M2B[=KF@R^XAAZY'T^/N6U25"U2&@(J9FH^U["0.XH55KD*-#S0M59+0[)J3@
M<WV;2JP;#24<^F[V;-%,F\2=M^HU+=Q=GPAW.K4QK)8I6PLK74;: E"SL$FQ
M)94:*TV0B+'CJ+OV05,1%>HV\.O7)-/M2RT3IE@T%F5HD0!@LC<A;?;TQ[QU
M7ND%:YRE5-NOUZND*8%)(V;JJWSQ7A)'QZ,3U0H=KL-AHI;R0%&-1]N%C3,L
M/(1EI+Z'66[8UF>@KWF2(>HBN0J#EZX&Q45<B/6*@JA,4#E@U2VD4&4S'< ]
M\Q6B&OM;>K$A=-0[*SL"4 +"K69JR2D,D;!(8P&2I\K$"$/NDAC.@[334/(=
ME/1TA RT8:8+VAV)[2()("$%,>KZE=BFW,O#LO+>:PVXK#;GG0G"%YPE7@K.
M,<@Q]\3_  G^_C],V"*QXISCY\9_Z_Z^3Y^8GY3_ %^O^$_RS/\ ?E)M#QO2
MS5FS[WK;55WU)(;ZEK+=+C?8K%QJ$YN9V0M$TNRV%N;::)S:VXP(DQCU$:0U
M@>+!;$:]6EMM*U8H1 ZI%:AP6MU-4*ADB>Y0+38>7DN,7\!M]58?!O;[^0R#
MF)CMA;C]O=:N1(7-B^+(BZ)&9,ZJ$B-19Q$@N:U94BM4<3$2<1/=,Y/-!WEH
MG:U@LE;UGM;66P+/3WE,VN%IMQK=DFZX\@AP-:)H&)/,,CLI*:<%5DIMO&"$
M+9SG#B<IQLH9;7&XD995,H$;(1))(S'O&!9$2$R8<E'!?$/Q1S$S.&_8OFJ[
MA=D8*90R8%T0$P)3*RX/@)D8+V^&9B)XG,KD=<:]F+"FVRU*J<G:413\"FQ'
MP$47-IA24K21$XE'Q7#O=SZ7'$O!Y?\ 9W$N.86WG"U8SJ(B'E[8@?/(>;MB
M!\WC(#7Y>(CR>,UK(.[GMD F..V,R12<+$RDH3)$J"F9A4F)"<KB9^"2$B$I
M'CF)*)^<YVQ%7K!34DP5 PQ+$P"S&RS#\:$\U)QP[:VAP#VW&5),#8:<6TR,
M1AQEMM:T(1A*LXSL7Q<]T\\L\\]T\\NB1GS3S\V<@'+)^+X YGX8X#,A($$R
M!+#QK(9D9 /?X!F)B1#WGX8XCWGV]\C@(_0EROD8J/*U?9MDTYNP1L.L1VL2
M]PK#4$4+$V@"/6UDB6AT1!L@''S0HZF/82#&!BT-N$(0K*^XO-:5!3ZA"I=9
M#G[>L]UD$DQL>[$M?5M@N2F0-J'B,D2SXPP>P5UFCV@ML$I#(X$'172^)6LN
M(%L5G(=';$%"6*9'P$,Y,WBG'R>./MQ_1S&,Z*1M%<AY..AI6=B(V6EQSRXN
M-.D@Q#I$:*:2_)D!BOO-ODL1[+C;IKS*%MBH<0I]3>%ISG6"B28 SW$I4/=$
M?-2":"(<S_NKE[5I@RX&6&(1,E/&)^&%S/M#6RA4S[0QT*8^5!_WF0E3&]D<
MEXUF?':,S'N<L, RV&\[.0[3,AX>P.N282&SO'.$X]C6I_"2?'.<8QZG*_'.
M<8_;G'-^)[_'Q/DF(F X^.8GY3V_O<3]T\>^8YCMDN8[8YB2Y^&)CYQ,_+V^
M_P!_;.6B2CG5D-MGA..".H8*;04PM8S[GAZMDA*7,J9=7YD^1MS"5J\V/+C/
MCCF(]^./?DI&./?DA_>&/Q(?OB/>/OS,^WS]N(B9Y]O8OE/\I^Z?E/W9AFR-
MKZRT[756_:^P*;K>JH*'!58[Q9(BKPN#2U92,)B2F2PQ,DD*2K#+&'<NN>57
ME3G"<^$1N4LU+-@"QQ2"@(Q@V$(R9" S,$<P$24P,3,#$S/MFX*8P6$ $0J#
MR-(1F16'= ]QS'L(R1",3,Q$E,1'O,1G7Q^[=/2RZZW%[1U_(JMT7&3=5P#;
MX K-CAYDI0,3*0F&3UYE(^2.0H,$P/US!1:<CL+6[C*<6"4T7,KDM@O4:P8F
M1F&@34NLK$@_>&65Z]BP$3$224.;$2"SF((:N5"Z#"4F+2%O='C(4.37>4%^
M[,)L6:Z&^_V;7J67!L$9E#FF28XQCC&.,8XQCC&.,8XQCC&.,8XQCC&5NHW\
MIO?']NNM'8Q_;GVS:GR<Y-?_ .F=G_\ D]9__??_ %C/HFY_^K/H;_\ B+K?
M_P#Q=+Y9'G6SYWCC&.,8XQCC&.,8XQCC&.,8XQG$/-:C@3)!]#[C(0SY3K8H
M[YA2VQVE.K0.(,VZ24^I*,X:'':<?>7Y6VFUN*2G,3W!72U[(.02LV'"UL<R
M1 9*8!2A-C"F(^$ $B*>(B)F<W6LFL!8R,$PQ 9,A (DI@8DC*8$1B9]R*8B
M(]YF(SY8 A:KMCT@T;/A:3N;NS[SON+OT)VZN^D^S%7OL%H9CV2(D^OTGKVR
MZ8#K:*D^#[53R;!+6<:BYC)E4Q)Y;ETH:<L=,H%$P$BJMX$;9V^@3 PZJ]>J
MXV@=_P Y*&BT/%4D%L@F*/2+C603V?!'OG0U9S\=B6*U]?41,&LNG;-(JB[=
MJEX885Z(8]]B8 8%Q;1@7^RN$&7U3,LLCM-#CM-L,,MH:99:0EMIIIM.$MMM
MMHQA"&T)QA*$)QA*4XPE.,8QC'-9F2F2*9(BF9(IF9F9F>9F9GWF9GWF9]YG
M$1 Q C$"(Q$",1$1$1'$1$1[1$1[1$>T1D?[:C]DRVM+Q%Z>G*Y6=H2-9E@J
M+8K?'FRM9@[*2*MF,E9F-CEMFG! /KP2L4=Q*GE-I0KQ1E2<T[RK#JQJJMA#
M6$H9;_K F7+]1*IX* ?-?RQ780F"W2## P&0*U3.LNRIEM1NKA)$:@F(DR@"
ME8ES(\KEO9Y1$A,E=X@8%,&.N7T7_6?L-UMI_:"D[P!K$*]=.PMHO-1M=2LL
MY;)*VHLE,IXT]?R3K:V06EZ:LP4E(CC3 K9+4A@YI^+;BTQZ7NQY*D:+I^E7
M1%0]<O=5AI+B973HLZBV]S7))I24N=Z6RL_+WL-E<ZYV2B\5H!HN]2W<;"X]
MHV8MUM03;7;"B?>5K*Z;<@D1%:5 P.SQ (J4P356B:H)*>;0-57'5_I&M<CV
M[?NUMZN2_3C>#P1&T =7!.UQ(FXM"H?:A\:TUU0&W$267VUF^]T2:T*$'P&L
M5*B,/TLES:CQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,T,=V^SLUL;<DYHC6Z=EP-WI%_&U'!"5O
ML\]H&+N$P?K7]U^_6N]!0U*NDS'ZTI5"99'C+>L)YR4LI[L4,"R'A<GSF!Q:
MK6=@82RD*NHCNI-_*4:7I<IJ[*RX8[%U[^SV=FMK=37-P1:4Y=FR^HJ%]]]@
MS6E=6/\ 2D&D:ERTQ+CV>_LFC5U*Q27<^I7K)LWMH]8'-4T376ISQ9"]G'1>
M;H%CZ?\ 76<U95I:DZ_D]5U8NKU6=E'YV7A(YP!&<!GSQ#KSTZ\E_#R_?:W%
M>]T+1()\J2<)QZC=@8;)XF<&/96)/:B*G95.JDZB9J1,^D-%4DI96F9*N8$H
MB(@DIXM.#$'@Z>^TO8;-5YL6/6 _8*V-I=^RNWVC%I5JX+["; B N4T&" 07
M;&!;DZ%T3<FW#]G'WZ^UJ(N"M:.[<UG!*KRZ?M@G3DX]8M;%6%Z4A3Y^(>@9
M5QK)F*Q+1")\$,./F$DC,Y2KD4(G7V#>HI*!V;-]34?$KI[YNJ7I2V:^(@FE
MZ!%6(JN(ZGJ:J+/B\@G++MLO5I%91XVSKF:5UE<E#GZ5ML[K=8<S,B*R<^X,
M/7 6 1>MI%D"T97AYG0&<E=_P'86>[1;-L]G@(F*@@HNST#2<Y&146#DU,DU
M37#=?K*H)UE8-6Q/S-4<CYDQ#3.,'H;1ZO.*@16&^,_;1L@E=ID_9V325!%(
MZ\6E=K0JRU1W_2A(H]4]DD!K@ %;*;0U1B(2%$S954,0=<&%>;;!QUV]ZG6$
MK8%)3VB3 JI 0D6$PSD3KUTI@=$;.G=MG;-NFS[>=1FM7UXFSPU!K8]6UXQ8
MGK0U ($UY4ZD+8CO>SJ%N66RLR4VIAE+#9+27B_:+"&DBG8J]H&VZ[7/O6N)
M$[)ZJI8IT>$B7IJ\ JU8EOIU+EYLB63()2"XG!#K*7<R":L;"*M:."%,[.PB
MQ;(GGW6'=Q5D L6M(%B!2(^1C#*#NP.B=*:][;] +[1-2ZYIUXM/9_:";)<*
MS38"$LT^F4ZK=AY.23+S<> /(R"9"29:/,240[@DMMLA[SNH2K$6;<^_'\)G
M\N/US9Q,#$FQ,F&$2H(PN/,%$,3C*E"$D#N-,$I3CY<J8<6EW&,?+G*.5KJ6
M6*=M"6>%SZSTJ;[QXF,48 SV]_@(H+V]_;VR>N8*>AC \BUN6;%SQP8 8D03
MSS'Q#$C[Q,>^?.Q5.MN\#-3]9^K(G4JTU?=?7_=_[H>P^T$L]4(76UPBH22L
M<G:[-6=G1$R?>9Z<W]&3#=;E8MZM,2,/F<E79YO T(S@C=L!=C6W%4QJ4M;T
M9?TM_0,=Z5MTW])OZ>+IVHQ(M4=2UM6!M8V1$*EK2%PYB^4+C#3E);^N39M/
MW74(7]?L@7ZA=$#ZDK[NOM[0ME;%V-+K5%KPHAW&]ZPIJ+T#)=$J^CVTMN_7
M&]J(*3IW:E3U11--VVFRB>PM,U(-9M12A4U$$0VO-,;GUH['SVZJ*:\&:Z:?
M>8%QUL(.+F,2K4L:2!CIUW0U.V?8?Y9L4=&BE;8B*&UO'58V65MKK42=$%4:
MQP065>,XN=R5>:NPBBA:5(NUX)3"Y5L]M8LU5M*YK*J;2B_;*%ZQ(W(L7+$*
M'TYPZ"JFR7PIM<.["KCK#TG1DI?+5#;#[-BGO"=I+16JS&V37H]9:L-0VE6&
M>M-8 BUAYPW 62B%6(HZ/?+Q\(1&,8L!8A+ [>>-K)LUM5JF.B;&Q#7]'/MK
MN]K1/8W>I;Z.J5V1#M@DTNGBJGX0GQJB!L5H9<&<Z5[PV+&Y\?%=,;7>U=?Z
M;D(+4IZ4*QJ;*N^"*'6.ITK4+I[6<.8@Q53*)'!8")],*Y+[=,MUIW2\4O)C
M]QKM6HM.A8#-4SM.M/-,=9;K*[5G!C;WC4:9YF)::U[5QL2CCC,^9B<;"*<M
M4X0%.E&P]2ZL-K61M"1/BVDV1^LXV4U Y>QFJ]=.OEQ#80#=2'?02JV;4A$^
M6'9;-:$+>=39'K9;PS7 H]<B-<O9<PKLV ODYC[)\KV,-"RQNM%;3BFKZ?[_
M .M&K!9]<:M[7 0-UM_8N2,D)*=I8^Y@8'8/8+5DQ7[19 (Z2D'Y>UFT6(G7
MG H-V.L2H=!2,3<4?A65R*\B];J=>\U@:M1TS6>52.Y"K-38?2#=M)D5$J>U
MI;#1#>:EJTK986QGE2#E#O;)3;%FW5\C)FY9-06^(:U(](],ZU10;8.(&M=J
M;"*0/ S*4R/9,FHIGK7$-Z5BQ5"&MMTD^Q$!=]9TS40L/5'B*!$06P;:WV+L
M$;L$NX12399VSLN:(S!EFX-F!VU)RL\=2Y]I:LV*DJ"]1MV(4:[FXZ*K;"L?
MQUJFI=TTI/5]A:5BL5,7ORLO6U/)J\=8ZBY41!/+?+R5LZB88"D:GK2SK;<?
M]I?LAOG9Z2KD;)DSB:4I1*FC G).3<9R LB:/2!:ONNP=[WN'5 W"RM6_JG5
M!=21%5B(N>>F)ZA[WA[KMVEN5Z>L-4A[2Q8ZPU5C[#25VBO'W&I0LO$Q\JPY
MXJYR*HR+]HSQ^=M/J#HW;DEB/5U7:&M6W^O;ZJC#4LM4Z6WV"FV@4?D7:M:F
MWXGQ5A4]>Q/?6U"H-B!=0ZOH,>FUZ-R=K<1H[%":[^QHU[CJ%#:HKV7*E,(]
M;4)B_5S,4(A.G?;6GHI%]>TS;K;?_?>Q)S1.L'NOFC93K]KR,MFVHFP1-0V'
M 76^VNU]>@V8H!V:2Y1):4*@(\Q(HMG-F!GX9?9UO%._I1)D-NIHZ"CM=C;L
MD01KT;7=W+4U-U62%PKNMU^S!2DBB .TBM46J[52%@*5N%6*VRDH8F@W8[.S
M4JTD1-F;1:#2ZX&MU-ALTSK[+8ZXS-AL(O&5JT942N3W7)VOU4W+U\VA==M=
M?*#<]MHE+?5K_<:Y,1\7.Q9EMEY:PRX3T/7X.0H%CVV-KF6/).<.M]M3/!LR
M=;#&/+@ZFN)3S*!GJT(IU5LL5:5A]36'9F0LPP=:T%W&]LQ6I>LJ68TS]S"7
MN.S8N;&ZNVVHJ3M/ -A+;%Q@IMVJ46-@E')U"$[M(VT5&8$YHKM51V:-6)JK
MJJT5T:DT_K)A19CL%7-Q26Q^E/:"\=>['M"&UU2[V%MC0VOL5R]V37VR-E5B
MO-QESKL18)&!BK>BHE1\_43# 3&Y4*/L3DD".\/@WRVR&MK>H-_X);L*5[2G
MI]3L14'*#1ME7G@T&&!(K[NFI:F60@A%E-"7P"K!%%<"?>T6N!DA4MUMW4VU
MVF92L;5:-=?I# S'>,NH6K2;JZK#YX)I PGUEP5 =NZ.VF'&6VWA]9?B_)V)
MHV/J6H*-6Y,&975]U6WN)&["H0)6(XXI,3=D1O\ WB7&-@$/5>LI:F109)P4
M-S*]M:ME6QK*46%>K5O_ *)Y7XCDZ=>AT_6ZB9U35I6C 3=KM7I;%G7^>R*I
MM@^$I@P<$9K<F+0[&X*#]+&C^DN'-<N LO?MZ/3U'26K=</*%>YM-M7 ZBU2
M9)8"6V278\A1])T>@AL -LQ6%EH%'02O'CX+(2TA+R\>/]"G,*5C_7X_T\T9
M(2QDKCA<L.0B?:8"2F1B8_A'&$P<*5#)Y8*PAD_/DX&(*>>9YY+F>>9_GG,Y
MIDF.,8XQCC&.,8XQCC&.,8XQCC&.,95Q$:&!W.R>&VX.38>MK_OO+9!.&9-=
M=V2 Q!NE"9>R(LB,9FY=D4G#&"$,R!#675-J2A/%@!#J#O&)@G:@O+P1<'X;
M@0J9'GM[@AK(@HCNX.8F9C/IQ6&O^AN$.D6+U_TD+]%W+7Y*P['IJR=X%-[/
M-"[1T:C&JEDKDZZS@.Z)G+1\[6?,<<8QQC'&,<8QQC'&,<8QQC'&,9QC./#/
MRXXQD!':7(+[,0&_TSK;8L-IFPZI56LB*RX^].7"!M"9E)OK<)0@=$,H3(OJ
M5*<4_AS#B<(RG.*D>F+=E/Q_6P=/B/W>"=(>_(IGY]_J/KH>/EV>"?GWQQ%9
M7ZAFH9SV_5<[R9CCGS?7 :08B/EV>#ZHF9_>[_-$1V]L]T^\SDN.,8XQE&;-
M_.1Z=_N8[^_VS=?>,9>;C&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&8A?[I$ZYH]NOT\DA4+3:[,6:40(WATIP&% ?D"&AF\J0E9#K;"FV4K6A&7
M5I\ZT(\RL,9KNH7=3>8]NTX9N[4VN*QJWL)<*[1J*_1+O/V38%"LMZBCYRB1
M^RHZ4KL97))J9&CW(R2/I,H:-!RJT*<P7'^)6']?GC-H'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8R';?UZT5?IN<LMTU!K>T62S59VD6&PS=.@I"=FJ<^ZAYZKR
M<P0$N0,@'G&T*>BGB%ANX3A"VE(_@\C%2A%X"L!"TZN^T$#$!9=4,&5FO&([
M7&ABUFJ60780#,>XQQ)Y6]U<Y8<G4%X52DIDJPV0-;X1,SRJ&@Q@GX^WNAAQ
M/[Q<RG%14;!Q@$-# !Q41%!CQ\9&1XS(8$> (TE@4((0=#; PHS"$,L,,MH:
M::0E"$I2G&,3M:QS6.<PVN:9,:UA2;&,.9(S,RF2,R*9DB*9F9GF9YR!2EI6
M"4@"E+$06M8P   QP(B(Q$",1'$1$<1&<_FF;XXQCC&4-[8_RB_1Q?WH-@_[
MI'8OC,??'\I_Q'+XY_9GP^;_ *_;QF<_GU]D_P#*RN].F>P^]=1U_1G64^"U
MAM_8^OX4^5B=CN29L54+?+P$>5(N#7X899Q D>RZ6H<8=E1"G,MLMH\J$L99
MKT6'^4P]QN\W?7KYU7V5IWKY6J3MJ;M,;.S=.B[X/90682A6JU#+BWI:ZRD>
MAQPZ#&9>]I!(1D9U]*,(=RAQ#^OY8S8O*]T.T6O+CM*#N>TILZB[7](PUJ70
MUL8!!2515TW:];@[CH&3); <'5!VJAY.L56-+1@Y:QK+$Y*20T IZ'2][Z70
M=6P1-V.P1LMZUQ1 CMM+,=3HLU6QQ\5S0WJE%T=G;+]:^N<27HK,3MOOV,NL
MK:(@:=#6ZV@M83W,UNW?K>G[U78AR1S%;9Q=M4V08DM-]01$?MZX&UOHR[-N
M3:6*MLK9\YV!G5R[.QB%V>T]D-:V76EA?$N<Y$ , :5K[S=I@4,1XR$QS9\>
MQB,]@4LK^,=2I5G6C$:76//_ +1:Z7Z9ML&T,VG-L;#4ZVY;MA85/A2;',)W
M,S$"NS-<!B8D8QM^/KW<(5/;7I]5]1TDA7B:JTU:&TV=2K6-+8AC@0I*D%,3
M,N:N+/<0>\PMO;LSW!D^R,._I>^2HBZKW#V_0DZ+6-'Y@MBZUT'U^1=)2E%^
ML%</9GMC2!\G/0LRV6CU!J*V-A*0VG%JJ:9\"*-K?@[5!?3W6.\VU1(=[@JU
M>N-/T>B:8Q'=%O1TH9M(3'?%FTZVJ>Z+"5C-M4216M?48BK:&[T1KZ-MA]J8
ML;?I_:]26#O]YB,)MNE.J:P9$4U4HL1'E69'!VO.V6\.T&S:8]4-@;\OFN+6
MSVJM</7]:;MU[U]F0XNK[Q@ZQ4$SDK>&XK)[=3A2R*YB :?]M$)]:X:V\MKU
MJ9-?7;"U^J9+R'I7IZ[%Q;P*LP]EU/UM7F_"UQW6?7Z[7:WPN7!*!%:(&(8S
MED=UZY-L*7-,IZJV.O92>@XM)BCT5T5;=0EA<@B*6VV&R8]<SY&V+)2)$I4B
M&YT7M490!(VG/]6.ZM[(K  4;FX1M J]_$FGFP64OGCW9N]@MV7+JE+;?FF!
M!VI!U+CS:,MK3G,[6BYS6BOQC+& (P@JL2 'VB0H*9)8,@!8(E[\%$S$3/$0
MJ5*5* F2PO&!R4N&P42P>^08T/A)B^Z0.!]A*)")GC-?&\>\'8*)[;Q=^J=;
MW=KG06I^L<U=]ZZ'VE1(R#LT]696_NUD_<--CHR5L!A$OK%'N^<<:P;AJ4KH
M=@CT!9,4*O/.8V*U+JVS:LK&J5+5Z^G9@YAG3NTO5]XVAMG1"YCT5JW13KKD
M')BM-F+\B(T3AG4&O-I?3Z:==L["=UM'DF0&%;ZE1KZ,K&G61>_GBO?LVZC!
M)7[;754,O';,@@3JSNWL3V+MU-(L&P>PVPJ_^X#UIMSDUKKL=K#3,&$;?2+P
M1.66>@+ F,E;BN:#C(XM:H=I_'L@> V66B'L)7Z!-047-IYU$J:G4U+703RB
MS66M?1'16QL5O1(^V]MCLK]EY1$S8*W(*F87Q'G3M&Q%2$EY/-JMO;\8!->P
MPPZOZHU]9DV'Q #Q2ITZR@GLE,(@W#WGR6Q^*[=WK36B._%VLPC^WB.HFVKO
M#U!4G+CPA=PK[T)5+A"UN7L+4>2,.; /V]RNO2F(U_*0@0U/M/OI=6OCP\RT
MO3UH50=V_LV=/M,IA*K3U]4'T_7V<1$%V*8EB"? #/DLUK4@,$7$>A10%V_L
MZZ7,54+54-T!2$-*JM^E9>LTQGN#RR+J;V+)AP0A:4)20B)%7*Q^ERVIK8NR
M)V[UIH8X-<OMOU P11=S25E>?VI7Z14]@19)")W6=:9BM=NU^[1;%AM3Y&96
MOF!S).( Z('8.(L)";,UDH(8M[)FP1K)?,*J2W4=8#T9L3O/&6,K5RODRS1D
M$N:]  ARJ]EZUYSE21)L6C&8K4:^IN; 5SW68K;KII_4U)=-10 6;0(K^F>!
ML2CSM7*7L$3XV5=3.R%BWZ)M>$N]1K%5OFF-A8U];%:_N).PM<3)9-<A;4"?
M3[B9 5<V2;:C9T4.9".@H\R)EV"1'4.M^I?=D@%LHU;Z9="[%G:4B785"FC9
MU%YE"RQ<09PVFY@=]5_PD8^1;%K:HPB&&G%RQ39"Y)576708IDL J^TJ^I2M
MG(C*[*8@A<N.]?;*FJ:8-CBW7(<GQQC'&,<8QQC'&,<8QQC'&,<8QQC* ;TW
MS0]#]LM;'WD](:;OJ0BCPK6<Y2MTZ4V; ND&)QY%Y?'B0V'33F6$N$^HQYFV
MU8PK*?,;'9U=;O:<V3@?4T"K*C[Y,[J>9_C #$D?',P,3/'$3GWSHCH3?==_
M11U(C1HEQ:/JU>\N3QW"**G3&P!:IGNB%G;<T$(8R13Y)[3,9D8F^@!PDF"'
M) O)("/%8,$(1A6$/C$M)>8=3A:4KPEQM:5I\R4J\,X\<8S\G/3"4&(D,\B4
M00S'RF)CF)_MB><^$/2VLYM=X2MR&L2Y9<=P-44@P)XF8Y$AF)XF8YCVF8SE
M\SD6.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,91FS?SD>G?[F._O]LW7WC&
M7FXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG72\1&3\5(P<T"-)
MQ$N"5&2D::TE\0^/.8<%,#*97C*'1R1W7&7FU8SA;:U)S^WC&4YUKT+TIK.W
M4RT!RFS;6%J]\DG4M,OFP9NV4O613XCL<P96(61<5EPZ(BB"(>NG3A,P77HI
MYT*(>$0KS<8RZ_&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,H;VQ
M_E%^CB_O0;!_W2.Q?&8^^/Y3_B.7QS^S/C^SPSX\9G-%6P?1S^@'L]\NMDV+
MJWJ 7L&?MEAF;R5,[3;#F"+?)2Q9ED?E0TWT; DD[,/F+.'P./ZDE3K?J6_+
MY$\P]WI@,UGM=<!@4@8'=KB0$,S!"0RR)@HF)B8F.8^_/=U_HM^DNW71;J_1
M_P!:6:MI*[%:PCIG<N0]#@ABG):NF0,4P"$P,"D2&8(9F)B<D3K5T1]"CJ3=
MU$V%U?USU=A-[5PR3?U_)T+8Z)JVBFEP<G'RBX:+^&DI[6\J!+E6W\8 (RT(
MLA[P1Y/6)V3M]58:":^RH/<R9@%)MH8PYB)*8$ 813,1$S[1\HF?NRML_HZZ
M_P!+1L;3<=$=6:K6U( K5_8]/;:G3KBQ@*"7V;%1:50;6 L9,QB3(1CWF(RW
M-JWIT<@K#MS6UDF]2.S&BPX_L%M^O-UR-G<T*0/EW$QEYL ,=%2&1[P5*C>U
M!K2.Y;7GE#EM(5D@=QVR#TQ4B^LI*KI;J-*ER0,_1WMG-A*]?3%0D0NL2^PE
MJ:T<P5EBV",N,9\H==Y/"HP?M]Q2LW24TA";=#5+J&ZS:\A",U:ZAJDMEB?'
MV5X\<S"/AZ_6,?T<A:S,=I]6Z2J=3;AW9EV1O,%UFL=.V2MPI;?OIX.O_N<1
M6RY7$DHW"WWHV%+3)X==<0LA*'U(LG!:BLE4<UJUA2:X(K?$/@*Q"5(:BK)R
MA2WI&96\%BD5@XQ!<"S*\3&VL&PIBW84QEJ7V9B2\T5Y<3P?8F(8TT-+ABS(
MF29+&281#D;TSL9T%D=AS>W:C+X?NMMV#(5RSG6"C7&L/U.[Z_UB_+6ZUR,1
ML*O5XNENP^K$"#76V"C"MD0J(6,DGB'E#L*U245*C(48!2>C>;EKQ:LP543<
MUM+:@1K,V+JV-VF@GT0A*[.\;W"LK+&'F[ .S96)+-MI9:76JKP,PUSKA7FZ
MF 3/;Y[*ZS[]@7<$^OJQ8R2"F SF35M?HW>R5'LUU&H6@KM3M4O3<W:";MIZ
M(AU4GX2LYN$S8RX:]U")E8Z/MHZOA+\(6P, 6EO/O4<V0SYGN1V%*UU-6PL+
M&M4KH+7@R0@9JJHLY+6&H(EM9E1MF"^K3!;5'9$H1!.&2V4QMRRRBDSL6++P
MO$L#DQN.LK&N%];8*56X:NM"(O+-@$-:52Z83(C87KGO+K]N2IE!=>YR++K6
MOW(ZM%5L"L35(=J33L6-(P06:C8(2O247$GPI I\ 0W%-Q<E&.-DQ;Y V/-B
MZ\;)Q%JQ+#ES7)-C3[VC:K2(6*MD2*6HMU^Y?FJV!784)JDUB)A,TD%6"?2U
MX6$+2IZUK&!6=:P3839KD,0M]5QJ>*[""8DV*< G)K.(Z[L_MC1O6+5U][-[
MJA6L5BE5<>%M]CBZ@U9[/\$)>;# S"X&885)R,(J3DVRS8I+C@ODR^4L=:D*
M\>99;55XJUGQBK<W]=JC%HQ-=S[K_15(N1VD,H [)C)L$Q4#63QP4QG3K*LV
M)*4%/=KJU[9+GOD22-:OZFT=>>8['L75"([)$FFM0R7L/%&]M[5]&K"3=4"D
M>L]/W):6:]HP'6@&O^O5*N\I)U[;B[<]J>)HQ98H(2(YENGV$S 39X(4"RTE
MW.&U$X3GH0NVC9V86IX;16VM:^VY7PV!O:?25]LZRQ\'!2JOJ_3PFWWESXUI
M5,P <51$+&L5;(USKSUSKZP;W=HUG[BMK'*E$C/98=M=HH&UR$3)CG,9$3#,
ML/H*W:#E_>V@5Z9V+K25V6W>-L2NONPE-"&EMB-&V4=JX3A&")BT1U@R)(GP
M[+P#Y:G(Z'<A6D",A-#I0 (.JFNIJFKT=?7P-<2(G44V+-M]2VSN&)EEG9(N
M63LB9L*^3''(FP"+66$FP5GM:EFR>\!L#'8MS:U*L@ZRY"8A8JUT(2I': %6
M48K@X4[MLE(T70[Y)[,O5-6.ED'GFRC<C#5)9+TG88ENJR99Z"!\N.'34(PU
M737GTY(D(QE$4\IX9M+&*\B+5RB8ABC&PCQ<=X&-RQZ^RGL]X(;-O]L>$1]K
M8CSG!,B2R02-$]PD29&:S^X9E<C-)7@J-YCB8]*DH37/Y)7, N1&8C,@U_3]
M7:RC&]>:PK5(HD/%X=.:I=*BH.N  8.=RZ\:FOPK C(WM;RO6.DY$1Z]S/F4
MM><^/)B:QPC),-HH&*X=Q28J$9F03$E,P$1S,B$3$>\S$>^10M:B*1 %D\B:
M4P,!+B]A)D\1$G,<",E[\<1$S[1&2%S3-\<8QQC'&,<8QQC'&,<8QQC'&,<8
MS%K-2JO<O<WPEAA);-?G(ZQPZB4J\X$U%.+< .96A2%^<=;BU8;4I3*\Y_C&
MU^&.0NKI?X_*L3\3 <ONC]U@3R)1_*9^7RG[\Z>MW.TU'K/JVZZI&PHV-;<A
M4QQ8I6A$;"#@HF.U@C$241!CQ\)#.91C&$XPE.,8QC'AC&,8QC&,?LQC&/DQ
MC'S8Y-G,^?SSSQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8R&^PMR.U[I#:EVC;
MI3M<GUBBV.9$ONP6"BZ74'P8YYYNPV,,);99L;%J3[4Z".M+IJFT"H\<NXQG
MG[-Q(J$P;$5>7U%$[Q2]L ^XA# JIB"AMYJV$J@L@8++AH$EF$D$W*"9?:6N
M*\VRD7$->&>(&&M#&!YVQ[JJB8"=MHR)+JBXQ(2&"BG?H]]H[SV14-KV"^7>
M7VS1FIV(=TE9[[#Z[I&U++%.U@4B<(M-4UT,'#5:M2=C]8]0F[#$QMP3 D>>
MR X=;:4OO.3"J5>'UYK7O6[(23#?.Q>N T_5X;)H253ZY"9LC>70*:H*BK\"
MGR]8\A;?+:*4/BQ4FC3,FBN55SV!%8]66M%O%LM7*O237.X/F)_J>PVH\+)Q
MRC73;]Q](WK=S;.E&--O@]-]XHA6&-FU_8^)YI_<>A5&.*7!Q49[I]@4V/C&
M"</8,]ISZK*/9W/-1RWFTOC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&0MO/
M?%'T!5 K/<DSLF5.3@56I]/J,2Y8+I>+7(MOO@URJP;3K&3I!T84LPAX@@.-
MC(X0N2E3P0!7R6V,Q?0G9^C[](M4'&U^]Z[OU'5%N6[6.T8$:NW6#CIUI]Z!
MF\L1TG.0<M!32!2L R\#.2H6"!20271SAWAT,9$.Z^S>WXC<,MI;0FNZ#9YN
MFTJ%N-YLVU+=/56M"/VPF5&JE3@6:O7+-,24T8U#%R4H>4*'#Q8#H:$OEF/N
ML#,9/G7#<_[OVH:YLQZKG4J5//M-<LM2/+'D7:];J+:YJD6V*8E!,)&EH\6Q
MUZ31%RK+;*9*.]E-R..IY3*&/]V3GQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8
MQQC'&,T6]Q.P6YJ5VUL5=@=LW&EV6L.]8D];=&Q2 $5?L(#>[Z;&;V-F8XB*
M)-N/P:KJ"42'L![&-?!10UB?]0D[*W=>GI&QL9BWPS_VL?KME69,P%#HY?2=
M?8!N^V"CT\3MV;*)VA3*R=K4Z[F.\P9MMAE=+X!*O7_R:M;"IL$C)OM=5!MK
M%:OI>/<6P==>J6-&![VJV]FY'=Z433AG8?MIM(CL?8C-3;KG')V-L/7$7JAH
MVJF19>O^RU.N4F4'NR9-'3&%$V]B"(9FHN5GH^28:UNW7AY0CV?U[F28=?-F
M08Q2YNWF[7;*N4&CPNATN/2H[33;M(B,$ 6W,F^B_)$N[:4O4 4^3P3/>&L*
ME"QD5*ZM,UHW%L'O?U77Z@M:]^E<<B8DQ2Z]6H>NB(9*K;K\#$JAJY*]'#OG
M;.R-S#0TQN&Z;B!F^OQ=Z[#P=L:!P-H'L:G9"H<76<4('$@.TA3U<5+LN4 ]
MY\E@&NA6#R_^T5DD]9"JLZ[8E7.+FOK%TM.EVYG#';%NPU.P?OU$\8%=J*]A
M-%K0 >=4ZQZ(^WRP \^T3XN5?4!Z+9MM]1HV.E5'[-3H4+=5>GM!SWF$LACD
M*?+2':I[K@R?@[YES>>PML6;N%T)KUQT%.:ZJ,1V?VG[@V&?L"@6./M2A.K/
M880!(M<KTH58XOWL"MR4;5*B,)";94&9E!;C2,T<F^_^/O\ E[<_[LVO*_9G
M_5_JXS.?+7MOT%?8?86U=F7R-VSIH*-NE_N%LCPSEW+!@@5BL$A+"CEX9KCC
M."66"VVR,,O/-8=2OU;BT>"L_#]C]%VVN[&_<#8:X0M7+%@!9%CO$7.-@B7:
MB8Y@2B)XF8YCVF<_4#I'_IR?1[T]TITSH;/2G63K.ET&HU5ER(T_A:_7T*]1
MK%26S69+-BB(), +MF.0&9F(F+I9Z''>?6CLWJS=UJV7JF=K]$D)LR1BZ^JU
MYF"VY.KS<&RD/WA B!>9LF39><]>4UC#+;GE\R_*E70Z:^CG9:3=T=F^[1:F
MJ3I,$>?R%#$-5$#WJ".8(XF>2CVYX]\\?]-'_3"Z'^DKZ,^J.B=5TWU51V&]
M1137M;"-7Z14UMI2O'+I1L'N[275,1@%'R9#SQ',QL+[)]*K1NC9>]KH"K7$
MK ;5ZN5320]/MYEVAQY2QUO9LO>R'K',44B)GHZ"D0#!8YF5@Y1R;CS4*)P"
M2,Q@<CZPM<JK;!7C"P5K?].;A2R:Q 0O2KM"T"<J"(+!-L ZN?B>KE7#EE$Q
M$?G]%OB=1V,8@J%?JBNUPJ4\IC?5M173();, T%#0?%A9FJ2!H0DP/N..;UA
MT+VGT/KN[U BPZY>8MTIL.R4^M%;$VCL.)T<^;7X2-H5)JELO$ JW7.J+GPY
MFT64VQ+BR8AZ4Q%UV+(!93A,^R.Q:U4TT6"G8JUUE2-HY*UL.W:V-IRUV%JD
MNZMJM>Y**EHC=;LN5,O%:NT1H4@K)OJL-K^.E-J@-F@AK& =6K4[+5M).F/%
M<OV1 65 A=5*8EH,.P;.^"I;H;<ZC#=9(! L1M)YG5._M.]@I*60=)0\S<^P
M]>&F+/M^:#(D(F9EXDN^Q"HV9;&-%G!ZU.I;"RU@7*&UT*[[FUJT$16U;^DJ
MVDT</DA*@?3VUUVUUH6'(*32>P"K8:Q]>&']<Q6L,[HDCR:K8>I6OMVSANPK
M=9KZDV$H$.ZRJ[1VFI>JJ+1A,!KD7ZPJ4X8 M?5E,!W"(3^^MO1?LOHJ&W7.
M,WG7[VTM[@5>G'R5IN-\W-!:WI^M=>2]>H9,'\.:K&&71U^QE#.R-3GAH>*B
M:TZ^(/,S4@/[2=+9<P]8ZFF1)UK:;3J.S8LK C?M[9:=->I9)<!YJY4M<X+6
MT$$V8>Q)IH"*N,AK@E=ZI9<N2KZZC2TM2LAC$A]6#;V%RZU<=Y^D:+;@12IB
M3UP*CA]P_+,CV&@/1U;(A[9N?9&T=M6O3,[MRQ5V?/H?5+<VP&:<[.0]>8AI
MFXS%AOE>'L1DI:'&6%#UH80:MU", #CH5+^72B%X2"*U"*:3M$,[38[!27L@
MUT*]T*@A04WW=>8+:S;5G96NVS9;9\4@M%=(QHTGON#9=Z>2#5T-<;UJ\3+C
M*3[[8M$D9\%%7CN A5"KW)7X2:3#8TIB0-\>CRFM@ZKL-.JW8K?%FF9>0J#S
M47N[:TO<M>O"P=TK]BD<2D"Q!>L*)6!$D,QRO#+;9KK*GL89PYG&J9%>PTUE
MJ4OKT-]I=G:6U<,8=77;!%RPJMW3 #8<M1)$CX"188E,04S$5Q)6==MZBVM2
MZ_I=QK:YK80+&QL=?8IH98@?B-"6N%Q"'QQ*Q(/B&(RF6T/1&[8(OFR)2@VG
M6EOU65M'0EVU3J:[VO8FNEUBFZVD]H6&UZT>OFOX65L$/#HLFQRS:,?"-OE1
MT4CW"8VR*,TM^+7RZK7H)M"-UM':[=P62<]3V:VUTHGIK4^=D=Q6+VL4E26>
M7E=RLA;G-*P1"/4MV L>MA7-<+VFBNU0J62PV[NI-5N]@]0S,0%/8!K3:8!
M'7OVW$E?B@.+;Z9ZV;8@]\=>)"QZVJ6LJEH:D[J.(>I6U=@;>@YR9VJ57HB)
MKHUOVA%0EW+?$#A92P3HAT=F*!=5 HC3"%J>;&O5W1#MI:8PB)G3]#05TFI2
MH(YW$;:S8'Q%/F7333J(2]T \G7[BN/&H3/FM#]DK4UC$1/4<[US!:T^T*ND
MN:M:C!GP@=MNU:R%I+QK70AAQWOC*R;&]#R=?K+M&WFJTR;9]@67N'9FYZ7B
MYTJ5P=NX:.SI0B1-S&.O+)U;)!NR;:F<K;@#75GU=/M[S[RN722RC1KUT,\5
MFMHZE-3U202O<(ZX_P HF;0"B8.&EIN-6-CCU,<E6B1I3(SVFW:]G<5KMI)/
MHAM=4^S59VLEVII='*Z?LZZ0+[(U6-F!WY07"#"0:R/5",A+NA_1X;@UEV4J
M&UK)9]9G!U.[W78,YN")*M+^^=LAW2@,5 ;3=]0?#CPN-;4V1\LU"$MV.36^
MN"K_ +-6X0S!YCO7JV%(/8%"O$MU#<:Y==,#"M@S9]2AO4;O9\\0.SHU0^KE
MK6#^1,B"XNM'I"X#$,*M223/4-6S1O*Q8[I9JXU.GC6/U^HF)F2I;!L$]I.\
M$B#WPQ#[/CM#N1Y2RWCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQG4SL#!VB(D*_98:*L,#+#.A2L)-QXDK$R8;R?*
M\)(1IS3X9HKJ?D<')9=:7CY%(SS1BUM&0: ,"9&9 Q@AF0*#">)B8Y$Q$AGY
MP41,<3$3FX,-90:S-9Q!1! 4@400R)1!#,3$$,R)1S[C,Q/M,QF+T/5.K]6C
M'!ZRUS1==ARCZ"I,2C5.!J8TB2TCU31!S$"  T6^VU_%MO$(<<0W_ 2K"?DY
M-+&$ *DSE:R(@7)%( 1\=Y $SVB1\1W3$1)<1SSQ&1=HP4GVCWR,#)\1W2(S
M,B,E\Y$9*9@>>(YGB(YRJ]F_G(]._P!S'?W^V;K[S3-LO-QC'&,<8QQC'&,<
M8QQC'&,<8QQC'&,<8QQC*O=H.O4CO6*U[+U&W#47:&G+UC8>M+-*0J[+7F98
MFN3M-GX:RUYJ0B")*"LE0LT["%Y"E 9&/68U) $8($2TZQE!-KTF]]7AYW?6
M[]X!P;NPUPU!NE^UU6WZK :HU?5P)>=BJ97#98Z:DA9O8EP?4T;?YA]H@4Q<
M9 0(D846*4XQE2:/L[3=]W*1(;XV)LK3 4C#PVN:5O!/8&MQUW":D6Y6R$Z2
MV_+QI&0I; BF\SU8GY)N=L-)G["?5\6@1U8^./Z_K^OY8SZ!]/:^UYJW6M1H
MNJ0@@=?P<6C%<2!(NS#1HQ[KDD_,/31!)A,X?-FF$R\E-EF%ERYYI$@22^^2
MMQ3&27QC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,XKH(3[[)+P@[I(_G]
MG?<9;6\QZS'@OU+BDY6UY\8\%^3*?-CY,^..(]IF8]I*.V9^^1YY[9G[QYF9
MXGV_AC[HC[HGNB/N@H^4Q^$Q^/SSUIC(U#@[J0 TNB)6@5Q(S*7!D.9SEQ+"
M\(PIE*\YSY\-Y3A7C_"QGB/:9F/:9&!GC[Q']T9_A'W1\HXC\,3[^T^\=TEQ
M/_>F>9+_ /:F?>9^<SGM8"$%6\X,*..LES+Q"V66VE/NYQX9=>4A*<NN9Q\G
MG<RI7A\GCQ$<1$1[1'/$?='/SX_GC[^?O]HY^_B/:(_LCY?AE;.R77(S?CFH
MIF VS<=,W;2FPS=C4NXTZ%I5B)1)2E"N.N9./DH6^UZR01L>77KM+9QGV)HL
M<UL0ADA*4+;<8_K^O[LC+XLW:?ZQ+<OX)=8/THXS'O\ C'Y3^N5]U?0NXEXW
M/V5UO)=^]K P^EK-K>%KDD-HSK6V9-#7/6<'=I%^2=?U>Z,^X%)RA 0R@F1T
M(%:;;?2X0E;BF/?\8_+_ )Y8+XLW:?ZQ+<OX)=8/THXQ[_C'Y3^N/BS=I_K$
MMR_@EU@_2CC'O^,?E/ZX^+-VG^L2W+^"76#]*.,>_P",?E/ZX^+-VG^L2W+^
M"76#]*.,>_XQ^4_KCXLW:?ZQ+<OX)=8/THXQ[_C'Y3^N/BS=I_K$MR_@EU@_
M2CC'O^,?E/ZX^+-VG^L2W+^"76#]*.,>_P",?E/ZY7K9E$[C4K>G6K5T;W[V
ML;";IDMKA6.3)T7UM<.AFZ%KTFW1:XUYC6#0@ZCI!E A>3F"4NC*R@?#+_E<
MXQ[_ (Q^7_/+"_%F[3_6);E_!+K!^E'&/?\ &/RG]<?%F[3_ %B6Y?P2ZP?I
M1QCW_&/RG]<?%F[3_6);E_!+K!^E'&/?\8_*?UQ\6;M/]8EN7\$NL'Z4<8]_
MQC\I_7'Q9NT_UB6Y?P2ZP?I1QCW_ !C\I_7'Q9NT_P!8EN7\$NL'Z4<8]_QC
M\I_7'Q9NT_UB6Y?P2ZP?I1QCW_&/RG]<Q'8&ANV52H=UM0'I"MP%'5FHV2P!
M"D:0ZR+'*+AH8V1&'?2UJI#RF7GAD-NI:<0XIM2L(6E>4JPQ[_?,?EQ_OG,6
MT/J/MWM72&G=GSGI ]MQ<UL75U!O,O& Z.ZT,A1TI:ZK%3IX(;1>K7RVA12C
MW6!VRGWB$,MH2\ZXYA2\L>_XQ]_W3^/\XR5_BS=I_K$MR_@EU@_2CC'O^,?E
M/ZX^+-VG^L2W+^"76#]*.,>_XQ^4_KCXLW:?ZQ+<OX)=8/THXQ[_ (Q^4_KC
MXLW:?ZQ+<OX)=8/THXQ[_C'Y3^N/BS=I_K$MR_@EU@_2CC'O^,?E/ZX^+-VG
M^L2W+^"76#]*.,>_XQ^4_KC/6;M/X9_^D2W+C^W]Q+K!\G_\4<8]_P 8_*?U
MRNNCZ/W'V?>.SE7F^_6U8P+26\1]85HH+1?6UI^:A'=0ZLV"J3E%E:O>:(/Q
M,7F5C\.@-C"8#!$:RQ[4V2\ZQ[\^W]\<_C_&/\/^5BOBS=I_K$MR_@EU@_2C
MC'O^,?E/ZX^+-VG^L2W+^"76#]*.,>_XQ^4_KCXLW:?ZQ+<OX)=8/THXQ[_C
M'Y3^N/BS=I_K$MR_@EU@_2CC'O\ C'Y3^N?I/6?M,E2%*](?N1:4J3E2%:3Z
MPXPM.%8RI&<IU1A6,*QXISG&<9QX^.,XS\O&/?\ &/R_YY>(=MQIAEIUY1#K
M;3;;A"T-MK?<0A*5O+0TE#2%.JQE:D-I2VG*LX0E*<8QAF<]O&,<8QQC'&,<
M8QQC'&,HS9OYR/3O]S'?W^V;K[QC+S<8QQC'&,C_ &7M?6.FJP_=-LW^H:WJ
M0S[(S]CNU@C*W#MDD*\K ^3Y4D8=1#V<9]6RE:G5X2K*4YPE6<,9VU*O-,V1
M68FZ:^M5?NM1GADF0MEJ\L#.0<H*K/AA\&3CGB!"6_'Q3G+3JO*K&4J\%8SC
M#&95QC'&,<8RG?9_N1JKKTB(IKM]U?C>%XE8*OZ\UK<+]#U@N3D+'(MQPDM+
M#N/N3 M<!\[A1A8D>0^_AIL41"GB&UI8S$=,=KBI'=9G7K:UNU'(WHNMN6>L
METJ7]S21*Q3$L2U7G*++S$S*1DF"P0,=%'L2QC4['I+=6%&DAO#<8RQ&YMPA
MZSU?9K]!,Q5L-B7HZ)C@,3H0,4N>FI4&%CFYR9QDAF(C!C)%@F6)4VX2P T]
MD88@I3##C&5YT#VMEKYMU[3-OFM1VF=*J5AMT?,:EL3I[,4[4Y6OQ-FKMFA#
MRS2PG12;/%JAY5@Q?O)M!R#HZ*?80V\QF(=ANZY6MMJ6'74!-T"IAT"(KDI;
M)^]P]SL#)LG:,/O14(XBI,MCTJ!4(D=9=TGS"$^T$*:C(.0;CI%UEC*@;/\
M32ZP/K^OHK3%OUY&VJ=:/<VW?K1%W.^:TT@[%2C]?5&GJIHD:BPR-@G17L0;
MQMAJ\2)7%LV6:.#8)%%=8_K]?R_3-0??_P!(%0.R]DJ^K=S7JHFB5FL[!I,X
MWJFP2]OU;-V&<BXR3I6YX6M!),=E 7Q,25?6R^?97J?9VW8Y"#'$,2*W]?E_
M=_7\,92/0F^ZIKCN!4+5?]1[AGJ!0Z938F.C9FEU@V;H(S[LR&_"2<5,,5@
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MQ'O[_P!GY3/O_;_?_#&7KYG&.,91CN3.2L7(:I%F[/9*;IN0.M*-A3L <7"
M/3*8P5JFPEOL\?A!M>K4D\_+*R_[4 "?*CQX)I["EBM$OY8S4O4=([:O%5[B
M:^B.NJ^SFN>PFT+*5JK=%WLD'&U^8KL]6X,:/B;[/6=Y.P)*I:;F17XVJ6^!
M&E_?$;$#B5+.'QVC%,?U_7^.8UV2Z8;PT?T-V[K"D:BEK1L6LUB+G+7O>L6O
M$M.VNHTZSB66WVBG9D35WZ-V;+U=F=S%P42@4T.R&NDQ\YD7(SN,3\OXQ'W3
M[_\ /[^.?G./Z_K^OSS1%=-9ZNWGN6GZ*Z;'W*A:\G:J]==ZC2;6S*IK>[P0
MB@)2M0TQKN3E*X?99<MP0?,_+**?+,"4:(1)NNI1EW/]?U^6/\,[C55CW[U^
M[-1UTZV0&E==[$T[?B]?SE3C!KX)K6W-8@Y606Q#QLO<#?#X11"R@+8PA^#;
MG))B$)%=>.BQ)5A_7X8_GS^7/O\ W9V?<;>7;7LQ"1>[K-"TBI0-K H^TMQ_
MN2_"V"V18]=339%%AA !@K//)+J0C4&'*YC6WS;%&NDV(\*3&9D$QR&,J1?8
M/150D(][J_5KD.W+48<*R,ST'>%Q$;..!RS=@?!<0PQ[98$QHN!Y5AL[,0T4
M9%X4O#JW\M8^[F(Y]O;C\/X?U[YF/?YS]_\ 7/,_AS_RR0*4"/-Z-N&N >AF
MR=B[)V'F5L>N=BU[6TS98PBGE@B5(-ZJ2T>RS*U@FO608XJ0>A'V!19M&)5P
MF2&>6GF<Q_;_ %^'R^_^IC[MK/33HKW>-;8VJYIFEGQL;33M'"UV<O0#UJJ5
MYB(R/@[G8;)6%P@,5)C&2)<T=%1\[+)5!E-ANE82R4XE3']<_P"[Y_=_7\/I
M9U[TMK9?4K4W7?<9,C)26N41LY!6*J6"2A[#KNU1Y\E(03M!MP6198%RF@RK
MM4BY'"6\2, RZ$>&X"<0(IF(^_\ GDR:+ZS:]T(7;IVO&6ZUWB_NQ:[IL'85
ME-M=OG1H)E]B"B,GE^0:+@(1LLS,7 PP<?%BOG'%X&6682^XS.8AW:T[<=XZ
M%DJ91H^"L$X!<]<7A5+M!BXZN;$BZ#>(.VRNOYD[#;[(@EK!B7HUM\X8N+08
ML7WJ*_'9)1EC(&ZTZHVC)=F);L!:M/*T37 -,E:F]RR\U7)"Y;"F"K=%6$65
ME@:<0;"#5VEA11,9729 \F6)<G#_ &0>.CD+04Q_7]?A_7]EM]I=8.OV[)N-
MLFUM2TR\SL2%[L$E)R*0\8N*]H]J]SR#K2VLR\-DC*GLP\K@V,RXMQ61?%US
MS,9-X00<:&+'QXHX( ([(@00C+0P@8@S:61QA1V4H98'8:0AIEEI"&VFTI0A
M*4)QC#&<GC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&<8T,>0#+ +:2^*:,^
M(2POY4/#DM+9>:7C&<9\KC:U)5X9QGPSGY<<B<E=A+4-'O4]3$M'F8[EM&0,
M>8]XY$ICF/?WS=;#4P&KGM8LQ8!1\Q,"@AGW]O:8B??*4];.C-)ZW7'-NB[]
ML"\I@*._JK5,%<WJ^N-U)JLBQN6IVD5IV$A(D^6'5+>QHS,VDN9G,QL5%1OM
MWLP>,+LI:Q55J6%ZBU:#5(N[%O$6KE;157T]0AT+[$1%15FR1L!(NM/>Q]EC
M#[>V*R(V+2[''B6FQMKB:H<RE5W?6$6MM9$F2;IFTZLJ06;256""77!8&43=
M_D>;8XQCC&.,8XQCC&.,9138O0R@WV;VA<!KU?:C?;_MO7&\:]<X)RN/2&L]
MCZOJ 5)KLM5 ):#/B3PR8,<H>8B;2%. R*9,YM;;;:F<,Q(!E0*D5'L0VIL-
MW>%PBLR:OJ&HJCM*+@:!K*FZLJ("($7*; .!L,6$Q9?8BUWA92MJ6::AI33R
M8Q*M9MK.[I6A,2AB[:=A9@X8!0!+4*B7(FWR6 Z^Z-K77?6<;K:M2DW8$M2M
MBLM@M-E>%?L-MM]OFSK':K/,K %!CVSIB:D2RE#1P(4>$RID($4<0=EI%IC
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MF)!D8Z9B) (AILLEK*F/6-/.-K0K+,Y+?&,<8QQC'&,P,W:.MHV?GZI(WVG
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MQ,3$3$Q/,3$^\3$Q[3$Q[Q,?//WS&9QQC'&,C.];GU%K*8J5=V-LZ@T2>O\
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M[,KI["X6R$QO2]GJ0,8&0;$\2$ /P@ 1$ L ^S%<"*_@@<X6M7331K*H1$5
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MUC;-;M$&-;J)#T6QU.UHT=MV#NLM4CRMFV\R4J6;3-5T"*)93"0K!Q:%UT'
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M1ZE6YNHU_?S239E0Q*^V9W;\H9)CC&.,8XQCC&.,8XQCC&>%?+C./[/F\?\
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28SD,*5G"O%6<_+C]N<\8S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g197729g08v03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g08v03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1+H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $LR^2!(X0DE-! 0      %X< 5H  QLE1QP"   "J  < E  "')R,S,S
M,38X' (% #U-:6-R;W-O9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T
M:6]N(%,M,2!);6%G97,@3VYL>2YD;V-X.$))300E       0;%J4L4I>6(Q[
M:?&?<Q#;4SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              <8   70          $
M 0             %T    <8                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   <8     4F=H=&QO;F<   70    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !CA"24T$#      (4     $   "@    ,0
M >   %O@   (-  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M((],SQ97D ]\K+N,_IG3_?7F_? IO-3C[YGW7ZM/.*C?9+R ]S]H_4X[R/\
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MVQ;C.=L97Z,G[&2:H/H]XU?,W1.\;.V;A)RV<)]1#MHKHG.DJ3J AVDS&+U
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MU?<?^8#^RMTK>QZG\B"GPI^&Y_)LXU_\51O[7,=\NEKS?L'_ !<?XS3W'_F
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MXG<CGKIVV9M6GAIG*[EXZ<)-FS5%'?M:.LNNX6.1%!)(A3'554.0B9"B8Q@
M!$-G'O-#G]Q>+_\ &['^7Q\NU:V0@12YY=V]O\-O_P#5?7EA==>[?Y?\ :MH
MZPUR\;IH.YIJ_7"6HDBQGW5$T4E0[+&74USFH5==*&K]J?/(>'81,FZ2\L2R
MC<S5FJ=N*J>-$"R&H+P6L<P!H(P'2:AC .,D#5N.7RJ>5S7S4^@ASFO).D@X
M9I())!V&_+M^[AO!H[<TGJCCUM"F;CO5$UYNBE[OWE(<C(V_ST-6K,O99*]3
M<F6U3:4Z[;/I6'FZTK%K0LP O&#R-(DW9N#E0[HE:AKW2-<P.<QT<?5Z02
MT @8&,AV<@;@\U2F<QC'M>6M>V23K X@'=QP=\9&G&#C&.2ZYX)^*4:\=;U/
M1,2_@=87SD=OB^:0BGS5Q')HZBLMX>.ZH\B8IRDW4BH&7Z/9>#8^+MTRQKY!
M9%$B2Q>MM5CK&C.7-C8'G.<O#=]^T\@<X.1OOE7TN>K)QAID>6#]Z7'&V!@<
M\8VQRV7T[S&62JPWU1=+D[IP[!J#N3+JS<AFZ*KD&S=1H69UAX\F)^X5,#M0
MPM!:G,8B!0(N1;J*J9D][3 FP7+) 9WRMF3@EVKJ;AI(W T\]7,\L>(\]NIC
M'27PCEKW3^Y;C$Q8>&QAHK>%NM#P6%Q<? T$.:!X>K.1CO4=9V#QP5@Z(XB)
M82B(QDH0&[@XE'H86BH&.T?IAZ^\9.%P[/I,!?2 :5S"W<8<W]LW<?+VCGV@
M>C.%[]LC7'!RUW[5PP?D[#\A/IPMDZ@/J'+%>F$3")A$PB81,(F$3")A$PB8
M117CYG'MU';UR@U;)!U47<*D22('_P 1SB!0'\ =>HCZ ](AE0"X@-!)/( 9
M*H2 ,D@#QDX'K*J[RAL*<MQXW$*<-).*V%"FSR$J=0D69RU\7_=4X=)VW6<+
MKG)U[ERX9I,O2!P45#T9O.'V/;>[7H>P3&LAZL.!>T.)V+]) P.UH<#Z0O ]
M)SZ9W1[Q@:MD[Z,6&O,_4/9%.^/JCD0/ECE8UY_8O?&]@[6D*S\;T\G,>R @
M'BC?H B B =T3H B'0!'IZQ .G7U9I'_  W?PG?=*]U!CJ(<<NJCQGGC0W&<
M>A3! !]8=?6'^W+5*OG!H40'PC7/0G:Z]G7O%D0+VA'H(UV[]/B]?1Z/5Z/P
M_A',B0#N: ]NN7[K?_58[/T1-_!C^X57;A]N70NLM<>$$^&Z_P"OJ[74^<'*
M=:>A+=8(1!>0A7;B&;J- @'SGQR2\K%[UDU9H,G"DBL?Q9NDNH;L9+.V1SZ?
MJPXGJ(0TMR<'PM\@;'F3\I/C4<+HPR8/+0.MDU!Q R#CL)WR-E3;C<S?:7?>
M"8MW)M!>GZ>85SE*RH;S8*1XZ!UM;;_8G<OHJ/M2\P<&5:F%]7+)PU35E2,E
M8TPK1"*R"P]SDLF'BJ;'@OU1$AN,N !#PW3G4-6,@9!V.>PPQ@M-*Z4$,Q(!
MJ)\%Q<"PD'9NW(G&.0SLK_[IMM V_P"$9X-M-(SD#=;UJEGN>S;EL5(D&4VT
MJ>GI^CJ0L;!7*;ASN6C8++=EXAQ7X-\]\8558.WZ+,I# LI QKF4\YD!:U^A
MK X8U/#LY:",G !R1\14[RU]1!H(<YFLO+2#AA& '$>-V, _&OKGF(LM5EY+
M?*T%_I(:U^@L&;ZP\[Q]HZ_^U N;=(_PN _]XO#G]W<%9K-"NDIA$PB81,(F
M$4<?EJ?G!]&3"*1A$PB81,(@@ @(#Z0$.@A^$!PBT5WJ_7#Z,2A7M$J+J(0D
M%Y9&,7K\6JP2DW0&!S()M3MA1(]7 Q@6<E("R@"('.(>C/+5' _!M70MM=5P
MIP[46UE7/<&T$]GM\M&VNJ<]T5C:=].Z(5,^IW73!G629.MQRM@R[72.4SQW
M&M9,8F0&9E3,V3J8\:(M8>'=6S TMS@8V"SL%5ZW5V(QE;@(> CC',H9C#QK
M2-:'4,'0RAT&B**9SF#H4QSE$QB@ "(@ !FVM=EL]CI10V:U6ZTT8)(I+=1T
M]%3@D8)ZFGCCCR0,$EN2-LX6-45-35R=;55$U1*1CK)I7ROQXM3W%P'Q%8B+
MUOKZ$ECSL-1ZG%31S*F-+1]?BF<CVEA$5C [0:IKE,J(CW@E. GZCVA'J.:Z
MAX.X2MEP?=K;PQP_0720N+[C1V>WTU:XOR'DU4-.R;+@2'>'N"<J::Y7&HA%
M-/75<U.W $,M1,^(8SC\[<\MV!(&1L-@L[,U^"L39)E/P\9-,T'3=\@UE63=
M^@D]:F$S9VFDZ35(1RW,(F16*4%$Q$PD,'4>NTN5IM=X@CIKM;J*Y4\51#5Q
M05]-#5PQU5.[7!4,CG8]C9H7>%'( 'L.[2%!#43T[B^GFEA>YCXW.B>Z-SHW
MC#V$M()8\;.:=G#8@K&KT>F.4)IJXJM>7;61TD^L#=:(8J(S;U$R9T7<JF=
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M4K::)]*,PF0M?--\+2#VKL/*H>FM(#^>?0O_ "W'2A_H <Z;P]^CY?M7>?\
ME59O\7C/8OC/I._4[;_Y9<!_]8V560*<@AU Y>@B(A\8/OB/^/-$-@/B"Z'D
M>,>L+SVR?QB_.#].53(\8]87,9;2^G)^MSM.G-8:]EZG:)]S:[)6I*IP+V"G
MK.\=%>N[#,13ADHRD9IT\(5TXDW:*KQ9<H*J+&.':RX/>""'.!:, @G('8 >
MP#LQR[%:6QD$$-()U$;8)\9':?\ /=?OKW4&H]2-'3'5NM:!KEF^.51\VI%4
M@:ND].7Y!G9(9DS!R).H]@5NWV.H]GIU'#GO><O>YW\)Q/J!.!Z<<T:V-F=
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MR]8)\,JR(4>D/-KJ*+EZ"(@1E,B"KA, +T(FF^2=D#H =\D7)-3'_#&D_MF
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M)8Y1-H( ,41\Y#6OJ$!_[BP9OK#SO'VCKNS]]!ZOC7-ND<C/ 9R,>^+PYO\
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MP/PAR(R#\1!!'QA=%"^TD9&JQ!;;7#2EY9/Y*EL"3,>=W;(Z+:-G\D_KB!7
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M(U#(R#NK&R1OU:'L=H<6/TN:[0\<VNP3I<,C+3@C/)90#%$1 # (AZ1 ! 1
M/PB'K#+5>O.$4<6K85Q==PCXR*?<BX[LG?BCVNWW0K=GO.Z[?QN[ W8[7QNG
M7&3RR<>+)P#X\<L^E4P,ZL#.,9P,X\6>>/0J\;BXLZMWE;-)6J](S:H:#OIM
MFTJM1<BE'5-[<R,SLV$O9H8C-0LRK$%567BRBNW*V<KK*F[WO#$'9T5VK+?#
M7PTYC_UC3"DGF>POG;!JU.9%+J!8'X#7['4T8*UU9:J6NFH9IP\][ZCNJ")K
MFMA,X&&OE9H.LLR7,PYN';[Y(5AA9-#+&<&;HF7.CXN=84DQ5.AU$W<G4$O;
M,EVA$W=";L=1$>SU$<UN3@#)P#J R<!W+('CQMGFMCI&<X&2,$XW(\1\8]!V
M7XC%1HD;IBP9BFS$1:D%J@)&PB'3JW+W?90'IZ.J0$'IZ!QJ=DG4[+N>_/X_
M'\N532W8:6X'(8&WQ;;?(O48N* 6O:8,>K3LE9=6S<!:]!ZE*U_<P[GH(=0!
M+L]!](>G&IV'>$[PMW;G?TNSS/I.4TLV\%NWP=AMZ!XN7(+]5XY@Z627<LVK
MA= 0%%5=NBJJB(#UZI*'(8Z8]?3\0P>GT^OTX#G 8#G $Y(!(!VQN!L54M:2
M"6@D<B0"1\14P  /0&454PB_-99)NDJNNH1%%%,ZJRJIRIII))E$ZBBBAQ*0
MA"$ 3'.8P%*4!$1  P 2< 9)V ',GQ(2 "2< ;DGD!XRH<5+1<['M9:%DF$O
M%/D@79248\;OV#Q PB!5FKQHHLW<)&$! %$E#D$0$ 'J Y<]CXW.9(QS'M.'
M,>TM<T^)S7 $'T$ JUCV2-#XW->QPRU["'-</&UP)!'I!PLAEJN7RXWYQC\(
M%>]L6RU:>YIL-8:YE7#)2MT96J"^4@4$8YHW=('>%:*>,"X?).7G>"<1Z. (
M/3LYSV\V#C:LN534VOBV.W4,A8:>C-()#"UL;&N!>6NU%SPY^=OA8QLOKCHY
MZ6/S-G#O!MEL_&_0+4\7<44<50VZ\0LO(IVW&22KGEAD; 9F&,14[X8-.D#\
MZSOE<>\S7PIW_B(QO_!1OJ.:SW+](WGU%_P+?JU[?W\_S(/_ &8:OV^W\)3S
M-?"G?^(C&_\ !1OJ./<OTC>?47_ M^K3W\_S(/\ V8:OV^W\)5)K_J;DKJ?P
MBG ACR2WVVWO+R]R3=UF1;0YH@*_'-YE!%\R.F+= %A>N#(K@<.WV>Z$![/4
M.OD*ZV<06WCG@MM^O3;U)+5AU/(V'J>H8V5H>S :T.U.P[.Y&XY<^^<-\9]%
M/&7YF#\T=4=%?1Q+T=4=%8S#=Z66N%<;G52T,CZ>H:X2R=6((FOC+?!!UYWQ
MM_4 ;U#_ "#_ $9]!GE\K?NA?DHJS\1O[RD?_GOMG_JI<LW_ !+^FK_XG;/^
M74JYOT3_ *BZ?[><7?\ 5=Y7R E^.6\:[S Y?\U-84.?LE_TOR KLY5-:V5@
MY)6MXZDG=(5"#V*VUP>52\G1VR8_Q98:K<84?&%WC!S4)%15G)=TC@=9&Z**
M%[L-='NX;ECPXENK'['L(() &1ON/<F-[99IFM)<R3(:1L]I8 X-V^%CD1\1
M6'Y.DNSO=*>O]+5VW0=#\,#2Z'&399:*<U:=U=<**YCDMT6"Q5J31;2D4_F]
M!J.(N207:D[4_%(]XH<'*BPUBQH+GN:74A=C!!#VD$-#2,C9XRT9\>^1A4EU
M=9I8"&U36Y_8Z7-(U$C .2W9Q().W85;*A\8ZN/A ^4,A/Z482>NX?B-QYUS
MJ^:L5*1DJV1M'HW^*L%:JLA(L%HT[I&.1AFLPTCSBZ3;&9I.2E26*4\3Y7=S
MQ8>0>MD<X!V#DD$$@'.YSSY[J5L33++E@+1%&QA<,@  [ GQ=O;_ %*M.F:]
ML;16N?!7[<N^K-JO*CHV'Y*Z[V1&5ZC6:TW77S+8*#F'U^Z?TB)8/;8>N)(U
MYM%]ZQC'(1[=S%&.F5JJ10)'N:]U4P.9J>8RW+FAIQI+O")QGMQMV_)%&'L;
M3/<Q^&"5K@&DN:"7!A(QG! 'K"YG>-8[#W3IKG*YD-";6CHS</A%M 7*(I%Q
MHLJPL<_K5-+4C62GG$*@5RIY&/&LG;F3$BIS1*/C#.8\3?-7K5"]KF,DA >Q
MQ;32,+@\%H>"_ !R.>0!X]\=A5KFO<R4EC@'53'@.:0='@#(VY;=NXWS@G"L
MWS7T?9J-R=X_;)IT1+4;CW4M27>F)+:NXWPN_(S7>S9B;BW2<V^U*TC7BL4G
M9JLQ2@4[O#P;YVQ\FEB':S5K(=H\4#]4;VD@R.D#O"E,;G-P<@/)&1JWTY[!
M@*::/$L;@"(VL</!8'X<3ST[X)&VK'RKDY>+4:]UKPWKD17]F[@UW-^$3E=L
M6Z*V5H=SK*,KD#-5FW+2JA=4JQJ3>HZR"?%-W%IR$>PC%EI X@V(BX(12XR>
M%,26,<*=K&AK]62US1@.[7:0<C?D=^Q1]4"(=(>YAJ-3M3-( +2<ANV&EV#X
MCXLA9[E#I"XM5?##0.N-56-M6=D\:=&*TN&J51?(PETO2,#:H^Q#5X^,8E8S
M-B(V1BFLP6*27>]",DW8=L$@"L,C3W&7/!<R9^2YPR&Y#@"2<X))(SVGTJLD
M;L58:T^%&T- ;@$X(VP,$C !P.S<[*P.K^/S.R\_=D7396GT9VO-^#^@JC6[
M)<::22A4)WQRRMK= Q+V78K,4Y@K$S9O,M&QBODVAP1<@5%02'B=(6T[6L?@
MB:0D-.^,#!VW(^7'H4K6 U#W.9D=3&&N([<G(!/([;CF.U4)9Z0WI7-'^#HM
M$K#[)K&N-)K<AX.Z1C+1QMY6#6\U8+7,--8VQ_I>=;.9%_$-(%NZ@V,U'Q$B
M^K+64:.VK=%HX%<N09(S)4-&DN>8BP]9U>H!F'MUCEEVY!P#C<[@+'#) RG<
M0[2P2!P# XM)=AIT. [-L[D<P,+ZP>#HUE"T.E[BL,!9]F6)CM#<,I>')-A:
M05X]L&<RO7*[&RCFCZU781:D?7995B1ZY?DCF2,E.>5%RI'4[U=;$J'$N:TM
M:TL9I\%_6;9) +M\D9\9VQNLN!H:'D%QUNR=3- S@ EK<# /Q<Q\I[W+?POZ
M;_H^7C_J#2LVL?ZEZW[=TG^ J5SVI_7=M/\ N\O?_45D5F<T2Z2F$3")A$PB
M81,(F$3")A$PB81,(F$3"*./RU/S@^C)A%(PB81,(F$3")A$PB81,(F$3"+
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M'<#(R,''(G=6-FR\,<QS"[.DNQAVD D;'8XR1GG@XY'$&D<YV&TGQWNKN/\
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K1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?@;Y9OY0_P#*7"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g197729g09v01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g09v01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &"Z^89 X0DE-! 0      %X< 5H  QLE1QP"   "J  < E  "')R,S,S
M,38X' (% #U-:6-R;W-O9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T
M:6]N(%,M,2!);6%G97,@3VYL>2YD;V-X.$))300E       0;%J4L4I>6(Q[
M:?&?<Q#;4SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]       $@ U     0 M    !@       3A"24T#]P
M'   _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             F    /F          $                          0
M           #Y@   F                       0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   F      4F=H=&QO;F<   /F    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   )@
M     %)G:'1L;VYG   #Y@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      ..P    $   "@    80   >
M +7@   .'P 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 80"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MKTOT?JK;Z/?DY'3,:[*I&->Y@WU-,M$>T%G\A[1ZC%<@#A)3Q5>'BP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&%+M"(BZ*82:6?#5#C&V=:?$CRBBR2CHP:I1FF,)I1))119C4)(,!11981:
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MBK>3(X$*UF>7$DM,%N"0D-.">E+*,*+V'Q7X7[^AMT@?\(S'\+*5RACGTXO
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MW46@:$Y1IQ<T2E6Q+Q:++T)8UG)5&]%@ULS^B'LYMK6M:[->C6LUKB\L[0-
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MZ<AI(=5- H.(TTO.!36Q*@7REFYFVQ-RYPJ%-:$Y@MS]'%5?25 W/*Y<XO\
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J$E)-T>62$)VBQE:,V(8QZ+,$6,8 [&(6PA&(HL0M:[.]LL&]]O=UG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g197729g10v01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g10v01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>:^9C X0DE-! 0      %X< 5H  QLE1QP"   "J  < E  "')R,S,S
M,38X' (% #U-:6-R;W-O9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T
M:6]N(%,M,2!);6%G97,@3VYL>2YD;V-X.$))300E       0;%J4L4I>6(Q[
M:?&?<Q#;4SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8             !(,   2U          $
M 0             $M0  !(,                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !(,     4F=H=&QO;F<   2U    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      /:0    $   "@    F0
M >   1[@   /30 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ F0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MUTP/HB6[6?RJMS&.]-W[B:KI&+3D4W436VCU"VH:MFW;O,L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 7(!@@,!$0 "$0$#$0'_Q  >  $  @(# 0$!
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M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(D4?(3]%/V$$201
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M?4TI#]+>P''VF9YR8,HWH<QAEYHR5\ZRCA33<MM=J6V95/*LMLMV'>V/>@)
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M(>H2DO$HS/LE*221&?L(B(O81#E'H39G]'FG,S,S'6>K]RQ+'8=7:V -SN2
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M$0$0$0$3A7Q'_(?V#!\OLK^,1*&Z:/V(JG^<W(W^(NJ')_0C^QWIO^F>K_\
M>_7):S/HY_DZ?ZI)?0ZS*L!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$BCY"?HI^P@B2"("("("("("("("("("("("("("("("("("(
M"(")PKXC_D/[!@^7V5_&(E#=-'[$53_.;D;_ !%U0Y/Z$?V.]-_TSU?_ +WZ
MY+69]'/\G3_5)+Z'695@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(D4?(3]%/V$$201 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MKO?!P]*WU3H'[UU%^<1\S_PW\R/#U!?C>(_R.N]\'#TK?5.@?O747YQ'S/\
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M._J&;T]D(2 #>U-74GK;H![JK,NCF!L ;D WW)$5N*M-_3E>,A&-I^GZ]C,
M210+;.GQB(Q/CO:F+>4W)+=IR?*;[BO+\T,^$E<JT]*FN:G%XK"1?XYC-H3[
M7UWZM!#5&*,1?J_/]%1--!H+Q$1*#_'VI';MP._UMOCFZ^93)1F\^F;XO2TT
MM6F5X^WC](*"P3WC,C,C5YGB)1D9]S[GW";CR&_P"=X$S-#OA)4SU=)VW.(3
MIQF[G'N6Y-'V,ZM.B@I>)1^%9)3Z2N*?B4DTDKP&??MV-([?H;?8_&)N?D7:
MU_*YIZF-E50]0U#E6J.9&P=>NOCG#-DR(B-HX_EFWV+MX>W;V!)/BE$]9N6T
M>XZ3NHK'9"GGZ'4Z;A[>4F?HZMDY%E;6UAGYL># @L$9>=*E2%H98;[EXW%I
M3W]H^?JE=EN&Z5*SOW<9@J>+$)DU.Q4>\JJEOB!,NZ?8E>76]C*BA;@6;P4%
MJ+%7?XV('V9YA:3BKESDCI"X]XSR[75TG<9[FSI<GV5CS!B:"MT.%@9NYI5:
M&XP,1_/-5-EG\@B"_8/NV]=;,M&VUZ4F2TLVS]'FNE_4.D9M5U28U>O:M>^8
MO$Y0HMTW4EKORU=36JVO?54CBH V6V+L" 9YG$KLIZ>U/!LHLLR6T#3*$PVW
M&,U]>I:<UE&,Z%;"U246VL#9X5U(>1WV.WNEX<M^F_*[/04%'SCU':+G?85;
M?4#R-G=)24W.-10P,<YFJ+38&ARE'EZ>2K-IKZJL*DS3=#8,19\^Z:=L93*X
MKWSF='2C3Q6<3#[F;EFW&YNYU&_L/SR2]AL[62,=*'L5F2E:ZJ^SVF=E^P@>
MMK<XN,O*KIQ<6JG(%:H<&J[(9ZJ>"(G.ALO(R:U?9[K;'^6JP4S-O@^\%MN.
M>!YV?V69T65CO\G\E7F*@[HH1\G3,+?:63:4-ORF] >DLRM[9^D2I-O*>D/6
M#S"X1V:BGE(0FUD,OJNDU,:/6<?2Z:,Q,4!<.JY+\DI7C(H5%'JS8[Y':';;
M,?)="0VYJ8Z;9.J6JMWJ^1GM?COE>.58KXV,MKWDDN1ZRER8_</<&)70K@<0
M)O%_**<N3SIX*_7NOGJYD4W@.A:S''T:Y4QXO(/5%75?A\1I(V_2$1FK%#Q>
M)*O.)[NDU^8H9]P^,_\ J3^#;XOMQ+]%?^*NY^N?(>7UOQ?$/188DL!$\ZNH
M\VV>MGHM?NO"=$K]$:/7FZ1^2G2N5L8H/<U&39/K>5 ]'_\ N>-*C21A(7^B
M5_9_])Z*A)IYE?"+8?=:BZZ2-#CZ;F>;7<?<[66DU]WP/1QM!R#E:.1QIL*5
MFVK8,R'8QC;>L[&'7/K=A2$DS+<(DI6:5)UQ#VM9JO<V)3\A-<Q>:C>LY&3Z
MAZO3:2&V2TU/OL-]D)#+M(\Y6MTIZ:U1[1K&BY/!OGUHQGRS?=6-P#94MBE1
M[7M,-U(E<7' /+',75+Q)L*3;]1G%.#9Z.+[%:7D6TS6*@[Z\N)G)=<ZYC=P
M6IR-Y I+^SJT.WCITE95V+:6&WHTEAHS:.PM=1?J1<E:#1G5=.(N)0]@QLI:
MZ]=.2%L1Q>#BKDU):%M7B^25);8;0NUA'3[4"X68E_4;69%R+W\<NVA+C<JR
M.R:\EL6XU<ZVY5XX9=@3OT749E='B*C ]$_%_31SQ9]+=9D,]7\K<E<:Y>EV
M&AVN6IWD/1N*:>99ZK.OM.7QI>+::VP=7(A07Y=;35ZW[!4R)M7=Z]J)R\Y:
MZJ<+(Q;L3%*!<?)R\9:!B-8 7->GX/:H?CQ>[)LQDJ9DK5F?:VEL3!7'Q':V
M[/3-3*R20]V)1F6WG-*A@J-G9S77\-P*,=,AKN+VE:T]@L^;"J*E.+6RZ:*=
M57^C5$]E$:=5L%$:)FNF1VW7VV),)OPQWVD/O(;=;4A+KA$2CTO+&^XO8MKF
MVPO:A+):Q<EK%8A25<[L"5&X/E-Z%5**52MJD6JM4J8 -6BH M; %@&0 *0&
M;8CS/G&@<A-4-T[9*;37-U5@Y.4\:2:3#1$>5)-PU?J203)+\1J_4]N_<C+V
M"*2GR._E[YH_\&TEPNF&J6DG$UCVWW[M$3A&2?4ZM)+]%-DC(NS)F3G@[$2?
MC\)$7L&3YG;X9%3]#'AMXG\?^/K?7,WW&)+ 1/,/I>7&9Z^.O"-<DM.H>=XP
MDU'I)I\Q>/*B0ECT7\,=,MR.:B3[4^-KS.W= ]QKP)Z2Z3:HCU?;/6T ;?-8
MN]KE[R> ('CL0#L-A/SKZ-RB>F[TW5YO(:J]G3-N)W-BQT0:>%J[1 V%:VFO
M=1[7BG/<[&>G@\//T5/(:\R'(&9^$8Y8Y#ETW5+6X;89WI\K\_;<.Y*#=<;:
MV9FD7C-]7\BV,JJL'XE55KG1FIJHDFN<;A29B_/[H0I$FD;)5J=%A0/D:]9D
M5)EDKB^KV:'I>*,E64@\UR*;D)9B%-*CB0"#7U3=LC3[T#M71H(QK+,5>>4+
MUUK5<DX[*P8%>Q?7:NR[GN^>^T_/I\Z*-3J[[F.\YIU?*E3BXW6CR!S+B>$I
M,;*4V%OIM+I(-WAMW)L6,TK<VE=+GLLV3<%6J142G(37>#Y25-J8-K8FDZ Z
M"NW4<+#U4T#(!_Z-R,G5];%8"5\%9FQLH9-;V]YD]:%BD$5+7C)K.3J?4"GG
M3@YU^F5W&G;;4L>G1-"6[D]@=@HR,5L6SLFGD,8H?:YV/52.F3K<R_4MT_\
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MW8:=BD,02>)1F1N5MKIC^P/A21=NQ=OP=B[?@^P<ZGZGG(1 1 1 1 1 1 1
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M$9J+2RQ:D+N=E!4$D@!0S*NY)V  Y;D^X F2T4OD7545[=RUUK3<[#DQ  )
M)\2?<"?K2D9O,'3[RI05T.;9XC<Y.^9F.VB[&QRD^HH&(6==TKLC0,V-DE<=
M!5;:W6Y$%F:3:25)4XW$0N2F>RIZGN6P<%H2YVL._;)IOQ\=T5@">7/)J(+!
M5XLN[!K*U>M78EZ5M7NYM:D+6!O8._7=8C,ON&U%BD EN88 'A84UAT> ^#=
MK(M+>NY3BVQJM!KZW&+LJ*P;=K:6\N*FZNJU%VEFY813L38E%,3$0;!OR'W(
MC<:*ZF2E98%;LZH1QY5Y#HS[JKG%K6RZI3L=[55E^5@%@Q*L%(.V176:[K%"
M%:!2U@4@D+D9-6+6_AX<#9<A+DA> 9@6VV-ARNF/H+@Y"-OY>(XO8Q4U$9</
M4+MWO4LOTQ\HT5$6<FT-F0](DGZ,RPRI;SDCNPALW2-!:N#6ZHX*NY 1&!#/
MR7F.(\V!KWL!&X[8+[\ 3,(E=BLZ!61.7-AXJG%N#<CY*5?V"#L0_L_/>$HK
MDVD^#9XQA4=E-XYQ^FKK^EVN@AV&1F,6T$JS!)89O5'+=TL*.[*3;3(-#'A1
M7)$GUI*\$I$2+%F2H^-F[IIX,+.Q1>@(V%BY695@XP0GP/?OMW6P[5"NNRPN
M HY9*5"L6DJ*S<U+'Q/ IB69UK.!Y+7BUFPCQ=BU:HC,XVS+/\6?!X6\:L.U
MPG&60M[A]YB!G-'IJE-T\35O)HD22:J=5:QO1'[>(_7-OJE))$Y!P9"6)GZP
M)C18'%:CN.VVRUJQ)+%PB@$#=K A:L+RYCYTD@@1;U+6;;$[58&_.S91L*:+
MW.^YV%29%1MY;< P8^PR.UW<7:KI2XVU-EQYB:G$\;:B,S/=E1$1::+)FU\/
M7RL2B0J]A2I[+OIVB@KBL5LNQ:M&W5-)FU\60HV2CJ5[TYU@OLN(70 EPV<<
MGU= !N+&L]5L.]1L4;H.19P!);PQ7%=FU?,9!1CX(R8U&%D7.2=NVJUYU!'<
M"%O;*@JO([7U]Q56KEDS6V,.>[3SU5=JW$D-OKKK)$>/+7!F);4HX\M$67%?
M4PYX7$M2&5FDDN),\;'BC['A8'*-L>+A+'I<J?)@MM=E;$;@.CJ?%2!)N Q7
M?VE"EE]ZAU#IN/,<D967?S4AAX$&=D,1 1/AM+!FIK9]I))9QJZ%*GR":22W
M/(B,.2'?+0:DDMPVVU$A)J22E=B-1%[1%?:E%-M[[\*:WM?8;GBBEFV'O.P.
MPF]5;6V5U+MRL=*UW\!R=@HW(!.VY&_@?BFK6FU?2/S759Q'(SW&-M)O<W4:
MBMIMN[1,:2OJKNK9NX*)"7)"I=;*57/HFKA-RR<\A*Y2$N1D&^+MF-=7D7XP
M'<MQ[_5W%7)AW3:E 53L"Q-ME=?@-P]E:L SJ#79ZNVMEO%$978-;Q4<*Q8S
ML2W@%"TV-N3MM6Q_:G;%XO2=T/3K!RJA\=\<2[-JZE9QV!'LY#\QJ_A5:;N9
M3.1V[13J+*+3K19OPU))]J"M$E:":4E1P %U#@%E:NVT,/$&NC(&)>X/O6G)
M9<>UO*NXBMMG($%:5)4\%8/565) (LOI.32A7?<-;CJU]:D;O2#8H* M*[V'
M$7P<6&:U17^;XI9LL;76]E=T+%TM^^:31T\F^LHD>K*W3(DV$6KB/2WH31&^
MPT25R$LH42CBLLX469 1[:ZE9F[8Y$A;!2>/B 1WB*N1(06'@S @[35XZV7U
MX^R)98:P YX@=TH$+>\;BQ& VY%65@"I!-<T>?\ @]+J_:H7.&,_2^1G<YI=
M#;7MI15M1E(6GRE]M83-Q*=VYN/OP\Y02;&T<I6+6%"8D1W3EK9;GNPK9QW5
M\Q"4^8LJW#M8%BK7T5X3VJFR\B =0QJE=@JM:S*"0 6K5FNY<5JJV<YF-7EU
M(J[OV+\N_#H9AOX-;9C7L*P2ZH@+*&=4.=W?&OP=>8SA;MK#\:WV5@3[6)<7
M-+91[>'2KI<K;;&6NPA.7J94LSI:EV3'A5L*SG267XTUJ&NN\Z8U Y:H;V!Z
MT[-EP8H^Q%=]..R[*"P;NWUH=U"UMX6LA9 TM555Y(J%=C!Z4(4J=N^2$8DD
M*$(!8'ENP![8<@@;F<7Z'A5.5S2>*IV)AY:^F2JS.1<P5="B3[6#%D2["NCQ
M8J6E.VD&+#EO3XZT'*CMQGEODE+9F4CTV5V&MD/,5O=L!N#37:M+W C<&I;G
M2IK 2HL=$)Y,H.E5M3U"RL@(6K3Q'$A[:Q;76RG8BQZ_;"$<BOM;$>,MX1R:
M B B4[8\[\6T_)<SB:^U%90[*-69:TBP;J9!@-VS6QFW-;2L5*GY1/2I3LZC
MEQ'&U,-(.0_"CLN/OR4M%M4C7+8U6SFO(?&:M=S8+$Q:LPG@ 25-%P92/:/;
MN]GC63,6D4"IK2JK=6]J,3LH2NT4-R)V"D6,H/F '0D@NH.N'(F.Z$^39;-_
MS'D>'H.@L)5]':>U4K,5=Y.1GKZ?GI<Z184EL:7HS]C6O-,.2YAOF[V@R6F+
M%MZ&U]C3]>UW#2JG U+-J6VK&M2BNQW"C*068Z*C!EY.I)05<E<!GK+H"T\-
MU#Z,/1_U+E/E=0=(:'J&6+;*SF7X5==]K(%YL]U7:M< .@8W'=.2!@NZ2NN,
MNF[X-SEMZ= QW%/&TJ\K;'45L_-/R7D:&*YD-+.RET^]6,7DAU,5FU@GX724
M:D1Y<%R2B.N4VV?T/TW=5FJNX:SFM7;CXN0&4H0B9E(NI6P]O97XDHR^0L2Q
M-R4,\]9Z"/1!7<]#]": +$=DV[5OME55R4^7;LI1U<'8$J0VVWC/KTO3-\&?
MD+&WI=!AN&JZ]HXTB58T3UPZ5RSZ-6.W+L5-?ZX](=GE5M+GIKVT*F'$\$CR
M296APZ[];]3)1?DC6<YZL>JZVPU\&(3'4M<0 GB*^)5R/91ME8@G:25^@/T1
MV74T#H+019>]*5AZK5W:^Q:ZMR;O 6.P"[_/>:[B4Y@,)\&KR+YKE-T^9V%"
MA(QR[>PN95)7Q*8]M1V.GK&YJU;E:G'(6=@(M;9,%,PXK<UEACTJ1%LFX-MN
MJ^JT%Q?6\I!1D9&+8Q9"HNQ,*G-R?$5'Y74+TH[FW%KEL(^5)W36J]!OH>O-
M8IZ!T2QKL>G*K48]P9J,G4#IV,W$W;AK[5:Q:SLXKX*0+K$J-IHX]^#4XUA_
MHB4>!X=MJBE].EV6AJ%U.JB4#5723-#Z8]7S;>7)EHEP(CBH"JBNLG)1=GDH
M*(V](:IY'5'4MZ]K(U;/%;@KN7:O=_6L/$%1-2!U<VYM'S_%$5U9W7G7S^CI
MWH9]%6G9"YNG]#=.C(H(97;$3([:FK(N[H3(:VH@+BV@G8N64JH)2SCO_G][
MQW85E6O.Z3-KK95A&SM4S7S(;3)VSM8FVC4<>,T:/+G^J5)GHKTMI?3![22:
M)C]6/AV5VBS9U=K&%[[D%BXHL>O(?EX\EKMKL2Q]]E=&5CR&TZ30:%I H%:4
MU"E B!:TJ%JUFBOMC85\ULK-:;#=74J-B#,\$4F@(@(@(@(@(@(@(@(D4?(3
M]%/V$$201 1 1*6YSX=C<VY>IRLV[DT42!IZW029,-CSI<AB%%L(CT*,YZ1'
M]"?>;L%K9G?K_H[C25>CN]^PUV]OD?+L9M)'^>8.3A\O_P#/UCN;'P;AP\.7
M)9Z;NT+!QWYG&/GML<;.Q<S;P\?;]6[>X(*\^0W*['6;0]$]MNGL_8;3D>H3
M;9:DS.#JI&/PKF>B3>-*Q=A%U-!>1)FLN52[?:9^WLJ.5;0Y,&#3M2"DUU*;
MGF)<N>L\K[,BVM;/6\E<C/H;QQ\E*ULLJQ0C!B,?UQJ<FY+6N[JT5TGB!S%
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MK[7MR')W9GM8L2Q)E+%6T5]R\DWWD6W%O%P>"5U5L02":,>NG''$\0M2A?9
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MH\.RDYNDF6K,&4_'(WV6)*XQ-..-$;B$+-2",R(;*.3*OTS ?;.TU=N*LWP
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M3;&<MG85T^IAPFH*R21GE,>VUBM=9L(J-ZE.++94E7==Z6!*W"JKV[.T7-2
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MW/VE[?:$201 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1(H^0GZ*?L((D@B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B11\A/T4_801)!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$BCY"?HI^P@B2"("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("(")%'R$_13]A!$D$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$2*/D
M)^BG["")((@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(D4?(3]%/V$$201 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1(H^0GZ*?L((GR/5E;(<4](KX3[JN
MWB=>B,.N*\)$E/B6MM2C[)(B+N9]B(B+V$$3\O4U/\U5OU&+[H(CU-3_ #56
M_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]
M1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&
M+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_ #56_48O
MN@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]1B^Z
M"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&+[H(
MCU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_ #56_48ON@B/
M4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]1B^Z"(]3
M4_S56_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&+[H(CU-3
M_-5;]1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_ #56_48ON@B/4U/\
MU5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]1B^Z"(]34_S5
M6_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&+[H(CU-3_-5;
I]1B^Z")V*4I0E*$))*4D24I21)2E*2[$E)%V(B(B(B(B(B(NQ!$__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g197729g18u29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g18u29.jpg
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MN8]L]FG&3Y/<^[';IZ_R?\!;N@WT"UK[S^-@.N8]L]FG&3Y/<^[';IZ_R?\
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M/=4RQ*>>5A;KTAK.R\MONNK3A3CCJ5+6K&%*SG.,9YG8_P"NQ[Q79K'&/_\
M-<^Z3VZXLCK=A2W&W97<_.O"2ZU(D2VG)'3G3WG&I4MG$>7);6YLE2D2)3&,
M,2'DYPX\SC#;BE(QWO&Q_P!=GWBN;=^;S4VX\FN.GP2=_3W]>IWK5%/Q)T![
MN>O76]!)S5$B4)WIOI;D0@16XVZN?.C+V/EF7-4ZTTXJ4^AQ]3C;:\N94A.<
M-B=#MV9&@.T5H.@<G2FW&O\ XUQJ9/Y).I.\GE[ZY!#KABEDL(*=S_Z\R2(O
M?9C((=.U0F)CY7A&%Y83(V2YAGOL-HPKP>$]]A",9[<)QV-C&Y]@?_\ 179H
M7P8FVN#&Z6DZ>CEUYSNN5DFIE9+H"Z]B"X[<MEA<[IXJ4M3+4]C,:<TRI_93
MF6VYD;.8\M",I3(8SEI["V\][S&Q_P!=CVU=FAN =]M<'TM)/]]>$SKABD,Y
MS/[G_P!><[*I$64K,SIUJ$G*I4)*TPI.<O;)7G,B(E:TQ7L_Z2.E:\-*1A6>
MW.Q_UV><>$5N.\=[S\]#< [[:X/I:3S;OS^:N5&Z\'(>'<1.@OK]BX>6AQ[$
M;I^JS&'7&V&8K;CN&MF)\(M$6-'C(6KM4EAAEE.<-M(2G&Q_UV/;5V:"XC=;
M7(]#2>W7)]?Y/^ MW0;Z!:U]Y_&P'7,>V>S6>,GR>Y]V.W3U_D_X"W=!OH%K
M7WG\; =<Q[9[-.,GR>Y]V.W3U_D_X"W=!OH%K7WG\; =<Q[9[-.,GR>Y]V.W
M3U_D_P" MW0;Z!:U]Y_&P'7,>V>S3C)\GN?=CMT]?Y/^ MW0;Z!:U]Y_&P'7
M,>V>S3C)\GN?=CMT]?Y/^ MW0;Z!:U]Y_&P'7,>V>S3C)\GN?=CMT]?Y/^ M
MW0;Z!:U]Y_&P'7,>V>S3C)\GN?=CMT]?Y/\ @+=T&^@6M?>?QL!US'MGLTXR
M?)[GW8[=/7^3_@+=T&^@6M?>?QL!US'MGLTXR?)[GW8[=/7^3_@+=T&^@6M?
M>?QL!US'MGLTXR?)[GW8[=/7^3_@+=T&^@6M?>?QL!US'MGLTXR?)[GW8[=/
M7^3_ ("W=!OH%K7WG\; =<Q[9[-.,GR>Y]V.W3U_D_X"W=!OH%K7WG\; =<Q
M[9[-.,GR>Y]V.W3U_D_X"W=!OH%K7WG\; =<Q[9[-.,GR>Y]V.W3U_D_X"W=
M!OH%K7WG\; =<Q[9[-.,GR>Y]V.W3U_D_P" MW0;Z!:U]Y_&P'7,>V>S3C)\
MGN?=CMT]?Y/^ MW0;Z!:U]Y_&P'7,>V>S3C)\GN?=CMT]?Y/^ MW0;Z!:U]Y
M_&P'7,>V>S3C)\GN?=CMT]?Y/^ MW0;Z!:U]Y_&P'7,>V>S3C)\GN?=CMT]?
MY/\ @+=T&^@6M?>?QL!US'MGLTXR?)[GW8[=/7^3_@+=T&^@6M?>?QL!US'M
MGLTXR?)[GW8[=/7^3_@+=T&^@6M?>?QL!US'MGLTXR?)[GW8[=/7^3_@+=T&
M^@6M?>?QL!US'MGLTXR?)[GW8[=/7^3_ ("W=!OH%K7WG\; =<Q[9[-.,GR>
MY]V.W3U_D_X"W=!OH%K7WG\; =<Q[9[-.,GR>Y]V.W3U_D_X"W=!OH%K7WG\
M; =<Q[9[-.,GR>Y]V.W3U_D_X"W=!OH%K7WG\; =<Q[9[-.,GR>Y]V.W3U_D
M_P" MW0;Z!:U]Y_&P'7,>V>S3C)\GN?=CMT]?Y/^ MW0;Z!:U]Y_&P'7,>V>
MS3C)\GN?=CMT]?Y/^ MW0;Z!:U]Y_&P'7,>V>S3C)\GN?=CMT]?Y/^ MW0;Z
M!:U]Y_&P'7,>V>S3C)\GN?=CMT]?Y/\ @+=T&^@6M?>?QL!US'MGLTXR?)[G
MW8[=/7^3_@+=T&^@6M?>?QL!US'MGLTXR?)[GW8[=?F>O^0W_+D]#O=!XS./
M2M['3R,G]YC'LY\5$[!(SW?1_P ,>(\O/L83G.<8RV'^LQ[9^](%.,__ .>Y
M]V/N436U:(ZNM.]0AVQTJIJOU1V73A< Y:]4;@UA?M/[*" R<IZ# .JJVP0
M*27 29C"XB3]<<,A&Y>6HCQ!N2\TTN"VE( 4<I2= I"DJ3/1*28/F,&IMOH=
M)2G,E21)0M"D+ F)RJ D$\XD5L6L-94;3.OJAJK68!FJT"A X5;J5<C2R,]@
M,$'(\'#@-3"TP@3DH81_)P[-FR9"_9<>7GT\BI2EJ*E&5*,D])/HJQ"$MI2A
M RI2 $C70#<-9-7OD:E3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE43U,Z-ZIOJQ^0&?5*\Q/4S\Z?&
MR/C'F-YP>=/D#Q'QSR3X'R__ .H^-^(>4>__ -#XYXM_H>2S'+DGDYLT0-\1
M,[]W-,5'*G-GCE9<LZ][,QT;]>FNB55ZU^H?=(M6P.FCHD*[/TB4(%8E"VC=
M]_Z]U&]L<6')RP[MPK=*F!;:=B4TO-@R7ZN2L3@8H<$>+%\!(<29&RY<66T'
M*X]E6.^2&U*RSK!,I$CG D Z3,UKI?<<&9IC,@DA*E.)1F ,9@F%'*8T)@D:
MQK5D]<#U^_D[Z[]<S7?W<<QLV.O/N5=JI;2X\G3[\=BGK@>OW\G?7?KF:[^[
MCC9L=>?<J[5-I<>3I]^.Q3UP/7[^3OKOUS-=_=QQLV.O/N5=JFTN/)T^_'8I
MZX'K]_)WUWZYFN_NXXV;'7GW*NU3:7'DZ??CL4]<#U^_D[Z[]<S7?W<<;-CK
MS[E7:IM+CR=/OQV*>N!Z_?R=]=^N9KO[N.-FQUY]RKM4VEQY.GWX[%/7 ]?O
MY.^N_7,UW]W'&S8Z\^Y5VJ;2X\G3[\=BGK@>OW\G?7?KF:[^[CC9L=>?<J[5
M-I<>3I]^.Q3UP/7[^3OKOUS-=_=QQLV.O/N5=JFTN/)T^_'8IZX'K]_)WUWZ
MYFN_NXXV;'7GW*NU3:7'DZ??CL4]<#U^_D[Z[]<S7?W<<;-CKS[E7:IM+CR=
M/OQV*>N!Z_?R=]=^N9KO[N.-FQUY]RKM4VEQY.GWX[%/7 ]?OY.^N_7,UW]W
M'&S8Z\^Y5VJ;2X\G3[\=BGK@>OW\G?7?KF:[^[CC9L=>?<J[5-I<>3I]^.Q3
MUP/7[^3OKOUS-=_=QQLV.O/N5=JFTN/)T^_'8IZX'K]_)WUWZYFN_NXXV;'7
MGW*NU3:7'DZ??CL4]<#U^_D[Z[]<S7?W<<;-CKS[E7:IM+CR=/OQV*>N!Z_?
MR=]=^N9KO[N.-FQUY]RKM4VEQY.GWX[%/7 ]?OY.^N_7,UW]W'&S8Z\^Y5VJ
M;2X\G3[\=BGK@>OW\G?7?KF:[^[CC9L=>?<J[5-I<>3I]^.Q3UP/7[^3OKOU
MS-=_=QQLV.O/N5=JFTN/)T^_'8IZX'K]_)WUWZYFN_NXXV;'7GW*NU3:7'DZ
M??CL4]<#U^_D[Z[]<S7?W<<;-CKS[E7:IM+CR=/OQV*>N!Z_?R=]=^N9KO[N
M.-FQUY]RKM4VEQY.GWX[%/7 ]?OY.^N_7,UW]W'&S8Z\^Y5VJ;2X\G3[\=BG
MK@>OW\G?7?KF:[^[CC9L=>?<J[5-I<>3I]^.Q3UP/7[^3OKOUS-=_=QQLV.O
M/N5=JFTN/)T^_'8IZX'K]_)WUWZYFN_NXXV;'7GW*NU3:7'DZ??CL4]<#U^_
MD[Z[]<S7?W<<;-CKS[E7:IM+CR=/OQV*>N!Z_?R=]=^N9KO[N.-FQUY]RKM4
MVEQY.GWX[%/7 ]?OY.^N_7,UW]W'&S8Z\^Y5VJ;2X\G3[\=BGK@>OW\G?7?K
MF:[^[CC9L=>?<J[5-I<>3I]^.Q3UP/7[^3OKOUS-=_=QQLV.O/N5=JFTN/)T
M^_'8IZX'K]_)WUWZYFN_NXXV;'7GW*NU3:7'DZ??CL4]<#U^_D[Z[]<S7?W<
M<;-CKS[E7:IM+CR=/OQV*T70G5,;V5LBV:*W%I:R]/.]ZI4ANQFJ09M-9O\
M6[KK4H6>KZ;MK^_5-U(\[!#V%IL':19,4 .UX@0#XDC78A:)*7%;82D+0L.(
M)*<P!20H"84DZB1J#J#K!T-9;>*UJ;6@M.!(7E)"@I!,9DJ&A@Z$:$2)&M=L
M"I0>#%DC1:6U %!X$PH3G2,Y2Q"'CX[DN;+>5C&<I:CQF7'G,XQG.$(5G&,^
MQRH"3 WG05<2 "3H ))Z *^;U'ZN>LW==3 [5T9T,TTEIV^#(EFUE8=O]6$3
M5MXMM(,,HG5JWS]?U[1NT8]7AV80]$-"ALZW2BR!TR,LC$@R%JCHV"TT@E*W
MB%I,*"6BH C>,Q6F2#H=(FM5+UPXD+;MTY%"4EQ[(I23WJLJ6UP"-0"9@B0#
MI5K]6CND?P$.G[Z]Q/\ A)YC);]>OW/^6LY[SR=G]X5^#3U:.Z1_ 0Z?OKW$
M_P"$GC);]>OW/^6F>\\G9_>%?@T]6CND?P$.G[Z]Q/\ A)XR6_7K]S_EIGO/
M)V?WA7X-/5H[I'\!#I^^O<3_ (2>,EOUZ_<_Y:9[SR=G]X5^#3U:.Z1_ 0Z?
MOKW$_P"$GC);]>OW/^6F>\\G9_>%?@T]6CND?P$.G[Z]Q/\ A)XR6_7K]S_E
MIGO/)V?WA7X-/5H[I'\!#I^^O<3_ (2>,EOUZ_<_Y:9[SR=G]X5^#3U:.Z1_
M 0Z?OKW$_P"$GC);]>OW/^6F>\\G9_>%?@T]6CND?P$.G[Z]Q/\ A)XR6_7K
M]S_EIGO/)V?WA7X-/5H[I'\!#I^^O<3_ (2>,EOUZ_<_Y:9[SR=G]X5^#3U:
M.Z1_ 0Z?OKW$_P"$GC);]>OW/^6F>\\G9_>%?@T]6CND?P$.G[Z]Q/\ A)XR
M6_7K]S_EIGO/)V?WA7X-/5H[I'\!#I^^O<3_ (2>,EOUZ_<_Y:9[SR=G]X5^
M#3U:.Z1_ 0Z?OKW$_P"$GC);]>OW/^6F>\\G9_>%?@T]6CND?P$.G[Z]Q/\
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M),=*;8EL*4S):2EYK.4+3GDG"%.+4-REJ(]!42/X5%E)0TTA7?(;0DQJ)2D
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M>57R%+M =L# 2W''3K)6#<T0T5NX^%,ID8,7L4N+N!.8QJA*P 03REA$$2%
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M8T?$>F+><CP8C*D,-U+45K4LQ*U*48W2HDF)DQ)TU-7H0&T(0)(0E* 3OA(
M$P )@:P!Z*T7D:E3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*5556\6E64Y;F]J<YQGL::[.W&>S\/S8XLX?%]?\
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M>\\17X*;\DS^\<NXL[^CZ_\ JM#NO:^*]["/Q*>>(K\%-^29_>..+._H^O\
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MI&$0=C#(15Z5,BNO>*.M=JEPX,F5F!%B,ON2'<QOD& 88YP^^53Y/1P9X?\
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M6-S:OA!=M[JT7C2L2M;EL[6WO[*S=;("%!2[Z*KM^K>:\?>AS'":<XLYHA7
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M%F^_F>+M1DIC^&>\OPIQ]KA!>6UPQ:*LV;6R:LVVENAU12VXZL**@E(  <"
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MO]3&Z=,11(!(1ZM:\.31P$@^@A-G9-OQ8!40O)9]N8B#*??7*PY$@#VVL1_
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M<'8=6P^KQ%O#\J5CZG@G#7"+K%;>YQ3"+##[Y2'0]C3;JT D,*'*92PI9+H
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M;+02*]-%*VR3VPH6JT9NY6EM7 _,I=I9KVJB,0>\$MEE;NBWJ^3J<7*D"3K
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M!XR=!FPB$T<B3&A2X<J/)<:>CO(1@I4)E*A&AD$03N!TTFLA:"0 M)*@2 %
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M(@R*J#B^5+@ #SB5$*02AL*=RDC(,DD(1*BK0S(WU&3]Y]25@K&XKU0[9?\
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M$01H 8!4"1."^M(42 2%:) U A)@G,-3FY.A)@PD@:6.;U1[[DDQ;<D?K>@
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MN2U !\@Z &"")CF+) Y(2(&Q2! &A/16#; @RHB4D& =Z@^">4I1DE]1U)U
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MVP2I<W;+NLJ=JRPBJ_;Y1K4]H)VT[FO:O(5>V!89"0/R'N";?+V-6<!RNOG
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M2XV<E74 "<B@$Y@/$1F8*($X3=DM!(0<FURFSY\&R$*L+D'F(+LB*6#BL%N
M2% E(22D R,VOJ2-ZMTZ<X)RE[,4@H*0LJ"22(.4QOW22"0F9($QO @)G71K
MB#M>5I9^JW)%^AGV*W(&J9$)9;*%MW!M0U:-E_)/M7(LX RC=<**PT])BZD'
ME3\YIB3 >@XR&5%.>1EB9\V0J.GF(R>=4 ;Q+C"<Y1E5F!RQNU*PA/FY0.<:
MSE!)$Z5CU3ZV=M74+02=?U5#,(L-EZ;1L>7'GAZ^]=H>[M L[;)88 %K66:H
M#@B=/CK<1+M=QS!#0Y<6)*LQ7Q;$V992DJE4 !SF)RE#@1J0!FZ!H).I@56E
M]Q020@&2U&H$AQO.=Y.6-^\P!&IUK2]E=8A*M53I;VU5JDQ(U5N$$K9.T6;&
MAYNYT742J4'LI2R0,!R<H,DCKQBQ1[9>([F3D:74JO:(=>6^7?$R5Q2U)=03
MRT'*F-REYB(,Z\J(3NU(G2:DI\@,K2!D6,ZYWI1 ).AB4S*M^@,28JG:+ZJ-
MN[J<9F2)^NJ&%ST]:JV?,+3=27^PU,78]BZO\^)Y0UL=&UZ_6@=9KDQQ+K=4
M(Q&S1<+%=QYX#G)*2,7+C2$2!F4<ZD]^D$A*LL!.0DD],P.@UAMY;G.A(R)5
M.112"I&8DKS@ #H.I'YVLCM3I.Q6_:^G@5HV%"$Q+ 6)W)0P@#!EZR*L%4'7
M6Q"]>WJ!6#YBPG*U$V%0H5;NN*V6.%2(9NP8'2YBY457@XA6Q=E,E( S D'>
M 5))  )2J1( W5%Y@7EOE< "I46U@1$$A*H)) 6F"4R=#T@1R),=Z(^Y'?1E
M#K2LI4G/_+V,XS_2E6.Q258]"DYQG'HSSHI4% *29!W?^_77EG&UM+4VL0I)
M@C[P><$:@\XKT<S4*<4IQ2G%*U^O>TT#^J5^M<YS'_"K](^H5ZVP^:,?0_N-
M3/*JVZ<4J$L?M+._,:_:&N6L>%1Z3]1K2Q'YD_Z$?U$5G]VO4;5^DK[LN8,<
M-P]=Z\N]ZE!FGVXKI>-4@A<^^,;DNM/M1W)[0]45#[C#S;*G<.+:<2G*%2<3
MF?*08*EI3/1,":C9*",/;61(2AU1'2$K<,?MBLA%]0?27!;J\B-,KM>E 7+C
M#"1)&LK(!)T)D&"JEJO<V9"E4Z#.U]6XE4O]0MQJSEF -8EU"SBK:HI(KLYL
MFJ)0[KO((!)S A6J@G6>492H :F01$Z5L!QD9=R2)@9""F %*TRB  L**M!!
MS3&M6.-OSIX>#L$DN28HJ+81=%GHGZBV$*73RODT'Y"A7<:1H\29KH,Z#O@&
M0$-76)7:V^!M,.8.)+%$?#.8R.3YX*N^29U,D:\HRDR!)D=(J6T:CS2$GD*&
M4P(S#+*1"A!4 ((@P:H\'J9Z<&+E8Z&*$QO)%?&J*.E0VN;)(C62SV._EJ-.
M!T6NC*:Z2V3,)V*MD_&S>OX]G'D90<HAR2ZX$(NQ9;-R HG4Z05#0!.:5$F$
MP"-%0=1TBH[5K,4QH!FD),$E66$@"5$JYT@@D'60:U>E;(T+MBSIBTE8*XV
M #$75)B'2R<B&%'7>%7[8&FIM\FOMA1Q:RP2(.P1Q*3#)\@W'<(9@+R$(.0(
M%*T#64@DB,V^)!TF2!$3$;ASBI)4TM7)A1 "IRG3-"@<T0"9!B9.IC0QIKU%
MI$@=*#OTVJOB)RT.31;U>$.#ICC9.8;;7*@KAJC2%MF2) NA3S2U()SID].<
M2I3[JXR9F3/3)G=&_P!&GHJS*F(RB.B!%24RNU\BS*CD 8><Q.=>>FL3!D*2
MS,>D"5 'WI3;["T2'7P2E!7G'4K6X)4H:O*H><L\2=-3INUW:SI^W7TZT@;H
M$>@=$?5IZ*_$UVOI@0A2009(L;%\1'#4C(6( ^#XOXGXG"AX8\7BQ?%/]5\7
M8;;9\7_T'>>"_D\2>DZZG7>>FD"(@1T0(]523$:-&\+XM'8C^'?<DO\ @&FV
MO#27LXR[(=\&E/A'W<XQEQU??.+SC&5*SV8YBLU[^*5GR6? 7/"<8]#CSCV/
M^?AH3CBL_P#YJ5C/_/&>;I,VOH 'J6!]5<$(R8P!S*4I8_WLJ)_B37$N7MHS
M^@M?KY/)6O@U?3/V4U5C'SEO]0G^H[53YLURJM($!'+1WGGGWFE-/>"QAO".
MS./!H7VY[Y.<]O:KL]'H[,<UWGE-J  !D3K/3YC73L;%NZ0M2UK24*"0$Y8(
M(G60:A;.5UQ3"H4):;C'"%K%XKY$@S582^2\=N=)UY$\7PAA:<^'NNR*-7&^
M^4GM(V4:CT-K=<:K%PXH$A"2!OWZ:*5T^*E1] -;APJV20DO. G4 Y-94E/B
M^,I(])%4>!M[0!4J,##-HCI\PR.F%!+L-J9(&$8D,;8CG9#-M#E!7YA"N5*S
M6L"-;(*(V2G@R5NK\0G6HRRN,EYX DM@1$ZG28&Z9B2 3N!,'72H]S+20 ^X
M9!(@)(( )WY(F$D@3) ) (UKCL[GZ?GD5M7JF-1W+2<GUH;#GBC8TE#-C+$(
MJ$Z#9Q1 +&)4I4>UV"NUI3URB@8RSUBKPEMY<XZ)8F-L]K^3&@S;SNB9!G70
M$Z3H">8T[F6FGY=T9C D)!F0-04 IU($F!) WD5N/FF*\8Q$\I.>-99S(Q&\
M)&\8S'PO#>7\,]GA/ X<SAO+O>]YA><([[OLXQR'&E^(G^/QJSN.QUKO\G9K
M@E!%8!QVY9JQ1A$5XF'"-2"<Z!!8=,V$G""@!+;LE32%DC9@D/%"8*59DD2,
MZ'"B-/2)++:\BZ6=R$G0G23H!)._< "3T 36#A%N-[S@U U*!J=P[W>9$#GF
MH^KM4^YA$6*M'WB89R:7')FX8<B)\= F)P$LPIF?%BR$9B%ALV)WZV4MO^!\
M/&6]&=9><&Y<!@H2#H>?G$CGYP9HG";=0D/.D21N2-08.A3.^I R'K%<$%S]
M@L4<&" #)IHZ9+S8 T4&#C8KTTB5*D)BF8H\; AQY$N9-ENM1HT9AY]YU#;:
MU8"Z62 $)))@ 222=P G4FAPA@ DO.  $DG(  -222F  -YJ1\SQW:K'C[_:
ME*5JQVL=J4+[["%*QWO;A*LI5A*L^A7>J[,Y[,\QQI?BI_C\:SW'8ZUW^3LU
M^>:(WL5GR@]V)[WOL]]'[$]]A.4]]GO>S'?84G*>WL[<*3G'HSCCC2_%3_'X
MT[CL=:[_ "=FH^$'K!.08B#K%&GRJ\4:"'HT.; DOA#+XP6:9$EF65+<'$G@
MYL,5:@RTLR7!Q8;-2UF/.C..YXTL1*$B1(WZB2)&NHD$>D$<U8[D6YF'G#!@
MZHT.FAY.AU&GG'37!<8J+5LAT99U_%JGU\I:8@G$=U3CH$*0"BB<_,E,7,)K
M$6?80S&8STEN6]XZAUB.ZPU(<:<9<C-D3$Q.N\@D#?T T[DV^;+MG<T%4<C<
M" 3WO21ZZGL5 ;G"<X(/9PM2D(SA3&<*6G*L*2G/>_RE)RE6%)QVYQE*NW'H
MSS'&E^*G^/QK/<=CK7?Y.S7[YH#NSM\??[._\'V]\QV=_P!_AOO.WO>SO^_S
MA'>^SW^<)[.W/9QQI?BI_C\:=QV.M=_D[-5_#5.<@O$H=BR5A1[&U493X-/E
M_P 4LB[$Q4WA,QL*Q/=B21M@D)'G,R6VFJ_EJ9*..#X4"=(CYXRYNR)&DZR-
M(F=2-XU'3S3-8[DV\3MG2)RZ9#K.6-$G4'0]'/$584TZ KM[V;(5WN>]5WO@
M<]ZKLPKLSV(]&>]4E79GT]F<9]C..8XTOQ4_Q^-9[CL=:[_)V:\O,N%[[E?$
MU]CCC2_%3_'XT[CL=:[_ "=FGF7"]]ROB:^QQQI?BI_C\:=QV.M=_D[-/,N%
M[[E?$U]CCC2_%3_'XT[CL=:[_)V:\5TN)WJN\F2,+[W/>96EO*>^[/Y/?8PG
M&<I[>SMQC.,]GL9X%TJ=4ICGB9CUU@X.U!RNN9H,3EB>:83,=,51)<1^%(<C
M2$90ZWGLSCV4JQ_PK1G_ (D*QZ4JQ[./9[,XSC&XE25I"DF0?X>8]!KANM+9
M<4VX,JDG7H(YB#S@C4'[ZXW)573BE.*5O'./7N*K55]K'/TV3_<Y?<=^/H)^
M^N=AGS=?Z]W^VNLEJTATZ2BEZ/V.ZLC9-IE[(J]H7(O($?&AE;?!UQLFY!TX
MDMXQ +C:[I6OVG$!]:I8NKQ3QB4PL:[F9$B%K 2 G001H=0"I(/H)41T$P-^
M_:+;4J)5&;,DRH#5659'F(" 8YA)/37[*Z/-66BH1:K/MVP3M'C2K27H M%A
M )'T.'=P5L%+CTHD*K44D^/&LW6<4K4RQD[.2A28(%O)24'%1AN6U4"3"0J
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M(TMJ#6;C3NN]7T"C/,Y*9:>J=1! 'F\FX-3%F,H=%P8SB?*@RA4<=/[%?ZU
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MR(S9LJ<TYLT"<P24 SOD))3/02*X@O3&H@A 45#:PH(DD"'5<0$G#JD"A2A
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M<>)UFI@[ 5(A(X2NEJ?56!XR%DNB% ),*.Z4DI!4E2@E125:D0)) !D@JUK
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M'#]]<JY>VC/Z"U^OD\C:^#5],_935N,?.6_U"?ZCM5/FS7*K1Z9_,9?Z7_\
M"US1NN_3]'[S7H,'\$]^L'V177KJ#O\ NZK[$TL$U/5;&:$FK;5&KK+C@7BE
M376"FRZ)6K@T9(P*;9'PT^N4$S:[B/DDK3K,<A8A,I@E>78DJFNU-I04K*B
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M1I4MF96'#]KR!=2^XY_Z6FT61N(G*6FCQ=I*"$BE0RJ4 00"0"#(]<"?3 ]
MK80HJ0E1D$I!@C*=1T2J/1F/I-:#R-2IQ2O4^[AAAY[/L,M..Y_Z-HRO/_\
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M;IQ2H2Q^TL[\QK]H:Y:QX5'I/U&M+$?F3_H1_417Y7,XP%@]N<?[#O\ 3_\
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M$=3^.F&GW*>QZF: H_$^WRH^3C-GM-4@NP84F;59YT[,Q21L=C.:%& VE>H
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MIQG^0KT]ZI?08>S\E7? ;_&'QZ1S[QSUYN_L3;J+K8EA1W<[9)W'GRDZ)/\
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MT*JU4O$$F D:16PT,$PP-L,ROSSS+8\6U%')=,2JG6%DIF(GCLU%>#,2)#C
MZ(TUDK6H0I1(D'4DZB8U.NDGUFL!"$F4I ,$:"-#!.@TURC7?I5QCA T.0U+
MB"!D64Q@QAF3'@16)#.+"29,'\-/--)<;P<+QXY4QA"L>4R3#,Z;X>2TAU.)
M/2>;^ @>H:#H%9@#< -_-TF3ZSJ>DZFJT$UEK:M%_."N:]H]?/>*8'^6PE3
MBB_B"66(Z87E*! 8F^*)CQHS&(WAO X9CL-81WC3:4Y*E$05*(WP22)Z8F*P
M$I!D)2#T@ 'U@5>.1J5.*5D!^1%E$Y#L1&$M]N$+7C/\E]U';A;R<8]&,+SV
M8QG'^WWOA,^E>>=-E*DM@*.N\#H!W ^C^&[FKR=^XT[<N*:$)W%4Z+4-"L#F
M!W>>,W/4-RVM.G%*<4IQ2M?KWM- _JE?K7.<Q_PJ_2/J%>ML/FC'T/[C4SRJ
MMNG%*A+'[2SOS&OVAKEK'A4>D_4:TL1^9/\ H1_4161<Z=>4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4J<K?MW!_.>_9GN4W'@5_[?M)K=P[YZQZ5_TUU(7+VT9_06OU
M\GD+7P:OIG[*:V,8^<M_J$_U':J?-FN56CTS^8R_TO\ ^%KFC==^GZ/WFO08
M/X)[]8/LBLZV]:.FBM&Z/+WP<TD$L4&5)+ZYF;7FTB$7'2XI, S,+4Z5;%MR
MQ[L8S(JS$DB(<8RR5D5YEU],Q\8E="0X0<@60=%90H@Z'0QYIW\TUU%EH%)<
M+8(U25Y01!&H*MVL:CGCGBO1"V9TQ+?IL ?=])>,V() E42'%-TI+Y0 'B68
M(*57([;^%N#AL.-= HUN$C#,5F);!<1"$Q#4=H4N:R%Z$A6AT.A,_P "?V$\
MU,S7) +>H!3JG4 $"/0,P'[0.>LS(V'H5L&IY@6/=.GP7J8_*(4S,NEW*F5$
M%F=,8 W@H'''*D3$I@OR82*U<"C,.8RW+$*$'"27Q+\>0[,!X*!APJ'*Y043
MSB2"/,0/V@:U FW*8S-A)Y,I*0.942DB- %=!$$Z55M>;>Z(]8$:YJNHGZ*)
M:18=V#V;%82XG+ [8M V-$$;!JI2RW HD]FW%K7U 68A7AL)N4,?!%[TX+=&
M G6HI I#R@5*!.B- #JE224F (@!L SK.69-12NW00E.4#,X),0%I5"@23,D
MN*(C2"K<#!L-;@]%&K=F7':(2\ZRKEZ@S"-!LCS^T8V(=:)W4O!;(U1FO3;$
ML2#('SNJ6!<0-'@,O1B-'*U\%&@N#SH[(EY:4I(44]\.3OR@ZDQ, +DF=R@3
MO!J0#"%E0* H2D\K=F.J0)C4IC+S$0 -U31"U]"X>NR/*ICI;%U03<93,A$]
MW5L,# O;(B>;FK4U(PW!8LK=?F%3<B5A*9^ 4@D56[Y-<ER,X >)T#A,<V8G
M+(_A,".F!OK.:W WM!(5^A 5!,^F),CFD[IK0D,=-,PA(MJ(ND914',NFPY5
MFQ%HSQ .1JQ>+6-A7>0:\$J2/G #M3A +?9'9+,@<4K,8:7F-20K3,:/Y3O>
M7K CE:R)2(\X,@<X.F^I?DM5?DY&91/)D93E4J=^A$$\Q$'=7%<WGTP1W(YU
M_:VDHKT]@G>62TFWTN+(=8$^/ZZ-6UR8_.;>;2*S7B5"+FWW$9'+"S*K.DL+
M'NP&F1S=E7S" %<_* _;(4!SS(WUC:,Z'.W)E0,IYN03/F@I)YH(.XBO#5YG
MI:N\,Q5--S=%6: +CD)1^M:[\Q244<Q<52Q1APP%KZ76H?G&X)G"S29L9M9)
MX;*@$DNNQ'66\J#B8*PL<P*I&Z"()Z)!$=.E90652$;,Q)(3ETS2#(&Z8(/H
M@UO$6#!@YE9A0XL/,V4Y.FYBQV8^9<YY+:'IDK+2$9D2G4--(<D.]^\M+3:5
M+SA"<8KJR -PWZGSGIKE<4IQ2G%*<4IQ2G%*<4IQ2G%*XTQR,U&>7,RC$;#:
ML/>$QC*5(SCLRGL_XLJ[>]2G':I2LXPG';G'))"BI(3.:1$=-5NJ;2VM3L;,
M).;-N(Z(YR=P&\G0:UBTC+*GW51T+0QEQ>64.*PI:6\JSWJ59Q[.<8[,?T]G
ML9RK/\K/5$P,Q!,"2- 3SUXYPH*U%L%*"HE(402$SH"1II_Z3OKT\S4*<4K>
M.<>O<5A3G^\<_/5_Y9YUT[AZ!]5>)7WZOI*^LUX<S4:<4IQ2G%*<4IQ2G%*<
M4IQ2G%*N%P_G _\ 0_[^>:MKWBOI?<*Z^+^$8_5'[55"ST/.T]0;:UC@P[7O
M5&HMNHGE]F)@@\$\[JR3K^2S4!4F%B:X.P0\<1$S,A^,*9PSXU'[_P ,B-PK
M*ZVJ)RPJ.F%3'[:NPE.=BY1,9B$S$QF0H3'/$S%8_J'HEH^M<5B<1,.$#E,,
M2WJMYH0S%0K(:IO%1-DCT- <_:]A'BH-BY0"MS5/LEQ.6'!JW6R!!+CJB6\V
M&:5O%4Z:$:SJ2=1FT"0#$#0 0 8D3731;I3$F2DZ91E&70Y2"5$C-*I))E1$
MA.E7.?T<Z.G0:Y$2%,P9%.!ZZ 5,K$L!%1(!#U=$VL-J;L/,U<R%(E-"-V[,
M#DG2<*>@H.LKC<QIQV -?AQVJ]=09*B01H<V6=T'>A)$'0CTU+8-P  1E"0"
M"9&3/&^0?"+!D$$'7<(L&P>F#4NSS.L3UN&&9A'4B1+=1<C6$I#2ED';*->1
MC)+#+^%34LVK7%/*ON]^S((8&.#"3TP.0(CY1+BTA0!@*F=.D$?4HC6=\[X-
M94RA>20>1 3!Z%)4/XH2?/$&02*J\KHRT>_!@CV1UE@1Q5<UW7A*8=I*]@Q6
MJIIR71CT9J4Y*CJL(IBS'P\J=*8D,' !::#/0R8UW,?&=JOI!DJ)T&N:)&D&
M# ,<Q (UK'%V]!!$!($*.F4DI(F=1F4)W$$@@BILUTI:?/UR?6B(X\N(2N%0
MOLN8W9"C9)RTTG7M?U:&)YD>&RVI>:56QXZ4VMA3:IZGK!&3%L*(A2)@.K!!
M!&@4D"!N4HJ/\3/\-TBA8;((@P5)4==24I"!ZTB#YY.AUJ"1T6:!P&\V'ZZ;
MF5-0P8+>JLJV6%820@;T_'>EU4MYE$]N5Y0):/.N4LI+:EMKDH'"2Z,,FX>2
M+V=LN9D3),P)[\.;^@+&8>D\U-@W$02F ,LF-&RU.D:ELY3K'. #K4DGI&TZ
M]&N*#$:V64GL&D[0U_=K)8[D>*V*RUO;X#6-4N+$\D[+3EN2NLZ=UV$$RH+4
M1P1% J?B820*%YL_&U7R8@!)2I(   *"HB!Z5J)F9GH C.Q;Y4@DJ2M*B5$E
M06$A4F>A"0.@#3>9TVBZBI^O;)L"W@D%G['LTH/)VPH7*R2+TOR,W.9"PFD.
M90PW&$1R4R+$?6T\4<A*BP9I&7"%B6(,5+*@D&(2($"-^_\ ]W>:29DE 25$
M22HR9,[I@>@2=\GFF *T_D:G3BE.*4XI3BE.*4XI5/M)CQ5G(^.K_6)"/].I
M.?2RPK'9WOH]A;V/1[J6^W/9C*T9YLV[68YU#DI.@Z3\!]?[:Y.)WFS2;=L_
ME%CED;T(/-Z5CU)UYQ6;\WZ\[3BE.*4XI3BE:_7O::!_5*_6N<YC_A5^D?4*
M];8?-&/H?W&IGE5;=.*5"6/VEG?F-?M#7+6/"H])^HUI8C\R?]"/ZB*R+G3K
MRE.*4XI3BE.*4XI3BE.*4XI3BE3E;]NX/YSW[,]RFX\"O_;]I-;N'?/6/2O^
MFNI"Y>VC/Z"U^OD\A:^#5],_936QC'SEO]0G^H[53YLURJT*GOLM0I6'7FF\
MYE=N,+<0C.<>!;QVXPK.,YQV^CMYI70)4F 3R>CSFN]A"T(:=S+2F7!&90$\
MD;I(K/\ 9VDJ3M6P!K$?-EH<L(%:!1F14T2W&=B,[-U?M1+CZ9HZ<[E_)[5
M"$I3;K;>1,TLUAK$QR%-A4)4M(("=YG4'Q5)\W,H_MCT5TEEAP@EY @1HM&[
M.A?.>E 'H)K(W^C37#Q@Y.1L&]L!+9:\W6W5-N;2UA[!88&[-F[^JLER:_4G
M;&+CU2_[2*/0H80V.8)C %9'G4DFV["JQRVBX R"0,H,*D#*E!YX)(2-2#J5
M>:(0Q).W3!5F4,[<$A:W$^<0I9W'4 3SS'%NB+6<^%.B#]C;!KZC% )ZH/RA
MDVC2'C&M;%K'5>J[55W&S5.*Q8*CP;3E)*K.C8\0Z,.19JQ,^&)GR!*\[5<Z
MH!A6< A6B@I:@=#S%9T.A&_76A2P?_[TB4E!AQ&J2A""(,C7(#.\&8T,592?
M21KLMY],3+M<%#+K5>H.GMBVYE30Q61'4H8H%CO^0DG%;S/?EQ+!0(Q"N/G)
M1; ]LR4@RFR$5L:B#C:+TY(D%!DA6I;"@F=8W*UB-0#I2&.4-LB%!P1G1IM"
MDJ@[SJG29B2.B/32NCS4U%M2+4)-$GI</9<O9HI$B%1&I<&;.G;%*OUZ18(%
M4AV8U7&B6S#3\*.;,3YT5 \-GQ]R:@K/+BXM0@IWIRF J/S=8F >3S ;SS0!
ME(MTF0ZC1682IN?SC$Z$B5$B3II62SN@N R1'2 &_-F-N%"995]M1Z7K\_>"
MP29JF\:Q:BPB)?7Y(?.,3XUR=GGK!88<XM*(,>/QYK+./)+DMJ=9;&@&4 *"
M0<P4=R@0-- (WZSK4,C0(RW"=3RB5ME49%)TD$$G-J2-^OFK4J3TIURH+ZF(
M@NXFZF,WA$$5.G2*18ECS^K**-HB(3^:J2F0WLB;9/VE:-I;)EE<8*8E%K1"
ME2G'G8V8S,2XH[,E,E!DR)"E9IU'1E"4QS &*DD,I#H#R$AP!*2EQ(4A(3&A
MG>5E:YZ5?L'A3>C35]-K%GK,>Y6XFU;8L.,6GSI518E)\5WKL7J!4N"P+K(\
M?$2_;]F&A:V<0W&DUR"(C83DHS++32G%J(.6(.D!7B);YS,PD&>DDZ#2B4VZ
M0H;9/*B25M[]HISF@=\HB.C3?K6LT#25*UU:9%L#'"TJ?)SMA3D<C-$KAXSN
M#<Q_>%BSA$4=$>_U"T6*:.#=\_G+0-MAF=X^1P\2=BI2U""G3D<Q_,0$#U@:
M^>II4RDR'D?GZ9T1RW"X>?F)('FK;O&XGOF/\LW]KD(/0?4:LVS76M^VGXT\
M;B>^8_RS?VN(/0?4:;9KK6_;3\:>-Q/?,?Y9O[7$'H/J--LUUK?MI^-/&XGO
MF/\ +-_:X@]!]1IMFNM;]M/QIXW$]\Q_EF_M<0>@^HTVS76M^VGXT\;B>^8_
MRS?VN(/0?4:;9KK6_;3\:>-Q/?,?Y9O[7$'H/J--LUUK?MI^-/&XGOF/\LW]
MKB#T'U&FV:ZUOVT_&GC<3WS'^6;^UQ!Z#ZC3;-=:W[:?C7BN=#;0I:Y4?"4)
MRI6?#-Y[$IQG.<]F%9SGT8]C&,YS[&,9SP$J)@ R=!H:P7V0"2ZV  23G3N&
MIYZS Z;<*O=XWE3<)I7^A:SZ,KSCMQX9W&/96K';WJ<]N&TY[,?RLK4KHLLA
ML2=5G>>CS#[SSUYJ]O572\HY+*"<B>=7-G5YR-PW)'G))@.75HTXI3BE;QSC
MU[BL@<!E,K7G$7T96K./]/']C.<__>YTTNMP.5S#F5T>BO)KLKG,K\G^<?SV
M^D_IUX>0RGO7^WC_ .=S.U;\;^"OA4>)7/5?SM]NGD,I[U_MX_\ G<;5OQOX
M*^%.)7/5?SM]NGD,I[U_MX_^=QM6_&_@KX4XE<]5_.WVZ>0RGO7^WC_YW&U;
M\;^"OA3B5SU7\[?;IY#*>]?[>/\ YW&U;\;^"OA3B5SU7\[?;IY#*>]?[>/_
M )W&U;\;^"OA3B5SU7\[?;IY#*>]?[>/_G<;5OQOX*^%.)7/5?SM]NGD,I[U
M_MX_^=QM6_&_@KX4XE<]5_.WVZ>0RGO7^WC_ .=QM6_&_@KX4XE<]5_.WVZ>
M0RGO7^WC_P"=QM6_&_@KX4XE<]5_.WVZL]G'3);T)4=GPB6XO>+SX1I'8KO\
MY[.Q:TYSZ/Z<=N/^?->V6E*5!1@YIW$Z1YA73Q.W>=6R6T9@EL@\I(@SNY2A
M_"JZV*-LXSAIMUK&<]N<-RV48SG'L9SA+^.W./\ GR\N-'>0?2DGZQ7.3:WB
M9RI4F=^5U GTPL5[/)]@]V3\^;_>.8S,]"?8/9J6PO\ _4]\G\2GD^P>[)^?
M-_O'&9GH3[![--A?_P"I[Y/XE/)]@]V3\^;_ 'CC,ST)]@]FFPO_ /4]\G\2
MGD^P>[)^?-_O'&9GH3[![--A?_ZGOD_B4\GV#W9/SYO]XXS,]"?8/9IL+_\
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IG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g197729g24k76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g24k76.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( , ") ,!$0 "$0$#$0'_Q  >  $
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M<L'5X187)#16LC5#1'2"L_$V8V1SHJ/B"25UM$5E)H3"_]H # ,!  (1 Q$
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M>?:Z>";W_$>-_)X#_ Z>].Z^4C-OYK@'W%T[Y:]PVG;>?:Z>";W_ !'C?R>
M_P #I[T[KY2,V_FN ?<73OEKW#:=MY]KIX)O?\1XW\G@/\#I[T[KY2,V_FN
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MH()$#=OX=56OTKBFE*:4II2FE*:4II2H\W=_\D^Y_P#_ &\S7_\ UNSTI7G
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M_B>VVQ'W4L+T]+BEOC-8"POK=["6V07!ASEEW606KQ!6RO;>1-MI_9 DJ85
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M4D8#E>@$*U1HC"-1SD=K_8;#+#%L;5:8C;BYM^\KAT-E;K?XQ"V0E69E;:Y
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M#_=?3^@NRGO2CSJ_^U4[YN_TA[$>JG]W;Q9_+!9_1G!_NOI_0793WI1YU?\
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MZ5SXC?T*?E(N-_Y=K3Z);=?=#3^KS8KWE;\[Q+[73OVY_2N?$;^A3\I%QO\
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MZ5SXC?T*?E(N-_Y=K3Z);=?=#3^KS8KWE;\[Q+[73OVY_2N?$;^A3\I%QO\
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M(0Q2%>C>HA'O57+O_#=A-D'\.L'G<':4Z]96KKJN^;\9G'&&UK5";D 2HDP
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M]=<3^LKL_P#E6,7D&TE464W=9>2*\>,>!8V/7PZZ0Z;(Y*><%YYE9<O1>P<
MFCBP%.(X^:--\,+]5;8;9XCA6,(PS"UVZ$ML-KN%J:#RP\OI%%OQR4I ;4TH
M^+(5IF!S"LBPS"FKJT7<OE[V9#82LH2M(*1KO).:2(,0..M?IJ*WQG(:$,N\
MO+&HOZ*Q5BW8ZE&)=@-728@(Q85)52$.^M6V(H2*K7"C$>HNL37)UV%VJQ/%
M\5N+3$[Q#R.\W7&4=$RT2\AUF"CHTI)(94ZI222($\)KG&L-9M&&GK="TDK
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MS<(Z"X2N"Z[^+;<;!6DA2CE25 %!22G,<NI*0#2Q2U06DN,-JSI@$9-\F#O
MF-^^!J=YJRX/#2@!E13CDQI(AGCR %0P#@,Q"",$HR.&411N:\9&.<Q['(YK
ME:J+K9H=S *24J2H I4#(((D$$&""-01H16/0Y[4#RI2#V%4U]>PWUK[7?Z6
MN<YY#T^ND.>U'Q4?2IV&^M?:[_2TSGD/3ZZ0Y[4?%1]*G8;ZU]KO]+3.>0]/
MKI#GM1\5'TJMOP(!:WBZV,<G/RRTWQN_P';^MRIK%=N%D[*8V-!_91S_ $[7
MEJZL@OOIF0 ,QD@)'YIY*)]%;U?PE3>OAS GQ?C#QA5_F%]K2G<X_P"T2O\
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M#!C/<_P_B1S"!>5Q$4>M-I\<%P^[9MN?V:T4$K(,)>N"D*7J 0M+04&QI"7
MYJJ0$S6'6:E%*\OCJF)&J4[I,[IW[QPFNTM:FT@@-!'<G:"!'EQ1@2- 1 H%
M.V9J-01?A,.]6]0R^?+J:].:.UB*5))!"1)@SJ=\$'=J>,;@9!T)%3"DJ2"
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M(WT+S3BVBC.,DH*BM\I1"GE)2<OLL.=01;-6ZNG4HI*5"%!8]EF!U*M9X 1
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M$V2[ASL(*BC(X8"A[%:).GP[^WG8_(8ZW^1X]AL8O5U%3(;T#53K]S(!>FN
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MW28&E0-D^%3YTR5D\.:8-A!DFB5MB09*NP]T*A62(4KHZ6J*4QZL;W6,1K)
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M85:%+RU#.0A4RJYR!J8T 2V"L$Q"7))RS&+8.TFV:N;MV4) R#B?%)*@!O\
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MG[-)',=HIG5S] ]585N-$=*P?)80WN')L*PU?!YC:3JL)O3&@,<-Y H0;I9
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M)6X\#<#&]K=W, H[@T&SRZZQ')JZ:.:E[35^2X;C=@.QB$"V=4W--67-4PQ
MDG1[-&W!81''AA&7YE]S#$]B+79/NP;:;-8I=*6KN:V:+G#W[,H.%73[.)/6
M%S:K65,J9N<3NF+E27$-]ZMMVSMRD!*5(V,FX?4IFVN&0%-K_%N!04EUM$-.
M@2)! *$J@Y2<ZA"9C8\9+[<N(:Z'9?\ @.#86+L<IS=F!!AU'<Z(L9HJ\340
MH8,:(-7RB'>,R'Z.UUD[GSJ87@.PE]:X2]8*3C&(VMBC&\39SWUT]B*@%/N]
M)>NJ):<N[BX<";=+*'&^B*^E*$E&8MK%PA)6I:DH)#:$PEMI&B4I2A.4KRI2
M))*B.J2!4ZLVNQ_;D-YF5KEBP+W(\J]U"U$,U<<5M%K\EFRY=G($>%+FG2CQ
MB:<X2 )&:CZL"R3+'8X;M\WFU^+[3WUALYAVSPNL)P["N]7,5NV[I@6#EW@;
M#5O:,NM.L6Z57^,,M)<;6AYQ35RIME 60X+-NS;MEE164+4^%J 4(< 4$J.I
MX-%;F:8X0<U9?BT_-I,<.:87C%OV(,V3-JI,R1#&,[8_5RD2:\K ^'0HU<.3
M D.<5H7O$58\A',9$8\QLFVXYLSM/C=@AV^M6;>]MF6[CIVP_!2AFZ0MQ3BD
M+ 6Q=-!*>D2E:4NMD9J9-T5YV6G F0I"W"$@E4CQD$:I,$+!]B"08(*ZBO;_
M #'#L=7([J:Q<;7-,JRW)H];*HJT3ZL5E?4000(<Q#DFF=:<C2)219# 2"PX
MG9@VPHL20SV/^#5CNU&QW=N[GS5NA.-V)PK!.Y_C5VWC&)!%S:WEK<.7F+7.
M'LH3:7#N$+M;=VU3<MNN-BXNE!^T=6ZRO!L<M O#KK/^*<4X_=,HZ-*R%M*T
M;2LP4J<!4( (E(S)Y69[7S.]G[-?;:1S':*UKG5S] ]5.U\SO9^S21S':*9U
M<_0/53M?,[V?LTD<QVBF=7/T#U5Z*N*MJ.X;][&KZ';=9*GM@$UYWV6TVCP4
M\L1MO^8*F+@PRZ?U%?-7EL\(SU)[?V:].Y_OE_\ E4%G'(^CUT\(SU)[?V:9
M_OE_^5,XY'T>NJL<45F_W$Q[ AA4D7,Y-C)M$8,I7DK\8'%M5B,1G(:^)DK'
M5Z/ZG*T*]")\)[<4VLOBU9-VH *;LJZ2002AE32L@@_GJ6,VLP(2))-7EBWT
MSI4)\2"!&DPHR=23NX1K$DU73%J0<RWE66;1HME')4@D-%+(#M+,A,(T;I0)
M#PL-'D1>Z"8\;^[(<9PCM>(O2GGK:W";;OJTQEJWLN^VF56;ET\VT+A-L"ZZ
M4BX4C.ECQU9O' 2"?%A2@K.L'>GIF7RK*H!:1(RY@ F2-Y4<H&@))GB=)QP?
M=#%,4Q#.\-O]M!W>96%['C8XU^*+[C18DZKK%AUJ6$ML@54"))*0X%D.C")&
MD!E10M<=@5\)]TC9':SNF]TC#L8V2Q?I]EF+:WL?"=CB+B;!DVH/?BFNB5D<
M2W<.O,N*MR5K<06E)@)%9A9OM6UJXTZP.F4LQF;'&"D%2M4E(D@2  0>523M
ME846V$>)9W0H>23:^OFQ9D$2UM,&EL9<T?N6P GDBMNI(S2F,;-EM\7$@N"Q
M; ]D:7$2_P"Z/L+M3W3%6^!X4O L,MMC;6RP5O%;AVS5B^TB E#EZ]<NX6Q=
M/VEHRMPM-6UVL*5=+NE/LMN.JKO8]#9](\LJ=4\I:U(DY&U\,@(&91$RH1XH
M1J8($90Y<P=G"W@EY-/GY&.8=<@II9Y!'OPZUG)XJAKXCU&BBJHK(MC$<.,A
MIMI5">XZ@*1K_6/<+V<PWN4(PJRL,.M6KBZ;MK7'[^U2O-?N.Y XI2UF"TT\
M0ZTB$'\6#H2K-BFT#!Q1AYXN'I&\[C25@>*4R0!H%R4^+Q&[3A5OB- *,^7U
ML<%H%D(5KE>QXD9UH]KF(]7M<WS:K.M7<_@HY51%]LK?0VTMU:@&VVU.J68"
M<B4E94520!E$S$1KH-:UD#G(0D',HA $<5& .T[HJIV45$NLISXY8$,"C67(
ML[6VBLD'BD&^2:?90!P(JFF27 LW'C1C"9W^_#*T3#O&T;_(FVJ+C#DW6-WC
M7>]E=%_$1<.*"6D6Z%+<>=43JEI!0L%2H&4 ZB"=IX6];J;%J71FM49'8UA0
M )!T()A4P-Q\7>*Z',\0W0VLAPLRR7%,GP*#>FC5M/.EMI#5>6C$ =H",> X
MLPE;:CC#F&I'3FU91S4D#.PX.SWO,V"]TWN&]W7'T[/X#M/;8OM/LXU<K5:V
MZ;FV=[W4MIFZ:;=?8;:N[?ID(6IMM94EQ,I2 7)DINK&7"RXVR]JA2T$)<"=
M08,*$)X$ \=8KAGK74P+ U;(H<JQ'(68FX5H(SH=K%H*J>GNA6A@QP-6396M
M3-G0QSXTR--51+&&(TA5"DYW1.YOB^-WN%XSA&,7-C<X)@V)-V%@FU20_<+;
M6NV>#CKA;66[A%N4MO,N(4IEN5A20I-PS=(AP0V0M;:2I*I( 5*DC005)*A(
MW@G0:U,6;8W@>*;5U\B@C4H\FG64.7CJX^%499Q9DA/=2'91T<T8@@C2'DDO
M*$ Q'(UXEYQ8QET]W*ML.ZS==U7 ;*QV@VBQ#"U77>>UF 8_=O/65G:MN)0Y
M?L6=PZMFW0M!E#MJH.H?2AMU8<?Z)?;%[+#T8>Z\EID/D9FW$ !:R0"H0D">
ML1K$@5!_#[E0J3<J\QDW,,#-U#(=&(G0D'*($20@B)S1J(VXK(CH97NY]<BM
MK!"^$1[5^K.R=_WO<N62C^+N@%(D^Q?0B=!N/2-)5)!@*2@?G:ZEQ!L070F"
MDPH=1/[B2?0*OAX1GJ3V_LUL//\ ?+_\JB<XY'T>NGA&>I/;^S3/]\O_ ,J9
MQR/H]=/",]2>W]FF?[Y?_E3..1]'KKU%<)#4;PT[+-3R1N"5"?U2:\R;5Z[2
M8R>=^]\XJ=MS++1_43\W[MU>9?=4"KNAN0O+GSSW,%Y_"\_^,-CKTAA7^C,-
M_P!PL_\ ]=NH5Q/CK]C[-7YO6>L?-6!=A?S?[6K^NN7]GXO\ZKSQ561J+8K,
MY4>02+(ER,4IQN"Y$*1EWF-!5S HQ[V=X3X$J6LP#>I2P6R6]LC>IBX_M2X6
ML!Q!0)25(9:T,$AVY9;4)Y%"E!7ZF8[JN;1,W+.B2<X(\7D">,B>7+?K%46V
MOIH6)6MKAC(!#K*BMRF*V0T3SG;(?WII9+V-1$:"24B<G=3W(8*O4A'/<NBG
M#F;"@K0** 3.@*R0/@! !TW<-*RQI*4*R1O3FB-3XH!X:R1KY#H:O!15-E8Q
M:QE+4!YC[!'""0 &,ZPJY"]HA8S#<G(T2IWA*BD[G-[1N&Z(NW76VU*90EY>
M8C*M?1Z<3,$@:@&!)/&I5IM+F4$E '& 3J( @;P=TQN&NE8AMK85,3<;/L@G
M/&Z5DQP8]5&,<98\5U*^6V3*5KT>I!H^7%!%8Q6A,D)0%>(L=PTQA_%1:=\N
M)0M:GG $0D@(*1'2%<!*D9R1 WY23(BKYBV#BP5$  %))(&DF! W0#J)TXZ$
M&K!FB 2$>)3-14% +-.%3#(4DN3UD(XAQ$Z%.<B]\BM<JM>]4_C(J) *<4Z2
MXZ27'"25*$*D[R1.@!W"=!$"I7( ,K8$(1P,R8UY03QTW[]\57N[RNPLI/CI
M:MC3**HIZM$(X)4)_"RXTDJ-;S[:$EUS7,5RN(/FY4>B/5%SG"76[IM&=L*6
MP$H2M2084I"0<I,ZP@$J&L*(K'[LN-K5J1F3NDP4YB-=VZ( X<*K+)S;([3+
M+RH?-#81&TU?&%1DD*1E=<O->'?>OB.Z&Q!$B6PS.EN5$**J$%5:X0>]-I1T
M:U+*TJ2$$JCQ3^54M"5"3O0<I(C-DXP"(LNJ65)@3.XZ^-E(,2>:B1\($"K*
MUN)+4X!%LI#ICKVXCGGV0I$\BD.RP(LH@&0U(Z!#:5HPCFNC 3NN /K>3M#<
MFO<1O';^X=EP%L*4BW08 ;3!"/+)@K)WDR=XC);9A###< A2DI+AG59/,;M!
M(W\.R48>' PL>.0O<\3'Q813=OFKV1[*Q*Z98N8Y&B:3JEF*Y2*-J*1K3H-K
MFL5N4V=NANUMFW$)+C"<P40"4K4)4I)B09W[]8G<(L75*#BRF4H63(X0(\4@
M&(W\Q TBL=SS'):&D650C5$2&(\J"17HPW0JO)T+R5$<J(O3\7)53_')-+!
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M@;5<Q%<J(YS?XVHJZ3#;@'LBA00) )*TD"-#N)&@\;EK4DPLDE0$)3)5 .@
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M*&&Q=X-Q(QYTF362A.D= SC-!)'>,@7.:K^L?)"B>-O"KA /1K6AMU)*<BE
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MT=PCN?)7N<J(B*B)MO#W2Y8V:U*45*MF2HZ&3T:9)D3)WGKFL<<!Z1<0!G5
MCK/6*D#LK\_M35YG'-78GU5TUYCL/KJR_!T)6\36T"^?EDQ/C3_!%EK&]KU
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M&_4Z;M.KG4)Y)5/F19?..0AGD9) TB](RC:YJHCEYIZ$Y\T7T(OS:N4J B3
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M/-(I%((8 2&.1517=+E1ST\N7-J<E7S]"_,NKUI8(&FNHW ]>L^KC5HX@Z\
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M5.F0F$H4H YM"K,%!1!F9JX1<LSW:K;JTG1,>@1;ZZH::<L"7539$)@*>L;
MZD+&GQVDFQ3,*R>HT[<A[AJ,SFM4S])=W'939;;W:+"+7$<2N3889?7MHM^U
MOK5MXO7]RBYZ-3+]L]D:>;2A5NI1S- *\0Y@D3-@IVU;+K"@E\MB<Z04%"$Z
MD*$!)2HF3!S DP-9 J+W)-JMP8]>./[M6F)OG&A1G.(X631X#[1I([GE#TH*
M]DNGQT*1C&%<U'?P;NG4G<W5CA6UNRZKA2F[2VQCO=%TX$I2K#KFZ%J4N)*5
M*<*[%L6[@0"I:4DQF3(N;?I7+6Y"%)2,LCQ=5*2%99UU(4E1TYPG69L!P];9
M[CU6$NG4.XT,;[NXN<D,^72#M@VB7=B>0&6IWG 3FZN;!B@,UBJR.  U&_IZ
MB:7[LVV6P_AJTM]H]C;N]0Q:VF%)=M\2<PYRP5AUJSTEJE+;:T9$W#URX6LX
M2M?3KS@G,F^M+5]#*7&G@"LK<.9!.:5$@F=2#(  @F-Y TB2WR6^F;LT$B^F
M1IB83NI>6;)D.M-$]U)(,6?@L>MC1)TL4B6YUNLF>V9&.&&@!L>%[A(U#;0P
MK9O"5[!WK6"-FV1M-L'A]H;.ZNVE)P^V>Q)[:5ZXN+A#!MFPUA[C;"F7F7'W
M'1T>12B5)M@I??C?2$)4V\5J6$* 42VE+:$ Y1JHD*,K4@F3H2*Z?B]JQ[M[
M?Y?B@5KZ^%,HH0I91E(MF,ERR//&WPL7Q,YC?$"&2.]R-5JLZQ&:HG$9W[B=
MNYL7B^&WETJ]NKE5_>)8*T V91ACSMH5A]8:MBO(I2'0W)(5X[?XQ(5:XQ;)
MN&%E9B1"PDI"LJA(!DC0)*E:1'C;R=:^[6RZZDV:R#([R^+)]P)</P]RQX2C
MMLPPG:RJCV5H=%<P:2[BQJ+*;(Y*O9*5PQH1(HTULO:=EX[6X?A=C9H/?[*T
MW%NM+B%VN"8_MBM-LPR0%DL6#5Y;--)C*6T)_)APQC-NI*8<*@D(<3[(".D;
MMC.8$[U0HK5HHJ5F5)55QG;S/QJPQ2JK)M5?+EF./OJ^QLIJ0I$2<;JC-JPR
MV$?'L2R;(S(<)Q!#>SK PKBO3NDTB>YXSCMCM!>XDS=X2-G\93AEQA]E;-OM
M8A9)*7A>J:<0AVS0U9ME^Y"75H40ZI'1I4&T9>B\<2VRSTK8#C2"%K*@9DIR
ME0(,RDD3&@W@&:SVLE!J:O)[7*;"/-D^,**KG"HI8HL2O/61%#%LX\@TJ2Z5
M*))EME69(<.&6!(8R0D4 Y#B1;EKX0>P>TPBS+5MT"%W+!Q%I]YRZ;NK@NO6
MCK3;3*66$L6ZV+9#[KR+AMP-EY:6\DBT EM1?4E15*<T$(2"B0B"DD*S$$N'
M0DQ.@J!\PK-U-XX%QAF%2,.K,/PHN/!#97"7);?,3DH:VY:<K0SAD7'^N:-L
M09C&DRHR,)-.92];]A;)XCL=W,L:PG:G::RQ;'L;Q9^^?5A/1VZ\"PZWML5>
MM>]WVV4MDWUREJ+P,O):SDL6X;;1D$=<L7.(9F$*+:6Q^5*=5$MDG<3R.A(D
MQU37^2;(Z.+(BWT*+$M:V0:LN(M<\A*YTJ"UB^*JW$YG6#( 4)6"D(TP'/>!
MZF0223?9WN5[:X=W1-B,%VGPVU%C:7C3K"+,)"$6QM'5,=&V@#*EM*4IRM@J
M#:90%>+6M,0MW+)]YI<K4A4%2@"3.LQ)!G763/#KEWA,MNO,,UK1(107M."_
M)\)%$R533PU9%<QRJ\9BAM@M3M=+'-B/4J*YHWZWCLXYT:KAD$^,E#I$DCQ$
MH9)3.@\4(@=7&#6-7B<Y2L:2HC?NG5((X\9X>B+X]IOS>Q%^ORY_X_CUE.97
M/T"K" ===>2C'P:T[2?-_DI]NF=7/T#U4@=?:?76_7B6:KM@-WFIZ78%D"?%
M\<(GK\M:(V;TQ_"/]_M_\XJ4?_(N_L*^:O-[X1_[HS7HO.GGZ#ZJA*>$?^Z,
MTSIY^@^JE:L]][)UAOUD5M$DB*$-/"P"*8)"(\+\?,"UE@()C6C[D:YLLB$\
MIU>5CP#8)Z#+TZUMM$XE_%W%CQDL,HMI$ZY3TJDQH#"UJDG=E*9() F['\6P
MD:YG%E4Z@@& #_Z1!!G<>=2]C]5144;%@V-Z<"U.//D1TN+:YN(]**8II/*M
MIY-BH(,5L<88?.N9#[ 7,AL<\<IXS:%:V&V/V5Q;%L;V>V<PFPQG''RK%[ME
MO+=7;3CKCI:;)6I2 ZIO/<J;2 XAM*5J4I:8S2U>=?2TA]]PMM-PTHYE)2L"
M M0)4F4#V&X [CO-9-C=7-W,M[ .$4LZU!6OBV63RBV:8A'L*J+("T@:L98\
MNQ#*E0:]U2 S8T5T*NY(LT1#B>[2?=M[L.&[&6+N$-XG>87M/BZ$M6-W86*;
ML8,5ADMONA;C2 I3*@MEI*U.Y%I?4C+DS3F'8>;A0*$AUE$ES,L)Z49E9H/C
M>-.AT' B)K!)%?9"@U8@//8>_B99S\4IH=JS(;^O?:H2<E,^\MR/61) TLUD
MSQ3I5@-A.IY9+8T/HL\)[IEIA^R[UYM/C%UB5WL^PRG%<3<MDL/794\+9-VZ
MT%!MM+SJVTEYQQ"%J4 <JB$FZ[U0C*&DI"'22AM)S%$G1L$[P"=QUTW#05C^
M<7NX>V#**\G86N,PZCQP4EV(!7M :185\ZM%&L8XTB2!H:/);'C2%>@(,LK)
M#2Q@C>],&Q/;[9WNG6MWLYWY=.V-[=X:I-AA[C=EBB6&,0MWUW-O=9KMM]]K
MH^D-HI'1W* I@(+BFU#LZEZT0'$M9%H! 4XDJ;)*2,JP"% :^*9T.OEBK&[S
M&MG-U,1R1LB=GV-[<7>/YF,$#P,B2,$J191S&JDN9 XY".@)8M<-LB.P!3UI
M(C!""%@ML_A ]RW:';KN;XIL)LE<6S"\5PQ5DEVYNUVY<9\'7%K9%VX;RI*$
MOJ;7=HDI>1F*6U)5EK&[&];0X'GBM?0.9R$CV)S!2TI4H$:I! D;C$@$5G>Z
MMWCVZVX6YFX<5\C%*3,#N<.$LEIC0G3,=BXW-GW4"AGS(#76J 9[K2$CV$5\
M%))#3 =;P$EOP:>Y1M#W*.XU@VPNW%PI_$\,=O6PNVO1>6]O87*TJ3;MK2I:
M3;A:WRT@0INW<;2L(6%"K&]ODW=\Z_;*1D6K,$*1"BO+'C1$*D#@9U@ 5AF,
M8CE>2XYCX;K* 6,MEA!K8S8YZI)$8M,KA5MA(?%2P;:PX$ATDX123(&.=B.0
MJ$<]Z3!V,P+"<77=89AJ4/AQTBY"W5(2M\*0\IM)7T3:G$D@E*$_F@1E3&0V
MUPX\PA5PXD$Y2$@B3ETUTE4;Q.G'32)<FV+L9P.%C62DKYE'43SQJEXL=",\
M LL#PHK979ZBQ&Q2DDOC"=+;UN<R.K&##$;$X1L)@N"[:XCMI;,W;>)XS9*L
M,31WTXYASB5OVUPX^+525I;N%NVK)4XVXE!\971AQ:UJKONARU#)*1T9"FP
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MQQ7JJM3FJ2.T+#]GB]CLM8+SL=XOKLW$@H4XZ]=/K>) &92E9C! *BE" ,P
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M:)$I+\LJ0X<@+DMI';_X8$(W#8R2,(A(&9Z&F<,:0S<T.%[%>^,"Y;S &(5
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M  @'4YM#OWU%()4TVDDF)'C&8U, GR$3SXC?7=R++$9Q9.+3Y3I,T+WFB$K
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M5PH-H==MRD+0]E)2A)T*5J RA23H9RR(5 "@*R:PN6W6AF6A#@)!;S %1X*
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M.O$Y,&,V.V0,Z]2)\!_)R?%\:?"Y?XO^S5'Q"2?&&\ZQV#F?O%5\SJ1ED&-
M)G[_ 'XUB60;6@RF9!GW,FU82,J.[8Y;F@<Y2,*CE9THK5ZFHBN;TJYBN8O-
MBN1>Z7RVDI0E.N^0#]R>/_2.B[8N%*UE0.^)C>)Y<)X? .-87FN(/ACEH=R(
M&-%>L&0+X!NIK%Z>HGI<J(J(Y%Y\V\T7RY<JS;F83I,Z@]6OPZ\N&_KHNM%$
M[XC3E(TTG3<#QY>2HY"_PF)VCCB@R"#!!'$,>&,YRNF25')<&0YCW"037-?R
M1S4Z4<G-RHB:J@DN)&XDZSP &D^6-=W4#PHR,BSH=!&[76#!/*>OK!K.,*K!
M2JZLB2E8Z*#K>5@_@O.]SG/1QG(Y%)T*O2Q%\FM1K>7)$1*;JB,Q"0"8(&_R
MG=KNYGA51M(4 %;A/.3\/S[O+I4U/"OA& $=L2(C$1!#<C6]"(OFOG\)?+R\
MU\^7/T<]6H,J\8>,9,F1PY5=1I$PD"-X&G*#PY\H%?2,I'"$&"V7(&UO(3T-
MY>2ISZ.;D3S7E_%\O3Y)\?)7!B-W7U5R 2 !K'7PZH!] ]%=;<TUO/"H"Q[5
MS7_"7IF(U&^?DB=+D5/+T>GT\DYZY0L SXH/(@F3OTW_   QO@5PIM9X+B>!
M3P&Z0#H1P.L"H6R2JN,<G070_=A(LA"AE13V!B1WJ[FYKFL558CD<WEZ$^+E
M\]PA25I)(&8&08@CASW$$\(W\JM'$K;4-5!)U()D<8^#T=6^HXR;'ZV]E'DD
MBN<^)$(V4YQS*]_>8O2CV=7PQL1%3FB(K%ZN2>;DU60XI @GB2-!QW:GYH'.
M>=)20LR1K$P.',Q&@/'YZS'@YP$U=N!FU^CFCA5-!'J(X8[FO&4N1S(LYZ&(
MK>ZCHHZ!K@"3FU/&%>KD<OPMB[$M%3UY=*S!*6D,!40E16LK( U!* V.<9^2
MJQW%"!T:!&\KB=0(R\Y ,GE)3(XUL7[*?R_:NMB9A[8]@^C43 Z^T^NK\<++
M%;M]<(B._P"65@OGS7^\F/:P3:=0[_9\:?[&WO@?ZZXZA5TP!D._V1XGD.NI
M(_"'CZLIVU7_ -07J>O^^,+^4W_ZZC^YZJ+7$AI_>&-\_HU\@?W?#PXO4RI&
M_P!B>7/K(K75V?WY?_<UL/..KM/T:LLAZ^P?2IV?WY?_ '-,XZNT_1ID/7V#
MZ5?(\,,D)8\D(I$<XWA. XF%"8)6JPHBB(]S"#(QSF/8]JM>URM<BHJIK@J2
M000D@@@@R00="""F""-"#OID(W3Z/I5$E]AL'&K&MN,8QHXXJLGAN(V/QE<Q
M$(L9\,S:4!>3NVK9;>NOBN,G6UA6N'V^C$=H<'#[32L/LFND"UE[H0ELE.49
M?$&0*.8< 2.1DQ-89>=$XKOE]>0IA(7XP"N<^-&FGD/"!6-OR+';%'* #CRA
M%($@98"190#,<K2"*$R,DQS">BL($C!D&]JL(Q%14U@*V7F5%MU);6DD*2I)
M"DD;P00-9WSK^_(PZTX I$+!&B@1!X:$;^6G*#7\(D69ULD0T"JHJL<WGU)Y
M+R7S5%Y_XT_[TY<$G?(X;]WP'R>6N?%(@CCO '+EN/P1VS-:=UHY:J'/MX+D
M<^ U3E8[G_"#"O6K'(BHKFN:U6KRYJJ<O0J)J]85G(2K=,2),$[OOS\M63XR
MI4I.]/5IQ)Z^K4\#&IK-GWBV.#;9N$B1DM1K,,]Z*@@LD#YL=U\OA->KD1JI
MY*J^?)-4LL.O<<N@B23!U(YS]XJMFS-,P(D$D:P),[M8T'ITKOHEA%@3FB.1
MLLZHU6([DK4Y)R1WGSZ6\T7SY?&OHUT(4H2! U)ZS/DU.[M[ (!DP=#$<YWZ
M_<2/)66OL4(K&L4:/7_^5R5J>CRYIZ?5_P!GS:Z:CJ[?O_UJKF&FN_=QUT]=
M<SQ$-J(AE&\G)%^$J(G)>7Q\O)?+DG[IH9_GOF.O7R:?SKDQQCKFL2O)T ;G
M/YQF)R7NIW1HB)R^-%5$]'I779.;41OXF=.>H_EN'*J:R.'7)F!''J,\^J*Z
M"@VZ3<JYA. 6]KL>CO.ZSMZT,>.QZ)%,L<-;8V$67#E&=+6.TX@QY7:CN>XO
M9<H5=D>#X4[=N@W#+B;2%$N@AM15$I2@+2<P)@*(! $F>!BKV[2VB&G$EW,!
ME@J@:23P&FZ3)UCB:M-A&W.-;?5YX./1CM?,(TMC8SCNF65B4;C.$Z7)<YC5
M8#OF;'C@$"*!"$40&/*9Y,]M+6VL6RW;-I0%&5*))6LB8*U99, D ;A)C>9Q
M]U;KRLSBE*(W;H'4/&T%9MV?WY?_ '-76<=7:?HU3R'K[!]*I[X7A<M_ML5]
M5^]?1R_O9/\ Y:_]RZ@=IU__ &'$]W]W'/\ 2M]0^?MW56820\V=?9=0X'K/
MS5L\XS45=GA\OBRZD_\ EK36L]C?],'_ '1__,U5_<_DO^(?OK5#TKZE]BZV
MK4?5;>(/ V6L.FS6*^=%FT$D,"UD0GDYK02'2'-*0*->U$K["0QZG8T7:C3)
M;Y#R#8- P./VO2VO?"$9G6#XT25*9/LT  :[RK0R()TXR&'.Y'LBE94+'5&;
MKW'<.!Z^%5\E6<:I2 *JG!(Y/@*YZH4C^KFO6Y>:]74Y>?->7Q>A=8& 5YU+
M&@, [Y(.NO'RS._0#?/E02 $^R/'0C@!K/+T[]U90&%<V$81)UA%>PJM<@'"
MY-1/+DB^?HY<OB]'J].J4H!(2D I)$[Y''3B.$;Y^"JN52AJJ08,$#3CI _?
M\.M9$E(U6(UQ*N)R3GUK#:157XE3JY<^?Q^:ISY?%JEGC6-=-)(W :[^41H(
M$P:J90. &F^ =XY'?OW;C76!JYC)[  M7#CR#,22^-'[3QM5W)Y11V,(XSFL
MYJT8VH][T3DU?+ECVVF*8]ANR6T&);+82C&]I+'";RXP;"'%A",0OVVBMFW*
MEO6Z2%*1JCIV2]*64NH<<0JJELALW+*'GBVPXXE+JP@2$<8 D<=_B\O+BM]L
MAP^5<F/FU7=2+K=6MGP%;-N,PF7$BRE#.!"Q["EG27UM+"A!0DAX8M;60X)4
M0R#84;4=\6'=MN[2K:+$ME]I\$=PC9R^=Q%6+67]'%89>8.\LW#BE&Z;0F^Q
M&\NKET(3T]U=73Z9 *DN)6-A&UP\):<8=;<6(4F7$$N(GQBM((2F03OUX &:
ML1;[>;:YE@T-P7B!6LIB195:"XDB@R*]\@<TU?( R<D;P:3H@2-&YJ &@T#T
MH!SA+HZUVMV\V1VYO;2X8>N;@XNV_9X@YA31NF;Q+991=-%=KT_?:;:X<:<D
ME]94I1\?QS5O;.VN&05J"64YB85XA!3XWCR)R R$@ZJ'BQ-5(Q.XM85Z2_BU
MH#A*W(J&4<('#EC20^NGU\]\,G:00I)X4UCQHCF]11%8P:K+8WZ$[:_@Y=TS
M:C ;;:9Q*L;O]IKC"=J+O#PM%GBC-YBEK<WF*"^MGV;5ADI>O>C";92BA:<B
MVV4J80,=L\7L;1Y=NVHA#8<;SK$)X92()GQIF0-"!J (K3PF_C&J,LW*ROW&
MF%FP]U\TILBK#2RL+6QK.WCEKY$*"G*/,KQ&;*GSS!5IUC2@RHS9(W$<DEMQ
MW&\;VMP?%,#LK!*KO8? -FKG$,.1D.*/N/VN)!;=N@*)N+GH;!UM#+;LJ#:2
MA!S2%AB+5N^E]2I#SC[8T.0I"T@%1D!(5FD2<LB=^[93FFWW>F@S.NRR167$
MZO#'F JX\6QA68(JF>#QXGB>[F$AGHPD:2 [45S G:TAN[Y8[C7X1&VO<NO<
M0P/9_"2,';OPJ_L\>9Z&W?>2 E*$6R\KK"W$@ NLAIX)4@/E:,C:<CQ'#+?$
M@%K6I+B$PAQLG*9 R\@H'0QI(C<=*CBV MY1Q0=XR28UBY;H\4=LH8ZU;4LA
MPQ^#)W2%E\ZYA O$9),4TN*\*L,QZ?0%_NJ;;=V;N.;9.;(;$7MOBZKRPP);
M%E>V]R,5PG%$E.+O8>Y=IM IYFV66,0L\KSC5M>-W#:ST@;;Q$6-MAU_;IN7
MPX@)<=4I22G*ZD2@.!*3$@A2%$$&9)DD#Y9_8+F#L<@.@68S5 9SX\Z>!!,-
M(F C"."(0B->4#!C:XJ%8YR.5$]#58/"_P $7N![;]S?:W:7;':O#VL!M+S#
MQAMIAO2MN7=TMRX0Z;E]AAY[O9+*"M =\0+<6A#:%+#K@8_B=M>M,,,A*B%A
M9*$E20=QE0&[Q9&@/C:@1)@:YQ^QCNZE @.A#,(83NIJM7J3J<-$1JI^=TIZ
M/-/F^A:%I,'K'E^_[]]8F4E.A'I]/J_G5E^#R)-%&W".^063 (?%A@<SN)!;
M8!CW/NBT#%_@4EI'+5^,>Q.XX:0FE54:-&YEL_FZ"XE)".D06U'<HD>/''30
M:Z#A4+B,9VXB8@@ [D@@=6^=W$^2KI<E]2^Q=3]1];M=^&]6S6YC?7AUTGK_
M /-'ZTK@1 QG#"=W?C'^<5)O:M.?L*^:M&'A5]2?Y*_9K>69'W4/54-D5R](
M]=?CH?4G2YK7(JHJHK.:*K51R>2IR\G(BIZE1%TS(ZN&\I.XR-XYBF57+TCU
MU@67[68WF<F-96 3Q;J$%L6+;P7H.4D1I7&\'(&5A8TJ-W'D<QIPN,!2F6(:
M,XQ7/CL0PVSQ)(#^9*T@A#K:DA:0> E.4B=8(/,0=:NK:X?MC*#*21F0H!22
M (]L"D]8/+32H8F[/Y+22G$:(.15W<?VSUR=B<(2O9VTDUAG+S<U'=/5!DS>
MX@W&<*,QS1MP^^V;O6B56I3<-3XJ0H(>B-Q0N$J,Z>*LDB3 J=ML487'3#HU
M$ D@9D SK!$D<]T Z3I7]%KJR&YL29XBNG#Y$;%F +#E.8O4SN#%(8-Q!JJJ
MWK8CF*J<N?H76./VUS:J*;EIQI7 .(*0="?%5[%6@.H]'&8;=MGDYFW4KTX$
M$@D;B)D'>?& (W< *^*576YQ(_4 3N749WFYZISYKS7S1%^+DB(G_9SU;E4$
M:21NX1._B=_P1.LFJF03R'EX^G[C=7&/4UMBQ(4R=(C2X<R+8U=M!7_A-?90
M3(>,=$\VO'W&=J2%Z=N1%(:,3^#,_6-[8;*X5MIL[BNS.-LA[#L6MU,/ !.=
ME84%LW+"E Y7V'4(=0H $E(2925"J]L\;9]MY!(6A04DDZ3.H(' @D$:;P=8
MBHDW1C6$O,9F4BAQVVD+'_ >+C27=%F\DP<N0\<9 A:!2( **CVE<QS'#:;I
M55+J/N"=Q2][D*]HDW^.VV.HQ-=NSAS]O:O6CC-FPIUQ:7VWUO$.NK4T5(:?
M?;3T0(7J FXQO$QB'0%#:FU- ](%$*"E$""D@),#6 1/ =7;;5V%+DN)6R20
M\Y3+8(YL*2S^$$8,9J/8YCD7RY$1&KZ%;Z.:HJ)Z'?2I"TZD!23E,;Q) @F.
M,GX(J(MU(<:5)US $1)!@;QVZ:SPTU.7F@-943H%0Q(!9,P+!$"UW/N&,-J^
M8W->US^:HXR<WB;S(U%<Q$U;N9UI4D.=&HB N)RC2 -0"8!D\R8G6JZ(2#XI
M(S:C49IZQ,'GH> XBNFQFVOI@JZ+<>#\#8#/+AAKVE;/IG1(4:*>'>PY<9XQ
M#.994<)4?#,LGNMCQWQR!D,TUL/M?C.U>+XUL]BVR&+[/L8 MQ?A%Y_I+1VY
M6^XABV2ZJV93<NKMTJO Y9K?MVD/(0\[TKJ$)GKI*+9#5RV\RM3Z0%-^-F2G
M*F3EF "1EUUD$@ '3,+](\ZABUMF5AI!;2N9%EO<53C(R2)XR"YJ\A3<FN$3
MO&>KHKBED&.C3(7;06ZPVTA;J5NEYM"5QE44=*V,Y3[',E!@QO.O$Q$K2EXK
M.4I 25:$G(H#2-1XN;=,G76:BR_J&QE7M1VHSR:]S>3>I&M0;%<B>:]+&-:G
MFJHU&M3R3EJ\L[:UM4N"UM[>V#[A>=2PRVR''E !3S@;0D+=5E"5.JE:@(*H
M,&/<*CHHE6\ DYC&^ 23UQP/6-U>\XQ,A4).@A<.3'1YFJUJ.1R\E^ ]O\5P
MR-YL>B\N;7*B^2JBR33G F=8W&9W3NWC@1QZ]:LW&])'YLD1Y!((.\&-VL#7
MG5V^#Z=DEEM<:-<5\N+45=[-C8I(EA()IJE[6$E1(G6WG)A5EPMC'BS&/<-!
M.2N:C7US^K86!O.+L$I>!RMK4AE9,9VP!!!(URJS),2)&_2L<O$CI?$B5>,I
M(TRJXZ'G,_#K)-6M\*OJ3_)7[-3&9'W4/55ID5R](]=;R.']O3LMMJWU8K7I
MZOB?K1^T$'&L2C=WTYU\JF+<0RV#[7]YK0ON$+_C]G'P?^E^2_'_ .NIOSZW
MKA^MA9'_ ,);?\E%1*TG.N=^97!7,]58AVOY/U_MU=UURG[A7T:PO+=O:',D
MC$LFS8<^'R;%MJF4D*S$'K[CXOB.V5AHI'<W*"0(K&/<X@4$5ROU&XCA%ABJ
M4)O6.D+<]&M*E(<0%1F2%I()2J!*52F=8G6KFWN;BU)+#F3-[(920>1(*2)&
MX&.)J#<CQJZP.P,22R]O\6DF(:#:1HZSS4XA1_$2(V0)""P@0B[<A\:S;'\&
MZ*Q@YQQ2^7B=9;0[)7%DZI_#F'+BS7$-MA;CS"LLJ"TI024 I)#FZ%0K+ )R
M;#\70ZE+=RYD>25',HY4+&D$3N)Y;N1'#M:>Y@SAM-7(*4+FYJO&]BHU6N5K
MFKYKR>U[7,<WR<QR=+D145$PE;:VR4K2I"DDA25 A0(T((.H@Z'30Z;ZR-MQ
M"P"C*H$2%)*3.[EP)&@).G#C60FEO./MG:4#$3R,SX7+ESY>A5Y?'\W+DBIY
M:Z554HF9!$:\ !ST&O+YN-1#N.8@:.>)"K.<8#Q1U545R$(G2UJJWT*G/T^C
MT>CEJLP)6#P$3K&D_?[ZBRN"4@ZYN G?,;I[?(>RJW0[Z&'$\DJ2<U-[HUM7
M&*9O4L4CFH>2UJN3R56/5S>7-41$^)$1+PI/2(5ND&1/60-3KPW;B-T58A0#
M:TF"2I(&LQ$<MPC7GU$U+N(RX_N."-#1B258R.)5=_&<WR>7FJ]3E7S5554]
M*ZHK]EQ*1OW'B.1)U C329^&X;/B@"?AX\I!CF9F?@G7.YE@&O".+(<]Y>GM
M];555<YR<T&)J-YJJKS1$3X7SIRU2"2LS$$'2>6FI';NW3SBJQ6$@ ZDZ<QJ
M=WECF"*_'LGGB,>R38U2M:G9;' Q5:B)\%7*Y'*J^2*ODGI]"\]<:!9A*5:[
MR9W<8&NG4/@K@9HW*'(I'I//=OY]6[HG9K-ICMC7&4RNTJ]+7F%##YISZ4?U
MHS^,UJ_"5/+DO-?CU4Z//HA G734\==W(=0/*:Z]\+284ZH#6-P $=<>3?IU
M'<LLOH+^O ,QR2/$2R5\":)X'-F68Q'D+#B/$]4--:&.<ZQ@]1D"$Y%'VQD<
ME5JSNC"T,.J2HY?$;<4#&I&8)B0-\;N&^NB[EE0*5NH)$F2I(($[]"=-VGS5
MT./;.93N%,!/CQ;7':$IV1)][9%'72K&O:1CI;JJM>(LN0YP6N%"GR(P8+RF
M:8)I(AD1,MP?9;$+PLO7+:;>S+@4H.E2+A;:2DGHF\I(SCQ0IS(/S@"(F%N\
M38:SH:4M3H3$H 4@$@[R!PXC6)YS5VL2P?'L(JUJ,;KUA1"27SI*OD&E29DX
M@01R3)DJ20IY$EX(L8'6]_)@(X B:P0AL;M*SL[:P83;6K0:9220D%2B5*U4
MI2E%2BI1WDFL;==>>45NKSJ5H24D:< (2  . [9K*>U_)^O]NKJJ.4_<*^C5
M[>& :I@-ORY)_P ;Y_Q_^I<?_P >L&VF4$W[0,_W1O\ YUQ5Y;A008( S'@>
M2>8J1OP@C.O)MN/1Y45[Z>:?WPA>K4?L!_=L2_\ /8_Y:ZJW>]'D5\XK7KV4
M^;VKK8-6E.RGS>U=*4[*?-[5TI3LI\WM72E8Y;8;CURIRS*>L?.,U>FS\%']
MT0F02!%(%-0;932A8UC&.:9%[;4$J]OX.K6XLK6Z2XEYAE:G$%)<4V@N"4Y0
MH+(S!21&4A0(@01%56WG6E)4A:DY2" %$),&8(F"#Q$:S4?V.V^12%1L6YIV
MM8U&L.6!,87XTY/&R41J\DY+U(7DY57DQJ(B+B9V/,F+\*3K 5;ZB3IN=(T&
MG;$5+^&2?]GCR.3\Z*Q9^P9[HZ"RJ]@S*4CV.L:VOK'B-9C:1'K$).DR2+$B
ME1%')0,<IS">YHCQ7(A%N[39=MAY+CUP74H(4&TH* HC@LE:M)&H"?&!(D;Z
MMWL36XE24-A&:05%68P>0 2 >O7?N$340YK@.98N6RA0L%G3\7#>V]A2+B4<
M-A#A54ZPD3H=?"I("^Z->R%',(!8[:P40)1$9"<<"-,Z,Q'!+Q-W</L6X4PM
M94@,A! 2J3'1@A0RZ@@)R[M\BKBVOF@TVVXX0M(@E0)&AYDQNZP=P G=B-=9
M5AC,%/(^OLT<T<B'.$6)-&BM:YH5!)8,_6YCF*C$'\)7)THO-%6!<M[EM106
M7$J) "2VO,23P20#,]7/?K4@E]I2<P<;C?.9.@Z]8CKX<ZE>HQ?([HPHN.U,
MI@'(UQK&XCS:JK$-S'$1_BSPW$EN=TM:@J\$LJ/*)QFB Y3MO;3!,1O%@%E;
M""-77TJ;2!$B 4YE3R2DZ[RD&:HO7UNT"0L.$Z96RE1W\8,"-)UW@U)]3LPX
MY$-EEMXH;4:UE71OD08S^3E5ZS+%W1/D(]J,Z61&UJB7N(\DA'-5N366R]LR
M<]VX;E7!"9;;'E(.=1X;TCJU@1CV)NKT:2&A[;V2B->>@\L$Z SOJ4*S#,7I
MAB'68_3Q.RU6L*."!9+NK^.\LL@WRCE(OF4QC$*5RJXCW.55UD35M;L)"66&
MFP! R(2#'60))/$DDGB:CU.+625K4HG>5*)^<UD793YO:NJ]=*=E/F]JZ4IV
M4^;VKI2IWX9!(W?G;1>2>5Z3XU_P9/\ 7J"VF_T#B7_D#_FMU58_*H\I^8UL
MNXQ&H_:,:+Z/?92KZ$7_ ,VM/B76M=D#&+__ .J]S]LWRBKRYGH])G,-V_C6
MK+L-^;_(;]FMHYC]RKZ56'C_ *WIK\=&&]KF/1KF/16O8X;%:]JHJ*US514<
MU4545%145%\TTS2"" 0>!*C^^GC[_&D;CKI5:]Q=ETDY*'+,8I8TM);49<5$
M;P$%ZS&N1P[.*TJ1(SE.CC-L5-)?(>1H"B:1%,FL<QG"7;I27K,-A<%+B%>(
M% $95 B!F@2>9C29-2EE>):A#P\4&053V \!NT\O/6-I-U%C!41:&6"7'.6&
M6&\7;DAE1B*(T<PT5>EXB,<QZ(JM16JK7*U476$O,/,/+:=!0MM1"B9(!UU!
M,RD@;]=8!YU/I>0I"5)25(($$ R=-W/,.(.H.G"OZ%>V)59T8Y)1BIY(H>I5
M3RY+S<[DGKY^GXUU3*$[RM)$<").G "3VBJF<F#D,::E.G+4B/5U5W(Y+R(K
MRP&PWJBHPAE&-6/Y>2ITJJM<B\OA>7HY<_1JF0."IX;B-#/:-3I7(5O\4 GR
M;N.\'?RDC=H#6&V "B)+62.$H)9%65+$P+YGPDZ>^CU8[K<)G)6]7/\ BM;R
M5$Y:A\>MKMW!\9?P6RL+C'TX7?KP88@RWWNO%6[-T8:+EQ02I+ NPP'#TB2&
MP0"*-JAU =40RIQL.J22E63,,Y@'>E.H2)F(&L1C]+CN.TV238E;;6UOC8@#
MF0_?$<TN>.65G.S?XJ1)*TT&09D8D6.^*(D8H9!D*5LH88ND.XEL5MFK [[&
M>[7LYLX_MO<8\]<V5R;3#L2O&+)#-L&5]_,I<::*GFUK:9M5%%OE4I+BNEBI
M&_NK93H;P]QU-LED!045)"EA1!)28$D&9CJF0:Z(+W@KK69!8AO&Y0X0&H_I
M<YBMLWHJN5/)'=]KFIS3S8B_$C7^DE02$*!@,DD 3H @)TW2 D  Z<QOJ$22
M$J@ YG4B-((A1(UTF.9F=YWUS-N,:,.?D.0+)E!G7TV*>QAA.P@FF@0(]:%P
MVL$)6H\49A2H]"$=((9SC.9VAB@&, L,.QS&\>MRZ;W:!C"6;W/"6THP=NZ;
MM.B2#(41>/*65 9B00 !EJJVMQQM#:S(;S 1OE>0K"O(4 @SO)(B35@\0O(N
M)S)$?(Q)*IIK>Y#&Y'^-@27%(\J(57/8: 9I.;0*-I(9&*T+R1B,!%\&?A(?
M@;X[W0,93M5W(,>PC9K&,3O+BXVCPK'B^,&?<> 7W]AJK.PNW[=];R5+?MEH
M6PI;JWFW&R2V<LPC:#O-"F+T+<:0D!E34%:2#"@O,4YA$%*@0=X(KJ<RO*6V
MLWRJ*2ZOB/C#"^''B%7NG8\JNEF,C&=PQ!O&+DYBHP4<+$5R<^C=GX*_<3VK
M[B.PF)X)MIM):;1X_B^..8L\,-5<>!<-83:VUFQ;6#=VVPX7'4,*?O7S;L!Y
M;K+(04VW3/QF-8BUB=TAU@.-MH:Z/QDD+69"I44D@ 'Q=292=XJ+[0GCFBKB
M3S]8G]44S@/&X)7)T\V.<B)YIY+Y*UW-R+Y>GU$@Y97H0--#&@RJC0F(*4\8
MD B#K4*N%2F52= #,$;O)&\[^NL=K,)RV\NR4-/"D9"5PE<>21/ PJUAFKVY
M$VQ5C@!$Y>M&#Y/.5S%:$)581FI*RM';\Q;ME.50"UR"EN8(*QN\9(E'%0U&
M@ULGWD,>S),S )@JCD#$1$SQGR&KY[<8)#P##:;&8S1=^+'8:UD"1'-FW$E.
M]9RD>X;"/"^60C8B&3NBALC <O(*<]@6K*;5AME,$H2,R@",RX 6K0B,Q$B)
M@0!I6/.N*=65P1)41O)@F0)ZA D?OK..PWYO\AOV:N,Q^Y5]*J?C_K>FMT6^
M*=6S^Y">O$;E/_=7ZTU@9C&,-._^V,?YQ4D]^2<_9-:2?#KZD]B?;K=V<<C\
M8U$Y?UE=M/#KZD]B?;IG'(_&-,OZRNVGAU]2>Q/MTSCD?C&F7]97;3PZ^I/8
MGVZ9QR/QC3+^LKMK&LKQ&'E=06MDJ@#L(.5734&CWP)X5YAD-;UM5PW)U!E"
M:\:R(I3@[C%(CVV5_:MW]LY;.>*%CQ5^R+:P92L;CHK4C-J"1(FJ]N\JW>0Z
MG7*?&!,%2>*9&FH)U(,<-YF*4VRS3M$:2=2* *^4**68^18B:1.;$EF!$'7%
M(-%5J*R4QSW(%Y@-<LD>'JV4N<CI%RR7!/1I <"5QNSJ/Y/CH$N ::U/>&VR
MI +*PC_6:B=1KE$'21SW=>['+"+!HF^'MJLN-D:U',]T^T,,A>IK>89XBG@R
MW*Y[&O[,HKV/(QI&L>]K5QZYPZ_LU9;AAR-84D9F^0A:<PXZ#0\]((DV;RT>
M$H=2(WI4<B@8Y*U[)TT)J(K>%(S":VNQ&*^\MG'078@.4D>,TJHC9$^:-KXL
M"(/R>\\MXQHBHUO6]S!OJ65G=73J6VV5JD@9BDI0C]M920D0)(C4=9UH7=TR
MTA2RXDQJ E0),"- )[=U21+VW?@>/X##E&ADN!Q,BC7CX+'N!-E3K);YBLDE
M& YQ59)<R%'+( -Q8Y!JT,5C&QTGL?LDVF'X<DE)=:4XTM0D9LX4Z==%&%R!
MNWC0#2K#"WE/75SH0E0SA*C,1"!/:)ZR3RGH$<]L^N$H6F$6:9SPN:QZ$4<"
M802*U_ER:]K"M5$5442>2)S5,14$E,$C>)!W$C01IKF$R#J>J*G$D@Y=\DR(
MX]4#=N[. KM11GNC21N$]@>^9PV#8@QB5SNLB(QJ(B*XBN>Y4Y<W/55Y^G2$
MI 2E*4I2- D #GN&GE@[Y/57?54Y@=_'>8/'4G[[S.F/S58&% G&5WAA641C
M^XURJGB3^YX7HB-5>0Y$@92$=TL&%I"$=TM54X46P!GRZ+; 41IF*@$[XUDC
ME//37H 8$$Z$R (!2 0K-NW1.O"378&QZTR$364=#:6KSNZ!R 1G#KU>CU8]
M7V<E0U[&C>CD)U2.I%:YB-5Z=*R=GAM]=%*F;=Q25'1TI*6X)@G.KQ"!O.7,
M>&I&6K6ZNK9I*LSB<PUA)!/8#H=1J8&NIX5E^.<.33F=)SJ< XFD3MTM#(,D
M8X>A4<RQLS1H<QR/>[S! '&<SMHJ3BM(YC,LL=FVVRE=ZYTQ!D--E01P/CJ(
M2HF9]B$1S.M0+^)K7HRG*#^<K?'4!(^"K(5E+!IJZ#4U<0,*NK8H(4&(!B-%
M'BQAM$$3$5RKR8QJ)U.57.7FY[G.557*D9&TI0A.5*0$I2%$ )&@ Z@-/GJ*
M4"HE14J29.O&N=X=?4GL3[==LXY'XQKC+^LKMK=AL,G3LWMRGJQB GL1^M)X
M]_IG$O\ >G/GJ69_)-_LBM$NX %7/,V7DG_*[)/2B<__ !S-]/GK>&'J4+"R
M$_[);<!^A1U5&+ S*U/LCQ/,]=8CX=?4GL3[=7>=7/T#U5U@=?:?73PZ^I/8
MGVZ9U<_0/52!U]I]=?O85/1R3_L3[=,Q.\S\ ]5,HZ^T^NL,M-ML.N)Q+2=2
MM]T#<O$284RQJW2G-\FEEMJYT)DL[6HC&GDL,9&-0:/1B(U(R[PC#+YP/75C
M;O.P07"C*M0/ME(*<Q' F2.!JX:NKEE(0T\XA _-"I&^= 4D@;Y\;6L%N]HY
M4*.LG#;NX:X*BYX]<3F6M?,"BM:84>PL'>ZD26YG649Y=G,C.>Q I' A.\/&
ML4V+L'V7%X<E5M<@9FVRZ3;K4)\516E:T9MX5F4D*$%)22!)VN-W3:T"X676
MBH!1CQTIYR(!B/:SUGC&%KM'G]X5((:J-4CD*Y%M9US#DQ(*]M5<<D*&Z1,E
M.1$<@HP1C:4W;8:3$"KY(<>MMBL6+B$OKMF6B1TC@=*UA.;4)2E)S*B2 HI$
MQ.A)-\]C5JI*LB'BN#$I2!,0"25;A(W Z?K5 ?$+M7B^T]IAWO<22"'=8WET
MZ\+.L;&?*N;C&ST/9L9(Y)RU\8[V9"1@V5L:$/I8@&A9&C1A#OMJ,,M,.:P\
M6K01F+K2U$DK7E"%9UJ)()DDD  2=!&ZTPY]QY;Y<43 2H#@F<PT'#A/,#7<
M*CC"R9&>=54M!5VE[?S FD5]?7L1YG1FJ,AI$AY'AC1(D?O@&>;+*"*)2B8\
MK7D:CL5M[&XQ!X,6K2G72)*00(2" 5*42$I3.A)((D3I)$BNX;MT9W%$#>-Y
M)(X <21KJ8/EJY6-</\ F%B!MEF.3MH;$@6+&KJ0<6V+7O(B.?XF;-%X)TAB
M+VWBB1Y >MJO'8&$K6+F-EL."A1Q"Y*%DC(BT*5 )@$EQ;K9!5FTRI24@"<R
MIA,:[C2B06$:"9Z4$&=P@ Q$:]<P>-2;'V+J&QD#.RW-YYU:U"2G6-1%7F@V
M,>P((=, 0PJ]KRL:]#&8IGL=((QHT9+M[&8(@ *;?<(_.6^4D[I$-AM)!(G4
M$C<#&E6JL7OE3^,2 > 0-_43J-.O^>:8]MKAN+/<:FH(8ICSOD/LYG<M+=Q'
MJ14YVUD658H,2&*, 6R$%'$]PPL8QSD6?L\/LL/0$6ENVT 2<V7,X2=\NK*G
M#U2K0: 0!5D\^\^HJ=6I1F0)@#R)   [9WG6LT["\N7ER]7).7_?J^S*Y^@>
MJJ&4<O2?77YV%^;U^A/3Z_3IG5S] ]5 E(W"/(2/WT\.OJ3V)]NF=7/T#U5S
M Z^T^NGAU]2>Q/MTSJY^@>JD#K[3ZZO/PR!Y8';IR7_E=/\ 0B<O_$U!ZN>L
M'VF)-^T3[D;_ .=<5<LI\4ZJ'C'B>0YS4B\? ^O)=NUY+Y4=VGH7_K\/U+JR
MV",6V(Z'\NQQ(_U:^5=KL@*1.GBG?Y?W?OJ@/AT]2^Q?MUGV<<C\8U:2.8[1
M3PZ>I?8OVZ9QR/QC21S':*>'3U+[%^W3..1^,:2.8[13PZ>I?8OVZ9QR/QC2
M1S':*>'3U+[%^W3..1^,:2.8[13PZ>I?8OVZ9QR/QC21S':*>'3U+[%^W3..
M1^,:2.8[13PZ>I?8OVZ9QR/QC21S':*>'3U+[%^W3..1^,:2.8[13PZ>I?8O
MVZ9QR/QC21S':*>'3U+[%^W3..1^,:2.8[13PZ>I?8OVZ9QR/QC21S':*>'3
MU+[%^W3..1^,:2.8[13PZ>I?8OVZ9QR/QC21S':*>'3U+[%^W3..1^,:2.8[
M14X\-84;OGMPO)?*\>OH7_!T[Y]0>TBIP/$A!_(#\XG_ %B.!JJR074:@^-P
M/4?FWFMD'%\WJVE&G_M73>G_ /#6?JUKC9$QBQ/_ (5[E[9OG%7S_L!P\8<N
M1YUJ\[*?-[5UL[,/N4_2JT@\SZ/53LI\WM73,/N4_2I!YGT>JG9_Q?6O/VI^
MZ\O4FF<?<I^E7!3.\D]DCR:5A>3[=8QE?6>Q@M!9JQK17=>Y8EL%1HJ!=XH;
M5\2T//FR/-9(BJG-KPJQSD6TN;.TO!#[22HZ!T! <3I&BYG0<#(C2(-5FGG6
M2"A:C!S!*E>+/$:Z#-N)&O*H@#BF4UO*NEXS;6I!,Z5M($JI6#)1"E$A!-DV
M4>4)SV"8=1F"QPV'8U>IZ/:S!WMGL30XL,M(=:S*"5)<:!(F4DA:D$$@Z@")
MT!B360M8I:E"<ZG$*RRI.3-"H.@5(!$[N0B=YC%+8+8*N;,Q7)4(12]+'4-H
M55<)_2[I(&*8;V]?DA&.49$Y/$YXU:];%>%8DV<J[2X!U/BM9Q _605I^&1K
MPJKWY9D2'D[N)2D_")T/9UUBY(N1RH9'UV!9-*BR$(T+VTT\;D1KGB<G06*T
MB=)&/;S>Q.:)S1%145:R<(Q!9"N]GB!S0J#N(]E&HUX?#NJF;VWW9VSIO)!
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M.\U1JXD[LW=I4E+:VG4&<RRH(R\02A1*CK \3-/5K4PC%6B"5I6E8W #-/\
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MK:X$F=-D$7R'&B1S'*[DT8W.5$UJO"G$-8E9..+2AM%RTI:UD)2E(4)*E&
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8^:T_V1'$_IG^<U<LCQ3J1XQY<AS!K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g197729g30q34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g30q34.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0H""@,!$0 "$0$#$0'_Q  >  $
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M^IV7,D+<DRWWI#CCJNK\O,RL_(LRLR^W)R+F[K+KG+NQ^[9]E'LJKI5&E4
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MMZ/R<]<Z8E;FV6IQ87<Z['EU^4[K7JF!:P<TM69BM[]K#9;4S6OFQ&MZZO\
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MR*>[7<[L[=N] L? &_)T-#9 WK>A[325H_6G\4_<'\EOY@O%?-Q_5F_W]?\
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M?M]/7>9LXWCK<:O"MP,*S#J*&K$LQ:'QJC7OX9KH:LU(4V>SM0=NSVZW,=S
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M!Y/^0%8\8N(W?L-G^5(371VV:^%4]IEZRVTCZQ:Y7H^]>KO^OD5-JG/,H=7
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M1# @*.;U^:C6ERY\I24ID$BDOVZ=GDI>T)5)E/>JM^B&FDM1VF66_272?2/
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M^U>Y3\ J1HN^< ?I77C/I7_X^/7?D.M[/\Y]._2*UN(Z4!^O#Y;J?N%EO*5
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MC6M.G^)=,UO:FVU*4E:E(1M2T:VE"M[3K>U(UO:MZ2K?XIUM6]ZUO6M[WO\
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MXD-P(5V-OPT"K[HK!6#[[OJ!V6\*%\@'14=TAEXB]^.WWOE.J-C^(#W6[S"
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M4V+15O+W;1]3*@=JGUBVFH"4B!=L9C3)5;9F32HEN,>C"2,&2HHK@V*64 Z
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MS/4_)8H/2O&XF6CX^063,1<?-1JFN469P7$R.TIBX?,)9\,\A7B+2!=EO\(
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MF[B/1SH?F^N<]6^$>9R\:[C>GL1V_P!'=>UGPKS23K:\A=P8.]K<=:-P8(K
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MR-I5K2M<-SW$<=U/QMO#\[C_ #_'7O39;C&V_'#/18MM3?%Q+:+U[+%5M+8
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MU?X%_L%9_B1U_P#J!CYF_P#6'^"_W1\K1^K_ +3_ .*/NK_ O]@K/\2.O_U
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M_P#%'W5_@7^P5G^)'7_Z@8^9O_6'^"_W1\K1^K_M/_BC[J_P+_8*S_$CK_\
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M9NH;D722M/=$W[K\XJU:1U--2Z^X,A?ES)^L((+,Q%0XOTTCZB3IMGY#OO\
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MGR]5+%^9VGGY\Y5)>@!@K-@Q8*(LJ7,@4=JL4)9&8'N0G7E=, ?(! 8, ?(
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MI+FEL)C;&2&.&$#VQD8<6]E '8A[7+IL$_#9M;[1W:(\#0<,/ AJ%8[[[!M
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-$8B,1&(C$1B(Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g197729g31l85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g31l85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X<?":'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/G!A9V4P,#=B/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @
M(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*
M(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I
M;&4@3F%M93H@(" @(" @(" @(" @("!P86=E,# W8BYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,#8M2F%N+3(P,C$@,#8Z-3DZ-3<F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,#4M2F%N+3(P,C$@,C$Z,CDZ-3<F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($QI;F4@0VAA<G0F
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($-A;&EB
M<FDM0F]L9"8C>$$[(" @(" @(" @($-A;&EB<FDF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($--64LF(WA!.R @(" @(" @("!";&%C:R8C>$$[)B-X
M03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A
M1&%T93XR,#(Q+3 Q+3 V5# W.C P.C0U*S U.C,P/"]X;7 Z365T861A=&%$
M871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP,2TP-E0P-SHP
M,#HT-2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E
M871E1&%T93XR,#(Q+3 Q+3 V5# W.C P.C0T*S U.C,P/"]X;7 Z0W)E871E
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R
M871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XY,CPO
M>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O
M<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%L9T-704%$+S=1
M07-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%L9T%!04%%
M028C>$$[05%#5T%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E1
M04)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!
M341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF
M2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF+SA!04519T%8045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!
M445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%1
M14%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G
M8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD
M55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4
M,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+
M5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"
M0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*
M1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&
M53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L
M6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ
M;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O
M84%!=T1!44%#15%-4D%$.$$W+V]N;G1D63$R-C!Y,G-'.4\P;28C>$$[:V=N
M;DTX2$Y415-054U*64]9,DDR6D]8559!,V]A5FMT,TY*0F%45%)X1V532TYN
M4T9F=$]60DE5934V649E65)F;6XU,V1R468T5B8C>$$[;4EN0CE5;4MD94I"
M*T@Y;'1P;2]D;V9%8VIS85I+;&5O=69J:C(O84\O.$%S5&M66#1Q>$18=DU(
M-6DR>E1P<%!L5T<Y5DI1<T5Z828C>$$[:$=N<5)C=T]2:EI%2VMP+VQB93E.
M>G-Q:G%U<&9M9&,V5DQ*<"MJ439B<45,<#9-6G5O<FM4<DM':6%T63!#0TEU
M<W989FI4=5)J<R8C>$$[<5%W87 K96)Z6$)M,'E#2D98,$EH1UEJ56]Z<W,O
M2FYP>6-!22]W.%1514)C3WEP;C59,6(X,7!F36M#87AP:U-A1F1";75:>7%2
M4R8C>$$[44UL=79&630P;FY01G!25#1M871A+T0P=T=K4%%-0UA9<3=&6%EQ
M-T9867$W1EA9<3=&5TTV+RM9,VQB4714:S!Z55HS4SAJ:%,T328C>$$[87AS
M,55K6FM&0T\T2S<T859D-68O34113F1M:&ET0F-2+U=,95,W:&MN:&%/3F\T
M6D)(2E-1,55L4WDQ,S<K3F-A5C%V*UI(:U,T+R8C>$$[=61B=%A02&Q4;E$P
M04I*;U)8;TLO9#1J1VQ74B]M8C5$9$,O-EIG46-P:T%C<VA*=&I34V=90V](
M66IR,GAP57@P5'I8-64Q,E<U:28C>$$[,&TY4SAE,$546$AP.'%+2C U>#=K
M04=O-C V2%DP3T-L5&)&6%EQ-T9867$W1EA9<3=&571T=&5S8FI8<G92;S4W
M9#=Q>FEJ;6QI4R8C>$$[64Y-;VM*2'AX52M';%!(=5!(1E5Y>%8U,6]K8U@O
M2S4O341X<$M7*W)O2G!#:W=I1&96-U@T439V-D)02&HY<&5F.$%S85I,;V@V
M3"8C>$$[:U5S9&HO35!Y531H2S9V05!R0VAO95)+;&QB;U)Y03)P.%(X1F]X
M,DYC3DMY0B]T4B\V,R]'<'=+=7A6:65V5U@U;WI'9&1',5138B8C>$$[84EY
M9S)X;'1*+U9724]$>&1Z3DMH4$19:U(W.75054A:0T$X>&%&*V%E<&%73&5,
M5V)#,75L;58T-3='2S5T0T5%8VET>DQ45#AX>28C>$$[6D1X;T]N6$A:56\X
M>&549GI2=F\W1#9L<2]O0S-T4DA.1D1E,V-$1FQ7;$=K0F-Z4T9J>4UR57%"
M5&EU-5DR17!R;W5I+VU&6G!R128C>$$[3V]Y3'%,6#%V3#E7;$8Y3VE*3VI/
M67=L1E=305-2>DI(*S<V96M8*S K1%I#;'!N;'(X>&)C,T0O<%(T-5IB3WET
M,&MM=6UU>6LP5"8C>$$[4FDT;&IJ:VE-4T9O,6MQ5U9Y>D5'=EA$65-K.&QL
M*V,P=7%7;6QA,61+*V=Y5WE.<D=P44<R:6I!379+-$A,:$9+=$EQ<6Y%1'A0
M3"8C>$$[9DA:1'1','8X-393-DQQ1C)7<V].2VIJ='(K2U=)4GI80WEX;B]E
M;%5&,')T0W)P>G Q4$QW2F1L5&)Y9C5C+TU',CAX<F4V=&132B8C>$$[<#!:
M;54R-S,P,3)':5IP4%)I0U!65TM":R]F3E)Z>#,V-&MH3#!427$W1EA9<3=&
M6%EQ>"]84$E8;%A83'0W=E4W3#$W;'A%1$QZ:R8C>$$[43!G16=11&EY,$9*
M,W%/*S%E9W<R<7!:*U,Y07,Y4BMV,G-5<U5N,5E746A795E196E++T0V6$QH
M,4I.86135S9M=4YQ;&-V-51E4B8C>$$[6EE5:&%X8TQ';U)#='A/<D)22$1$
M44UR9S=X,G%+9G X5&IA2U=Y9FQ"-4)K=45N97=K6F]Z25DQ3GIC8U8Y66MV
M4F95;U!I6FIT,R8C>$$[2GAT2V0V1C54,$Q1<')M6%,T1W1Z9#AF6%@Q6DA5
M;$-X1&-86F=$.%HS*U=.<6TK0EA9<3=&6%EQ>&4K+TUV>699,U9X6E0S;V4O
M="8C>$$[-5=G*V\R-"MT6$1Y2T%31FAT>DQ*,W X44<K,UDT85<Q12M9=E!'
M<6HO8T@U9D=N=W-+<F4V-4HV4'IP85%E<$PO=V)*:E-R9CA#828C>$$[<'%F
M>&5:+TU.-7%%6G)Y,"MY+S-(5UI5.55:650V,&<O=T)A6$<Q5%119DHR:&%$
M9'I48519,G1L2$Q&2$-69VA#4T52;&UQ.'136"8C>$$[2DPW,49E;4YQ;FU"
M6&YE;#(Q:W8U=%@Y<TQ7+T9Z0D(Y82]336MS4FAL5U962' Q15EM6E4U:%%R
M4VUN169$44$U3&]R,%%I;W!K5B8C>$$[66-0>6HX:2MP2$EB2GDX4F1L2FYL
M-GEN.3A4.%@K-U8K1B]&9'-.<7DU=T]C6G!U1TY$+T%,131&6#1Q:V5Q95=:
M8C!Y16$Q<49R>B8C>$$[:T0P:&Q21E5"9V5++T)51'0Q*R],23522&](1GDV
M67HO:FU09"]9:U!N;GE:8C9H;W-6<&0K635B1TYR;%A7-79*27HX46EL44Q%
M9B8C>$$[,U9(4%!L,5!4<&=-<C9.<TUF1#%*.3=%+TYN:U!23#(S,&PW-WID
M<'1V2$99:$Q68F=12D,X45AI=F]"6&IP1#A82W178FPQ66II1B8C>$$[04Q9
M;G5G95=99$UH.'AO,VU$5'(V>'5R86%,5C4S<6I23V95:VIE-31455@T3&PP
M66QL4'!X>&=5;U1J86]$>6@U0W-)>F5W858U<R8C>$$[=')M964R=&Q",#$K
M17-D=4I)5TE,47IL*TA#07!%=TE)-71U4V-35E5R;GE$-3)S.5)T6#%R>DUB
M>GEJ85<V2%9N=6)I-%9P0VMO:R8C>$$[;41217E++W%F6D97,D=Y,#)"8E93
M,&IY0C5M=')#5T\Y.'IW,UAL06%.1D99,VIZ>6DR258T-59A4S-:+U,Y27AP
M=TI%;CDR9G5B5B8C>$$[2&51=DME;C)F;75/+U18.4QU<FA9-7!O8E!4:79Q
M3F)Z32]"1D%K67)B4FE18T5!24A&9FEX2E8V<&M5=7A6,DMU>%8R2W5X5C)+
M=28C>$$[>%8R2W5X5GA.0EA&5TU89C5M95-,64MV-E13-'586C!J<W)66DQI
M-5IK2E5Q24EL850W47!5:6U';%$S*TEV4&5R8F%*-6985&)D<28C>$$[1F(W
M6$I05&%N96QN05AL*UA.,'AP5W8X03,K<$-V;6IZ0F5A;V@R97=T5"MJ-TUJ
M<GAA3S-0<78O<S54:F%P>C5D.' V2C5E1GEM;"8C>$$[,F1V85(S3&AY<T51
M:DY&54M!>E99=#EM=GIQ92M*2W!X9U8R2W5X5C)+=DPO3#$S8GIF;F1R:E=K
M:TYZ1DQB2#%:235:=55B=W@R,"8C>$$[3$DP6C113CA56BM*96)E2D$R175I
M2'!T=SAY45-01$@V<WEO>&II3&-E8D%60SAJ5VQ4=%A)<&58>#9T*V5N<5=Y
M>39:04ML>&1C4B8C>$$[0U9&1TEH-&XQ96IT=$HO2VQ#3CAL<W(Q0C8X-"]$
M:V$O=T1!;DEQ=GA60U0V5' X-5EY=VAI>#5-86M%;71E>'I7-FIS:E1:<C0T
M6"8C>$$[6G9Q,W<Q330X:6LO;6YY2F]V;5!41C V-CE30S-%;VUB,$-&6G%2
M=DAX2EE.=%-5.4UY=%!P35='*T-01&)84$I+6$UP2G)(-5!A4"8C>$$[<6XQ
M6G Y4W923&)1*VE*0S9Y8WE&-$M3<VES<7%&2G!'9U914U-!0U=R:S)W5$A1
M9GDK:3!+83=B5#E6=6A&9'=344]S9VAA4E,P:B8C>$$[>E)U<V=25%=/5S5N
M8F5T95E",E5$1S%5,B]+-U%4.5I1>7DO5F)I,G1,3G)50TE)67)*;S)8;E)0
M,W!B,%%#6DLP0EE$630R<DAR3"8C>$$[.&I,5WDX>#9B9E$V;SAM:S9F1D=H
M<UHT;&0U2&IL.5EN,4%554-6=#509RM,971A-TAI4E1E:V9K8F$V8G%5-W)Q
M<VMU;DY92EI7<28C>$$[4$5N,6U*:VU39%@Y5"LW64-324=H:CEV1W)X3%-F
M95A0>7IT=$@Q<CE,>39L4&4S0WEZ>F]J<$9'=G$S2FM-:VIC1G%4*RM954)#
M+R8C>$$[-4\R06Q,33A#=7A6,DMU>%8R2W5X5C)+<&1R=FU,4G1#<TI,-U9B
M=4LQ9VI6;B]E3W%-+T56-&]'235.-$%B;D=L63E"*UHK;#9J1"8C>$$[1R]L
M-U1D4S$P>6HT5W1B6F\T5F)W931U1$1#4&5J2$133%905B].1%5X.$5/;2M8
M24=&0UI79E5B<&9C2VXQ94%F.$%"3FIS;&\O;"8C>$$[,4AF02]W0TDY8C%,
M5W59<$IB=$XY5714-&8V4&%#1E0O<VDR3G%M,VQB>6AO2&QE=RMO-E!B3$)%
M5UIM96DK;WA::3-X=4%'86QA0R8C>$$[=E%B66MQ;D]"6%EQ-T9867$W1EA9
M<3=&5T1A5'!R3BMA,G1A:7-135-7-E).8T-E2&M*1VAT>3!B47%';DDT:$=(
M3C%25%5Q=%=,128C>$$[.49:=S=H15IZ5VEG:S!&5'1V<TU#<TI(-7@K4T,X
M0V5V34=N-3A0,U1%5FE(2V%P1E(K-E-J=%1S9'$T859M:FMC-'A88W-A1"]9
M;B8C>$$[07$O1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%L5W%E82]+
M*VQ&:'%E<C)D;7DQ<6LX.&%.="]K<W=9-#!R1V1:+T],>7AA5R8C>$$[1%AE
M;5$S;70X5U933$\Q=41(4FU#,3E:;WA&,S(K3&9$=V]T1TIR9C5I-FUO3VYA
M0F)A5$,S>$QC879C.#5#<#9F-E!A8SDO6G!2:B8C>$$[<VQV+T%!9#5L=CA!
M9EA03E8T>58U0S(P<$4P-DEE2RMO=G$S0D@O4%59,G%*<W9Y,3AI,F=K-&%.
M0DY,34-S='AC:')M8V=I:"]F5"8C>$$[;5-4979:<V)6:TYT8E%7,79&8E%)
M231)5D5C55DV2W%I:7%0641!<7!I<G-69&ER<U9D:7)S5F1I<G-644U'<3(X
M,G)85VUP2D,P,28C>$$[<$A(2DMI4VAP5D5P64QZ:G X4#)$,WA62%EQ.#4P
M:4M*+WIQ,75A3EI/8U9Q<V,P:&EF9U-98E9G;G%G=$9245%12TQ*56UP2V-A
M4R8C>$$[-DEE:75I3VI)-FAK645-<$91465O27E+56Q(:VIY:'E2+S!.848T
M-F-'34M%9VAI.6%K9%-X<50S-S1B5D]8*S%(+W)F.&%N07$W1B8C>$$[6%EQ
M-T9867$W1EA9<31K045K,$$S2D]+<UDQ5#AZ9DEE;5AQ,DXS<E5(,70Q3$-'
M2&Q/,W=M:$(Y1EI+3B]K;F,T85<Q3"]L655D>28C>$$[=UA33D$Q:E5W+SA!
M9%1,84<Q:&(S.5,Y83)&4&9';&$O4V8U;EAO+S!B4DY/,&Q2*S%F,VHS3&MF
M.%DW84U,+T%-;$UD;%%E;V554"8C>$$[>D,Q3V5Z:W5V3GAT26]P:$I08C98
M8D,Q2$-H0E5023EY>CED=64S=#-X<TE2;B]+<V9,.#0O,TLS3W!A>6$Q079R
M-C1D0B]Z>6IE3R8C>$$[3"]H8V)3;75L*U1V2V5L8U1P=6I75F\V9EIK:6=J
M5C8K4$U$:V9V>'15-'=+-T9867%T;&QI:6IA5U8Q:FI11FYD:49506134V5M
M2R8C>$$[=&\V3V=D1T1)=W%R2V%G:C))>%9Q4U-/3D,X:D)%6&1M66=!9DUN
M1E5V=69-,VQU,35F5V16<S13=E536$5357(P*S!W>'!5:6HO3B8C>$$[<GE!
M.%%C871'>FMU0D)$5S5L*T)I=&5&=#9X;V%62&E..$Y&8EAT*UE3>E9';2M8
M=&%V=V$K;DM,33)S5&5"-3-J5R]W;GAP:E-,4R8C>$$[-C<X.2MA44-P,#-3
M=$E06CE5,6%+=GDY2S)387 O,F54:FI*-4%T3U15-#1F5DM).359+V]V;41Z
M6F1Z86]8.'<R3FU7=6EW3VPV4B8C>$$[9#-P665M9RLP,T5!06HY<%15,4YA
M57E:=U-(5#=1,%(W47A3=6E46&1'4BLT2G0Y4S%3.&]B>EA03D8P=TY/3G)A
M4F%C;$]V5#!);B8C>$$[*VYN:V9$.'@X,G=A;TAL1V8K;$DK*VUV.$AA4F1$
M+U-F3&UT87$U<%=85DY33$$Q<#%2-W1H5&(K5$1W1"MC4'0O56HX>$TX<V-V
M;B8C>$$[2"]I:WDX;657-V)3+TUM;U17,VPK,#!70G)72TM)=T=*<$-!-TUW
M67@K2DY4+W-F055%=TM&1S)72V-Z36E594=/,6)H;3)63U,X-R8C>$$[,&I4
M6C,O3TA69%1K=#%T<5<U:$(K<WAS.'%C3&-*23!!;&M906Q7<%-.2V1Y4V%:
M3&]R,$=D1V5'4D5)1$UP0VLQ;T-2458T;%0Y>"8C>$$[>4MV368K5E(K63)L
M=$I7.'EY4FU"85!(1TIU2DHR2$=S=7EW;CDU14]Z13ES;&%V5&Y(>'@W+W1(
M8B]9;DEQ=GA62UIV3F9L-D)P,28C>$$[;G95:&$S8WAY3$E'43AL3D1W1$%&
M=T0S5V]Y:4]P>$5K0U5B:G-D*U1)=U!C:T8Y*V-8:T<P1%9V6G S6#EI1S!U
M6"]!3T<Y34HO=R8C>$$[,EA73SEH855T*V9(;&E5;$Q',FML;#=F5V)R5')*
M3R]5,T9Y:D1P+TQK*T9E24I4+W=!<G(Q:30Q835T;WAO96PR36%+66)Y.79J
M8R8C>$$[23<O='%J,F=:2E=!2S%64T]0:G9J45<P4B]J1T,Y62]P2'HK,&-B
M:C0W8E).3F50:C=#85=/.&M(>C)X<GE5;%DX=C534TMJ-F@K;28C>$$[9DU5
M>6UQ3F9W871D5C<W4GE2<D)4-4QH;W-43TDV<3A8-6EE4DY+,6DQ:C!V>6QC
M4D%2<T5V2610:G1(:C5F<TM*4D-E3&-46&-$8B8C>$$[=FIW1FEC.$(Q0V)Y
M+VUZ1W=(,6)26FA506<S;#=P;' Q.6UU;6(O:&-)=WE042]*:$Q6-&\X-5)(
M>$-(+W=#5F]A=DM3:V1H<$9S928C>$$[9VMU9&%I249E-49V1$Y7;F5J9F9K
M=D%N,T@U341R.$@X*T@K;4-6-GHU,S@Y1S4P,#(Y,6]K84YC:C%K9TXO3T]"
M0D$Y4VE1:W%#4B8C>$$[,$<U<#)Q0RM%5FQR8UER9C5753!0;5AZ,TQ213%#
M>DEA9TUT=F]7<4U2.&I,3W%'=G5A6D5W<FU14&E&1W)I5%%%:B]!2FMV,4Q*
M3B8C>$$[42]-5CEO.55K3DLO,V5K5SA0.$%W6#%M+W=#;C!:56-U26,U=TAX
M6FY,4'!J;69G4#!K2E U:&HO3D<V,'AL1W-.>4UK6D5::3 Q4"8C>$$[<W-$
M*WA*3V4R+WAD4'5Y:69A3VIX-WIZ44$Y-GDO36ME:D9++TUG9G)42F)$.'<U
M,59*+TTO0DM62$,W<TE31%1V-F5N369O,WE0."8C>$$[<39$+T%&84@K;6HO
M04U5>3A,5B\V;5!M9BM)9"]H8GI23'9.-79M57-F:7!Q44EP6"]I<3-T+W<T
M-% U6#!0*W%W+S P9C%S:&<Q6"8C>$$[5TE(*VU0-D%O6#-K3%4W;7EU65IV
M3GIY<DY%,%II:W8W-6Q)6E-#0T5U155G,3-":F(V96U0.$%,3V='-7EW+S X
M5TTY2G)$>6]F-28C>$$[<W8Q+V]D6B]L6G!!<S=E2S0Q:3)L-%)O:D(U3#)3
M9T%O479/*T-G9C@X=U X;D0O04,Q;U1U36M0.5!&161&<7AZ4"MW4#A!>%@V
M128C>$$[5D8K5G9K-4=$1V)3,TE.950R:T5R8F1Q>E-3:6YS4E1"+TQ/:2\Q
M5$@O>7-J*W1S+THV:GHO,&E/5'E.-5EG03E+-S V0VQA1T14.28C>$$[3E9H
M561J-E1!9F1G4&)E:4@K57@O=T-N2#8Q+TE:>C%K4#A!3D@V;"]L<GEX<$=M
M85=T:VUT6$%H1'4U9W-I=')(5C)*2D-W>'!)0R8C>$$[82]Z9DMM4FHW46%0
M2G9#550X0U0X=C)-261L6F]I<'EM9FE".3,V,#$O=R\U5&-5;',U-S@Y>F,O
M5W)M<#AF,WA962]Y,T%N,&I)9B8C>$$[-G5/9C,X2410*U-O5E5G1"]7;'AF
M95-M1G!"<'1O04Q(4B]2<# Y2T=+269R5$EY-U1M95=,3$PO4VHO04A59S-1
M,&M)8VI#4'4O628C>$$[1E<S=6)W4$U2<'AJ<3E347E+5S)'-3,S4'9L1TA8
M-G%:;&5#46\W97%0-B]U,F)4:'AJ;$EB*U-T.5IV>C!S-F8V,&EJ.59C=2]-
M-B8C>$$[:G!I*V,T+V]T2&AW+VYF63<V>'%0+TQ)=B]),&8X,#0O;4Y4+W%1
M+S O.$%X,65$2"]/*WAU,FQV,W5*1G5)5FEJ0V=O5F)M0W@V-R8C>$$[.%9X
M,'5B57EY>4=706A%0595=4QF<B]$2#AD+U%:27=%4G=M>BM03D9:<U=L-4AB
M=UA"+S5Y1798<TQQ,T1',U)T5&EE1U0Q9E)7,28C>$$[:4%J4BM0<&QU8F\O
M3&Q8:65.841I6F1%9%AR8D5H4U%+:T199C=68VEL-6-V-7 K8VYK=$)(-5EK
M:VIN2#<Q,5,T;W),,&]41W4P<B8C>$$[,6E3;S)98VIT:W%6-F4U*T]08CEO
M-R\W135&5BM+;T-,44Y(:6ML:T9Q:DY->&1Z2E=106LQ*T5/5T-$,E=G>D5/
M9S U2DIH0S5C+R8C>$$[4TXR>GA:9#56=C!:<'8X07EY42\X:3 O<&Q8.&LV
M5"]!1DQ(+W!)+W%4*UEY9GIJ.'EP=&]M:W-A;3%3=G-+9G%Y4#AJ85 O049,
M2"8C>$$[+W!1;CAX:R]N2#5Q6CAU-DM73$<Q53$W1714-W$U0U!9;6MJ27E'
M34%N.&-U4U1Q8VA&171R-64P561,4U V450K=DQF-4LP,SAW328C>$$[9DAN
M,W1J461(2%,P:D@P62]W06QA8BM912M04'9A3V=A4C9I=CE854925&E+9T@U
M:DM:9&@V57I%*T1C93EK3E9K<7)60F\R;&IP8B8C>$$[25!V>3,K4V1.+TU$
M2#AX4'9B1VLV8T]K0R]J+T%&>"]K;E1F>D%V-6I*,W)8,%A3,TML<F14>$Y2
M=69X,S-Y=DHR2G!*,7A9=V%..28C>$$[9G=743%74616-#!R5$(P=$EV<%)4
M*W-:64]X.4=0.$%*62\Y2U Q351Q36XX-"].971H67%+3&)2041P4D8O<&PP
M97HY4$5536-"+R8C>$$[;6HY5$4U<#DU*V$U<E,Q655A1D-$,4)59E!W>6-T
M2FEK2TU):V4T24=3439L9C959CAG*S1:8C1C931-94EU.4]0.$%K2#-$2'<T
M.28C>$$[=UAI3%11=W-P5F\Q2VM524E"0D=2;&AH245'24E0:VM3239U5T=&
M5D-R1V]50V=!06]":&IH:$5504%"-4M:13E7+U1J+VM(,T1$-"8C>$$[8V4T
M231I,D519$9!*U%W:4E(24Q:8VE):3A554MV9T)18B],1T5)>$921D)34V5B
M95-1-T9867$W1EA9<3=&6%EQ.#@P;3,Q;5 X028C>$$[3VY7<$=I6DY);G,P
M94]53$MS8VMY>'=)=U!*;&ID=T%.,$)O2T$P3U,V2SE$>4MO4%4Y63!Z4V]9
M-712=55T67!:0D1'.&AO0S=!<R8C>$$[0B]W2VMN=T%*-EEQ:6XK,4@O<F8X
M86Y&5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,B8C>$$[2W5X5C)+=7A6,DMU>%8R2W5X5FHK;2M2.4@P,WI2
M9659-U(U:&4S-DUL,4A)-&Q1.&Y$,55Y0G!%,R]:5G=V='-+1S%:0F=63&1E
M."8C>$$[=394<G1T1&)A;D5:;UE*4E!';UIK*TQG,%IQ5DEQ1VIK6E-0031Q
M;4Q)<E4U0W1/;4MT96Q(-&9R>%9)=DQV;6%Y,7DK,6$P:'0S:"8C>$$[9E-R
M:')E4FY)26-R2DI&555/,WA1<V%(.6MQ92M%<6YV<%(K2#8X0W4Y2U!W+UAI
M<5-76&UB5')Z>E9Q4&QY3T=28FY464E:-5IM,B8C>$$[4G972BM&3S4T:FI5
M.4MM;F)#<60K;$@T9G)W2S<P;R]$.65+<%9D-G%B9GI"<"MK3&$K<70Y2$Y-
M,#9Y8GA*04)Y6FMP.6YK-DQ7=B8C>$$[5G-+<'(V569H*W9!<G93:CA0,31Q
M>%!Z;C4Y,#=Y=F-P8C-&;S@W>3)Z6$UB0U)%53A:-%E#<E902F8W+VQY27!1
M8E9046=+>6$P:R8C>$$[9W5R4T<U4D=62C0Q:U98,EE"=T=!658R3RM"5F(P
M;R]$.65+<$(U=#@P5UAL=4,P;'5,8WER9'E00VI",5%+>7=V2T]65'E03# K
M4"8C>$$[=W%F,4%K2VU/:5@Y=G$R:E=/<5)2;4]/*W0T<FA9,DY755-O1S1K
M:F%Q,6]C5E(S<%(K2#8X0W!6-6PQ=3 P2%12<44X2FQI.65#0B8C>$$[=4QQ
M;D@Q-59J-6MU>3=,>7)T=FA#=3AU87%D63 Y-W@W6#9S1FYM9U%#45-Q-&=C
M>&U21T%7<6QL3DYV9D5Q;79P4BM(-CA#;TA7-R8C>$$[*S(P<E-,=E5P5E5X
M,FM44W-(8U)Q46]R=3=B1$-Q56554$]D:#5M;G9O<F4P;'1J6DQ#-V5Q5DI)
M;4UI,$E5;6I";U<R<CEK<64K2B8C>$$[5FMV<%(K2#8X0W)*=E-I:&569T]-
M86QJ53A244-V56M!9E1I<D9F2V8U9V%4-6LQ339F8E<P:U5Q5V=V2&1M1%)K
M1U%X.%599F)&3R8C>$$[3&-H=%)V1V]"259L=G!2*T@V.$-U.4M0=R]8:7)#
M<E@X>71-=5!.8TAL,4Q+47I46%9Z84,V4U)(:2\P84U0>4)"*V%S1%-J06=C
M<28C>$$[6DML6G(V569H*W9)<75X5C)+=7A6,DMU>%9P55)3>%91<&,X;4E&
M2VUL2VXV0FER94MU>%8Q0E5M;34R2C<P1TMU>%8R2W!2<B]M:B8C>$$[4G1"
M3G4K<$\V0S1,:$I%:65126MA:#5*2D-G8FA':3=S>#)'1VQ5;C@Y951%.5AN
M<F1K=F]-235Q>F]/3&YN4E1V,5!P3E1X<&I3<28C>$$[;#4U>#AQ5U4Q>$)E
M879A5S@Q<45A-&IK;5)745-"4VA913EW-FXV4FI3;T\T.#<K43)A-V%857)7
M63)&=6)I-F12-C-#2#%04THU2R8C>$$[1W(K.$9/23,V94EX;W%R;GHS-4U"
M6F8P,UIC:U8S6F974W9'2G5,;6QE>F)9,'%L1BM9=FM74U%X<G)T;4@Y5F]!
M<E-Q:$QQ+T%H928C>$$[5D]1-61X=#,V63!Q,CDX.2M10DA+8G)73$=55S-R
M339E;VMR2V)D87DP4F541FQ8<T)81VET<3%X-34X;S)J>5%486Q"1DQ#:&M%
M2B8C>$$[64)M4EE&=4MX<BLP4%-D5'1J4V]34#A!3D1Y1$IA5%AI-GI!3&%#
M=D]2=5,Q2V]825933U1%2W924E@W>&I3<7 X+V51-VDP.5=B5B8C>$$[-U V
M=5$W9U1/<3%72UEW1F=R-VME<7!#-V(Y<V%+<VAH:VAK:%-30FQE1U)1.&)O
M459:5T915DDR24]"5BM+=$]I4TE59%$V34M-<B8C>$$[0V]).7=C5F%J:&EJ
M<C9A2VQA5C1G0W1!04]N9T)41E8R2W5)0D9$=40Q1TMR26]966Q#>%)R1W%I
M:7%O04%(6&%M2W(X5F1I<6UL="8C>$$[8F\O3DEK5GEZ35=#9TAK,S)J6'A.
M3CA65DU69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<D4O4&XK1"\X06-F
M.$$T:SEF,"M5,R8C>$$[<"MJ-B]$,"]4+S!J,2]1+S-4=RLS>BM';EAA=45+
M.#A8+VQ26#%Z5794*W-E:#9D-3EF<#8Q4%4Y93,Y5VQF,S-0-TA';3-(;EAF
M;"8C>$$[:W0P2G1Q,R]!0W$S.5!A="ML=C!H.60Y4TPV=G@K=# T+U5B4#%0
M<6YO8C$Y1#!V6#5F2%1R.$Y-1S9Q*VMF.'%G*W%A-RMJ=G)(,28C>$$[6#9P
M8V9P86XQ=F@V2'$W.&57,TQN+V0X9FDK,3-R:G5L039X+W=!<4XU2#8O=T-V
M>2MQ>2MR5#8U6#!V<E5V3#%A8C$Y8C%0=&1U=28C>$$[,TA(9$,K,2\U56HY
M5RM$-G@V1D0V6% V-U-N,6$V-65N6'0V9G(Q+WEV9DAD2VQB+W=$2VE0<3DW
M-EAQ+U9U5C$V+RLY9D=N;U-E<B8C>$$[=R]Y9E,U8V%9-V]49EAV*U959G!'
M-2]42'(O<$@P4CEB.50V,S9N1#9V0CEU;C=8<&5N6'97=&0X9#!P1'%V+T%#
M;U0V;D@K:U!R4"8C>$$[,68Q2G93-2]8=6Q'-55R*WIW*WHS<#E/3S9#;51F
M.$%+;2]R,&9R+T%&<C$O<E$U970Y930O6'9R-V8S;&9H.68V>'IR6&9H6#EN
M2"8C>$$[9%AP3VAF;R\Y0V%F*VIA+V\W-G1$.5-R>7(V2'!J,#8X=FDK>%1R
M=FM5;S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$O=T0O,E$]/3PO>&UP1TEM
M9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z0S W1#1!0T-"131&14(Q,4%%
M139%-C,X045!1C8S0C8\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z0S W1#1!0T-"131&14(Q,4%%139%
M-C,X045!1C8S0C8\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T
M86YC94E$/GAM<"YI:60Z,C9!-C!",41"031&14(Q,4%%139%-C,X045!1C8S
M0C8\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U
M;65N=$E$/GAM<"YD:60Z,C9!-C!",41"031&14(Q,4%%139%-C,X045!1C8S
M0C8\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$
M,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET
M:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HQ,T)$.#DP03DU-$9%0C$Q03!&-44R,3(W13(X0S=#.#PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP,2TP-E0P-CHR.3HU,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0S W1#1!
M0T-"131&14(Q,4%%139%-C,X045!1C8S0C8\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#$M,#94,#<Z
M,# Z-#4K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S
M=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R
M;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM
M;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%10
M9SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXU,2XP
M,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C@T+C P,# P
M,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&EC87,\+W-T
M1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @
M(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI8G)I+4)O
M;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A;6EL>3Y#86QI8G)I/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A
M8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y
M<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N-S4\+W-T1FYT.G9E<G-I;VY3=')I
M;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\
M+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&:6QE3F%M93YC86QI8G)I8E\P+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI8G)I/"]S=$9N=#IF;VYT3F%M93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^0V%L:6)R:3PO
M<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R
M<VEO;B U+C<U/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^8V%L:6)R
M:5\P+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM
M<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE
M/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7:&ET93PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D)L86-K/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M35E+(%)E9#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+(%EE;&QO=SPO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!'<F5E;CPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#35E+($-Y86X\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--
M64L@0FQU93PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($UA9V5N=&$\
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],34@33TQ,# @63TY,"!+/3$P/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ-"XY.3DY.3@\+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ
M,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TY,"!9/3@U($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XY,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STP($T].# @63TY-2!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.# N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/34P(%D],3 P($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3,U(%D].#4@2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,U+C P,# P-#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^.#4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/34@33TP(%D].3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXU+C P,# P,3PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXY,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,C @33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,3DN.3DY.3DX/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @
M33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TP
M(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@33TQ,"!9
M/3$P,"!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX
M-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXQ,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3DP($T],S @
M63TY-2!+/3,P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXY
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XS,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDU+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C,P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TP(%D]
M-S4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW-2XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-S4N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@P($T],3 @63TT-2!+
M/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@P+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-#4N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<P($T],34@63TP($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,30N.3DY.3DX/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/34P(%D],"!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],3 P($T].34@63TU($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDU
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^-2XP,# P,#$\+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],3 P($T],3 P(%D],C4@2STR-3PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C(U+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C(U+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,]-S4@33TQ,# @63TP($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,]-3 @33TQ,# @63TP($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],S4@33TQ,# @63TS-2!+/3$P/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXS-2XP,# P,#0\+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXS-2XP,# P,#0\+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,"XP,# P,#(\+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3$P($T],3 P(%D]-3 @2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXQ,"XP,# P,#(\+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXU,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3DU(%D],C @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDU+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,3DN.3DY.3DX/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3(U($T],C4@63TT,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C(U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C(U+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,SDN.3DY.3DV/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/30P($T]-#4@63TU,"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C,Y+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C0U+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^-3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^-2XP,# P,#$\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/34P($T]-3 @63TV,"!+/3(U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C8P+C P,# P-#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M-34@33TV,"!9/38U($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C4U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C8P+C P,# P-#PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M-C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,SDN.3DY.3DV/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR
M-2!-/30P(%D]-C4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXR-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XS.2XY.3DY.38\+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C8U
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STS,"!-
M/34P(%D]-S4@2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^,S N,# P,# R/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXW-2XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXQ,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,U($T]
M-C @63TX,"!+/3(U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXS-2XP,# P,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XV,"XP,# P,#0\+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@P+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @33TV
M-2!9/3DP($L],S4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C,Y+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C8U+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,S4N,# P,# T/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/3<P
M(%D],3 P($L]-3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C,Y+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C<P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TW
M,"!9/3@P($L]-S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C<P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.# N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^-S N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA;64^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P
M5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @
M(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]
M,"!9/3 @2STQ,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP
M($L].3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^.#DN.3DY-# U/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STX,#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXW.2XY
M.3@W.34\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3<P/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C8Y+CDY.3<P,CPO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-C \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3DN.3DY,3 T/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T],"!9/3 @2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3 @33TP(%D],"!+/30P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C,Y+CDY.30P,3PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L],S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,CDN.3DX.# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STR
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ
M.2XY.3DW,#$\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3$P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/CDN.3DY,3 S
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STU/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C0N.3DX.# S/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \
M+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y"<FEG:'1S/"]X
M;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4
M>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TQ,# @63TQ,# @2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3<U(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW-2XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D,],"!-/3$P(%D].34@2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,CPO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3@U($T],3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],3 P($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M-C @33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXV,"XP,# P,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# S,#DY/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,#,P.3D\+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N
M=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O
M8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MCL:2.4>:%+LK*5'$%.,KD35$H\E$!&0I4;&YR)\:FLD02=EEG+"S#QE)PFG
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M6[Y4*](L$#BY)4;-I+ D%0]M!:X(L&O<$6O/MKF;QE#8"BL%5JMC7+DTZ.K
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MDS?!VQL2M1R]Y7!C,E:I*Y+VA.N962.Z='UZ<F]J8'Y6V=%-S;L\T-2Y( T
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M-@+DG<FP W/( <A(?;N:G&)[FR*O$5E!5.;S,%5;M#\;#)^15LAL!,K4MBF
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MW9V*&I>ZVT D:B;[;BP!L2; "Y%XFK3!(U;BH*5K,3K(#:0 +GLD,2+@"Y)
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MKHX*C=A*3(6]"G/5JU!@@EDD$F&#WH(=[SH!)  ))(  YDG8 >TF<) !)(
M))/( ;DGV 2KZGG'QM)K^!6:FELL>HM9<=E\QBA<:J&X9/*C(=7R],USV7OD
M#8(&XSB)1B&.*U WR1\E4=9F]L7N+8@./]<YMZ=3;U%34R64%2 ;N@6["Z@,
M6TL6&X"DDBYY RKSBEI5[L0X+* CEM*^DQ4*6 6XO<"UP.<V%QY?<?&R8L4*
M,G"M<ND"FNT*:0L<-G,AKIM<[=TD%5;/);38HVX5O$WFQ-.+1N'M,EE+4X/?
MQZ->E3B^E$<^*QZJII+6%AJ-BRAB$](A2=1"V-R 0+'P-NFM3! U'?2 0K%
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M7+N[K=A$Z)@\7KB1\6:;B29@=03)_K-*S E-[3R$L>B/B*]=<DZ4-<0B9K<
M8I(RTY#W=HT8G?"##[=6E*5-&746%5S<6#7M35CRLBW8WY%R#N-J@I:I6J.K
M:54TJ:V-RH&JHRBU_P!(Q"BW,4P1SF%X7)IRSV7.XO#%_(MRXCQFIZP9Z_\
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MN*V<X/<@=$+,T("=?,Y:Y.)Z9$E*U]IAYQ8-?QSH!8V ))Y  D_@)PD*+D@
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MTA8F9I:$OE-[<C3DQ9F8W9BQWW8DG<DGGXDDGQ))D@JKLJA1ML !R  Y>
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MC+6#RP]H.QO94:)('L#]4'0G7:'VUTUF9F9C=F+'Q8DG\YJ554650H\%  _
M3UO,1BDC-)/D,8CS\>F+$4G.>65M=#2"A"[Q%$F+DQXRBQ#^N( -A#L7UMZW
MOWP&8<B1[B1^Z"JGF ?> ?WS-)4J5"E3(D*9.C1(R"DJ1(E)+3I4J8@L)1"=
M,G)" H@@DH 2RB2@!+++"$  A#K6M<Y\YT #8"P\!/WQ$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$AN6\B^/D D9L.G=[4W"I<1I.(^+2VSX3&Y&2%6E)7)=FL;R^(
MG,O2E$H(6)]C2ZT<E/)4%]Q1@!BF*=1A=:;L#R(5B#W<P+<]I U*:FS.BGP+
M*#^!-Y,F0DXQ$8B,1&(C$2MG*>[*GHRH9//;9OY1QYB\;"@6N<Z9"HB[R=.
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ML)>S?I2K:9>G*.'T"4,B$+C-[WT$2'>NF]"Y=6M>HU.B/Z;@G_9N/]J93F=
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M['W4W_O D9;_ $BKC3(^I52<6.;]LJ!_U8V.U%&--BK>_8'E*4E@NSET'O\
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M6!7_ )MY'F)I7.WG7&V&&W=?K,+A+>TFWN$?Q/Z/$]/I$1N?H98YY>ZI4_\
M?N,;LKDJ;_0T6W%[^SSY*A]O?[>YS(__ 'U_'VZX_EO\N"O_ #7R3\EHWM;S
MKCK*!^/69YA/[K=\?Q8Z,4^\X]Q+6Y]7E>(_*V%J?CO/CZ=\JC/Z*EXN7K?_
M %TF:O;_ &ZW*R=_^'3KG#TK_P (!6WP_DQ\!4 3MYUQUP^UA[1_'_#,?@ ?
M9._8'1,OI\;YJW]3*\7_ '90X^/*1-<TTY.!AYH)##6V)L2D[:=S7Q<U.[K!
M)CB#@C2KC2'A[$WMYVM[T:J 2ET,P)282O03MD'_ ,\^4QTG>773Z-\13XPZ
M,\CZ/^%<;B6P6>9OP'7PG$F9/@<1A,2E7 YK6PO$7%#Y/DV*4D8G,$PV %2L
ME#!/F")BFPN*^NX*R3HM.<HV79UBLWQ])!5PN'S5:F#HBJE1&6K01\'@1B,1
M3(!2D7JZ5+5!1)0.EJ:-=)D\UG'G">$'DR X*O0AJTH42U4@ K- WK%B0)9.
MB3U"70!==E%B4%:+5##L1^Q;_OWR5<^Z3>)>@W@W..EO"8K"\88E,Q%1\PP"
MY7F>/RFGF.(IY-F.9Y<E'###8O%X!:3ECAZ+XN@*&/J(:F+9V_)N.\)DF"XH
MS+#\/U$?+D-$@4JIKT*6(:BC8BC0K%GUTZ=4LMM;"F^NB#:F );S^B9\A&(C
M$2JW+F[I/1L"B3I$EM=1UUG%CLU>:L&X#',-55L6Z1Z5/Y4FFY+0[QQ<N3.R
M^,HH!&6L$GC!;K/9K$FX]]1%*1^9;105&((8Z5+:4])MP+ D&UKZB;&RJ=I3
M7J&FH*Z068+J?T%N";M8J3<@* "+LP%P-YJ?$#E8/DXG<CTYD*=T3)4''.9/
M3_ 5YSBR-ED6S#7V1SRLEIHG)W*2OD%^&L#N<V"7#<VYBG,=(=P;6=52J5:E
MU5O2%WJ* PWTHP"MR%PUR.7-3;:<HUNMOZ)LE,DJ;@,ZDLIW-BNQMS 87EU<
MHE\8B,1&(C$1B)I<X_J#)_?*'_X@0Y;1])_V57_=M*ZG)?VE/^V)NF52R,1&
M(G&";BGRR]Y:GA<MDS5.#[&?4L8+2RMR7-*!Y$\*DS5LJ-R!V/B*A,2/R3-M
M[JV[:!"T+U"4HKJ '^)G%73)Y7> \J7B+A_A-^(\ZRO"=)V:X#AW@C$9EBZ'
M N;971S2L,KR_$YUB,PP>$PU#'85:#XBG5SO"4<-CZM3*CA\/13[(3^@<#PM
MT7UN#,+C<=B<)A,RJY51KXO,5Q-2IFF&QST5ZZHF6)4J=:*54L%I+@W%2BHK
M@ESYS-+L3C3XI4[\\H_FG?D:1F]VBT<*CG%R+^F +K]0IRB</:'L>]=?JF'.
MIIVO\TS736?U^O3/Y=F%_G7DG\&XBQW.%Z0,D:]O +QEC?A8$'P,^$?A/H[J
M_=])F-IWY!^'L4H%_'_%J)M[2=O&4/L7P@N<=DZ/#..<O->5D']W<AD=B+I
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MSCB>@?0.K>#U>^5TT1]"Z96,FR>G[OD>G8C= [=_NZ^S^&\_71_"1^2B;?\
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M0/\ X(E_)>/Y.?X1#_M =$G_ (5P/_II'VQT0?\ 5/B#_OU7_P [CZ(<MO\
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M$:"WMUG+8\04Y@BS8S2+3V1+LOJH@1S=&-BP?K@]0$NH6G8-8KU>HWTWYM<
M:9GHU*A=!9U .AJ?4FFA44V)J;J"K:P!8.1O8 WN.YN8IOC$31;*L2/U3"7Z
M?2<B0JV:/I@'J444C#],9$M,//*2I4C5'8T@<G=>H4*3RB]B*2Z2(BA&+W-4
MA;$JQ:GDJEF"BP)[V(4?$D@#_FV\B[!%+&Y [@"Q)[@ -R3_ /\ =MY DDYE
M5DQQ"KI:TQJSIZ*V:D47PP1: Q M]EK74#<T19X>IQ(VP]V;TK<B:"II&T(F
MA,X+Y,^.SCMLB3)(E:->6FL%%RSJ2JZ'ZLEC8%R6 4&W?I.YL !<D"5FL@5&
M 9M:=8 HN0@"DL1?NU#87))L 3/(IYOTB%_9T#3N8R:'N#C3[&ZVY'8R-;5D
M0D%_I8VNIQBE4@.6)7)(OG**:P96G.;6-U;&!).(DJE[A'D[ZB,,=0]B3I4@
M.0A-G84[AR!_1TMS()TFU[1U].XM<J2@+@=E34TE 3S!8,IY$#4+VN)<#*9=
M-+G']09/[Y0__$"'+:/I/^RJ_P"[:5U.2_M*?]L3=,JED8B,1&(C$1B(Q$8B
M,1&(FO2*)1>7)TZ641YFD*=(:)0D+>&Y(X:2'C+$2,])M248),<,D8RA&D;+
M,$4,1>Q; +>M_+\6\$<'<>Y9]C<:\+Y#Q7E0JK73 <095@LUPU*NOHUZ%/&4
M:HH5U&PKT>KJA25#V)!V8',,=EF(7%Y=C,3@<2@95KX6L]"J%=2K+KILI*LI
M(*FX/>)ZV1A8XTWE-,=9VQB:R3#S26UH0I6U"4:J.&H4F@2HRB2 F*%!AAYY
MF@:&<<8,TS8AC$+?IY)D62<-97A,DX=R?+,AR; H:6"RK)L!A<LR["4RQ<IA
ML%@Z5'#T59V9V%.FNIV9FNQ)-%:O6Q-:IB,15JUZ]9VJ5JU:HU6K5J.Q9WJ5
M'+.[LQ)9F)))))F6SU95&(C$1B(Q$8B1]'*IKR(NQCY&XJVM#L:6:4-:EVI\
MWRCM:T<6'1IYA999O:'9@"P!",80C%K8]:%K\=X*\G[H:Z.N(:W%?!'1_DG#
MG$->C7P]3-,!YZ*_48E53$T*:5L75H4:-<*K5J=&E32K45:KJU50X^BS+BWB
M/.,(N S/-L5C,&K*XH5>KT:T-T8E::LS)<A69B5!*@A209!S]BGSL8B,1&(C
M$1B)JDC@L-EYB4Z41=C?CD/LD.=&Y,K.(!W]XB2S32Q&:3C']8U-L6R#1:UL
MPL6]:S\_XUZ*.C3I'K9?B./.!.%>+L3E1_R=B<^R7 YCB<)3+]:^'I8C$47K
M#!U:G;KX)G;"5W :M0J$ CULMS[.LF6LF59KC\O2O]\F$Q-6BE1K:0[(C!>L
M5=EJVZQ1LK";(E2I4*9.B1)B$:-&04E2)$I):=,E3$%A*(3IR"@@*)()* $L
MHHL 2RP!"  =!UK6OM<!@,#E6!P65Y7@L)EN69;A,/@,OR_ 8>CA,#@,#A**
M8?"8/!X3#I3H8;"X:A3IT</AZ--*5&DB4Z:*B@#S:M6K7JU*]>I4K5JU1ZM:
MM5=JE6K5J,7J5*E1R7>H[$L[L2S,26)))G[YKE<8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(E2N6T5!/6^C(&X39TB<8F5^,3),F2/6++:LD]DQ[5>6:YAA4=ET&<6:3E
M*T+XW,MB.C.W/+5J0QF OK(J5"1KCTJFZB=)=K E:9*DJ'"G4HN5:XW!* GD
M6!&X$IK+J"*6(5J@#!69&8:6-@RD'8@,0"+A2#L2#"_A[T+=-%ME@-ML-C^T
M$*F.HX\F^DU[2Z]UDRGD%CSXRV9;+$XRQV=U4(A5F*CXX[L,$,,2.C4Y))"K
M<VYN+7MZ%//$5$J%2I!W<[(J65B"J$ #4R]H%N1%K2&&IO3#!@0+(!>HU0LR
M@AG!8DJK;$+S!N3SG1W,TTQB)'-NE3!36LR0P*.-LKE;HR*VAJ9'>1_1-N4"
M=P?#5*A2^_"'WT@6]&J4. 2]-:C:P:4*((B-J-*"I);4-1TB^Y O:WLN+^'.
M1?5I.D!C:P!.GG[;&<[810_*VMHQQ_D,=K^JGF?0;APJXC3&)O-L.2!B0.C+
MJ!&P>SFN3)JY<3'2.*%D;D&IA&/@B-]3(G)D,:#WA0A6)1Z&J4F:K=F"M6%9
M2$N=]6I"I8;]H:6O;8WM>9EIU56F0JEEH]2P+V&VG2P;2=K@W%@=QSM-6B'!
MJZ*TA+EQGC@H1(J9FLYX9SA]MISE+DU2^,(^,M;\8ZYF<=(@(8RX@>W*:H.+
MK$IB#H7+$:)G4SMV4/  !BB))))&NC$5#J#JM90@ *DU7JNIO<6"FJ;BQOI%
MN9M%</41324J49J+%R>TO5)21AIMOJ%)=)U;%C?EOV!S'-LC6<- //9'?U[M
MW[ET/+]!\14?">GQM 5WZ;N[T^C.FN_OT'KYO4S][>7T6V=;+]U5-](U?=M^
MMSM*:B[JUV^\I[:CI](#T>7M\;R2LHET8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$HMS^:
MXU)JMKN#O$%<; DDVNJ*-E8-*6\)]QS;&VQH]&YI8+3)9#;M9%JYG&&^/LT+
M?U[46R-#XX/,O+C+*VMFW5>@7(K\.2'9@0H5#J/5K4.DE5("-9226%[D66YY
M"9\2 R*I4L6<!0*C4NT S ET[0 "D[ DFP N1,-P:D,+6 D++%2K;VK=J<XT
M78[F6AR5N/D=\.#=\5E[R@BS:NM^22-;$7".CC[A\51M T1<A:G&+2%<E)$J
M2)4G:X;8G18/50:*:4[Z" 20@ -[BQ/(W$4"NX!<DI2<ZZCU+:P2 "Y)%K&X
M',6/?.@69YHC$1B(Q$8B,1-+G']09/[Y0_\ Q ARVCZ3_LJO^[:5U.2_M*?]
ML3=,JED8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$I;SV^@9W']:W6+/JH@T==I5'T0$URU
M$?>L-G;L5I<XM,$#6#2\L$PD3ZXK$ 'ECW7SLDG+8N8 .C$(6T:@ KJ&KK 5
M#D@'T'%,J.6K400 +[ZAI(-CM*,0%-(AF502+:TZQ6(W"Z!VB21<:>T+7$CS
MPX2U;;64QCY'#Z.\4XLU29$9&G6+,3Y"&F\"U;6 E3/?U<6!&HI<,&6(4R!K
M9AM5GMJUS"B+;TK2^NC<@[4D\3Z8/7&J2-]1#%+'T=2DHW>;J?&X!.\<*+(P
MZD41<6*@J*@L.UI8!UMRL]SX$]W17,TTQB(Q$8B?F(TH)A9(C2PFFZ&(HH0P
MZ,,"7V[,V6#>]"'HO0@['L.MZ#W![NG76(GZ8B:7./Z@R?WRA_\ B!#EM'TG
M_95?]VTKJ<E_:4_[8FZ95+(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)SSY>2?FBSSB/HJ
MA:G5IX[&Q<I3.;(I6!PFW.2S%+MN;F0L31^!6E,H[$446)8MM:@AY8()>4P6
MNBA:C+@*1(F"M4:*(HE27(-2YTJ[,E(BPM=D!:][[%J:_P!+NF:L:^H!!:G;
MM.BJ]56W%PKL%  MN%JL=QI%KG$>&@]Q.0U&\NJFR[9L&_3UJ(/(-%>$FL V
MRXC("ULA!%FEWK*<%LR6IT![/I4>W,<1A40CSD8!<I*2*STIAA'<2&#@:46F
M+]7H"Z2-KV9;ZS>UR68CE>,*5*$ZG:H;=9UA8.#O8%& ";7-E4"]YTCS--,8
MB,1&(G#;D8GA:V^.2*&1IF,WEN=R/X7*.&HUZ5,.TRZF1H^/ZAX65$H/+V^E
M0!KL '(Q3<BB,C"P)(Z;*OU@""R*NT[<FKJZ5K]5U=;KO4UWJ6U@;:BO5A+[
MEK!=Q,%2W65=6GKNMH=1Z^BU*^G>^D,:FNQM:^K:=R<PS?-!EC=+G8U,F:DL
M>V@1.K*[DGKW1Q3JS36I8G7B(-3D-"HDLLTXG96C J!BT7O1FP=WU,NIM36Y
M8O<HZD!5(&I2MP2P)L#?D)4XJ-8*$L&5MRP/9(-K!2.8\9Z?4V)]SP[\0//Y
M<R-J7K5/E7ZYV]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?
M<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9
MOHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<
M7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+
MUJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@
M>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL
M3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?
MS-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?
MKB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6
MI>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._
M$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU
M-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K
M3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGR
MK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RY
MBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GA
MWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$
M>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7
MU:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4
M^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^
M7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<
M\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9O
MHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7
MJ^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+U
MJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>
M?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3
M[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S
M-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?K
MB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I
M>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$
M#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-
MB?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3
M^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYBU+UJGRK
M]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAWX@>?RYB
MU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>IL3[GAW
MX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U:?S-]$>
MIL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^5?KB]7U
M:?S-]$>IL3[GAWX@>?RYBU+UJGRK]<7J^K3^9OHCU-B?<\._$#S^7,6I>M4^
M5?KB]7U:?S-]$W7*Y9/CIKKL737=O6M;WTUUWK6][UK>_GO6MB%O6OEK>]]/
MGO$3YQ$8B,1&(C$1B(Q$8B,1&(E(SN8:LNRRV@%7#-IC?(,OBV;;>IJGT^@M
M\UNT$)@*V^CFPF5X":B!69TI%-RI""8^8:"#FQ<&I&._J>S?5V^KZW1;;1_6
MOZ6GM:;6*_K7VE'7'7;1V.LZK7JWUV[EMZ.KL7U ZOU;;R[F42^,1&(C$1B(
MQ$BVY;2;Z>@#K,U36LD;II2U1^'PYK.)(>9U/)0Y)F&%PIG-4:VG3K9'(5Z!
MO&XJ]:;F1$8L?G@U,S-;@K(FB:V"WL-RS'<*H%V8V[@ 3;F>0W,@[Z%+6N=@
MJ\BS$V51?O)(%^0YG83Q\?K93WU1%+WBD9#HTEN.J:^M%-'5*XMS4,)$]BC3
M*2F8]R*3(BW UL Z!1&+2T:0"H9.SPIB-#T4%43JZCH3?0[)?E?2Q6]O;:*;
M]93IU +"HBN!SL& 8#N[CX27LA)QB(Q$8B,1&(E1(;R MMPY%(J"GM)Q.,"6
MUM*+1-E<0N53/O@4=9I.R12.:D[$MJR$_"5,\<G-U#&2D[PY#4!ATO%L BF4
MTX=K4T%/K%<GM!+% MR02;=MKZ0!?8>D/&4K4<U.K9 .P7N'U6 8* 1I6Q8W
MMSOI;PEN\JET8B,1&(C$1B)2Y\YDMT-?^7*&?U=,(>P<4JCB%RG.RAUC+N[V
M?$Y8OO%J2'Q:/,SDL+:A+W"CG8N,II ]I'9Y(?V<YU:(R9YB<5XH%A1*LI-9
MV2UC92N@FY(WL'%[ @6-B90:X4UM2,!117)N"7#=8!I )M<H;7-S<7 F^TQ>
M<MG4]L.I+1K)'5=H5[%:VL)0S,TZ+L:.NT"M=3.FN+.B&3:B\-/"]H9!6<VC
M\J8Q,(TC4N:DJEJ?9 U.J)P'!T555U?4K%EW720R:2;C4VUF4@WWON 1:22H
M69D=0CJ%:P;4"KE@"#9=[HP(MM;F;RRF5RV,1&(C$1B)7?DG?#AQ[AK-,DU9
MR&Q&]?-(1%7I0TO4=86R(()G-XQ""I ^JWE;IR5%E.$H1A0-,;8WYQ<5(!%J
MPM#8!8](K*5,5&*Z@NS$7!)-E+6 &W(<R0![3M*ZM0TU#:2VZ@V( %V"W)._
M,\@"3[!O-8MWD?(*EMJKH,LKID>HE9LZA]=HGI%9S<59FGJ9?$@E/[)3VHTJ
M4/\  HOMN/43:1FS-E<F-J1O+VFCCJTLRI6+J4PZ,VH@JI:Q4Z;+W%[@!C<!
M18W) N"1(O5*.BE05=E4$,-5VON$M<J+;FXMN;$"6ORJ71B(Q$8B,1/J,78
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M.]Z]M"U\\1*15KQ]Y#P=BY4%*[LK$$OY!R*13Z)RJ)T_)V4-96(]UK$*W2/
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M/0=:LUNT6! !6_/D3()D7AZS1'%ZA9XS9<0L=1'YC?5C7DS7A&9,;7-W6QR
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MOY%1#D7$5YD<D09G'7M-:546-+HS(A!>#&-Q:M:KMP;HXN;4R58:)Z2&N91
M6TW2ZP5TO28JVI*34CN-)&AT4C:]^T";GN-N8 @:#VJKJ72]5:H-CJ!UHQ4[
MV([-@1X[C;?V<DN#0[7Y #Y ,,9X[V$X/]21JH93"^2%>NTR9&Y+"Y1,I-&9
MA"G1D<2%C8Y"^G\B:95'5*+:"3(B(\<4[LBEH.$XJ5?13ZLFHH#EP:;!3<@
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MWMD9V3POD$ZLJTIVFG#,@36#R'X.76E;SVI:<>VMW$N61&1/K$H/+4!+/6S
MF-GIFE66 !#::I*&L+/  ?62UPJ(NDG13Q"$WYFLK*#R_5O<^/LD7H%F<Z@-
M57#U.7(461B/>VFP\+WWY18/"^03.P;:FB><,R$BQ^4G"GD$D0GM2TTYL:N*
MKC5JU[CBDXM0$![A+05^K U+2@ 3-PG%-ZLH[1)N]\6L%"C23II5J?/F:H<
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I1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g197729g42g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g42g02.jpg
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M P$1  (1 0,1 ?_$ !X  0 #  ,! 0$!           &!P@$!0D" PH!_\0
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MAA@@<;&3]$>",%CV8\*#$93_ ";CQF6VD?S^2=;WO($EB68DDG)).23^IJ8
M4!5   P !@ ?H*Z<S_6U)_LK9_CB<L3\J7ZQ_P"6JM_S8OI)_A:FN55;3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I4*,_P!;4G^RMG^.)RU/RI?K'_EJJ?\ -B^DG^%J
M:Y55M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE0HS_6U)_LK9_CB<M3\J7ZQ_P"6JI_S
M8OI)_A:FN55;3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I5+VCT5PNE='K_(;9U2E@.EVG43]"
MII,S'CF)JR+NV!;*FE;^U$D%GT[8#QIST:06?VED<U*<6E.^4M]$U:ZL9M2M
M]/NIK"WW>==)$6B0(,R'/=EC',K(&6,9+E0#73=3\0NB-%ZBT_I+5>J-'L.I
M-4\G[CI%S=I'=S&Y<QVJ%3Z(9+N0;+2*=XY+MR$MUE8@&R;5:ZQ1J\6MMRL
M:JU<%%5.,V"P$8@D.+B)6AO[\TA.=9C1T*=<;9;VXXG;KSK3+>ENN(0K1M[>
MXNYH[:UAEN+B9MD4,,;22R-@G"(@+,0 2<#@ DX )KL>J:KIFB:?=:KK%_9Z
M7IEC$9KR_O[B*TM+:($+OFN)W2*,%F5%W,"SLJ*"S 'K:'T*B]1K4*Y<YMU>
MN]5(+?:AGZP5AF!;ST5S;,J/^5"==;1*BNZVU*BN[1(CN:VV\TA?\LLO+*[T
M^=[6^MIK2X0*6AN(VBD 895MK $JP.5895AR"16OH74&A]3:;#K'3VK:?K6E
MW!=8;_3+J&\MG>)BDL?FPLZK+$X*2Q,5DC8;753Q72]FZM6.%<EZ1V>ZM%7Z
MCRRE6.^65D%$8G&70E7%R2Y%L5"DRX$>5/7%BN)BL/S8C+KVT(<D,HWMQ.NB
M&1U1<;G8*,\#).!DURKN(T9VSM12QQR< 9.!53V;UURNL76T\V>BVXOT"N=1
MYYQ^!3@0>%..W2Y=&I0;HT)-0C.%XS<H)6**6D6J]'S+P,75 8 ^2GR/Q83+
MLN8A<JK\!2K/N)P %;:<_J6X4#)8D "H&9 Q3DL'5  !EF90WIY[*IW,3@
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MG!555PA1R5)!V\[E"@Y.00O>MO>M/,);T!Y^)\DJ70;=2S$>KJ! W1MO(5@
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M9M$$N,LA$JV!@IFRC\*PH;L#!AQ_2]D?UYM!IR7IUXLA,]R1K53X+M@ #<<
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MTY.B4P4.DOR(@2.[J+$BQ-*=BC8#DN2TKS+JCJ"XZBU6XNWFG:S661=/MY2
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M>??=6W&APXS;TR?,>8A0F)$M]EE>Q:6ES?W,-I9PR7%S.XCAAC&YW8\\=@
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M2?<X &22 ":X_5=5T[0]-OM8U>\M]/TS3;:6\OKVZD$<%M;0*7DED<^RJ.%
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M 0@@YP0_L0 #DUMK@XL*$XIR816W@\@ -YU3X8B37W+&\%ECV ,%$:6,?N)
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M0!2IDN/#E/,ML.<-$GF.J9P#DDXR0JJ68@<9(53@9&3[CO78)9/+C9P,D;0
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M.,@%<G/;NA4]P>U/.#!2I*D^:I5E]0:-22#S@8(SGU!AV[YKO?(WL ?WBO\
M*:O;:MT*G=4N'GFG=KC2;I36:H Z>!5#J@F]7'GS3!.?+9#!+A:0D:6*LHZK
MG(\&T5HI##R09>"1=2PF,N059%D*>EMQ4Y8JK<8R54G()'!&<@@9AF$@12&5
MVC$@W+M#CTABHSG 9@"& (R.,$&K8(>D*\%[)4N.6.A=0K3W0K(=I?/NA&P
M6/SNZW.MTBP]%*UD-*8LLFW1Y2*?4;67@%S=.$5<TFO$HP4^0EZC,28"(E&<
M,AV@,R@G< 6"@GC'XF P"2,\CO4C*H=4*L"S%58@!68*6P.<_A5B#C!P0#FL
MF\:^(,,<\V<'O/1ZMT7I'0RGD7C?IGT&0Y%2!Y()RZK= J<@B]=;-!D'0SJ(
M1@E6[Q,#TZC1;?=GA=8+2X=6=@QX[TBY[?\ >R*K*JB5XX][8+%2. <'L&7+
M-M7GOFJ8[G,4;.&9C"DLA100@8$[B,@X)#850S8!XJYCGO'C86[EJBT Z@="
MUJW\;IEOZE7Z<U.Y74Y_H =1YW(YY2T.F(TB<(M;_0ZT-=DUL4=DUI^6DE;H
M8"N2!QR= 6[E0V4!*NRJ6PS",L'P,<%=I/)&>RDGBK#<(&*X<@,BLP7**9-N
MS)]PVX#T@[>[ +@U)!_LCE9+J<3F4<7=]0B73['Q$1U!P.*3S,MV6HC#1.R<
MXB3TGU6QLL*56K&&</3J=#HTJT@B-2'VR794,BWH^2X3?E?PARN3NV$@!NVW
M!R"!NW8YQCFLB="^P!N6*!\#874$E<YSD8(R5"[A@$GBM8Y55U,4IBE>2/OJ
MY\6<Z!6I5_!\8ZG&Y'5;I M?+/2U$[,_R8)(NT>B685U@7;JIPSLU/U:*B#!
M31NW)-<>E,"K26B0+G2I,<[%-[4"R;3MWJ'(P\97<<9!0@NAPQ(]^X'I;(QJ
MSE-PW!&V [ED#[!G:=X(1QD $=O?\2X.=^^8VXC/G+@[8^\M].'ZY!SK8_HC
M*"S<>[P5U,4N':(B+!(EG]0C4934^%^O3)IS<5]G9>;,([DR7:)/S'RNT[VR
MO'IY/!Q@9'8X &>P%7Q_EIZMPV+AN?4,#!&23@^V235XY"ITQ2L WST[T7E?
M>[R'Z7L34>)B4J9Y>VYPOI90EV$A#XG*Z(5%#N_P^A(Y?3K S9!5E'#*W8>>
MN2CD2LOAQTUPT6@R6=A8U:,%<E_XOWB ("^T$QE=[#!&2&P,Y/ -:[2LDC!L
M",?A_=L2YV%B!(&V*00< KR!C.3FJA@>MO2K%JY'R<\YQ-R_>CZOPRX\\MP>
MAW9%1YG'Z*'Z[:[[7;;6I75)!/H;]:KG*51*791MHYTU9S9[[I.MB(@A44E,
MPQ8=QOVQ%PREERVTHJD$)A02_*X8@# 8YR*Q-+E(R8]\H1E8*VU0P<L"-^6V
MA/2=RY)Y ]]P^:^F6?J_+=V&[1@;%PKW2.V\IL[]8B3Q];+FN(]GOW'9UD C
M"A,V1$"[2[1MV.*#FFS<L"DIL+(,E7A[D^11*H1\+G!5'&[!(#HK@$@ '&[&
M0!G&<#M5\3ETRV-RO(C8R 3&[)D DD [<X).,XR<9-C&?ZVI/]E;/\<3F4_*
ME^L?^6H_YL7TD_PM37*JMIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4KP?^(W\4+HG$NGS> ^>&*.2*HJ^HEMN[NI-G/URWG')\-D%6QXPJP*'6.NQ
MVX4YY)Z&>4HB08AO!&/PE_F^N]$= 66K:>NL:T;N.,W&ZVM05MX9[:$(QFG>
M2(R/!,Q= 87A]"%A*=PV?#7VAOM,]0]&=33=!^'R:)<72Z9Y6JZTWF:G?Z?J
M]ZT\*6.G6]M=):VVHZ=&L,SB_AOB;FXCB>RC$+>?Z$>(?(E8\M\XW(D/R;1V
M+HK<:R];Z*<0\Y8#M@(:V1D"=/S5O3F! F9+DI0S(>5*($%S#!+>YTS;4?IG
M5?4MQU!?84+;Z99%H--LHB!## GH63:H"&21%7) "H@6*/T+EO?O!7PETWPQ
MZ=WR/)J?5_4*QZEU9U!>J[7][?S@W#V@>8O.EI:32R )(YEN+AIKRY_?3;(]
ML9U6O9Z8I3%*_)^0Q%9<D27FH\=E&W'GWW$,LM(3_-2W'7%)0A"=?SVI2M:U
M_P#N\U[N[M;"VFO+ZYM[.TMHVEN+J[FCM[:WB09:6:>9DBBC4<L[LJJ.214X
MXY)76.)'ED<A4CC5G=V/951068GV !)K+9SUSSH-8RE?8&V$ZD>XY$8* FAL
MV$4(MJTC<<?M9%E;\93N]M-SD?4V\M&U,-NL*:><^"NJO^HKX+=-=;:[T=:Z
M+UGU8FC33:=;:]TI;:)J>F:[K4+K$;/1M^M6TEY9/.6MX=53,-S+&SVD-Q:O
M!=3>JV'@]U+>Z9:ZC)<Z=IYN56:2TOWN8)[6V8%A)<XMG$<H4!V@.&0,!(R2
M!T2O;_9O1?6@#C=.YV<HU>:?:E*=682*M!EM/U-MLIU*?#R4P5Z<U*=CQXBT
M/?:;^4U]&OM.^->+_77VTOM#](30>&O@QU7X4]'07<%^]S)U-'H'7G4L";XH
M+5$O[KIJ^CTN43KJ%Q9V6GR1W'W>%1JEW$OD7/8^GM+\-ND-15M:ZDL->U%H
MWB5%LC=Z59,<,TA,27L33KM\E)))E*;V/D1L=Z=]5/-MBM@03,[3?KL3E_80
MI=2;.;?AC4-+VB/'E3GGB;<M]3"&G93D-N,M+ZU-_ER%-[D.]NZ ^Q'UGXA=
M+=/:C]I[Q>\4=>U'[K$\GAW#U4;G2]$2WD>.SL]0U6YN=<AU*\>TC@GO[C38
MK&5+N22$:C>-";R?C]7\3=-TB^NX>B.GM#M81(P76&L!'/<EU!DDA@C2U:&,
M2,Z1+.TJF-5;R8PWEI. /,."<;,F;U^MC C@"+I,Y^S6J!H=5&IC7T_>5N>Z
MTY!?FLZ6AITE)>=6AQU$3:=.;3OZ4\*/L8^"_A'UTW7G1.@ZZ^NO:S6FCP:K
MJMQK%CHBW$8AO)M&BGA^]?>KB'?%)<WUYJ$L,4TT=LUNDK@]'ZB\3]=UO2GT
MS5]0L(K.)TDO)(DBM9)]I+Q+=L)/+6-6PRQQQPJ[*A8.5!K!OIWXAQQ^2.!^
M4),LVP(G.;NEXW2WRPM;KJV& P8(DM$=;VS,=20_,G21;*I2FX20<MQO<AU7
MVWH_2T8#R:V%C,B#[O;?> CX )DDDV,#E1MVJ'(&6\Q>PKP+7>LY2T<73I:8
M1N?O5U]U:2,DX$447F*1AB'WNR#=A?*8C<:LH34_B&=Z #YUKZ11> 56Q"HS
MSX>M5V2[<M0B$1"];EQ)B99(3,6P[O<F'JXB)D5]2H[\2.MM3;6H\_2VFRLL
M-I<ZG-$Y DEE46Y96/X2NU'4$>EO(=67D,W<[T=MUGJ\*/<7UIH\$T8)B@A9
MKG8ZY]2MN>-L'U*+F-U.5*J00*_XU\*P$$.FYO;[3&NP-"DMUP+4Y!D%J9K3
MVU*(V*4M,>7&=^QK[2!8N4^A"WW75%W/MH0YM7_6<LD<:Z= ;:3'[V2<1R[>
M!Z(ARI&>2[J,@ >6,Y&GIGA_#%+*VJW"W40P((K=I80V#^.9O2P.W@1QL<9)
M\PX%;$7X1\G*2%3KCH9"0,G\J)]!BT:5+7\VU?:-.;.*</QOJ9;5^,97.8^7
MW&](^U(DMO<".I-;'F?^OD/F+M;*0\#GF,>7B)N3ZH]I[$G(!'93TETZ?*'[
M,B'DMN7$D_J/'$I\W,R\#TREQW&,,P.DFJ12V(,D8Q4:PP-FQ7H,P>R %-0I
M<*2TIB1#DQ41$L/Q7V%K9>CNMJ:=:4IM:%(WO6^)-S<%E<SS%U(96,KEE8'(
M96+9!!Y!!!!Y%<X+6U5&C6V@".I5D$,81E8$,K*%P5()!!!!!(/%<2D<[HG-
M1CX6@5"O4X5)EN3Y4&NBH@MB3-=2E"Y4E,5IO<A_[:&V4N/;6IMAMMAO:6FT
M(3*XNKF[<274\L[A0H:5V<A1[ L3@9YP.YY/-0M;*TL8S%9VT-M&S%V2&-8U
M9CP68*!DX &3G   X%3+->MJOE24K2I"TI6A:=I6A6M*2I*M;TI*D[UO2DJU
MO>MZWK>MZWO6]?+';M0@$$$9!X(/8CX-?+++,=IMB.TVPRTC3;3+*$M--H3K
MY)0VVC24(0G7\M)3K6M:_EK69))))))/)).23\DGO6       ,  8 'P . *
MJGNO'*UW_E%PY);)ID2)M<4<ID[7),>'8JR?KYH;9ZE;*_)F19\)H[4[6%"V
M0.J? GC]D1<9,Z#,B;>C.RC<QNKKC*YX/8@@@@_H02#[\\5&1!(C(<@''([@
M@@JP[C*L 1D$9%4*)\M]')7!KIG6?0LGI71JESB\\\Y 1C\IJ-2J'/7>AM"&
MK3>25)9GFV+Q=2S->"#93Q,N/K4<&V7% ZT%U8"DEVPRJ%V)&%4LK/ER6;;G
M"AN-JC)/ )SR2<8JL1,6WO*68*RH=JJJ[L98J,AF.!W.,9  S4%Y[\/X!1VZ
MVZJ^MHD!.C=IZ1L%3*&*H?-14[L_&F^-E*]SSGT,N5B\^JH^*RJ[N"8I8NHQ
M?#%K/3)+2[$\U%RUP6SZ?X47+$LQ"/O!9L#<?X<D#T@#VJ*VX7'J_B=L*H51
MO380BY.T?Q8R<L6/&:F8OQ4 &5VNUY%[,.MU[Q(_XJ:DJ#PDKD@'H(*#N]N-
MZE[2V82D&VY^CI4J%O<A:?R]:;3M43,222HYF,W?W/\ #]/UJ7D#:%W'B P
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M<?/&3)T[-)'#Y^PV H4/6$^;(SS!PV2GEBDV5/F2'W*V8L2S')./8#L,  #
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MQ&V0\_NGQ'.^TVO6$#ODG'JZ8'MN1;,4#RM6$O';4J,Z7:!$F[BF/J>MER5
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M$:W+A/[E0I\T)&GMABA")(W]UF:3@RY/UI94XXYN-%^SQ#:]J[02V[WTSQ3
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M&"%T#GLA8!C]%SD_TJI*IZYX_,Y\9Z1TZXT;AU?&=Q[OPR'-Z?T"KU<:8/\
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MJ9NSG>.__JQ)%Y6-N<;!)YO.=H7R0 W/"^NICZZ^#A\9CJO)I(JV>UXOJ^-
M.BC+'&B'0[378I*9'U+BM&(+MW:!TM1(0W,=<9:+SQJ?QWI:XDK<MMF-)C#>
MV:/D0>3D$;PH) XXXRW/OC]._M.ZTV[N(MDTJ72A@PAD_"2 0#AQL)&3C=P.
MX.<5,.,?!C^,34N64:NB_B76'B8\6"CM1>3UGK/:G@E!0\X]*W783M8(1JZO
M\)<A>I/Z(VL4F6IY$&3,C(9EO8DO;-G8FU$A)_&50%OU.1G^O-872;GR$A%W
M+!&HPL5O/<P",$D[5:"6(@#/ 4@#L. *S)R7X%/Q= /?>HV*!Z'&\<G2=G-J
M]%0.RVETCU[1DRQ-E_1%J+TKH3&S+R$F#.KN.#Z3+CZ0E1)[Z'=V/?69C0>4
M7[?N]@&S QW.!QV&TGCXKA1T;9ESY<"V4B&4B_L+JZT^_E,[B2X\S4-/FM]0
MD^\R8FN_.N&%S.JS3^;*JR#\O5/P-OB_' 5<G3.^#/7DB&;6PQ7$=D/CS5::
MGMM_D'T2.R+J0-4#:HL=J>T.//%?K1%<9&2VVW'8Z&]L@3^Z,7'<IN!_3T[C
MG^6/UJB7H6P=EDNH9=:*ATC37-3U+74@$HVRM;Q:[>7T-LTB?NY7MUCDDC_=
MNS)Z:M0/_#\?$VG5P0/.>V^<!X[82!#56V[9U@M%$L(@LL?H?U-U:-!D1X#>
MOP/JC_7%<;:^;/U,J3\XF_M 3B!SR3G"C)^?Q&MB#HJW@01PW>IP1*H2.VBZ
M@ZA2U@C VK#;VRZDMO;P1KB.*W@BC@BC58XD1%51GOAO\.1\0FSE+M&Z=T7G
M/#!HN:B$'*3;"GIG[_0IY_3Q80/K$A]T2(TVRR[I5H4"./J?CMN V_M/+8LD
MU&V4+L1G)'( V;>V 21S[]L@8//-5CH?3G&U;.'3E2-8 =,EGTPRP*24AE.E
MS6C2P1DEHX9B\<;,[(BEF+=YU;^&F]RASU$C<[[5R;IXH@14@\<ES#/.=<]<
MV_&U^MK$OQR[QJ&J/K[JWP"GS>G8B8WZ4MO[$C>$U*WPQ:-U.,8&'W#XSQCZ
M'CFL0=!:/9+>);:=8RKJ<(MM2:Y1KJ2\ME$@%M=27C7$ES:@33$6\CM$&EE/
MEYE<F\;#_#1^KX8$TNM>UZ.<+(%$%BPT^F6NN12Q!,1U40;*,L&C+@F/.D:;
MBO$D0)RH3;JI.HDC;?V5U#4+?(S;8&1DY4X&>^"!G'?&1GYKKG_T.\.!-%<C
MI#IR2>"2.>%I=-211+"P>)F60R(VUU4X='7Y5AD&IO/_ /#@^[C-4(2^D=[H
M_GTC^M2&85-C2)W2I4N$TTW_ />22%9*Q08],U[:D1H;$^;,6RUMZ>B$[M$=
M4Y=0MBPQ"9>/Q, O\AD$G^@_G6SK/@_T/U1=)J'4?2G3VHWT<2VR7%WIL$\_
MW>,DQQM*H4LB%F\M6+; 2%V@XKBW3^&R]V-=DI4(!WKFURI$MN(X9['/(GJ\
M5HNF9#VY\?5%>41+&'TQ])=$(#%E1"<E_<8M* ,Z<F9E=0M1&P,17O\ NPJD
M-\9/ &??/;VS6W9^%O26FZ3=].:?TUT_;:!J6\ZCIL6FVT=G=M(H1VN;;RRM
MP^Q5".Y9DVJ$9-JD6=T7^&M]B,TNR+JGL2C= -MC77!M., +34(ED>;6AS8I
MVP+*G6!CDIK3B8[LJ&Y"<DZ9CS7HD1UZ9'K2_M@RG[MMP?Q#:2/U P/\Y^.:
MXO3_  /\.=&OK;5=*Z-Z9M-2LI/.L[F'2H(Y8)@"HEB8A@DB!B8W"[D?#H5<
M!A[B_!5\0=M\'>33O,.]E:Y(N]OZS8.BMU^LD$G(5/$$*U4:W$"2CZ(S#1(@
M\]6))>0W <E"H*"+,>)(=D?FK5IWLT<\V^,$ *%)(P6().<?0@<\G'TKTK2=
M*M],6\>*VM8)]0NOOMZ]O#'&]U<"W@M5GNI$56N)Q;VT$(ED+,(HHHPVU% W
M3[ Y=:NT^;>J<OI#<!VU6X.-A!VR<S0^ M^+8@Q-W4B8IMU+"?Q8+^TJVVK2
MG-(1_+ZOGJB)@LBL>P//]#7)3(7B=%QE@,9X[$'_ .*R>*\H=AYWZW[9ZZY\
MS7Y-CZ+WRN#CE3(G=-0NC>6R_!/-'/[%I+ST9YFI])YMT[E]AO-/VG3,>SA8
MA6J')*6;6%*5JXS(\20L#A(SAL<K*'D8>_*,K!3[@\CL<T"&1)I9EVDO*/23
M^*(QQ*><>EU9"R^QP0>""+3[3YQFNUVNR(H7LGI"V K[,M53,3O1;_#[]RV4
M3K)>OSGJ?T2A0Z,8BU8N.(R 5GKWY\_\X;._)6-,NPH\9N"2<D$I&I7#?N]X
M< @X*L2,@C(/'([BK'B['#R$-N!,I1D)!!VL,>D@X89[=@>U9LLWB^^"?(]0
M\S2^)!.XDI4+L=PG6AOTE>J5#Y_VCLO2+=U2<_,*FX#]SOM+J]HN2E0+J:EV
M6[&FP3<\Q1W2)"0MZP3*9C+O*?@ 'E*Q9$4)P =JL0OX1A><;@!51@81"+RP
M^?,8D2LH621RYR2-S %N&(+<<KS7[=%\H^HR-9],<>9;I?2!GM3DO(J-TSMT
M^SLU.50;8*X^'X3VFURJ&D%*D'HQNI@8ESY[ KLEM+MLG3@!]NMB&6#SV5FB
M!B?U+Y#NRIC=N4N9$&<C!R2KDXPH!&3Q67AE*S1G:PG1%9\[2K;!'(=N#G(&
MY<?Q'!P.:U7ZWH?H.YR.;P^+?8<J:8'10?2(0PY0ZK<Y+EA"AX-)^Q;.A<[Z
M5$'\[9EL&]]*A5H.W=232ZTZ'T7ACRX$I5"T:[B_?*E20Q QDGA67+=MI)P.
M<XSD6RK(=@3MA@V"H;D +RRMZ>^X 9/'?!!Q!&\ ]>=\Y=MHA8!0Y_2[9\)7
MRQXZH9:44A2W1W:N35#T-'NT=L\_ 7*#UQ5NN7+RT(\QO39*:&BE%1T2:]$6
MW>;A/,C8;MJW<TS#'=':,KQG!("L"/;.,\UK?=G,4JE5WM9PP(<CAT64-S[#
M+(<^^,XX%6#V'ROW>Q7GMH$!S+FERJ_8/9'E/U*-[+8[I%'6:D5SC$SSC"LE
M)9K$BK$BTNT!X?&K,W3Y(\V-K[M1O99ETE!-M2@=D@DL8"$LRE()8B@7(8OY
MF&SG\)WC=D9W*,<8(L>&0M( J,'GAF#DX*B/RLKC'+#RSM.0,-R<Y!V[Z@Y=
M:NL57EXBHMP')E3]*>;.HE]$)FH3::KR_LM0N]J<CN*;<T_/;!!IRX,/6D[F
M2DMQDN(4YI6J(F",Q/O'*H^KHRC_ )(S^E7RH750N,B6)SGX217;^> <?K6<
MS7G;M57">W+3RL31H/6>X>FN==)I%@?9J<D^2Y36:/YNK%D'1BMMK%FKX6]Q
M8-$ZLCF.[<"/U>NW,@!L1.#N!+G+3:)$)@#EMB1LK#D#<6E8'TD$KEDW8()4
M$ ]JJ,4@$Y0*'DE5U) )V!8E;D@@-A7V9! )!([U5?%/'/8QO0N9W7J(,,1B
M5_VKVST818M%JK5VL4"N7WRWKFM2*3I86GU6NRKU%OZ]OEV@ 2+%$R=R"(TJ
M:;;0:(3>:,HRJ3DP1Q\*5!*S%R.23MV]LGGL0.PC'#('1G .)Y)>2&(#0[%/
M  W;N^  .2":G7G3QY;^.S?(#^JU2:^CC3GKU%]W6W8$7>XW;;>D]4VH.H,&
M+^JHF,P0[Y=M7T)AR!T+3FG50V%(A),'\WU$A_*VY_\ P&#],=OUJ4<!0PX5
M0$,^[&.SME?KQW^*ZST9P/U7U3O0Q\7^FR.-A/1'C[KE9T.L]"K 6#4^/]$Y
MS:>I?O8._P X)=,N73WGJ]8-U14.^AZ6FEN"1J781B$4#6W,4D21D'\9BF0\
M,26=7"X.\(JC*Y]).<GGN,2QRO(,?@$L#CE0,(ZLVX;2Q;@X.X#&!P00W0U'
MS5Z!XWT4-UL9S.E=H^Q;/B(C7>=$+Z,K$H"%]4>P9_>>?WD*7. BH-Q):DQ(
M-8Z8(4F*;',3H"!:+"B 3%2,M+&ZE-S)Z;?U;<Y,46QE.#G\7*>W?..#6%BD
MC;?L5_5=>DL!@33^8I!((Y7AQW^,XP8H#^'MT,%RN_T4L/Y[;3L_X7D3R+5B
MRG&UP(/2I1/M1<O60+Q@=HF(YO =N-)%AY[[414D6!%N3!<=\2TPQ(W"EE8%
MP/O9F(]RGH )P<%O2V1SR>YS6!;,$92$)^Z>2#V ;+D@9&0@W*!^@&1Q7=2/
M&?67>V7.?;X%JOG.NK]%\N]/DSZUU^JT\;3#/"J7QZO+@VX,9H!:ZFE5>X<I
M=Z+39-(LB&#DFRS@Q!FJ2EE+"8QYR!%"X#(LJX9"Q8.SG((8 95]K;AD;0>>
M 'D/O8MN97:%^' "F-44@@J2=I3>NT\DD'!))]?,TZW:8I3%*8I3%*H;O?++
M+TF!S8Q1S80'>^0]3#=4J"[1 GD:P5G0ZW;*0; GF14N&3C1#-.O5FA1"D%Q
M]X,7<&%E#BK$)X9+LC<+N# E70HV.".0P(SQPRKGY&1[YJN1"VTJ0&1PZYY!
MX*D''/*LV/@X/MBNQX#RR?Q[F[=4,G(=DLA:[=4Z7;3(T:\($R;AV3J-QZU:
MHX,9)G$Y4*OBSUUGB*^Q-(39Z0D"!LA*D3E2'EXD<.V0" %55!.2%10@R?DA
M<GVR32--B[2<DL[L<8!9W9VQ^@+$#/. ,U:A(*+,?9_48B).V$OH97M;K3C;
M<I"6Y+6G&7&U_:D(0A+S6U;;=TA.EI5].OEA69<[3C.,]CV[=\]O:I,JMC<,
MXSCDCOW[$5Y-TKX%?PR*5:KK:=>=X=KW<Y+C[=>NUFLE@JU/9>E*F/0:4'<(
M1]"8RWMH2V[+?)SXD5I,&#-BP5O1G=IKZZ8 >81CW4 $_4XYK473K169O*#;
MO9B2!GGTC/'_ "1V'%5[W?\ A\_AO]G;K>J]SZU\#E 23LN?,XK:?TY5I@2/
MQ].B#T.\C[V,2PUIC:H,P/!%$8KC[_URI#"]1TRCU&Y3.663(XWC\)^1MV_S
M!R*A+IEK)MPABP>3&<;A\'<&'\P,_K6@@WP:?AC QS(V/Y YG-0S";@[EF7+
M,;(OH0PF/N0]/*'Y4A4UQ*?NN3$+;>^^I3R%(<WK>J_OMUG/G-WSV7']-O;]
M#5GW"SQCR%/&,Y;/UR#G/ZUT?#?@J_#=X0FR_I/G"I='>LI%J<N3VZ+$ZTZ"
M8C_D?C":RW;H<V*$',_DN?<7&C[)D/IC_JQ*?N)$^Q*2^N9,?O-F!C]WZ<_J
M>3D_\#V R<PBTVUBW>@R$GO*0V!\  * /U(+'W)P,3V[?"2^&_?[+3K6=\B<
MDAE*-)3*"QZD(ET,#+4B2F6VQ9JQ29U?KEPB(DH2YJ):19>/M&W8RVU1)$B.
M[A;ZZ0,!*3N]V568'@95B"0<#YP.X&>:D^GVCLK&(#;[(S(I&<X95(!Y_F>Q
M)4D'24_R9YG)5\M597#.9[KQT=*$EA,>J"X,2:.F-*8DQ7$PF(ZDH<:6I.E-
M*0XWOY+;6A:4JU%;RZ0@K/("#D8;W^G8_J#P1P>*Q/IMC<Q/#-;(T<B[6VEH
MW'.0T<L;)+%(I 9)(W22-P'1E8 B%\Q\%^.>.5K=1YUYWYH  ;GR2:X:P2"Z
MUSI>FTOOKF&W",U6UH9:0EO\C[3:4:TVA/S5\\S7ES.0TLF[ P $C10/T1$5
M 3W)"@D\DDUPK=%]+3 ??=#L-5=<[9]:B_;5RJDY\M+G53=SQQ \K"DBQ*Q9
M@@9V+=87^'IXN.=+!]=)>>Z*Y>ZXTRV*(L-%((QM4;Y_BR)=7@DHU6)3(OS_
M /CS"(:5);VAA6G?JBQ%,5BXF"E1(P4]UXVGZC&*X"?PC\.;C58=8?I>SCN(
M7AE-I;3WUIHEQ<6VT6UU?=.VMU#H.H7=N%00W5]IMQ/'Y<)60&&$QS^\>1/,
MW2*H6I%TXK1#58-QTQ2(W8G0_;K2'$/-[8G"W8)* ^TZVAQF5 F19+*TZ4T\
MC?SS FD!R&P1^B_ZKFM0Z#Z-U.RFTZ\Z9T=K6<)O6&RBLY5:-UEBE@N;,075
MM/#*B20W%M-%/#(BO%(C*"(U4_"7CFDU492J_P"<.4-UL.TXU @EJM#LKZ$N
MNK><W)*671<M/=4M>_F_/G2GOITAO3GVVT)3G[Q-_P"XW/)[=_GM5ND=%=*:
M'9)I^F:#I\%LCR2GS(C=W$LTK%Y9[F\O6N+R[N)&.7N+J>:9\*&D(50*RC?"
MU\"Q>G3^M)\TT)ZS$8BHD@5,04G4%/ULICN2(_-9A%ZA1I"FD(4G;->0S'F)
M43BLL%7I$YW/WF<# D(YSG SD]^<9Y^>^..W%:L'A]T9;:V>HH.GK"+5BSRB
M=!*(8[B6(P37<-CYGW""^FA9X9KZ&VCNYHWD269UD<-*[U\.;PST6M2*E9?+
M_)F@LE^/)<_:E>US\NAZ-M6VE1;)07ZU8X6MZ6MMYN&68;DLK<8D(=96IO;[
MU<?^ZQ_0X8?T8$?\5S&J].Z%K=J+'5]*LM0M!*DR0W4"2K'/&&$<\1(W0S('
M=4EB*2*KNH8!F!L*I>//+=&!"JW5>#\T%" L-F /936H4R4EAG7R2N43()EE
M",MU6U/2B!&9+GS9"W94R2_(=<=5@W$Q[R'_ (_QC'\JV[/2].TZU@L;"RMK
M*SM8EAMK6UB2"W@B082.**,*D:+[*J@9Y[U$*%X!\;<POMHZ;1//M$KMVN.I
M"3AB,R4DM_1+DHF3&0XB>2EA*PQ-E--/SH]9&B&9KK3:Y3;NVT?+)N)F 4N2
M![87_DXR?TR3BM>UZ?T.QN[B_LM(TZTOKO>;J\MK.""YN/,D$LGGSQ(LLOF2
MJ)7WL=\@#MEAFI/T[QGY9[/##0>H\-H5SC5Z8[."I+"U?='/2-,IF-QY,5^/
M)3"()CQD$QJGE#BB(T9!"+)3'9TB(GE7LY&?T7V[>WM4M2T+1=9BBAU?2=/U
M2&"9;B&+4;2"]CAN$SLGB2Y218Y4R=LB .,G!J[AM'JH8;"#"!+8H0-AQQPX
M4-DSH(Z /B,(C1(,*#&DM1HL.+&;;CQXS#2&66&T--H2VE*=1,CDDD@D\DE5
MR3\GBN1$:   $ #  9@ !V &> *@_////#.1H.M\HY/1.9(M!'1>S(Y]71],
M182J=.Z23.)KC(W18@G3[^DS)^I$A.GG=)<UIQ?SDT\KXW.6P,#=AL#X&0<#
MZ5%+>&//EQJFXY;9E<GY.",G]3S7+MG".-7TO6+!>>:4ZZ'J3.V3IANV!8EB
M+U$EMQEW9"L$C")DP#.V[&CN;EBGHDC;C#*_N?4TC:0FE4$*Y4'N   ?J .?
MYUDPQ,060,5Y4DDD'Y!)X_E4\_;8C_2E_P"ZE?\ FY'S&^1_:O\ JI>6OP?[
MF_W7RFLAD)TE#$E"=?/Y)23*)3KY[WO?RUJ;K6OGO>][_P#]WO>]_P ]X\QO
MD?VK_JGEI\'^YO\ =?7[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z
M4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?
M@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'
MF-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z
M4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?
M@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'
MF-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z
M4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?
M@_W-_NG[;$?Z4O\ W4K_ ,W'F-\C^U?]4\M?@_W-_NG[;$?Z4O\ W4K_ ,W'
MF-\C^U?]4\M?@_W-_NOWC QT1Y$AAN2EUO:MHVL@0>3KZDJ1OYM/2G&E?]JM
M_+ZT*^6_DK7R5K6]8+L1@D8__BH_Y S60B@Y .1\EC_P217;9&I4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2L4<(]667K=T
MYV*/<Y"U:F=WY'T+M_#["*NLZQFB-'YY<.<UR2QT$#+I]?AU>P6$+UJBVT1#
M!G+5#CM/V(%.G)D@8I$Y=)$$5B&):-UC<%0,,RL1M]1) *,#D#V..<"B.8NR
M@J LB-)&0V251E!W J,$AU(QN&,\\ G:^4U?7Y2)#$5AZ5*>:C1HS3DB1(D.
M(988890IQYYYYQ26VFFFTJ6XXM24(0E2E*TG6]XI66?,?I:1Z-F]C<31G:?7
MZ#=P8BCD91AP@0OU"M5#K%]J%_FBG! U=6U:@MDBF!E?>D$YT4)-%K+NP#+I
M ..MEB\L)ZMQ8$L .%96*E0<G.,8)XYSC(P33%+YI?T[0K#:<Y+*RA@Q&!MS
MG('/&.<Y U7E5757'8;T0Y?R?I?21-4(WLG0:';+D/I8EY<<G:I=;!SC# &$
M^U")OLR"CD-,-#L465F(V[]4,62E::@R)(NYU7(7<P7)[#)QD]NWU ^2.]1=
MMJ,V"VU2V!W.!G'OW^A/P#VJHO)OHM7IFBVN[1X5/=" >@3Z97;ESNTE;?S_
M *,-@5FIFY=GJ98[5J<83%%'K 9H)B)-"ZTQ9Z6=W$FRX;C"D3EC\M@O.2H)
M5@ RG)&& )'( 8<\JPXJN&7S5+>D@,5#(<HXP#E20#P25.1^)3@UJ3*JNK/_
M $[L=EY]U[SGSV-0HQ>I]RZ!9.>$[W)M;0Z35C0GB?9NR#&1549$$I-CU+B\
M=G#3$F>4K$42@X*D#7+"_P#J,,98B!DE;=@QJ&"XSD&1$.3D8_'D<'.#G'O6
M[E7B7:"LC%2V[!!$<CC"X.?P8.2,9XSVKJ:IV/HDKT0?X==J%3!D'7/#'3ZQ
M9J3T Q<)T*MP;U&I@&)TD(5Y_3V:D;O<>1,.U5@46LT"0NIW\*@A+_:J#!?)
M1?+$BLQ]00AE &[;N.TAFR%[$D*>5..<#"N_FF-E4>DN"K%CC=M&X%5P6[C!
M(RK#VR=+955M9V/=M.UWT=4^,%:/$A4FU<>ZOTZ)TM^UMKG*G\H.\B&&0S=,
MBAY&V@ZH?5XK^CTZQ1)ZYXB;#9K;D'<8O*M$8,3.&]2NB[<?^8?!W9[^GL![
M\FJC(1*L97TLCN'W<Y0H"-N.WK[Y]NWO4&\D^JX/J0+.LT)7-AD&;6:9>:Y5
M*W?R-KZ$(J-Y:+R@,OHP673JV+"3)L,>TWIZK&+A7D6*-:JQ&/D7*JLL5S-$
M8CM.XD%E)*X4LN,A3DDX)]PIQM.!NP,0R^:-PV@$*R@-E@K9QN&  3CV)&<K
MD[<G864U=6&.V^L[MY_N5G@W?EU6-4N/Q_LO6:?)I'1R92_3HG(44YIJ-<:L
M8Y\"!56#>3-T'5L06A6^Q1@QMP9'G:FM%)3P2](5D VL0=Z(V5&T%]W8AB25
M"DD;1D9.1CG7DF:-CN0%=CN-K>KT;<9!4 !BV =QP2,^^+AXIURZ7:T=6YQT
MVFUJF]"Y1/IRR+=*MY.[5(Y7;]6DG@!<88-U&CEX\N/.AV*ODQLP E*703):
M-,<CF$0A\'15",I+*X.-RA2"IP00"P/!!!!]\8XJQ'9BZNH5D(_"Q8$,,@Y(
M4]\@C'MGWK0V5U96-7/4%EH]][#5.S4:K A/-N7@^LC2W,[P:Z*4G"K1;[-3
M:C23H$K0:,\/Z3>B%=2BB5\')L3=J+ODZZ-D+D!XD\]=Y08(48DLQ4AU"@$*
M&9@0S91<^HD# P3W(%'FLK.)%4!5#Y1BY]3%54KM7U-CT@9R<@>V;.\R]?L7
M=./">B6ZE1.=6ERW]8I5BID"RZN$(&:Y3UN\<J)M1K,D0"079E3*6\01)0*B
M-IU+^RWIY#29#L94$;E0VX81@Q&W(=%?MDX_%\FI0N9(PS*%.YU*@[@"CLAY
MP,YVY[>]7M)4^B/(7%9;D2D,NJC1W7MQFGWTMJVRR[(2S(5';=<TE"WM,/[:
M2K;FF7=I^A5=6GL<<GV';-><]P]L]!YH ZJYTGFG,:\4Y5U3D?.;1<QO6+0;
MXE4(O6P$,\T9O5U>Y('LX233=DZ^-/C6J/)B[_>U .3RU=!V I*K6P(58IM9
MR'5V4% '8J<85=Y!SR?Q?PL!N(&=8SLH?<J HZ*2')0!QDEFV @K[@*?Q*<@
M$XV%P7ID[LW&N<=5)5K]HRK]5AUF_04$7B\>-&)(4]!E0"4L4!GS!1:#N,7$
MO% ($OL9/B), PY-,L;&JD4([*#G:2,XQV[Y&3@@\'!(R.":NC8NBN0 6 .
M<C^1(!(/<9 ..X!XJ=VTK/!5:R&Q;0%\B'!%2<%FTGW:K67)4""_*938;.P'
ML#U>"?6UK90VT",N"X6GYJ!<Y3.HSD0 2 <X) .!N/\ (9&3\#(S\U)B0I(Q
MD D;CA>/DX.!\G!Q6$ OL?H]L\Z=.[Q3Z-P\W X_:NJ#;*>>[I8H?+;94^5A
M4%YMKYU=8?'C! LV6F[DU;;1BNAAPLP)-389BQBF!3IJ\PJ)%C)D!=5(&P%@
MS' #+O QCG(.2".!SC7\YFC:15C(0N"2Y"$(.ZML).3P<@ $'DC&=Z5@R]8J
MU7K!($D0$@Z#$F7P1=M+)8*\3@1YKHDHTG>TM$1JWU0YK:=[2B2RZG6]ZUE!
M&"1D'!(R.QQ[C]#6P#D D8) )![C/L?I49ZM;Y]"Y_9+>-?H460"C19;DWI]
MT?Y]1!T%9&'')DK#;HU?M#PN,-'/2IT9K09U!2?'B"'9@AJ>LO!RHW,!ACG/
M"KN8\9X&1G]>>!SSC%8=BJEAMX_\FVKWY).#C Y[<]O>L!0/B,P2=7XJ0>$<
MFI1?IE*O?2#Y;HG6C +FH2BTKHRN<B[+7;5"YL3,' O1GFW;;6S=@J].$UNF
M)T2NDH46>&@B>P;?!D&78*RJ J98LR[B"NX %1P0&8EN%!&2-;[R-L9PB[E9
MF+.0H56VY!"DD,>0Q  7ECG /I__ .__ %FK6W5-=YZWKC//)]H@@MV^WD9<
M>M<[HS9#0M^[7HJU)<$!-D=1"+HL1$C0R%CMYYH84W5:.!L]K>'38@.0PN:)
MO;&< <LV,[5'<XXR?8#(RQ R,U"1]BD@98\*N<;F/89YP/=C@X4$X.*R$(]W
M6@^ J5_$\D!+YU'KOD4CUV=+Z%/8M-6->M%U/\ ?2035%D#;:-YH/O-6/V4D
M9/U*0<&3B$8(-02%HCD;C  S*7.[=,$PN01#NSN.[(+;2  &QP3WJ@7#$*P0
M;<0ESOY!F"XVC&"$W G)7([<\'TBS6K:K)WL3TZKRWR0W>0M-UTJ[10=KLP.
M@Z.[K;<^M\\KTNY="LA<Z@4=<!@:S5ASZ=$EAY<>?;R],IOW(I"WC7TW0Q>:
MX4MM7(!;&>6.% &1DD^V>%#-R%-4SR^2C,%W, S!<XR%&YB3@X 'OC!8JO=A
M0WZ=W$]3T?SH!INC@<Q$LD*\=&4<W#BU&]#Z0KHH6ACPJ!4S1XRNFHA6*U[D
M%0FJV*N% DQ6SBK!,:#X$7[II"V",%5Q^)=VTL3G@;N!P<E6[8Y&7]\L8 (.
M0S9_"P4L%QCGTC).1C*\')QK'*JNK)WI7T[O@Y;E5<!4W5_L-_Z7RFMV2%HY
ML%'H7.>B]CY[Q25T4E+2)+IER8=OZ968%<JJT0)5L=V<?AD(PZK6&9!MCCWA
MR6VA4<CC)9E1GVCD<84Y/....15,TWE; %W%G0$9QM5G5"V<'L7&!CGGD8)$
M&X[[%(]5],= \^KHX 4[0GNM-6!N';R\^^TB/SJ\5NJTLUT2JSJ2'!B0G>0-
M@_Z@\OD ;A89+M7C-_EQGY/Z[^VI/"$C63<3N"8]("MN4E@I#$DQD;6R!SV/
M;,4F+RM'M V[@?5ZEVD!2RXQB0'<F#G [')V[JRBMBF*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5E[COE*F\9M JR";ET&TQ
MJ;3K9SGE%8MTNI.U_D//+O::];K)3J9NNT^N'" V:0IM(@,S;V:N1N "I=>%
MP2L="2KI6UY6<$%57<RLY4'+LJE0S98C(#,?2%!+$D=L5)"J,"&8[594#;<(
MK,&8+A0>2JCU$G  SWSJ'*JMKIK%7@ENKYVJ687#-UNSABE>L 4@UI^ 7"&H
M3XTL+G,*_P"UZ'/@29$22UO^3C+JT;_EO,@D$$$@@@@CN".01^H-8(# J1D$
M$$'L01@@_452G&/,'(N V?J%JYB%F!)?6258(V >X0<F"AVJE5AE4%P +#R-
MR8D%44;LA)1,ED'UDYTQ3,AB!^) BS>5Y JL00@('&"<DL2?UY_3C]>:@D21
MEBHP7()YX& !Q_3/OSGVXK0F5U95=];YC7NS\SN_*K6^5BUV^UXA7"TH))C1
M2T:+/:^C<F"Y.ADARWV%Z0[J*5&% \Y*%0C LF,D2X,B2.4977NIR,Y_^"#_
M $(/P:BZ!U9&[,,'&/\ Y!']01\BHUQ[B8SD+W0BJ;=;;Y:NI6V#<[M;+@S3
M(! H6%U"M446AD1SVH46I0(\&MU,/#TY$KK9&:XTM\H0G+TQ]C+N7VC 4(NU
M0-V -Q8\LS'N3[X^!6$C";N2Q<AF)"C)"A1PH4=E'MGY)JZ<A4ZH/K/!O^K%
MWX[>'>L=/HS_ !.YR;_5@-*C\J< DK1-I%ZYM.GV+=WY==3TIJ71>DW"NN0A
M9T/#::)ME(K,<] @%8UB2;%==BMYB[26W9 #*_&UE'XE4\@]L=C5;Q[V1M[+
MY;%@%VX)*LG.Y6/X68<$=\]Q76\F\[?])>@=*O\ '[+UJ\.]4L!>S66NWR/Q
M^8+:)SI,;]%;'GZWR2L=&V'HP2*BIT:O%+T4  JVMR/L;*(*T22>3>JKY:+M
M  *[\X'?(+E<L>6(4$GX'%82+8SMO=MY)(;9C)/ R$#84>E06( ^3S6CLKJV
ML^VOS^S;>XTKN,OJ?2X$JBU*X48;SL?%Y2YSLA6>@S*60NP\PDORXK?)/[BF
M<]J3TF1%O<*1 T+6R%=&1R!)F78),(R;5PQ5BWJW97=MQA@O&X_P^_.<"JFB
M#2+(7?*JRA1LVX;:6!]);G8.=V1SC%=-P?RW4^"369XJ[=#O3P?FU/XU2OW_
M #*G)U0N3T.22E5FC@5U2GU)\G'B+))1-L5R>M-S+M#16BMDF.15N/YDE,@Y
M55RS.Q7=EG;&6.YFQV[+M49.!2.(1]F9L*$7=CTHOX5& ,X]RV6/N:TWE56U
MC<[XQK5JLW>#EKZ_V6R!/1-?*U*_4<HOD>@D.JRZY.K@*M4^S0>1P^JU0#1_
MU(A8::*&=%3"'W B7M1!DJ9/'Y12X3$+& B QG*L-^<YR21OV$MP&)7)4!>P
M J@P F0EW(E!#*=F ,8 4A ZA<DJ-W#$MR235P\CXO#Y5)NQR9=[MTZ[]$*A
MR=OOW0/V<U8";5; 0JU7!#,"@5"B5$6'"C8;CD:(+K,-R03*&2I!^9.)/O9!
MWWX&U5500%7=@9.2?4S,23W))X  X JQ$V;B69V8@EFV@G P!A0H  ]L=R3[
MU<^0J=8\JOB^CB4]&'WOH'2>X5CJ-Q5T*T53K47DDR$Y>8]B$6&O69JQTCE-
M&Z#)F4C0$* HD,Q<RH>I5D0'#!QD9D(&6/N:=CM(54*+M!3>/3@@KAG9<')+
M84$DDD\G-"P*-X9FD#MN8.$/JR"#E45O3@!<L0H  ' JV^#<%Y_YQHLOGG-8
MQ*-79MXZ%?GDEIJ9\S]9Z/<S5T+1TR$1XJ-#A<DS^BA&=LJDL@QHULC+)DTS
M2LV$DC2,&8Y(55_DJ@#^9QD^V2< =JLCC6)=JYQN9N?EV+'XX!.!^@'?O5NS
MXSLV#-AL3I8MZ7$DQF2<#4-4X<Z^RMIN="20B3X"I<1:]2(VIT&;#V\VC4F)
M)9^ME</^?_\ ?I4SR#[?J.]8FK/AL15Z55:='] ]Z,2*%TF)UVC6^P1^!3;8
M!Z%L1>PEELQ.3#X.-%]#+7R'T6Q2+<5ZH)O)ATW^FV8"2 64<P7R\SY8GRXQ
MN4HP'F ,OIP.9#MV[1MV;1C(((XJ@0 *%\R0[6#JQ\O(;# DXC ;<&.[>&YP
M1@C-:7X[RFN\2YT YI5I98@' NG)FB)UP:LL3*6:Q%K98"<QL*," H2R)\X3
MFMBZ^$"5X0R^V+ AA0>'"'QZG<NQ8@ G'"C     &23V Y))/<DGFK$01J$&
M2!GDXR2222< #DD\  #L !4RL@F8= E@X^QFZA/)07XD.T5ML$Z> 274;2R5
M$M6<)9*Z].AK^EYADY7S(IU:=-SALR.IQA> <$$@$ ]CG!_0X(./H0?UJ1&0
M0"5)]QC(_49!']01\BL=&_#H0\+>CR^]=VCGC/:8/?;Q:HK7"G9/1NA J54J
M#3W;E42_#BW,I8*C J)3I-6"#:*+C,6>MA[J546N ^,<;N$Y!_+CP$,8!\ST
MJ69FVD.'!8LV3N[$J,+Q5!MU(_'("9/,8_N_6P4*NX&,H0H48 4#(#')YK:
MF%)&BA@Z86('Y< ?"A2CI9H4R5-28L9MA\L39!# H-H@2=;5,FM!@PD4W)>=
M2.&0(FF8K5)Y). ,GL,X'Z#))P/U)/R35XX &2<#N<9/ZG  R?T 'P!71W:N
M%K57984'>;3S@H^]">C6ZFQJ?-/#]Q);,EQF/$OM4NU6D1B#33@^>V1KDUS\
M*2^J ] ()BSXQ2 <E0PYX;=C_P#JRGCOW^N1Q1@2,!BI^0%)'\F##GL>/H0>
M:QZ4\ <U)5ARL-=)[ );L=:[-3.LEQA#G;9;M=5] 7V?TKJH>\ZD\WE"023U
MK,V&2/G\J%<X*5>%9#0^L31##T3\*X7# YVH<%&0$-B,QKM0KA@3@ #UEP<#
M<#5'W9-NW<XR)%<C;F19&+.&].%RQ)&P*5!(4CC&ZFFFV&FV64);:9;0TTVC
M7R2VVVG2$(3K7_I*4ZTE.O\ \UK6LHK8JK^K\3YAVX2.#]-J<"SQ@LJ?/ OR
M5/LS0),D'G@91,1+C.M.Q)K@@G/@J<UM:'(TI]AYMQEUQM4U=DSM)&<9_4 Y
M&?Y\_6H/&D@ =0<9Q\@D8R/UQ6::O\/[DE*ATNO5:X]0$4"L".$C[%SAHI39
M-7Z>2\Y%8IWF-FO<J;1Y-L9-1RXX/+LC-&LU+ 6M@&*$&PDD$U*%R[#<.Q8L
MJ%CYF&P05$@PP7# $8)QN#$9)!S@U4+=   SA0$RF1AC&<J6.-W?E@" V ",
M#%;JRBMBLX^B_*?%O4=6,5KJU:7,E$J/<^?CK<(DZ'VZK@;Y&AL6#]N$769D
M)A]]X8((::)#2@UR>(&O3!TM$9+6[(Y7B(*'LRL0>02O;(_F1P0<$\U5+#'*
M"'&<JRAA^(!L9P>>^![$9 KH6_%?GB%U3GW8@5)36KESHP;/#7 4U^,/,ECE
M614')MDBR/RUD),(4TPJ'(CR(,AR5'861=GLHVQO/G2%60MD, #GDX!W<'Z_
M.?TQ3R8]ZN%PRDD8]R1MY^@[=JU9E56UF/N_C_@_HN7%+]'J6WK+%(<LD;M8
M>6L;890KD738G5:Q5ILO:)$>36W[ @K#(Q7(FYK8FS6)(4@&*S6"L2Q)7CX4
M\8?@C(RZ["1^N,?ID#((XJJ2&.7EASE/4.#A'W@>_&<Y&.Q.,$YKK>=^1:5S
MGHXWH<&Z]!.-ULOVD[2*<>71/V]3"G?[?N[],?@E@=%"= L+90ZM]R'%O-VM
M<6$T^E6V9$P>&F#,M,S*5*J,B,%ANR1&NU1@L5''?:H_Y.<+"JL&#,<&0JIV
MX!D.YN0H8\]LL0![< UJ[*JNIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE5W7^M<WM3?.G:[;Q)9OK51F7SFZXKCRM6^GP(E?GS#XGZV4?<@QX=JKTAQ
M3WV7--EHN]-[WM>D2*,-V5(V':V?8G. ?UX/]*B'5MN"#O!9<>X&,D?IR/ZB
MK$R-2IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KQ="^#>^57CO"PU/O%NA]*J?A_KO&#
M^K%UTO)KE$ZE;J1R 6"%T&3 U)E5$0^5J=B%)M%1COR:S!C"R0YMV1%@(7N&
M>-G<E1M,Z./2,LJE\[AG!.&'!.#SG-:0@D"( S;A Z'UG"L0F-IP=H])!(''
MM5F5OAG;J/<:WU'G'%7*-0Z[WH1<Q_E\?T2FP)40"[YDZOQVUVF/('FYG,Q3
MY_HMXJ%C*5H=8)"9H.GS;XZF1T,P_6)$2Z%2K/N8ICS-I[^8C '(#'"J1G'!
M('X1FIB-U8,J;5#AA%N'8QNA/!*CU,"0"> 3^+@]#2/&/0U<]+[[" L!V[1/
M&GG;C%?>HW10LZT!;S7]=4C=M12)EY>8H_YQF#8JI"F%[8-AB.A"8NJY8GM!
M/S([)IEW#80%\UW.5P"IV[,[>>,'@'*YXYK"PMM.\$MY4: *V2&&[?MSA><C
MD@;@,-Q7H/YR 72J\6HM>Z#7*E4K2)A$XDFN4@?!$5X4+0>*JK4=H,)(EP04
MJJLJ#O60-6BI*J"+(Z6'56?,KL89(<HD(+L5)(.#D\DG SR<$\YP2 2,$\YK
M8C!"*& ! Q@=@,G' ) .,9 ) .0"1BKMR%3IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
4IBE,4IBE,4IBE,4IBE,4IBE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g197729g53q79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g53q79.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ']*^@48X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!S>!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  0X   $<0         !                          $
M!'$   0X                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   0X     %)G:'1L;VYG   $<0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $.     !29VAT
M;&]N9P  !'$    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     %:4    !    H    )@   '@  $=    %8D
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M9LVO;_PW\[C^FM])2E5ZGU&CIF$_-R YU598'!@EWO>VEL"6_G6*TL3ZY_\
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M=%3T'H= K;1T_&K%)L-0;2P;3</3R/3AOL]>OP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!30%> P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
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M,,1[C&&E3XK%D=Q]0+$,C=5\@LQ([1=X3OM3K$\(-2F0!$6@:2#7DU00H+"
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M\AX) ?P<T B"-(N( $67#2:0();#<H+2 <IX7!^\0>]=?>WA-Y<M]+7[=";
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M@ (J(N#:;'VQS?&T 662/2$H"(Y4L8'017=H.IE[ V#4 .<B#;@'$?Q @VU
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MM^DZ]R=1)]HJ:]=U=PGLL;9C!HT:>\P/=H("G3IBF.;C=SCJ3Y?ZU6;?([T
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MM;SN<YQESBX\W$D_>;JP  0  .0$!9!SBZF$3")A$PBA9@W\01?_ /:KHO\
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M*YU:$N E+3+)?.'LLDG:YP4>R(*%N2EI6-@1"TVL3<@1 ]T+R:M5]9Y>\WT
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M*B1+RW1(K,"K+]!E-K PG!57/:&DNSN <X#6)( )O$>XZ+,YY<3%=C6GA )
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MIIC<:CS8N>G^0/SBD:&1D9VQ,8L<75V=%YR="W-R!(2:J6+59Y*9,G*,..,
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M]/+2%[CMJ7;</G--[64Z=4%[2]CR2Z.#@V6C*#JZ3!U$75%7*'!SG.9#70X
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M7K6A>X0H"22QJ5 ];/6KC_>KG!4,U8N4*%1QIP\+G.<2YQ+B;DDR2KP   !
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M50WL+V7TU/J;ZUJV H[3H]7G2ZM@J^4T:E'8>/JU7ASS3!&%IT78H#,")-$
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M%L\IW57$0>Z_%;?^R)M[!_\ '.LWJRV2!Z<[8QE0M/$?M>!V<#'>6^ 0/?\
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MH$?Q"-@TC!Y$D]PNOGXKRT'Z]/H[G)%Z_O\ K[P8_3U]?\+YKE?V>OV^F_\
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M-]7NCTX!0-R5.FTL=7%<X*-%^\5*SSA#,%G<XN<7.,N<22>9.IM96@   6
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M\+??2Y-_$93_ .<<;FK[*I\#O),[/6;\0\T^OOPM]]'DW\1E/_G'&YJ^RJ?
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MSUF_$/-/K[\+??1Y-_$93_YQQN:OLJGP.\DSL]9OQ#S3Z^_"WWT>3?Q&4_\
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MF]=)FMACS(E1-+0W)]"%HE$@2)TQ7KOV"P^N\K)+B2XDDW))))/,DW*D  (
M  T L![EZO.+JICJV+Q?7@?UM5UG]NR#Q>W]6'D)Z\<P,1G6D')=6IDMEK;X
M#< ZZW+6=B9FFL.D&8!LKE4%9W.2*8C.Q.",<A^";PQI+Z,UV;MPI"NQU&E?
M='5MVYLI)+F1 <8!'"\G,=V<PS[MP>[^( @$08F  ZSB!,.XR+6Q>8HK4<&Y
MRHF%4$_H952$1J.OHS4LG;7Y)*4,CKQBBS8V1)]325OWM"_@=F5*C7_3"+T2
M.(CQ*TX0$F@ ' \N+WEX(>7.+@1!S$DFW"ZT-@- %Q @S,B+7XVX\5G/(KJ8
M1,(F$3"*-VM_+#Q5:W2 >7X?.Y:HG#C-I_6,/F#G64]9J:LBT*I($ILJN*XM
MYR8D\'E\PA:<LTUU;FQU&2H  .V=4Y_$)/B+G4*C69R!$!Q <"]K7>BYS09
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M$PB81<1>I3(T*U6M]=HTJ12I5ZT28IWM,02,T_T3E --/W[H(_0DLLPPW_(
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M'2SJ5/HZ\. <74 [(\NS96N!ET#,00,Q$@D2"5QK8=3D& *I&9L1);%I,6F
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MMS40X$Q?CX=DY3^:W(/5)DNR=*5!"?:D\"5/H\XLK:A2;H0BTY/O!!]Z>8$
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MARM,EPWPD'T7+\<ZQND/R>=I=&WX;JUZ#]+]@=)CC<(^GM#;6,=7P+<$PO\
MG=$TSTIVL#5J@L%,_,S!!^D9J=XL^_7X J@?8B&2.E9^9!LAKZFBTO<?,EX[
MT$5DRUK+?$<=DBPGAA.QOJME.-()>$S0YF)7!0UFGDEN!2<:0PTL)VQZ])D
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MV@WW21^8'%:"^,NV&JA?#6*\'LG2AFIQ+WU:#HET+W?Q2" ].]*RE4D (/\
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M2!JTVTZF\ 8 QK'.8&NS$M $@'+#B+Z D+C""\Y'%S,LDDEP#I$03,$B9:#
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M"YI:G0:$QS;&]Q&V+"G%M&N1IE8V]P(T+1*Y")069M(L)T(6BE1&RSR]"%H
M]:WOU(NPPBZPME9BFPUE*:6PMF/+5DG-):!*!L.*7F'&KBC4 2M)3"UAJ@\Q
M6 96PJ##SAG:&(P>Q).LWYHNP"66 L)0"P * #18"@A"$L)80Z"$L(-:T$(
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(ZF$3")A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g197729g63f26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g63f26.jpg
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M(1876"(QEI?3V HC,CA!47>!MA@S4V%Q>)&W)"5"<G.AL]0T-597D[&R_\0
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M<;/AQEE@TQ^$R 7&=M$T#.QB/.BN/UF(>E# I$FQZBLP3N"VS;&?+=L[?9Y
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M!'K? D%" D@8C0ZA#@5HU,L%G"QUAG"^1$Q9URN8\[N<@ 9W,",@A>,\YR0
M"<X&50J-AB),!?9YR>0I!(()&2,\8!R1QF;*7;!MYJXBV!\.)&FH[DF)AUR*
MZY[;<AZ-GU.0I$N*KS<87G&69#J?+.,9SA>%)361M)!]/_/K@U8#N (]?_/I
MD5M',5FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2J[U3^=5O'^POK1_C?M'R9
M_1K_ #Y/\L=5+^FE_F1?XR58CD*MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2N>'>#Q/.J_0\7B%LZV.VO;)..TJI:)U[B-8-GV&1-
M\D"U2Q3;Z(]4#SWEI2P:LT@<Q.0B0@$P;(,X'.7PV\LQ]D87U=N%'QY]2/@,
MX]<#FM6XNX;88=LN>T:<N<]N/0'XDCY9KEG'ZY^)7XO$A@_W!L)SHATE(O-S
M!762A2'H^XME UK2ZPC8DTC%9DQ6Y#?IRXY>AC$1B5%CRANGXBGFSRMDR6]K
MD1 33#CS&]Q3\1Z<?\OXMZ5J>5=WO,Y-M;GD1+^D<>FXXR!\0W]#L1?7JCX7
M%4Z>=BINW=/IT-7:(_KH5JJ%3X&D;4[L6#60UEO%B^T*]QG]UV E.V+;?M0#
M%;"LDJMJ$V(32J^/'UL#"A#XPZB6Y,L>Q]Y.XL3O&TD@#&P(,*,':,Y!))).
M2=B&S$$I=/*"E0@ C.\ %B6WES[3;@&.,84   8JPFZ+ON49V8UC4]>VYQ-0
MG"]?KO-6C4K8%B2"'FME$&B%E+$:EHC8(&(BW@:V3J(:1;]H:T%UY RQG%N)
M;RX=$P15,;%AR"=IRHR0O89=3P2"<*V>!\ ;G9Q(H4G!"Y&UCC+'DX1NX!49
M90,$Y&<C$=JK]L*H[*HPG6FSODMPL8L#]G=1/:T;OL_:,T5=V)!&/3?F._M'
MAXRX 1V;,V?,G2)<&OT&"@N3-@U."HY?,:J58LN0#@ONVA<CC.(Y#W]W')8X
M /.,2LP8;6P2 0F,EL-SC\X@''+$Y 49., &?*!:B<3K+KNZCK .MLUG3-$L
MKMOV61FTB$>B)J <D5MMQG1DW^;77I@[XP\31[]GS$F*7&D%IC>'2N:V&9&&
M,9<C"@'!R0 ![(// [58K'RE8$$[%.YN > 23C=CCGC/WGO5=(_<S80N !D;
M!TG!HD^\U&@D-;C2=FO2H]MNFPY-9C#ZQ(LCNH8M8KS=95:([MUCD"KEU$PQ
M-B("Z2<'AI,KEIA7G;)NP6W8"^RJ[N<!R3G'&!M)(&[)&:A,V 60+N52H);E
MF(P,[,# (SR6&#@'%>;L%;]N;5Z:;\M@(IKJ@01&L>V-(V/53%.LNR)9B=JR
M;LO6IYRDW6%?]8,@89A=.*2P\T[1+$]&;)CY$T4XJ%)'RT81)HP0S9:)E((7
M&[:PW+M;.-PR P['GGA*7>"4@JH"3*P*ELE-ZG:VY<9P<94XSR/2NB/->MFG
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*^3\AB,WEZ2^S':3G&,NON(:;QE
M6?).,K<4E.,YSG&,8SGZY^F/KQ2N1OB/^)S#ZP+KG7CK;7FM]=X]R^P(U5J:
MO(^>L551?#K4.ZWUF \GX>!'2AZ<* ORH+Q=F)()$I8BL0YYEK:M[?S"7D)2
M%.78\$X_57/J?4\XSP"<"M*ZNQ#B*(>9<2<1HO.,]F;Y#D@>N.<#)KX>&WX9
MKW6HG8.T7:&SXWGWQW#A\OL7:!IY)B-0$&&$)ETG7[[K2&8Z&(F&A!<_ C06
MI ^,S7*Y$$U&*W!FKBX\P".,;(4]U1QNQZM_CCGGDDGFEK:>43-,WFW#^\YY
MVC]E?PX)'?L,#OU^YJUNTXI5.==]G;39MI;*H-YU4YK,+JE0A%PN=@O.OEBA
M3EC _:&N(E)@VR6[C!:!G#C;D)$]J+]4$W!TA*V$\6X;7=#A.K]4ZAT!I_3;
MK*UO?6O4&M_7"L+&*1KN+5^FM(TZR6&<%',FJ.9%#20[\;:\1H/7$>O]1:UT
MS#TMU3IU[T\;1=6NM2/2QL+9]0M/KVGHK:7U1JE[<&\M2)(S!92+"2$NVMWR
MHT_;_B/]9=3-/M?:U%N*-X4EN,$=C1!BGL>>4IR<+NPHLEI6,9\G0C1M7YO)
MK/DKT_/3XO:;K%Q)I_ASTQUAXJ:DCF)EZ*T&]O='MI1V^O\ 4,T46EVT';=<
MQ2W4:;ESR2!VNHNJND^CX?K'5O5&@=-1E-Z+K&J6EI<S+C/_ *M9R2B[N7/.
M(X(7<X.%X-<L-2>(,0WIXD&K"P,7'@5JRAY.H8T"/ 8)1VQ)J:,LDMQ4UX5!
M+R7VRP%F8HYEB$J-(;2VAM(%F0J7]7T;HOQOGZ&/4?5$FB]'3OUCIVN770,T
MMOJ\UAT79Z3J6CWFFW.N6*/!+KNH7M[;]10&!A%"EK;Z;/)"\MU:Q_E#3_'W
MP_ZD^D7H-GTY:WNM:;>=+7G1=MU%#;/;PW&M:CJ>G:XE]%8W<,%[^3[0::VF
MS7,R12;Y);N*-[.))I_TB\MK]F4XI4$=F]M6'16B-D;9JM'G;'/TL-'(CJA
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M8-4Z78&JQN.3%J\_KS!T[7 %TU%7H97<IV4*WJ?V?&/V4;<)A4L6!KF82CL
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M?#>#1>L[5HI5U6XGM-6M8[2Y251$EI<R"U34%FC=CF&)XD:/B[D\W9%::O\
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MY'O\:@^S WL%&Y2,D#E6##D_,#CUJ-B_5K4UV51#.2MBEBJO=K3M4"R/,!R
M4J>ONW(>^))9+\L,2=CLHNK#3XHA5IP2>_69,FN$"90'.D1G9"5UW#@$J$.1
MR J;,?N[YSR,]ZB8D;:<G 8N #P2S[\]C^MVP1QQDBL42Z5:0)5ANKSHIYX7
M$S79,14P@-(XB3ZA5--5.MDG81<//"DU"HFA==D5#S@LH")D81-)L22$E90O
M(3.#GC//Q'!+D@8((SO;D$$<8((S6/(3;MYP,? \J$4$Y!!P(UX(P><@@XK#
M'^L77MH3\IL%M6& 3*].LN13!?7]+"/Q VK[9IZS7^$.K]9 #AT;%*VW\)8'
M0C ^EC"+U7)L!Q<N5(67R)9,Y YSC.&8\L'"DDD]TXSSC//PP8HL8+84C(&5
M4<(4+   #V7YQ[.<''QRL_J=J"Z(>LE>MEQ&OF39NR,6BF6<)*];]@,=D2!Y
MJ ]."'1#L&>OM-MX8O&8LA^%&E W!TJ$7K\0EQYKKP0#@ 8(/H(\=B#D>4A[
M^ASP2*R84;D%ADDY4CU,A..",?G7';L1ZC-;X?ZW4,Y9 MDCD;575!*U2:PT
M& $X#869&U?(MQ#5<^8R4$E9WS+7!F\6$[75PR$.'-+/0'[5"L;08.Q!B)&
M(X.2QR1S[6 X[CA@H!]<=B,G,C&I(.6& HP",>QN*'D$Y4L2.<$XR#BO3GKY
M491?9YPV:M-@([6I,G71R1/<K<!P;3I>#&71(QVN5D$_.6ATY-=AE+8]9S Q
M.4Q!D^&/7(AOX\P^R   A# <GD8Y.2?AR!@'N>>:>6OMDDDNNT]NW/P SW/+
M9(]/6H>W1TGJ&SQF$U^SDJA8<'7C"BD^([9ACS!![43A<>^%8*5U;B9>-)47
M,5Y1-2(3S!)Y465F<A,:Q)RIY&X;<8!VG]?!S@_MMGCD''%0>!6'#$'.<]^^
MS(P"O["^OH?C6;'=/J?.J53%;#LA:W72J;&%[;B;  #A.OI3.Q:U1(FLZ?8P
M]<!,R -?36*8*!P(80<Q]GI<@8Y\P%2 Q0D#D8\Y@6V@!64IM/M>R6W$$GDY
M8DY[\_'FL^2"JAB2P;?N "G<!M! &0,* ,#CCX$@_/K/UAM'7KW8+VWUVRM.
M(F.NUR%00]8;)%W1=7#03QXZX5L5E-3QXZO2(S#4LM\*U'G0XL5N-&$I;FXE
ME$ASLP?CN)]6) &  "3\/2D41C_7R,DX"@9R !GN3C!QSVQ\*E#5O7;5>H"<
MH[4:^UFQ2J]7*FJREFH)"Q-5VKBHHD:&CF\P62+(U;4-B7-@HD?!R2.,S<L)
M=SCRB\C/P3QDG SC).2<9QG_ ,*FL:H<@<X R<9P!@#.,X_\:B:3TMJ*WJPW
M!V?M<:%H@8/7-<U]$G7Y"!K0!6=BZZVC5Q-*?+Z_GSTQ@EGU728Z?M;*MRBE
M<#Q )G)".."N"I^<><JA+9+'VAN)5D);# <AF/ &"<C&2##R1D>V^% "CV2%
M 97 7*YX*+[V[(&#P!B4ZAUITK2K)5KP+HPB9L&HC[W"';",18Q*ZR7]G61-
MOOQ<B==83(DE[+9%D";\M"64#<&SXT&R+#FB Y^!D=@5+':Q4E1POLC"@#M@
M#C\!GD5(1HI#!1N4, QY/MG+$GXD\_+) P":G?D*LIQ2G%*YW[DU=O"7MR^F
M]?5V[6"HV]>NYUP<G6^N@E2ZQ6;?HIRV:YTQ,9VT-DC$W:AU;8L$^-NU/IH^
M;8BQ)^+L46/)X28V$= BAB 1NQP3ABLFUF]@^ZQ4^RS' 'LG'&LZ/O8J&(.T
MGD#*@Q[D3V\^TJMD,J@DGVN><!H_3&_1>P1+NQPMQ77_ +?7$KDA9MCBK=68
M'64]J4Q7:AUML5>Q=SL@]>:ML@@'L1PTJMFJW/A!IDF/LTT]+0+D9D=-OLE<
M[1PJE3YH<$R#(& RY &0<GE16(XY PWJ<;FY+ CRBA B*[CDAL$\%>"0Q[&=
M=.:YU[K'LGOBOZUHE-UZ!E:;ZW%I(2CU@)4Q$@K(M_9F)()OC0$$?#>(/Q(,
M**]-<95)=CPXK*W5-QV4HK=F9$+,S'>XRQ).,1\9.>.34XU5990JJHV1'"@
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M\8Q+B#VDNO1J^ .6@P]A;K;*$0 -;'E31%W+CB?4W!@2%--8<D/8;C,O/-Y
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MZW=.E40:W V$[KUUNV_9PD8AJ8"JS,E2F&VW<H>6P&3C [G/INV;L#DKNXR
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ME],X\O+//K&E=.=/Z&@31-"T;1T VA-+TRRT]0.V MI!",8],5KM([^^[O\
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M#CS"XRKD:J#*@J0:>(42.3B-R9E=GXA!&P]@F89& =S$MDL<@Y##!)&6!(+
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M?T8M?TR2RTKI36NC+UY8I4UKISJSJ"YOXUC8EX%MNJ;[J/2&AG!VR[M,,Z@
MP3PMDGHV/BYUM:3"2>_MM1C"LIMKRPM$B)8##E[&*SN-R8ROY[;R=RL.W\XZ
MF:6PTVWD*6RMMM"%/YL!3W7E(3A*GG$X>PQAQW.,K7AEEIG"E9PVTVCTHQ!?
MY._Z+XMH(#TMU"TL4$44EXW6.OBYNI(XU1[F=5NEM%GG8&65;:UM[82,PAMX
M8@L:Y/B]UN79OKUH%9BPC&G6NQ 22$4F,R%5!V@N[O@#<[-ECB"73W4\J)):
M@*L0N6XTM,:6@K\8B,]G'\6ZJ-*94E]"5>7K:RZWE:<J3AQM6<+3YW7/Y-CZ
M/&H:=>V^CMUGH&HS6\J66HQ=0'4H[*Y*GR9Y+&_MG2[BC?!DMS/"TL>Y%GA<
MB5=RU\9>KH9HWN!IMW"K@RPM:>29$_602Q.#&Q'NN%;:<$JPRI\ OIQ0(<%A
MF79[L]/2E7Q$T<0'"V'5J5G.%,PEC"'L)2GTI]*I,A2LIRK*_P K"4\C0?Y-
M'P?TS2;2VU#KOQ2N=7C5S>:IHFLZ-H%K<RM([*]OI<FAZO\ 5$2-D0(]]=.S
M*9&E._:NQ=>-'4,\\CQ:7H:6Y(\N"YMKFZ=%  (><75OYA)!)(BC ! "C&3[
ME]2ZLA*DP]@;/B^I*L8QD\/<1YYQG'Y2&P\?*D_T93ZD^>/IZL>?.K)_)W]
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MOC]<<8/_ +768R/4?G-,FX^1S7)_WL70]SI3I1?_ ,/D/W=IEKY5GJN-J^Q
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M5B:D/URN(O%]K-(DW&R1XI 1(DURE1;$];3\9HP&5)#A9K&3(E+F2,::*&8
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MI+>)+D=UJ0,1#93!"Y4;VY.Y1CM^R2?PJ+"8% ) 0S$,?+'LC:QS[W[05?\
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M'?;[?#9QZ8YJ@R'S=F0.2NW'M8\O?YG?L&]C&,9]<\5A@'7_ ')'WUM&PO\
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MKKM<A*9FCT,OL$I;DVD[$W;E &9,%2&W'W_0A?7U/!](E)=Z@2OM*L2=L7#
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M3 DVIL]@:3;#N#)ML*HT@$A 7(&"2,DD#&0., ECVSC&1G-53,ZQDQ@EL$Y
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M=5&>TNR-L56VPQ6F#&P5VL?J/:]UD5&/K>)9==6.4-UMLMC78: <3029N9M
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>P<<$Y[ +_@!FI1Y&I4XI3BE.*4XI3BE.*4XI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g197729g65g59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g65g59.jpg
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M 0$! 0$! 0$! ?_  !$( %D G ,!$0 "$0$#$0'_Q  ?   " @(# 0$!
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M -@T?@M>!G_ "O\ ^_-I_P"N>C]M'._\OG_R^J_Z#1^Y$\.W\F\;_P!19?\
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M)%\T(5147U+IYRXD6?&?A3HT>9#E-&Q)B2V6Y$:0RXBBXR^P\)M/-&*J)MN
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MJA"I"WV^L3!#4P,1A7.M]\1PC(0PYBIR_.<R6($^1BFWV/N9)<UT%Q!)J79
MDB)%A-. 8."#LKTA&7&7R8%A]AQS<M \H=6\C1\D@PJ3(Z++<),AK\YUOG]
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MLG""V+>TPI]F"$$P15-,($#CEGC>;VV]T+<A(=CCUO.A@;DNHJK8)5JP+?\
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MO?7V.?ZDWYZ'J7/!-]@=S_O]!^A7FDU]-W^\(SC_ .>7_P ,=T[]R?>^@?\
M@/[1U!GA9^V7R'_;GYK^O0UR(_,5MK]@LD^S9^J^8[]G:G\/C?.#KIGN;[WN
M9_BY:_HCFJ//1+_MUN[_  +_ +:'ZF_>SZRI?OB_,EKG[X!?=#N!]X+].8U9
MUS]_L%I#_-)IG^*N^HRP#Z_O/Q6NOS&=6T\2'N<P'^EW!/GYVGNZ8FK#Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g197729g70s36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g70s36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[20J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ) Z^DC X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!S:O7
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  1Q   $;@         !                          $
M!&X   1Q                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   1Q     %)G:'1L;VYG   $;@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $<0    !29VAT
M;&]N9P  !&X    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     &>$    !    H    *    '@  $L    &<4
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ML_\ <?"I_5Z?])[\C^=OM6FDLS/RQ5U;I^-Z]M?VDV?HF-!8_8-_O?Z3]O\
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M;JZFX]>?T_T:;&VV_;.HTU9%N+Z=/L78+G?K8>C&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-UL>J\0&IC=5GSY&_BF*#&^*TS$E:6-Z0%J5 1/H737SBU$D:S"IS.&(1/\
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M[8X'7T8(&!?*9B_&DF%M[4C]I9))2ES=53<S('%R231&D;:@R>Y\@ .[,3P
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MS<1 $X.)<>BC8TM %RX118EBL*/2A4(L&SS![ '>HLS,<LQ8^K$D_O-9 "C
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MY>SO+>A=FAT1J6]S:W-(G7MSB@6%#3JT*]"J+-3+$:H@P9*E,H*,)/*&,LT
M@"V'?K.W:OD=8R6EXI?!:MM@?ZR^;^0(I:@VY;-#X6&6(:P..8T81*G*2*:K
MCLSBS&H84P C4+W$^*F-11>AF*3- ]V\V!/<XXDE([9Y/V&>>?QS57APYY5,
M]\<?Z5JQ4-)TW0,-15]1E6U]44%0[^*DBE;1)BAS $X8 A&L&W,"%"E4+5 0
MA$I7J &K%0_]10>:9O8MT,S,2S$L3W)))/XFK  HP  /H,5DUY_Z/<[;\;?2
M$E%<MJP"*U!2UHSUZK>NW9I8([<CZB:6PZ'MUHN9C0LDCC#8HN1+G/</979E
M:Y*X+TXY-]22M*))J^U;;-&-JDLZ#)&2HSSM\@3GO@D>6#S54PS&QR0 I.!Y
M^F?L>:I/>4/JFYNO?#-2?6;3$I-RLK\=MTSU'#[,$B'6L@N%DI^O6Y2YNJ!X
M&4R.,AA=>+7!ZCRA7LY9'MJ%KRV?)*2]JPV*2L=PR$AQ*@)7Y@A+'C'(!8#/
M;L/L<, 7B5L%2C'![$@#_, _NK/;B]GA?1S'X<*Q[R3,<UYW0>/KR'R2 ,UR
M*25<.>Y!!;K70:%/IY4B4!;ESU".:F]B=(>Y&C4K8XS!(?F8Q /0%95LN4]Y
M:+*MXL()7(.&4EAP>,R=P#R< ^0JM/B\)7&1L<@-@C@X!\\D+YX^HKIW++3"
M^DV#@Z%>0<EGEM00[P7];3VET5PJBC&'<X8>AG>#-4Y9=/YQ253.XYS-'X>[
M,+B5HYU9V=,FD;<:G,;DR\N4F4\8Q AC=1A@N<X*;L<8^$N2".V<#TK"_%L$
MF"/"8J#ZY]?4*!Z?ZBMP.*+,\FRKQ.^-F2\QUQ0UO6(]46@*M!5U#8D[ABHF
M*-B=(AJEV8U\::7=:^KGN+$E*'52[; (:<+:L*/4C6'&9KR+!X\PD9D4.=OA
MJ"._/V^F/K5RF3PXRH!)49W$CRX[=\UW;P!*9NLY?ZF5V8VL#-8ZKR3=LJ;
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MRJ9W9=X*.79]WK'VMP?D:XZ"]E^F2=%^S]R%O1O5NI^KG52C7G5&JQLTDB3
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M)!![@C@@_:I @@$'(/((K(#PA?P;[<_FJ=^_W=WFQ=?/'_@1?RU7#\A_OO\
MS&MI,UJMIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KR ^2#]
M(#ZCXA[L?^4FB0^.E;$P/YH-2>2H.L),\4S'%[:D=(P3?YU>MJA*3+7=(K*/
M4LU7,LX/9TZA(H?$K02H*&/?AM5EB\0K-D>0,8#G./@W>0'<D@9! S6M),4<
M+E,'UW$@>6<?7_OTMS W7OCS7P>$FR@V3<%>/9UC<?.GS[!CGF,=$]O*3VI#
MN3D5S]<+!(Z-Y@DB\3GN/O#UH<]G<-4MABI.I;WUP2,=3".W8XQ++R & *1>
MF?)W'F,;0<]\"I O+CNB>9'#/]O-5/[_ +>>\="\^TMR_5\:IB@*WB]5UE$D
MNDS-%8HW@1) F;  *ES<E(]FN#Z_.0RPJ'B1/:MP?'E9L:QU<%:HP9PM=F9V
M+,2S$Y)/_? ] .!V'%7!0HPH  \A_P!_YU,61K-,4IBE9&=K]X71S/<14$C3
M'6AT<<&2/O+4JET7FR]S/1N'S25T<0N#++6AL5)4+FB5)M)"$85P-E;"/1ON
M 8/XYUU[0=;Z5UI=/MK?2FMI8+:>)KRUOY)6CE+I-+XD%Y#"R1RQNOAJ@D&.
M0<@G]H^P;^SQT)[5NB'ZBU74.JTU.VU#4K&\BT75] MK2*>V\&6TM3;7^BWM
MW%-<6EQ#,9I)VMVWY4IAE7L=9WAU)V5!6)H@*)%3,>/*4%67?Z9F<D13D+:]
M67MAI"-OB]Q<3%86W2=,Z2EQ<Q ;'+2[2(UO5D(-JMG2M>ZLZWT^WATY$T2V
M8,-4ZC2"6,2_G9![MH%K<222EQ$%26\FEVPR^)X91UCW\OJOH#V1^PWJ'4;W
MJ.XGZZU.-XGZ5]F\M_:SO: 6T+?E'K_5=/MK:V6$W9DEM-'M;16N[4V_CI<P
MR7/@WOIFB:WH>.&1^ ,NTYS@;I;)),YGB<Y;+W<7N$H>9._*-;6.:Y0<8<?[
M-[*0I!GF@0(TA(]E9] T3I_3.G[8VVG0;6D;Q+JZE8RWE[.>6GN[E\R32,Q9
ML$A$+,(T13BOSSUU[0NJ/:)JB:EU'?"6.V0V^E:5:1BTT;1+(8$=CI.G1GP;
M2WC18X]V'N)EC1KF>9U#U,.=JO$5UQXF$2CRDM&_RF.,:LT@*DI*\/;8V*3$
MPS#"@J"R%JH@T9 C232PFA#LL1A1@-"V( M:UIKVSMF"7%W;0.5#A)IXHF*$
ME0P5W4E2P(# 8R",Y!K5GOK&U<)<WEK;.R[U2>XAA<H20&"R.I*DJ1N QD$9
MR#7(M3RT/J32]D=6UY0B,&5I:U+DK@DV:7O6C"]*4AIQ.S"][UH8-#]P-[U[
MM:]=99#/#<)XD$T4\>2/$AD21,CN-R%ER/,9R/.K8;B"Y3Q;>:*XC)*B2&1)
M4W#N-Z,RY'F,Y'G7)9;5M,4JLO8;8VK.;[A6*VY"J6((&]C0JU*1.>I1#& K
M8Q)#S2Q&IA"V &Q")&#8MA#O>]^W7IY7K:*-^E];=XT=X]/G,;,BLR$A<E&(
M)4G R5(S@>E>1ZZABDZ4UV1XHW>+3K@QNZ*SQD[<E&()0G R5(S@>E3)7+8V
MM<(BQ;8W(6X"B.L*@\"%(G2 /4#:$81GG!3EEZ,.%H(="-'H0Q:#K6Q;UK6=
MK2XHHM/LA%''&&M+9F$:*@9C!'EB% RQP,D\UWM*ABATZS$,4<0:UMG81HJ!
MG,$8+,% !8@#+').!S7=LZ%="O&CVO3W ##V1>]A>2;B7N?DRGYS;"XR2WU2
MEAS29\+=.MJ1Z^0B%@WPRTVE6OE<2R=-:9M6/4>(2I'10[&+5KNI^M'N*X[H
M1M+L002QR,%X1@HEC/<A"^-P&3C!/T&*UF";F,B,HS\PW%& [%@O8GSR.?6O
M7+3;]5\IJ.L)'22N/KJ;>Z_A[G5*R)D!31=17*M@0'0LR.)0$IPI6/<=$W::
MTP4Y&DZ+1)/P2O9[ Z#!@S!L[@2&SWW \Y^N>]; ((!&,8XQVQY8J2<Q6:P#
M\PD8YJ4] <=6!U2I[]K:%P2,WXWP?HCCUTE:&'5K-9Q'V5N7L$_-I^&RV[6J
M6S=F:B&F$K&439%'8G;PSR +FWB="$^U 7"2!/"8DH620 EE4GD;R%P">1W[
M'RJF4+N4MO  .&3R)\C@;LG'&#C/<<BLX*@LKH[GR3^.CM+R-1&]Y$RNWCX[
M!YV<Y:\53/)_8C3-'JZ$LNH9)<,=A,<D#\PV1<5(-,;8S%C^WI#W9^"M#)EB
M5V*?3";"$;QHXB@/C1, &"KM"L&VEB 0KGSR.Q&>#58W#8[AB-CC)!)Y.5R
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MF**'1*BZEC,31V(V',D_2QIB@+ UL:><,RD(%#1,"6Q*E+DK6> !S>\A6I#
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MO-.'83R1IR' 'AHRP[G$8<V>SUE>OK)"4>&CE6ZKWEW0'6TCN;L=Y=IS(Y5
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M &UK/6(B1JJ1HJ(@"JB*%55'8*J@  >0  %>P1$C18XT6-$ 5$10B*H[!54
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MJVC:+;Z7?HWN\_C-J'3P>UM+BZ >S\<M-X%Q C!YR5-]4TX[FM<("XM5]?\
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ML^VX6:'$*_)^H+&[N>H#>"'1K0Z?.4@LX;&&2W58I"R0W7A*D-Z87RA=D <
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M?8_63NE86^1;>'^121MB$BETDA2!V=EVR@$Q%5.#3I"D:CFM$VK5B%2+109
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MT =M>/\ _P [2O\ T->?/2N@$DG3U)/?,]UR?4GQ\Y_&KY0.#1FLX9&*^A:
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M8\T-C&TKGJ4S*0_)QV*1]$N>')2/1!2139%&TK!5P.V22  "<9/KR0 !DDD
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M>I3-#<N=%"=K;UCLYJ"$"8U6<2W-3>2H7N:\TLH1:-O0ISUBQ0(M,F)-.,
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ML[FT:>FUN?7EI85TQ:R$@;H]S()%7<=S*1G@8X.,_-@9'''-1,R@9PV Q4G
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M7BG+7L!Q5*HVQ.1%<,BR'A?D3\^M3-N/JG22.Z,296S'KBK87!:XE93X)8S
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MG)YE/'].QM@--[ VN4A4-C"C,4$,Z-$!4JT=AW9R"Q' P %50!G/"J !D\G
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M6/<=M+_+)<7%G.XY98]PV!O<(>;)=X5 DES--)L4GC#(ZV9)'V8V"[.*+G^
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M(76-J'Y(]EMKRUIEVB,>&C;U1F#H&;# 88("6P0>"%!(R.<8SFL[F&TL!M)
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M>/M+94Y73":.VRD2!S3-'U)8X?)IRVQE2?*MJ9.!/A7Q('8#SR% 4?*0,
M?7 &>:R5^':,^6,DDXSGN3GMVR:[ST30<SNN_N*Y$(]F,ICG^SK"NZPF1<N/
M*<7RQ6VL'N#4;M(V 2&IG1!&GV=R:9GC5+$OTN01N*KTQ*H\L(TN%8*K]]S
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3*<_A5P\A4J8I3%*8I3%*8I7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g197729g71u06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g71u06.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M*ZH$VV-E0G* Y(-G#N+<#FJ4T?6Q70G.S_B/]9&<V\_WB7XFNNS?JJ\UFI\
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MX)"Y-G*,Q\6X[0%H$<GU,C4,KY%96+G+CQICM:!;'OX<#W=HW$M9NP/(2?\
MX@'I3LG"?!I7NU>BZX;U=)_@PHS"+PZ[U-SG:;_V.@4NZ1TL#$E*]<) L&?,
M('R(#,A$Y>H\B+&9EJ0RUGI\29,XQD[TK(01:[MJ,PZT0"0+Z?.:9\KX\&\>
M!MV,&Z?:&=5;IP>">GW<RA56]<^Y^A%^#\O']7U4@G7_ &?UOC7/?2YGS9&J
M)_K?%*3P$ATX9<&^.=$;BQH"D7885JK=C'Q 8ZPP1RI$&"P[$EKF;G%@7>Q2
MRF!';$,A(1VR!:WKR?"0U6:NB3,1FS,47=0?.^-<AQ[2R+C+WL:J\0VW0L"Q
MZS5>K_% ]3>:^=V3J?1)O/\ J;'ESUUVKQWV>JU"MPJE^D#]CCT3I7(NM4YB
M9/-%*38Z3)4A'7Z6',FA#(!9\Q%1'9%M*ARFEQ96"J&3O<*9D+$D8_&4=6-
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M9*';P5+3;6>);L]='$B\XL5ER3"OO+4YQUJ0XG*+E=<AR*0&(8&E4"F!4@*
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M7RU-*=SK_6#%>=W=;ZBCBY-< >A.W:H3S'-H=<2=B31]2:EVY%@AA-E10AM
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M&^8H8'_E?[BRFCUO34/\DU$G0:=]V;_#OLL_E:CF2]0K_P!/2?PBM$YX6#]
M=+?CK=X_)WMS=^(\[F#'S\V )]2+,=WC%>!.*KPC]E2J^7DI*CT!H<3697D?
MRQ.DE9DWSEQ"7+.T4-S$U)D\OICSQ3GE=8"Q0%+GN.!E*E5P)&K=<C"13VUQ
M1[%= ,Q&VFPHQ,6>^R\?K'X8L/$>&-V1SP39OULWU,KW.$W>+&;4(? O*BJ4
M\<@4*'E0]!)>I=)I_.:R*I=!JX&F5$&W(:$5JLBH04(.3+F2",S<0</98BLK
MFD)<LA-=2WIV9/ERIDE;LF0\ZNC,6)9B6)ZDFR?+J?AQ-%55 50 !T % 6;/
M_<VC(DQB(Q$8B,1&(F@=5)&0_.+J4KU9C7$S!KQ&3 K4R(\1BE7FV%;4S(%Q
MDKF&&FFOJ25A("?Q$TEC8L=M,Z7'5JR464$[02/%TK[_ "^?EUE7L*Q !(!X
M(L?R\_EY].)!'(+Q8>B^<[0;7S@70)6ZG*AA*V6K9CFX><4<Y?7B%F42JUD4
M$/5,)%Z61N%71^+K'O2@(*-88Y&0-)PC,O1U"Y%&XMR+-[B!O.WD79V;6XOD
MUP>!FC%L;':%X/%;1>T78-4-UCGR /3F5L\:. *QV:9RJI\E5QL54^6G)[M/
ME]_J5_>'A"KO%9](V.YI6?3784UV//D$N@%'S::6(&(K\NA)AGV7K%)A%[YK
M*;R^^W W;"+(#[K8XTO]D59-WQQQGAI7V*NP!"=O>!J!V%:497KJQ)H"BO/-
M'IU.%C"?T/Q(= (?=G/K1OOT./+^[O?J_P!*Q]=MSZ3GZM?Z1O[*OU:_7^K6
M<UD=#4Z2 >H!^<_C\&$?+Y?A0WY?B7XS\ON,7Y?B^E:5HK\OI?\ WEI6M*^_
M?[5]K6M_5^?Z\FSZGI7W>GRBAZ#K?3S]?G\9Z8\.'$W)5$BQHJIDE<R6J.PT
MQN5+<0VVY*D[:0G;\EQ#32%ON_:=4AMM*E;TA.M1)D 4#]HST1_NSPO^[K_F
MC?5X_P#?^(3)/K<ORQ_V:6(S.:QB(Q$8B,1&(C$1B(Q$8B,1&(C$2%+OV612
MNE\^YMKE/2;0OHSKC(JXUR5RUNI#'8.I,D^DTW9^FUJX-_EL-'T?)J&5$JF8
M.?9BU[9P[IX.S=4M6;<HV]0=UF^E4I')X%D<]:',HS[65=C'=T(V5QUNV!X'
M)X^5GB37E)>,1.5?Q</>W)_%'EJ^,69T9:^F]7K)KGU Y3%M(L-9R[=O%$P1
M*XOQ76B)./4:K&=DRR)5D-+C2"2!P!+T625;E1^O2:=\^5:L(A#,]$@5R%\A
MN/0"^!9YJIQZW4II\+[J9G4JJ!@&.X43YD "R31YX\Y/GP\?68OVUY(Y9Z$%
M4HMSY%DC&0,^K%IR"^H!>E&IU4)K%G6X(QLZ'E2Q+DB"22.@.;TXY#E1(\R)
M):3GJ,)P9GQE@U400*L, 18LT>>19FFESC484RA2MV"I-T5-&C0L6.#0^0,N
MQF$Z(Q$J9[="MGO.UBAR$1'(4>Y\A,$FYC=0>TX* =<I!LFF*QT 58*-()?<
M8$C8R-;:\>!2I^H\::-<2ZE]C7 :R#R.UP.2.2C#G:0U<T:(,QSB\9'VD/0'
M@.I/4$7QQN4BZL3]N,"N<7;RF/"JB3C'.2@&\C2,(0U48QER)%L]EC&HXIKS
ME7Z>"B6"$1C34#]\V B;%$,1V5M?;N+4F:\<LN4FZ8%2#;5T%&\A)((_U$@C
M[/$E C8@*M"&'% \,;KNPH!L<;0#]\UWR]:.#GRI"%R&E](K,H!6"H.3*Z*#
MZ $GS8(SKO1V34YYSI+NK+8[!9KZ[9[5:+C.02+6$H2VFTG'K2.+C!LY1D'O
MLIL@^$J>2BD>[P %H*!0 Z"JE<1QGW%84"/$&' =KY?DDM9)Y)/4V")<_,9O
M&(GEG?[%,_[+(_\ !7B0W0_(_P!I!?E#]EKS7_8#QS_#NN9?)]9D_?;\1E,/
MU6+^&GX1)^RDTC$1B(Q$8B,1&(C$1B(Q$8B5XMO[4W#/[%/27_F_S1FB_59/
MWL?_ -<R;Z[%^YE_OCEA\SFL8B<]?BC^F^4>6_%':[/U<H0A1^C4NX<8I(X.
M/V3+6&_]#I%H'@A<2.IZ*PTPQ'CD3)6;+E1H\(0*G.I4_+^Z0I71I<3Y<Z!!
M[K*[$\ *K DG_H"NI/WSFU>9,.!V<D;E9% Y)9E(  X^)/H!<Y7&OB!>Y/BK
ME)?*_A?\_L7GO@&UI%])]K=@@-A3$%+K+>BX+G,$>^9APCT1IYQA.JU+LER^
MM('3ES>:1]:-N]8T^#2#?JF&3)U3 G(/H7-=.AYI>OO])QG4ZC6'9I%.+%T?
M49../L#DW\K-]=O6=*O"7PK?-WAAIZWA8I#KOH8^F5(N_HSIJ4&.@&B13[;A
MO=>^].SFZ6*)R7Y*Y4<9)DG"K+R6K39+(ZPS(1RY]5DS\&DQCW<2\* .E]-Q
M ]>!^R!.K3Z/%I_$+?*;W97Y<D\FO](OTY]23S+45G]K/MG_  [>7O\ $KU]
MF1^J3^)E_#AFX^M?^'B_%FEB<SFD8B,1&(C$1B(Q$KAZ_P"F]2XSYA[CU3BE
M#WTWJM$YX=L-'I&H<\FDT;A,:4WMP2)<9+&F1C"GS#X,4^P4-LCW!0Z0Q,F,
M.HTPJCY45VV(S ,W2A\^@OI9X'4\3+.[IBR/C7>ZJ2J\FR/@.3ZT.35#DR@7
MP7_9/K#VCP&_WGU7SR+5BU:Z&JO4FXP*B2H\*^A7!;,TFEL"1==;?>JI->QC
MYP5I@9.3*9&J8_%PI>1)Z-;APX<BKA:P5MAN#;39KD>HYH\^?0B<VASYL^)F
MSIM(:E.TJ&%>A]#Q?3[[G3*_]?K_ #2VT$#;65BP-]B7],>Z29,=D((/42K+
MOJ@!)#GR>2\8HH/H%HCS$;^A%AT$JW(3M<J.I',J%@Q')7;X?,ACML?)BH^;
M"=;.%90> P;Q>0*C=7WJ&/R4R +/[EYI6./6?H<X6;AW:M\4/]9D<P-#+&+2
MP?"\.E>@M\@,=&9K!*ABNGZYRPBQ$ZBR3)V<;75/V=JOD 4?4MZXP,75;&UG
M"!P0>"_=[PMABF[@,0 3Q8/$S.= A8@@A"^T@CD)WFPM14/L\16R0.:H7-Y7
MZ[XPF5'5NP28@ML9>GS31RJ=%KMX%'*58./UQNL-\R,4:+<9YNPS^V45NOB=
M08Q^R+L]0_)@.V1K1'E0X[E_3FU HJ5(8.;W!JH!&OR%-N*E:EN^3UXIKL,&
M!4H*VE;))=:'!-C:#<QZO87,!QVX#[,Q:*^+KS53=#O+HW225PL";!4C]R+K
ME\N@T5=_K#-1$5R>^?D&0J61S*4O%E"5.1V9#NF(!%$\WRH I@HIMVT[B15'
MGRN.^4$W8 JO"Q8V"3X NX;0.;''G4M*/(02T"$4&2XQ :2B1B ^?#>;D1)L
M&8RB1$EQ9#2E-/QI,=QMYAYM2FW6EI6A6TJUO>1%$@]1P9J#8L=#R)Z\1&(C
M$1B(Q$8B,1&(C$1B)7_U8%?L7F[M@.-J#MXISJR0V]$]CM0=[=@N:VF3LRS+
M"?84GYZU^/#3(#:]IT= 6 3]\"S],)K*A]&!XORY\J/\B#Z$'D9YA>)QZJ1S
M\>/0_P#8(]01P8]\D1:!9N'GP0.*T1J\ZRVFOGQ4V#Q2*AU<P4,C%Q<^#P6F
MT2D(T_!E-MOM2 >CZFGOD1F/Q]P4M6S;E<$]:!!&\CX$'(68_P Z])7"%*$
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MG]A.UZRE:J,=&/&:I0P?,:_)CIGRWAS(RBUIQ8  U &O1!SC(A$6#,D1'B3
M\8F9^'QCL&=F (!-T6+'XVQY-GGGGRL]9**515)!(%6%"CX4HX%#CCCSH=)0
MGX?%0H@*[=A+U'E-KYB5FUWG(*W02X^$Q :)UF!,'QF#!K^1;DYJP]'*,_5L
M/0FR96[L [@1L2A+XL.<'D;5OJ&8J@9U86Q6KNCR>-[J%' 6@I(J[(('/IU4
M,Y5&4E5#756O')V(2QY+66HW5 \RCU&A]=*=BO1$31NKV+DI)7$9AX"-ZN!%
M(OVJQ'[7#N F@QB?6PLFEL((V[CI\N/?WSX):HE"LT9[\0G3&&;-5&0(+9 P
M#@$J?"24(+$(=W1P#XB-PK@<7=7+L0KE"<=C>/$!W@8*"XH>)"0:!VGX7 ]:
MX5ZS&)I&K]'Z%?'Z^*APNZ2 _8H3+/>HBS/%)%5'T=HIT"O:$R:$+K-\C6Y5
MF8YQ%M'W\^Q&FVIN_&ENW+X3NV[19.RT^K^LO=2F]Q*E:W5Q=;>,QCRBMP9B
M!XR''ZSE" OB%;0&!O8#UYW&7EKU:[N$X)R>M1;73H_3:]SFH!^C&>AB+)T9
MLN<%TZ%!L#S1 1=*?/G%)!UE^0^?G3IVB>MNR7(NGI/U$8$H7<D':68J%I:!
M-C@@@"O+RF]9!C4;EW! '+ M9"T:IELW?))N>[RA^RUYJ^?\_P#(#QS_  [K
MG_U__P!R,GUF3]]OQ&3A^JQ?PT_")/V4FD8B,1&(C$1B(Q$8B86Q$R 8&3*"
MJZ5MI&#%<D0ZT$D@H98R\CY?9@P)5F,  #$AWY[^PX6-#8>OEOZDI'ZOG( )
M ) !/)-D#X\ G^0,@D@$@%B.@% GX<D#^9F@</ZHKMO,:EU)JBVWGXJ[A ]G
MK@:ZR:;(.RZU80PXZ$,NIH]KN(F(T0@DF_E!DEFRD5YE]N;!CZ^DIVV1-C%=
MP8J2"1NJP:(\0!X(\N/C*XW+H'VE=P! 8J31 (/A)'GTNYN=SNE0YU5CMXOU
MG TRFU@<^6L=ILY6$# !!D;6MOSBA4B]'A0HS?S2G;K[R$[6I#:?FM:4[JJE
MB%4%F)H "R2?( 2S,J@LQ"J!9)(  ^)/$^0CLGQ%OB >Y?B& PWPLB9+?%Z^
M(/\ (:1U$MQT<NB(BV)JB2^Q]+N-CNM1/RAH8 =8II&"C<>.3C"1551&J,DK
M;I BP^NFFT^#3$ZH#O#3LH<[N"0B@*W-\V>EDV?#8\3)JM3J-2HT9_5@%%<H
M-O(7O&+,#[IVD5SP*!NCU&X1\#/DVKFQW+WOU6\^]._2/HR9<SJ1$GKE01Y"
M]R&Q@BD/D)L@X)'N.O1(PZRDGJ@]#TUN+0PWV=,(Y7UST4TZ+I\?/N ;S\2W
MD?B!?VC.O'V<F[O-2[:G)]L^ 'X+YCX$E?LB=P@0$'5PXVNUD,)KM?#0V1X<
M$"'0Q <5 CITB/!&C![,>%!AL(UI#,:*PTRTG6DH0G6OEG$222222>22;)/J
M2>L]       <  4 /0 =)!GKW]DWU!_P[]K_ ,-;-E\/UN+^(GXA*9OJLO\
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M))-D^_YF=P1<>3"B*%5<>4!5% <X_P#V?7SEO\QF\8B5W]>_LF^H/^'?M?\
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M-&^IW3C*(<T82I4VGO0+[S>M6B\1)[CJ3S>Q0R'!'%8'W])@FAN/&'D=,90
MEB58%=I"A^H8-X6*K73DFP:J99 YI5 ((.ZV9.A4KXD!8>?2K\SY&1.0U-ZD
M<] UN55J[3)D-TY+G@*K;;#? [) S82QL@2U<[8!K-ELI0_-(OV"P%S@:.2E
MV H3<E2"3F]DYE7.YB;+=.2H4\ "MH)  J@ >@'3I+H-J@$!3S8!+"R22=S
M$W=FQU)Z]9)65EI#_<>?2>ET5RO0!D$D4CF0YP.J=>+CSO0HR&E??!9V+9Z+
M%FGV)@6<ED@R/3&7 ,Z86))*9AS'7V[HVTW="B#X0U@^1#<$'_KJ.DID7<M
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MM5T**'1_DU#A,?.)!B1HL9K3<:#$;3I*$(9CL_ZB,PP:;4ZS,N'38<VISY&
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MB7*V,_/6IXD=L1PY,)FCQHI+<D$2I4N0F3RA::1+SY$DF2GRY)G9R"QN@ .
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M![S'B(Z':1<]!/I9^FWVJ1?_  +]#&3LO29%5L':?MEKFTN%\#@%-0NCSMV
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M#L7&^JR/L6\V=WU?A%ZD@L#UAHWPX?%]!^BX/X=73\MK[.US+S,-7C[PM/\
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MJ.]&=5%E28,E+;[:FEJCS83T>9#?TE>]LRHC[$F.YI+K#S;J$+2_]^O]X_\
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M)L! *'_E8^M"_P!GUN57$ *9LA-MSWV7IN.W]OTJ;Y^B_P R_K[OO[V'J?\
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M5"$H\JW=/9  :JY##D,%*D D-1#+1(') //$IWR4"25Z^\IX*DA@2 5L;6L
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M.>1<'-C )W70)H!B> QJJZTK<'GPGC@R>*U8(%KKX6S"FR30P^+A%X#9@04
M%$1)\=N3'U/"FHD L,E::<3]:&0AQI3"_FAUI*M?+,R*)!JP:X((X]".#]TT
M!L BZ(OD$'GU!Y'WS-Y$F,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$@V
MT^>J!<K^[T&P/6F5*E)H+I"MQ[*0'5(H4Y:<+67GIPF*'*BR)I.IGS#YH3IV
M?L<V7B""SH]TD&&2XMQD95VBOVN:%@,*8 ^C#@^H)'0S,XU9MQN_#8LT2A)4
MD>JDV/0T>HD0U/PSQ^A%.72ZAHE A<XZ<3ZE*BSE_?)-L+2>7@N:#!!61"<$
MCD@A:Z5S6\NQG0TZ06OW-*C;I\I5BCD"L^YSNP8&CN0(/LC>6L=39W,O7W6(
MZ55%TZ*4VW2L6-_M'8J &J%#:K57+*&Z]9$LOEOE=M/W$Z=:LDMN[?C<LF U
M8IK5<@G[+4PM%L-K"C4:TH;82]1KXT&_(;D+@QF5%IHX?"*V.QSRU1E90 *\
M/0US0)8 GT#$D?R-@ "YQ(22;\5DBS5D!20.@)  _F11))W"X\4I=YML"Y&]
MFDDX3-(9>C0"BX@PI_)OTD-UBCNDHFFG%..UZY!OO<=49Z*F7#*%(!),UAV+
MJ' =E! JO%Y=-RE&KYJ:/R!%$26QJS!C=C;P#0.U@ZV/@PL?,@R&SOAS@E@8
MO4.4%(1H/0KF9OI^'!V$82]8;.3M1FV.ORU@GB1R)8B]VLI54*US;"S6BDR$
M4HVJJ2K];EB+C/D&WGW5"B[Z"JXN@0% L58L&[-T.#&;X]YBQJNI))\N02QZ
MW7!6B 1L[WDKD,B):1S\>R.BK<"-5\B+5897W2-"LG)Z_P 6/NC-I;3)B2BM
M$JP*)(<W(=;;)0?Q6*U'F29BY$#,XKIP0>GFKEQ?R+'[N)/<IXNM,""+]4"&
MOFH'WS^I7DOC,J_M=,_!)#=MW/,SY\]S8TELGLQ9#-O3'6X:%DY8AL58[";)
MB9-7E 23.R<J'*GS!RDPTP,KA=E^'C_H5?W@"P;' XN#A3=NHW9-\'J2?,&J
M))%4>:NN)FZKYNYK23M:L=7;/BBM7<CZB.MFWGVYL"/S2D<I_!R;,MM]N2-?
MK/.*4^^EI,>8HP":GHF-IED8\R#D9@0:(-\5YEBU\>=L?A1J!B52&&X$5Y]:
M54H_"E6^G(OUD^92:QB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(_Z1S@-T\%!!&2!T
M1^%V.OVP26K9!L:8&':R1:)BIL22]%FQ]_3D-:2ZS(B2&7FEK0I&M[2M-E8J
M; !L$$'I1%'T\I5E#"B2*(-C@V#8E?B'A[A$HK%/,A)SI4=5;=6XB+"5)6@=
M-?O /IX2U&K*HE,U9K!,M*>P7XC;F'+3#C68R<?/D4;L:&#+.@SO56*+*> %
M/A*D 5P -BUQ8 H<6)GW&.[ YVE>23[P8$FS9O<U\\DD]>9M37ENC+Y-RSE4
M\Y<G-<LK^@<&ZBK!+#7,^X4J<^H7DG8"[:I+T^=T2"8-3[5+D*>(N'B7YE'D
M(-F@##4.O>MO9P!XS94BP*;< /3;P!5<<=.)/=+L5+;PBMP-,;%,2>;W62?B
M;%$ S;GN \Z_(UEY\.AD@=?LME#W!7X,2<C3 MDKDFKSJV3 //(D-0=@)]-K
MDT=#>CRQVW1R6IL.9%?DQWH#L&#<$@$<CJ#=W\[,L<:E2O(!(/'4$401\BHK
MY36"OE3D!@Q1;!+$27#//;1TFU 2$O\ "S#JI77.C1>K7V#);L HO&;BF+M
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-,B3&(C$1B(Q$8B?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g197729g84y44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g84y44.jpg
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M!=?326!*BVU*RP'!(#L"0#U(DL:'AHD#6@?&%T;GME=4I*YK=VA<F<FMR1*
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MBB/EC(S0F/QN<,*QD:6-QCDPB[/7$)1QYX:EA&VW<=0+"R!+PC5#N-[_ )O
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M*TARB[4A\X!\C><*;D:EOB4UHMM"NHIQ^3<9:V;0C<HE/8[%%UL;D\*]-?G
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MWMB=T<FEN2($:=,8>Z.JU<60DT8E)  ]4L2IS<]51M+ %555+,S=%4>[))\
M!-5URTA259V=@B(@!9F/AR0 ..23-5'&_M.E,=F7:>W3R&(O=FKRL+>XYPJJ
MN/4OCJ05L126SN)N; =5,4AI3L)KV_R>:(M'E;3R$;"O2%_*<+P%G,,7;T6:
M?(TZ)L+,CLS@^J0&)W$XS@+[,CIC,RUZD@ZI[.\"J]:I6P]<%EQL SC);VX_
M2SCF=MSF[2.32#@WSO;H'&KIXC\K^-K'1;R[QJ7J8D1+V:.VG:<'1L<MA\J@
M,HE\;>6AY8SW=E<S$3H!:T*SSFY>E)&<G-.4T 74DE+:["XRN<9522"&"D$<
M'I@Q?J2U&HVAZK:@A()&0&90&#*2"",C@Y'V2VUQ=IU!Z2D4U@;;3%Y7VY\?
M:DA5M<HI+5+=!S66DX?+(Z.1MJZ1F3&;1):_2!;&T2Z8"CT81.2@$:)/=##P
M 2KBDE2Z<N V]$#N4K#9]=@<8& <#) R>,\2U]4M990CV=VBM:5V^H",C.X@
ML2N6P,\?7C#T;[4V:S#M$(_QSB-%R^5<:9EQBKR[(U9S5'&Q,_;;+ E+%I'?
MKH\.UC(6Q)QN;XJ^EMCH(<4!8".8(5G^K#FXO11DSI@*#87 =;&0KDXRJYV8
MVY[S(/CMQCQD!JF.H%8K)J-2N& &<,1^<)+?-[3Y;LCH1,LU+VL%16Q/*?:4
M]/WG$*BY&S>45QQXY$RUEB"2M+7F45,=236Y$V()DX3^,I)(>R.1,*7RJ(M0
M9"-.+0B&_92K2:#:9E5CO0M6 UE8)W(#CJ<!21GD G'MDTU:.R#8ZI8Q6NQM
MNUF&>,!BPS@[21S*"\M>UH=K79*5*XOPWDG7\ =>>=/5.W\GODXTM5.W$QLD
MU7,%CPUE?$CZX/(&Q^'LLQI+>F1O)DS<T/96Q(G!I7-6KZM,%9N\-;'N6<UY
M)=,J"I(P!D>."<9\N91=JRX3NEM53>B"W ". V'4$$G!\,C! /0\3])&8)Z4
M8B,1&(C$1B(Q$8B5VY*)$BB+5^,]*G/'J_>/)6AG$EF"T4;<T,"87H0PBWHL
MP.]A&#6^Z/6]Z%K>M[S9HB19=@D?[IK.A(_^6MF/6@&NK(!_WO1CD \?&:N)
M88LLLH "B@ *++#H!9980@   == A  .M!"'6O;0=:UK6O;6LQ]>LV  < 8'
MD)[XB,1&(C$37)R4C\WKM/9UT3[F$LJ&$EGN_P"+9H=)8CB,#:9RJ9X*T4J4
MYZ;H>;(75(WR@%C#E== 631%:ICY'E#@WFEM:1@9-%15MJ+5O;]+"[F*Y8OC
MG'3;AB!LP<8R2V:T,NYVN-:\[<L%7<=HKZ+D\[LKZV_('/26LIODA27(+Y1?
MB=G[;./DEZ3\HO3T+TB],]=]2])\;UAL;O$\[Z.Y>'Y?QNYY4?B^'WB^_4];
MUXWJ5SG&?'&,_9D2U+4LSL8-C&< C&<XZ@>1F;\A+(Q$8B,1&(C$1B)"WS]\
M(-_4W]K)RQ?F[/V/YC*V^<K_ &_Y1)IE<LC$2I_)/@SQ.Y?K(JX\D:4C-IN,
M)3.:*+N#NKD#6O:43P:E/<49:V./+*I4I#ST2<\*5::I((."8:F+),//$;;7
M?;3GNW*;L9QCG'3J#*;=/3<0;:U<J" 3G@'KT(E-IUV%'9AS&'R2+-O&]N@3
MB^M*MN032&RZ<E2F+K#R]Z3/;$)]DCZR"<$!V@'D%.[,Z-I^P;(6H%28PPH5
MZZ[5*P8V%@#RK 8/L. #]A!\I0W9^D92HI521@,I(8>T9)&?>#,.<;_P>+L_
M*6CSXW6=%GWDQ('IS*5E22RG5R8 ,#>E+.+3M,?98&YQ]*G+.\81[FL<CW56
MN4@)V28A2DEI-3M[1U#D%2*@!T09R?,EL_4/"0J[,TU8(9>])/RG\!Y +@#V
M^?'E+BUMV2?9T5%/8E9]><681'IU!'UOD\1?_6)P[&L<@:3PJFMX2HGR5.38
M)>VJP%+6\]0B.$C6DIUB;PU2<DTNAM7J74JUK%6!!&%&0>HX /,O71Z5&5UI
M0,I!4\Y!'0C)ZCPDR7\-QK.:Z3E!J;E%U_IH9Y8YU!MF$/U#D9&85+*<C]Q;
M??/:3Z"12,T<82J9C6HX\2UEC+PF<D^VX1!G!=^8-6WULD!\]*RP<IC]=0V<
M^)!$Z:,WBW=ZN 2F.MH4H+,_\-BI!!Z*01@YQQ5_ 5-5]U.DR3LG':6PU7>=
MC7RTR675._.%[QEZLF5R2P%[ U2XJ;D1H9\>F<H<Q12:J&+;BUQ3R<>/85Z]
M$&1'R?4%T )L![M:R X[LA5"@E2">0!E0<%LD$=)!-,$LW 5E>\:P%E8V*68
MN0#NVG#,<,1D+Q@GF22(<)7B,1'B9&3+!;59G&P^\C7%66P*B@2L-OP2QH<E
M"C)$YC$U[8SIR0O4>.8LTN+;C22_+#4 ,*X;@3:=I_.! .>FQD;RYSMQ]?LD
MUH*K2-P/=%R>,;MRNH]V-V?'I.@J'AS=_'E97:BGK=K, -\9N,/':X0SVM9+
M(MK5'&=E?V%IL*MM,M@1G38ND;/+7YO61J3#=&Q&H2Q]X L/$E=FMXZ]R6;M
MZ-\[;:FU@,=Z0=K94Y (!R,'&1Y$12BRK;W;I\U559N0G/= @,N&&"02"#GP
M.>,&%2OLX5KB\1F;(WBIIO*HO;',N8!C%O0%[D-?/$+Y<W6EN,YI&2S2=L>&
M29P!P8HTD;)2D$X(75)\IFY4QD%O2):S=74X#*0Z@K2,HP#!JD*9R5(*L"<C
M@],-P08G2Y(;*L0]S;74[2MS[\<$$,N%P>AY&!G(V*U# 4M75G#( C:8,Q%1
MAE(0&-5:18^%0-(L&,Q4X:B\65/,A5,S6<O4*5!254]N:H0S3#U"LTXT>\SN
MQ=BQ+')ZL=S>0R<#)Q[!-2+L15PHP,84$*/<"20/KF1\C)1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$J[S7H9]Y0<4;XX_1A[:8W(+7K]UB3.^/Q:PUF;5ZT9!
MI"AR WDJ%OE-"([APDI!YP C[X"3=A[@K*G%=B.02%8$@=3B57UFVFRL$ NN
M 3T'/CB:PIGP$[07D!QNKSAUR,MGB<30$=EO'AKF J99+FC\]EM)4^,9DEB2
MYRDK@[-1\FD1S)"%C6Y(TC"A0N36O6&@"6-*D!H6ZFNQK:UMWD/C<4(#MT(P
M!P,G/7@_;E;3ZBRM:;7J[L-7G8'#%$ZKDGJ<+@\8P9EV%=EBDX^<UZ%Y2<:[
M D:./,4-L>L^0\:N:SK,LZ2SJ"2)O2*84AAC[*5<E4-_R:EQ 9 K9UK@WM!Q
MJ) :F[J@2O9L3J"]3UV $E@R%550K#(.0,#D<9P3@GV2:Z7N[Z[:V. &6P.[
M.64@;0"<XP><<#I)9Q<X:\G^)'#":TO5-J4^GOE;=4YM2(2N2QJ32>KS&J5S
M]!)#8I*FLL4?DH .\:3KF%S<V4>EC,J<-+FDQ48D*,'&RVNRT.RMLV*I (#9
M5<9!Y'7GGW3M5-M-+(CH+-[.&()7!;.".#R.,CIU$@?'7@SRQJ6U.6/,!^D_
M$UMY8W_"HK#8G!JTA-D,_&1A,C*M$J52F<%'.C;8LNDDE&C*.<7 DQ M2*M+
M3-+W AU\LVRLNK9:J@+#76226*]X<^"\%0 .G7W<3E=%J/;<32+;%"A55A4,
M>+<AB3XGC]\FG9H\2.7?$$ZYHQ=DTXXRVM[6LZQ[YU^*QILU+-V^V;*=HT:Z
MH=K):K+8@5XC:6A<!O;M-JJ2%.)R0:E^6)@G WS46UV[2BN&553UBI&U0<<
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MS\S/S<XR/L<G\J;[&5>D5F;!BY.!= ;*:7H\JT7,3)5J^'1EVAR*2V0T6D]
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M+(H@D$QBK/#W%T 2M1-++*SYBFVT*T:16B5'NJB,Q09*PW9YQ9Z +::6G\$
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MG(,=7-4S65'$Z3B4,J!YE<GC+7'6>4/TUE,J=)+,HQ#G94\S%_=6HE+'D\?
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M2%YP];5JEF\&LL59 K95L$JP9EP0P)# G@D$<":BEJV/964(L"!E<LN&7(W
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M.11D;(ZPMQ7MKPD+0SI4;>D+Z:U\Q.G+#[:]O;,9)8DL2Q/4DDD^\GF;@JJ
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M:VDQ$G5*@!/(2E^,O<E"5L:&P@Y24I>GYS4D-C S$KWIQ,"B0'[R=:&QU0$
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M<9&\O1*!F8FU$T-2$G7P*1MS>2G2)B]?0622 .OHUF8DDY))/F3D_:9K "C
M  \@ !]@G;YR=C$1B(Q$8B,1,!O]&N;[9[3:.KMMAI<&!*\M;)'&Q%3XHTVQ
M^2K8HX26/%A=*F<Y H;WQ5#&$Q2K7R!6^(])S@-#NV@4G!%K35JE#:?XKIF#
ME6:QCJ>\+H+%1\KJ50%1:X "!#D%E) F-](SZA=1\;U*L@95K4:7NU1S6SH-
MVF9RKFI"27+C!VLH)F?,R39&(C$1B(Q$8B,1,'VAR:XXTD X=Q7U3E7"(!L8
MT\^LJ'Q1:+IKKH!"![>$:U2</7L60G3FGFBZ!++&+>M;FM5C_(K=_P!56;^
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M,UOJ).YI4CLA3N"9.\M+DQ.Q)*HL)I9;@S/"9$Z-BL(1:T<B7I$ZH@?4LXD
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MG!R,9.<9QC)78SE*^]+9NL5W4X)"IN"@CY()Y&#D =>LYH-9ET7 V6W!Y-R
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M_*7*:-Y8_8E:7%7)$SO",8R]Z4&$*J7DR8O?0@*PT6N\=/N=#3\[>US#JM0
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MC\GL^W]IB./_ ,?6/SDW:[NW_L+L9Y,W=_\ 4]?NI*#N[WKYOB><BL=Z=/\
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MVC_Q5O'35_:?'KT;_P!^ C\B/MTY[\RR>U7KJ#$&^QI%34Q'S?*AW\0IE:.
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M_1U5F?JD85]H/PI1=?&Y)U@/N_'RCT-?_P#CR*93WO\ ^O7+U]#/2E^G87:
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M>LX/0/LP?+]./1M?/&ITYQ]NL7_M.?[2?IBY_,?D[?"M:/#_ ,*[47GKSL[
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M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)K Y2,D\CUR7](4%/V#;++R
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M \R9<G*9?&(C$1B(Q$8B,1&(E0^2O"*A>4:-_/L".')9@_QV,1,Z>,CBYH)
M5'8E)UDJ9F@19"XIK7HTCD[/VTQ;BA5;2>O.9J411YVC VU765$;3P"6"GIN
M(P3[\ ?8)3;17;DL/6("E@3G .0.N/$^'B9:YK;43*V-S.VD^6;FE"D;6]/L
MTX_9")"G+2I2=G*##5!WA$%%@\4\TTXSN]\TP8]B%NLDDDGJ3D^\RT   #H!
M@>X3[LY.QB(Q$8B,1&(C$3%=WU(P7Q4L^IZ4.#RTL-@1Y7'W%SCYJ$MX;RU
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MU,C,XK6EJ+TC9B%2"/(T#4$UO:R4B#9Y"8LQ7Y;S2G8E!QHMU.P=F8*%W'.
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M39SKXR6M2QB7R1G9V)\<"6=T3'('=&G0R-$O;-#7(%!Z8*H:81Z00]'IQ!-
M'>21@K!BN['."2.?#D<R#J74J&*Y&"0 >#P1SYRJ0^#SB4RULG;N0$T2R>OJ
M0DO'$Z3KH'5;\1(Z@DJF.'#:548>HHL86V0MI,49DA#^WIP)7D@HP$Q9).66
MW%MUW?\ +?FQAK!;C<XPXSSD$'!R>/#P(E7<'"XL;*UFK.U#E#CC!! ( QD=
M<^L#Q+BUK 6*J:Y@%7183@.,UM"HK 8X-W6C<G43%#F)!'F@3FXF  ->X";V
MY/M:M&  U2G9IX@!V9O6J78NS.<99BQP,#+$DX'@,GI+E4(JH,X50HR<G"@
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B(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g197729g86d56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g86d56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6\(:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!R:6YT/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @(" Q,S,N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(Q,38P,30F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(# W+4IA;BTR,#(Q(#$V.C Y.C V)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(# W+4IA;BTR,#(Q(#$Y.C Y.C V)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.^* HB Q(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L;W<@
M,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI8G)I+4)O;&0F
M(WA!.R @(" @(" @("!#86QI8G)I)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!#35E+)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B
M965N(&9L86=G960@9F]R($-3.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I
M<R!L;W<@<F5S)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(Q+3 Q+3 W5#$V.C Y.C$T+3 W.C P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M,2TP,2TP-U0Q-CHP.3HQ-"TP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 Q+3 W5#$V.C Y.C$S+3 W.C P
M/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!
M9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O
M;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D
M9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR
M-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG
M.FAE:6=H=#XQ.# \+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!
M9T5!<%%#;$%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!
M04%!0D%!<%%!04%!14$F(WA!.T%10VQ!04%!05%!0B\K-$%$:T9K8C)*;$%'
M5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O
M2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS
M8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!
M.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!=$%%04%W15(F(WA!.T%!25)!44U2
M068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#
M=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%
M04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9
M155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS
M4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R
M>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D
M;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!
M.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%
M0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2
M-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#
M:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD
M65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N
M<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ.'HX-S9D
M-3EU+U F(WA!.W-D>&]6>&,R*VYA9G Y=&1U9E9U;'1P2DER;61P649G:4)H
M;FQL44EP5FE#1F]F1$I$:WA.,C-P9FTS.#%*3F(P3S$Q2%1,4T=W=C<F(WA!
M.V$R=6(K65=7;VAK831*-7=+,&8Q:4]'4T551&5U5D9F1$=G=&QB+VE0.#!O
M9DU/;V%F1&%R9%%(53=H8E8W:E0W:%DT-T-/,4TX4$,F(WA!.S5J94]*+U9D
M1$5#4U-R+V$R6E9$45=Y;$5N-6HO;D9(<#%L3U!,,$TY>DY)>'59271.,5E'
M2TU#3VM496]Q56LK3G9J0F%-,#8W8G0F(WA!.T)&;%=4>F8K8VQS=#E#3E!7
M.6QT6F)T>$Q0<&PP9V1%=DEO25EO=E-K4E=":&Q-<7-/6'=Q4G566G-A0V)+
M2F)Z,2MB075R1T4V1D(F(WA!.TA'56TK=51Y5T]P34I8:G5P65971EE234EE
M55-*25!78FEE6#)G36%#,EAA6#5R+T%$675T9#!*3E-S:%DV9$I.06138414
M8G!K360F(WA!.S-:*W-)<$]B=3A::&TO9$Y)0T96<48O:%5Q>E%7>3E6>4Q*
M,DMP8C5L,4,Q,#=13#8O=3<R5%0W93)I85-3.&A%8E-2:&0V;W-Q4V\F(WA!
M.U=044%Q8U%P95@V;#4R.#=P*U8R:V%T<#)Q=UA7=5AM<&5J-C!1=%HK551#
M85-/,VPY2E1#2F5#;T@T055/4W)D:F5Y6&%8*V0K=G F(WA!.W%/;S9J95%*
M3G!&.%E(,&$Q=5I)-T]+,FAC6%!X5%A#>%-S5VPK<69#1W)5;F%M2&A2>$IR
M3BME3W-Z-F)C,T9L-6930GA"9%!A=F,F(WA!.S-,3U).85=K3C5)<W-+>$DQ
M0DAC0VQ(,TEP=#%!-%4X4T@P-S@V3F5T23<K9E5B2S(Q0S-L;FYA=VY3.&ET
M-&M%1G!B5'1!2&%*43 F(WA!.V8K:V-K:UII>E9P>#99,'1P+S5J+T]&9$<P
M3%%D5D=N47IJ5S=793=#3F1007%E9VMB*VY'>C(O2U(U4%5O;G=,52]01VQ-
M:W-V=GHF(WA!.S5A,FPQ0E P3$9X<U1+1#9T*W-4<4ER:U<Y3&A$0U1%-V<X
M,%)E8DU"=&IW<GA+.7HK6FYM2S8X:BMC.55T:%I7.2]O:WI286596D@F(WA!
M.V0Q:&)J=VQL:6UJ<41W67-H6E%(26]65VTW4VLW25A4+W=!,CED<V8P<EDS
M5VYR9C-/:D,V:W8W<3<Q0S-H6"]!16%D8F)H13979'(F(WA!.T=W85)G5C5+
M1W T;6EL<&)49GDO*V%D.7%-;79813%N82]5.4TP<416<D\R9VUL3C-+<C(O
M<D]O5U=/4&UV26-E659A8F)(;'-+5S(F(WA!.TPV9BMF3W!W:2MU3'5Y:'9O
M-6)M5G)+3DQP56I32T]',F(V=&)Y<F(Q=5IM86-N:59".3A00VII5%<O+T%$
M,VQT<G4T=$ED1G0U<%DF(WA!.V(R4WI$3G%C345)5TY78FY*8U-X<F)O>FAF
M:&HY470Q0F]A5F5&4$4Y6&AK.5-*2DMC96%H=4Y1859&8595:T@V36EY6%EQ
M-T9867$F(WA!.S=&6%EQ-T9867$K94Y5+S5Z1C!+=S%+-W-8.'0S5'1A5%-1
M331U27='36)L4U(X2&5M2V]B+V]D4%%0*W!:=78K:VE0+VUJ1EAF.$$F(WA!
M.U$V96=F.5-Z9&8X05-22"]!33!9<3<O;V1045 K<%IU=BMK:5 O;6I&6&8Y
M1' V0B]W0E-Z9&8Y2D5F+T%$4FER=CA!;V1045 K<%HF(WA!.W5V.$%P26HO
M04]A35966E K8WIV3&EW>'5V;#8U9#,U8S1H3V=+57!3<$M53F9B1E9,+V]D
M4%%0*W!:=78K:VE0+VUJ1EAF.41P-D(F(WA!.R]W0E-Z9&8Y2D5F+T%$4FER
M=CA!;V1045 K<%IU=CA!<$EJ+T%/84U69"\P3VYO2"]5<S-8+U-22"]Z4FEQ
M92M89CA!;DQ$>7)R5W F(WA!.S9F<'<P=6$S;C%#84\S5E=K-6-(;&-)=&%2
M,%!8>'E*2G9K<60O;3$O=T$U0F%:*UA/=3)U:UAE:GIA:$IC,G=U:$Q&2VM9
M04QS;D<F(WA!.VI+9C5-:W)"+W=$;V1045 K<%IU=BMK:5 O;6I&6&8Y1' V
M0B]W0E-Z9&8Y2D5F+T%$4FER=CA!;V1045 K<%IU=CA!<$EJ+T%/84TF(WA!
M.U9D+S!/;F](+U5S,U@O4U)(+WI2:7%$=68K8W902CEZ<59N<6,S;$\V92LP
M.5I5=$IV<E-J9TQG2TI2>$-H5'E#1#=14'1I=$IN1"\F(WA!.T%--6QE6#5)
M2G!F.%!4;S!10D5B6$U96C8O>2]",G=&5D0O;V1045 K<%IU=BMK:5 O;6I#
M<G8K:# Y02]W0W!:=78K:VE0+T%*;W@F(WA!.U,W+V]D4%%0*W!:=78K:VE0
M+VUJ1D1V*V@P.4$O=T-P6G5V*VMI4"]!2F]X5C,O439E9V8Y4WID9CE*168O
M3D=+=EI0>7<O34]Z."\F(WA!.RM622]-3G!A=EI2=DY*03%V27=D;&%),"LP
M04)U0T1I<DQ-5F1I<G-69&ER<U9D:7)S5F9M<#5S+W=#57 Q:B]!2FIR;B]K
M.#)+57 F(WA!.WA6=D9867$Q:7)E2W5R:7)S5F1I<G-69&ER269Y-B\U5"]Y
M,R]W0G1/,"\U4')I<C%V.$$U>DHO.&U&<%@O8DU4+VLO2FEH-$AI;#(F(WA!
M.TMU>%9R1E<X5F1I<G-69&ER<U9A>%9V1E@R>"]Z:5(O-4M29BLR:&,O<51&
M1#)J1EA9<3=&6%EQ-T9867$W1E@U<65B4"M5<#%J+VTF(WA!.T]U9BM4>EEP
M4VY&5SA69&ER<U9D:7)S5F1I<G-69&ER<U9:1BM84VXO2#-L>C(Q2S!0.$%Y
M6%A&6')8+T%$;50O=T-40S!R+T%,6FDF(WA!.V8X;C5C55!!.%5U>%8R2W5X
M5C)+=7A6,DMU>%8R2W5P:7%,,#-4<FDO=EER4T%6:VM93%AS050Q4'EY>D9I
M335C25EZ:TEI>2LR+RLF(WA!.V-9.4MM,'(X=%=S<%=$=$AQ1G=1-#)$0FQJ
M24](4&A/3UA#5T]024II=SEA>7!M-T9867$W1EA9<3=&6%EQ+TY4>EHO>6Q/
M<V8X>#$F(WA!.WHO>65B1DM667$W1E=W<DA906XU67%U34UO-F]W*V<T<71+
M3T]Q;C=S5F%P:7)G0V5G>%9E24IJ,&I9+U%C5E=L1T)O=TE)-F=I;4LF(WA!
M.V\O4W1&=F13;CE+,5%U459$,#=":E1K9EE:9&AW4WE'9S$U36=J>F5O*U1R
M9E(O3$AM2%$W2E=7-#%/-S%#,$1"<45G3DUG2C)O44(F(WA!.U$P.3@R95--
M34=->#5Y3&AX37-S-S520V0O.$%/6D@O04I-2%-V.$%T;4HO>69K>E1/93A$
M>%,W1EA9<39H.$U69%1&6%EQ,G%/>&\F(WA!.W%L:C1!5GA68S%V3V]Q,&)!
M94I"1TMR47!X5DAA2$-S;7)7:V)R>5(U541!.4M6>3="1S5G3E=5,45L-GAP
M;6MA5C5E<UI3<F-9-FTF(WA!.U-785%I=$%/;&%$3VIX-%E9;VUU5'%P-4I:
M1'4K:68K8V1D6&HQ6#AV,W5O:%-%6#EW:V9I46]48R]4;6<Q;554>45J:S=4
M0D%X:E(F(WA!.V5O6FET<G-69&ER<U9D:7)S5F1I<C@Q4$YN+TM5-G@O>DA8
M4"]*-7-5<%=I33="5D972F]!359:6'!8:W%A5T583GEJ*VMV>%-%8DLF(WA!
M.T(X-F(T;UIJ-54X;C9.8W1-,35&2UE9>79'4DYO<5 P1$)2>35%-'%M;FU$
M>6PU93!Z5V].3V1,93!U<&Q744ID6%-2<4EZ5&0Q-3@F(WA!.S%/+S)446YW
M>%9N4&PW>4(U2G8Y23%'85-A>G5',"M26359-UAO,%)P>6-/>&9F=R](1E8X
M4#5+9FMT8GI-2G)M+VQU,E0Q<E,R;' F(WA!.T=*1%-T4#=N8U8Y.%99-35W
M.'0O;')O2#%Y2G)M>FAE0D]A4E,X<$AF8T-I:4DX:E=T3VU+<UHP*R\X07EQ
M;3!Y,VMJ;6EK,4]2;5,F(WA!.V5W84MA26]+:TMY=DHK-V%O<'1Z<G8P>%9U
M+SAS84MI=U0V4D$S-E-U4S531S126&IJ:59U4$Y"24-N4&U#0GE*,C=D1&U.
M>$=C>4(F(WA!.SE-9G948517.35R;6U833!5:TUD-4MY=$=K:G%%;%-4:65!
M-4IW-4EZ.&518G0Y;6TK6F5$36-"-&\W9F,P-6-)>4-I:TAK-CEN=F8F(WA!
M.WI,,$,T;D9*6#%3,#5$9F(Y*W4R-4]3>3543UA%5V-)0TEO4%0O.$%N36XO
M04UM1G!8+V)-5"]K+TIL8DHT5F%78SDP+T-)5DDV;G,F(WA!.TU5<#=B959Q
M8U=M-4AW-TM4:6AM2&QF.',Y4#%/2C=I96)G:5!X36-90EEB5D9386I&535I
M+TPW>75B<%E);G4U>E5P=VI65S-'+S(F(WA!.V=T3594>3@O24<S;3!L-S=G
M.6]N<&E:5FQE3C5':4I!16Q%1W=Q4C-R-UEQ:V9L9CAG-TQ5:DY*8V%G<V%W
M36EP0TA":VQ:>E1I;T$F(WA!.T\Y861C5E17-B]*<E0Y3F4X:"MP6$IM<S!E
M4V-#845C5FI8;7A.5DA29#A642MN9FQX-68Q1%%O.59H85)R5U-5471*2%!&
M27EY32\F(WA!.W!Q<G%Q<U9Q,G=Q2UI#8WA%13EY:FUX6%4W3%1R0R]L<W9,
M,S%A-$M-43$X,%-Z5$U"<U8O9DPV64A)5DA&064Q5&Q/2T)M0DM86&\F(WA!
M.VQ+;W)/4RMU>51B=U$V>$%V<E=%,71'<U5C.&E%35EP-&QO9TI52&=Y0F0Y
M;7)7<3)X>65#4DE'=T0Q4DM(14M3=3DX*V%Z9%<X;'0F(WA!.U!(03A5:6Q'
M0E$Y1"]S<S)E5'1#8V]M2D$S8V%/;&E$93<V>2]W0V-3:E@X<%8O-V%&,2MP
M37=(2EIK;C5O865T+W(P33EJ3W1P;W$F(WA!.VU73S5J<$EB;4-'6#!,>59%
M*T=I,C!O268T:5-.>'9T:'!&<%!Q,S5S,V%H-61,='=)>F)V8WAX6'-"4FA(
M*VI,>3EH8FQ(8TYY.5(F(WA!.W)25%%Q<$-';C)V<VUK16\P9FY*;V-C-U=-
M=&QD5#9L2#9#;3-T1W,U+U5K;FU7,U950UA,1TTK;S0K0V)G,40P=U5N:51Z
M5&905VXF(WA!.V%L9%171G9B>GAA:F)X,V(S5G9-<V8W:')34EEI<W!34C$O
M948V<'=*<714=&I3,G@K>2]/6%-)+TQL;F8V;F$S2#9283)I;G9B5S$F(WA!
M.VI1.&5D<$1C=$MI=$Q8,%<K<TMQ1717<&]E*TY+0W%49FY2;TYV-F]U.4HQ
M4S)E3U-A1&A*2&)L;6YT<$EO-5E6-%1T.%,O5T5A=C(F(WA!.U-/:')T:E,R
M:')N.#5B83,Q<#1P9$YU;# R,6=L1W!P=VEA-71B;4LV4S-0<6Q:>D59=C-G
M4#=S<V1X5'9J4S(K2&9.;B]+539X+WHF(WA!.TA84"]!0V5B07ED-69G4U,T
M9#)P.$%&2RLK2W9O8E1B5%1T5S!U3T])4U%7-D9"-F)R>%HQ6&-E3S(R*TM%
M9R]-:E5.4#AP*U4U1C F(WA!.VTU;'0Y8C%7.6]%46AL4TM"5F1P2W1U<DUZ
M,$9-5F5$,TXQ8UA--WHS17)45%-'<GE/4WI%*S5/2U4S.'0K9&9-,VQP<'IO
M,39B6DPF(WA!.W!E1GA%5E-22%AB<6MI=71D=6\S>%9M,FYF;3,U;W5).50Q
M>E<W-E=7-VEI.412<&]O3&8Y,6-U<D9D:7%R>$90:3)*>%$X,'4W>38F(WA!
M.W4U,VYU6E=M;6M*6FYC,4I*3E0K2GA3;V=K67$Y>3AL-C,O:7IY6%EA8GE3
M2'I";S!O=$5U,T1"1W-74FU8;G=$2&MJ<4)8:G9M2UDF(WA!.WEH37EI3$(V
M9G!4,%0X95=,0WHP-BLO4W)*8S-*16LQ=3A,3E5-1BM&:5-%*WED-D-V=FM:
M5&YK,D%-4C%T04QY3'EZ0VMF-6PK6$,F(WA!.VUW9E5R46ME+W="65A->$0P
M;B]N36HO>5E7;&8Y<WA0*U0X;4MV3W9*0V%D0F57>C-Y;&]#03-W06LX>E%I
M;SA-5F5R-GHU6G5.5%,F(WA!.T(W4F]O-#1G>G%'<4]4379W13A19&=C5EES
M3F-N.&@R0S,Q.6)#-FYU,FU&;&%.+V-Y3W1&85-7;D4P5&QS0C%/2W-3="]Z
M<R]-93 F(WA!.W9,<35S3E13>DXP,THT;W)A,C1$86=#2SAB8V1V1$9+9"M8
M9GHY.'DR.6Y.<"MV;'14<W!G2TUH155Q;FU'22M(:7!5*T=+12LX<68F(WA!
M.VUP1&1A;G%N;4,T=#%S-V)35FEU64Q&2%943459:U)H:5!T;FHR>%9G9FUN
M.#-V3RMV6"MO>G9Q36QV8F%J>E-7,6HT<41%*S-":4$F(WA!.T-F:#)/2W-B
M,$Q8=%$P9E5B83ET2FY2;TI9-6I'1TE6:D=W8T)H,%!4=FM:>$5G465Q6'0P
M96LV9'%N;$]X,7)Y.6).1'%9=791;FXF(WA!.TI6;&QH;E(U66YO<DUI>4E)
M*TUQ.6TY<4A+<V,T:C!K*V],4V(R6&MR5%ED3VAV-4QF-G1F5W=,5WIS5RM+
M8TME1F5X5E@T;'-O>C4F(WA!.U!%<DA$8SEF24I!<FTK94YA=%)B,VA!6&E'
M1E-0971$;6-H.6MF.$%/2D@O04I+4F8K,FAC+W%41D10,2]+,WE!;VE#84Q$
M1S!D43 F(WA!.VE'4EI*47IH,E<T9%=$>F=S;W%*4W=W,E551FLS:T0X=C=+
M14Q084IB>%1K5W%E<F-Z2T=-.&-T<6M38W!/<E(S8VMA2U U=F@V3%(F(WA!
M.W-R4RLQ+TQ(>5)A,VDS:T=N<W,X8VE44FLS3GEY;S94:3989VI3;$9(<G%(
M24%O5#$V;D<Q<$AA8C56=$Q,6'1D,6=S2DHY8TU!;%4F(WA!.TIW-%(R.$EI
M0SAU4C5%;FM39'5W<'181S%P3%8O3%!Y,F(V95-70EAS2DY-='1(9W-L.5)#
M;'1A=5@K2UE0-FIL<5)I=7AO9S8T,G0F(WA!.TQ032\U6"M83F)S2C15:BMQ
M6&,P.&QY3'-.3$IX:W5*26YU1'<Y4E(K.$9U<2\U4%599W)32T@U82M3+U)N
M:$]N;#%U63-I=5AE-'4F(WA!.TAK;%=39&)H>DI),&AD;6%607A9;FPR<E1'
M,7 K9EAM>B]L2V19+S5J<FXO04I03F=:2T]I6'E7;#1$3"]D4T1I+W1V<V-6
M9EA(:T@F(WA!.U=T2VYT3%E06G=8560T231N6F\P3%)S9FAQ:$YE2D9C55!/
M9GHS<VUN.&LR,#!7;F-M,#8K6G)R56=O+V1X>F]%4TYM1RLW<&ER-2LF(WA!
M.WA3-T98<2ML9C@T*RME3'HX=4PW>F1,8U%7=6Y1,C<V:$194U!*-G-S8TM-
M-TYW0T91,T%F0E4W*S)+2&Q'2UA9<2MI4'E,.'4R,&8F(WA!.S5C>C9U.$MM
M.'9T5U=#1U5J-'93:6EB:V\Y=51$1D1*4'I4=B]+<393.&UN5W)X15)01D5:
M4T1)6&8X06%88S!P:7)W8GEV3D9**UHF(WA!.V9L=%DR-4-056).5U!B;#E9
M56Y&3#!N+T%*>DHO=T1*:&%6+S)Z12\U4'E9;UE8*U5D+UE.<3AD=F1+<E-#
M3FM4;4)3<$DT:V9Q>%8F(WA!.SE)5VMF;#(U,$=71TLR.4158F%0,49D5TI%
M<7%F:G%+-T56>%8T=BMF=6<V:3)G84YR84]R85IB>GHR6FI*4$Y*6#1Y.4]L
M1T=+=D0F(WA!.SA5=7A6;5@K05!03&51<%!-0C Q,#!',FU$=$]6-'5W8T5C
M*VQ74F%D5#!R:6AH=4M867$Y>B\U>"LP6%5H;V5R-C9T=S!D<CE:9W,F(WA!
M.S!G5FU(2BM%:FQI3VTR=WE%.%5*+U5!5G5N<$@U:'A*66%F8U!(<4%V6DDT
M;E=9:FQX0C9!2W@V-'=X4FHY24$Y>4Q,-6,X>G-494DF(WA!.T1U>%AM9FMX
M3E Q5GEA6#)"+WII4B\U2U)F.$%T;UA0-FMX47)*-5<O3E="63)%,F]Z=WIX
M<2MR5R\V4TAR354Q270V5G$W5%5H9'(F(WA!.T]M-G-G<'-7-5I+=WAP1&IY
M:BM:.7AD-F8Y9FEV8FE'0RMS8FUW.6$O:6MJ=$E)3E%L;61B>%!72#%M5EE4
M1CA95GIT44XT=&A&1FPF(WA!.S,U5S90-3(P*T\Y4&UI-74U6G!%9T%J=5A7
M5U Q5C4K<DI"2CEB=D=O.5)58TEL-F-51RM!<&IB4$U$2C)+=7A6,DMV>E4X
M,F8X<%0F(WA!.W)(+TUD8R\X;FUX4VQ72W,W+TQR.'<W:GDO9$='8S@W85%Q
M3GI3;%!F9GAX42MK;"MO*UHO265Q86E5*W0V4'%-6G1.5V=H,VQ6:'@F(WA!
M.UI*=W9I:DUR53EV9D98>7@U;#AG83-O*W%Z5VQV1$QQ3F]H2&]8<TU,.%I&
M24)"2VIK5D\Y0T1I<DMF>30O269Z9#5N,4M".5)G9E(F(WA!.W1'0E8U<GDW
M46=S=DEF06M22W53=U!Y>%8Y5C9S*W$R.6AQ6&Q30S!G3VMT<'-S5G1D;50P
M;&1N46]!1V)K0S0W<BMR1EAX5C5G+TPF(WA!.W9Z;F]L,TI$96%,94I'<%!#
M9C!*1VI:97A6=T-P*R]&2W0U8R]++WIV<G1W:3(K:S-%1F]D-4Y1=5EN9W1O
M,4(S3%-Y0E4K:71C5F4F(WA!.S8R97!A6"M82&QI,7-B<3EJ=7)M0TMK15%)
M54E:4GDY6&-M:&-B*S%C55!#=D]F;FTX,38V66HT270Q2&AX4%EE,DM53"M8
M6"]+9BLF(WA!.U<O.$%T<#)N+THY8U9E="\X-6LO*U1#,'(O=&U*+WEF:WA1
M.$AT-35)2E9L:F)I>3E#355V9%!Y>"].0DQQ*W-T4'95-4=A4DE7:S4F(WA!
M.VA30DEE0D1K.6I8-U=+2'%0-6<O;$,R=3)5;6QJ545J<TIL.5-054%!.%9V
M2VQ857I!3G-$.6=T6'9I<C5Q.'AF:SDK66UI6#AT<RLF(WA!.V@S;#=!:"]D
M6#EL0DQC5S!Q;F-.2$Q'<%4T<%)V:T@X<69.5W K87)',3%,4V)Q>'1U66MC
M,W-,,C9/14E01&Q+1DAX66]F669M,U@F(WA!.W W<GDS-6\P=3<P:6%+,6DP
M>3514S!00U5.17E-;RM%06).-#1Q+U V94=31U9O-49+3W!O5DEO4FEL=3-T
M<FDU;5=',VIA85IZ4DDF(WA!.S!"6FEF641&6#%F*UAC9&PU8R],8E,W1%5)
M+W%Q4DUB,C4Y46A';G5*4E=L1#!20CA03&9&1'EN.'@O>D=T-75&<&%R>5%%
M:V]'<'DF(WA!.T\Q0S%/9SA-5F534WEV3$DP:V@U3S5,350S2GA3*S%V*V-3
M4"]*4TPO=T)T0S4O56U+2'1'2W5X5C)+=7A6,DMU>%8R2W9Z53@R9C@F(WA!
M.W!4<D@O361C+W=$2C5S57!6:7)S5EI2-50O36YZ6#585C P=35P1$E'5U-'
M4W))47<T:U5Q359:5%IF;E)61D]O,DAQ>DQV>E%G9C F(WA!.WA1;3!(-2M1
M5WE..5=T6F]86493>7-!4T0R3RM+<DQ8."]P;VIB<S%S+TLR:SE73&I46FI3
M=&%K,2MY359:65 K8W-*;S13<U9S638F(WA!.S=M3DDQ<%=G2#=69D1&5TPK
M8F8K8VPO365S=TI"1D-!:V)C;$5T06])<G9X4VQ4=FER>7)8=DUE<F$W95!D
M-FI-6EI88FMF0W8P,7@F(WA!.U-L;4MS:"],<B]L4"],9B]!1S W5"]K*VU+
M=E<O=T1N36XO>5E7;&8Y<WA0*U0X;4M(9V5+5E<Q=3=I,6Y784)Y:VE';TDY
M<U9E:&4F(WA!.U90>G0X>39)6&IK26UG;$1,241Y645-<%AD4S%$,7A1.48P
M2"]N274Q=&)+3T4S<S!(1'!%1DE55CA!95=+;WI54'HT,$15;$IU3&TF(WA!
M.TMA-CE-4G!C>DI6,%%'<#0W9T)J6')41E523"ME5FIQ=6M$4W)V5U9I=&U2
M;UIV,VEH;E(Y<4TS9EDP>%9I33)H9FQ093!L=DPK,VPF(WA!.U X-C-#4G-2
M6&]A67%I3%A5=GER.'1X33)M9E97=4M':WAL17-T1#%O,V)B,GA6:#-N=C@S
M8C-7,VET-U)%:G1R6D9H:6]#1312:FDF(WA!.W!!2G%7<#-0,UEQ.#-D,F1I
M>D5S>D=P2C9K-'!A>%8Y<V8X04]*2"]!2DM29BLR:&,O<51&1#)J1EA9<3=&
M6%EQ-T9867$W1E@U<64F(WA!.V)0.$%L2V19+W=#638U+S503FEL05%M,E!W
M>DM62"LO13-0,TA&5VIB3V52:DEK5F1Y>2M(>4Y$:7%L5$9867$W1EA9<3=&
M6%EQ=6HF(WA!.VEK:UE*1W!::C!!1F-65C0W94)#-75P47!59D1';$=,2'<U
M0W%J1E4X+TPK4TYV4"]L=FA'14$Q3S W:VXK+UAX3TMV8W8X06Y*='0F(WA!
M.T-8.#%T3D]S.&911VE39E9X24=A23-"95E20U1J.%%8;#,X858R<FEH.#1Y
M=$=S>G!.0T9913$Y36Y9*S(W3%1&2W<R-%IV,TQI460F(WA!.V%F6F(W:C$K
M:D9616=G,$EO9D1&6%EQ-T985GA6,51I<G$T<3=&5C!C56MR0EDQ3$UE=WA6
M6$9T1$='*W-39TUV*S9K*TEN+T%'42LF(WA!.T5F9FER-U(O-7A-35HO2UI3
M:6Q6+U-&>E%%,5!235506G-69&ER<U9D:7)S5F1I<G-69DEM="\X-&EF;5)F
M-C%F,S!/<&%-<U8Q8WHF(WA!.U12<3@Y,$=#>5-&:'E!=&E+,%!J:6Q$<"]W
M031B+VU-67ES;7 V37)J9%=7939.9EEG,G=X47!J+VY$9CAZ=V%J5F1&0CA2
M4&0O.$$F(WA!.UI,:6Q56"]N1#<X,$%A='%E:'E6-C@U<F\O:CE6<FEQ-R]O
M5'(X=S-(>&%H;S!:.%5U3&]J-VUT9C0T;U=.+WIH<BM9=C=/<F%0.$$F(WA!
M.U1,9&8Y:RM+5F\O-7<Q+TUN=G$R:F8X04DV-B\W2G-65D4O-7<Q+TU)9F(Q
M8E-$-T-A-4@O67-C54QJ+T%--&4O;4]U,%8Y;V1F-7 F(WA!.TQI-UDO9#E6
M07A65"]W0VA09GI4,W!Q,FEQ1#%#>C-A:C=H831P86HO=T-C3G9Z2C5J,616
M,%E*,S1Z6%)0-#)W>%9-+TLO+T%$:5HF(WA!.RM996LK861+,5=B561)83%S
M3'E#-6M22C=L<$-K56=C:&$R>6IL465)>%9N2#4K+VM*-7<O35!Z5%IA=&]T
M-7 Y=F)7,6UT<S98:VLF(WA!.S9/6$5J=E5#3T=956\O:FEH-3-&+W=!-&8O
M;5%Y96YD86IO>F]".$5I5#-8<4Q4;TMM,3-(=&EQ1U X07IH="M:;U!W-G!O
M=$(P4'(F(WA!.S-94"]!1D,T<78X02MH4&9Z4W)6=%4P4B]W1%=N=7HK=3%X
M5F-0.$%N1&XX>%=R>C%(4FQ08FAC6%90=4YR+TA&5FHO05!/1W8U:R\F(WA!
M.W-A<F]X*V,Q,% X07-73TMR4#A!;U1B.'IF.$%Q-F%*+W=!:C=V.$$W2F-5
M=2\V13(O33<O<39A2B]Y4'4O.$%S;'A1<4HO>FAR*UDF(WA!.R]W0S-Q=6HO
M04-7838O:F)9<790+T](9C5J2U0V9"]O<D1X:W5,<VXW:&%G67%T4"]/2#,U
M<6)G871O<6<W14Q09$M$.'=,55EQ,6(F(WA!.R]W1$]',S5J97%V,6I63DA%
M6#=8<'I84EEJ,G)B05EQ*VEF>5@X:#9P-4@X;&I1=%-A,F%D3&U76E1A4$I*
M2'=K0S!Q,&E235<R,RLF(WA!.TA&5V0T<3=&6%EQ-T9867$W1EA9<2]/6'I4
M-6LX>$HU;C%D13%3-U96=F)K2V]N;$%!17)504%B1DYP6"]I9GI*+S%D8GHO
M<$EL+S4F(WA!.W%X5WDW+T4O;50O<38S;B]!16M3+W=$3E=+,EAF-&XX>68X
M058Q=E K:VE8+VUR1F)D+VEF>DHO,61B>B]P26PO=T-A<U9T,RM*+TTF(WA!
M.VXO5C%V4#A!<$EL+S5Q>%=Y:6(W>FHU:'5B9WI,9C-&=4-!4%1I;FQ#-T-N
M5&QG07!B2T@O=T%4*UI0*W)R968Y2D5V+TY71F)D+VDF(WA!.V9Z2B\Q9&)Z
M+W!);"]W0V%S5G-T9C1N.'EF.$%6,790*VMI6"]M<D9B2S503E!M4EA6=C!P
M9&YI46%'95=H<"]S<U9T;79K6#AW=DTF(WA!.T9Z-3(X=G=3>2]"2G%&<DA*
M4FXK24Y/;EAF2WAJ<G%T<RLO-7DY,6)68E!Z.7!C9&YE5#(P8F%A:%I)<$A1
M12MT2G51<$=7265%+S0F(WA!.VLX>&8Y6%,W+W=#4CAV.$%Z5FEL,RM*4$U8
M+U8P=2\K4CAV+T%$5FER=CA!16YM3"]Q-EAF+TDK6"]M<D989C1K.'AF.5A3
M-R]W0U(F(WA!.SAV.$%Z5FER=CA395EV.$%Q-EAF+TDK6"]M<D9662MB4$UV
M,6(V=BML3'(P*UA0*RMK-59P5#=6830P<6HO:51Z1B\Q9$QV+T%*2'DF(WA!
M.R]W1$Y72W4O>$HU:2]W0W)P9"\X:C5F*V%S5F0O:51Z1B\Q9$QV.$$U2'DO
M.#%9<3<O16YM3"]Q-EAF+T%#4&PO=T-A<U9D+VE8>D8F(WA!.R]W0EA3."\U
M2'DO.#%9<2MZ+SA!;D9854PV*R]+;$IR>31K=5I6=G)H0DI+>&1G<6A+0W)%
M-UEO97=9<3=&6%EQ-T9867$W1EA9<2\F(WA!.TY4>EHO=T%P5')(+T%$2%A0
M+THU<U5P5FER<U9D:7)S5F141D1Q67!44W=S=$UK<R]8=6YL4FA,=UEO4&=#
M;FHQ8FEA16IL:UI%,G(F(WA!.V5Q5VUH47=+,6AE4UA%>&5J27EC449O86UV
M>G=22E!-2VQ75%8R2W-H+TQR+VQ0+T%#,R]!3G1/,"\U4')I<C%V+VY-;B]Y
M65=L9CDF(WA!.W-X4"M4.&U+2&=E2UA9<3%I<G-68GA6,DMU>%8R2W5X5C)+
M=7A6.7-F.#1K9BM3:U@O=&]84#9K>%$Y;WA6,DMU>%8R2W5X5C)+=7@F(WA!
M.U8K86YM>B]L2V19+S5J<FXO:S@R2U5Q>%8R2W5X5DU.1S!3+S%A9#1B2D]B
M4G(V:W!/=U9/451K934S66)+0V9B27IM23@Q6E-0>3@F(WA!.W5:5RMP,F-%
M;'ID3#EU-F$T=#199'5V1TEI4U9H-$4P4"M334%-:GIP5FMF-5=E6F]P4#E/
M=$)%=G=L55-E0C-C13<X94QV5&)X>&PF(WA!.TML5F1B.&Q83G!P0FMU-V%B
M4UER8F\W>E)88T5J<V5R3D(X84TS,E%E3$-T2S!'*T%C43@Q3$,W,GEU3$\T
M83-N54Q);U9T;59G438F(WA!.V@Q25I345%664A9-4U',55-2W5X5FM0-61F
M.$%+9CA!;'8X03=A9' O=T%N,7A6-C,O>FU4+S5-3%-V*S)9;B]!0V9L>%$X
M1'A3-T8F(WA!.UA9<3)Q1FE!3GEE9T=+<#-$-5(Q3#9W:TXR.&1L>E1N>6M,
M>3AA+W-Y2F),4$EJ9C5,2T0T-5@T;3%G6"M03E528V589$-T0B]P9"\F(WA!
M.V9+83!$4C9F5D-F67E4=VXX36I+5U1P169%+W-+<5(P1%(U;S-E>C%69U5&
M948S851X369996@Y84<O=5)H134Y62])+W)P54)C-D0F(WA!.W%S1F=M;U!!
M5W-P1'A&=VA6,59Q:V-8-&MM3FI46EAO4TXX;4IG;75Q<&9K;&1I<G-69F)(
M+T]*2"]K<$8O-V%&>BMP355084U69&DF(WA!.W%L9%AD<EHR.&QZ9'I*8C(P
M4353>GES15)&2&1M66=!9E!&5EA&6%EQ-T9867$O3E1Z6B]Y;$]S9CAX,7HO
M>65B1DM667$W1E4Y,$0F(WA!.WEX8V%H2DA*24-)0S,R0EAM*S-B8G W-'$Y
M43!4>5908E=J2TEV<3%U-FYG26%T27-L86AN<G5W-FEH8G8W57EJ3D=7,&\X
M=V],2SDF(WA!.THX:D,Q.4,T:&U35V9I0S1"<3(T,TA!+T=+2'942416>$)Q
M44UF9GE4=V]R5W9,=FU.,%=45%9E3C0V*W!73G%V-$%B2'!H+TXT=C4F(WA!
M.W=2=W-A,4A1=DYL.5EV6F%J3$-,851J-C!%:4E:2$-S1S)!555)-B]%5C9D
M8UDV<U,R9T1)+UEK45E*-7 X<%=O;%I93%-3>%I/2U$F(WA!.WE->E-",5)1
M=GAI<D%6<%@T96Y43'-56D-0<4\V0U=%86IP;#%95$-/9&%":%9*0G5R1'A5
M-4Y52FER269Y-B\U5"]Y,R\R,#=4+VLF(WA!.RMM2W97+SA!;DUN+T%-;49P
M6"]B350O:R],:6@T2&EL,DMQ='1B4S-%>7A2:7).,'A6-E(U0CAH-G1,9'A8
M1FY'1&9+1TYT8U!49VHF(WA!.S V<4="*TQJ6&EA5C55<'9M4'%P5D-Z.4XW
M*S5)6DA*-5)H=&<W-GAQ85)J;"LY57-F=%8S<GEP;#A+;U9Y67-R<SE.,$I,
M54-/,SDF(WA!.U-*3WIJ;'5/.4=R:%<P=G5F3&-6*WIY,G0W-DI)<#9814Q1
M+TE5>%<P;6<X:%AO=DI%=5-L>'!J268P9V<U:C%):#A82#126&QY56,F(WA!
M.TXV8W%::39U5E(R*W9O;4QY<EAF3$YX6E-Y;4Y4=U4O1D=195,K4'I!>DI(
M2E5I=W$W1E@R>"]Z:5(O-4M29BLR:&,O<51&0W!.-5<F(WA!.R].35A'<S,X
M1G$Q=&-E6F%.8W1A-F=O=4QD;TQT5W0V:VE*5317;DM,.3-)+TQV5'!K<D1'
M:6\S6&MF.'@T=%8Q2S=S>&908V5H9C(F(WA!.V5J,WHV:5AA3T4S66MT>$E8
M=49D=61V>E9#,5-(-&QU3D%Y=')33$AL3#AY6F)/.35897$K;VUM,W8V36IA
M."MR370Y2DE046IB,#<F(WA!.S8X36=60S-"-5IM<#-/=WAS3%)A,51Y,RMA
M,7A09D,R;#%#0U=75S4K<UA386EO=#5O6DQY2G):8DM,,656<UER8TYY4$9#
M84568FPF(WA!.U1'=W1&-C-A,C!D=&)25SA:9&\T;$-+,'-J>7510E0T<$I#
M-W5F9&E4:U=3<FER<U9F;7 U<R\U4VY74"M9-C4O=T-4>EEP4W)&5U8F(WA!
M.V534$M-,G,S:4]W2&]H:%%(<#$S2DAH:6@W2%EA8G R;'E,1D-N<7IQ3FIX
M1DLP;U-C5E-/8GI$<G1X<DUT:F1O,7!:22\W:&M9;T@F(WA!.TA%;6Q6<#%0
M6$973E1E9&9--BM::S W,&MH9VMK0W!W6&DO<$AO,U!R,#-/07A#;W$O,5AZ
M9&%A9F141E9U<$-!1E9$>4UF=W1Z6G$F(WA!.V=&<6)D34A"2'5485,V8C5O
M.#@S.#AS,5A7,VE2,VQ!0FI5;%50158V+V%P<TUK14I&2#4P.'I2>BMP3&1.
M3W!.5$1/039'=BM38U8F(WA!.UI,<#=A6C5P=%I)65E3;#5%=G%Z,G)B3'9S
M5VA913<Q3TMS13%#=VQS<'948SAL66-K8V1#355P>"M86"]+9BM7+SA!=' R
M;B]*.4TF(WA!.U9E="\X-6LO*U1#,'(O=&U*+WEF:WA1.$1X4W%7,79*8UA%
M8T51<DI+=U92-VLP>%8W:C5$+TLY8E<R5U,X5E=U5TE9;6QE2VM$>#<F(WA!
M.S1O6GAQ1VMR66%C-U=R.$9+:$MJ66=K,$)&4&,T0TQ&1EAM,VQ45#=M-'8W
M<41Z3C9/<'@O5UAD67)M374W4V]704IN57!)83AJ4E<F(WA!.UER-UI24$(O
M35!$*T\U3G,P,7I59$UV3DMJ4T-/-71J2U1V1&-,1V5.2TAR0R]J;%%X-F=F
M>%)0=R]A;EIJ,G9E6DY..'5W5VLP5F@F(WA!.U!C1U@T0C9S>E-G8V%C;EE2
M:4%D.7$Y8V9!>E,K<68K;#(O5VUX,TLK=&5:3F)H<U=645EJ3G=K9F=05%1O
M3TY%4VE6-U9P;'505'@F(WA!.VE196-U.#@O;7A2.7)P3G1Q,FI7-U@X2T=E
M5F59;$-G3CE**VY-:$1X+WHW-4UU3D)U,6M#<CE7;7)X2V9:1DMF,7A3>$Q&
M6#)X+WHF(WA!.VE2+S5+4F8K,FAC+W%41D1).5(O3BLS3V]W-F1P3FI*8U@V
M86AB,G0S8F,W4V1N:6XY669U6'0W<#1K;#5W9$IN5VQD>&AP1G%.>BLF(WA!
M.V1E;'II>&TP=3%N*V\O5V])=%=V3&U.46M#4W=Y5%!&4EIF53ED5FIR.6QK
M.38P=S!T;W5B.#4Y16E94E!O*W$O5WI#3&]7;G R,W$F(WA!.T<R83-A-5=B
M+V5J:'A-56)M;DQK0TM&831+5S%+-2]/9E$T9TQH<E<X9VAG5C5,<3%K9VEA
M6C1V<5EV26YJ9&)K26=E33$K244Y:48F(WA!.S8T,'1O<6(X-&9,,79%2'5R
M2SAT:4QW,D4X37I78V,P57=-5WAH3GHV:V=P3W)(,&QE9S8P>'!B6D(U33%U
M-S%V>3=B-FQD<$=K.',F(WA!.VQW:DQ%0T5P1&-34DQ135=0,E5&9"MU2E-N
M94)8-7%E8E X06Q+9%DO=T-9-C4O-5!.:6Q!,DYO,3%D2D%P<'E0>$XQ;T(Q
M3TMV;VXF(WA!.SAV.$%33&4R9VEI8T)7=4-'9F%M>3E&+VAI:&Y:,"MY:'$V
M4FA&3WIB9E)I<D)F3DYR6EA%='IB=$]I4C%"-6-L2$4P-CEF9D954F\F(WA!
M.W9K5WE7>71';G5/9'1(14M58FM$5VQ.+T=M2W$R<V5556IU<F=1>$Y$04-P
M9VA)-4\S2V\U8VIX0V=%67%R:E-W,6YB45-Q0UEK3$TF(WA!.VQ+.&E25'0X
M.%992G(O:VU.,VM+,GAK:#5$:7@K0E)8<4LY<U993%IE86XP;EAX8C)-8V8Q
M2TMB,%<S*S)Q='@U0BMW>%9K+S5J-D@F(WA!.T$P53!Q>&=32&TO3F1X-FM1
M<G14<GI">%9H2#5D9CA!2V8X06QV.$$W861P+W=!;C%X4SEB+S5Z2B\X04IH
M858O=T)S>% X06LO2FDF(WA!.V@T2&EL;E@U4S91=#5R<'5P0BLW=$M30FHP
M<7!R5#E72T@P6F]S<TPR9DM08VMN:U!!-'%P-C=D46962F)A<71+=T@W=FM"
M=#0O4FDF(WA!.W)'+TQV;%9*-34W=3AK8C S8T=/,U=V655$13%X5FQ4851B
M=D1,8S--3$=+6E9I4C5V:$LX4U9(<$MF;FER1615<UET2S%'5U=W=4LF(WA!
M.U%K97%B6GAU,G@K0VQD-C!P.4]+=&DO,"LV:5=+-W141%=H-3 U4C$K,5%S
M0G1V,GA63C=#,VAA4#0K4$%B>"M(2'1V.'-667@U<7,F(WA!.TQB5W1/=F):
M5U9N9T99,D)$5BM'=D@V96U+=FY6,4M/>4A9<6%(-DU5=G1F+VY%:B]W06Q)
M=CA!,C!,;CE366]:,FXU52M227IY:G,F(WA!.TI9,D1P2D<V6&PT<E)T17IT
M2#940UE'24LP>FM"2T%%-&)24S90.$%+=GE&2$I%-F%504E19U=,,7)J,&HV
M4T=.1V5,,5!49'5$1F4F(WA!.U1+4U%D.&)7;#ER*U=F:W$Q4$M+=UEU23)H
M1'E83GI+-&EE03(S<#AP2E=B9TE72W%T84PK>E1',7!U-2],3'E28VAX4'!V
M4#%),6@F(WA!.V8Y+V-#<4IB:3!58E-$+V1!-"]J,3-X=&%D92]L;C5+=DPR
M93EU3E!9,TXQ2UHW;#!U3&U0,4A:;S)03E5K5E=8;&)X<T9)-&=R5VPF(WA!
M.V-B5VLY,'93<D13<D9,1W=I.4<Q:EHR4U!K>E5-:G1)*S=L:G5Z:SEC0U56
M:7(X,5!.;B]!0VQ/<V8X04UD8R\X;FUX4S,U6DMJ54<F(WA!.TIP+V1M;&9M
M359E-3)L-FQV<'1P3W)(6DAC;$YZ*S=O9&@Y3TM&83$X-&593E=H35=N,D4W
M3GE!0W5L4U)3<%DX4V%$-31Q<6%N;S$F(WA!.VY"2VPY<61O:5AL>79':DE(
M9'5G2VEG4$QE;4MS-#!30C=V5'=H:DUC3D%I:$YN,DA5-T5,5$96;FUC-FQB
M>3)T+TA,-CEM,&E7,30F(WA!.VI!1F]G-U96;#0P<GDK3$95;F<Q83%K8C9U
M:VMC;'<U65)X;S%A:%0S<C,R-EEQ=3E),T-35U5Q<6]9:#-7=31*,S9D<U9E
M1"]M5C4F(WA!.UET3$QZ8CE4,#DT9V)L;%E102]'2&Q*2DQD=7941E=76&5L
M>E=0;$-Y=&)T+U5N44AK-4YA:71/+W-C5F5E9FPV2V9M1#5C2&AQ9' F(WA!
M.R]W06XQ>%,Y6B\U>DHO.$%*:&%6+W="<WA0.$%K+TII:#1(:6PV<BM68GAW
M-E1Q3$MF:CE$;C<W1C8O=WA1>FY48G4Y,4,X:G-.1VPF(WA!.W)03E@Q2E$S
M=WAG0W!:9TU65%<K.'1A9F\Y;&9A;$AQ370S<59L1T1D0U)G,%HU141I>6="
M:#$R*TQ&538X;3)D.7%%<T0K<49J:V@F(WA!.RMS4V]Q-W)&<V5+,4I(3#1G
M359:12MI4F%T3F)713A,=TDP<6Q(5FY$>'-X-#AX56M6-S=J1E=&*UI02WE7
M5C%E>&%R3DDQ,6%-47,F(WA!.W%K0D-V2&M#86IU1&EQ5VI454U)=30U,F5'
M3TUT-F%G37)G1&-51F$K,DMP;S%X8DYP8U-X;&=S<4MO1D-J2TA3;W%'-E5'
M2W-8,#,F(WA!.U1%<SE596$R0DU.,T<S,7=&<6HQ239"0W9H.$Q(;&ER=U16
M1D,V:$]",#5K+V9V:6PY;F8X-&MF*U-K6"]T;UA0-FMX47%R-4\O32LF(WA!
M.T]-6$M8;7!T96E*2F948E5Y,&8Q;&15<E1G6G5(2#9H,5@W0C=J;FMR1$=L
M0TA1+WID83(Q2C4W6%5)<$=N=$IR0W=I,49M9UEO='<F(WA!.W,X8VLW-FPY
M85-*=6-:-4DT,T$O9%5"1T]Y3C)E95%R3'I.83-/<VI763=N,$I,9U-71GAE
M,TAR5$]R;#):9E13-'5963%J<494,#$F(WA!.VHU1'%G27=&:T=8645U>%8R
M2W5X5BMA;FUZ+VQ+9%DO-6IR;B]K.#)+54AP=#)B5SAJ;2]:0F]W+W=!:S=(
M1EAR96<V;DID86).6G(F(WA!.TYW=DDO:71&;TMK:TAK;TY/<$=+2&\O:UIR
M=3@X;'EX,DUV<&%K,'I,3S=5-44O0V$W.5!H,D=+<$@U:71R-DA69$=S>&1I
M-G5,3W,F(WA!.W0P:'!W:4)935-74%5T6'!81EAO4&MU6%<Y4S O55ET36II
M=4DT<$932EII<4U88FM75TYI53-P,D\R2V]V>E,P-#!M>3 R-2MQ<G$F(WA!
M.V,X;VPK<G=38S)9=T9D;DEQ3U-S,GEH<U9E9'@R5W5Z871Q:RMJ.%E,:3$T
M14M1;VM,4V)%<5A',G=/2W U9'HV;&(K5UIT4C%S>#(F(WA!.S$O15%T:D]+
M8VUA;$%J8V5V2VAX5C5H2G!I-G U;%16-5=356-!.&=*1$AK:$A(6C8X479I
M2UEQ<&5D.6175T(R9V5L=&)X='=Q2U8F(WA!.TY+3#DU>%9G6#5D;79N+WDU
M+S(P-U0O:RMU2UAR6"]/6E X035-3%-V*S)9;B]**U1&1'=,1DQ,=DEM=2]5
M8FMX3S,W;'9G;%=M-6DF(WA!.V9:<69,1D0P>GE6<D9J;UAM1#9Y2F96,&U:
M5VIL;%5%;&%I<3%&3U$S<&ER3"]/97%1,U=G,U9R;W1M,')8=U5Y,U)+;W9%
M34=**TDF(WA!.V=N<%1&53,O04-K5RMM.'IA6EEQ1V@K<E=23C1Z14501VEO
M<DE"=E=R34U66FQO5%@X6&Y456LQ1%5)949S=U,R4FMI43-$:TYX4DLF(WA!
M.T)4.$9..%9E5S9T-6AK,5HY66EN1'DS36DS045V2%DW37$Y0C1I;4MR=DIE
M<656-U!Y-T9B86I-24PV4&U,<%I224<S66M&84-N,F$F(WA!.V1-5EEB9CA!
M;3-5-3E3359P3#E9=&ML8U<V0U W4U9)5FE+5G%6>%97.'DK64I.3# U;VUK
M4DPR44YZ5F%%46]2=4\K-7A6-&)02S F(WA!.W-Z>70Y<'E74# T<&9A=B]!
M1&E2+W=#4VM8+W1O6% V:WA1.6]X5C)+=7A6,DMU>%8R2W5X5BMA;FUZ+T%*
M4VY74#A!;4]U9BM4>EDF(WA!.W!3;V=G,$EO8U94=E)0340R6D-432]%14=/
M4E1U=C Y9'-66FYP;FUI-FI5=D9C35%X<5A2>7!9+W=#5E1:=CEL:6AN,FAA
M='!M<%<F(WA!.S93>3A236\O95)-;T%$1'%W03).9DA&53DP1S<P=E1T6'-R
M;5<V4TLQ*W1X4RMP>5!W2W!(665W<&EQ05,Q:'9*-&)U<6HP;5IP6%(F(WA!
M.VE#-U9"0G%!2S<W;D955'%/<G@V5DA.<7)3=$I0440T;4Q3<TM"5E)72G)X
M2&AI<D%B-WID8UAS-6LQ3G!B>$]284LP:VM0<' W,'(F(WA!.S19<7AV5U!/
M.%-S66\K36%D4%%T;$-G52]M26]$.4]+<TXQ3%8W;2M)1$AJ14YW9THS4&EF
M2$9+6B]L,G),-2LX=#%&2S9L8456+S0F(WA!.WIR:7(S2"]N3&)Y,64S,VUQ
M1%=056IT-T-W,#)&2DIP:$I2-4I,:5%,1VA22$)B971#4G1I:#@V>5=%<6]8
M:F1*,$@R;6I.869-14(F(WA!.W9W>%-O4GE34D]S:4U66E1515EQ>5!4+T%$
M3VEQ1FM,=U-N-U5I13AA53EJ6$9$3R]+2&Y/0T9L:'4U:F-76%=-:SAI:F(Y
M:C(S>%8F(WA!.VXQ;C5Q,'E+-$8S6EAO=#=M2D<T>7%X:F)I=T9A155X5F9.
M-7@P5%=B4%-,8E186#8Y67A44E0S1#AA=DI+=TEC149J5V\W-'%U=%DF(WA!
M.SE/<W).66UK4G9456@R,F]4,5EN1E="*UDO33!S;#%01&%Y<DQ::V=C6D9(
M86XR9'$P<FER1S=R>E-.4$1-:S-O>71S4'$Y165N>E<F(WA!.VIF:FER1#E9
M,7%7+V8T4WEX-VQU4C-9;BMB1DM82D<W<T%O<51I<C=9+S5X3FI-9C542W!)
M2D=O6$YA1V\V2C-'2TAS,DMU>%8R2W4F(WA!.WA6,DMU>%8R2W9Z53@R9CAP
M5')(+TUD8R]W1$HU<U5O2S-V6&E91C!79$]H:FQ(254Y:C%8-DU685IB4U1K
M67DP6#AI3E)X-S%98V$F(WA!.V8X1&EQ-DM/+U-*-4EF5453+S-J>&LX4CAY
M=3)+='!Q9"MG*T=D,4DW9VM(-RMU2W):3E(Q0U%5:W5:5T$S;UA9:CEE2W!L
M6F5C4$TF(WA!.U9P15EO-S)6;VHK=S=S4G0Y3TMT6'9M-U@W=T%46%1M9W!8
M:U0O>$EN1E5'<F%T9'%A3DQ*2"LP86YH=#0O<S1Q;W1"1DAY16MT6$@F(WA!
M.S=-9$=(,'17;C-6>%9U935I6E930T51<796<3AN62M*86<O041&538O3'-K
M*V8X07DR4V%N.4HR;E@O:D]U2W9A4#A!;DQZ5TPK,C@F(WA!.S<R3F=S,&@P
M-C8P>4TS3FYZ26ED;&YK-'-6-F-L23)A;4M(>CE,8G9'9VYH9FY%869%<&]6
M2C=-3WAX4S)L-4<P4FIU259L+VQK5VDF(WA!.U-!+S9W0C5F-TQ&5DY)2357
M06IK0VMN65-56"]!26)P:7%O,7!Q1G9'2G=K:7A%:T-:83A#4G1S>3=9<7-.
M+V9L94IU6E-V47)Z86XF(WA!.S8X5F%T<GDW=%@U,CAZ=W8Q-4EX53=F3$95
M869-=75S<%9R,EEQ,S)G5T\O>GA645,U,5<V:S12>513=3-254Q%;C9":7)B
M-F)02%8F(WA!.W)Q4DE$6&1:1W$Y9CE15F(W.%9747DR54QK=$-B:VHW26,X
M1G(W:&%K+SA!0EEQ=$UL>F13:$9'-VYA2TY1:3$O=T)6840V8U9F86XF(WA!
M.R]/2TU0;R]L4W-F3EI#3E%U951)87)5:$112'941D0R5$9867$W1EA9<3=&
M6%EQ-T971WHO=T1+;E!8:SEF.$%W-S8O22MR>BMO."LF(WA!.V1F:356,W)8
M<EA&5VTO-54Q4F5F*TAA52M#=C%(<#=9<70O-4%T+S,W9CA!,#19<31F.$%+
M;#8W9C1C<B]W0D=/2W$P=B]+;W5).5@F(WA!.R]$+TAT>2MP52](1E9(+VM#
M,R]F="\X051J:7)V*U%,9CDK,R]W0D]'2W%S4"]+;BM1.40O1#-,='<K<%8O
M1$96<W8O04-P>C%'.6(F(WA!.R]$=G%F=&,O<5!,-F$T<7,O=T-13&8X069T
M+SE/3TMU2"]+;#8W9C1C<C=F56-65F)4+VQ54#%Q2#9N+T%)9BMT.#$K<BMJ
M.5,Y5#$F(WA!.TLO1'<T+T9Y<C!P:7%0.$%-4#A!>7(W-C1N*TDO=T)%+UA/
M03E0.$%34#%B,694<6%C9E<K3&I7=4MP8D@O>7!R;5!4+W=!3S@K,T@F(WA!
M.S9J6#A-5E=N+VQ3,60O.$%$9&8K:DA&6&8X9U<O=T,O8B\V8TU68U K5DPQ
M,B]W-5@R*V\T<7%N+VQ52$%6+W<O=T%+-U8K<%5R:7$F(WA!.S,O:T1L4#A!
M<&YA9CE'3TMR-&8K5E(X=C-0-D$U9C5(,4MV-%EQ-C0O=T-64CAJ.5DO44A,
M=C9N,4MV-#1Q;R\X9U<O-SEV+T%+8TTF(WA!.U9D+WE"8B]V,B\X07!W>%9E
M4#A!;%1N<&UN*TAF4W)V5#9J>'(K<D97439$+V@S-F@O=4$K<69O+VTS*SA(
M<&5J>B]A+W5V:#5E3TLF(WA!.W!J:7)S5F1I<G-69&ER<U9D:7(O05 O6CPO
M>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1-9G,](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]-86YI9F5S=$ET96TC(CX*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#HU0CDY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P
M.#1"0CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^>&UP+F1I9#HU0CDY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P.#1"
M0CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P
M.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S
M<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP
M+FEI9#HU03DY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P.#1"0CPO<W12968Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP
M+F1I9#HU03DY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P.#1"0CPO<W12968Z
M9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR
M96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4X
M.3DR,S1$,T0U,45",3$X-30Y1#<Y-S9!-S X-$)"/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Q+3 W
M5#$V.C X.C0Y+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU0CDY,C,T1#-$-3%%0C$Q
M.#4T.40W.3<V03<P.#1"0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,2TP-U0Q-CHP.3HQ-"TP-SHP
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ36%N:69E<W0^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI;FM&
M;W)M/D5M8F5D0GE2969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @(" @
M(" @(" @(" @(" \<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H
M/D,Z7%5S97)S7')R,3$V,#$T7$1E<VMT;W!<:6UA9V5S+FIP9SPO<W12968Z
M9FEL95!A=&@^"B @(" @(" @(" @(" @(" @(#PO<W1-9G,Z<F5F97)E;F-E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DUA;FEF97-T/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA
M9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R
M871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U
M<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&
M;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R
M:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.
M4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI-87A0
M86=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS
M=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I
M;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z
M36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @
M(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D-A;&EB<FDM0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O
M;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y"
M;VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,CPO
M<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FEB+G1T9CPO<W1&
M;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI8G)I/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^5F5R<VEO;B V+C(R/"]S=$9N=#IV97)S:6]N4W1R:6YG
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S
M=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1FEL94YA;64^8V%L:6)R:2YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*
M(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA
M=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL
M;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G
M.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U
M<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X
M;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O
M=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z
M>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!" %^ P$1  (1 0,1 ?_$ !\   $#! ,!
M       '" H!!08) @,+!/_$ &@0  $# P($! (%!0@," @+"0$" P0%!A$'
M(0 ($C$)$T%187$*%"*!D146(S*A%Q@:)SFQP? 9)"4F*#8W0D9XT>$S.$=2
M5I>V\31#9W5V=[37*3576&9R@H>DI[=(56)C96B$IK+_Q  = 0$! 0$  P$!
M 0           0(#! 4&!P@)_\0 01$  0," P4&!0(% P,#!0   0 "$0,A
M$C%!! 518? 3(G&!D:$&%+'!T3+A!R-"4O$5,U,D0V(6<N)%9'."DO_:  P#
M 0 "$0,1 #\ G\<$1P1'!$<$1P11O^6GQ0>8N]M=K:H=8OW376N@5+4;F_HV
ML^A]D:3U&@WWRW:::".7O(L#4.KZDP;LG4%QB]3;E&I+-.O.ATM=5D5IB)19
M,J>\F4QYU39Z;6$@.8<-(L<YP+:CGALM#8![I)D@F-0O6T]JJFH 7-J OK-?
M3:V'4VT\6%Q<"1WHCO 3-KIV;GC$6+%TJT1U*K6@.H5CR.99RNU+06WM4M2-
M!],8U\V'9]E6_=EWZB5"\KPU)IMI6=;\2=7XEKVU N2IQ+DO2I3*+-HE%52:
MPF9$Y_*G$]H>UW9QC+6O=!+BT-@-))L28L!F5U^=;AIN--S>UDL#G4VRUK02
MXES@ +P),DY"")4OF)\0V7;?AI3?$!Y;; <OV-5+&MN];<H%\B#2X]N0*S6H
ME&JTJ^J?'NRBR9C=L3ER:14Z?:%>J4^35 R_2#4J6AZ7QEE"=H["HX-(<6DM
MO,7[I@YBX) '&%NIM,;+\Q3;BEH< ZT28.(2,C8@&9RE7:I>(R+9U4J6D]\<
MLVL=I56P-!Z/S':^5Z17=*:S:^@^F$V+J"]4YUUU>W[ZJD>Y*M2W[&;;CT6P
ME7/,K$:K2)T %BWZJ$A0EN)M1A!>:;!#@7N&&(! @'%FZ(B^83YF'%KJ3VX:
M8J5#+2*;"'&7$.,QAR;.?(PG^C/BY:6:W4;4I^U-+;C<NBR=(K.UVH5H1]6N
M7.IJN73.]KI8M*)-N*\(6KAL+22Z+4GRHE0U'LO4^YK=KMH424S,2S5Y2TT]
M5?LKF%LN$.>:9."H(<!-FEN)P.32T$$VLHS:VO#L+"2UC:@ ?3,M<0+D/PL+
M29<'$0+W2373XN]X7)9>AEV<O?+74;_GW=SR2>3;52W'=1='JY$@W+3]/U7[
M&HFFE_4/5BGV-<E6ORD5&GU6S+Z75)VGM-B6W=M,N]RDU.9:QJ>QLH#GBI4P
M@4>U:<+P8+L,N:6X@ 9D1B,@C6,.VQQ##3I%TUS0>,3#<-Q -<'@$N!!#IPB
M' WPRJEX^++1K5U"KEEP.4_F(O.D4/F<J?)R+UM>7I$JCUGF+7;IN.T=/J)!
MKFI%%JSWYS0PA4RYJE%I=IVLU+I[]7K9,EUJ-D;,2T.[6F":?:X3BGLY@N,-
M-A>UR8,!:.UPXM[&H0*IHXFX"#4B0T2X&_$@-$R2OEK/C!Z1433G32OU'3&Z
M*!JEJ+J/KOI6]H_?FH>C6FZK,NWEJGHINKK-T:HWM?E&TP:B4R=+HU/MM=.N
M&=+NRJ5^EP*;"0I-2<IX;*XN<,0+6M8[$&O=(J?IAH;BO>9  @RAVQ@:TEI#
MG.J,P.=3;!I?KEQ=AB8 @F2;:JV79XRFF,"VZ/>.G/+WKMJ[;$CE0M7G.NFJ
MVTK3>B)L#12K7=>EG75(N9FZ[YHYDW19-5LJ<U*MZVEU]=<6\MVCRWJ93Y]3
M9#97$D.>QA%4T@#B.)X (B&FS@X03$#.]E#MK8EM.H\=D*Q(PC"PEP,ASA=I
M&0F9M8):=!.=C5#6GG7UYY?$:&R8FBNG.G&B-_VEJVS7+2:GBGZLVW==P4FJ
M7?1W;[E5F73+X31&V+*@6[:3=9MM5)K1U!9IJ*A1'%Y?1:RBRIC[SG.:6P?Z
M2 0#AB1J28-HFZZ4Z[WUZE/!W&M8YKY;D\$@GO$PZ.Z V1!Q1:=DO'CKR4<$
M1P1'!%JNO7FHYN-,?$"Y?N7*Z+;Y=+MT>YCJCK&]0:+IZK4B1KIIKI]IG015
M*3JAJ+6*O/9LI-&KLUZ+3)E-B6I!BQZLZ]0J-<M=G1?K$CR13I.H/J U ]@;
M)=AP.<XW:T 3(N1?*Y 7B.K5F;13IEM-S*A? ;B[1K6Y/<2<,'40(-@258.;
MCQ"]1^6;GCT(T+39=CU/E\NNR+%NO6R^ZHFO-7G8434W6=[0:V;BIL^/6&;<
MBVS2;\K5B)N 56ASI"X%7G*CS(JT,J;4J#:E%[\1%0.<&-M#L+,9&4R6AT0=
M$K;0ZE7ILPM--P::CC.)H<_LP1>(#BV9!L5@5H>*[*?YP>:*RM1*/8MG\F^@
MVC.M6HEOZLLQ;FGW_=%0Y>M1-,-*=2:B$QJG+H55MA_4&Z+XM2U8%!H*ZS6*
ME:L0,2WU34L/Z.S?RJ9:7&J][&EI@-':-<YO,'"&DR8 *R-K_G56N ;1ILJ.
M#[XG&F]K'VR(Q%S1 DEO-+U)\5?EZH%F:JW9J+8?,)I-4]'Z5H[=%T:=ZB:6
M"F:D5"Q==;ZING.GU^VM;=(N"NM7';LJZ*D(-5CP*BJYJ.]#EP)ENHK'U6F2
ML?+5"6AI8_&7M#FNEH<P%S@20(,"1H>*Z?-TPUSG-J-P!CBUS(=AJ.PM< "9
M!)@Q<&Q$V27:G>+O:-LVO;57L7ESY@K@NQ/-MIKRMZF:6W?9+=FZCV%/U CT
M>LTVHBA&JU2/4ZY=ENUN%,TQH"JC#;NJ?YT"JU&VRUYJ]-V4DD.J4P.R=4:X
M.EIPR",K $'$8MI.2P_;&M:"VG4+NU;2>QS2US<4&8O<@RP3WN4+X;0\4)BU
M.:#F%T?UQLS5&/9%&YC-"]&M-+TM_2MU=G:9.ZTZ6Z?56V[?UHO!NK!F!7*[
MJ!<=2IK(@1ZT_2 64U=$"EN4Z;*'9YIL<QS<18]S@77=@<X$L$9!HF\3IP$;
MM45:C*@?A[2FQA#+,+V-(%1PL"7&!G&L""7R<O'.!IYS.W)J/1],K5U(5;NF
M]SW59LO4BO4*B4^Q+CN6R;FDVE<]'M]^+<M1N>).IU7B/J:B7A:]J2:K34?E
M>C,U"FYDCE4I.IAI<6RX X027 $2";1!' F#8P5Y%.LVJ78 Z&DMQ$ -):8,
M7)SX@3F+)%5^)[R]LZR_N.2;5UPBEGF.7RF535.1IF^G1JBZ]2%I;MZPZC?2
M*LM"JA=BWHB:*NGTV>W%%0IKER&@-5"(X]KY>IAQ L/\OM0T.[Y9J[#G8@@S
M$Z2%S^:IXRR'B*G9%Y;W!4T:73_5I$\X7RVEXIW+-=ES4JF"F:P6]8UW,ZQ.
MZ7ZW7)IQ*AZ/:P*T&IM=K.IK&G%PPJC4:Y4WJ/2+7N2H4[\L6S0F;E9HD]JV
MW:K*2S'>'9J@!,M)&#$P.[S,9 ;B$0)D3!,3>$&U4B0(>&G'AJ%L,?V8)=A,
MS8 Y@3!B4E&HGBRT>C:4\N>L>G'+)S 7K9_,'KUI_I10%S:#;$6;5+7OBF&K
M0KILT6Y=]TT^NW#6F5B':-E56HV_59E6IU>I=S&U9=-0W*VW9B75&NJ,:64W
M/-SFTQ!D".9$@6B5AVUC!3>RE4<VI4:P2&B0X3+8<0218-)!F9B+Y3XDG-[K
M+R]4_E3M?1*U+W1<_,5K;3;-JUQ4?2BGZJU6VK9@6E6KIJMKT>S9]YVE3YVI
MEQNQ(;-$ILVK" *%1[WF"6S.IL!Q<H4F/[4O(BFR0"[""20 2Z#W1KS+>:UM
M-9]/LFL!FH\-)P8H$$P 7-!<8R)RF\A8QH_XI%IR['T1_/RV-7M3-3^8C4+F
M3H&G-H:2Z"SJ=<42!H+JA"M.Y*'=EHOZB74JBU.R:'784VX*\Y<"Z//AV[<4
M](@3DTZE5,_9R'/PEK6TVTRXN>(E[21!PB<1!@ ',7.8RS:AA9B#WOJ.J!K6
M4S,,> 01B,80;F8@$YP#V:R^+395J\MO,%S#:.Z'ZO:H4#0^X9-IQZ]4J51K
M=T^NVN4B_P!W3ZY'$5N#7Z]=5M4N@56)),A5V670:O,:DTB93*/-I=0-0CUF
MS$O8QSV-+P# )+@"W$+0 3!&3CXH_; *52HRF]P82)( :2'83)!) !X@$Z B
MZ>7JES<V#HOH#0=?]2+.U5MZ)=-3LVVK<TH<LYN7K56[[O\ KD:W;2T\I]DQ
M*L]&>O.L524VTS3C7$1&FDNR)%0:9:<6GBVDY[RQI:8DET]P!HDNDC(#6%W=
M6:RF*CFO , ,P]\N<8#<(/ZB;9QS3%-$?%%9J4'F KFK5CZI/U6/SKU'EGY>
M-";<TM,/7NLN1=(;%OZ3:=9M&;6XE-37+><F7C5KBN:K7%3K7BTB(P\U6Y$2
M12'9_=^S$8,);'9=I4>7=P=\M!!B8(B  3.F:X4]JGM"]KI[?LJ; R*A[C70
M02!(N220(UB$ML+Q2N7NML:2PK4M#6Z[+]U<N;5JSH>D=*L6DP-3K,N30JKT
MJAZM42^:#<]V6_ A5NS*C7*6U)MZWZQ<EQ5AJ6F3;=)K4=MYUOG\N\8B2P-:
M&G$7=UP>"6EI )N ;D #6%OYJF< :'N<\O& -&)IID!X<"1=I(L"29D A9@W
MXCG+T]KXC0-IC4!<IS665RZ(U13;4']R96OD*@/W#*TG%:-=%T&XV6(TBF+J
M0L_\T/S@8=H0N8U)M3 G8/P8^[^CM,,][!,8HB(UB9B\1=7YFGVG9]Z<9IXH
M&#M )+)F9TG#AFTRG[<<5Y"."(X(C@B."(X(C@B."(X(C@B."(X(C@B."(X(
MC@B.")MNCO*UISHCHM=>A-HU"[9EFWA7M7;BJLRO5*F3+@:FZT7-<=UW6W"F
MP:)38+46'4;GJ#%"0[3)#L2$U#;G/5)]MZ3(Z/J.>\/($@,  F.X !F2<@)O
MX0N;*3:;',;,.+W$DB9>23I&9M;U2&7#X<.CM5TVY6K!MV_M8M/*WR=VM*LK
M175>T*U8KVHL"V*M:U+M"Y:1<C-X:>79IW<D2Z:50Z*[66IVGX0W4:5"FT84
MEQM25[&T.#JCBUCA5,O:0[#()((AP<(DQWLC>5S.S,+*; Y[32!:QX+2X @
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M'?/P R?3OG@B",?')V&P^/MZ')[CXYSP15P<Y[^GIVR?AZ;>OOZ]R(.^W?\
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MNIV&J4TGJ=D2@E APUN$O*4\$)PG/!)M/V/7YTS6USE9K%]V[I38D:^K$4S
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M]J65JLW8:M%DDGN8Z0@@0;%^$$6$NE7IOGGU1O:Y=-;3T6Y?[7NV7K/<O-C
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M;_E,N?\ '[_Z.,+;<AX!- WS[;^A]![C&-_AON/;@JGW\KCIJ5NSJ;&?\N3
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M+9:AJ6'Y#C;#24 ];BUNHZ&DX_SBX$8^7;(XH)$P2)$&+6D'/Q 3KKV7H):
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MAD>@/<YV&W;_ .KGV&W!55!V^).X'W;^_;'QWQMV!%S2I25=0/8I([_YN,9
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M*W(3MM^7-<]_7_P'3KL,=QWX(H!)V]^WH,G._K@^_P!V/;/!%49SDDY[Y/\
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M#8;=O?&YQCMMVQMN15 P<[D '_8-L]]_CVVQZD7J _0]_P"2CNW_ %OM7O\
ML!HW[[_CP12J."(X(C@B."(X(C@B."(X(C@B."(X(O$2Y^Q_AO<X/?'[YW7/
M/M_E,N;T]\[_ ._@H,A:+9<.2:7"=99?:7)8$EA"^IUCS%->8@C[2/,0DJ1D
MC9202.W8\%4H,*B6;<7V(%67;<[R5+3'KJ_,ILF0G 3&8J#(26"YDE!D)"
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MO:?W#KK:MQ.SM,Z=2.:^G7],J%?-.F1E,Q+79N::NKO)I[TU9BH86M*$+<*
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M9= -[$=T :7XF4[2IJ]Q\3/'DDI,Z03D.N8/8>8YL#DCLH#[\#U^7'=.T?\
MW'U51.D C+KF,]_-=R/E]O.?CD@'& 3C@,Q.6J=H_P#N/JNQR8^GI*7G%!0R
M<NN'.^V,*]0>XWSQIPB()@\?8^A^N60=H_\ N*ZOK\GOYK@SM]EYW'XES?\
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M,(I+7TV 8M3D)QDC\NZY;9]?J.G1'W]]_3X<  +!.NO50"<';/;;Y#X=^QV
MQ^&-C40.W[=\9^_;8;8^7MC@BJ/PW^&#W[8^.#D[[>^>"*A)&-MO7!.?7X;C
MX[;[Y]>"(QC!^X9R<$_?\,=_E\2*GJ>Y(![#&Q]1G._W^^![D50?8';;M@'[
MNPS]QW'IG@BY)4I)^SD9P< [DYSN!L<^F=CN.QXH)&1A%W)D.']=14GN-R,;
M' ^7N2!GMCN#H/.M_+TX(NI:NI:E?\XY ]1Z;X^7?  [>W&29)/'HHN/<^FV
M,9[YR<_S;'[]^(BIZYQ\1G/KZ?#[AL,Y ]2*AV/;/J,D;8QG<[_?_-L21<L]
MQ\ 3]_<; _/&^<^W!%QVQ@Y/N"1D >O]'?'OZ\$5?GL/?89(V'???&=]]NY'
M!%5)R2-]@H^OQQWV]-M]_8#@B]0'Z'O_ "4=V_ZW^KWP_P! -&_3T^7!%*HX
M(C@B."(X(C@B."(X(C@B."(X(C@B\1+G['^&[S@#OCF>UTQL"!_&9<W<>R?7
MX_$\%!D)S@2FA[#/SW/Q./?X8QOC@JJ>VX [#N<Y^)_8#D?/;@BKV'8?=M\_
ME]_RSP1<=CZY!]/CW&3W]@!WQZ;<$1M[=N_J<Y.P]1D[CT/P)X(NUM"5*(4>
MD)25$A)5G<#'KMDY/W>G:@3.D"<IU'Y17)JGA0*NKJ*<$H( )!W!2%=).V"/
M0GWQCC;6M,NQ AN<VCQG/\CR)=@AAP@A+8^SU8RVG*<G!!R,@D$=C^J<[CC4
M-/\ 9:-6C[^'11=(:95LGH/RZ" #\4G;?T]![;$26\ >,"1>-8](\(R5 )R^
MH_*O=*3)@RHLAIMN4MN3$?:C8RIY3;B"T@(2"XI*RD)/2#ONG<#C#P#3<T.:
M&ND&[9$Y#"3)B]HRX)!DC..%^NI3S]0=:[SMRZ++N:Y:#;\.H1FUW!$H,%Y/
MUR"W5*='IRV*VSY8=C.SHT4O(BO+\Y$=[!2VKH/'H*6P,J4:M*C6J-#GN!J%
MI$.%0N[I@& ;2+$#$"0MA@#0XD2=#D #J+W-].&N6-7/S:_EZAUVBJTNTYB(
MK<!Z )4:@)9E18JTA+28SP/4VZTL>:E\>8XI9PM1P%*FS[B?L^T-K_ZEM-3#
M<TR26<8;I&F7G%EESI@<+#J!].6B9C+D"0490 I/ZRPI7V]C@8] ,G&<D=O4
MY^@<Z8U(UF2=+_O_ )SXKY?8'&3G[Q^SX9_V;C**A(]\'MW^XG!]CGYX[\$5
M?CG^GU],8/P_G'!%N9^C[8_LO_)#L?\ *H_OD;D6C<V_IC&<[9'I\R*2[]-A
M(%J<A.^/[O:Y?^P:=_[>_P N"==>B@$#&Q&YQ@>GP].P.#C/^[@BIGM_22/C
M@_'YG?N <X)%7VQVWV'KZ#'8=M_NVSWX(J'(& =O3[O0G^G8@ G??@BKV/PW
MS@=MAW/Q^ SL/3@B/?< X./V[GW]^VV_QX(C&=A^.WOD' V.2/GO\>"+N:8=
M>R6T@@$9)4E.YWQN<'.,;=AGOG>Q/#S('U3KQ55QW4 $]!!.#TK0L]O4))V]
MSMCL1PPGD>0()]OLBZRVO_F>A/R/J?E[G&WKMV0>!]"B[$1WG-T(*@ K(3A0
M  )R2#]E. >DG (Q[C@&DB0"?"_L+CSY(NI2%('V@=P<;@;COV)P23G./7X#
M@01F$5,;GVP,';[P<[G/])XB*F??W([CT[*V'OMMV)'J,<$1W)^(P._;UW[>
M^/NWWX(J=^^"#G?VV 'N,]_Z/;@BJ"01GO@C;MV[GOZ_ =\#WX(O4"^A[?R4
M5V';?F^U>[?^@&C?!%*HX(C@B."(X(C@B."(X(C@B."(X(C@B\1/G[R.=WG!
M[_\ &=USS@ Y_C,N;?;MVSP4&0TL$T 8P-O7M\<>A.,>VV-]AMW*KEC[_P#O
M]_AZ=OV9X(C;W]??U[?U'OZ<$7'&2,D'!/OGOVQM@#![D]MO;@BJ$G(P"23C
M"0<]]O7<;#;'RV&Y%=:?3W)"W4 MI*65D)<4IL@A2,J2"G*RD$GH&2<D^@'&
MFM))$9"3) @<;D3' 7UB 2*!/5]?PGEV/RKUN31*;?NJ5TT?2.RJM%:E6U(K
M\*JUV^;QBJ("Y=FZ:T1AVY*M3% )\FOU44"U'W%EIBOK=;>0WZ;:=_TVUCLV
M[:%3?&UAQIN- BG0V=X'>;6VFI%%K@)FF'.JW P21.Q2J 26N@FQC3,1Y<[Z
M<E7LO0G2^YZI-IEBZ#<TFO$^GMJ=74IE7M'1VB*;#86'':!^:NH<UMM72H-L
MHO1F2\5-X+3BBCCF6_$>V,?_ -1NS=KS);AH5MO>UMC)-=^R40[,$!M0']0!
M%E06M_4V3)!XSY@R,I@B,[3;KM>U;/N:[W[)A<BE38F4NH)I=>?J=^ZO";;J
MRHH6NM.0Y,&!&>3T*(*J<A#F 4LEL@CUE;9=_P"R[,:NT?%C60PQ4?NC8J;
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M2]3*I'04Q*K3W%*+$V,25?96G9;945LN!3:MTDDJL!^/?Y?U_KZ<$6YGZ/L
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MT(4I12X."JU[K0I*BE600$^Q[X4D[$CL1G/[-^"*F3G[ON_'OOGL1[]^"+U
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M!)QE3A*4(&X45 >O!%-LY*N7R#IGIO:]J0X3;54KD6#)KRDM /-L*::6&T
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MS!C-.5G\JK=V7-2+#HD!ZQ[.I5NH=;N2M%V4]6J^E#@DMOEM24M)>4VA;:"
M&T%(! 2 -3Q&(<'20,K@38VCE)XJASFF6G"8X#7F0X9B3'/B$V/4[0O4C1JE
M*N^B1ZA-H-/N%ZBR9LE+K*%ELI*I2PVV<T]U/FHCN$@I2HY*CC&<+9!+0X:L
M<.Z8RD @VM!!'#+.FI4((<\EIMD!XS:8G@8CDF_TCE\Y2=5;QAWK6K09L?5F
ME5V-=*+GAU!(C5.OL243/,D+<*V)(?DH<6EASI<2%)[E1/&IS@!H(@M&4?\
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M]*P,J:2GRG$D@H6DIVQP56 C[\X(^61^'X=S\MB+U /H>W\E%=G^M]J\?_\
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MD5QMU]ZJ,H0RR)/1A$:=@DNR%(3T];B>H>:@!>!G@KU]TW?F:Y;K<U*TDO\
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M2.RJ[?%PU6+#K?U9^0_(1*8?JU72\Z@HID"F(4'5,E]/0%I+;;(*EY2D')+
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M?4GI8=>5(824]L-/A;9 [$=)[G<\$2NV_P V&J=!;+#$Z&ZRII*%->2I@$(
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g197729g88z21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g88z21.jpg
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M[G!QUGJ,_#6BN3#<CN*GJ_),Y>(D6Q_HKLI%@LNT<I"("43)*G # 8H]#%$
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M[A?)F=EV?3G*?4&Z'2]<B)IQ4MFQ?XJS:<V&T-3MJ5E\0G>X:OZE+&2>/T$
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M[5;VPWMH]O&/LQ06NZ;*^OHHP/2%75!A<=/2V6/2DJWSBI"/B_A-\:[0T 1
MCO9VC9ZFJ' /7HLO4-N-V9CAZ 8Z+9$H_2!$G7M"^.?:=V<?B'7;=C^;8:M#
M= ?ZJW.FEON#,QQW/O4-QIWC9HD?6?$KPXU2(#B7<VR;[1R?]>32-V1Q9^;+
M&H^2#M4#I\G.6IMORVGU-E< T7D5KNO[!-;EW.RT*X[3G[+9ZT6NM0-L$ZI[
M!''K)Y.09BOVHQTG'*@H(JB 9GXLVV8Q(-+WM@L5Z?+L#V .>KX,#!!.#T]Q
M]*T;;M\6DE\AMY_@[A^@-U-<[E1B2Q7'DG7B<^DG'F_3/O4V1++FO?>I&O)S
MBC7TC%ZF7UCIZR7ETD0?43I_*?<1VIC  _-.JB9/X&,F;Z(XLC[5L^6T'<4Q
M'YM_J<%HI/;!^'TP-C/R(/MFMO:0^,^NCIB\2O"S3UP"TFV=HZCK<J _G*-3
MW<8B?D63I]RIY%9DW$S8]N_KQ\Q>0=R;&ZE7@M>K5'0];=HF]%&CM/74"WM2
M[50G5,Q!MY5#IF,599;NZY%_*.QMO\V;9T:U8=IKT7.KSJ1V93?3-;JP/.1;
M8R!@#%99\*=Q:O\ ^^'B]O[6(R?RECM]])V-ILR$^J&9-OV*:H\1'I*G5^ME
M)#R/G-35J7C9HS1HN5]7ZUKM:EGX'"4M!D7$U=)CQ! ROOFZS[B4M<J"IP\4
MY'\PX3%4QC@0#&,(ZO4M=U;5NE=0OIYXDQY=N"L5K%@8'E6D*QVT6!P.B)3C
MBNSVIX<[(V1YK[8VYI^FW<X876IE)+W6;OJ(+_&:U?R76JW09O65GO)%ZR6"
M@DDSAFIKMJ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I6-F9F(KL3)ST_)L(6#A6#J4EYB5=H,(R+C6*!W+U^_?
M.E$FS1FT;IJ+N'"ZA$D4B&44.4I1$)(HI)Y(X88WEEE=8XHHU+R2.Y"JB(H+
M,S,0%4 DDX K&O+RTT^TN;^_N8+*RLX);F[N[J6."VMK:!&DFGGGE98XH8HU
M9Y)'9415+,0 35(6W(7>W($QOP4-=0D)K=4YDD.1>]D)N,K$^@!A(H_U?J^,
M\C<;HQ,0WB1UCGGU1KKI9(Y$O>")1,;JVT72-&Q_**]EEO@,MHFD&*2X@;&0
MFH7\G7:VK@\200I<SJ",]![>*Q[_ -\[^8_S5[>LK+;C$K'XA[X2]MM-OT!Z
M6GVQMFV\C5]9A*GKM]1OYM)TZ5U95\] >K*$X?VJX_JG>W*GD!LEPMZ/*_2K
M$VT-KU5+_DQ:SJY",G5D"^I0]ZW*45.4"&6547 5C1_REM[7TZ1M[1K%1]F:
MZ@;5[T'^D9]0,D(/O^3M8QGL .*R5\(]5U@>9OGQ1W[N.1_\=8:+J$6QMONI
M_P#A#3=LI;WSQCD#XK6+ERN"[-("YR\;[/WAM'+>:5T'3; \']<?7=6=V"_6
M'^Z</KS+V%VX,(^HBLL<1$1'(I-Y;GD'2-8NH%]DM!#9(/\ 52TB@5?T ?LK
M+MO /P?MG\UMAZ/?S'[4^M/?:_.Y^<D^MW>H2R'_ %W;FMV3X=<24T_")Q@X
M^>'TZ"!M-Z\.)@_OCGKQCG'[1,81'ZQS%.YMQDY_'^M9_P#[2]'?Z"?'Z/;V
MK=KX0^%"KT#PSV!TXQSM#;[$_>S:>6)^I.?K6JR_ GAI-?.<<;]5L% 'N(O6
MZVA4721NO4#H.ZJ>&<H*%$.I%$54SD'U(8HYD1[PW/%P-<U!QV*SSFY4CY,M
MP)58?,,#FM7>>!7@]>\R>'6UX&!R'T[3H])D4^Q272S9R(P]BC*1[$5KQN$%
M:K/5?2F[>1FCW*/XQC'5W;,[>:6FN4>J?G:1MHU\AGC4#?2;(^1,8@BD1=-+
MYF3#=<\^!JNE:)JRGAWGTZ&TNB/?IN].^$E5C_2/7SR03S6N/@IINF>O9>]?
M$/9,B>J"VT_=5]K>C*X^SYVB[K.NV<T8/>-?))7T"15R*QSFX<RM"%,\V!6:
M[RPUJR 3R%KU+"A0MYP[$G4Z\B^U6[D'U1O0HD[2 RI,Y!RRX^(JA"* 0J)I
M%MML:P>FRGGV[?OQ';:C+\9I,KG 6--15$N;/)R>J[AFC' ,PR2,>75_&'8@
M,VOZ;I_BIMN$$W&J;3LOQ%OBTA7+/<S[7EN)])USI4*H@T2]L;IR6=+(A0C6
MHU9M:@;II<9?]:V-G9JQ*"LB1VW*LW=,7[4P)OX>9C'B:$C"S<:L/@2,1*-6
ML@R5Z N@4#D,;GM0TZ\TJZDL[^!K>XCP2K$,KHW*2Q2(6CEB<<I+&S(P[,<'
M'J.V-TZ#O+1K;7MMZC#J6F7)=%EC#QRP3Q$+/9WEM,L=Q97MLYZ+BTNHHKB%
ML!XP"I,AYA5T%,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE44YMHL9YYQ?UY=%/ TWL;D97*_M,JIQ)'3Q&-8M%BH
M-(L "8$E*[;]A0]>8R+=<2HO%D&3 Y^CKPENNVJ7A77[VT&=4L=$GFT_ R\)
M>XMX+R[A]Q/;64LS(PR5#.X&5R/#O&E(+^;PRV_K+>7L_</B'IUAN@,2+>_$
M&FZGJ&@Z)?C[#:=J^OVFGP7$<F$E>."$MB0J]YD446R*3=NBDW;MTDT4$$4R
M)(HHI$!-)%)),"D323(4I$TR%*0A"@4H   &<D26)9B2Q)))))))R22>22>2
M3R37MZ(D:)'&BQQQJJ1QHH1$1 %5$50%554 *H      %0QR-W ;0.D=B;B)
M7RVHU"A"3 5XTJ,(64$\BR8>7&5".EA9=/.>+XH1SKKX?9X8=_>6Z-/,=4SC
MJ.,XSC]'%4D?RT9\9Z1G';-5KN_.J,@N9:/#&L5RF35UE=9.I> F[%M%"LIN
M-SN*Y9;]7-53%9CZI:;/%P#[6]4D+=,['91TRC#C(P$,SK$T_DS VD6$F(RD
ML &P0%SZ,A2P.0">H@=)QV)SQ4+7 $_D*%+%,@LV,R8+!" &(!4%BV..  3V
MC76W/[:MH#C3)W[05*UW4>1SN<90MU0VS?[94V,XE/QU8J&M_E&VX\Q4)';7
MN\F:=<U^ O3^CU2:;1D;%UV\3=FF'D+ U:%1YG2Y8QXR.@*<8R6(ZR>A1C)7
MJ()Y4 9-BW$A\HM&JB4D!@[%0<@!,^6 ';DCJ*KQ@$L<5)%6Y@7V_:XT9(P>
MMZS7MN;AY+[>T@XH;VU2%MK\!7N.FTMO5O;UI&TLX6IO%V[JGZ6EDJ],+0+=
MC$7>\4UD_C)UO^H)>AB56?+$HL:.&  ),BH5'22?=QD9[ \BKUG9DC(4!WFD
MCZ22P B>17.0!W$?!Q@,PSD=Y@XG;ZMO(:C7.U6VAUVEK57;%WUM$25(O,CL
M?7NQ(NFFC6CB]T"XRU(UX_FJT>P.)VHB[5J[1NO.5&:7CG#Z+59.E;)4"%0&
M+916.0%92W/2P!8 XP>YX(SSFKX9#*K,5"]+LF58LK=./4K%5)7.1G'<''&*
MM%D=351"F,XRI>T#V;7: "3: O/'J&V1N6%C>@1##:S:^)5ZE6)R@EU;1UHN
M=-4L7O=,A6[F99UR-F7I5E3$<K]==-)<[-L)[S+36FM2V.F2R?XU].:S,]U"
MK$]3V]K=" 1]UB:=XDP,J/#-&@MM)\?=RZ?H $5AK?A_9[CWC96X'P<&Z8]=
M6PT;49$3\G;ZIK&CMJ/QBJ$DO(M/M[R<.["5[WYR->YTQ2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5H>S=9TK<-%L
M.N-A0B%@J5G9@SDX]8ZB*A3)*INF3]@\0,FZCI6+?(-Y&*DV:J3R.D&S=XU5
M361(8,RPO[K3+N&^LIFAN;=NJ-Q@CD%61U.5>.1"R21L"KHS*P()%:+<NVM%
MW?H>H;=W!9)?Z3J</DW-NY9&!5UEAG@FC*RV]U:SI'<6MS"R36]Q%'-$ZN@-
M5'8.^6W&E(D._@7W,/3T< )1-CA9&)@N2E8AT0 J32RPDRO&U/;BC)N"39"8
MB):O6J54*L\E(]TN?N'I'7;FNDRI,FV=3?F2"5)9M"N)3W:":)9+C30[99HI
M(IK>(86-U Q7D\$OBOX;J+.>PG\7=H6X"VFHV=S:6/B/IEH@(6+4K*\>VTK=
MC0QA(H[NUNM/U2Z;KFNH)9#D]J5Y;\,]PP,WJ7<=ABZ6G:8Y2(M>JN1];F-3
MO7+18Q/%BY)I?V4+$OP,H5/H,5*R")E0("3@R@  8LNTMP0KY]M9G4K<'*7>
MCRQ:G"P_I V;RR*.^1+&A !)4"MO8>./AC?2_B_5-P#:>J$8FT;?%E>;0OX6
M. 8Y!KL-G:R-D@9MKJX0DX5R>*EC7FF>+)(V.#6=0U9(,(Z[Q6SXU]65XJ<5
M0OD+7F%3B+@E+MGCYV>9856-CZZV?&>',2#:HQ8"+(/!'1SQ7D#%;F*X@;!4
MK-%)$<$DE>EU7'.3C'?FO2M/U'1M3C672M0TW48B1(LMA>6UXA(  <26\L@/
MI &>KD5FC\8./:CJAO3ZAI!E]8(BA0.Z'2%&K$*]?2;8\8UZ^5(O'2DG(RD.
MZ615<PLF_=R,0JR>N%5SP>8_J'4?5]KGO[=^_;CZUL/*C]/H7T\+QVYSP.W!
M)(/<'D8K3ZYQ8XSZ?EVMIKU3K]$BXRM;-K:$&,B2.I:".XI>H3>SYH\=(+>!
M\H;@YHM;),S!W/CK-FKLH 126EEGLBFXG/0BR2N2IPB,[^G(484$X'4<#'>L
M6>2PL$,]S/;V<*JX+W,\<$*]9!=B\K*H)Z1D]0XS\S49UG=W #B= _H=:VO&
MJJHP4>%6;:XU*[<7V8-(),6<8W:L:=1 M,PV4!C'LF35DDP;MTD6Z8$333*8
M^;NWVQN2_'FKI=XD0&3<7B"QMU4G)8W%X8(>D=R0Y_7@5YWJWC)X5;><6L^]
M-#N;QFZ$TO0[AMQ:H\F/3$FF:$FI7HD;LJ&!?GP,FNRYW1R<W@4T3H#3,IIB
MLO0\%?=_)*,"%?LFQ^I%7M)T<U=*VJ=D/!.5U$N;NYJ<*94I"OV;I$QTLS%T
MO0-)_*ZSJD>J3IRNDZ%)YJ.P[)=ZLRBWACR.F06BW,H!)1E(!.@EWEXE[V4V
MFPMG76S=-GRC[U\1K86<\$1RK3:+LF*5]4OK@H1+9RZU+I5D6"^?#*A*5/.B
MM#5G1<%--V$K-W&[726^4NR]FVUPF]N.P;.9$&X24PY2330:1T>W#R%=KT>F
MA$5Z, &C!#Q%';EUI]7UBXU>:(O'%;6MK'Y%A86P*6ME;@YZ(E))9W;USSN3
M+/)ZW. JKW6Q]BZ9L>RO4M[J]U?6M:N_QEN3<NK2+/K&OZF4$8N+N555(K>W
MC_(:?I]NL=II]L!%!'U--++.6:FNWIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K!V"L5JVQZD3:J]!V:*5Z
MBK&6")83,>H(@)1%1E)-W+8_4HB4>Y(>H"(? <F@N+BV<26T\UO(.TD$KQ./
M?AXV5AS]:P;_ $S3=5MVM-4T^QU*U;[5M?VD%Y;MD8/5#<1R1G@D<KVXJLT]
MP.X<6-P9V_XX:K9NCF$XKURM-J@KWB/43E/4S0HE.(^ICE$#&'U$1'US>P[O
MW/ .E-<U%EQCIGG:Y&/EBY\T$5YM?^!GA!J4AEN/#O:\4A.2^G:;'I#9[Y!T
MHV1!)Y)')/<FO)NIN?9DV3VA5RXN1T^+I=OKRI4J U4VM/(%D\3Y P5]W"3:
M,2!"RC9T#F)I4-3W4FJ\>?)1K$MDY1BN4II%T?8-NS= MEE-ZI)8DR&QTQCY
M15.@]1M">6+8QR2<'VK2#P%\'S<F%=MSJ @40Q[GWA&@D#/U*(DUY4 " 9'3
MT@#@5ZJ1OL_.&4:Y*[#CW0Y5P00$%+0C*7$1Z#U^>6V2<T10!'Z0*%,!OV0"
M&83[RW0ZE?QU>1J><6YCMOU?#QQ$?HK9VW@'X.VTHF&P-#NI00>K4UNM7S@Y
M]0U6YO PSW# @^X-6/INM-<:Z;"SU]0*316AB F9K3JK!5EN9,! 0(9&%8,D
MS% 0 >T2B'4.OQS275_?7K=5[>7=VV<]5U<37#9^>97<YKT71]M[=V]&8= T
M#1=#B(Z3%H^EV.FQD?(I900J1P."/:MVS$K=4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2M)NVR]
M<ZT8%E=C7ZET*-/W>&_N=HA*PS5$O0# DXFGS))4P"(!VIF,;J(  =1 !R[2
MPOK]S'8V=U>2#&4M;>6X89[96)'(^\BM+K6Y-N[;@%UN+7M&T&V;/3/K&IV6
MF0L1W"27L\*.>PPI)R0,9(KR/K#+V9%>]H)>^>##D9I\-I7;5<'KLT6I8HA*
M!C+*W66C+)L9M,JK%8$G[%2XZI4XZB)T"-XZ-GW*KEV>S._ Z!MK[K^%6(Z%
MJ7EJQ?BVD+D>R^6,O@$DXZ>^..*\Y3QM\&3?,1XC[3$S*(\MJMND ;)!;XEB
MMN,C +&7IP"2<&O7JGWZB["C FJ#=*G>(<1* 2M0L4198WJ<!$@>>AGCUL F
M IA* J]1[1Z!Z#G.W-G=V4GE7EK<6DO/Y.Y@D@?COZ)55N/NKTO2->T/<%M\
M9H.LZ5K=GP/BM)U"TU&WR02!YUG--'D@' ZL\'Y5MF8U;6F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2O@F* E 1 !,(@4!$ $P@ F$"@/Q$"@)A /7H C\ '%*P$Q;*K
M77+!G8++7X)Y*>-[L:S$S'1CF1\L*0./((/7*"KSRXKH MY<JGA"LD!^T5"=
MU<$]@35,@=R!^FLZFHFLF15)0BJ2A"J)J)F*=-0AP Q3D.41*<ABB E,41 0
M$! 1 <I5:QLU.PE;C7$Q8IB*@(AF4#.Y6:D&D7&M2B/0#.'SY9!J@41] %54
MH"/H XI6O579>NKTLX;TJ^TRWN&9 5=MZS9X6=<-4C"4"JN$(QZZ502,)B]J
MBI"D-W%[3"!@ZUP1W!'Z*ID'L0?TUNV4JM,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE?!$"@)C"!2E 1,81    #J(B(^@  >HB/H 8JA( ))  &23P !W
M)/L!7F19^0N[N6%UL6I^%C^-INM:E)+5_9_+><C"3<0WE4@$LA5]+0:W8SMD
MZT(8OF+$LJ:*0*H"S5>.17@IV5[V#1=*V[:0ZCNE'NK^YC$VG[;BD,,AC)RE
MQJDPR]M"Q!Z8 /,)&&#D311_-6I>(.]?%76=0VKX,SVVC[<TFY:PW-XL7ML+
MVTCNE&+C3-FV3XBU6]B4CKU!V-J@;KBDMHY+"_NI%U_[.+C-6'PV?85<E.0V
MQWG:K-[#W[+.MCRTLYZBH<QH:8,I5FS8BIU!:HDA5'**(D26>NC)@J.#>[XU
MZX3X>RGCT6Q3B*RT>-;&.)>W$L6+@L1CJ/FA2>0B]JZ+0/P=_#;3)CJ6OZ==
M>(&XIL->[@WY=R[BNKN3)8DV=X6TR.-69O+46;2JG2KSRE>HV24X\: 58^ZU
M=&:>4C.SP_=RFLJ4=CX?3M\/RAH06_9V^G9X?;T].G3-&-:UD/Y@U;4Q)G/6
M+^ZZ\_/J\WJS^FO16\/MA-!\,VR-H-;%>DV[;:T8P=.,=/E&R,?3CC'3C'&,
M56&]>S?X^RDB:X::1L7&+:#8#'B;[HJ8>U$C=4#>(FWDJ@V<$JDE#G5  ?1K
M>.C%GS<3M3/TDC!V[^SWQK4:?#:F8-?T]N)+/5XEN2P[%DN6'Q"2@?8=GD"-
MAN@GOYIKGX.NP;JX.K[/34?#3<T8)M-=V/>3:2(W'J6.XTF*0:7<6;-Q/;16
M]J\\9:(W"*>-:UUR5W#H78U<T!S93AEQN#PL/IWD[6V81-#V7(#VE:UB\1I2
ME:T>_N $/#2+Y:(D5C"@U2!%-"7E9[[0M,UBRGUG:AE'PRF74] G;S+RP3DM
M<6C\M=V:^Y]4D8Y8Y)CCUNWO$C=VQ=PZ=L+QH6R?\;S"TVAXF:="+30MR3\"
M/3=;M@!%HFO2<=*CRK2X<^7$@1([R[]),X:OHRF*4Q2F*4Q2F*4Q2F*5\$0*
M F,( 4 $1$1    #J(B(^@  >HB/H 8I4;SKY]LC7,JXT[L.$BY.;9N&U8O\
M<UC;C$1[UJ^%J[<IM!6/'20H*-GC$Z9U#E;N0,8Y#G0%(U1P>1]X[?N-4SD'
M!'_K_'\&HAUAQ2J]%MT9LVUW?8VV=JQJ;XK>YW>TR:C=@>48.8V11A*RQ<HP
MT=&+LW;E!".>$EBLB* +=8JB2)T[F<D8 "CY ?7/).35 H!SR3\S_']^:E;9
M&E-4[?)'DV718&XC%).T8M:6;'.ZCDGYD#/",7:"J#IH#DS5L984%DQ.*"8B
M/S Z6AF7L2,]\54@'N*QNH=#ZWT6WL##6L;*0L38GC1\XAW=@FIN-8*LTETR
M%B$IIZ_5CTE?,JJ.")KF\<_A]X]B*)""Q;&><?[_ )T  ["M/H;2,O)Y[=VS
M48P$H:P76/I#*==-EZ]KFH4><EJXYL:0O.V+:6&Q'A)"Q3EJ.!7;*%>,(%!Z
MC&QBYGE3QA0#R!GYDD=ON&< ?I]^*<$%FQCGOC  ]_E[9)_W5L@'TQR/K!;#
M1KK3;PC%O5VU=V=K"T5^QR%/LC9!)<J\#;*\[DD6,FS3=MEGD6=RHTD&+KR,
MU'O8F07:N1#(<,"I[X8$9'U!QQWJ@*2#*LK =F4@@''S!^H./NK;-56>3MU%
MB96=*W+8F;NP5>S"S3%)DK:*18Y:F65PQ1,8YD&+J=@)!RR1,HH9%HLBF954
M2BH:A !..W<?<>:N!) SW['[QQ4AY2JTQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2O/#G/=+A<9+5?#/54PX@KSR4?2B=XM+ 3>=H6BJXB"^P9Q(P="MW]@:B
MK7885C$2?#[UCDU6[UPS73[7:5K;6L>H;HU&)9K30DC-I;OCHO-7G/391'W*
M0MB:7 )3\G(055@?GWQNUG5]7N=K^#NUKN6QUOQ&FN5UO5+?)FT+8^GKUZ_>
MJ>R3W\77I]GUE4G_ ,*ME>.>2&1;JZSUK3-/T.L:UU["-:]4*C%H1,-&-2@'
M:BD F6=NUN@*/9.0<G6?RDBX$[J1D7+EZZ44<+J'-RM_?76I7EQ?7LK37-S(
M9)9&]R> JCLJ(H"1HN%1%5% 4 5[-MK;>C;1T+3-N;?LHM/TC2;5+6SMH@.%
M3EYIGP&FN;B0O/=7,G5+<W$DL\K-)(S'>LQ*WE,4IBE11N[3%$Y ZQM.J=BQ
M9)*MVA@=N*I2IA(0LDF!CQ=AA'"A#^2FH5YX;V/=%*8H*)B@X379KN6ZVQTK
M5+O1K^WU&RD,<]NX;'/1+&>)(95'VHI4RCK\CD$,%(Y7>NS=#W]MK5-K;AMA
M<Z=J<#1E@%^(L[E03:ZA92,K>3>6<W3-!)@CJ4QR+)#))&]9.">TKO+5S8G'
MC<<B:4W7Q<M*&O;--+"KX]VI3YJ=]K+81O',9PH-EKJ)B+*N#K/')X\DF_4\
MW*'(&^W=I]K'/9:UID?EZ5N"W-[;Q#&+6[1@E_9<>D>1.<@* JA_+0=,=>:^
M!VY];NM.W!X?;PN#=;S\,=3CT#4KURQDUK19XFGVUKY,A,C'4=/0J[R,\TIM
MUN;AO.N647RSD*]TIBE,4IBE,4IBE,4JMO)BH[6V/5H#6>N%RP<)>K E#[3N
MJ4BT:RE8UV5!1::3A6:YR+OI&P%+[G3,U!844UE$7**;5XJ^97*0#U'N.0/F
M?K\@._\ =5K9/ ]^Y^7_ .__ $]ZF>CTBKZXJ<'2*9$MH2M5UBFPC(YJ7H5-
M(G4RBRZ@]5'+UVN95V^>KF.Y>O%EW3E1194YS4)).3R350 !@5M>4JM,4IBE
M4QV6#BA:UWEJJ= D96;_ %[:Z^L[U(&,WJ+&2V4PGY!]3KK."4S.G+1MMG9!
M2&EYT[&OOJX]CF3:0]ZQ;UF-Z_:4_(C/W#'(]SP.PYS^BHW'H=0.ZL%/MD@\
M'Y<GOVQ6J:%^0^FZI(M:E?7O(G>E^BJ*>Q-(:7I4R)92J4."I%?C'[S7,!"U
M&DT:!8PY04M%D;C)O4SNU3REA?GAX@MTC%SV"*I;'?W8L3ZB22?D.!P,=R;(
MD$:]R[L%ZOL_FJ% ](   '<\DDG)[5<'6]27I%+AJZ]>IR<LC[QE+!)HIG0;
MR=HLDL^LEJDVR"ACJ-VLA8Y:4>-FZASJ((+II'44,03FC)R2?U?=[5,!@ ?K
M^_WK>,I5:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7G!I%(M_P#:+\R;X_ %
M_P!!O7VD=(5!50 .+:.M,0\V);4D $3>"(6%!,#&)VBH1<W7T,<![C5B;+9.
MV+-/3^-+W5=6N0. SV\B65L3\_R!]QQCZ"OG;92#7OPA?&#7;C\I_(_0-E[*
MTAV&?+M]4M)=P:JB9ST$:A&,D8++(?9B*N8?>&H4[2\I"NQ:FE;XZ>EJQ(UM
M:7;)3#"<@J-';,F&3YBH8J[3W=0)B)MKETX*FS3A92.=^8$KYJ"O$]#X#=)P
M0"#\P6*C'S]0(^>17T-YB=73UKU D$9Y!"AB#]RD$_0BM&_"\XP>ZM7SIM[:
MS)";I;.GNK)A6TQR47=VC&>A*L\<PL@HJ1HH@VL]EKU<64660(2>FHR'$?>+
MQ!L>[RI<L.ALI]H8Y7@GG] )^X$U;YT6$/F+B3[!SPW('!^\@?>0.Y%9QSR3
MT:C1KKLAELFN6&FZ\N1==6Z8J+E2W$B]@*2T# )4DK>MI2;I]:59VT5Z&3A(
M]%T^-*2S1CX/F3F3+3RWZ@I4@L.H \>G!/5S[  DGZ&J^;'TLP8%5;H)7U>K
M('3QG+9(&![G%:E&\T.*DM5;?>&6^==&I]!F:Y7;I9'$XFQAZU/6Z7"!KD/+
M/7Y&R+61E9@08(-#F\8BPAXY$B"!\J8900O0V6!*C&20!DD8^0JGGPE6;S%Z
M5(#$G !)P <^Y/&.]2/&;RU',[2E-)QE^K[O;$-#OK!)4(KDY+$W@XQ>$;2,
ML#-5)/QV#%Q9(%!VY;'62;K2S%-4Q3KD ;2C!0Y4]). WMDYP/TX/ZJN$B%_
M+##KP3T^^!C)Q\AD<_4?.J;V%(NO?:AZ[E&  W9\A>,UNJ\ZV( %2D++JJP-
M[''S2P!T%1\VKBB4.FH<3 1D44RE 1[L[: _&[ OHW]3:+KUM<0L>Z0:C"8'
MB'R1IP92!@ESG/M7SSJ"?B#\)O;]U /+@W_X;:MIE]&O"3ZEM>_CU&"]D QU
M3QZ>4LU8YZ8<J ,DUZ/9P]?1-,4IBE,4K$S\W'UF"F[)+*'1BJ_$24W)JI)'
M742CXIFL_>J)HI@918Y&S=0Q$DP$ZA@ A $P@&5 R0!W) _75"< D]@"?U5#
M7'OE%Q]Y64M*_P#'K;%0VC6A*@#U2NR/67@7#@AE$F%IK3XC.R523.0ICEC+
M'%1CXR8 J5 R1BG-?)%)$>F1&0_4<'[B.#^@FK(IHIEZHG5Q]#R/H1W!^A%3
MWD=257_3.W)O9]QWQ$/(R*9P&K=EGU[7WK('8/I)6,BVR\XI+"X<K(&60?N"
M$;F9HM4P;G*11(ZA!6/<R](7YD9/Z3Q5H))/R!P/X_56_P GMG6$+95*;+[!
MIT9;4GU.C#UA_8HIK/A(;#6G&]$9^Z5G1'PN+@O6+(E7$RH":7/7IL&(+>ZG
M_@ C$9"DCU'(''IQU<_3(S\LCYBA= >DL V5&,\Y;/3Q_I=)Q\\'Y&M#E>5?
M&6#J\;=YKD%IF(ILQ:)^DQ=KE-DU%A7'UOJB[YM9ZVVFG4LE'*3->6C)$DVP
M!QX\6#)R=Z1$B1S!412$D!') #$!3GI/8XQV.>/G5IFB #&1 I)4,67'4.XS
MG&1[BMI=[QT\S9;5D#[+I;EOHV)6G-PA&S\?+NM:QB$ [M)U[BQBEGCZ#4-7
M&+N:1:O6Z;QQ'HBY;H*D,034Z']/I/K.%R,=1SCCY\\??5?,CPYZU_)C+X(/
M0,=7JQVXY^ZM AN8_%.>;W1S&<A=1J!K:NN[9L=JYO$%'26NZ]'K,VTC)WV)
MDG;24IB48[D&3*32LC.,<QK]RDP?(MWAO RXQ2CIRC>HX7@^HGY?/M[5:)X6
MZL2(>D=3>H>D?-@>5_3BMW3WYH]Q?Z_JE';FN%MEVV++-5>A)W"!4MEDAU()
MQ9R2<' E?#(RS ];:.IXKIBW71-#MUY$#BT2.J%/+?I+]+=(X+8. <XP3[<D
M#GW-5\V,L$ZUZV&57(ZB,=60.Y&.?NJ(=<4:R4+ECO!S'5Y^UUGM&CT>[%ET
MFHIUYM?(-=Q6I.+:J%Z(DEI1DHI-R"*8 HJ4$EU>A11ZB047GD$C]!Y'\?\
MI50,,>."/EQGC_U[5;K+*OIBE,4IBE1AN;<>O>/VL;=N/:\X:LZZHC%O*6RP
M%C9.7"'C'$BRC!?J1L,T?RKI%NX?('<$8,G3DJ **)H*"3M&]$:1@B#+-G R
M!D@$]S@>WSJQW6-&=SA5&6."<#YX&3^H5W-6[;U?NZF1>P]07^H[+H\R3NCK
M12YV/L$0L<I2&5:J.HY=<K60:^(5-]&NP0D&"_<W>MD%R'3+1D9&*NI5AW#
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M/#KSI'FN$LX)'\S6=NJS/+T&02VJ]<L\MN\<]QJEZ]-<F-#\@8M"4U%M"J7
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MYR>3]><_?5,<8[?=Q531X>6%P'EI'EQRJ<Q@_-,V;;$9Q[Q1/ZTU9-&%474
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MKPR@"2,X8!E=>0""K*2K*RD,""0015+>>*ZACGA):.1>I2RLC<$@AD<*RLK
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MRE0JF,('ZPQSE\%%(*@9*Y8X8X!4_G"J[Z*2+"\Y?:'5=CT+$^_..UP(BF
MFA-7#5[Q_/J& O0OC/G:2;@X@4#& G<<3&]<['<'Y7:6Q[EO\9Y.NVI)[M%:
MZA&D('^BBDK\AG KY[\-%%GXV?A#Z7 ,6@O_  ZU=4'V4O=8VQ<SZ@Q P.N>
M5$D)QDA<DG@U>C.(KZ#IBE,4IBE,4IBE,4IBE,4IBE,4IBE54V#O&YT;9LQ
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MC<W8*W$I 'EPEBHMH3R?RN \[C!*]$(]/FA\1K>2>Z$MR%%K9%6M8L]7FSA
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M-/@_5#]HW(V74.B)B&MZVQCJ., 8R>RDE1]P)X'M5_0F<](SECG'NP 8_>0
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MMZ3<RD"YOVMXPNHVA=KII8IK@KYT>HVUAZ.YQ5?0E,4IBE>7W+K?$YN.PO\
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M?&0<K(L'FJ>.XD!]NQ(JR*PM()%DB6="IR%6\O?+S@C#1&?R7'/9HV /J'J
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MXXG@ZG''!5AGCGYOV-*-V^._BGO* ^9I>T](T?POTRZ4]4=Q=P3G6]QPHPR
MUAJ?EPR 'D31N!ZCB]V<-7T13%*8I3%*8I3%*8I3%*8I3%*8I3%*8I5*N1-
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M;I'2J*-OY3;904B=>U1F9-P%-8O2*HO=G7,0!1&&KU<;%<R#(\B3PY)ZTZ^
MM%LI==KUFVM!COFDU;5F-KM[32);ZY?*_%.A!33[7E3+/<-TQL(SF-7[B1HE
M;Q'Q;\2[G;J6NR-DQKK'BCNQ&M-OZ5 5D_$T$RLLVY=9/J2RT[3HA+<0M<KT
MW$T)/0]K!=R1=_CCI"(X]:CK.M8UXI,2#(KF7MMF<>(9[;+K-JB^LUC>*+'4
M<'._D%#D:%<JK+MHQ!BS466%MXAM9K^L2Z[JEQJ$B"*-RL5K;KCHMK.$=%O
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MD?/L44@^QJ1K:X49:"4#YF-OW5()3%.4IR&*<AR@8ARB!BF*8.I3%, B!BF
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M#N(<AOK*.6U=7$Q8,8MFVCHUFTCH]FB1NS8L6Z+1FT;IAVIH-FS<B:""*90
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MZ@HL4#_7^+*/>H/[R93#]GVXJH&2!]?V>]2YBIZ8I3%*8I3%*KQ:8$UGK\I
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MO)91RHQ+I-%:1RHYZE<=*],<E]<2+T=8C3W6)1&#]Y7U'[LXQ4\@
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--3%*8I3%*8I3%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g197729g93v29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g93v29.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X?2):'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/G!A9V4P,34\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @
M(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@
M(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL
M92!.86UE.B @(" @(" @(" @(" @('!A9V4P,#5A+F%I)B-X03M5<V5R;F%M
M93H@(" @(" @(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" P-BU*86XM,C R,2 P-CHU.#HT-R8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" P-2U*86XM,C R,2 R,3HR.#HT-R8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86PM0F]L
M9$U4)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @0TU92R8C>$$[(" @(" @(" @($)L86-K)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C$M,#$M,#94,#8Z-3@Z-38K,#4Z,S \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 Q+3 V5# V.C4X.C4V
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C$M,#$M,#94,#8Z-3@Z-38K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T
M:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$V,#PO>&UP
M1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA
M=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%L9T-704%$+S=107-5
M1VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%L9T%!04%%028C
M>$$[05%#5T%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G
M445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!
M=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%
M2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M+SA!04519T%O045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"
M05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!
M04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"
M04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C
M>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I8
M5T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP
M-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53
M355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$
M9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X
M<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD
M;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C
M>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!
M=T1!44%#15%-4D%$.$%*.4DP:E%H<$9R6C9T-54Q63,V5B8C>$$[930Q1S-J
M;7%Z3F-+0D@V6C1J:4QF:V$Q<GDT:G!5;39I-#1Y43<P+W5F2R\U53(X<TEI
M,&9Z3&524U=Z4T]Y5S=Q,&-X2RMN12].228C>$$[=U-">35L458V8U0Q=U9*
M4$A$=EE0-6LX<WEV<D4W95AD1C%74%-4>"MR<&0R-VU954%"-6-14G5D.$E"
M66UC93E++SA,95IV*W)2928C>$$[+W=$4U!,+WI4:&]O-#0Y-W8X3&5:=CA!
M<3!8=B]34$PO=T$P-#!6-#0Y-TE03$=J3F$V;&)(6"]!0S=E,S)M;4(T<#0T
M-V59>7AS>B8C>$$[<U9:2T=)8VAT.6\Y*VU*0EDT-7AS,F5V-D%Y;%!,4#58
M<6I88F%,-6AC2F-S<U=N*VA,-G)W0TES<G4S15)G97%E2D%K-6)6>4Y38B8C
M>$$[94](93@X=2],1W9'-FU.=&\Y.'1S6D=-2VTS;7%%<65)3W@W92M3;W-/
M3U!E;R\T5SAZ9CE7:3DO=T-K95@O;6Y':79(2'9D+VAB>B8C>$$[3B\Q84PS
M+W!(;"\U<'AO<GAX-S!46BM7=DU#97(V,FM8=D)L549F<3AO3$%3;U-".$DS
M-&<T44-W;$].:F9R*V=S,$AL<CAV85!Z,"8C>$$[6'I+.')34T]'4S T4D)7
M;E9O:U9#>E!26653=%9Q:S<W6D-I,CAC3SE&=S96*U=H=F]P<"]+9FU&655U
M2EI'9U-'5# R:$TX:E)2<R8C>$$[0R]0*S1+2V%/1'E(8V17<$HX4TAE<%(V
M2"M80V%49&-V3%AM2CE7;&A:8F9L8G0V36-H445%56-(-UE)0DYA03E$5$=I
M=FE1-S$Q<B8C>$$[-64O3&-Y,&9Y+S5G4D)8:S@P17)C:5%E3D9J1W=$,')5
M,30Q-G1J4EAJ:#-S174O3$=S+W!/6G)04TPU8D@Q,DYT>G0U95%I-6YH>28C
M>$$[<798:C%Y44)A-51J4C-::#5A,&9Y84Y'*W)E6F9,1W1Y86DP>G,Q.5I7
M.'!01#%%6E%!>F]M-D)L*WHS<CAW46):47E1;U=53#5Y."8C>$$[;V5764Y-
M<UEV2S)N-C%D-G X1%AT>DYA>7@R+T5Q,55#3V=C4T)U3F%%<C%O5&E!56UC
M3VA99B]!25<X>F8X059O=F8K:V58+VUN1"8C>$$[4EDX8V4Y,RM&=DTS+U9O
M=F8K:V58+VUN1VEV2$AV9"]H8GI.+W="5VDY+S92-68K86-A2SAC93EK=FQ0
M4F)/,G9O,S@P95A.5#%#=R8C>$$[1G5Q<D)B47EQ-GEI.%(R3$5C3G9116=P
M,W%/;C)G>4)9-#5X<S)E=C9!;E@V1B],*T=E27<K5U!-33A!=55A6F)I1BM8
M,614.%-+628C>$$[,E%C;4(O5C@X:E)B4$5H,V]U5%(O=T%R<'!)=S-L8GI,
M0D5J1&5#16AM5&5V<6,R:W%D:#EM;F9'<$HX4TAE:&PP3#AT,VM6<'9,6"8C
M>$$[;59&9'=:1FAH3D54;%AI=DUT6&)R53E/;2LK3D9(:5$W,'0X>F57+TQZ
M95<W4F1",%16;#$X4U)F6$=K=' O4DU1:69N=S5!+T9Y-"8C>$$[8W8X04LU
M8V9H<&A!2VUC3VA9=$(U6CAY3$9C0G1*=D%7:D%51S-L,U!Q26%$-&9!6DE!
M=%5P:7AV,2]1530X<&%,2%HS1C)F35AL9B8C>$$[56129VUH159U:U55,%II
M9'!&-5,Q0493<V9+9S=N8F)R:U-#,D1*2'9:0EHV0BM8;C%13&,K6&9-:3-5
M<V%I5FA!6%=*=U%Z1U!D928C>$$[5S1++T8K>5(S0C5#:6YX260V<EEA9C5"
M=&115#%F2C)T,VUN;4EX=C8P37=L16AF:TI#161!,48K17%'5W97;S99.$I4
M-&M/.5@O=R8C>$$[-RM79'1B,DU%;6<V-V5Z4$9'.2]D45%80RMN2358,4DQ
M5U%25DM"971#2VLY4E-J4EAJ:#-V3S=V>79R=C%Q8C9R<$=O9E9F56(P4"8C
M>$$[571P969P,5!(;%)A5G Q>59&:'AX-S,R<BMK25 U2G8K4D4S+TY'5C!Z
M-'@U+TEU+U-%2#AK,R]!0TEM+W=#84UA6&I(;CAI-SE)428C>$$[9GE49CAI
M2G8K84UA6&I(;CAI-SE)469Y5&8X04EI8B]!2F]X<&5-969Y3'8P:$(O2DXO
M>4EM+S5O>'!E365F>4LQ9%1T5TQ"4DU3:"8C>$$[;W<Y0V)9,$)P.6IW3U!#
M=FE$>BM26&9P0T0K4V(O:U).+WI2:E,X63@O:UAF<$-$*U-B+T%*151F.#!9
M,'9'4% U1C,V46<O:VTO-28C>$$[151F.#!9,'9'4% U1C,V46<O:VTO=T-2
M13,O3D=.3'AJ>BM25W1Q9'%P54U*9UA.1DAO5&)M:$Y0<V5!>#16.%%E9GE+
M-SE)469Y5"8C>$$[9CAI2G8K84UA6&I(;CAI:V9N5%10.%$V1TQ','9B<E1,
M,D]66F],>4]'-2M&;'(Q5E!4-4-H-DA%0E!I0W5V>4Q#2#AM9FUH2U1A=B8C
M>$$[-3-U571$8FQ*3'!B5S1->GET2EAA4&=O:D%J,C5R2GER:'!(:64O-49(
M5&53=D]&>GDK=&5C<C)90T=32TY26C--43508W)-1V(P6"8C>$$[:EDX55AI
M1%=V879(8D=K*TE04#5&56LX<65D4D]Z1'IP92]595E9=U!:5&QH2#A*9%!5
M0C5B,$\O561/:$Y7;#A1969Y2V=N;'HX>28C>$$[63E:=%AI.#%Y>F%)1S53
M<3!&=VMY>'4U1$EI*VQ)2E S4BM&;F8T5S9D36%8>$(U+TEQ.'9K>GI48E!C
M6$=K96(Y4FEM;6YE-6%'-"8C>$$[='!P65-Z>4\S0E%Y='=8:5DQ-DXP2C=G
M0G!F14AN.&EG<E!Y9"M:3%%W3F0K9#=U1UEQ,S%M2T<Q=4IL1&QY5CE.,T5:
M24,P1S9J=B8C>$$[:E,K25!0-49M=FQ+3%9D2S!Y-'0Y8C%3-#%M-VQU6&UI
M=5=T2EDK151"94U62TXY:V=N-F-(0W9I1'HK4E1N.4E19GE49CA!26EB+R8C
M>$$[04IO>'!(1U!0-49A=7 R<D9G;VU*43!996A.<V%!,"MX-$A(:%AX0C4O
M27)V,&A"+TI.+WE);2\U;WAP94UE9GE,=C!H0B]*3B]Y228C>$$[;2\U;WAP
M94UE9GE,=C!H0B]*3B]Y26TO-6]X<&5-969Y3'8P:$(O2DXO>4EM+S5O>'!E
M365F>4LQ=%1T5DMH:$U#-6]O.4-B8S!*<"8C>$$[.6IW1U!#=FE$>BM26&9P
M0T0K4V(O:U).+W=!,%DP=D=04#5&,S919R]K;2\U151F.#!9,'9'4% U1C,V
M46<O:VTO-4549CA!3D=.3"8C>$$[>&IZ*U)D*VM)4#5*=BM213,O3D=.3'AJ
M>BM29"MK25 U2G8K4D4S+T%$4FI3.%DX+VM63UA7.4AI=4I,85<K9VIU268W
M,DIP159L*R8C>$$[1#%F:4)/,S=S8W9L=F=:<59R-6LX=C-D>DAA,C)O,C@Q
M>DM+>'=*27!D:'=%;7DQ<CEG,7A637-69&ER<U93<30Q9E1.3$YZ3G%.>B8C
M>$$[2&%X4UA+4DDX:#1G=3!+14-V,%E3=VIZ4'8X03!"86YM,WEY-6=#-FYB
M.')K9U%Q6$%:=5):5C)/*S519UE+6G!V:7)S5F1I<4,Q3R8C>$$[6EE0<3@W
M9VQ)<$AD9T]T1F=K2G!H1$-8364O.4)9;F(O;D0U5&QK:U-23'%!>$)'9C%9
M4W!#>4)31S1K."\R:C(W8F125G!M<70K8B8C>$$[;FLP0T9V5VU-8W$X;FM%
M4C1X5F1O>#9M*S-X265L9DA';%%C9C4T95(R;$5B3F12,7!6:D1Y04I&45!G
M6GHY,S T,')-.48Q5T16="8C>$$[2W1D4W0Q6DEB<4U327(P-4%(>#1L:#EX
M=TMI3&XO96%8+U5B.5=)4DQK;'-V;6)Y.5E20TLX,4LS9VQI16%Y4E!+;V--
M-G%62$=V2R8C>$$[<F,Q;U!C94]%<DAK:D)Q,FQ%25)E455K45-X+W9%*TI'
M57-'1RLT2W%46#)/0DMI;FU,44I*4%-457)6<$M%.%).1U125UI3979::R8C
M>$$[66918U92.&-K8VMA>5)S2&IC0FMD5%5%2&-%16118U9867%L:RMQ86)P
M;C%Y-#%#-6ET241C2V=L;5E)=DEW>#!&5#AS2EE2-6XS+R8C>$$[04M!-C4X
M>F58<F%666)J57)A2U9Y=U)(;%%%;$I$17<S4#=-:6Q4-%509V-$3G!F3DAL
M>#=6-W1.4W1M=#1U4'%Y0U94>$PX94E9028C>$$[,4)036)E*TMQ>#%Z4E%Z
M26(K,D1)5D1+6E5"0F-%<EAF.6]!,'A61#-(;7IY>&)X*W!0<3%P1VYP*W95
M>DIV2#9N;SAX=G505BM$+R8C>$$[049T=75+<35U<F$W1VXS3G1+<S!%:W!-
M8VE%1E-04FLW:D-/<D-8364O.$%1569G6G!0<4AM0T-%>E)X3V=E04%U.'!+
M<C%K-4%#;28C>$$[+T51350R<'9L5V]J;#1F,UE";#5T6&IW0DYM<2]B*W!6
M:#AX859*-F%M8T-6.6EG5U0T5'E#+T965DLO17=(>$%D8W5J0U9B:F1F2"8C
M>$$[:#-O<3 Q0S!U>7=G8W-65EA)2W-H-'98:3-X06)(:6-416AL1UEL>5)/
M0FUK5CDU2CAS,S)O5#9H9%=H93=U0U!7;$5K<49G27A&>"8C>$$[*T)L*T5Q
M:3%8;V%!-#)Q;'!8:T1Y=G!6.6(S,6YB3VPQ8D%I2U)P6D=P5U P<6M->$)0
M16YR-#1B5FM70EA9<3=&57%U=$IS3E93.28C>$$[=$PV4#%91&-+,T5->3=R
M1$A49%-$:%!2:$AM9F8K9TI2869L:#50=$AI:V=T6%=34#1765-Y1&UM,S=T
M=T-&6E!H*WI4>#A45G1M>28C>$$[>D%R<U9D:7%%=F=Z4U=G5G5$1U9G<E5R
M42MJ2G91-%%W;'I(=B]15T-P*UA(;3 V9V(R-#AZ:5HQ84EX<3%Q<$E%439C
M>3--8CE#1"8C>$$[5F1Y4'1(1S)A8BM79DMF;6)48CAZ870U9V)6-U)O<$DR
M=%I)1FI7<D9#<$A%:V)C1#(W-UDR<DM6=$Q65'E71D%E=%%O0G%10C1E,B8C
M>$$[0E925E960W%!<7%+0419041&5D\U+S-M;"\Q1R]6:453-4UD=F9)2&QF
M5EIO.5%U-U9V<C5E0S57-FIL:VIK4U="1E=.:TMS2U4Y3B8C>$$[9'5H;TU*
M2VIK;WEF;%HU26M%=V%W8B]327A&2697;4I)05E6<5A/.4=)>'1+1E U3BM1
M>&%35SA.;DI#6%%)<WE44T8P-#=O5C5L;"8C>$$[<6YA<6XS<FIA<W0P=E0T
M3DXP,C P-C-,1T-Y:&IT-%,U<3-#2D%I.&IT53!'0E56:7%3-FYO3VXV-6(S
M,6AQ06MA,&$T4G!)-#5':B8C>$$[-3A962]H8V]14W9T:%!2:$AM9F8K9TE7
M-"],-WEV34E%*W)V1D)A*W(Y5W0T6EAJ:6I-.')3>6Q),4E58WDW02]W0U1T
M,$%X=&UQ+R8C>$$[-$<X=2]O=6)41$1)8E<T4T]/8T=6>7II3&E%3$=V6#DR
M4&YG=%5U+S563#5&34-W4U=,>5))=D)!.#@W1E9R>6]#6'(R2#-98E9U6"8C
M>$$[.'%F23AT<&)7>C),1DQ/15<Y;S-R5&,T;S%M339H5S4Q<7-J8D4W.75M
M3G%N<U9H8E=#5T9R8F=I3EHU1W%Z1C):-4DU6&0R6G%K<R8C>$$[>G-72CAC
M4C%94S5J,R]O2UI91V%5,VYL<E-,:S-%<C)Y>51Z;S!B37I-<$MT>DI4:TYW
M<F5Q,6%F=T=41U%H>#4V845R2D<U1F9F*R8C>$$[=$)7*VIA<$)B4&),83)H
M:&-+<$18135::$=3>49M.5!R6')K:DEE8EA(1DU#<6HX>BMP361(,#9E,#E6
M-2M03G=S86-:2DIA4E)L=B8C>$$[5%=R9U5O1S=$-SAJ2U9T,DQ'63@O=T%$
M;VU746)K3CE5;B\U8EIV=6@O-G T8CAM2$-E."]:*W S,5-F+VQT;2LV2"]!
M2W T,S5,=R8C>$$[;G90,F9Q9#E5;B\U8EIV=6@O-G T,S5,=VYV4#)F<60Y
M56XO04]7,F(W;V8K<65.*U,X2C=Z.6XV;F962B\X06QT;2LV2"]Q;FIF:R8C
M>$$[=D-E."]:*W!$5W1R4#8Y-2]P:W=P34\P3R\W;5 O:79#4WAJ13)D>GHX
M=31E4THK<50O.'1S,S-1+SA!5E!"9FMY-%0S;C=0,4\K<28C>$$[5"\X04QB
M3CDP4#A!,51X=GE8:%!E9G,O53<V<% O>3)Z9F1$+W="53AB.&PT5#-N-U Q
M3RMQ5"]!4$QB3CDP4"]64$<O2F5%.34K>B8C>$$[.5-'=7)79C$W4#A!,'E9
M,6U084AB.7I*+W=!5C115TUO;7AU969L,TAY5E9J3$]Y3'%%:&1A1FQ(;T5J
M;#!Q4%0W-$PX;5A#93@O6B8C>$$[*W!C:T5J<4=3+VQ:5#!:4D-2='0R:GAV
M>5AH4&5F<R]5=2MQ5"\X04QB3CDP4#A!,51X=GE8:%!E9G,O53!,5V,Y3#)B
M-V]F*W%E3B8C>$$[*U,X2C=Z.6XV;$\U=%HO<3AV.$%P:S,R1S=1*T@O1U!#
M0VE55%A-+UHK<'4R=%HO<3A8*VU49EE8=$0T9CA9.%-6:D4Q>E R9G%64"8C
M>$$[<6LO+T%#,GIF9$0O04Y5.$8K4V5%.34K>CE4=G%K+R]!0S)Z9F1$+T%.
M53AB.&PT5#-N-U Q3RMQ5"\X=',S,U$O.$%64$<O2F5%.28C>$$[-2MZ.51V
M<6LO=T1Y,GIF9$0O,51X=GE8:%!E9G,O56LK<&%L8F%*8E@R;V%H9EA-9'!(
M3VEY4U)X2DIX-5)2+T5W4TIQ1#,O04DU228C>$$[;&I'2G,W;FXU9'<X:TQ0
M-3$X=7=R8D]D6'5*26)W>7)B6$5526MI8S(X:E)3.%A317%E0E)I869S:791
M:6\K1$QH4&5F<R]5=6HX-"8C>$$[-D$Y;$IE;E9R;4]#1FM75G!)3U!&<$9$
M2TXT9#EM-UDO0F5%.34K>CE316(X>5!)>712+TTT6#0O5%5L56]X-494>%!O
M,$E"1S5'=R8C>$$[-S0O0F5%.2\S9G%8>B]M0C55:75L=$8Q=65E-FM-2W=W
M=W=R23!H=55$>$-0:D12=5-K9#EU:'@K0SA*-WHY;C9K-&EK4R]I,#8X="8C
M>$$[3E%L;'0U-4,P8CA9:"]U<51S67=14C!)4%1#1'HR67EI8D<U-2M88V9*
M35!Q:R\O04,R>F9D1"]!3E4X:F9K>314,VXW4#%+538K9R8C>$$[;D]B54I5
M6'A):"\V<#58:WI19TQK44%N9U!E9G,O57%,8GES;UIB-E9L4%%G46MF.&TX
M;4I!:7=J:%!E9G,O53,Y56XO=T-7,F(W;R8C>$$[9BMQ94<O2F5%.34K>CE4
M=G%K+R]!0S)Z9F1$+T%.53AB.&PT5#-N-U Q35HQ;E50>D9T.59V4G!M;3(Y
M,W!W35ES4S=+<D5+26YL3"8C>$$[5F1F=%9L4E X<6QA069%<S!R=69-4#5P
M,G1H8C-2,%9,:#%74G)U0D9(2VE38D91<VI-5'<V2T)8=S5D43=+<$AZ6"MC
M17-D<3!(;"8C>$$[4T9F550Q6G5C>7%11#EL2TY)<%9U-7(X<5DW2WEN>7)R
M3W9A:S$X=7)A861/83%K5TM+;V-#43AA=59:=&Y7=$M-=3(Y2VUL8T-P+R8C
M>$$[:7)&9DY6-35Q=$Q74B],9'-T,61T9DET=VI!2&I$.59Q5T%*2"LW06<K
M;G0Q16U%95HY+S9!;'1R<5@U<V5R6G@S96Y7;VHK<TMT-28C>$$[3$=666U)
M4%)I2WE,>$A(8T5+83<W3%%61WI.;FU"6%EQ-T950G%Y4E-*0VMP2WA/,&EY
M1F5O57=39S R4&)#1T5U63DO=T-G=D<W3R8C>$$[5#AQ1G9"1&)A:G%Q,TMY
M4G-:3G0S64DP0VQY=DAA4TQL=C-8-'I11$-Z5$AY=G!N:V)Z0D]U;#90<D]Q
M<&-W3$I,8GE%3$-Q:$A1="8C>$$[=T)15G(V:3%(:#1B67%N;'0K4W5M5SDP
M3&AD9#%8;7)C:TEM5E-V-S!3;6I+;TEQ=W)8>#-W5W).4$PR:5%A2'!%1VU1
M4U!,2$-:1R8C>$$[.5-3;DEM5U)P5W)X04@R;DY-0V\R-2\S;6PO,4<O5FE%
M4S5-53%46&9/=&XV:U=L845.4E9'0F=K85)9:V%$-F]R:F-S4U@K<T(Q-B8C
M>$$[1&%G-S%W<4]305!M4#@P4F]Z6#!M9U)X6&E02S,V4%5I57-I4E%S<6QL
M:W(X4F%E:%563$MQ,"M+<%5R22]-9C5T;C%':SAU5S9X<B8C>$$[24].2D9:
M>DAY;V%*-G<S0S<W:U9X,E9U1'I2*V%Z,T5V4'EV14QD631Z1V975E=A43AE
M6%8K:#-P=#A053%P5$A:5V$V4E!Q32MN428C>$$[4V%L8G)A,WA"13A#34A5
M34-2.$I"3WAP6')G5FEV-6<S<5=E:U144V%B86%O;C92:59O3#9625EL<F)J
M-#9Y14M4,G T13ES:W=J>B8C>$$[4'8X03!":#)Q82]Q>C-I=&9E5SE(:G5F
M56%*16UM9TQ-<3-.6C5&67EQ05AN36Q24V]02W R8D9M<7AE8EI8<W T3&9Y
M.7!N,5=Z3B8C>$$[=$A/>FQF5$-M16Q3;UIL-7)Z:E)564YT6&IU8U9117-T
M,&(U=5!K6%%V451J>&EK;'156DAK-4]R35$W9F%606502'AX5FYQ4"M83"8C
M>$$[859B>F%R2'!.=$TY=$)D5'A%=U94,&@Y5U5Q45-F,U1S659)3W@K15E&
M6D)A:E-X8C9B*VEX171G6E=-071W;VIO67!+,$,W9&5U228C>$$[-G-*8W@W
M+S!&3DU$3FDR<3)(;5)P8C971F]H0SA:15IL6E1U<&Y-6E!)1E%I1C!:=2\S
M54TU47AZ:G=Z1FHK>'=S:V-W2DU33U@O1B8C>$$[9EIY54Q#.3%(-G-';#%U
M2G T=T-K0F4Q6&-0>61:94139C-A2V9S=#!.96]Y=WA!-40W,G9(3U9B>C,O
M04TS-V5F265A8BM8<G4U=28C>$$[5VUA4V8Q;S!32DXU24I#2FQ,:5@K-4IO
M0V%D9G<V6D-9<'E-17I+.3<K6%!E*U-C-5<U2T<K=2\X551F.$(O8FAP:GAE
M5'9R=B]&128C>$$[,R]!9C(T,'9&-4\K=2\X049%,R]!04@Y=4Y,>&54=G)V
M+T9%,R]!9C(T,'9&-4\K=2\X049%,R]!04@Y=4Y,>&531W1B>CDO969U2B8C
M>$$[9#5H*WHO>%1(-S131T5:8FYB<BMG26XV-R]X4DXO=T@Y=4-M9D8U3RMU
M+SA55&8X0B]B:E,X6&LW-C<O04U55&8X0B]B:E,X6&LW-B8C>$$[-R]X4DXO
M=T@Y=4Y,>&531W5R>CDO6B]U2F1P:BMZ+WA42C<T44=%<&)J8G(K9W%O:W1W
M0T):=4$S,G%2:F9A;2]W0D%W57HT=DIT6B8C>$$[-&QB:W1R27)B:6]J04Y$
M=6-A6&DX;"\Q,R]I:6(O9U W8V%8:3AN9EAF.$%I:6(O04E$*S-';#1V2E1U
M8C,O4C5F,T4S,D<O63EV;B8C>$$[:$%22U<S2C%T92\V4$8K-&TK=W8W2'0X
M.%-&:DQB:W%F6&8K2TIV*T$O='=5;FDX;F989BM+2G8K02]T>'!E3'ED.60O
M=T-+2G8X028C>$$[9U W8V%8:3AN9EAF*TM*=BM!+W1X<&5,>5-B53E/,"]8
M3&4Y<TY19W57=$AU16532TUT2'HT=W X3&Q#0U8W,"M2>5)$0TUT>G0Q+R8C
M>$$[445*8V53=DLX=V=4-FAC>%%7=G$O5G)E1FYJ:6I-.')3>6Q),5E+3UID
M9V8X;F)O0F=:.%AK=51Y9C5E6%0W;7=.<F508EAA4E)4228C>$$[-W4Q5F=#
M:$%#5R]Y2VYX2DHW;D9E3'E14"]+<W9)<&=70U138FU32D8T24AL;EEQ=&56
M051*6'-0=7A8:3AL,'8U82M2-6)3,G1N,"8C>$$[;31+5V-)=#=2=E5M-7A2
M<DU:,4-T>G)66D<R2C,W9$U58UAK;G-35S%H2%DR,79B>FE.2C5(2F-&;5HU
M16QD,EIM2DQ->G-72GA!-28C>$$[<UI3,T<S6#E"5$@V-R]X4DXO=T@Y=4-M
M9D8U3TXT0TM',VU)4%5C4#=C85AI.&Q(+U%Y4U193E4Y5#93-S!.9C$T9"LY
M:G0S2VE82R8C>$$[2EAH8E-R53%.17!5;F9"4U%F2F0Y9"\T;VTO-$0K,T=K
M.%AK;$8Y-3<X<C)';S-7;C-L,S9.>EIE;#8T6DA)0FYA3E5O4418*RM8."8C
M>$$[5#)A9W!K9R\K5F\K4U%9+U9V.$$P56MI85E34WAU<6A&6FM.4U)T.%5B
M1#4W9%-":'!65S(O33-Y2F-7-75%,6E"67='8CDU>6I9:"8C>$$[45-31F16
M63=+93).2VXR;F%J639J6G@S;&I-='AA>6ES57EB<7<Y<T-O;D95:S%(>D1O
M*VA,9%A7<3-!=&]*3&=O:VI":4-Y5V=N228C>$$[*T5(.6E&:5!(<#%)=VQH
M2&UF9BMG2F9**V%8:TM.-59B5F\V>%%I-&%I4T=S5$%S1U=I+T9S1'-.>#-X
M<&UY1%1.5S S5DQ9,T]N6"8C>$$[360Q8F@R:DUS5$)L-6]E3$-O+WHW-$92
M94MU>%9#,VA!;7-Y96=M63=B;BLU:S=$0T]R0UA-92\Y0E-#2#AZ9DI%;VHO
M=T)Y4V\P;B8C>$$[4&EJ;S1A<UE*2VMC9G151WDY96<V:UDP>E9"*UEV;$E#
M8WHS:'128FQ!+W)X=D=32D5%:4UO27%Y;$=$5CA-859%-F8U,SAP-FIE=R8C
M>$$[,E9L<6-.>&14-W=X25-3=S1S,5)T-$EC1DMN;4MQ5GHO=DY,+W%.*W)%
M26QY4T<T.#AE5W1.;E=Y=C=O,C!I1DEF56M2>$5:5$5K=B8C>$$[<'$Y3TIB
M:$EH<#<T4T9J>5A3+VU$-4QI<5ID670P04%A<DY46FA5159'.5%14CAX-&I"
M4U5Y,&Y89$DQ949P=$UU-#=U2F9T4$5A9R8C>$$[5DI'+R]!;D959FER<U99
M6C4W:T$P=6%,-B]*<'!M=C1X.61H5UHS:E=/,45Z=4)#>4@T631M63AQ<E%E
M3DUK=VIZ4'8O44=,869Q;28C>$$[:5=C.$9X3C4P9VMI6C-#:4]7-%DO=D53
M1D)1>4@T54E*4$QP4F%K54Y1>E5M=5EK9SE'2#AY2&E%83$Y5C0S9'%X5D(U
M;&TW0E-O+R8C>$$[;E!I=W=Q<C92;V9M8E=I,&5K9FU*2F5*<#A94UHT;U=!
M36MQ14)I-&9I-%EQ5U=H3D(P-TA!:#9T06MI45)P3$E:6D952SAP055U=R8C
M>$$[1D,Q0G-+.61S0U9+-R]V-TPO:DUF*U1-;45D5T5U63DO=T-G;VY!>EDY
M<79M94-#5S5T,6U%1%%2*W%72S@R2V]:9E9)54AO;V@V-R8C>$$[,7)4<FM-
M*T1,2T@W<V=(,T].3%91:5-*9$)F,S,Y>79B*UHW4C0P3%)48E4Y950P=T5J
M<3-!1FIY66)K+W-L=G=.3%DT-4%B:U=K828C>$$[:4HV2#E33W-.5&IV1UI6
M:6MH6E5J;'!+1D95;#5C1TA%=#$T2')I63 R47E#4TUY3%EG3')13D1U-4=L
M=710=#4U2$Q&,VMI4GE3-B8C>$$[0TYQ:VIE<4EQ+TE9<6\O-%<X=695<')(
M.4=7,S%3-$-R4$(V83A816)M4D%W<'9X9&EY*T)X5E)(:VYY94E"04Y&<W93
M54%+=F]2-R8C>$$[54)!<'0O;&XW.&)6361-,'EW,'EX:7-B0T515VM)26EI
M5W!!-45S97!*,TI*>%9&67%L:W5M861Q3%AC3B]B4EA54UA#=6MC>4LV:"8C
M>$$[>$%I.&='0C-O>$=%<TDX>C<O,$)"4#A!;"\U26-Q5S!/>7%V:$-G0D)$
M1&EW02M*9FI0=VYB0F).3TQ(5#='=V<K<C)6=DAB46-M9B8C>$$[,&]L0TQY
M8SAM3D)4<51I<4EX5C)+;U<W04TY;41U1$TQ4B]Z>&MW:G%W;'I(=CA!,$9,
M;#AK*U5&2DDP87IQ83%B,%5R=4-+,7!7="8C>$$[1%-U0S)A=% U53AS>GEE
M<$YP5G))+TAH>6%&0V5)5E5!3E(P-$EQ+TE9<3%A*U903$YP8U(S3G)P5G)"
M4$,S2TM73T9&6E<T;&%G9R8C>$$[8F)-9G9X=%4R>%93=68X065A6"]!1D<O
M5FE%4S5*5R]L8GDU9E5U8GI48F4T=4I647E3>7AQ>D5Q9U5'<$A8:4%0;&A+
M>#5/4&LS>28C>$$[;59:5&\Y;59C0E="9VI.44-#0C Y:&=T2TXP,U-.3C!Y
M3U=05#=D3&%/6GA*26EB2U=#3$5+1&]!16I644)T45EQ:DU69&ER1G9.3B8C
M>$$[;&-89'1)<TYH2'%(<#,V4U!(2D=K>%5#,4%$2DA*2D-R1FU)4G%T.6QM
M>51#4$TK+W=$44=(4E=(;7%7>6<Y5#AV3DQI6F)H3TU".28C>$$[0G%216=0
M=50X2EI2.7)E;$]H<4U$3F9O1VMA-F)X8D\K.&DV9$9P,7IC8V)Q8FEN3#!P
M0SAJ>69%.'!(1FI52C<P1DU696PR1VHV5"8C>$$[<#AK,&QJ6G<R<C-(2#$R
M:%)5-3A+.&5814-T3U)W2VI-5E$Q,R]F,E@O1UDO=T1*;51#3W)#6$UE+SA!
M45549UIO2S4P:7=M4UE'0R8C>$$[379-4&E:,35G;C1I2VEO<4MY3G0S<6-K
M2D5.8W-55&4S3D%1841F=WAV170Q8FE&>%0P>&%K0VEK;4]P.5=P2VLY*W53
M37<Q4G=Y1R8C>$$[,6HU9G1296MA5"MJ>$Q6;S-A4V=":6HY24)&3&-&;U=C
M+T-';TXX:DM6<SA73&<O<W!-8VDS2U V3G1V-7!V*U(X,R]!1%AL6$=6."8C
M>$$[369G;#,V3G1V-7!V*U(X,R].95!'5CA-9F=L,S9.='8U<'8K4C@S+T%$
M6&IX;&9$2#1*9"MJ8F(K86(O04I(>F8X,30X6EAW>"M#6"8C>$$[9F\R,B]M
M;2\U2'IF.#$T.%I8=W@K0U=L,'$P57-636],;FMX.65B8S!!<CEV=T=(>$-V
M:$0X170O;S(R+VUM+S5(>F8X,31/37(T628C>$$[+T),=C!B8F9Z5&8X:C5V
M*V$X94UR-%DO0DQV,&)B9GI49CA!22MB+T%*<G@T>79H:CA%=2]2='0O3DXO
M>5!M+S5R>#1Y=FAJ.$5T3B8C>$$[<%9O>%5S6E-54$I4-C@R>&]26#=F9V-0
M:49F0T@T2E=A:'!42%0W9U=-:VE8<&EB-G5Z>7I/;VLT;FI69E53=2]U36U*
M3#19+T),>B8C>$$[=3,Q8C@R-#=#,CE4>7(Y6G9&9&MU-C,W46AH>4A","]F
M=4%#<#-R,WE8145E2"M,2VYQ*V\O;DM.3W1*.4XX=5(O5UIH3#E9=#)U,R8C
M>$$[2FDT=D@V6E!+-5@W4S@Y:#1J=W@T9W!X+VEY:7!T6B].3E1+,%AL1#%%
M0FY72F8P:39S4%17<45K>3!9361H4VQA9'$T.%$W,3A-9B8C>$$[9VQB8V%L
M*V)$6#914BM6;WI:1S173U-:<BM1,6=K53%E;G)#;D%N-'9';7<S>#1H,W%C
M62]"2WE,5U!Z6G%V+T%$<#9I24)4>"]33"8C>$$[:'5)1R]W1'4W66YS3S-4
M9DAI2&5V:&HX175I,5 X,V)K5&AV3$M72"MJ5$=$;&5V369R05-S44I&=V]O
M5TAH-TA(:4,K2"M,2VYQ;B8C>$$[;40X,4Y)=&E*=DMP,4=65D5A,T9L9%A-
M<79+2#1C=E-6>DE%9FE70DE&05)8=WAS3'=$.$5T;EA0>F5%;'=V*T1L6DE1
M=VIC86DT.28C>$$[43!017%$3C U1#=S94ED-CA(-'-V4DY-<VUN,'4P;G9O
M<&)7*VQG:F4V=&AC>7-)<%=11C0K46-G.%=Q2S5%>50T62]"2W%U;%=I;"8C
M>$$[:7!L0F,X;5!R>F)M9T9F="M!>4AI1F9#2#1*8B]2='0O3DXO>5!M+S5R
M=V-:6'=X*T-89F\R,B]M;2\U2'IF.#$T.%I8=W@K0UAF;R8C>$$[,C(O;6TO
M-4AZ9CA!3F501U8X369G;#,V3G1V-7!V.$%K9DXO>EAJ>&QF1$@T2F%B4W)2
M:7!9>6MO95-N,35T:E%I=C(O031F14LK128C>$$[4'=3,RMJ8F(K86(O04I(
M>F8X,31/37(T62]"3'8P8F)F>E1F.&HU=BMA.&5-<C19+T),=C!B8F9Z5&8X
M:C5V*V$X94UR-%DO0DQV,"8C>$$[8F)F>E1F.$%)*V(O04IR>#1Y=FAJ.$5U
M+U)T="].3B]Y4&TO-7)X-'EV:&HX170O;WI49BM74T@O:U=N.4U(164Y4&AX
M-V<W.4=A8B8C>$$[+W=!<VM0.$%Y3%0K;5!%93EF1&HS0C,V33 S+T%*6DEF
M*U)A9C!X-&HS<C1C931/+U)M;2]W1$Q*1"]Y3%0K;5!%93EF1&HS0C,V328C
M>$$[,#,O;&MH+S5&<"]42&E0979H>#=G:')85&1/33DT1&%W:TQ-06]-83=$
M,%EZ='0W-4EY3S(W0T]/3FY98R\P0D4O;WI49CA!;&MH+R8C>$$[-49P+U1)
M.%(W,F9H>#=G-SE'86(O=T%S:U X07E,5"MM4$5E.69$:C-",S9-,#,O04I:
M268K4F%F,'@T:C-R-&-E-$\O4FUM+W=$3"8C>$$[2D0O>4Q4*VU0164Y9D1J
M,T)$6%=M-F-*-TU#,6A!85EH9TDQ,TAO>4AF8C)Y46MD.3)%<V-B1W<U+V]+
M2B]2;6TO.$%,2D0O04UI,"8C>$$[+W!K94DY-U!W-#EW9"MJ3DXO-5I)9CA!
M:U=N.4UE23DV*TA(=41V,%IP=B]!0WE1+W=$2710-EDX4C<Q.$]08TAF;WI4
M9CA!;&MH+R8C>$$[-49P+U1(:5!E=FAX-V=P,T]M86%,955I,&A"0TY1*VUV
M:#AS26MB-6]L:FI824]T=$TP,#(X4DYP0U-55W Y3F9$-5EM4G9M<V-C828C
M>$$[-4)5+U)M;2\X<VM0+TET4#993TDY-F9$:C-",S9-,#,O;&MH+W=#4F%F
M,'@T:C-R-&-E-$\O4FUM+SA!3$I$+T%-:3 O<&IX2'98=R8C>$$[-#EW9"MJ
M3DXO=T-74T@O:U=N.4UE23DV*TA(=41&4$]D.4AO96EA:&4R54YG=#1T,4A(
M8G!E<6EX3E=*1V11>DY%<3A51%!5=%-G3R8C>$$[5T%K,'=%23)D:'HO045"
M2CE1,3-Z0VML<#E7,#=3,DQI85,V4E!1;&E7351T.5=A3U5Y>$TO<5%"1V(T
M0CA*-65Y;U!M5UAH>#=G<28C>$$[,D=R*UE,;3%U8F5(5#E,=71A="]22G-6
M5T9:159L5#%F5U%4359:6$I",G=8-6QF1&HS0D%Y87HK86EU3U!K5WE93DE2
M>$QW+T%G9B8C>$$[*UE04FEY:V9&=%1W3D1H=GI89TAC2&]7;#)58RMM,G,Q
M+W!S1G)E>5)),7IB<7%/235#05=8;%1E:'E":V4Y4&AX-V<S9&%B<'=N<R8C
M>$$[=TQ714)P:4=!:EAC96I)9#EV8D-*2&9D:$Q(1WAS3V8V0VEF,%IP=B],
M2D0O=T%I,"]P:V5).3=0=S0Y=V0K:DY.+S5:268K4F%F,"8C>$$[>#1J,W(T
M8V4T3R]2;6TO.'-K4"]!0TQ4*VU0164Y9D1J,T(S-DTP,R]L:V@O=T-2868P
M>#1J,W(T8V4T3R]2;6TO.$%,2D0O04UI,"8C>$$[+W!J>$AV6'<T.7=33S0X
M,6%R1C5J:S!S84IC4U=A4TI%;7!+2$UB8S16:T)O14Y">F)I5%AI3TIQ83!"
M83):26)34$YN;5<W,65W="8C>$$[8G921W1B4SA4;$I05U5M1G9Q:V1X>&)L
M1V=O2&Q-9DDP*TE5<%A#449:9&M5=7A6,DMS9#AW83=E84Q:,VPS6C9B3G%K
M-75K5#9T028C>$$[0U-&.4)(9'I13G-Q;V4R-6]/<'ED6%1#4$TK+SE!55!,
M=FUR6#E5,6@W5S@P0V943$U24T]T>$]A;C%),T,X1'A"6&170D<O,S<P0B8C
M>$$[05I-<'E+6%EQ-T95=C%H,VII:6M2>$<V3DEY>4560VM7.'!"26\S5#5:
M2U!6:$QM4&8X06],>"]3+U!V;7E+>6=I=5!.96PX-4AQ6B8C>$$[2FMK37EO
M+T)"5E1#9&A+858V2T]693%*;4DW:S)J<DQZ<#4Y=FQM=6)F>D1O<$-647=&
M6E9737I/<&DU8V]W=V)J>49#96=Q9G-T428C>$$[8TE7,%4S;C-82E%:8F9Z
M5&\S,5I924,P<$1!0U9X>&UR5T]L1FMC8U Y5V@S-5DX4&MM,'AS0BMC1C%9
M,C$W6F%L<&1Z1F-2;W=A4B8C>$$[6#1&4G5(:G!':F9V060K6&)P9U!#=3=.
M3DUJ,5-,>2]$2'$P:7IA:W-&3'%22U5,,$YA559"*T=2-F]02F=F;698=&(P
M>E9*-4Q8>B8C>$$[5EDR6F@Y1FLP9398-$9G83%O1VMC2S=,>6Y"3D%/:$97
M,U9C;EAK9V-L1'DQ-7 X-S8Q8S-/;')R,FQ46%IS6C5)6DQ22$Q,3G=2628C
M>$$[6#5.1UEV-W=-869&5F%M;$].16="2V18;'8X06Y"271)3&I4-'!43&15
M6E(K-T5,1E!11&-L3#@Q,V]14',Q-6)K65!3;F13<V]F>B8C>$$[;D]T>$QC
M>F%E=6U13D=S.&A!26YI6C%,=$=Q:FU*1E5%2&QX6&999#AF4W4W,$A)2EEL
M-7985'9Q:VHS*VMY-G=K9#A':70T5DQS:R8C>$$[:'-I=G%51F0K3$964%II
M=E1Q2CDS-#9T8V5:.2]W0V=03UHY2SAR>EAV<DXU1#%(:&5-<V)U6DQG17)'
M5E@T5D$V3#EO5D\T1F9B2B8C>$$[5V4Y;%-B2C5P=&)4>E10<3A8:V965G8P
M:7!036]L3E=J:5-,:DA&>#1&9W)C4C!Q3BLK=W)B;71S;'5F>D@Q2TXW2T=,
M>79Q37,Y,R8C>$$[03AZ<G=92D5Y4W9&=UIG:#-B,"M1,C9&9DA).%!M;3)5
M-DAQ8W5P-EA$97DR:W1J2DQZ1%=S-'!):%(R5&9P<V5.4C=:16A+=&0O-R8C
M>$$[,%=8+T%";5 O2FU40T]265,U:C,O;TMH1'%D,4IF96ED4&U3,5EL174R
M-# Y4DAL5G=Y5C5+=D=*5U(K:F-X,'=M24$U='!I04]A0B8C>$$[6'I7-3$X
M84UD13%25%)#,F]'0E1:<GI14%%Z0GE$>#5C5'AR.%9E,BM2<&ER4BM93'@Q
M96UH86=*:U%30T9H87%757-Q<49C>BML>28C>$$[3E=017950E1Y<%9/4W%#
M;#@X=U(V=%EA6BMH.59A6%56-7A3:3(O9'!(-B]O1U-7<D)K5F%Q-U97<7%Y
M.&=#85DP=$IQ.#)R5"]6;28C>$$[=#1F<6=76D1D<&,X1UIO1$9Y64HV5'E!
M37-J0F1Z,54Y<4U657=X5C)+=7A6,DMU>%9$5VXK.48W+WAM2"]*;5!#95%9
M4C5N,R]O0R8C>$$[2G=-,UEQ-T9867%H3#5%95<P4C%$23!R0FQ)<4-$1$I5
M15I)9%=%=5DY+S9#;&@X:&53:599-DA:16]O5E-914Y!1'E!-F9Z8C1/228C
M>$$[<W%6-&9+2&QA0T-70TA38E))6GI',#!A=V]&8W<W4FQH5&9J53EF12M*
M>'-Q<$HU1SAM<$=),3!3>4-+2T%E:$@P-6,Y.70O:3,K928C>$$[4$56<$]9
M24EB94-/0T-.66])5D5C55-!2W%O;V]Q<4)S04)G4W1U9CDU<&8Y4G8Q66IM
M:5A*2DQZ>50U53%:-$PS561-:'5,;T)'828C>$$[4F=16$MP>%530E-"24%/
M>C%(5'=Y6$5506))=E0O2W9L=E1R,%AU;C9B8C)L>7-8;T-30D)(*S<R*T=I
M,$<S154R,C=93$M5,7=*9"8C>$$[:7)S5EE$*UHQ,V11849.2&%.8TI08S9G
M:V%Y,EEC>DE%<WI->DQW:VA'>7A(-V)C4C-P.6]71&\Q:FUF9BMG34LQ5'IJ
M<$UL>D)'4"8C>$$[36PO2$I9<DI,8U-01$]*6&$V;F%E3T]4,%I)-&%X3$EQ
M:F=V5F8U3VA%5U9P=&,V:75I5U8S86%N<61Z-CAS,$YL0D=%=4=74G)7,R8C
M>$$[:'5(<E-9;%5M5UE,.7!7;U%#3FUW8S!S93%8>F1F,C@Q<4Q8>F)Q3$)Z
M>5I$8DAI24)X;'%X855U4UEI5T9+.65.44)T241Y4F%:928C>$$[4V9-5GIC
M95HY3'1O=D]&+W%C8GER13%V3&$K;$=Y<$1),T9Z2DHS;V9I04Q';FI1-$I$
M8FMO97@S9CA!=E):9CA::B]!36U:37)(228C>$$[;VQZ2'8O45549UIU>%8R
M2W5X5C)+;V(V<&-F.'1S,S-1+SA!5E!$63=M2$-E."]:*W S,5,T+S5B6G9U
M:"\V<#0R3S5E13DU*WHY5"8C>$$[=G%L>"]W071S,S-1+W=$5E!'>#-,=VYV
M4#)F<60Y5750*U<R8C=O9BMQ94YJ=5AH4&5F<R]5-S9P8V8X=',S,U$O.$%6
M4$=X,TQW;B8C>$$[=E R9G%1,7)A>BMV968V6DU+5$1T1'8K-6HO-')Y4E!,
M6FA'2G,W;FXU9'<X:U0Y5750*U<R8C=O9CA!<6YK8DAC>C14,VXW4#%/*R8C
M>$$[<5A(+T%#,GIF9$0O04Y5.&)(8W9#93@O6BMP,S%3-"\U8EIV=6@O-G T
M,D\U944Y-2MZ.51V<6QX+WDR>F9D1"]W0E4X8DAC=D-E."8C>$$[+UHK<$18
M5G)0-CEN+W!K>')-93!/,S=M5"]I=DI!.#EM16]M>'5E9FPS2'E24#%3-"\U
M8EIV=6@O=T-Q95)S9'I0:%!E9G,O53<V<"8C>$$[8V8X04QB3CDP4#A!,51X
M<V1Y.$HW>CEN-FYF5DQJ+VQT;2LV2"]Q;FI9-VPT5#-N-U Q3RMQ6$@O3&).
M.3!0+T%&5'AS9'DX2C=Z.28C>$$[;C9L2S5T2B]Q.'8K;7IF66)T1#1F.%DX
M24EV:VE55%A-+UHK<#%T850O5C1V.4YM2'=,,F@X4"M-94I)=FMS66UU6BMZ
M.5-R.55U4"8C>$$[*U<R8C=O9BMQ94-X,THT5#-N-U Q3RMQ6$@O3&)..3!0
M+U901W@S3'=N=E R9G%D.55U4"M7,F(W;V8K<65.:G58:%!E9G,O53<V<"8C
M>$$[8V8X04QB3CDP4#A!,51X<V1Y.$HW>CEN-FM,8E=C>E0S9TXS3'1-4#)9
M9CDX>"\X5C5);FQS=VI%,F1Z>CAU-&53<61,0EES8FAY>B8C>$$[9F%9<$)5
M.70O=T(Q9S1V2FYW;G90,F9Q6&UX:UEG;3=L2D(U06Q93FI3;&8W=G=X-'9*
M944Y-2MZ.518-D]B+T%*85I/9T@R24]G-B8C>$$[9C=R>#1V2F5%.34K>CE4
M:'!Z03%&>DE#1%5(:$(Q.&8W=DAI.&PT5#-N-U Q2TXQ87HK=EHO-EI-87I(
M=$1T*S5K+S1R=V<X.6U%;R8C>$$[;7AU969L,TAY4E Q4S0O-6):=G5H+S9P
M-4=X,TTK13DU*WHY5'9Q;'@O>3)Z9F1$+W="53AB2&-V0V4X+UHK<#,Q4S0O
M=T-7,F(W;R8C>$$[9BMQ94YJ=5AH4&5F<R]5-S9P8V8X=',S,U$O.54X8DAC
M=D-E."]:*W S,5,T+S5B6G9U:"]W0W%E3FIU6&A0969S+U5X*R\Q4'HU1"8C
M>$$[<FQY;'!P34XS<$--;W0S.5))-5A"9T1B;&YO0C8S244P<G-+2V$Q0F]-
M;$Q29%,X+W=!=6]A9DAQ.6I&8C(X=DDS:&E11E5!='=A8R8C>$$[>$TY1SEC
M,$AW,$LQ-E4S4T%R3'-I;#)+=7A6:F9M0S@X>3)K1GA,-69T23=Y-2MT,'5)
M-5113$-,4&QY54%Q4S-Q0D%",W)K.71R628C>$$[4C5N,R]O0U9*-6TO36U2
M3&0P.')O4')$97!X:VY21$A$445*2E9Q:5-U,U0V3G1X43<R4TAG.'DO;3!W
M-7DK5C=D5DU%<VA4,3%Q2B8C>$$[55@Y,FXR>69J8F8U8F1D.$Y2-S$S6C5A
M4UA%;'!$2F-X0T,T94Y7;6=$0G=J:T%S9UE5-6-4=%A)2E9C5E%T-WDY87HT
M+V$Y6G%D.28C>$$[+U)K*U=%9%=%=5DY+W=#9W-&9SAX9FTX3T%K.'5W3T8Y
M5#%*0S9,56-7-$]&.5AS,C-$<6%D9'=C;%575S9*;#%J.# W5C4P5%(T3"8C
M>$$[.'5%:W1N-4I#:69U56%33F@V<$I0<4UY02LQ8V%#;VY29&8O041%=4Y6
M=%ED53AU>#)D:$EA6$YW:S933D@K-V,Q041B:FMQ-RLY3B8C>$$[*W5!9TMZ
M3$EP57)N+V5A6"]58CE7235O;'E95G)E<69M6&(S4FHP:E1)6G1+171S:3-)
M0W9/24=337IY3$<P<4)Y:#E106)B.&5U5"8C>$$[;TE&,'5F>D8K6G%+.5!,
M351M2T)82"MK2E=76&<Y471(4$@T=W9W-S=D+T%53SE+6' U<B].,D]'4S9U
M9DLP6'!2>#@R:&IK1'E%."8C>$$[;35"5E(R6FEQ.&%!3#A63G9T04$Q2'97
M>7HS4C=M-W5T2G-R<3AG3G1D>C(X571Z8D5%1T]2,$1/;$1V.$Q';5%+55AI
M<D<O36PU-28C>$$[:71.4'9:4$PQ=4QR57ID>')(0WE",$E-2U8U:WE28U8O
M=T%Q<"M88U0R,G1H2&UF9BMG2EIQ3W(O;59(2F%I,S!U17-43V)X14%L:B8C
M>$$[5E9U6%=$:$M:65=C=D5%-69U>%%%=#$K1E%!1U-O;7 O;4PK9TQQ9')'
M239K16AA>FDY34M7-4-0,59K2')-07DQ9G!T-%DP3%9";B8C>$$[>DPK87I2
M97!&-5AH-6M+>&=K;5)3<#-6:S5#47$Q5#A1239$>'%+1V@S<6\S=79F;D8Y
M470U8EA1<EI:<$Q13F52;&Q:-&)J-C!56B8C>$$[54AR05-C8EEC9T]H2G)8
M.6Y';V\S6F194S9L3&%A6DIQ55EI=D1.2GI504ME25-527I+1V-+>DI1<V]9
M,$\Q8T$V;VQZ2'8O045&1"8C>$$[>7IE8C,Q55!A>#(V868V:U5-,$9X>35O
M<V,P:&QM4FQ#.'96='I(>$97;RMX<%)J:%!$6&TS4S1A2&8K4#)T2%9F3FXK
M26QT1C!4+R8C>$$[04A#=6]",4EZ=S%2,6MK-4@P=R].,65-2G@K1497<E=V
M841"1G@S9FU/3S1T65HW0T=A3UI8835U-$IU2U%-03=,1U5K6&Y*+W5T028C
M>$$[-B]A*TII<55#;%9*8F)Z1#4O1W-I,6XX<V5P<',X-$UD.3E:9VAE0S),
M2W)E=$5S;'E(94]P8C1(*TU5;W%M;T)6:V0U<#=85GAB>28C>$$[4$\P8U9R
M2VLX4U)647,V<39S2D=Q439-2$AW.&5O<EAW1G%V*W4O.'4X,R]!04@Y=4AH
M66-8:S<V-R]Y-WIF.$(O8FIW<GAE5'9R=B8C>$$[+TQV3B]W04(O8FIW<GAE
M5'9R=B]!0S=Z9CA"+V)J=W)X951V<G8X07DW>F8X0B]B:G=R>&531W1B,SDO
M969U2G0U:"MX+WA42#<U228C>$$[>#5-67DS3S-8.4%24#$S+T%*9#5V*T$O
M='E00WDT=DHS,3,O04ID-78K02]T>#16-'9*,S$S+VPS;2\T1"LS2&A8:3AN
M9EAF*UAE8B8C>$$[+V=0-V-E1F5,>5$Q,64O=C=0.$%C5&)42#EJ+T%)<&LY
M.&M).#)-<&)J8G(K9V]N-C<O>3=Z9CA"+V)K949L>&54=G)V+TQV3B]W2"8C
M>$$[.7500W9&-4\K=2\X=3@S+T%!2#EU4$-V1C5/*W4O.$%,=DXO=T@Y=5!#
M=D8U2V1Z92\V4$PK-&TK=S,W2'0X.$EJ=6E5='54<F$Y+R8C>$$[,&5,.7A.
M.6AF,E!B-31M3S9X;'1Y5E!R=B],=DXO=T@Y=41H5'AE5'9R=B]!0S=Z9CA"
M+V)J=W)X951V<G8X07DW>F8X0B]B:G=R>"8C>$$[951V<G8O3'9.+W=(.750
M0W9&-4EA,79F,SDU*S1M,VU(-T@O04)42#<U27@U35EY,T\S6#E!4E Q,R]L
M,VTO-$0K,TDX3$QI.&YF6"8C>$$[9BM896(O9U W8V5&94QY9#ED+S5D-78K
M02]T>#16-'9*,S$S+VPS;2]W0T$O='@T5C1V2D185C<K+W,O,T4R,'@O62\T
M<&LY.&M)."8C>$$[,DUP8FIB<BMG;VXV-R]Y-WIF.$%!9C(U2&A:8UAK-S8W
M+WDW>F8X04%F,C0X2SA8:S<V-R]W074X,R]!9C(T.$LX6&LW-C<O04UU."8C
M>$$[,R]!9C(T.$LX6&LW-C<O>3=Z9CA"+V)J=W)X951(9%8X-6%X639T95=C
M9FPK-G4W83(R:'5O43=#5FIB:59654)'-G5E1F9S:6AQ828C>$$[,$)):7E7
M840U=#AW86YR14YN3&]Z5S%M67I*4&50-F]59G5W444U>&]/6$EJ8BM6=D5%
M66M"5UA:1DQS5F1I<5)A<C5K,')10DYC828C>$$[;$E9-#=M.5,R:#1Q5TIK
M83)6=U K0FI/4W$V65(U;C,O;T,W>3DU>3AU*UE'6DY+=798:U-.6G!)*TQ!
M<6I->4-T4E-T54\Q9F9P9R8C>$$[35-'4V0T175X5C)+;TQ5-4AI*W)Y;VAK
M9$I(6EEX,5EI0U5H4C$V-4M05FA,;5!F*V=S1S!Z.#!V349X85).3C53=B]!
M2S%+-TMQ;R8C>$$[<FE-<4969W=9;V9%<69E;FEE2DU",W-R5E X06QA=7!&
M,V1F2T]Q;3)8,4%(.4IU6EI(5E8K2&I107$Q5#A7,4-.-EDX2&UT;S9B."8C
M>$$[=V14:FLY36573E%D=E)H;DI#;6XW.4=:5G)X-G%E2W8O2V$K1S0T9DYB
M45,O;6QQ>6]K:W9L2%9#<V=79VEJ9&U6<6M/2$1);$MB8R8C>$$[971F8D1W
M96$R>3=43E%N,4AY+T1F5#)Z5VLQ>$(V:C)Z,7%H24]X-4MH*SA$23E52&ML
M8S,U9RM5.4]V>'!&.64O5C=Y2EDQ9FUJ."8C>$$[05=H17=Q-$)59D)V53=9
M5$5R13=+:U@U:653<&]*6F].5VAN5T='4S1D6754=C954W$W<T551FUO<E9O
M0C0K0F]/17!T3G1*,6Y49"8C>$$[5W1F<E=N>FEE14U9,DE"57$V.59:5T%)
M3D-$=C(S-EE#2U-J8U9D:7)'+TUM=EAM:#9F93-T;EIN54QJ-C-(1VQO=G%C
M;C51<'-V<"8C>$$[<$QV=#-O4&5T05HQ9$U).'HW+S!"3$Y2."]A-6%Y5W%P
M-69M2FU--6YH8WEE<$-S3GDX2TTU:6IL:2]E<6=+.%A/-T0Y;6A90TQ+,28C
M>$$[93 X-38S3G!%=#5,;S5G:U51;4UK>D9#:V]1=$EY:4QM1FHU;FMO0D\S
M>F\X2W!D9"]M;G%.;U4Y8GER<4E2;D544VA7-$-2<$)'0B8C>$$[56]$4W)!
M9%!T5D=(9S@Q=%@P3#AY9%0Q3%9,5WAU4$LR<%=)=4=22DQI5D-%:EEO>DU4
M>59F9T)8<E=T3S-99W@X,71M3C,O04PP5R8C>$$[6"]'62]W1$IM5$%/4EEY
M-6HS+V]+2G=-,D\V=#5O9V=L=6)D2FA!,79(-G)-5C5U5E%Y*W%1;T]Y<4EE
M=$17=$]U4GIA9DQ+2#=S9R8C>$$[2"MX>'!A=453465G=C<W*S5%5R]M:3!E
M3D,P8WAP5#$U0DAX4T]R8T%74$IH4W O6DQF9V%7:D9)1&-I,&I5>%!1+W%A
M=DIR=E=,2R8C>$$[5S$P-F584S=W9E8U,75*159J-E13.'1L1&(X,6E955 P
M-&U.3FM-;D8U2C-K1WAI=FUB>34U<S%$54).<$AM1U148F0T:6IX8T9C4B8C
M>$$[=4%W1%)Q079,;GDS-70X4%5D<5-"0T5S9SAH96,P=DQA96)Z:&-Z0TYV
M.$%31DM-9V1#-G-W0W))1E5L5DLQ<'17;S9994ED>3!Y3"8C>$$[>34U8V93
M=S$Q93-46"MR>GA*1&0S>D1J-FE24$DX43163D]);#0Q-S!Y2DMP,V=3-T95
M<FXP;E1D5&$U:'8W9$QM3TLU5U=.6D)8:28C>$$[-'0P6&M09FEX2# U26YK
M=VIZ4'8O445:1'!U;G=83#-53G)&1F-Y27-C:S9)<75Y2G-Q;&=+:TPR1U)T
M;6E-5F1I<G-645=P>'9,.28C>$$[6&E2>D<W>4]Q>41Q<$U%;T1$<#!Y565R
M0UA-92]W1%%70D@X<V9/0E)H2C5V=4IP1T%8,4A74E-%4EDQ4E%"3%-V-W9K
M>F9T3E=U-28C>$$[<7 T:#--<51(52]Y+W="8W9D4V$X:CAW5%<Q1$U5369R
M8VXY6FQ)16<Y8F="16=+3#9A<65056Y!2DQ43'1*<S5B4%1O3&%6;&%32B8C
M>$$[845O6D-V56UI;58U6&]/;3=F9#!Y2E-I.%95<FXO96%8+U5B.5=)-6]L
M>5%5;6@V3F9726EV8D=#-&IM-'EY<$Q'<D)P4%-%4$TQ1R8C>$$[-V5N.$9F
M1&)#5'5I4$I2=&9*+VQ7,$QM,C!I,&E-:V)1>49954A+3U)1:F\R,C9S<6=%
M63A24VHW2%1R1%0T5$19,CAD=$5Z1U)K:28C>$$[54M#>F173D\K0S!O;D98
M67%X<GI$-6-M,39'5S%I,4-F5'92=D)/,'1S>%(S<%HK;7%&;$E)2$]25S(S
M*TAA:&]23S9P<FIZ4'8X028C>$$[,$))-69)=C5G;656;W9/<WE11D5J9U%W
M0FEO4E%P66MT.%1.5&-K*R]82&E(8WIP34QZ>60U;F)63E5V3$AZ3%!B43,X
M4$-'0FQA528C>$$[47EC079*3U1L5G$Q5RM"5DLY0F<T:#-,4T)V4$E(;E,T
M='I"+VI+-4-S04=F,"M,,4(U5G)'-F(Q<C!O2V)D04U014\U86,S:TQZ>28C
M>$$[5$5O.#984'!+<F5S=G!F17IK04%H9R])0W$Q<#(K:S0X43=L<&PV=WEW
M>&%81$Y*-G,P5$)*2E18-&U7,V-&='E4=60Y>F=(5FI,;28C>$$[4&8X06]+
M65I&;6=B;E(Y4&YJ;D)T-'DX-$E:;EAM0V9I<'E&4E56:V%O-S%)>5%M43%3
M>%))3W<S445/9V%H0VIX2F17=VAC5459="8C>$$[4TYL2DUD5#9P2DMK.50Q
M>5IY03E$.#)Q3T=1,G-F3#5D55IO*VMN5#%L-4Y'-U-504U59G!!27!B9W1#
M>FXT43%"=FM:>G1S>%EU1"8C>$$[=2M62FIK1S5Q-F0T651*1D$Q=S1+9U))
M5E5K37="3E=)2'=G,38U6G=H5T@R=FTW>C5+9C,S:U=A1E)(>DHK=C)Z1791
M2&=O,BLY<28C>$$[8C1E14ET1S)V;6)Z3DMB5G!F2V0Q1$9/=%I#8FDS3'A0
M-GEX,&1/43(T33!L465G<%1F2&A#;U=$>F@U=VQE-$@K0W)T170V9TTQ,28C
M>$$[07!K6EI!;$EW858K13AG,6%9.$E7,%)D96%F3DU5,'%W*U0W>65/3U8T
M,&PK<S)Q.#%6;4-Y04=1;FDQ069%5G@T471Q169M:GI91"8C>$$[8T%E4S=P
M2G945V-!,V1T>&ME<4DV0G=Z049687$Q*S%X3U!#1D-V0C5P.'I34T]S;FLK
M.6E69E4T<V)I,%!,:$=Z2C!K+V)D3T@P9R8C>$$[.4UE14QA*TQZ3C5M85<V
M5U1Y;&1X4G=2>5!$26)I,6(Q;6I6:7%+1F1I0S5!07(T*S)00T9T46TX,F5B
M16ML5E!*;#0V>'-W1&97<B8C>$$[6#0P5G%";&\W8FYR>$Y-945,83(Y.#(K
M8TE'26<X;%AC-G%I<U<K=#)Q:W5W0DM+07I6-&MM<#(V63A)5S)R;GI4-7,K
M=$MQ95-B=28C>$$[5T]*5VM353-D<7 U.%=!54QZ23-(*U8S>#11<%)&>#5R
M.'=X-FQC5W-8;$LK;6=G57-T,'-T=7%V<S552T=C9%-L3FIT55DX25<Q5"8C
M>$$[4U!-6&U7.78W83)V4$MT>G!S1790-GAD>3-.=$EK6$972S=23S=0>4MG
M8D1A=C-V0T9T:S-"9D1"45,W9W9H:E%6<&]O,E5Q=W%P1B8C>$$[0U!9-#!&
M8W-587%&555!1D%065DP1F(T3#19,$9D=UAW>&]+-V=V:&I15C-"9D1'9W$Q
M64EL6C)684=1.&Y0:6%"9C%+36%24S=G=B8C>$$[:&I14S=G=FAJ458S0F9$
M1V=R=4,K1TY"5G)14DUY37DQ35HU269!,$LO<5DT,&EL,T)F1$=G;#-"9D1'
M9W)U0RM'3D)88T8X36%#=28C>$$[-$PT63!&4S=Z1VY,4VTO,%-A.3145SAN
M,64S9C U1'=U23,U0G%R.6IJ>DLQ*TE#;F9#1F595S%Y;C=U4DY6.#=2.$EA
M+U9*8EIM628C>$$[8TQB,4A$=3!40G!$43E84'A':3E-:WA66753>"]7,#AW
M96-(45-Y3C98,55U-T=%=VAV,UIG2C1%>F)!069T9GDT<7-/=4]&0T<O."8C
M>$$[-6QB5S%65$MT9T$P<$US:VAM679%8712=V=(169#=F9&5C@P-E<Q;TEM
M,6YZ:D]3:E-)>3)R*W%N<7I+9#(Y1E%Z2C9$04)Q-TUA1"8C>$$[=&EQ*S-V
M8FE/-%,X1W)E8G!98DI';BMQ4U=3:WIH<$DP1R]P2W)"4DPY:S<P0D\Q3C%6
M,%8R;'AE96].83@S4G1$14EY<E=B3$<S,28C>$$[5S-9<S-!=V)T2UDR4'4K
M,VAI<45J=4DT-W%+2F1C.#5Y5'519VEA,F%J<S9G96]/8U%(1D-A;6AP-V5+
M<4ET<#-U8FXT=%@X-#)R6"8C>$$[5$Y)<E,R-CA&0WA.37E!<D4X44)79TA%
M9%)T*S%I<3)(54IH8C-.-TAQ6&Y&-$I3>6M.84I73G!9;59E16-K9G%M:%E&
M94%P>7 W-"8C>$$[<3,K;%AA0U9O9%4X,VAO0T$O4%1Y5V\X36-23D=H545R
M=S4W8CAI5V]15%9684QU.&ES3&$Q+U1(;3)34U=C<3%Z.5%94T%"-&EY;B8C
M>$$[:V=O1S1336IB,%5K8C!!2W%D-D)O1V\V-5HO5S X>F5:3$Y9:4E(9W4P
M=#=A4FEI:&DO0F]#9FDU.6-5<' O9TLO.$%R1%1F-'(Q<B8C>$$[-&]N:459
M;6DT3'E1<4=!.5 W4VLX9U15,4$S<'1G=&%21VLK5&(W5#=U,75*4$UU<3-Y
M,G12-D9Z2D5Y4TM24VMO5TYE4CDK=4YR5"8C>$$[2G-#6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@O.6L]/"]X;7!'26UG.FEM
M86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C
M(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#HQ1D$V,$(Q1$)!-$9%0C$Q045%-D4V
M,SA!14%&-C-"-CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#HQ1D$V,$(Q1$)!-$9%0C$Q045%-D4V,SA!
M14%&-C-"-CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y
M,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I
M;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HQ14$V,$(Q1$)!-$9%0C$Q045%-D4V,SA!14%&-C-"-CPO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#HQ14$V,$(Q1$)!-$9%0C$Q045%-D4V,SA!14%&-C-"-CPO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P
M.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#
M;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D-!,C!%-$1#0C T1D5",3%!144V138S.$%%048V,T(V/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q
M+3 Q+3 V5# V.C(S.C4T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ1D$V,$(Q1$)!
M-$9%0C$Q045%-D4V,SA!14%&-C-"-CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,2TP-E0P-CHU.#HU
M-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T
M;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL
M93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$
M:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I
M;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z
M2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE5')A;G-P87)E;F-Y/E1R=64\+WAM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A
M9V5S/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-#DN-C V-C@Y
M/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XW,"XQ-3<T-S$\+W-T
M1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!I8V%S/"]S=$1I;3IU
M;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @
M/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86PM0F]L9$U4/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&
M;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N
M4W1R:6YG/E9E<G-I;VX@-2XP-CPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z
M8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.
M86UE/F%R:6%L8F1?,2YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT
M1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G
M=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N,#8\
M+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;%\Q+G1T9CPO<W1&
M;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*
M(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A
M=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @
M(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7:&ET93PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D)L86-K/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+(%)E9#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+(%EE;&QO=SPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0TU92R!'<F5E;CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M35E+($-Y86X\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@0FQU93PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($UA9V5N=&$\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],34@33TQ,# @63TY,"!+/3$P/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXQ-"XY.3DY.3@\+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,"XP,# P,#(\+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TY,"!9/3@U($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STP($T].# @63TY-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.# N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],"!-/34P(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3,U(%D].#4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C,U+C P,# P-#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.#4N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34@33TP
M(%D].3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU
M+C P,# P,3PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],C @33TP(%D],3 P
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3DN.3DY
M.3DX/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TP(%D],3 P($L]
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TP(%D],3 P($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@33TQ,"!9/3$P,"!+/3$P/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XQ,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ
M,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3DP($T],S @63TY-2!+/3,P/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXY,"XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XS,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C,P
M+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TP(%D]-S4@2STP/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^-S4N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3@P($T],3 @63TT-2!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@P+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P
M+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^-#4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3<P($T],34@63TP($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^-S N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,30N.3DY
M.3DX/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STX-2!-/34P(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C@U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,],3 P($T].34@63TU($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDU+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^-2XP,# P,#$\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],3 P($T],3 P(%D],C4@2STR-3PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C(U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C(U+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,]-S4@33TQ,# @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-3 @33TQ,# @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,S4@33TQ,# @63TS-2!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXS-2XP,# P,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXS-2XP,# P,#0\+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXQ,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3$P($T],3 P(%D]-3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXQ,"XP,# P,#(\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXU,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3DU(%D],C @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/CDU+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3DN
M.3DY.3DX/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(U($T]
M,C4@63TT,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C(U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C(U+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,SDN.3DY
M.3DV/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-#4@
M63TU,"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,Y
M+CDY.3DY-CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/C0U+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-3 N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^-2XP,# P,#$\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T]-3 @63TV
M,"!+/3(U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C8P+C P,# P-#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-34@33TV,"!9/38U
M($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4U+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C8P+C P,# P-#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-C4N,# P,# P/"]X
M;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQA8VL^,SDN.3DY.3DV/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR-2!-/30P(%D]-C4@
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXR-2XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XS.2XY.3DY.38\+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C8U+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STS,"!-/34P(%D]-S4@2STQ
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,S N,# P,# R
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXW-2XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXQ,"XP,# P,#(\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,U($T]-C @63TX,"!+/3(U
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS-2XP,# P,#0\
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XV,"XP,# P,#0\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@P+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @33TV-2!9/3DP($L],S4\
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,Y+CDY.3DY-CPO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C8U+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,S4N,# P,# T/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/3<P(%D],3 P($L]-3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,Y+CDY.3DY-CPO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C<P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TW,"!9/3@P($L]-S \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C<P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.# N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M-S N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @
M(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STQ,# \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 P
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L].3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^.#DN.3DY-# U
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STX,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXW.2XY.3@W.34\+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TP(%D],"!+/3<P/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C8Y+CDY.3<P,CPO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],"!-/3 @63TP($L]-C \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^-3DN.3DY,3 T/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]
M,"!9/3 @2STU,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+
M/30P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C,Y+CDY.30P,3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],S \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,CDN.3DX
M.# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STR,#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ.2XY.3DW,#$\+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3$P/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/CDN.3DY,3 S/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],"!9/3 @2STU/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C0N.3DX.# S/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A
M;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P3F%M93Y"<FEG:'1S/"]X;7!'.F=R;W5P3F%M
M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z
M9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^
M"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3 @33TQ,# @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3<U(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XW-2XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P
M,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3$P(%D].34@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.34N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T],3 @
M63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXX
M-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],3 P($T].3 @
M63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P
M+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-C @33TY,"!9/3 @
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXV,"XP,# P
M,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XY,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# S,#DY/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,#,P.3D\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N=',^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A
M<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 7L"7P,!$0 "
M$0$#$0'_Q  >  $  @,! 0$! 0          !P@$!08#"0(!"__$ %40  $$
M @(   <*# 4" P4&!P4#! 8' 0( "!06%QA7E]4)$1(3%598E9C7&3A4=WB3
MEK:WT=36(34V=K0B=2,QI"0W05&U)3(S-%-ADB9"9&6R@?_$ !P! 0 !!0$!
M               ! @,%!@<$"/_$ &$1  ( ! ,#! H)#@T# P0!!0$"  ,$
M$042(08',1,B0=04%1874556E9;3,E1787&4E]76(S0V-T)3=7:!D9*UT=(S
M-5)T=Y.AL;*SM+;P)&)S)L'A)4-R\42"1:*CP__:  P# 0 "$0,1 #\ ^#%&
MTI/.Q%HQJGZS:B'DTE:9]<6D>/B(L%3;1>,F9><>$Y"?=L0XIF/CX H_6=/W
M:".-6V=/A_#WTQG;9CK+0NU\HM>P).I   %R220-(T*7+::XEI;,U[7(4: L
M;DV L 3K'<6UU+O6FS 07((FTE3*3P9&RXQ+:FD<>N*"2*"*OY**4DHJ:UF2
MD\<68,2D-E@\IJJ01<BW,=*ZOV[=-KLIFE)TMP2&M9LA#@HP;0V*L ;\X6Z#
M<6BN93S99 *Y@RAU:61,1E-Q<,A9;75@=="#>(C\FUBY)1T-B S7)B7L4R<2
M%>*IWY2E U5-19(A'6/@'A1MBHDDJJF[&).6^Z::F^JF==-LXKS+8G,M@;$W
M%@? 3?0_#%O(]U&1KL+J,INPXW7346Z1'[UK&RMTG:^E>SC9%@LP;/EM8F?V
M29."OR+D8@[4P/SHW6)8DD=RP26SIN\^7PO@^JGRJQ^/9TTYZZ\.<-;7O;7W
MC^8^ PY-]>8^EK\TZ7M:^G3<6\-QX1&0I4UJ(D#(E:M+ 2*1W77>0#5(;(]"
M +388Z-:[F6>PW#D9KL&9/2VNSU-#&1C1T_QG+5NJKHSIH<ZV/ YAKK;3777
M33ITB>3>Y&1[CB,IN-+ZBUQIKKT:\(Y@]'9!%B.XB3@C,<+)H-72@L\,>B".
MC9\W3=LG&[(@@W<ZH/&JR3EJKLEA-PW5362VW3WUVS(((N""/"#<?V1205-F
M!!\!!!UX:'PQIN3$0XA#B$.(0XA#B$2K#?\ W<7%_P!LA7[Y,.9F@_BK'?\
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MCP#1^LU5,!]'\<HF95S#,X9E -\P6V8@C32_Y=;<#:HRI@5W*,%1E5R1;*S
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M159P]8.6[QLFHW634VJS+<C,MP"2+BX -B3X #H? =(IR/8'*UB0 <IL2=0
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M5Q>\8G<B,2.56Q'Z.@\?)@\ :_A\1K:I)O*YF4K=.!0$+&8\E"9BO+"21:/
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M6(?@,_<X_0QO]:)>S^.Z>K\7X'YHI/W(=Z/#?+3>C\H6T'6(?@,_<X_0QO\
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M\M-Z/RA;0=8A^ S]SC]#&_UHE[/X[IZOQ?@?FBD_<AWH\-\M-Z/RA;0=8A^
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M_P ---L^]_\ #ECNMJ[V&&8&=;#_ .DTFNMOO<9!=RF&E%<[<[T "@<_^O\
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M[^/@\N2=L<0ES9<R1AV#).1U:4\O"Z59BS P*,C"6"&#6*D$$&Q&L>/$-PV
M8A0U=#B>V.\BLPZKIYU/6TE9MUCT^EJ*6:C)/DU$F;4M+FR9DLLLQ'5E9200
M08V;?W!7W. D@@0;U;J[;OT4WJ#O0CHIHZ1=::KI.-%/!,_&:K:*:J:[^_GX
M6-L;>_\ X\H.U]822<,P.]S>^%4E[]-_J?&\>I-R&&*BJFW&\]4555%7;[:
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M9C+EJ&!1@H,MU9@1F6^JWN8HDRIC&2[30$LMPTTJZ*)LUF7*ZLQY1&0$'*Q
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M]LUKV%[7L.$9GDM[7?2OC/V<0'WA\H[/V>\GZCSW-ZC%[N6WL>ZSAGR;X?\
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MVV[.S6Z*KIV2$#UH1YV)CT/)%T[,L=] T;#T?&9.>B<">[+.2LD?LR@$AQ<
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M57S*)TYB8WN'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0BJ]R?C%]//\
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M#O/;+>-=X'RF[?\ TBAYG]6_.J__ +3%^?>'QW2XA[7P?S%@_4H=Y[9;QKO
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M7>!\INW_ -(H>9_5OSJO_P"TQ?GWA\=TN(>U\'\Q8/U*'>>V6\:[P/E-V_\
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MN\#Y3=O_ *10\S^K?G5?_P!IB_/O#X[I<0]KX/YBP?J4.\]LMXUW@?*;M_\
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M_9%@GX4HO]1+CFN^3[4^\?\ $O:+]5U,3U'O\@!_]G&?\)#F(G_P\[_RS/\
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MD%9W'Z_B4'(2-5RBVD)JNX(-RU:[NM]Y!.B@F,1])71/.,I-E2I)KHY=;?\
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MZ9<VE\JC/C10_9P^3^46'PT,>&-_C&5M>:V@N=#H/"=-![\,RZ<X:FPU&I\
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MK(D!]_J-V[UMUMLFY*8+D]:Q7^43;AY,MGT?JY87!R\"IM<#AR/@  _@CP
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M.2B<W;IOWK\O'<P90.;CQ:LHX]5DS2S9F!N&)4ALK*I!&4$#@-+:<;W!S$1
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M%/8\QL7K!7(>M1DA/PEV0A<UCFL  PB5#R</%2P*2 )&W$8 2(*Y%2A=Q&B
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MJR:0F*CYUOD.$I5 :5F2[:/>!P^RIMHQLE@HS % 6<H+Z] 7B<NI?@"=57X
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MRL>P>;-PS$)<N7B5&\R9,HJE$1%GH69W:4%55 )+,0 !<F.>;VMO-AJ[=AO
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MOS46)@'YEW$Z\:V1((8S)O6NZ&200*[^ 7-HM'4;;N1YUDR)DBP(F+0"620
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M S;D>$IS;0:B^I T(+ GWB 3?APOQ$0'4FP/A'#P&Q_,>(X^"\3%!KYKZP#
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M V!!)-K>#4C2VFG0(L9M!(]M8*5FY1<^-:,-7@FB_A2G@>(\Y-MI JCEE_\
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M%>E=-2#P]_(]YC(985=NC!.=EI#HM*7\G4/5.?&RESLD/0!;%0"M(5B)$,M
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M),.8=FLW<737L\Z7$/1 R/$?C=1\3JU&N"1-T&B*4M8EC4P>5AY851Q(()N
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M6KB#&-R2\EM3&5B,MN+<!:P-LH_)KH!I?V3=%:!A?-?HXF^O21J="?";FUR
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M(Z([2(*2R]K7GH?#;KM9KO"L=ELBV)!EULI!/>0<JM<XV7:[_P#B-]_^C?\
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M93+#\K;,>(?+;HR],=G;?NFL0K273^#!Z1L"P9'7YF6C"* 0U!@[-RT@W5J
M]LI,8T>R$TPT2:M(#.M [9KC18@]DXM1HDUPQ>(ODX6ES!2610P!%U)]E-:4
MHT'2RW\ !$5O6A6=1*=RA((#(/8R%GDW) ]BUO#F' #488'W3D/+7S&%Q7K9
M:I2Y9',Q,?AE4.I'5(IZ<C1OKX+[-LYF1F#F9[PL"DC6)9JD0 *F'Q9"7+(@
MVNKYAX4<9R:0"Y+R\@4DME;0B;R66V6]RW \+:^] 5H;FB3,Y0L J$H+J9(G
M9BQ;*+(0"+DYM!<7(E_JSWGBW;R8EAM659-V]>!*UJNPR%HR=Y$A0]-S<4$C
ME@P^&)Q9 T^DZ\A1#&"24@=HLE(X,=A,Z-39/0HQWVHFT_(CGE,V9ER@$^P8
MJ3FM:VFG Z\(N2:D3VYB-D"(Y<D ?5%#*N6][V)N> MQ-X^2]1>Z\=E9]8U"
M5"5B52H3*5=KW,7M5VQC4B3'-NK\BEM40FLY#'$EY6IEA-Y+*K#E$>V?/%R0
M]1Y5<L71#:(::9YZ7HY*J[C-E$JZ#3^% 9F!.750%!M_WC7P^"77SG:4A"9F
MGVF$ VY!F14*B^C,SLMS?^#8B+Z]=O=(5K9AM?/$*EEU@J(4]4=@W39(9.N:
MSCT0*W%$)5+XDS9U_*;3.2!_HY'Q154PSC9^7*A,F1#4:ZE+S4LB,LS:549A
M=5Y[*BD,V;(0K78( -3H2 #8WMI?TR:SE$0Y&?ZFCS'&1 IF*S+S"Y.N74 M
M:XM?6V'CW5J.MH-%K$,]:+:$QDE0\+[5S-;:154\>U_UJL@\A'H)9+UBWF/Q
MTA*'G"1\JK 8_P"%R<2"C;U8DB@9?A0))V(,Q4/+)Y1I0YK6:8HNRWRZ :#,
M="3I<"\!7#(KF3,"F4L]N<G,DN;(Y&:[%M3E6Y 4WU*@^R_NL]7_ !UP*BZ/
MN$Z$K.0$8V /#&D6U'V&3C_9.(=6I$P8N2!QBPB97-AS%H3B8R8$!2TKAXTR
M:UW$KC'H]!V&>8"TL%@"0>*@RC-!-@;C*+$K< D#6\2:Y/JA$N80C900!9B)
MRR&%R0%.=KJ&(S $W%HVCGW4N!A4M1TNI.Q(W-W\HLNK(Q#=B<-+K3.^*QO.
M!T42IN+F199<<0D!DM9L-E8)_ME%DZB.\E)JZ(XB1C71V)?4-+*V5B;'1&EL
M^<@C0#*5/3FL.D0-:JZ-+=6+.BK=3FF)-649:D$@DEU8'09<W\DQR8#W4@.!
M 2<A-JTF,R&5["NU%S67/XJ'B,1$Q"KJ$['7E1X\>C#RUB2$U(I:3)U>(CXK
M HELTD2Y3:8&$H$.R^!AY-("P * LTI%!N<SS):.3F"@ <^^HN/8C,0"86M
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M@LMI8V6QLY@P+'#<3)YYNQMR67-[^7IOQUBPV]C<^TY9IWH;  (4(EC:S9T
M<FI50&%;G"V.JYK: "PN#.YAQ[E6?3KQ$P;ZAOD:GB,9@5=I*V+!]4XM#823
M8&H9'6":4B3T4&1 T,9&(LB\PYS'BJ.Q(1LS>KN%U;8PG;$9K;-8Z,Y+-_\
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M7RU5GG52JWL29TS70&QYVAL00#8D$$"Q!BXN$X&Y*KA>%,5X@4-(>D@__:U
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M0;"'4@,22>&0L2CK!EH?-1T,EAP8+--'#DB98-6S?*BZBWO:?!VPKRC.JJA
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MHUR-D+,JS0KF6Q7-?*V6Q!RFUO 2;6-J>6EV/.7, &*9E#J&M[)2PM:XO?\
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MJZXW2525TSMHHDIIMKNFIIMMKOKMC;7.<9QGECAQB]'IQ"'$(J;9'XXO5O\
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M-DT(,7:.-M4G3-Z@FY;.4M=_^O5-=%7173&__5C7;&-O\??YC2""018@D$>
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M9U'//[.L"TH79D=CQBQ%K!$DQ<KJAI8 $;";,JGK#6DB%#@[N8A!KJ2-5^L
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MI&!!> FI6L64BRU3E.3+*LPL!=?J@!7ZD)H!SWR/,9!KE168D0:9F=G+A!,
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MEHD)0^-9$(:[T-;DT]FA!%&6I6 0J025NX.F0V<FYUT 0W/0=.D0_P"?_O\
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MB2VZE;3JDE;EAE9"@"!0K2C,9,JA0!D,R80 +#,;CA:D2Y S6"\X-F.8DD3
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MWB6Z;H6MJ&$.0E=,#S9FY8QT1E:2S&73@DW Q 3J$BD<8E9D:.$6,=C@WXY
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MRIPS6'"6BD'C;H!&AR"ON><Z=J('$)5"=7"$EC$TS6['<@#@RCAG8/=^9OH
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M7?EY%[L_3_:/Z 0\9^[/H<ZW>OJP_N&X[&V,\;[1^8L.^?H=M=^7D7NS]/\
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MIFRE);&4F29-4ZL@86%^:I)F$-DR-TZH6:9I*W,L2@9BK<,ZYSF5&!LK9==
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M+W*_A?;C_8^*1:[FK1UN'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0BJ/6?\ UEW
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MD<B'DRRI14#GDW<MRLP(7Y3*EE5OJGFDS9I?ZJ'(O-Y%58?52LUPP<L4 =5
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M+.:6LQR+39E3.$J8LK,V4 J H?DXH::"[Y)Y*HP2:,ZW ,]%=E4'F+(3.C.
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M=>(R* 56ZFDCL-W8KV 0EMM'Q4;>1N&R1I&2MX.2!/X @'&I(.;PYR%.-61
MX782L$F*&/\ Y4)+HZLFY_9BDQVMQ6LIL+HJ7#I5,U52OAZ3L/I,>QBEI7J'
MI<*24TH[0FGP]:"JJ%209*4%:)M0AGS1-QB;Q*>OI<&FX!@%=C>)[1S]H9F
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MH4JNN<S):"PRYFY[J<J%U#-[%;@L0"("IDD ,2"?N0CO;V5AS5(N0I*CB;:
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MV/(^\R_T!^R$/!&OY.C^KT_EQV/(^\R_T!^R$/!&OY.C^KT_EQV/(^\R_P!
M?LA#P1K^3H_J]/Y<=CR/O,O] ?LA#P1K^3H_J]/Y<=CR/O,O] ?LA&1R]"-)
M)@ ^61R018MJKL*DH0J )ZH[X36V'F6#@<\U24SKOC17+9RIA/?.NV-=_>VS
MKM[WO9D&Q!'00?S1# ,K*># @_ 18Q0R]>J%KS:8CRE:3(.#$AZ5CM8A"1V1
M*,#(X@('VV(+O'+<36)20+H2(7.HYJJZBEF0!#!4 W?RF.3D.(8QA]?2:B@A
MEO=RQ &ECE(XM;3*;75M#8%2;QY9DAV8%&  EJ@)8@W <&X"$ZAA[%UU'.#
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M3!YD83!EA3QR(X9P&T.M@,N4NS<3< #0Z7(((U!AV2VIY,Y0&X$DELZHHOE
M#7/.74 ,"&-B(DRWNT4FK"R$X(SIY_)A>XJ*K.)OD\<& A)F3RD* U;&46E?
MGGB4<'L"K@PM*Q&AI%5022#ZC$WX\K\FT)+#+F+@&[<VP).52=.<-3PL;>'A
M:]<R>4;+R=Q9>=<@ LP&MD8Y=2<POP(M<&(F:=Y;0>QJ+RQAU-F!H3+H 8GH
M5,#,E'11\D.ASF1-0[$86@@)=^1=DFFS)QJSRKLR!$0<@21?/BFT::5\@MR.
M5 *L ;@6U8*3HQX7\'$$:<8H%2Y"D2&(92PLVIL";6*C7^X$'6]HZ09V\MXB
MU^5<=5I%\E-W+QLZ0935^6D!#5E(*E!8=Q-D.KE>.R5@92M=$W&'^)<.9F0T
M0ECQ1=AH/SG,<DG#E1?WU  T<ZG/<$9+'0V)'&)[(F$9N1-M?NB2><@YMD*D
M'/<'-KE;P7C7H]O[G*B0!%EUI< T2A.#L2)(M,#1L<)1D<KL9F<):9CU>[(/
M8]'8E6KL@5/*$F#D.>E,=8.X\Y&XR2?#*0$WF7MFL H!-@MAJPU+-:W2 3>^
M@CLB80")-KE1=F) N7N=$X!4-S<$$C0C4R%9G9:PX?:3VKX_04QD"*;@'EE8
M>FQ12'KCR[$00\*5481I]HDJFKI, J[7#_=1F0 BEG.=6\D0\!A9:E0QF*+W
MN-+BQ(Z3_P#B>'!C;A%;SG5R@E,=19]<I! -]%__ "''0@7XZ</!NQW8>5TQ
M:$H,U,$CD]$TG);!KG=DRFYH0^F@B B"FL4D$0(B8T:WV1F17P%BP%2A4K(A
MS(DRVUCY%EA9S+2Y8=0')4N%;V(-BQ%P;D<!>Y%@==1%"3IK2W)15<2V=/9$
M9@H(# @'V1M8&Y (L"(Y=AW*O=B>00/=9),3#2)TS0$ZL-248)150,RAH";#
MSGRVR(XE1+>=$)N8C2$<:M=W-81!U)OBWJ:3E?63)2UQ,%Q>]]0;DE;$6TME
M!)^Z-HI%3,N+R6(:UK74J0 '!O?,<V8J!Q1;\;QWA#M+;34U"ARM$[M\/+2A
MD,G;,85FDD=16*2B$RPP2G15^K6D;&"8R#.#@:C$HP4E;XT'W>:%X_#=]W;X
M%3R2D-9^"DK?* 6#*,HLS7)!/@%^!/ UF?,NOU(^S57 +-E5E8EB<@LH(%B,
MQ(XJO$7B9/&Y!FT?LU,JM'S9!XU5SHHEE5NY2T604RFMHFJGG=+?7;X"NFBF
MGO\ P=]-=L9QBR18D>#2/4#<7\.L9/$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ
M"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(
M<0AQ"'$(<0AQ"'$(<0CGI<:<QN*261,Q^"SL$ +F&HO*KU#4DY&CW#Q!ALN.
M%FR"&KM5'5#99D&+.DM5,J(#7JNNK920+D#A<@7\%S\(_O'PQ2QRJS6O8$VU
MUL.&@)_+8V\$5;<=TZWCLDB<7L86>KHC**L0LW?!UHY44#_%QP/+#L9(#D&>
MII M&8^],EC>SD8UU:,HL9RJDFZU0:*7.18@E2& ;+ITZD @\+$V ]\B+/9"
M J'!2Z9M>CFJQ!%KW ))TX*8VR?=7K\HV3>ZR4QAFJU;K:OU(I(41.'STM*P
MPX*H=58: TBA%W!Y8LVPJ2T8:# RIAV_;"G8UX]<B_@'YQPLI)MQL,PZ.)L-
M8GLF5:]S:U[Y3;B1:_"_-)XVL+WX7VQ/MG48C,5(/7AO$0FE5B[>C\U;QXT[
M!+18P&/R,?\ *.&[!1X%>O0,>=OF+8JW:+/EMTQS=/<AC=OK'),;@6S*Q0K<
M W! Z2.D@?VQ)GRQE))RM+$Q6L;%2"1T:$@7%[7X#6-I!NTE+6(Z+,XQ)UW+
M@'$C4V)Z. Q5M\7'HT5V!2-^SSLUS\KM0YC788H0#?* DD_3=M 9 JX&%4V(
MRG6UQQ(4:CB1<=/2-=?RVB5GRVO8GFJ6-P>"FS$>&QTN+@FX!-C&O4[=4&U@
ML8LDA-M!D+ETC(Q(.>>"RGR?M(1$U:0(H/=NVS1PV::CC3EP^>OE5L#6T5#2
M29K/-(K'#9=BY)RQ4"[* 2 1P*Y@>/@Z.-R !<@1'+RLH<M968J#8VN&"'A?
M2YO?AE!8FP)'.N>ZU)XW8-ASB7/WY!X&UT:+PB5!M&H,G8&*S>RHD\,B6308
M!"2]L9"OW!!5LMN2"N&K5!;5\(7(3R+CC8<?NE)N!FRV!U)%CII8CX(I-3+T
M]E<D"Q4C3/D+$D6 #7%STBW2+Z9GWAZ^#%74<<NCL3>,%PHJ)QTE"I,*=GQY
M6%(2N/+B Z03+D8P=M/>#LVKQHU61?+@&N6R>TFCJ)"3(F6OH18DD,-+,5-]
M=;6N?>OX#$=DRA<7(M8*,K7-US"PMIX/RCPB-BR[O46XD[6,/"ID6L32CN@$
MB\CQU)A(GYB5S>$%FX7*PU%T\:12409^(-D_!DVVJ[QFLWU59*:NMQD/:]@;
M$W%Q<6 (OKH6!! _]XD5,HD DB]K$@V:Y93;I-BI!T\$=?,^V=%P"3S.(265
MNT3U?IAMI8R'1R0FU12\AWA2(1BHD&&OG"SXJYLFOV8Q!!%3Y3>RQ@T';.UV
M!Y,12)3L 0-&O;4#09KG4@6YK?!E-["UZFGRT9E)-UMFL";7RVO;PYEMX;@#
M4&V)KVTJ7#A11TO(QX':,.I:.D9&*R!FP.!F<3ET^4(@T%ANKPH)<0F%&Y /
M,M$51Q#5'44V7W-9R/Q/)-;HO?*1<:&ZKJ> -V MT<3$<NE_N@,I8$@BX"E]
M!Q(RJ2#P/ $F,8;W$HTJ4;C6TC=XW>%O%EGHL!D";Y>8*;/-FD1W&Y$_'-)"
M00:;Y:!GN[<OH_SL#?CF)Q!P/3&2X%[<!?B/8]+>^!X1<=(TU(5$HGB?!P-\
MW0MK<3T ZWTM>-2"[.4&+IA.RJK18.JP9FR O3Q8!;1T.R6WB+JR5R2(]N,2
M^&U? UFI5QL-'NGVCHKLS?,TCS0J,:#+<OE;V5@=3<GG!+7]XZ:Z::&UC$"?
M*$O.@YF:V@M8Y<][?!KX;FQ%P1&<][I=?AN[--_)3S-4E&%)J,;KP>8Z.RD0
MW E).(D@IC\BY>E!$C!A"SH$Z'MW.KEVQ4!N<,Y HW%+!)F&^@T.7V0X@@'6
M]N:2+W\-]1K$FIE"P):Y&8#*URMKA@+7((N1;P$:'2,8IW?ZY@\D$3<O)!GP
MQ;1H[$E(M(F)?P_1$@X)L&XUP.T=NW ;0071>J-DU6;HD(+ PKHL=%$!C8),
MP\ #[X(M[VM^G2WP@FP(,0:J2+W8@BPL5(-];BWO6(/1<$"Y! ZF?]L*)K$V
M= S.9Y&O8Q%64UD>S8(=+-P<9?9U5U+$E!(Y[LW:-1N5#A)?9/*0P(@J2?J-
MT/B\J0LIV (6]R0-0+D<1J1_^]!%3SY2$AFL0 QT)L#K<V'0-3X!QC7D.WM'
M!R800:.'PI"2&S8 $@7ADJ'Y+/XQ*FD#DVH_=P)TT>ZQV<OFL5-IM=EG0UXM
MJ5<MM(QC)[#DG() !  )L1I<%A?X5&8>]IQTB#42P0#F!)(%U.I#93;PV;0^
M#B=-8_@[MC6ID3;)H0-FKMG3E7AK4E2;N,N0+[<4?&2XX)"-&$C5$.D)"] 1
M1,ZDV+IBV.!,C .UB"6JQ#4?/),,H)49W*#6XN+ G2^@)L>FX( ,!/0AR UI
M:!SS;&S9B  ;:D $7L+,-1K;7/\ M4$B<H,0:R8F4A\K$#0C[.1[SQSBKUP?
M&V'(&(_61QT>LY#.MHU6YTMHWE@../G>R6Z+!B[;;C2!4)189E8$7(UT.A47
ML>.K :$^_;6PSPK%74JPMP.9=0Q S*-.:A-F"D] M8G;1GMU1LL+P@$*D95(
MM81%$;%F)>+R$(Y?+/HD G8A79N6'-%TFIJ*2F/%V"^4LZ:)%$6Y#P%XDZ;M
MQDN QL+*"38@\"5/YBI_-I>)6?+8J 3=K6!4CBH8<1TAA^?6T8S[N-08^7'(
M.YE1',@C)C4/(46L8D+]H$VS,$X!N2,/V(YRS%!T)AOL%</R*S71#X&A137
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M7F(]B$R@W 8&^ITUT4V!)L,Q %R0#X">[E+/5JF&L%'"/E,ETB@3)'908Q2
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M5+#%%BA-==H2W=).'!(BX7U47?.E%1=V-V9B;WU)T/A'@_)!):*H"HH&7*;
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M !. [C@S"]@;,1< 6 T/0-!X!PB#+EMH40CG<5!]D;MT?='5OY1XWCV9U76
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@0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g197729g95x53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197729g95x53.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !X -(# 1$  A$! Q$!_\0
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M5?T9//AW*@9I%\<*]WZ33L")M>> PU*IHE!>?9 \YC"\"\?%'T,5^2YSZZ[
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M-.--.--.--.--.--.--.--.--0]^GCU,[AZ#VYFF5]A]A?LMQ*XUZ;050/\
MA.R;-O;DLV38W906/X;<P1CC^RLKK6'Z_P H4SZOX&L5A,ZME_<'+,/OJB'$
MQZO\I,9L6Y#KGTLC0O\ !1BRFR;[K)*1<NN,EV_D+T=2KR(\TC\,VS.]^W.:
M7MQN;DOTYI9N,R*V''^JRUO^+5RVJI3<GRLYL&FNF)%F!YGE'A[W;0>EUSB8
M3D0:NYJK1NW^>VI?U[]?O[E:VY:&D^TJ]^(L@_GMEK4/GOZOB#_")MO_ $%B
MVK2_*O:V\:<::<::B#VMZB>S<#]0''^HM1@^!V>&VN<ZEQ4S(BOV0+E0PFP*
MC%K.U*8H]O%4M)K4OYY!&OKI(U'@A4A'N<]W)=JMO*R?@#^6O3IS4QJ!;RPC
MCY?RA'7O2VF@5"95U1=\N*&J.HO42]/'")JD^8^)S+,=\25;LM"Q_'9=%+R'
M#*=^S>^F2W#3.2PJ>7,>16IH0Q=B)9.$R)12'M-MJXA*2EJ7SD1:NQK -G[3
MU_IC"KC8>SLIK,0Q"BB20^WLY'HU99/*#@@BP,F-L[0V1/A JZX<JP.F5(A1
MI7K[>>A65=A<S6:ZLBN2YCY<-M-HGN3Y1N&2BVTT">KCKA V">IDB:QO+<OQ
MO!:&=DV66\2DI*\$*3-EFJ(IERC4>.RV)ORY;Y)T1H<5IZ3(<5 9:,O34!>[
M/7 RJRN9\>ZT:FKF!/(4.ORC9,9]Q=6[GO\ CCEK<+QNP AK9'N\*(TV]NY)
MVO8I%<-*CATGFEV2BMLC(R6V<ZT'K<BUJMLLLHB<JCLV2VXKB(GR^AAA!5%Z
M7"3@M:Y,]\?UO)G.5NU6&Q1CJZK$:WRH9,V?-4EZ!.+0U<F,$0R+U81^QL"<
M0A[L5H^6DTNG?#U:C&_C8N YW^$.3YV_2=:"YJ;X5_23VG28D00L/M_)_P"(
MJ[V_?Y//WY[/U"[3@O8*? 5Y.!7KR4$>Y]WJ"2Q'J5?AV^.?<GPU@G]T/XSG
MT\^SCF1>27ZXG9VI>.#T>_A)!4KCBM\?KO-*7'KU_'6QM6^MIN'$+Z/'^QVG
MJ6Z"'G8/:&X@):81FM6Q?"RD$T&0&6-1:E,:OE@#78JQZ.3W&,\>7^=:;*T\
MQA9&.7#S)D*DT$LFIL)U?@(R(X-O- J^]SB6J? %UE&(>/?-Z2Q&LW1PB!/8
M:<%J6_2,RZ"^AHO"FX]6V3\J%,>%/DQD6F$D5.7QXY*>[178'5'9#!A=@ZCR
MD7(Z25Z"V RM<)=X]:)&V6:FR*GF5"ZJRA:Y')'*UPY<"L-KB30)ARY8'O:"
MUQR<=?;12COHG6V2*AL2&N>!>CO#[#K9>[E." N6W1!P2!-C&WNY.&[I8^SD
MF%W#-I ,D9DM<*Q/K)?2AG!M(+G#\.4"+R@FBM/MJ+\5U^,XV\>Y^>-K.M1?
M^H[WNSGI9)IZ+"\*Q/+UV0S/9+%V43W$25Z8B[#6B-";4EB*Y2UR8A2'3N?[
M?IH4C:WW/59-VZP6#F:7"S)LJ']+5@(VD462[GF_.*?6KHEQT>6'IZ43Y1<\
M^G%2O%%XA\@V'+" HJ&FNURD<C*4MNY-!(R4JT2,I'2&\SSWOILZKJN*7':;
M0$3DE7ZFY?4TT]H34&KLKS(=V2[;V5K+"\^%U+AY<2DUZY7C===_->VQOSQX
MU0(08\<$HZ$ZX/A9\X%/810E30<=-MI<7UO:1(9>6J:VSFP#MI@+TN>4DN,<
M,,ATK)D=((1@! RVJ]+CS:J"%VLY\5^$;=83B-S>-+:9IE>)4.2,X92/"KL;
MZ<U4:?UV,Y_K"JK4=?)J.\^W(G20'N1H,D >-N)FW]7/O'M^Y+"TCK/'Z<:)
M_D>KPO7^0;+R,>&15^-+(TQUD&3+]E1LHV-U<;_;]H//E>2NSM+A%0R#EW92
M'B7T)V;/CUL8B3CGM "-&*>J<B4EU4Y3VM4VF^-+Q YM.>CX!BE;!:!>6XE#
MC=EE=HT!*O0DI]]9;#I\>B&U51 +C['[]>*;U(/5!U>U+W8N!6*4HZI+/_A'
MT!;XO3+$B^528^JKL/GCC5$5%>VQC<B>5]_E///M-NML;/ZQ73V^\2<#]+K]
MF4]S[N4;=<F"J\_!6U3[FNNYXH_%MB*)8Y1CLI(#?!.?51MO-J("BGJO7)AQ
M:1P15/>22A5$]45/?J0WJ3ZP6K]UW=5K_=-"-IS.+:> "GOX[-Q^N;^QF<V.
M(26P-9 ?B!A<KVQ!06[[&JE<WV2Y%"5,,'+'V6;0V=*P[84L@KB"R*N/1U:[
M=C';3E5-&P4FY@ *<N$TC3J<\C&(!,TLQLQXV\2SVPAXUGE<U@^037&X\*R&
M6LC%[&4:H(,%)D(W)I7WS+HCMS2E0R5.D[,'G&F3F2Y#NKR:<::UEM[<>M]$
M8-:[&VKE(&)XI4HV.0TQ9)23CIFR.%J:>N'9*=;VYOQ2?2UM?!.5(R.:96-'
M@GFB].HI[*]G-5U5%<ERWN50 X00!..IUYPE1MED.4ZW7"$$54'E2(47$\VS
MG%MN\?F91F%O&IJ>'P)/OJ1NR)!H2LPH,5I#D3IK_079BQFW'C$#<Z4:;<,(
M!=Q>M[L.^NY:#K;J2HK*^8EP=9>;!A/R;*[?W.5(9PL5QVP K:@J1?",#FLL
MJ1R?I*K7O^.*>Z?9.O89%_([9YUP1ZW6*]6XT5KA/:$Y4AMQUX$]ZF+<7C[R
M<KKASCQ^9-8V!UVUN&0HD4W58BV&2MR;6XFHJ\-G'IZN5&B07B7A!9<E7"$G
MS$O2&JV=\/5K<U+QN YW)3JGS)XZT%K3+%^_^QS<22=8?;_72Q]WM^_R>?TN
M>I]0NTZ*K"SX"/)[*_\ I*'>1?=ZAYOIZN?AV^.?AK#T\0_C.5/I@F.9$4'[
M)Z;4O+!Z/?\ ^L)2]SM\?KO-<\?KOCK;6H_6ZV)CEY'CO973M8:)!.P6SN<
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M )/@0&*BJ?.BZW)U\^':0(5G7R&Y4"QB1I\&4TO4U)AS&0D1I#9>G+;S+@.
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MMX*]WYNX>W\S%K^6<S(\ .%!26^:G)L,<F-NI3/ON&O4_)@E$E5K[GM$K$>
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M<J%73:]%5QTFE!9D9]ORZ< Z:\JR]*3GI^9%75,_&CN1M%N9A6+2<.R^HO\
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M[SW^5ANIMNL/\FKKS^HW4O\ <''^0KD_Z9<A_'EM_/Y&K[;1_:IVQ_@]PO\
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M[SW^5ANIMNL/\FKKS^HW4O\ <''^0KD_Z9<A_'EM_/Y&K[;1_:IVQ_@]PO\
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MMM,/P\!M\AL&YQQE0Q>LE:B5S;H\D*MPNMQ7WO1>AIYZ2A%PK;/<052%<O\
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M>T"^BK\^N:S^BO3FR+4TGK5I]DSGJ]6@X74U8RN5?*_XE60"!(WS_40?V?\
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MTTXTTXTTXTTXTTXTTXTU#CVMPC;W6+N#3=\M4X!<[6P7),-@P'?.&XS#*7E
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I3L9V.#VZLQ6"<9)H761M<H4%:4A%#:1#114.11"]/0O67SD1:NOK_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
